0001293971-22-000016.txt : 20220304 0001293971-22-000016.hdr.sgml : 20220304 20220304163513 ACCESSION NUMBER: 0001293971-22-000016 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 114 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 22714606 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 10-K 1 blue-20211231.htm 10-K blue-20211231
FALSE2021FY0001293971http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Memberone0.3333zerozerozerozero00012939712021-01-012021-12-3100012939712021-06-30iso4217:USD00012939712022-02-28xbrli:shares00012939712021-12-3100012939712020-12-31iso4217:USDxbrli:shares0001293971us-gaap:ProductMember2021-01-012021-12-310001293971us-gaap:ProductMember2020-01-012020-12-310001293971us-gaap:ProductMember2019-01-012019-12-310001293971blue:OtherRevenueMember2021-01-012021-12-310001293971blue:OtherRevenueMember2020-01-012020-12-310001293971blue:OtherRevenueMember2019-01-012019-12-3100012939712020-01-012020-12-3100012939712019-01-012019-12-310001293971us-gaap:CommonStockMember2018-12-310001293971us-gaap:AdditionalPaidInCapitalMember2018-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2018-12-310001293971us-gaap:RetainedEarningsMember2018-12-3100012939712018-12-310001293971srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310001293971srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001293971us-gaap:CommonStockMember2019-01-012019-12-310001293971us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2019-01-012019-12-310001293971us-gaap:RetainedEarningsMember2019-01-012019-12-310001293971us-gaap:CommonStockMember2019-12-310001293971us-gaap:AdditionalPaidInCapitalMember2019-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2019-12-310001293971us-gaap:RetainedEarningsMember2019-12-3100012939712019-12-310001293971us-gaap:CommonStockMember2020-01-012020-12-310001293971us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2020-01-012020-12-310001293971us-gaap:RetainedEarningsMember2020-01-012020-12-310001293971us-gaap:CommonStockMember2020-12-310001293971us-gaap:AdditionalPaidInCapitalMember2020-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2020-12-310001293971us-gaap:RetainedEarningsMember2020-12-310001293971us-gaap:CommonStockMember2021-01-012021-12-310001293971us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2021-01-012021-12-310001293971us-gaap:RetainedEarningsMember2021-01-012021-12-310001293971us-gaap:CommonStockMember2021-12-310001293971us-gaap:AdditionalPaidInCapitalMember2021-12-310001293971blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember2021-12-310001293971us-gaap:RetainedEarningsMember2021-12-310001293971blue:PublicOfferingMember2021-01-012021-12-310001293971blue:PublicOfferingMember2020-01-012020-12-310001293971blue:PublicOfferingMember2019-01-012019-12-310001293971us-gaap:PrivatePlacementMember2021-01-012021-12-310001293971us-gaap:PrivatePlacementMember2020-01-012020-12-310001293971us-gaap:PrivatePlacementMember2019-01-012019-12-3100012939712021-11-04blue:company0001293971us-gaap:BuildingMember2021-01-012021-12-310001293971blue:ComputerEquipmentAndSoftwareMember2021-01-012021-12-310001293971us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2021-01-012021-12-310001293971srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2021-01-012021-12-310001293971blue:LaboratoryEquipmentMembersrt:MinimumMember2021-01-012021-12-310001293971srt:MaximumMemberblue:LaboratoryEquipmentMember2021-01-012021-12-31blue:target0001293971blue:LentiviralVectorManufacturingFacilityMember2021-12-310001293971blue:LentiviralVectorManufacturingFacilityMember2021-01-012021-12-310001293971blue:A2seventyBioMember2021-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2021-11-0400012939712021-11-03blue:agreement0001293971us-gaap:ServiceMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2021-01-012021-12-310001293971us-gaap:ServiceMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2020-01-012020-12-310001293971us-gaap:ServiceMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2019-01-012019-12-310001293971blue:CollaborationArrangementMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2021-01-012021-12-310001293971blue:CollaborationArrangementMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2020-01-012020-12-310001293971blue:CollaborationArrangementMemberus-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2019-01-012019-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:RoyaltyAndOtherRevenueMemberblue:A2seventyBioMember2021-01-012021-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:RoyaltyAndOtherRevenueMemberblue:A2seventyBioMember2020-01-012020-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:RoyaltyAndOtherRevenueMemberblue:A2seventyBioMember2019-01-012019-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2021-01-012021-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2020-01-012020-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2019-01-012019-12-310001293971us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMemberblue:A2seventyBioMember2020-12-3100012939712021-10-19xbrli:pure0001293971us-gaap:USTreasuryAndGovernmentMember2021-12-310001293971us-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:CommercialPaperMember2021-12-310001293971us-gaap:USTreasuryAndGovernmentMember2020-12-310001293971us-gaap:CorporateBondSecuritiesMember2020-12-310001293971us-gaap:CommercialPaperMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMember2021-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2021-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310001293971us-gaap:FairValueMeasurementsRecurringMember2020-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2020-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2020-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001293971us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001293971us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-12-310001293971us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001293971us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001293971us-gaap:CorporateBondSecuritiesMember2021-12-310001293971us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310001293971us-gaap:CorporateBondSecuritiesMember2020-12-3100012939712021-01-012021-01-310001293971blue:LaboratoryEquipmentMember2021-12-310001293971blue:LaboratoryEquipmentMember2020-12-310001293971blue:ComputerEquipmentAndSoftwareMember2021-12-310001293971blue:ComputerEquipmentAndSoftwareMember2020-12-310001293971us-gaap:OfficeEquipmentMember2021-12-310001293971us-gaap:OfficeEquipmentMember2020-12-310001293971us-gaap:LeaseholdImprovementsMember2021-12-310001293971us-gaap:LeaseholdImprovementsMember2020-12-310001293971us-gaap:ConstructionInProgressMember2021-12-310001293971us-gaap:ConstructionInProgressMember2020-12-310001293971us-gaap:LetterOfCreditMember2021-12-310001293971us-gaap:LetterOfCreditMember2020-12-310001293971blue:FiftyBinneyStreetLeaseMember2021-12-310001293971blue:FiftyBinneyStreetLeaseMember2020-12-310001293971blue:AssemblyRowLeaseMember2021-12-310001293971blue:AssemblyRowLeaseMember2020-12-310001293971blue:SixtyBinneyStreetLeaseMember2021-12-310001293971blue:SixtyBinneyStreetLeaseMember2020-12-310001293971blue:OtherMember2021-12-310001293971blue:OtherMember2020-12-310001293971blue:SixtyBinneyStreetLeaseMember2021-10-012021-10-310001293971blue:SixtyBinneyStreetLeaseMember2021-10-31utr:sqft0001293971srt:ScenarioForecastMemberblue:SixtyBinneyStreetLeaseMember2022-04-012022-04-300001293971blue:FiftyBinneyStreetSubleaseMember2019-04-012019-04-300001293971blue:FiftyBinneyStreetSubleaseMember2019-04-3000012939712019-04-300001293971blue:FiftyBinneyStreetSubleaseMember2021-12-310001293971blue:FiftyBinneyStreetSubleaseMember2021-12-012021-12-310001293971blue:FiftyBinneyStreetSubleaseMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-12-012021-12-310001293971blue:AssemblyRowLeaseMember2021-11-012021-11-300001293971blue:AssemblyRowLeaseMember2021-11-30iso4217:USDutr:sqft0001293971us-gaap:ManufacturingFacilityMember2016-06-300001293971us-gaap:ManufacturingFacilityMember2016-06-012018-03-310001293971us-gaap:ManufacturingFacilityMember2021-01-012021-12-310001293971us-gaap:ManufacturingFacilityMember2016-11-300001293971us-gaap:ManufacturingFacilityMember2020-03-31iso4217:EUR0001293971us-gaap:ManufacturingFacilityMember2020-03-012020-03-310001293971us-gaap:ManufacturingFacilityMember2021-12-012021-12-310001293971us-gaap:ManufacturingFacilityMember2020-07-310001293971us-gaap:ManufacturingFacilityMember2020-07-012020-07-310001293971us-gaap:ManufacturingFacilityMember2021-02-280001293971us-gaap:ManufacturingFacilityMember2021-02-012021-02-28blue:vote0001293971us-gaap:PrivatePlacementMember2021-09-012021-09-300001293971us-gaap:PrivatePlacementMember2021-09-300001293971blue:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2021-09-300001293971us-gaap:EmployeeStockOptionMember2021-12-310001293971us-gaap:EmployeeStockOptionMember2020-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2021-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2020-12-310001293971blue:TwoThousandThirteenStockOptionAndIncentivePlanMember2021-12-310001293971blue:TwoThousandThirteenStockOptionAndIncentivePlanMember2020-12-310001293971blue:PreFundedWarrantsMember2021-12-310001293971blue:PreFundedWarrantsMember2020-12-310001293971blue:TwoThousandThirteenEmployeeStockPurchasePlanESPPMember2021-12-310001293971blue:TwoThousandThirteenEmployeeStockPurchasePlanESPPMember2020-12-310001293971blue:InLicensedRightsMember2021-12-310001293971blue:InLicensedRightsMember2020-12-310001293971blue:InLicensedRightsMember2021-09-012021-09-300001293971blue:TwoThousandThirteenStockOptionAndIncentivePlanMember2013-06-240001293971us-gaap:SubsequentEventMember2022-01-012022-01-3100012939712021-11-042021-11-040001293971blue:EmployeeAndNonEmployeeStockOptionMember2021-01-012021-12-310001293971blue:EmployeeAndNonEmployeeStockOptionMember2020-01-012020-12-310001293971blue:EmployeeAndNonEmployeeStockOptionMember2019-01-012019-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001293971blue:EmployeeStockPurchasePlanMember2021-01-012021-12-310001293971blue:EmployeeStockPurchasePlanMember2020-01-012020-12-310001293971blue:EmployeeStockPurchasePlanMember2019-01-012019-12-310001293971us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001293971us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001293971us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001293971us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001293971us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001293971us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001293971blue:A2020AnnualIncentiveProgramMemberblue:UnrestrictedStockAwardsMember2021-01-012021-01-310001293971blue:RetentionProgramMemberblue:UnrestrictedStockAwardsMember2021-07-012021-09-300001293971blue:RetentionProgramMemberblue:UnrestrictedStockAwardsMember2021-10-012021-12-310001293971blue:EmployeeAndNonEmployeeStockOptionMember2021-12-310001293971blue:OptionConversionAwardsMember2021-01-012021-12-310001293971blue:RestrictedStockUnitConversionAwardsMember2021-01-012021-12-310001293971blue:EmployeeStockPurchasePlanMember2013-06-030001293971blue:EmployeeStockPurchasePlanMember2021-06-300001293971blue:EmployeeStockPurchasePlanMembersrt:MaximumMember2021-01-012021-12-310001293971blue:EmployeeStockPurchasePlanMembersrt:MaximumMember2020-01-012020-12-310001293971srt:ScenarioForecastMemberblue:FourHundredAndOneKMember2022-03-012022-03-310001293971srt:ScenarioForecastMemberblue:FourHundredAndOneKMemberblue:A2seventyBioMember2022-03-012022-03-310001293971blue:FourHundredAndOneKMember2021-03-012021-03-310001293971blue:FourHundredAndOneKMember2021-01-012021-12-310001293971blue:FourHundredAndOneKMember2020-01-012020-12-310001293971blue:FourHundredAndOneKMember2019-01-012019-12-310001293971us-gaap:DomesticCountryMember2021-12-310001293971us-gaap:DomesticCountryMember2020-12-310001293971us-gaap:DomesticCountryMember2019-12-310001293971us-gaap:StateAndLocalJurisdictionMember2021-12-310001293971us-gaap:StateAndLocalJurisdictionMember2020-12-310001293971us-gaap:StateAndLocalJurisdictionMember2019-12-310001293971us-gaap:ResearchMemberus-gaap:DomesticCountryMember2021-12-310001293971us-gaap:ResearchMemberus-gaap:DomesticCountryMember2020-12-310001293971us-gaap:ResearchMemberus-gaap:DomesticCountryMember2019-12-310001293971us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2021-12-310001293971us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2020-12-310001293971us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2019-12-310001293971us-gaap:ResearchMember2021-01-012021-12-310001293971blue:April2021ReductionMember2021-04-012021-04-30blue:employee0001293971blue:July2021ReductionMember2021-07-012021-07-310001293971blue:July2021ReductionMemberblue:UnrestrictedStockMember2021-09-302021-09-300001293971blue:April2021ReductionMember2021-01-012021-12-310001293971blue:April2021ReductionMember2021-12-310001293971blue:July2021ReductionMember2021-01-012021-12-310001293971blue:July2021ReductionMember2021-12-310001293971blue:ResearchAndDevelopmentAndSellingGeneralAndAdministrativeExpensesMemberblue:July2021ReductionMemberblue:UnrestrictedStockMember2021-01-012021-12-310001293971us-gaap:StockOptionMember2021-01-012021-12-310001293971us-gaap:StockOptionMember2020-01-012020-12-310001293971us-gaap:StockOptionMember2019-01-012019-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001293971us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2021-01-012021-12-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2020-01-012020-12-310001293971blue:EmployeeStockPurchasePlanAndOtherMember2019-01-012019-12-3100012939712021-01-012021-03-3100012939712021-04-012021-06-3000012939712021-07-012021-09-3000012939712021-10-012021-12-3100012939712020-01-012020-03-3100012939712020-04-012020-06-3000012939712020-07-012020-09-3000012939712020-10-012020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________________________________________________________________________
FORM 10-K
___________________________________________________________________________
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                          to                     
Commission File Number: 001-35966
___________________________________________________________________________
bluebird bio, Inc.
(Exact Name of Registrant as Specified in Its Charter
___________________________________________________________________________
Delaware13-3680878
(State or Other Jurisdiction of
Incorporation or Organization)		(IRS Employer
Identification No.)
60 Binney Street
Cambridge, Massachusetts
02142
(Address of Principal Executive Offices)(Zip Code)
(339) 499-9300
(Registrant’s Telephone Number, Including Area Code)
___________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareBLUEThe NASDAQ Stock Market LLC

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒      No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨      No  ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒ 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
The aggregate market value of common stock held by non-affiliates of the registrant based on the closing price of the registrant’s common stock as reported on the Nasdaq Global Select Market on June 30, 2021, the last business day of the registrant’s most recently completed second quarter, was $1,398,973,030.
As of February 28, 2022, there were 71,433,275 shares of the registrant’s common stock, par value $0.01 per share, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.


Table of Contents
Page
[Reserved]
Item 9C.


FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
•the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•our ability to advance product candidates into, and successfully complete, clinical studies;
•our ability to obtain adequate financing to fund our operations and to execute on our strategy;
•our ability to establish and scale commercial viral vector and drug product manufacturing capabilities, and to ensure adequate supply of our viral vectors and drug products;
•the timing or likelihood of regulatory filings and marketing approvals for our product candidates;
•the timing or success of commercialization of any approved products;
•our ability to obtain adequate pricing and reimbursement of any approved products;
•the implementation of our business model, strategic plans for our business, product candidates and technology;
•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
•estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
•the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;
•our ability to maintain and establish collaborations and licenses;
•developments relating to our competitors and our industry;
•the impact of the COVID-19 pandemic;
•the effects, costs, and benefits of the separation of our portfolio of products and programs into two independent, publicly-traded companies; and
•other risks and uncertainties, including those listed under Part I, Item 1A. Risk Factors.
Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. Risk Factors and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business,

market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.
Summary of the Material and Other Risks Associated with Our Business
Below is a summary of the material risks to our business, operations and the investment in our common stock. This summary does not address all of the risks that we face. Risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K in its entirety before making investment decisions regarding our common stock.
•The FDA has placed our clinical studies of lovo-cel on partial clinical hold, and we have no assurance as to what the FDA may require, or the timing, if ever, of when the partial clinical hold may be lifted, or when we may resume enrolling pediatric patients in our clinical studies of lovo-cel.
•The FDA has placed our clinical studies of eli-cel on clinical hold, and we have no assurances as to what the FDA may require, or the timing, if ever, of when this clinical hold may be lifted, or the effect this clinical hold may have on FDA's ongoing review of the Biologics License Application ("BLA") for eli-cel.
•We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
•There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional financing in upcoming periods, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our commercial readiness efforts, activities to support a potential commercial launch following any approval of our product candidates, or other operations.
•Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
•Insertional oncogenesis is a risk of gene therapies using viral vectors that can integrate into the genome, and several patients with CALD treated with eli-cel in our clinical studies have been diagnosed with myelodysplastic syndrome likely mediated by Lenti-D lentiviral vector ("LVV") insertion. These events may require us to halt or delay further clinical development of our product candidates, such as eli-cel, or to suspend or cease commercialization following marketing approval, if any, and the commercial potential of our product candidates may be materially and negatively impacted.
•We have limited experience as a commercial company and the marketing and sale of future products may be unsuccessful or less successful than anticipated.
•The commercial success of our future products will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community. If we fail to obtain sufficient pricing or reimbursement approval for any future products, our revenues may be adversely affected and our business may suffer.
•If the market opportunities for our product or any future products are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer.
•We rely on a complex supply chain for our product candidates. The manufacture and delivery of our LVV and drug products present significant challenges for us, and we may not be able to produce our vector and drug products at the quality, quantities, locations or timing needed to support our clinical programs or potential commercialization. In addition, we may encounter challenges with engaging or coordinating with qualified treatment centers needed to support potential commercialization.
•We cannot predict when or if we will obtain marketing approval to commercialize our product candidates, and the marketing approval of our product and any future products may ultimately be for more narrow indications than we expect.
•We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product and any future products. If our competitors obtain orphan drug

exclusivity for products that regulatory authorities determine constitute the same drug and treat the same indications as our product or any future products, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.
•We may not be successful in our efforts to identify or discover additional product candidates.
•Our business may be materially and adversely affected by the ongoing COVID-19 pandemic. The COVID-19 pandemic has had, and will likely continue to have, an impact on various aspects of our business and that of third parties on which we rely. The extent to which the COVID-19 pandemic impacts our business will depend in part on future developments, which are uncertain and unpredictable in nature.


PART I
Item 1. Business
Overview
In 2021, we completed the tax-free spin-off of our oncology programs and portfolio to become a company focused on the pursuit of curative gene therapies for severe genetic diseases. Today, bluebird bio, Inc. has industry-leading, late-stage clinical and research programs for the treatment of sickle cell disease ("SCD"), β-thalassemia and cerebral adrenoleukodystrophy ("CALD")  and is advancing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector ("LVV") platform, we custom design each of our therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients’ own isolated hematopoietic stem cells ("HSCs"). In a rapidly advancing field, we have developed in-depth analytical methods to understand the safety of our LVV technologies, which are designed to deliver a sustained, lifelong response from a one-time treatment and to improve upon allogeneic hematopoietic stem cell transplant ("HSCT"), which carries significant limitations, including the ability to identify matched donors, risk of transplant-related graft-vs-host disease ("GVHD") and death, as well as to improve upon current treatment approaches used with patients not currently eligible to receive allogeneic HSCT. We have the largest and deepest ex vivo gene therapy data set in the industry, with more than 500 patient years of experience. We are also investing in research and development to expand the potential impact of our existing ex vivo programs through development of reduced toxicity conditioning and alternative HSC mobilization regimens, as well as in manufacturing process improvements. Long-term, we seek to build our pipeline by investing in in vivo applications of our LVV platform and advancement of our direct injection preclinical candidates.
European withdrawal
We announced our intent to wind down our operations in Europe and to focus on the U.S. market. The decision to discontinue operations in Europe resulted from prolonged negotiations with European payers and challenges to achieving appropriate value recognition and market access for ZYNTEGLO™ for the treatment of β-thalassemia. Following the exploration of potentially out-licensing the ex-U.S. rights to our three lead programs, we made the decision to withdraw the regulatory marketing authorizations for SKYSONA™ and ZYNTEGLO from the European Union and to withdraw our marketing applications for SKYSONA and ZYNTEGLO from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. We are continuing the long-term follow-up of patients previously enrolled within the clinical trial programs in Europe as planned but do not intend to initiate any new clinical trials in Europe for β-thalassemia, CALD or SCD.
Our Programs
Lovotibeglogene autotemcel
We are developing lovotibeglogene autotemcel ("lovo-cel", formerly referred to as "LentiGlobin for SCD") as a one-time treatment for patients with SCD, a serious, progressive and debilitating genetic disease caused by a single mutation in the β-globin gene that leads to the production of abnormal sickle hemoglobin ("HbS"). HbS causes red blood cells ("RBCs") to become sickled and fragile, resulting in chronic hemolytic anemia, vasculopathy and unpredictable, painful vaso-occlusive events ("VOEs"), requiring frequent hospitalization. In the United States, the median age of death for someone with sickle cell disease is 43 to 46 years. Additionally, one in four people living with sickle cell disease experience a stroke by age 45.
Based on our discussions with the FDA, we believe that we may be able to seek approval for lovo-cel in the United States on the basis of clinical data from Group C of the HGB-206 Phase 1/2 clinical trial. We have treated all of the patients who will form the primary efficacy data set, with the demonstration of analytical comparability and validation of our commercial manufacturing process as the key remaining actions prior to submission of our planned BLA for lovo-cel.
Our approach in SCD involves the ex vivo insertion of the normal β-globin gene with the T87Q amino acid substitution into the patient’s own HSCs using LVV, to enable formation of normally functioning hemoglobin A and normal RBCs in patients. T87Q serves as a distinct biomarker used to quantify expression levels of the functional β-globin protein in patients with SCD, while also providing anti-sickling properties. Lovo-cel has been granted Fast Track Designation for the treatment of SCD, Orphan Drug Designation for the treatment of SCD, Regenerative Medicine Advanced Therapy ("RMAT") Designation for the treatment of SCD, and Rare Pediatric Disease Designation for the treatment of SCD by the U.S. Food and Drug Administration ("FDA").
1
We are conducting, or have conducted, the following clinical studies to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD:
•The HGB-206 study is a single-dose, open-label, non-randomized, multi-site Phase 1/2 clinical study in the United States to evaluate the safety and efficacy of lovo-cel. A total of 45 patients were treated with lovo-cel in this study across three treatment cohorts. Patients must have been at least twelve years of age at enrollment with a diagnosis of sickle cell disease, with βS/βS, βS/β+ or βS/β0 genotype. Patients must have had recurrent severe VOEs and must have failed to achieve clinical benefit from treatment with hydroxyurea. We refer to patients treated in the HGB-206 study under the amended study protocol utilizing HSCs from peripheral blood after mobilization with plerixafor as patients in “Group C” (n=36) rather than utilizing HSCs collected via bone marrow harvest, as in Groups A (n=7) and B (n=2). A refined manufacturing process designed to increase vector copy number and further protocol refinements made to improve engraftment potential of gene-modified stem cells were also used for Group C. The primary efficacy endpoint for this study is complete resolution of severe VOEs, between six and 18 months post-treatment, and the secondary efficacy endpoint for this study is globin response based on βA-T87Q expression and total hemoglobin. Safety endpoints include monitoring for laboratory parameters and frequency and severity of adverse events; the success and kinetics of HSC engraftment; the incidence of treatment related mortality and overall survival; the detection of vector-derived replication-competent lentivirus in any patient; and the characterization of events of insertional mutagenesis leading to clonal predominance or leukemia. Each patient will remain on study for approximately 24 months post-treatment and then will be invited to enroll in LTF-307, a long-term follow-up protocol that will assess safety and efficacy for an additional 13 years.
•HGB-210 is a single-dose, open-label, non-randomized, multi-site, Phase 3 clinical study in the United States to evaluate the efficacy and safety of lovo-cel in the treatment of patients with SCD, with a target enrollment of 35 pediatric and adult patients. We expect to include data from HGB-210 in our planned BLA submission for lovo-cel to demonstrate analytical comparability and validation of our commercial manufacturing process. Patients must be at least two years of age at enrollment with a diagnosis of sickle cell disease, with βS/βS, βS/β+ or βS/β0 genotype, subject to resolution of the partial clinical hold applicable to enrollment of pediatric patients. Patients must have recurrent severe VOEs and must have failed to achieve clinical benefit from treatment with hydroxyurea. The patients must also be eligible for HSCT. The primary efficacy endpoint for this study is complete resolution of severe VOEs, between six and 18 months post-treatment, and the secondary efficacy endpoint for this study includes globin response based on βA-T87Q expression and total hemoglobin. Safety endpoints include monitoring for laboratory parameters and frequency and severity of adverse events; the success and kinetics of HSC engraftment; the incidence of treatment related mortality and overall survival; the detection of vector-derived replication-competent lentivirus in any patient; and the characterization of events of insertional mutagenesis leading to clonal predominance or leukemia. Each patient will remain on study for approximately 24 months post-treatment and then will be invited to enroll in LTF-307, a long-term follow-up protocol that will assess safety and efficacy for an additional 13 years.
•HGB-205 is a completed proof-of-concept, single-center Phase 1/2 study in France of three patients with SCD which also enrolled patients with β-thalassemia. Those with SCD must have failed to achieve clinical benefit from treatment with hydroxyurea and have an additional poor prognostic risk factor (e.g., recurrent vaso-occlusive crises ("VOCs"), or acute chest syndrome). All patients must have been eligible for allogeneic HSCT, but without a matched sibling allogeneic HSCT donor. The primary objective of our HGB-205 study was to determine the safety, tolerability and success of engraftment of the drug product. The secondary objectives of the study were to quantify gene transfer efficiency and expression, and to measure the effects of treatment on disease-specific biological parameters and clinical events. In the case of patients with TDT and SCD, this meant the volume of RBC transfusions, and for patients with SCD, it also meant the number of VOCs and acute chest syndrome in each patient, compared with the two-year period prior to treatment. Safety evaluations performed during the study included success and kinetics of HSC engraftment, incidence of transplant-related mortality post-treatment, overall survival, detection of vector-derived replication-competent lentivirus in any patient and characterization of events of clonal predominance or leukemia/ lymphoma. Each patient remained on study for approximately 24 months post-treatment and then was invited to enroll in LTF-307, a long-term follow-up protocol that will assess safety and efficacy for an additional 13 years.
•LTF-307 is the long-term follow-up study for patients with SCD from our HGB-205, HGB-206, or HGB-210 studies who were treated with lovo-cel once they complete the original study protocol’s follow-up period of approximately two years. Under LTF-307, patients will be followed for approximately an additional 13 years for a total of approximately 15 years post-treatment.
In December 2021, the FDA placed a partial clinical hold on our clinical program for lovo-cel for patients under the age of 18. The partial hold relates to our ongoing investigation into an adolescent patient with persistent, non-transfusion-dependent anemia 18 months post-treatment with lovo-cel. During the partial clinical hold, we anticipate continuing our clinical study
2
activities as planned for patients 18 and older in our HGB-206 Group C and HGB-210 studies, as well as follow-up activities for treated patients of all ages in all studies. Based on our discussions with the FDA, we believe that we may be able to seek approval for lovo-cel in the United States on the basis of clinical data from HGB-206 Group C, supportive data from HGB-210 for safety and analytical comparability and validation of our commercial manufacturing process. We have treated all of the patients who will form the primary efficacy dataset for the planned BLA submission, with the demonstration of analytical comparability and validation of our commercial manufacturing process as the key remaining actions prior to submission of our planned BLA for lovo-cel.
At the Annual Meeting of the American Society of Hematology in December 2021, we presented interim data from our lovo-cel program with a data cut-off date as of February 17, 2021, as summarized below:
•A total of 49 patients had been treated with lovo-cel, with up to six years of patient follow-up, in the HGB-205 (n=3), HGB-206 (n=44), and HGB-210 (n=2) clinical studies. The HGB-206 total included: Group A (n=7), Group B (n=2), and Group C (n=35), representing progressive adaptations to the manufacturing and treatment processes.
•The 35 Group C patients had up to 37.6 months of follow-up (median of 17.3; min-max: 3.7-37.6 months), for a total of 54.8 patient-years of experience. In HGB-206 Group C, no severe VOEs were reported with up to 36 months of follow-up in patients with a history of at least four severe VOEs and at least six months of follow-up. Following engraftment, median total hemoglobin for these patients increased from 8.5 g/dL at baseline to ≥11 g/dL from six through up to 36 months post-infusion; notably, HbS in all patients was less than 60% of total hemoglobin, and gene therapy-derived anti-sickling hemoglobin, HbAT87Q, contributed at least 40% of total hemoglobin. All evaluable patients (n=25) continued to experience complete resolution of severe VOEs through up to 36 months of follow-up, compared with a median of 3.5 per year (min-max: 2.0-13.5) in the 24 months before enrollment.
•The safety data for lovo-cel remained generally consistent with the risks of autologous stem cell transplantation and myeloablative single-agent busulfan conditioning, as well as underlying SCD. There were no reports of GVHD, graft failure, replication-competent lentivirus, or vector-mediated insertional oncogenesis in any patient treated in HGB-206. One non-serious, Grade 2 adverse event ("AE") of febrile neutropenia was considered related to lovo-cel. There were no serious AEs related to lovo-cel in Group C. In HGB-206 Group C, one patient with underlying cardiopulmonary disease and SCD-related complications died 20 months post-treatment; the investigator and an independent monitoring committee agreed his death was unlikely related to lovo-cel. In HGB-206 Group A, two patients treated with lovo-cel developed acute myeloid leukemia ("AML"). Following investigation of the cases, it was determined that these were unlikely related to lentiviral insertion from lovo-cel. The underlying increased risk of hematologic malignancies in SCD, combined with the transplant procedure and associated proliferative stress, as well as continued hematopoietic stress due to minimal clinical benefit in these two Group A patients (drug product manufactured using stem cells collected via bone marrow harvest and using a previous manufacturing process which has since been discontinued) may have contributed to the development of acute myeloid leukemia.
•In HGB-206 Group C, key hemolysis markers approached normal levels, suggesting a reduction in hemolysis: lactate dehydrogenase and indirect bilirubin levels normalized, reticulocyte counts approached normal levels, and haptoglobin levels were detected at last visit.
•Based on exploratory assay data evaluating HbAT87Q and HbS protein in individual RBCs to assess pancellularity of HbAT87Q, a mean of 85% of RBCs containing βA-T87Q was observed in ten patients with at least 24 months of follow-up, suggesting near-pancellular HbAT87Q distribution and with pancellularity observed to be increasing over time. Within HbAT87Q-containing RBCs, the median HbAT87Q was estimated to be 15.3 pg per RBCs (range: 11.7 to 22.7).
•Integration site analysis data in HGB-206 Group C also demonstrated greater diversity detected in lentiviral vector insertion sites, which is attributed to improvements implemented for Group C.
Betibeglogene autotemcel
The BLA for betibeglogene autotemcel ("beti-cel") is currently under review by the FDA for β-thalassemia in patients who receive regular RBC transfusions. The BLA for beti-cel was accepted for filing and granted priority review and the Prescription Drug User Fee Act ("PDUFA") goal date is August 19, 2022.
β-thalassemia is a rare genetic disease caused by a mutation in the β-globin gene resulting in the production of defective RBCs. The disease is characterized by severe anemia, and the ineffective production of RBCs can lead to a range of multi-systemic complications, including but not limited to splenomegaly, marrow expansion, bone deformities, and iron overload in major organs (as a result of blood transfusions needed to treat the disease). Patients with β-thalassemia require time-consuming,
3
highly-specialized care for life with many patients receiving RBC transfusions every two to four weeks. More than 80 percent of people with β-thalassemia are living with at least one complication from their disease, and patients have a mortality rate that is five times that of the general population. Our approach involves using LVV to insert the normal β-globin gene with a single amino acid substitution into the patient’s own HSCs ex vivo, to enable formation of normal RBCs, in patients. Beti-cel refers to the β-thalassemia patients' own cells that have undergone our ex vivo manufacturing process resulting in genetically modified HSCs.
The BLA is based on data from patients treated in our Phase 3 HGB-207 and HGB-212 studies, as well as the phase 1/2 HGB-204 and HGB-205 studies. Beti-cel has been granted Orphan Drug status by the FDA for the treatment of β-thalassemia and was granted Fast Track designation for the treatment of β-thalassemia major. The FDA previously granted beti-cel Orphan Drug status, Breakthrough Therapy designation and Rare Pediatric Disease designation for the treatment of transfusion-dependent β-thalassemia.
We are conducting, or have conducted, the following clinical studies to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia:
•HGB-207 is an ongoing single-dose, open-label, non-randomized, international, multi-site phase 3 clinical study to evaluate the safety and efficacy of beti-cel to treat patients with transfusion-dependent β-thalassemia ("TDT") and non-β0/β0 genotypes. Twenty-three patients were enrolled and completed dosing in the study, consisting of 15 adolescent and adult patients between 12 and 50 years of age at enrollment, and eight pediatric patients less than 12 years of age at enrollment. Age at enrollment ranged from four to 34 years old. To be enrolled, patients with TDT and non-β0/β0 genotypes must have received at least 100 mL/kg/year of RBCs or at least eight transfusions per year for the past two years. All patients must have been eligible for allogeneic HSCT, but without a matched family HSCT donor. The primary endpoint of this study is the proportion of treated patients who achieve transfusion independence, defined as weighted average hemoglobin levels ≥9.0 g/dL without any RBC transfusions for a continuous period of at least 12 months at any time during the study after treatment. The secondary endpoints of this study are designed to quantify gene transfer efficiency and expression, and to measure the effects of treatment with beti-cel on transfusion requirements and clinical events. Safety evaluations performed during the study include success and kinetics of platelet and neutrophil engraftment, incidence of transplant-related mortality post-treatment, overall survival, detection of vector-derived replication-competent lentivirus in any patient and characterization of events of clonal predominance or leukemia. Each patient will remain on study for approximately 24 months post-treatment and then will be invited to enroll in LTF-303, a long-term follow-up protocol that will assess safety and efficacy for an additional 13 years.
•HGB-212 is an ongoing single-dose, open-label, non-randomized, international, multi-site phase 3 clinical study to evaluate the efficacy and safety of beti-cel to treat patients with TDT who have either a β0/β0, β0/IVS-I-110, or IVS-I-110/IVS-I-110 genotypes. Eighteen patients were enrolled and completed dosing in the study, consisting of ten adolescent and adult patients between twelve and 50 years of age at enrollment, and eight patients less than twelve years of age at enrollment. To be eligible, patients must have received at least 100 mL/kg/year of RBCs or at least eight transfusions per year for the past two years. All patients must have been clinically stable and eligible to undergo HSCT and been treated and followed for at least the last two years in a specialized center that maintained detailed medical records, including transfusion history. The primary endpoint of this study is the proportion of treated patients who meet the definition of transfusion independence. The secondary endpoints of this study are designed to measure the proportion of patients who meet the definition of transfusion reduction, which is defined as demonstration of reduction in volume of RBC transfusion requirements (in mL/kg) in the post-treatment time period of months 12 to 24 compared to the average annual transfusion requirement in the 24 months prior to enrollment, to quantify gene transfer efficiency and expression, and to measure the effects of treatment with beti-cel on transfusion requirements post-treatment and clinical events. Each patient will remain on study for approximately 24 months post-treatment and then will be invited to enroll in LTF-303, a long-term follow-up protocol that will assess safety and efficacy for an additional 13 years.
•HGB-204 is a completed, single-dose, open-label, non-randomized, multi-site Phase 1/2 clinical study in the United States, Australia and Thailand to evaluate the safety and efficacy of beti-cel in increasing hemoglobin production and the proportion of treated patients who meet the definition of transfusion independence. This study was completed in February 2018, and patients in this study were enrolled in a long-term follow-up protocol to assess safety and efficacy beyond the study follow-up period. Eighteen adults and adolescents were treated in the study. To be eligible for enrollment in this study, patients were between 12 and 35 years of age with a diagnosis of TDT and received at least 100 mL/kg/year of RBCs or at least eight transfusions per year in each of the two years preceding enrollment. The patients were also medically eligible for allogeneic HSCT. Efficacy was evaluated primarily by the production of ≥2.0 g/dL of hemoglobin A containing βA-T87Q-globin for the six-month period between 18- and 24-months post-treatment.
4
Exploratory efficacy endpoints included RBC transfusion requirements per month and per year, post-treatment. Safety evaluations performed during the study included success and kinetics of HSC engraftment, incidence of transplant-related mortality post-treatment, overall survival, detection of vector-derived replication-competent lentivirus in any patient and characterization of events of insertional mutagenesis leading to clonal predominance or leukemia. Subjects were monitored by regular screening. Each patient remained on study for approximately 24 months from time of consent and then was invited to enroll in LTF-303, a long-term follow-up protocol that is assessing safety and efficacy for an additional 13 years.
•HGB-205 is a completed, proof-of-concept, single-dose, open-label, non-randomized, Phase 1/2 clinical study conducted at a single site in France to examine the safety and efficacy of beti-cel in four patients with β-thalassemia that also enrolled patients with SCD. Each patient remained on study for approximately 24 months from time of consent and then was invited to enroll in LTF-303, a long-term follow-up protocol that is assessing safety and efficacy for an additional 13 years.
•LTF-303 is the long-term follow-up study for patients with β-thalassemia from our HGB-204, HGB-205, HGB-207, or HGB-212 studies who were treated with beti-cel once they complete the original study protocol’s follow-up period of approximately two years. Under LTF-303, patients will be followed for approximately an additional 13 years for a total of approximately 15 years post-treatment.
In December 2021, we presented the following updated long-term follow up clinical data from HGB-204, HGB-205, HGB-207, HGB-212, and LTF-303 at the ASH Annual Meeting, with a data cut-off date as of August 18, 2021:
•A total of 63 pediatric, adolescent and adult patients, including 20 patients with at least five years of follow-up, 11 with at least six years and three with up to seven years across β0/β0 and non-β0/β0 genotypes, have been treated with beti-cel across our clinical studies. After participating in and completing the two years of follow-up in any of the Phase 1/2 (HGB-204, HGB-205) or Phase 3 studies (HGB-207, HGB-212), patients treated with beti-cel were invited to enroll in LTF-303. 57 of 63 beti-cel-treated patients across age groups and genotypes spanning a broad range of the most severe β0/β0 and non-β0/β0 genotypes were enrolled in LTF-303 (22 treated in Phase 1/2 studies, 35 treated in Phase 3 studies) with a median post-infusion follow-up of 41.5 months (min-max: 23-87.5). Twenty patients enrolled in LTF-303 had at least five years of follow-up.
•Of the 57 patients enrolled in LTF-303, 46 patients achieved transfusion independence: 15/22 (68%) patients treated in Phase 1/2 and 31/35 (89%) patients treated in Phase 3. All 46 patients who achieved transfusion independence maintained it through last follow-up in LTF-303, demonstrating the long-term durability of beti-cel. Phase 1/2 patients had a median duration of ongoing transfusion independence of 65.9 months (min-max: 19.8-84.5) and Phase 3 patients had a median ongoing transfusion independence duration of 32 months (min-max: 18.2-49.1). Weighted average hemoglobin in patients who achieved transfusion independence reached normal or near-normal levels in the Phase 1/2 studies (10.3 g/dL; min-max: 9.1-13.2) and in the Phase 3 studies (11.6 g/dL; min-max: 9.5-13.7).
•Patients with β-thalassemia who require regular blood transfusions need to reduce excess iron caused by chronic blood transfusions, including by chelation (pharmacological removal). Prior to beti-cel infusion, all patients in our clinical studies were on iron chelation. Importantly, the majority of patients who achieved transfusion independence (n=46/57) that restarted iron chelation after infusion have since stopped (59%, 20/34); and 24% of those who achieved transfusion independence (11/46) were able to receive phlebotomy (blood removal), which is another method for iron reduction that is only possible for patients who have sufficient hemoglobin levels without RBC transfusions. We believe this result supports the potential for beti-cel to reduce the treatment burden associated with iron management.
•The majority of AEs and SAEs in the beti-cel clinical development program were unrelated to beti-cel and consistent with the known side effects of HSC collection and busulfan conditioning regimen (including several SAEs of veno-occlusive disease that resolved with treatment). Adverse reactions considered related to beti-cel were few and consisted primarily of non-serious infusion-related reactions that occurred on the day of infusion (e.g., abdominal pain, hot flush, dyspnea, tachycardia and non-cardiac chest pain) and cytopenias (e.g. thrombocytopenia, leukopenia and neutropenia). Pain in extremity shortly after treatment was also documented. One of these AEs was a SAE of thrombocytopenia considered possibly related to beti-cel and resolved. There were no deaths, no vector-derived replication-competent lentivirus, and no events of insertional oncogenesis or malignancy.
In June 2019, the European Commission granted conditional marketing authorization for beti-cel, marketed as ZYNTEGLO gene therapy, for the treatment of patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype, for whom HSCT is appropriate but an HLA-matched related HSC donor is not available. We have
5
submitted a request for the withdrawal of the marketing authorization for ZYNTEGLO in the European Union, to be effective in the first half of 2022.
Elivaldogene autotemcel
The BLA for elivaldogene autotemcel (“eli-cel”) is currently under review by the FDA for treatment of patients less
than 18 years of age with early CALD who do not have an available and willing HLA-matched sibling HSC donor. The
BLA for eli-cel was accepted for filing and granted priority review, and the PDUFA goal date is September 16, 2022
CALD is the most severe form of adrenoleukodystrophy, a rare X-linked metabolic disorder caused by mutations in the ABCD1 gene, which results in accumulation of very long-chain fatty acids ("VLCFAs") in plasma and tissues, leading to a range of clinical outcomes. CALD involves a progressive destruction of myelin, the protective sheath of the nerve cells in the brain that are responsible for thinking and muscle control. Symptoms of CALD usually occur in early childhood and progress rapidly if untreated, leading to severe loss of neurological function and eventual death in most patients. Our approach involves the ex vivo insertion of a functional copy of the ABCD1 gene into the patient’s own HSCs via LVV . Following engraftment, we expect the transduced HSCs to differentiate into other cell types, including macrophages and cerebral microglia, which produce functional ALDP. We believe that the functional ALDP can then enable the local degradation of VLCFAs in the brain, which in turn can stabilize the disease by preventing further cerebral inflammation and demyelination that are characteristics of CALD.
Our eli-cel program has been subject to an ongoing clinical hold since mid-2021 when we received a report of myelodysplastic syndrome ("MDS"). We believe this initial case of MDS was related to eli-cel and likely mediated by Lenti-D LVV insertion. Consistent with this known risk, additional treatment-related cases of MDS have subsequently been reported, and all patients who received eli-cel in the clinical program continue to be monitored in accordance with study protocols. On February 23, 2022, the FDA notified us that the clinical hold on the eli-cel program would remain in place, and requested additional information about safety events and monitoring in the eli-cel clinical program. The FDA previously granted eli-cel Orphan Drug designation, Rare Pediatric Disease designation, and Breakthrough Therapy designation.
The BLA for eli-cel is supported by efficacy and safety data from 32 patients dosed in ALD-102, the completed Phase 2/3 Starbeam study, and 23 patients dosed in ALD-104, the Phase 3 study, which has enrolled a total of 35 patients. All patients who completed ALD-102, as well as those who will complete ALD-104, are invited to participate in LTF-304, a long-term follow-up study. In ALD-102, 90.6% (29/32) of patients met the primary endpoint of Major Functional Disabilities ("MFD")-free survival at 24 months. Two patients withdrew from study ALD-102 at investigator discretion, and one additional subject experienced rapid disease progression early in the study, resulting in MFDs and subsequent death. The median duration of follow-up was 3.5 years (42.3 months; 13.4, 83.7). Adverse reactions attributed to eli-cel observed in clinical trials have included MDS, cystitis viral, pancytopenia, and vomiting. There have been no reports of graft-versus-host-disease, graft failure or rejection, transplant-related mortality, or replication competent lentivirus in the 55 patients who have received eli-cel in clinical studies as of the data cut-off date.
The ALD-103 study is a completed observational prospective/ partially retrospective data collection study of 59 patients with CALD ≤17 years of age who received allogeneic HSCT. This study was designed to collect efficacy and safety outcomes data in patients who had undergone allogeneic HSCT in a period that is contemporaneous with ALD-102. We anticipate that eli-cel safety and efficacy will be evaluated by the FDA in light of the data collected in ALD-102 and ALD-104 in conjunction with ALD-103 as well as our completed retrospective observational ALD-101 study.
In July 2021, the European Commission granted marketing authorization for eli-cel as a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen ("HLA")-matched sibling HSC donor is not available. We have withdrawn the marketing authorization of SKYSONA in the European Union, effective in December 2021.
Manufacturing activities
We have entered into multi-year agreements with external manufacturing partners to support our programs in the United States. We have multi-year agreements with SAFC Carlsbad, Inc. ("SAFC", a subsidiary of MilliporeSigma), and Thermo Fisher Scientific, Inc. (previously Novasep) in the production of LVV. In addition, we have entered into multi-year agreements with Lonza Houston, Inc. and Minaris Regenerative Medicine ("Minaris") to produce drug product. In addition, we rely on specialized third-party testing organizations to confirm the quality of LVV and drug product prior to their use in clinical trials and in the commercial context.
We believe our team of technical personnel has extensive manufacturing, analytical and quality experience as well as strong project management discipline to effectively oversee these contract manufacturing activities, and to compile
6
manufacturing and quality information for our regulatory submissions and commercialization efforts. For the treatment of patients with our drug product in the commercial setting following approval if and when received, we are collaborating with participating apheresis centers in the United States, which we refer to as qualified treatment centers, to be centers for collection of HSCs from the patient and for infusion of drug product to the patient.
Adherent cell culture is used to manufacture beti-cel and eli-cel LVV. Large-scale suspension bioreactor process is currently used to manufacture clinical supply of lovo-cel LVV, while adherent cell culture for the manufacture of LVV was used initially in the clinical development of lovo-cel. We are also planning a clinical study to demonstrate the comparability of using cryopreserved patient starting material for the manufacture of drug product, which, if successful, would expand the patient population that our therapies could potentially serve following marketing approval, if and when received.
Commercial operations
We are building our commercialization organization in the United States, with a goal of delivering our gene therapies, if and once approved, to patients through qualified treatment centers. In the course of preparing to treat our first commercial patients, we have established commercial capabilities in the United States by adding employees with broad experience in quality assurance and compliance, medical education, marketing, supply chain, sales, public policy, patient services, market access and product reimbursement. Our commercialization activities include active engagements with stakeholders across the healthcare system, including those with public and private payers, patient advocates and organizations, professional societies, and healthcare providers, to explore new payment models that we hope will enable access for more patients. Ultimately, we intend to leverage our commercial infrastructure to support the potential for multiple product launches in the United States.
While we have largely established the appropriate quality systems, compliance policies, systems and procedures, as well as internal systems and infrastructure necessary for supporting our complex supply chain and commercialization activities, we expect that we may make additional targeted investments as we continue our efforts to build our network of qualified treatment centers, establishing patient-focused programs, educating healthcare professionals, and securing reimbursement.
The timing and conduct of our commercialization activities will be dependent upon regulatory interactions, marketing approvals if and when received for our therapies, and on agreements we have made or may make in the future with strategic collaborators.
Pipeline activities and strategic collaborations
Our near-term research and development activities are focused on efforts to expand the potential impact of our existing ex vivo programs through reduced toxicity conditioning and HSC mobilization regimens, as well as manufacturing process improvements. Our long-term investments in research and development are focused on potential in vivo applications of LVV technology. We seek to build our pipeline by investing in our in vivo LVV platform as well as by advancing our direct injection preclinical candidates.
Currently, our strategic collaborations include those with:
•Magenta Therapeutics, Inc., to evaluate the utility of MGTA-145 in combination with plerixafor for mobilization and collection of stem cells in adults and adolescents with SCD, through a proof-of-concept clinical trial; and
•Forty Seven, Inc., a subsidiary of Gilead Sciences, Inc., to pursue clinical proof-of-concept for an antibody-based conditioning regimen in combination with our ex vivo lentiviral gene therapy platform.
Intellectual property
We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business. We additionally rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity, and patent term extensions where available.
Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products
7
may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.
We have developed or in-licensed numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of gene therapy products. Our proprietary intellectual property, including patent and non-patent intellectual property, is generally directed to, for example, certain genes, transgenes, methods of transferring genetic material into cells, genetically modified cells, processes to manufacture our lentivirus-based product candidates and other proprietary technologies and processes related to our lead product development candidates. In connection with the wind down of our operations in Europe, we have decided to let the non-U.S. patents and patent applications that we own lapse by ceasing further prosecution of our pending ex-U.S. patent applications and not paying future maintenance fees for ex-U.S. patents when due. As of January 25, 2022, our patent portfolio includes the following:
•approximately 144 patents or patent applications that we own or have exclusively in-licensed from third parties, including 13 that are co-owned with MIT, related to LVVs and vector systems;
•approximately 40 patents or patent applications that we have non-exclusively in-licensed from third parties related to LVVs and vector systems;
•approximately 154 patents or patent applications that we own or have exclusively in-licensed from third parties related to LVV or drug product manufacturing and associated assays;
•approximately 7 patents or patent applications that we have non-exclusively in-licensed from third parties related to LVV or drug product manufacturing and associated assays; and
•approximately 27 patents or patent applications that we own or have exclusively in-licensed from third parties related to therapeutic cellular product candidates and assays.
Our objective is to continue to expand our U.S. portfolio of patents and patent applications in order to protect our gene therapy product candidates manufacturing processes. Examples of the products and technology areas covered by our intellectual property portfolio are described below. See also “—License agreements.” From time to time, we also evaluate opportunities to sublicense our portfolio of patents and patent applications that we own or exclusively license, and we may enter into such licenses from time to time.
Beti-cel and lovo-cel
The beti-cel and lovo-cel programs include the following patent portfolios described below.
•Pasteur Institute. The Pasteur patent portfolio contains patent applications directed to FLAP/cPPT elements and LVV utilized to produce beti-cel and lovo-cel. As of January 25, 2022, we had an exclusive license to two issued U.S. patents. We expect the issued composition of matter patents to expire in 2022 and 2023 in the United States (excluding possible patent term extensions).
•RDF. The in-licensed patent portfolio from Research Development Foundation ("RDF") in part, contains patents and patent applications directed to aspects of our LVV that may be utilized to produce beti-cel and lovo-cel. As of January 25, 2022, we had an exclusive license (from RDF) to seven issued U.S. patents and two pending U.S. patent applications related to our LVV platform. Corresponding foreign patents and patent applications related to our LVV platform include issued patents in Canada, Europe, and Israel. We expect the issued composition of matter patents to expire from 2022-2027 in the United States, and in 2022 in the rest of the world (excluding possible patent term extensions). Further, we expect composition of matter patents, if issued from the pending patent applications and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire in 2022 (excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio other than composition of matter patents, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2022 (worldwide, excluding possible patent term extensions).
•MIT/bluebird bio. This co-owned patent portfolio contains patents and patent applications directed to certain specific compositions of matter for lentiviral β-globin expression vectors. As of January 25, 2022, we co-owned four issued U.S. patents and one pending U.S. patent application, as well as corresponding foreign patents issued in Europe and Hong Kong. We expect the issued composition of matter patents to expire in 2023 (excluding possible patent term extensions). Further, we expect composition of matter patents, if issued from the pending patent applications and if the
8
appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire in 2023 (excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2023 (worldwide, excluding possible patent term extensions). We note that we have an exclusive license to MIT’s interest in this co-owned intellectual property.
•Children’s Medical Center Corporation ("CMCC")/bluebird bio. This co-owned patent portfolio contains patent applications directed to certain specific compositions of matter for treating β-thalassemia and SCD. As of January 25, 2022, we co-owned one pending U.S. patent application, as well as nine corresponding foreign patent applications. We expect any composition of matter or methods patents, if issued from the pending patent application, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire in 2038 (worldwide, excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2038 (worldwide, excluding possible patent term extensions). We note that we have an option to exclusively license CMCC’s interest in this co-owned intellectual property.
Our β-thalassemia and SCD research programs also include in-licensed patents and patent applications that are directed to certain specific compositions of matter and methods for treating β-thalassemia/SCD. As of January 25, 2022, we had an exclusive license to three issued U.S. patents and one pending U.S. patent application as well as 29 corresponding foreign patents and 12 pending corresponding foreign applications. We expect the issued composition of matter patents to expire in 2035 in the United States and in the rest of the world (excluding possible patent term extensions). Further, we expect any composition of matter or method patents, if issued from the pending patent applications, if applicable, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire in 2035 (worldwide, excluding possible patent term extensions). We expect any other patents in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire from 2035 (worldwide, excluding possible patent term extensions). In addition, as of January 25, 2022, we had a non-exclusive license to five issued U.S. patents, three pending corresponding foreign patent applications and 32 issued foreign patents. We expect the issued composition of matter and method patents to expire in 2029 in the United States and in the rest of the world (excluding possible patent term extensions).
Eli-cel
The eli-cel program includes the following patent portfolios described below.
•Pasteur Institute. The in-licensed Pasteur patent portfolio contains the patents and patent applications described above directed towards aspects of LVV utilized to produce eli-cel.
•RDF. The in-licensed RDF patent portfolio contains the patents and patent applications described above directed towards aspects of LVV that may be utilized to produce eli-cel.
•bluebird bio. The bluebird bio patent portfolio contains patents and patent applications directed to compositions of matter for eli-cel vectors and compositions and methods of using the vectors and compositions in cell-based gene therapy of adrenoleukodystrophy or adrenomyeloneuropathy. As of January 25, 2022, we owned three U.S. patents and 26 issued foreign patents. We expect the issued composition of matter patents for eli-cel vectors to expire in 2032 (excluding possible patent term extensions).
Lentiviral platform (e.g., LVV, manufacturing, and cell therapy products)
The lentiviral platform, which is potentially applicable across our programs in severe genetic disease, includes the following patent portfolios described below.
•Pasteur Institute. The Pasteur patent portfolio contains the patents and patent applications described above.
•RDF. The in-licensed RDF patent portfolio contains the patents and patent applications described above.
•SIRION. The in-licensed patent portfolio from SIRION Biotech GmbH ("SIRION") contains patents and patent applications directed to methods of manufacturing ex vivo gene therapy products with LVV. As of January 25, 2022, we had an exclusive license to two issued U.S. patents, one pending U.S. patent application and two corresponding foreign patent applications and 45 issued corresponding foreign patents. We expect the issued method patents to expire in 2033 (excluding possible patent term extensions). We expect any other composition of matter and methods patents, if issued from the pending patent applications and if the appropriate maintenance, renewal, annuity or other
9
governmental fees are paid, to expire in 2033 (excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2033 (worldwide, excluding possible patent term extensions).
•bluebird bio. Another component of the bluebird bio patent portfolio includes LVV and drug product manufacturing platforms and is potentially applicable across our programs. This portion of the portfolio contains patents and patent applications directed to improved methods for transfection and transduction of therapeutic cells. As of January 25, 2022, we owned three issued U.S. patents, three pending U.S. patent applications and 30 corresponding foreign patent applications and 61 issued corresponding foreign patents. We expect the issued method patents to expire from 2032-2037 (excluding possible patent term extensions). We expect composition of matter and method patents, if issued from the pending patent applications and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire from 2032-2037 (excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire from 2032-2037 (worldwide, excluding possible patent term extensions).
•2seventy bio. The 2seventy bio patent portfolios include LVV manufacturing platforms and improvements and are potentially applicable across our programs. As of January 25, 2022, we had a non-exclusive license to three patent families that include one pending U.S. patent application and four corresponding foreign patent applications, one pending PCT application, and one U.S. provisional patent application. We expect any composition of matter or methods patents, if issued from a corresponding nonprovisional application or national stage application, or corresponding foreign applications, if applicable, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, to expire from 2040-2042 (worldwide, excluding possible patent term extensions). We expect any other patents and patent applications in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire from 2040-2042 (worldwide, excluding possible patent term extensions).
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing the non-provisional application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent.
The term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration of a U.S. patent as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, depending upon the length of clinical trials and other factors involved in the filing of a BLA, we expect to apply for patent term extensions for patents covering our product candidates and their methods of use.
We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and third parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
License agreements
Inserm-Transfert
In May 2009, we entered into an exclusive license with Inserm-Transfert, which is a wholly-owned subsidiary of Institut national de la santé et de la recherche médicale, for use of certain patents and know-how related to the ABCD1 gene and
10
corresponding protein, for use in the field of human ALD therapy. Inserm-Transfert is referred to herein as Inserm. The last patent in the Inserm licensed patent portfolio expired in February of 2016.
Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include eli-cel, we will be obligated to pay Inserm a percentage of net sales as a royalty for the longer of the life of any patents covering the product or 10 years from first commercial sale. This royalty is in the low single digits. The royalties payable to Inserm are subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits.
We are required to use all commercially reasonable efforts to develop licensed products and introduce them into the commercial market as soon as practical, consistent with our reasonable business practices and judgment in compliance with an agreed upon development plan. We have assumed certain development, regulatory and commercial milestone obligations and must report on our progress in achieving these milestones on an annual basis.
We may unilaterally terminate the license agreement at any time. Either party may terminate the agreement in the event of the other party’s material breach which remains uncured after 60 days of receiving written notice of such breach or in the event the other party becomes the subject of a voluntary or involuntary petition in bankruptcy and such petition is not dismissed with prejudice within 120 days after filing. In addition, Inserm may terminate the license agreement in the event that we cannot prove within 60 days of written notice from Inserm that we have been diligent in developing the licensed products and introducing them into the commercial market.
Absent early termination, the agreement will automatically terminate upon the expiration of all issued patents and filed patent applications within the patent rights covered by the agreement or 10 years from the date of first commercial sale of a licensed product, whichever is later. The license grant ceases in connection with any such termination. The longest-lived patent rights licensed to us under the agreement expired in 2016.
Institut Pasteur
We have entered into a license with Institut Pasteur for certain patents relating to the use of DNA sequences, LVV and recombinant cells in the field of ex vivo gene therapy and CAR T cell-based therapy in a range of indications, excluding vaccinations. This agreement was amended twice in 2012, again in 2013 and most recently in 2015. The Institut Pasteur licensed patent portfolio includes two U.S. patents. The issued patents have statutory expiration dates in 2022 and 2023. The license is exclusive for products containing human and non-human LVV. Institut Pasteur retains the right, on behalf of itself, its licensees and research partners, to conduct research using the licensed intellectual property.
We have the right to grant sublicenses outright to third parties under the agreement. For the first sublicense including a product targeting β-hemoglobinopathies (including β-thalassemia and SCD) or ALD (including CALD and adrenomyeloneuropathy), we must pay Institut Pasteur an additional payment of €3.0 million. If we receive any income (cash or non-cash) in connection with sublicenses for products targeting indications other than β-hemoglobinopathies (including β-thalassemia and SCD) or ALD (including CALD and adrenomyeloneuropathy), we must pay Institut Pasteur a percentage of such income varying from low single digits if the sublicense also includes licenses to intellectual property controlled by us, and a percentage of sublicense income in the mid-range double digits if the sublicense does not include licenses to intellectual property controlled by us.
Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include beti-cel, lovo-cel, and eli-cel, we will be obligated to pay Institut Pasteur a percentage of net sales as a royalty. This royalty varies depending on the indication of the product but in any event is in the low single digits. In addition, starting in 2016 we must make under this agreement an annual maintenance payment which is creditable against royalty payments on a year-by-year basis. If the combined royalties we would be required to pay to Institut Pasteur and third parties is higher than a pre-specified percentage, we may ask Institut Pasteur to re-negotiate our royalty rates under this relationship.
We are required to use all reasonable commercial efforts (as compared to a company of similar size and scope) to develop and commercialize one or more products in the license field and to obtain any necessary governmental approvals in respect of, and market the products in license field, if any. Additionally, we have assumed certain development and regulatory milestone obligations. We must report on our progress towards achieving these milestones on an annual basis. We may unilaterally terminate the license agreement at any time by sending Institut Pasteur 90 days prior written notice. Either party may terminate the license in the event of the other party’s substantial breach which remains uncured after 60 days of receiving written notice of such breach. Institut Pasteur may also terminate the agreement in the event bankruptcy proceedings are opened against us and not dismissed within 60 days.
11
Absent early termination, the agreement will automatically terminate upon the expiration of the last licensed patents or five years after first market authorization of the first product, whichever occurs later. In the event the agreement is terminated, while the license grant would cease, we would retain the right to manufacture, import, use and sell licensed products for a certain period of time post-termination. In addition, our ownership stake in certain jointly made improvements covered by the licensed patents would survive termination of the agreement. The longest-lived patent rights licensed to us under the agreement are currently expected to expire in 2023.
Stanford University
In July 2002, we entered into a non-exclusive license agreement with the Board of Trustees of the Leland Stanford Junior University, referred to herein as Stanford, which we amended and restated in April 2012. Under this agreement, we are granted a license to use the HEK293T cell line for any commercial or non-commercial use for research, nonclinical and clinical development purpose and human and animal gene therapy products.
We have the right to grant sublicenses outright to third parties under the agreement. For each such sublicense we grant, we must pay Stanford a fee (unless the sublicense is to a collaborating partner, contract manufacturer or contract research organization).
Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include beti-cel, lovo-cel, and eli-cel, we will be obligated to pay Stanford a percentage of net sales as a royalty. This royalty varies with net sales but in any event is in the low single digits and is reduced for each third-party license that requires payments by us with respect to a licensed product, provided that the royalty to Stanford is not less than a specified percentage which is less than one percent. Since April 2013, we have been paying Stanford an annual maintenance fee, which will be creditable against our royalty payments.
We may unilaterally terminate the agreement by giving Stanford 30 days’ written notice. Stanford may also terminate the license agreement if after 30 days of providing notice we are delinquent on any report or payment, are not using commercially reasonable efforts to develop, manufacture and/or commercialize one or more licensed products, are in material breach of any provision or provide any false report. Termination of this agreement may require us to utilize different cell types for vector manufacturing, which could lead to delays.
Absent early termination, the license will expire in April 2037. We may elect to extend the term for an additional 25 years so long as we have a commercial product on the market at that time and we are in material compliance with the license agreement.
Massachusetts Institute of Technology
In December 1996, we entered into an exclusive license with the Massachusetts Institute of Technology, referred to herein as MIT, for use of certain patents in any field. This license agreement was amended in December 2003, May 2004 and June 2011. The licensed patent portfolio includes at least 13 U.S. and foreign patents and patent applications. Any patents within this portfolio that have issued or may yet issue would have a statutory expiration date from in 2023. This license also has been amended to include a case jointly owned by MIT and us wherein we received the exclusive license to MIT’s rights in this case. MIT retains the right to practice the intellectual property licensed under the agreement for noncommercial research purposes.
We have the right to grant sublicenses outright to third parties under the agreement. In the event we sublicense the patent rights, we must pay MIT a percentage of all payments we receive from the sublicensee. This percentage varies from mid-single digits to low double digits.
Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include beti-cel and lovo-cel, we will be obligated to pay MIT a percentage of net sales by us or our sublicensees as a royalty. This royalty is in the low single digits and is reduced for royalties payable to third parties, provided that the royalty to MIT is not less than a specified percentage that is less than one-percent. In addition, we make under this agreement an annual maintenance payment which may be credited against the royalty payments.
We are required to use diligent efforts to market licensed products and to continue active, diligent development and marketing efforts for licensed products during the term of the agreement. We have assumed certain milestones with respect to raising capital investment and regulatory progress. We must report on our progress on achieving these milestones on an annual basis.
12
We may unilaterally terminate the license agreement upon six months’ notice to MIT. MIT may terminate the agreement if we cease to carry on our business, or in the event of our material breach which remains uncured after 90 days of receiving written notice of such breach (30 days in the case of nonpayment). In the event the agreement is terminated, while the license grant would cease, we would retain a right to complete manufacture of any licensed products in process and sell then-existing inventory. In addition, MIT would grant our sublicensees a direct license following such termination. With respect to jointly owned intellectual property, any termination would allow MIT to grant licenses to any third-party to such intellectual property, without our approval, unless a sublicensee was already in place, in which case, MIT would grant our sublicensees a direct license.
Research Development Foundation
In December 2011, we entered into an exclusive license with RDF to use certain patents that involve LVV. The RDF licensed patent portfolio includes at least 31 U.S. and foreign patents and patent applications. Any patents within this portfolio that have issued or may yet issue would have an expected statutory expiration date between 2021 and 2027. RDF retains the right, on behalf of itself and other nonprofit academic research institutions, to practice and use the licensed patents for any academic, non-clinical research and educational purposes. We have the right to grant sublicenses outright to third parties under the agreement.
Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include beti-cel, lovo-cel, and eli-cel, we are obligated to pay RDF a percentage of net sales as a royalty. This royalty is in the low single digits and is reduced by half if during the following ten years from the first marketing approval the last valid claim within the licensed patent that covers the licensed product expires or ends.
We are required to use commercially reasonable and diligent efforts for a company of our size and resources to develop or commercialize one or more licensed products, including our first licensed product by 2016 and a second licensed product by 2018. These diligence efforts include minimum annual royalty payments to RDF, which are creditable against earned royalties otherwise due to RDF, and payments upon regulatory milestones.
RDF may terminate the agreement in the event of our material breach which remains uncured after 90 days of receiving written notice of such breach (30 days in the case of nonpayment) or in the event we become bankrupt, our business or assets or property are placed in the hands of a receiver, assignee or trustee, we institute or suffer to be instituted any procedure in bankruptcy court for reorganization or rearrangement of our financial affairs, make a general assignment for the benefit of creditors, or if we or an affiliate or a sublicensee institutes any procedure challenging the validity or patentability of any patent or patent application within the licensed patents, the agreement will immediately terminate.
Absent early termination, the agreement will continue until its expiration upon the later of there being no more valid claims within the licensed patents or the expiration of our royalty obligations on licensed products that are subject to an earned royalty, if such earned royalty is based on the minimum 10-year royalty period described above. In the event the agreement is terminated, while the license grant would cease, RDF will grant our sublicensees a direct license. The longest lived patent rights licensed to us under the agreement are in one U.S. patent currently expected to expire in 2027.
SIRION
In December 2015, we entered into a license agreement with SIRION, pursuant to which we exclusively licensed certain patents and patent applications directed towards aspects of manufacturing gene therapy products. Any patents within this portfolio that have issued or may yet issue would have an expected statutory expiration date in 2033. We have the right to grant sublicenses to third parties, subject to certain conditions. Upon commercialization of our products covered by the in-licensed intellectual property, which we expect would include beti-cel and lovo-cel, we will be obligated to pay SIRION a percentage of net sales as a royalty in the low single digits. We are required to use commercially reasonable efforts to research and develop one or more licensed products in the license field during the term of the agreement, and we must report on our progress in achieving those milestones on a periodic basis. We may be obligated to pay up to $13.4 million in the aggregate upon the achievement of certain development and regulatory milestones. We may unilaterally terminate the license agreement at any time with prior written notice to SIRION. SIRION may terminate the license in the event of our material breach upon notice and following an opportunity for us to cure the material breach. SIRION may also terminate the agreement in the event bankruptcy proceedings are opened against us and are not dismissed within a specified period of time. Absent early termination, the agreement will automatically terminate upon the expiration of the patent rights covered by the agreement. The longest lived patent rights licensed to us under the Agreement are currently expected to expire in 2033.
13
Orchard Therapeutics Limited
In April 2017, we entered into a license agreement with GlaxoSmithKline Intellectual Property Development Limited ("GSK") pursuant to which GSK non-exclusively licensed certain of our patent rights related to LVV technology to develop and commercialize gene therapies for Wiscott-Aldrich syndrome and metachromatic leukodystrophy, two rare genetic diseases. Effective April 2018, this license agreement was assigned by GSK to Orchard Therapeutics Limited ("Orchard"). Financial terms of the agreement included an upfront payment to us as well as potential development and regulatory milestone payments and low single digit royalties on net sales of covered products.
Competition
The biotechnology and pharmaceutical industries are characterized by intense and rapidly changing competition to develop new technologies and proprietary products. Not only must we compete with other companies that are focused on gene therapy products but any products that we may commercialize will have to compete with existing therapies and new therapies that may become available in the future. Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of therapies and the commercialization of those therapies. Accordingly, our competitors may be more successful than us in obtaining approval for therapies and achieving widespread market acceptance. Our competitors’ therapies may be more effective, or more effectively marketed and sold, than any therapy we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our therapies.
These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
We anticipate that we will face intense and increasing competition as new therapies enter the market and advanced technologies become available. We expect any therapies that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize therapies that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any therapies that we may develop. Our competitors also may obtain FDA or other regulatory approval for their therapies more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products. If our therapeutic product candidates are approved, we expect that they will be priced at a significant premium over current standard of care. Depending on how successful these competitive efforts are, it is possible they may increase the barriers to adoption and success for our therapies. These efforts include the following:
Sickle cell disease — The current standard of care for the treatment of SCD in the developed world is chronic blood transfusions or hydroxyurea (a generic drug). In addition, patients treated with chronic blood transfusions often receive iron chelation therapy to help manage the iron overload. We are aware of ongoing studies that continue to evaluate the efficacy and safety of hydroxyurea in various populations. In addition, a limited number of patients with SCD receive allogeneic HSCT treatment, particularly if a sufficiently well-matched source of donor cells is identified. There are a number of academic and industry-sponsored research and development programs to improve the tolerability and safety of allogeneic HSCT with less well-matched sources of donor cells, while increasing the availability of suitable donors. Emmaus Life Sciences, Inc. received FDA approval for and has launched Endari (L-glutamine) for the treatment of SCD. In addition to the FDA approved HbS polymerization inhibitor (voxelotor, Global Blood Therapeutics, Inc.) and the FDA / EMA approved antibody to p-selectin (crizanlizumab, Novartis), a number of different therapeutic approaches for the chronic treatment of SCD are under investigation targeting the various aspects of SCD pathophysiology, including: a pyruvate kinase receptor activator, mitapivat, being developed by Agios Pharmaceuticals, Inc. and being evaluated by the FDA with a New Drug Application under priority review; another pyruvate kinase receptor activator, FT-4202, in a Phase 1 study supported by Forma Therapeutics; a PDE9 inhibitor, IMR-687, in a Phase 2 study supported by IMARA Inc.; and a selective small molecule inhibitor of ectoderm development protein designed to increase the expression of fetal hemoglobin, FTX-6058, in a phase 1 study supported by Fulcrum Therapeutics, Inc. There are also several different groups developing gene therapy options for sickle cell disease. These include: CRISPR Therapeutics AG’s (in collaboration with Vertex Pharmaceuticals Incorporated) ongoing Phase 1/2 study for its CTX-001, which leverages the CRISPR/Cas9 gene editing platform to disrupt the BCL11A erythroid enhancer,
14
Aruvant Sciences, Inc.’s ongoing Phase 1/2 study for its ARU-1801, which leverages LVV encoding γ-globin, Editas Medicine, Inc.’s ongoing Phase 1/2 study for its EDIT-301, which leverages the CRISPR/Cas12a gene editing platform to target the HBG1/2 promoter to upregulate HbF, and Graphite Bio’s ongoing Phase 1/2 study for its GPH101, which leverages a gene correction platform (CRISPR / homology directed repair) to restore normal hemoglobin production. There are several other groups developing gene therapy approaches for SCD in early phases of development, including Beam Therapeutics, Sangamo BioSciences Inc., Intellia Therapeutics, Inc. (in collaboration with Novartis), and Children’s Hospital of Philadelphia.
β-thalassemia — The current standard of care for the treatment of β-thalassemia in the developed world is chronic blood transfusions to address the patient’s anemia. In addition, such patients often receive iron chelation therapy to help manage the iron overload associated with their chronic blood transfusions. Novartis and Chiesi, who provide the leading iron chelation therapies, are seeking to develop improvements to their product profile and accessibility. A number of different approaches are under investigation that seek to improve the current standard of care treatment options, including a protein that aims to improve red blood cell production and small molecule that aims to improve red blood cell metabolism. Reblozyl (luspatercept), a subcutaneously-delivered protein therapeutic marketed by Acceleron Pharma, Inc. (recently acquired by Merck) and BMS that targets molecules in the TGF-β superfamily, has been approved in the United States for the treatment of anemia in adult patients with beta thalassemia who require regular RBC transfusions, and was recently approved in the EU for the treatment of adult patients with transfusion-dependent anemia associated with β-thalassemia. Additionally, Agios has announced that an application for Mitapivat, an oral pyruvate kinase receptor activator, has been accepted for filing and granted priority review by the FDA. Some patients with β-thalassemia receive HSCT treatment, particularly if a sufficiently well-matched source of donor cells is identified. In addition, there are a number of academic and industry-sponsored research and development programs to improve the outcomes of allogeneic HSCT, or the tolerability and safety of haploidentical HSCT, while increasing the availability of suitable donors. There are also several different groups developing gene therapy options for β-thalassemia. These include: CRISPR Therapeutics AG (in collaboration with Vertex Pharmaceuticals Incorporated) is conducting an ongoing Phase 1/2 study for its CTX-001, which leverages the CRISPR/Cas9 gene editing platform to disrupt the BCL11A erythroid enhancer; and the San Raffaele Telethon Institute for Gene Therapy (in collaboration with Orchard Therapeutics) is currently investigating its gene therapy in a Phase 2 study of adults and pediatric patients with transfusion dependent β-thalassemia, although Orchard Therapeutics has announced that this program has been deprioritized as of May 2020.
CALD — The current standard of care for the treatment of CALD is allogeneic HSCT. We understand that various academic centers around the world are seeking to develop improvements to allogeneic HSCT, such as Magenta Therapeutic, Inc.’s cord blood expansion technology which is currently being investigated in a Phase 2 clinical trial for the treatment of inherited metabolic disorders, including adrenoleukodystrophy. Other possible treatments being investigated include Orpheris, Inc.’s OP-101, Minoryx Therapeutics’ MIN-102 (leriglitazone), and Viking Therapeutics’ VK0214.
Government regulation
In the United States, biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act ("FD&C Act") and the Public Health Service Act ("PHS Act") and other federal, state, local and foreign statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, purity, potency, labeling, packaging, storage, record keeping, distribution, import, export, reporting, record keeping, post-approval monitoring, advertising and other promotional practices involving biological products. FDA approval must be obtained before marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.
U.S. biological products development process
The process required by the FDA before a biological product may be marketed in the United States generally involves the following:
•completion of nonclinical laboratory tests and animal studies according to good laboratory practices ("GLPs"), and other applicable regulations;
•submission to the FDA of an investigational new drug application ("IND"), which must become effective before human clinical studies may begin;
•approval by an institutional review board ("IRB"), or ethics committee at each clinical site before the trial commences;
15
•performance of adequate and well-controlled human clinical studies according to the FDA’s regulations commonly referred to as good clinical practices ("GCPs") and any additional requirements for the protection of human research subjects and their health information, to establish the safety, purity and potency or efficacy of the proposed biological product for its intended use;
•preparation and submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical studies;
•satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with GMP, to assure that the facilities, methods and controls are adequate to preserve the biological product’s identity, strength, quality and purity and, if applicable, the FDA’s good tissue practices ("GTPs") for the human cellular and tissue products;
•potential FDA audit of the nonclinical and clinical study sites that generated the data in support of the BLA; and
•FDA review and approval, or licensure, of the BLA.
Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs, where applicable.
The clinical study sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical studies due to safety concerns or non-compliance. If the FDA imposes a clinical hold, studies may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies.
In addition to the IND submission process, under the National Institutes of Health (“NIH”), Guidelines for Research Involving Recombinant DNA Molecules (“NIH Guidelines”), supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (“IBC”), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.
Clinical studies involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor’s control. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical studies must be conducted and monitored in accordance with the FDA’s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical study must be reviewed and approved by an IRB at or servicing each institution at which the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical study subject or his or her legal representative and must monitor the clinical study until completed.
Human clinical studies are typically conducted in three sequential phases that may overlap or be combined:
•Phase 1. The biological product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.
16
•Phase 2. The biological product is evaluated in a limited patient population with the specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.
•Phase 3. The biological product is administered to an expanded patient population to further evaluate dosage,to provide statistically significant evidence of clinical efficacy, and to further test for safety, generally at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.
Post-approval clinical studies, sometimes referred to as phase 4 clinical studies, may be conducted after initial marketing approval. These clinical studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. For example, the FDA recommends that sponsors of certain gene therapy clinical trials observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by questionnaire, of study subjects.
During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Annual progress reports detailing the results of the clinical studies must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor’s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB’s requirements or if the biological product candidate has been associated with unexpected serious harm to patients.
Concurrent with clinical studies, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.
U.S. review and approval processes
After the completion of clinical studies of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act ("PREA") as amended, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.
Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use,
17
and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP to assure and preserve the product’s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy ("REMS") is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.
Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products ("HCT/Ps") which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical studies were conducted in compliance with IND study requirements and GCP requirements. To assure GMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.
Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical studies are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, withdraw the application, or request a hearing.
If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical studies, sometimes referred to as phase 4 clinical studies, designed to further assess a biological product’s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.
One of the performance goals agreed to by the FDA under the PDUFA is to review 90% of standard BLAs in 10 months and 90% of priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months, such as in the case of our BLAs for beti-cel and eli-cel upon FDA request, or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.
Orphan drug designation
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA or BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
18
If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor’s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity.
Expedited development and review programs
The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.
Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Under the Breakthrough Therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for the benefits of the Fast Track program when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.
Regenerative medicine advanced therapies designation
As part of the 21st Century Cures Act, Congress amended the FD&C Act to facilitate an efficient development program for, and expedite review of regenerative medicine advanced therapies, which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Regenerative medicine advanced therapies do not include those human cells, tissues, and cellular and tissue based products regulated solely under section 361 of the Public Health Service Act and 21 CFR Part 1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation. A drug sponsor may request that FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit,
19
or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.
Post-approval requirements
Maintaining compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any future products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products, include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer’s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.
Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. In addition, companies that manufacture or distribute drug or biological products or that hold approved BLAs must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, and maintaining certain records. Newly discovered or developed safety or effectiveness data may require changes to a drug’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, including a REMS or the conduct of post-marketing studies to assess a newly-discovered safety issue.
We also must comply with the FDA’s advertising and promotion requirements, such as those related to direct-to-consumer advertising and advertising to healthcare professionals, the prohibition on promoting products for uses or in patient populations that are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. Consequences could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with healthcare professionals, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.
U.S. patent term restoration and marketing exclusivity
Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration
20
Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant BLA.
A biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.
The Patient Protection and Affordable Care Act (the "Affordable Care Act") signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA.
A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant’s favor of a lawsuit challenging the biologics’ patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period.
Healthcare and Privacy Laws
In addition to restrictions on marketing of pharmaceutical products, several other types of state/ federal laws and trade association membership codes of conduct have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include Anti-Kickback and false claims statutes. The U.S. federal healthcare program Anti-Kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain discounts, or engaging healthcare professionals or patients as speakers or consultants, may be subject to scrutiny if they do not fit squarely within the exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or patient assistance programs.
The U.S. federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or
21
knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payers if they are deemed to “cause” the submission of false or fraudulent claims. The False Claims Act also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In recent years, several pharmaceutical and other healthcare companies have faced enforcement actions under the federal False Claims Act for, among other things, allegedly submitting false or misleading pricing information to government health care programs and providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have faced enforcement actions for causing false claims to be submitted because of the company’s marketing the product for unapproved, and thus non-reimbursable, uses. Federal enforcement agencies also have shown increased interest in pharmaceutical companies’ product and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. In addition, the Affordable Care Act amended federal law to provide that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Criminal prosecution is possible for making or presenting a false or fictitious or fraudulent claim to the federal government.
The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") also created several new federal crimes, including healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
The U.S. federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires certain manufacturers of drugs, devices, biologics and medical supplies to engage in extensive tracking of payments and other transfers of value to prescribers and teaching hospitals, including physician ownership and investment interests, and public reporting of such data. Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. Pharmaceutical and biological manufacturers with products for which payment is available under Medicare, Medicaid or the State Children’s Health Insurance Program are required to track such payments, and must submit a report on or before the 90th day of each calendar year disclosing reportable payments made in the previous calendar year. A number of other countries, states and municipalities have also implemented additional payment tracking and reporting requirements, which if not done correctly may result in additional penalties.
In addition, the U.S. Foreign Corrupt Practices Act ("FCPA") prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity. In many other countries, healthcare professionals who prescribe pharmaceuticals are employed by government entities, and the purchasers of pharmaceuticals are government entities. Our dealings with these prescribers and purchasers may be subject to the FCPA.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In California the California Consumer Protection Act (“CCPA”), which went into effect on January 1, 2020, establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. While clinical trial data and information governed by HIPAA are currently exempt from the current version of the CCPA, other personal information may be applicable and possible changes to the CCPA may broaden its scope.
22
The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers. In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other healthcare providers, marketing expenditures, and drug pricing information. Certain state and local laws require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Because of the breadth of these various healthcare and privacy laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have material adverse effects on our business, financial condition and results of operations. In the event governmental authorities conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare and privacy laws and regulations, they may impose sanctions under these laws, which are potentially significant and may include civil monetary penalties, damages, exclusion of an entity or individual from participation in government healthcare programs, criminal fines and imprisonment, as well as the potential curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert the attention of our management from operating our business.
Pricing, Coverage and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payers, including governments. In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payers. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. Third-party payers can include government healthcare systems, managed care providers, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers may provide coverage, but place stringent limitations on such coverage, such as requiring alternative treatments to be tried first. These third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety, efficacy, and overall value. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to incurring the costs required to obtain FDA approvals. Our product candidates may not be considered medically reasonable or necessary or cost-effective. Even if a drug product is covered, a payer’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
Federal, state and local governments in the United States continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Future legislation could limit payments for pharmaceuticals such as the drug candidates that we are developing.
23
The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, the emphasis on managed care in the United States has increased and we expect will continue to exert downward pressure on pharmaceutical pricing. Coverage policies, third-party reimbursement rates and pharmaceutical pricing regulations may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
We have proposed novel payment models, including outcomes-based arrangements with payments over time, to assist with realizing the value and sharing the risk of a potential one-time treatment, such as for beti-cel. While we are engaged in discussions with potential payers, there is no assurance that these payment models will be widely adopted by payers. Even with these payment models, there may be substantial resistance to the cost of our products by payers and the public generally. These payment models may not be sufficient for payers to grant coverage, and if we are unable to obtain adequate coverage for our products, the adoption of our products and access for patients may be limited. In addition, to the extent reimbursement for our products is subject to outcomes-based arrangements, our future revenues from product sales will be more at risk. These factors could affect our ability to successfully commercialize our products and adversely impact our business, financial condition, results of operations and prospects.
COVID-19
Beginning in late 2019, the outbreak of a novel strain of coronavirus ("COVID-19") has evolved into a global pandemic. As a result, we continue to experience disruptions and increased risk in our operations and those of third parties upon whom we rely, which may materially and adversely affect our business. These include disruptions and risks related to the conduct of our clinical trials, manufacturing, and commercialization efforts, as policies at various clinical sites and federal, state, local and foreign laws, rules and regulations continue to evolve, including quarantines, travel restrictions, and direction of healthcare resources toward pandemic response efforts. We continue to evaluate the impact of the COVID-19 global pandemic on patients, healthcare providers and our employees, as well as our operations and the operations of our business partners and healthcare communities. In response to the COVID-19 pandemic, we have implemented policies at our location to mitigate the risk of exposure to COVID-19 by our personnel, including restrictions on the number of staff in any given research and development laboratory or manufacturing facility, a work-from-home policy applicable to the majority of our personnel, and a phased approach to bringing personnel back to our location over time. Further, we are working with our clinical study sites to understand the duration and scope of the impact on enrollment, develop protocols to help mitigate the impact of the COVID-19 pandemic, and other activities for our ongoing clinical studies. Refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations (Part II, Item 7 of this Form 10-K) for further discussion regarding the impact of COVID-19 on our fiscal year 2021 financial results.
The extent to which the COVID-19 pandemic impacts our business going forward will depend on numerous evolving factors we cannot reliably predict, including the duration and scope of the pandemic; governmental, business, and individuals' actions in response to the pandemic; and the impact on economic activity including the possibility of recession or financial market instability. Refer to Risk Factors (Part I, Item 1A of this Form 10-K) for a discussion of these factors and other risks.
Human capital
As of January 31, 2022, we had 518 full-time employees, 80 of whom have Ph.D., M.D. or Pharm.D. degrees. Of these full-time employees, 330 employees are engaged in research and development activities and 188 employees are engaged in commercial, finance, legal, business development, human resources, information technology, facilities and other general administrative functions. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. We consider our relations with our employees to be good.
Compensation and benefits programs
Our compensation programs are designed to align our employees' interests with the drivers of growth and stockholder returns by supporting the Company's achievement of its primary business goals. The Company's goal is to attract and retain employees whose talents, expertise, leadership, and contributions are expected to sustain growth and drive long-term stockholder value. Consequently, we provide employee wages that are competitive within our industry, and we engage a nationally-recognized outside compensation and benefits consulting firm to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry. We seek to align our employees' interests with those of stockholders by linking annual changes in compensation to overall Company performance, as well as each individual’s contribution to the results achieved. The emphasis on overall Company performance is intended to align the employee’s financial interests with the interests of stockholders. We are also committed to providing comprehensive
24
benefit options and it is our intention to offer benefits that will allow our employees and their families to live healthier and more secure lives. All employees are eligible for medical, dental, and vision insurance, paid and unpaid leaves, employee stock purchase plan, 401(k) plan, and group life and disability coverage.
Employee development and training
The development, recruitment and retention of our employees is a critical success factor for our company. To ensure we provide a meaningful experience for our employees, we regularly measure organizational culture and engagement, to build on the competencies that are important for our future success. We have a robust talent and succession planning process and have established programs to support the talent pipeline for critical roles throughout our organization, to help us identify, foster, and retain high performing employees. To empower our employees to realize their potential at bluebird, we provide a range of development programs, opportunities and resources they need to be successful, including leveraging formal leadership training and coaching to improve performance and retention, increase our organizational learning and support the promotion of our current employees.
Diversity
We are committed to taking action to help address racial injustice and inequality. With significant input from employees and leaders at bluebird, we have adopted corporate goals to increase diversity and representation across our employee population.
Corporate Information
We were incorporated in Delaware in April 1992 under the name Genetix Pharmaceuticals, Inc., and subsequently changed our name to bluebird bio, Inc. in September 2010. In November 2021, we completed a tax-free spin-off of our oncology programs and portfolio, including idecabtagene vicleucel, a CAR-T cell therapy for the treatment of relapsed and refractory multiple myeloma marketed as ABECMA pursuant to a co-promotion and co-development agreement with Bristol-Myers Squibb Company, into a separate independent publicly traded company, 2seventy bio, Inc., or 2seventy. Our mailing address and executive offices are located at 60 Binney Street, Cambridge, Massachusetts and our telephone number at that address is (339) 499-9300. Following our move to our new corporate headquarters expected in the second quarter of 2022, our mailing address and executive offices will be 455 Grand Union Boulevard, Somerville, Massachusetts, and our telephone number at that address will be (339) 499-9300. We maintain an Internet website at the following address: www.bluebirdbio.com. The information on our website is not incorporated by reference in this annual report on Form 10-K or in any other filings we make with the Securities and Exchange Commission ("SEC").
We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.
Item 1A. Risk Factors
An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report on Form 10-K, including our financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.
We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
We have incurred net losses in each year since our inception in 1992, including net losses from continuing operations of $562.6 million for the year ended December 31, 2021. As of December 31, 2021, we had an accumulated deficit of $3.72 billion. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to generate revenues. We have devoted significant financial resources to research and development, including our clinical and
25
preclinical development activities, which we expect to continue for the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from governmental agencies and charitable foundations. We have not generated material revenues from the sale of beti-cel in the European Union, and we do not expect to generate meaningful product revenues in the foreseeable future until we obtain marketing approval for products in the United States and following any potential commercial launch. Following marketing approval, our future revenues will depend upon the size of any markets in which our potential products have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payers and adequate market share for our potential products in those markets.
We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
•continue our research and clinical development of our product candidates;
•establish capabilities to support our commercialization efforts, including establishing a sales, marketing and distribution infrastructure in the United States, and to commercialize products for which we may obtain marketing approval;
•obtain, build and expand manufacturing capacity, including capacity at third-party manufacturers;
•initiate additional research, preclinical, clinical or other programs as we seek to identify and validate additional product candidates;
•acquire or in-license other product candidates and technologies;
•maintain, protect and expand our intellectual property portfolio;
•attract and retain skilled personnel; and
•experience any delays or encounter issues with any of the above.
The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.
There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.
We are currently advancing our late-stage programs in severe genetic diseases through clinical development. Developing and commercializing gene therapy products is expensive, and we do not expect to generate meaningful product revenues in the foreseeable future until we obtain marketing approval for products in the United States and following any potential commercial launch.
As of December 31, 2021, our cash, cash equivalents and marketable securities were $396.6 million. As of completion of the separation, we had restricted cash, cash and cash equivalents, and marketable securities of approximately $507.2 million. Based on our current business plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the year ended December 31, 2021 are issued. Our fundraising efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our potential products following marketing approval if and when obtained. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
26
If we are unable to obtain funding on a timely basis, or if revenues from collaboration arrangements or product sales are less than we have projected, we may be required to further revise our business plan and strategy, which may result in us significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization of any product candidates or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition and results of operations could be materially affected.
Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.

We are highly dependent on our executive team and key employees, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and our turnover rate has been high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, our financial condition and recent delays in our late-stage programs have made it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives.
Insertional oncogenesis is a risk of gene therapies using viral vectors that can integrate into the genome, and several patients with CALD treated with eli-cel in our clinical studies have been diagnosed with MDS likely mediated by Lenti-D LVV insertion. These events may require us to halt or delay further clinical development of our product candidates, such as eli-cel, or to suspend or cease commercialization following marketing approval, and the commercial potential of our product candidates may be materially and negatively impacted.
A potentially significant risk in any gene therapy product using viral vectors that can integrate into the genome is that the vector will insert in or near cancer-causing genes, leading to the proliferation of certain cellular clones that can cause cancer in the patient, known as insertional oncogenesis. Several patients with CALD treated with eli-cel in our clinical studies have been diagnosed with MDS likely mediated by Lenti-D LVV insertion, and as a result, the FDA placed our clinical studies of eli-cel on clinical hold. On February 23, 2022, the FDA notified us that the clinical hold on the eli-cel program would remain in place, and requested additional information about safety events and monitoring in the eli-cel clinical program. We have no assurances as to whether we will successfully resolve the clinical hold. In addition, we cannot make assurances that additional patients treated with eli-cel, beti-cel or lovo-cel in the clinical or commercial setting will not exhibit clonal predominance in the future, or that additional patients will not be diagnosed with MDS, leukemia or lymphoma. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. The FDA has stated that LVV possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur, further advancement of our clinical studies could be halted or delayed, we may not receive marketing approval for our product candidates, and we may be unable to commercialize any approved product. It is possible that upon occurrence or recurrence of any of these events, the FDA may place one or more of our programs on hold, impose requirements that result in delays for regulatory approval for one or more of our programs, require risk evaluation or mitigation strategies as a condition for regulatory approval, or may cause us to cease commercialization following the receipt of any marketing approval. If any of these were to occur, the commercial potential of our programs may be materially and negatively impacted.
Furthermore, treatment with our potential products involve chemotherapy or myeloablative treatments which can cause side effects or adverse events that may impact the perception of the potential benefits of our potential products. For instance, MDS leading to acute myeloid leukemia is a known risk of certain myeloablative regimens. Additionally, beti-cel, eli-cel, or lovo-cel, the procedures associated with their administration, or with the collection of patients' cells, could potentially cause other adverse events that have not yet been predicted. The inclusion of patients with significant underlying medical problems in our clinical studies may result in deaths, or other adverse medical events, due to other therapies or medications that such patients may be using, or the progression of their disease. For instance, it is possible that the events of MDS and acute myeloid leukemia previously reported in our HGB-206 clinical study were caused by lovo-cel, in combination with underlying SCD, transplant procedure, and stress on the bone marrow following drug product infusion. Even if a product such as lovo-cel, eli-cel or beti-cel is ultimately approved, such safety events may result in the product being removed from the market or its market opportunity being significantly reduced. Other patients receiving our product candidates may develop leukemia, lymphoma, or MDS in the future, which may negatively impact the commercial prospects of our product candidates. Any of these events could impair our ability to develop or commercialize our product candidates, and their commercial potential may be materially and negatively impacted.
27
Risks related to commercialization
We have limited experience as a commercial company and the marketing and sale of beti-cel, eli-cel, and lovo-cel following marketing approval, if and when obtained, may be unsuccessful or less successful than anticipated.
We have limited experience as a commercial company. To-date, our experience as a commercial company has been limited to commercializing beti-cel in Europe. In August 2021, we announced that we are focusing our efforts in the near-term on the U.S. market and plan to execute an orderly wind down of our European operations. Consequently, there is limited information about our ability to overcome many of the risks and uncertainties encountered by companies commercializing products in the biopharmaceutical industry. To execute our business plan, we will need to successfully:
•gain regulatory approval to commercialize beti-cel, eli-cel, and lovo-cel in the United States;
•obtain adequate pricing and reimbursement for beti-cel, eli-cel, and lovo-cel across payers in the United States;
•establish and maintain, in the regions where we hope to treat patients, relationships with qualified treatment centers who will be treating the patients who receive beti-cel, eli-cel, and lovo-cel;
•manage our spending in the conduct of our clinical trials, seek marketing approvals, and engage in commercialization efforts, including for any extension of marketing approval of beti-cel, eli-cel, and lovo-cel; and
•initiate, develop and maintain successful strategic alliances.
If we are not successful in accomplishing these objectives, we may not be able to develop and commercialize beti-cel, eli-cel, or lovo-cel, raise capital, expand our business, or continue our operations.
The commercial success of beti-cel, eli-cel, and lovo-cel following marketing approval, if and when obtained, will depend upon the degree of market acceptance by physicians, patients, payers and others in the medical community.
The commercial success of beti-cel, eli-cel, and lovo-cel following marketing approval, if and when obtained, will depend in part on the medical community, patients, and third-party or governmental payers accepting gene therapy products in general, and beti-cel, eli-cel, and lovo-cel, in particular, as medically useful, cost-effective, and safe. Beti-cel, eli-cel, and lovo-cel that we may bring to the market may not gain market acceptance by physicians, patients, payers and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of beti-cel, eli-cel, and lovo-cel following marketing approval, if and when obtained, will depend on a number of factors, including:
•the potential efficacy and potential advantages over alternative treatments;
•the prevalence and severity of any side effects, including any limitations or warnings contained in a product’s approved labeling;
•the prevalence and severity of any side effects resulting from the chemotherapy and myeloablative treatments associated with the procedure by which our potential products are administered;
•relative convenience and ease of administration;
•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
•the strength of marketing and distribution support and timing of market introduction of competitive products;
•the pricing of our potential products;
•publicity concerning our potential products, or competing products and treatments; and
•sufficient insurance coverage or reimbursement.
Even if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and payers on the benefits of our potential products may require significant resources and may never be successful. For instance, following marketing approval of beti-cel in the European Union, we did not reach agreement with payers on an acceptable price for reimbursement in our priority markets in Europe, and we are no longer seeking to commercialize our product candidates in
28
Europe for the foreseeable future. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors. Any of these factors may cause beti-cel, eli-cel, or lovo-cel, to be unsuccessful or less successful than anticipated.
If the market opportunities for our potential products are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer.
We focus our research and product development on treatments for severe genetic diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our potential products, are based on estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower or more difficult to identify than expected. Additionally, the potentially addressable patient population for our potential products may be limited or may not be amenable to treatment with our potential products. For instance, in our lovo-cel and eli-cel programs, we have received notice of safety events of acute myeloid leukemia or myelodysplastic syndrome, and additional such events may be reported in the future. The market opportunity for our gene therapies may be negatively impacted even if our gene therapies ultimately receive marketing approval.
Even if we obtain significant market share for a product within an approved indication, because the potential target populations for our potential products are small, we may never achieve profitability without obtaining marketing approval for additional indications.
Any of these factors may negatively affect our ability to generate revenues from sales of our potential products and our ability to achieve and maintain profitability and, as a consequence, our business may suffer.
We rely on a complex supply chain for beti-cel, eli-cel, and lovo-cel. The manufacture and delivery of LVV and drug products present significant challenges for us, and we may not be able to produce our vector and drug products at the quality, quantities, locations or timing needed to support our clinical programs and commercialization following marketing approval if and when obtained. In addition, we may encounter challenges with engaging or coordinating with qualified treatment centers needed to support commercialization following marketing approval if and when obtained.
We rely on third parties to manufacture the LVV and the drug product for any clinical trials that we conduct, and we intend to rely on third parties for the supply of LVV and drug product for commercialization following any marketing approval, if and when obtained. We have not secured all of the commercial-scale manufacturing capacity that we anticipate requiring for the commercialization of our therapies to meet our forecasts beyond the potential launch, if they should receive marketing approval. If we fail to secure adequate capacity to manufacture our drug products or LVV used in the manufacture of our drug products in accordance with our forecasts beyond the potential launch of our therapies, we may be unable to execute on our development and commercialization plans on the timing that we expect, or at all.
The manufacture of LVV and drug products is complex and requires significant expertise. Even with the relevant experience and expertise, manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production, managing the transition from clinical manufacturing to manufacturing in the commercial setting, and ensuring that the product meets required specifications. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. We cannot make any assurances that these problems will not occur in the future, or that we will be able to resolve or address in a timely manner or with available funds problems that occur. Because of this complexity, transitioning production of either LVV or drug products to backup or second source manufacturing, or to internal manufacturing capacity, requires a lengthy technology transfer process and may require additional significant financial expenditures. Furthermore, our cost of goods development is at an early stage. The actual cost to manufacture our LVV and drug products could be greater than we expect and could materially and adversely affect the commercial viability of beti-cel, eli-cel, or lovo-cel. If we or such third-party manufacturers are unable to produce the necessary quantities of LVV and our drug products, or in compliance with GMP or other pertinent regulatory requirements, and within our planned time frame and cost parameters, the development and commercialization of our potential products may be materially harmed, result in delays in our plans or increased capital expenditures.
In addition, any significant disruption in our supplier relationships could harm our business. We source key materials from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There are a small number of suppliers for certain key materials that are used to manufacture beti-cel, eli-cel, and
29
lovo-cel. Such suppliers may not sell these key materials to us or to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these key materials by our manufacturers, and we currently do not have agreements for the commercial supply for all of these key materials.
Additionally, since the HSCs used as starting material for drug products have a limited window of stability following procurement from a patient, we must establish transduction facilities in the regions where we wish to commercialize beti-cel, eli-cel, and lovo-cel following marketing approval, if and when obtained. Establishment of such facilities may be financially impractical or impeded by technical, quality, or regulatory issues related to these new sites and we may also run into technical or scientific issues related to transfer of our transduction process or other developmental issues that we may be unable to resolve in a timely manner or with available funds. We have no assurance as to when drug product manufacturing using cryopreserved apheresis starting material will be available, if ever.
Our commercial strategy is to engage apheresis and transplant centers as qualified treatment centers for the collection of patient HSCs and infusion of the drug product once manufactured. To ensure that the qualified treatment centers are prepared to collect patient HSCs and to ship them to our transduction facilities in accordance with our specifications and regulatory requirements, we train and conduct quality assessments of each center as part of engagement. These qualified treatment centers are the first and last points on our complex supply chain to reach patients in the commercial setting. We may not be able to engage qualified treatment centers in all of the regions in our commercial launch strategy, or we may encounter other challenges or delays in engaging qualified treatment centers. We may fail to manage the logistics of collecting and shipping patient material to the manufacturing site and shipping the drug product back to the patient. Logistical and shipment delays and problems caused by us, our third-party vendors, and other factors not in our control, such as weather, could prevent or delay the manufacture of or delivery of drug product to patients. If our qualified treatment centers fail to perform satisfactorily, we may suffer reputational, operational, and business harm. We are required to maintain a complex chain of identity and chain of custody with respect to patient material as it moves through the manufacturing process, from the qualified treatment center to the transduction facility, and back to the patient. Failure to maintain chain of identity and chain of custody could result in adverse patient outcomes, loss of product or regulatory action.
We have limited sales and distribution experience and limited capabilities for marketing and market access. We expect to invest significant financial and management resources to establish these capabilities and infrastructure to support commercial operations following marketing approval if and when obtained. If we are unable to establish these commercial capabilities and infrastructure or to enter into agreements with third parties to market and sell our potential products, we may be unable to generate sufficient revenue to sustain our business.
We have limited prior sales or distribution experience and limited capabilities for marketing and market access, and we did not generate meaningful product sales following the commercial launch of beti-cel following marketing approval in Europe. To successfully commercialize beti-cel, eli-cel, and lovo-cel following marketing approval in the United States, if and when obtained, we will need to further develop these capabilities. We may need to expand our infrastructure to support commercial operations in the United States, either on our own or with others. Commercializing an autologous gene therapy is resource-intensive and has required, and will continue to require, substantial investment in commercial capabilities. We are competing with companies that currently have extensive and well-funded marketing and sales operations. Without significant commercial experience as a company or the support of a third-party to perform these functions, including marketing and sales functions, we may be unable to compete successfully against these more established companies. Furthermore, a significant proportion of the patient populations for beti-cel, eli-cel, and lovo-cel lies outside of the United States. We currently expect to focus our operations and efforts on markets in the United States and intend to rely heavily on third parties for geographies outside of the United States. We may enter into collaborations with third parties to utilize their mature marketing and distribution capabilities, but we may be unable to enter into agreements on favorable terms, if at all. If we do not enter into collaboration arrangements with third parties to pursue regulatory authorization or commercialization of our programs for markets outside of the United States, or if our future collaborative partners do not commit sufficient resources to such efforts, we may be unable to generate sufficient revenue to sustain our business.
30
The insurance coverage and reimbursement status of newly-approved products in the United States is uncertain. Due to the novel nature of our technology and the potential for our product to offer lifetime therapeutic benefit in a single administration, we face additional challenges in obtaining adequate pricing and reimbursement for our product. Failure to obtain or maintain adequate coverage and reimbursement for any new or current product could limit our ability to market those products and decrease our ability to generate revenue.
The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments, such as gene therapy products. Sales of our potential products will depend substantially, both domestically and abroad, on the extent to which the costs of our potential products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other payers. There is no assurance that the approved prices or reimbursement levels that payers will be willing to pay will be acceptable to us. In addition, because our therapies represent new treatment approaches, the estimation of potential revenues will be complex. For products administered under the supervision of a physician, obtaining reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.
There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, including gene therapies that are potential one-time treatments. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services ("CMS") an agency within the U.S. Department of Health and Human Services ("HHS"), as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products.
Moreover, increasing efforts by governmental and third-party payers to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for beti-cel, eli-cel, or lovo-cel following marketing approval, if and when obtained. We expect to experience pricing pressures in connection with the sale of our potential products, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. Net prices for drugs may be reduced by mandatory discounts or rebates required by government or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
Furthermore, because our target patient populations are relatively small, the pricing and reimbursement of our potential products must be adequate to cover the costs to treat and support the treatment of patients. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our potential products will be adversely affected. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.
In addition, the administration of autologous drug products requires procedures for the collection of HSCs from the patient, followed by chemotherapy and myeloablative treatments, before infusion of the engineered cell therapy product. The manner and level at which reimbursement is provided for these services is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product.
Although we have proposed novel payment models, including outcomes-based arrangements with payments over time, to assist with realizing the value and sharing the risk of a potential one-time treatment, we did not reach agreement with payers on an acceptable price for reimbursement in our priority markets in Europe. In addition, to the extent reimbursement for our product is subject to outcomes-based arrangements, the total payments received from product sales may vary, our cash collection of future payments and revenue assumptions from product sales will be at risk, and the timing of revenue recognition may not correspond to the timing of cash collection. We plan on commercializing our product candidates in the United States once approved, and will be subject to price reporting obligations set forth by CMS. To the extent reimbursement for our potential products in the United States by U.S. governmental payers is subject to outcomes-based arrangements, the increased complexity increases the risk that CMS may disagree with the assumptions and judgments that we use in our price reporting calculations, which may result in significant fines and liability.
Collectively, these factors could affect our ability to successfully commercialize our potential products and generate or recognize revenues, which would adversely impact our business, financial condition, results of operations and prospects.
31
Risks related to the research and development of our product candidates
We cannot predict when or if we will obtain marketing approval to commercialize beti-cel, eli-cel, or lovo-cel, and the marketing approval of our product candidates may ultimately be for more narrow indications than we expect. If our product candidates are not approved in a timely manner or at all for any reason, our business prospects, results of operations, and financial condition would be adversely affected.
Before obtaining marketing approval from regulatory authorities for the commercialization of our product candidates, we must conduct extensive clinical studies to demonstrate the safety, purity and potency, and efficacy, of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. There is a high failure rate for therapies proceeding through clinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical studies even after achieving promising results in earlier stage clinical studies. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:
•delays in reaching a consensus with regulatory agencies on study design;
•imposition of a clinical hold by regulatory agencies, after an inspection of our clinical study operations or study sites or due to unforeseen safety issues;
•delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites;
•failure to obtain sufficient cells from patients to manufacture enough drug product or achieve target cell doses;
•delays patient enrollment, or in having patients complete participation in a study or return for post-treatment follow-up;
•occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or
•changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.
We have experienced delays in some of our clinical studies in the past, and we may experience similar delays in the future.
Results from previous or ongoing studies are not necessarily predictive of our future clinical study results, and initial or interim results may not continue or be confirmed upon completion of the study. There is limited data concerning long-term safety and efficacy following treatment with our product candidates. These data, or other positive data, may not continue or occur for these patients or for any future patients in our ongoing or future clinical studies, and may not be repeated or observed in ongoing or future studies involving our product candidates. Furthermore, our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical studies. There can be no assurance that any of these studies will ultimately be successful or support further clinical advancement or marketing approval of our product candidates. For instance, while patients with SCD who have been treated with lovo-cel may experience a reduction of vaso-occlusive events following successful engraftment, there can be no assurance that they will not experience vaso-occlusive events in the future. We have experienced unexpected results in the past, and we may experience unexpected results in the future.
Even if our product candidates demonstrate safety and efficacy in clinical studies, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development. We may experience delays or rejections based upon additional government regulation from future legislation or administrative action, changes in regulatory agency policy, or additional regulatory feedback or guidance during the period of product development, clinical studies and the review process. The field of cell and gene therapy is evolving, and as more products are reviewed by regulatory authorities, they may impose additional requirements that were not previously anticipated. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. For example, the development of our product candidates for pediatric use is an important part of our current business strategy, and if we are unable to obtain marketing approval for the desired age ranges, our business may suffer.
32
The BLA submission for beti-cel is based on data from patients treated in our studies, including the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies, and the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies, and has been accepted for filing by the FDA with priority review and a PDUFA goal date of August 19, 2022. However, it should be noted that our ability to obtain approval of a BLA is ultimately an FDA review decision, which will be dependent upon the data and information submitted in the original BLA and during review, and the data submitted may not be sufficiently robust from a safety and/or efficacy perspective, or from a manufacturing and/or quality perspective, to support the approval of the BLA. Based on the available data from these clinical studies and the information submitted, the FDA may require that we conduct additional or larger pivotal trials before we can obtain approval of the BLA for beti-cel for the treatment of patients with β-thalassemia who require regular transfusions.
The BLA submission for eli-cel is based on the safety and efficacy data from our completed Starbeam study, our ongoing ALD-104 study, and the completed ALD-103 observational study, and has been accepted for filing by the FDA for filing and and granted priority review, with a PDUFA goal date of September 16, 2022. Whether eli-cel is eligible for approval will ultimately be determined at the discretion of the FDA, and is dependent upon the data and information submitted in the BLA and during review, and the data submitted may not be sufficiently robust from a safety and/or efficacy perspective, or from a manufacturing and/or quality perspective, to support approval of the BLA. Moreover, several patients with CALD treated with eli-cel in our clinical studies have been diagnosed with MDS likely mediated by Lenti-D LVV insertion, and as a result, our clinical studies of eli-cel have been subject to a clinical hold. On February 23, 2022, the FDA notified us that the clinical hold on the eli-cel program would remain in place, and requested additional information about safety events and monitoring in the eli-cel clinical program. We have no assurances as to whether we will successfully resolve the clinical hold. Based on the available data submitted from our clinical studies, and pending the resolution of the clinical hold, the FDA may determine that eli-cel cannot be approved or it may require that we conduct additional follow-up or larger clinical trials before we can obtain approval of the BLA for eli-cel for the treatment of patients with CALD, if ever.
Based on our discussions with the FDA, we believe that we may be able to seek approval for lovo-cel in the United States on the basis of clinical data from Group C of our ongoing HGB-206 clinical study, and supporting data from our ongoing HGB-210 clinical study. However, in December 2021, we announced that the FDA has placed our clinical program for lovo-cel on partial clinical hold for patients under the age of 18, which relates to our ongoing investigation into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel, who was 18 months post-treatment. We do not have any assurance as to when, if ever, we may resume enrolling patients under the age of 18 in our lovo-cel studies. The partial clinical hold has the potential to negatively impact our ability to generate the analytical comparability and validation data for our commercial manufacturing process needed to support our planned BLA submission for lovo-cel.
If our product candidates are ultimately not approved for any reason, our business, prospects, results of operations and financial condition would be adversely affected.
Changes in our manufacturing processes may cause delays in our clinical development and commercialization plans.
The manufacturing processes for our LVV and our drug products are complex. We explore improvements to our manufacturing processes on a continual basis, as we evaluate clinical and manufacturing data and based on discussions with regulatory authorities. In some circumstances, changes in the manufacturing process may require us to perform additional comparability studies, collect additional data from patients, submit additional regulatory filings, or comply with additional requirements, which may lead to delays in our clinical development and commercialization plans. For instance, following the conditional approval of beti-cel by the European Commission, we continued to refine our commercial drug product manufacturing process to narrow some of the manufacturing process parameters and to tighten the range of commercial drug product release specifications, based on discussions with the European Medicines Agency and evolving clinical data. Implementing these changes to the beti-cel commercial manufacturing process had the effect of delaying our ability to treat the first patient in the commercial context in Europe. In lovo-cel, we plan to seek regulatory approval for drug product utilizing LVV manufactured using a scalable suspension manufacturing process using bioreactors, rather than an adherent cell tray manufacturing process, and we will need to generate analytical comparability and validation data that is acceptable to the FDA in support of such process change. Over time, we also intend to transition the LVV manufacturing process for beti-cel in the United States to the suspension manufacturing process, and the timing in which we are able to make the transition will be dependent upon reaching agreement with the FDA, which may require us to conduct additional studies, collect additional data, develop additional assays, or modify release specifications. Following potential marketing approval if and when received, we also intend to transition our drug product manufacturing process in lovo-cel to utilize cryopreserved apheresis patient starting material in order to expand the potential reach of our therapy, which would similarly require comparability and process validation data to support such transition.
33
We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced, safer or more effective than ours, which may adversely affect our financial condition and our ability to successfully develop and commercialize beti-cel, eli-cel, and lovo-cel. If our competitors obtain orphan drug exclusivity for products that regulatory authorities determine constitute the same drug and treat the same indications as our product candidates, and they obtain marketing authorization, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.
We are engaged in the development of gene therapies for severe genetic diseases, which is a competitive and rapidly-changing field. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, more experienced manufacturing capabilities, or more established commercial infrastructure. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective, safer, or less costly than any products that we may develop, or achieve patent protection, marketing approval, product commercialization and market penetration earlier than us. Additionally, technologies developed by our competitors may render our potential products uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. For additional information regarding our competition, see “Item 1. Business—Competition” in our Annual Report on Form 10-K.
Even if we are successful in achieving marketing approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars due to the changing regulatory environment. In the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated to be “highly similar,” or biosimilar, to or “interchangeable” with an FDA-approved biological product. This pathway could allow competitors to reference data from biological products already approved after 12 years from the time of approval. In Europe, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data from biological products already approved, but will not be able to get on the market until 10 years after the time of approval. This 10-year period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilars in other countries that could compete with our potential products. If competitors are able to obtain marketing approval for biosimilars referencing our potential products, our potential products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. Expiration or successful challenge of our applicable patent rights could also trigger competition from other products, assuming any relevant exclusivity period has expired.
In addition, although beti-cel, eli-cel, and lovo-cel have been granted orphan drug status by the FDA there are limitations to the exclusivity. In the United States, the exclusivity period for orphan drugs is seven years, while pediatric exclusivity adds six months to any existing patents or exclusivity periods. Generally, if a product with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our potential products for the exclusivity period for the applicable indication.
Finally, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors’ products. The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.
We may not be successful in our efforts to expand applications of our platform technologies through the discovery of additional product candidates or complementary technologies such as reduced toxicity conditioning.
The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technologies, such as in vivo product candidates. Our growth strategy also depends upon our ability to leverage advancements in complementary technologies such as in reduced toxicity conditioning or in stem cell mobilization. Our research programs may fail to identify other potential product candidates for clinical development or advance such complementary technologies for a number of reasons. We may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. Research programs to identify new product candidates and
34
new technologies require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. If any of these events occur, we may be forced to abandon our research, development or commercialization efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.
Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our potential products or adversely affect our ability to conduct our business or obtain and maintain marketing approvals for our product candidates.
Public perception may be influenced by claims that gene therapy, including gene editing technologies, is unsafe or unethical, and research activities and adverse events in the field, even if not ultimately attributable to us or our product candidates, could result in increased governmental regulation, unfavorable public perception, challenges in recruiting patients to participate in our clinical studies, potential regulatory delays in the testing or approval of our potential products, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any approved products.
Risks related to our reliance on third parties
We rely on third parties to conduct some or all aspects of our LVV production, drug product manufacturing, and testing, and these third parties may not perform satisfactorily.
We do not independently conduct all aspects of our LVV production, drug product manufacturing, and testing. We currently rely, and expect to continue to rely, on third parties with respect to these items, including manufacturing and testing in the commercial context.
Our reliance on these third parties for manufacturing, testing, research and development activities reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for products that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical studies are conducted in accordance with the study plan and protocols, and that our LVV and drug products are manufactured in accordance with GMP as applied in the relevant jurisdictions.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines, conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, or manufacture our LVV and drug products in accordance with GMP, whether due to the impacts of COVID-19 or otherwise, we will not be able to complete, or may be delayed in completing, the preclinical and clinical studies and manufacturing process validation activities required to support future IND and BLA submissions and approval of our product candidates, or to support commercialization of our products, if approved. Many of our agreements with these third parties contain termination provisions that allow these third parties to terminate their relationships with us at any time. If we need to enter into alternative arrangements, our product development and commercialization activities could be delayed.
Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the products ourselves, including:
•the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
•reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities;
•the risk that these activities are not conducted in accordance with our study plans and protocols;
•termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and
•disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.
We may be forced to manufacture LVV and drug product ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills required to manufacture our LVV or drug product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty or there may be contractual restrictions prohibiting us
35
from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. Any of these events could lead to clinical study delays or failure to obtain marketing approval, or impact our ability to successfully commercialize our potential products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.
We and our contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.
All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Some components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and where required, must adhere to the FDA’s or other regulator’s good laboratory practices ("GLP"), and GMP regulations enforced by the FDA or other regulator through facilities inspection programs. Some of our contract manufacturers have not produced a commercially-approved product and therefore have not obtained the requisite FDA or other marketing approvals to do so. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA or other marketing approval of the products will not be granted.
The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.
If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other regulators can impose regulatory sanctions including, among other things, refusal to approve a pending application for a biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.
Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. The number of manufacturers with the necessary manufacturing capabilities is limited. In addition, an alternative manufacturer would need to be qualified through a BLA supplement or similar regulatory submission which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.
These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our potential products, cause us to incur higher costs and prevent us from commercializing our potential products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenues.
We expect to rely on third parties to conduct, supervise and monitor our clinical studies, and if these third parties perform in an unsatisfactory manner, it may harm our business.
We expect to rely on CROs and clinical study sites to ensure our clinical studies are conducted properly and on time. While we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only certain aspects of our CROs’ activities. Nevertheless, we will be responsible for ensuring that each of our clinical
36
studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.
We and our CROs are required to comply with the FDA’s and other regulatory authorities’ GCPs for conducting, recording and reporting the results of clinical studies to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical study participants are protected. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our future clinical studies may be deemed unreliable and the FDA and other regulatory authorities may require us to perform additional clinical studies before approving any marketing applications.
If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical studies may be extended, delayed or terminated, and we may not be able to obtain marketing approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.
Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to manufacture our vectors and our drug products, and because we collaborate with various organizations and academic institutions on the advancement of our gene therapy platform, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.
In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.
Risks related to our financial condition and capital requirements
We have not generated material revenue from product sales and may never be profitable.
Our ability to generate revenues and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory, pricing and reimbursement approvals necessary to commercialize beti-cel, eli-cel, or lovo-cel. Our ability to generate revenues from product sales depends heavily on our success in:
•completing research and preclinical and clinical development of our product candidates;
•seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical studies;
•developing a sustainable, commercial-scale, reproducible, and transferable manufacturing process for our vectors and drug products;
37
•establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development for our product candidates and commercial demand for any approved product;
•launching and commercializing any approved product, either by collaborating with a partner or, if launched independently, by establishing a field-based team, marketing and distribution infrastructure;
•obtaining sufficient pricing and reimbursement for any approved product from private and governmental payers;
•obtaining market acceptance and adoption of any approved product and gene therapy as a viable treatment option;
•addressing any competing technological and market developments;
•negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; and
•maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how.
We expect to continue to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase, which costs may increase further as competitors enter the market. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate material product revenues, we may not become profitable and may need to obtain additional funding to continue operations.
If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements are incorrect, our actual results may vary from those reflected in our projections and accruals.
Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct. We may be incorrect in our assumptions regarding the applicability of drug pricing programs and rebates that may be applicable to our potential products, which may result in our under- or over-estimating our anticipated product revenues especially as applicable laws and regulations governing pricing evolve over time. In addition, to the extent payment for our potential products is subject to outcomes-based arrangements over time, the total payments received from product sales may vary, our cash collection of future payments and revenue assumptions from product sales will be at risk, and the timing of revenue recognition may not correspond to the timing of cash collection.
Further, from time to time we issue financial guidance relating to our expectations for our cash, cash equivalents, and marketable securities available for operations, which guidance is based on estimates and the judgment of management. If, for any reason, our expenses differ materially from our guidance or we utilize our cash more quickly than anticipated, we may have to adjust our publicly announced financial guidance. If we fail to meet, or if we are required to change or update any element of, our publicly disclosed financial guidance or other expectations about our business, our stock price could decline.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.
Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. We expect that following marketing approval, if and when obtained, revenues from product sales will be difficult to predict from period to period, given the absence of historical sales data for beti-cel, eli-cel and lovo-cel.
Further, changes in our operations, such as increased development, manufacturing and clinical trial expenses in connection with expanding our pipeline programs, or our undertaking of additional programs, or business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses may also cause significant fluctuations in our expenses.
The cumulative effects of these factors, further exacerbated by the impacts of the ongoing COVID-19 pandemic on healthcare systems and economic conditions, will likely result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful.
38
Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.
Risks related to our business operations
Our business may be materially and adversely affected by the ongoing COVID-19 pandemic. The COVID-19 pandemic has had, and may continue to have, an impact on various aspects of our business and that of third parties on which we rely. The extent to which the COVID-19 pandemic impacts our business will depend in part on future developments, which are uncertain and unpredictable in nature.
Since March 2020, when the World Health Organization characterized COVID-19 as a pandemic, the related adverse public health developments, including orders to shelter-in-place, travel restrictions, and the imposition of additional requirements on businesses, have adversely affected workforces, organizations, healthcare communities, economies, and financial markets globally, leading to economic uncertainty and increased market volatility. It has also disrupted the normal operations of businesses across industries, including ours. As a result of the COVID-19 pandemic, we have experienced and expect to experience disruptions in our operations and business, and those of third parties upon whom we rely. For instance, we have experienced disruptions in the conduct of our clinical trials, manufacturing and commercialization efforts, including the commercial launch of beti-cel in Germany and the treatment of patients in the commercial context. We cannot reasonably assess or predict at this time the full extent of the negative impact that the COVID-19 pandemic and related effects may have on our business, financial condition, results of operations and cash flows. We expect to continue experiencing these disruptions in our operations and those of our third parties for an unknown period of time, as the trajectory of the COVID-19 pandemic remains uncertain and continues to evolve in the United States. These impacts, which may materially and adversely affect our business, include the following:
•We are conducting a number of clinical studies across our programs in geographies which are affected by the COVID-19 pandemic. The COVID-19 pandemic has had, and will likely continue to have, an impact on various aspects of our clinical studies. Policies at various clinical sites and federal, state, local and foreign laws, rules and regulations are continuing to evolve, including through the implementation of quarantines and travel restrictions, and direction of healthcare resources toward pandemic response efforts. For instance, the availability of intensive care unit beds and related healthcare resources available to support activities unrelated to COVID-19 response have fluctuated with the incidence of severe cases of COVID-19 in the surrounding communities, and we anticipate that the availability of healthcare resources will continue to fluctuate and may become significantly constrained, with variability across geographies. The COVID-19 pandemic has disrupted the conduct of our ongoing clinical studies, with the result of slower patient enrollment and treatment as well as delays in post-treatment patient follow-up visits. These impacts have varied by clinical study, with the most significant impacts being on our ongoing HGB-210 study for lovo-cel. It is possible that these delays may impact the timing of our regulatory submissions. It is unknown how long these disruptions could continue.
•We currently rely on third parties to manufacture, perform quality testing, and ship LVV and drug product for our clinical studies and, if and when we receive marketing approval for our therapies, expect to rely on such third parties to support commercialization efforts. The third parties in our supply chain have been and may continue to be subject to restrictions in operations arising from the COVID-19 pandemic, and in addition, a number of these third parties have experienced operational disruptions, which have affected activities necessary for our research and development efforts, as well as our commercialization efforts in the United States. These restrictions and disruptions in operations have also given rise to staffing shortages from time to time, which may result in production slowdowns and/or disruptions in delivery systems, potentially interrupting our supply chain and limiting our ability to manufacture LVV and drug product for our clinical studies and for commercial use. At this time, it is unknown how long these disruptions may continue, or the full extent of their impacts.
•The operations of health regulatory agencies globally have been impacted as a result of the COVID-19 pandemic. They have communicated slower response times to regulatory interactions and submissions and, in the future, may lack resources to continue to monitor our clinical studies or to engage in other activities related to review of regulatory submissions in drug development. As a result, timelines for the review of regulatory submissions for our programs have been impacted, and we may experience other delays of unknown duration in the review, inspection, and other regulatory interactions. Any de-prioritization of our clinical studies or delay in regulatory review or interaction
39
resulting from such disruptions could materially affect the development of our product candidates. In addition, we have been engaging in reimbursement discussions with governmental health programs as part of our commercial preparation activities.
•The trading prices for our shares of common stock and other biopharmaceutical companies have been highly volatile as a result of the economic volatility and uncertainty caused by the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of shares of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of, or failure to manage or contain, the COVID-19 pandemic will materially and adversely affect our business, the value of our common stock, and our ability to operate under our operating plan and execute our strategy. Our business and operating plan have already been impacted by the COVID-19 pandemic, the associated governmental restrictions, and the resulting economic conditions, leading us to reduce and defer costs, adjust our priorities, timelines and expectations, and review and revise our operating plans with the intention that it would enable us to advance our corporate strategy and pipeline during an extended period of uncertainty.
The extent of the impacts described above will depend on numerous evolving factors that we may not be able to accurately predict, including:
•the duration, severity, and scope of the pandemic in the United States and globally;
•the effectiveness of governmental, business and individuals’ protocols and actions that have been and continue to be taken in response to the pandemic;
•the impact of the pandemic on economic activity and actions taken in response;
•the effect on patients, healthcare providers and business partners;
•uncertainty as to when we will be able to resume normal clinical study enrollment and patient treatment or follow up activities, particularly at clinical study sites located in highly impacted geographies as a result of disruptions at these sites;
•the ability to obtain or deliver sufficient and timely supplies, given the disruptions to the production capabilities of our manufacturers and suppliers, particularly with respect to the priority given to the development, regulatory approval, and manufacture of COVID-19 vaccines and diagnostic tests;
•our access to the debt and equity markets on satisfactory terms, or at all;
•disruptions in regulatory oversight and actions, as a result of significant and unexpected resources expended to address the COVID-19 by regulators and industry professionals; and
•any impacts on our and our partners’ offices, operations and facilities.
The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments which are difficult to predict, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and other actions taken to contain or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical studies, our research programs, our commercial-readiness activities in the United States, healthcare systems or the global economy. If the ultimate impact of the COVID-19 pandemic and the resulting uncertain economic and healthcare environment is more severe than we anticipated, we may not be able to execute on our current operating plan or on our strategy. If the duration of the COVID-19 pandemic and the associated period of business and social restrictions and economic uncertainty is longer than we anticipated, our cash, cash equivalents, and marketable securities may not be sufficient to fund the activities under our operating plan for the time period that we anticipated, and we may be required to revise our operating plan further. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.
Even if we receive marketing approval for a product candidate, any approved product will remain subject to regulatory scrutiny.
Even if we obtain marketing approval in a jurisdiction, regulatory authorities may still impose significant restrictions on the indicated uses or marketing of any approved products, or impose ongoing requirements for potentially costly post-approval
40
studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. We have experienced interruptions in our marketing of beti-cel in Europe due to safety concerns arising from our lovo-cel program, and we can make no assurance that we will not experience interruptions in any marketing or other commercialization activities in the future, whether due to safety concerns in any approved products, or due to events arising from programs that utilize technologies similar to or related to ours.
In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with good manufacturing practices ("GMP") and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
If we fail to comply with applicable regulatory requirements following marketing approval for a product, a regulatory agency may:
•issue a warning letter asserting that we are in violation of the law;
•seek an injunction or impose civil or criminal penalties or monetary fines;
•suspend or withdraw marketing approval;
•suspend any ongoing clinical studies;
•refuse to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us;
•seize product; or
•refuse to allow us to enter into supply contracts, including government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved product and generate revenues.
We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, reputational harm, and diminished profits and future earnings.
In the United States, the research, manufacturing, distribution, sale, and promotion of drugs and biologic products are subject to regulation by various federal, state, and local authorities in addition to FDA, including CMS, other divisions of the HHS, (e.g., the Office of Inspector General), the United States Department of Justice offices of the United States Attorney, the Federal Trade Commission and state and local governments. Our operations are directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations described in more detail under "Item 1. Business--Government regulation" in our Annual Report. These include the federal Anti-Kickback Statute, federal civil and criminal false claims laws and civil monetary penalty laws (including False Claims Laws), HIPAA, transparency requirements created under the Affordable Care Act, as well as analogous state and foreign laws.
These laws apply to, among other things, our sales, marketing and educational programs. State and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and the United States Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the Anti-Kickback Statute. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government agencies have recently increased regulatory scrutiny and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay support, funding of independent charitable foundations and
41
other programs that offer benefits for patients. Several investigations into these programs have resulted in significant civil and criminal settlements.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert the attention of our management from operating our business.
In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, imposes requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions In addition to HIPAA, as amended by HITECH, and their respective implementing regulations, California recently enacted the California Consumer Privacy Act ("CCPA") which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. While there is currently an exception for protected health information that is subject to HIPAA, as currently written, the CCPA may impact our business activities. The California Attorney General has proposed draft regulations, which have not been finalized to date, that may further impact our business activities if they are adopted. The uncertainty surrounding the implementation of CCPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.
EU member states, Switzerland and other countries have also adopted data protection laws and regulations, which impose significant compliance obligations. In the European Union, the collection and use of personal health data is currently governed by the provisions of the General Data Protection Regulation ("GDPR"). The GDPR, together with the national legislation of the individual EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals for the consent to be considered valid, the transfer of personal data out of the European Economic Area, security breach notifications, the use of third-party processors in connection with the processing of the personal data, confidentiality of the personal data, as well as substantial potential fines for breaches of the data protection obligations. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in the European Union. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to €20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any activities falling within the scope of the GDPR. Further, Brexit has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.
42
We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our marketing approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.
The use of our product candidates in clinical studies and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients participating in clinical trials, consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:
•impairment of our business reputation;
•withdrawal of clinical study participants;
•costs due to related litigation;
•distraction of management’s attention from our primary business;
•substantial monetary awards to patients or other claimants;
•the inability to develop our product candidates or commercialize any approved product; and
•decreased demand for any approved product.
We carry product liability insurance and we believe our product liability insurance coverage is sufficient in light of our current clinical programs and approved product; however, we may not be able to maintain insurance coverage at commercially reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.
Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain marketing approval for any approved product, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidates the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our marketing approval process in other countries, or impact and limit the type of marketing approval our product candidates may receive or any approved product maintains. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.
Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our potential products, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.
In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 ("Affordable Care Act"), was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug
43
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, expanded the types of entities eligible for the 340B drug discount program, and a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D.
Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. Various portions of the Affordable Care Act are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court. It is unclear whether the Affordable Care Act will be overturned, repealed, replaced, or further amended. We cannot predict what effect further changes to the Affordable Care Act would have on our business.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction, which triggered the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2025 unless Congress takes additional action. These reductions were extended through 2029 through subsequent legislative amendments. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration’s budget proposal for fiscal years 2019 and 2020 contain further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payers.
The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our potential products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop product candidates.
44
Our computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product candidates’ development programs and have a material adverse effect on our reputation, business, financial condition or results of operations.
Our computer systems and those of our current or future third-party collaborators, service providers, contractors and consultants may fail and are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. The size and complexity of our information technology systems, and those of our collaborators, service providers, contractors and consultants, and the large amounts of information stored on those systems make those systems vulnerable to service interruptions, security breaches, or other failures, resulting from inadvertent or intentional actions by our employees or those of third-party business partners, or from cyber-attacks by malicious third parties. Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized groups and individuals with a wide range of motives and expertise. In addition to extracting sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. The prevalent use of mobile devices also increases the risk of data security incidents. If we experience a material system failure, accident or security breach that causes interruptions in our operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in significant reputational, financial, legal, regulatory, business or operational harm. For example, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed. In addition, we rely on third-party service providers for management of the manufacture and delivery of drug product to patients in the commercial context, including for chain of identity and chain of custody. We also rely on third-party service providers for aspects of our internal control over financial reporting and such service providers may experience a material system failure or fail to carry out their obligations in other respects, which may impact our ability to produce accurate and timely financial statements, thus harming our operating results, our ability to operate our business, and our investors’ view of us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to material failures, security breaches, cyberattacks and other related breaches.
Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations to third parties, or any data security incidents or other security breaches that result in the unauthorized access, release or transfer of sensitive information, including personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us. These events could cause third parties to lose trust in us or could result in claims by third parties asserting that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to increased harm. While we have implemented data security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or data security incidents.
Risks related to the separation of our oncology programs and portfolio
We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of 2seventy bio.
On November 4, 2021, we distributed all of the outstanding shares of 2seventy bio, Inc. ("2seventy") common stock to our stockholders in connection with the separation of our oncology programs and portfolio. In connection with the distribution, we entered into a separation agreement and various other agreements (including a tax matters agreement, an employee matters agreement, transition services agreements and an intellectual property license agreement). These agreements govern the separation and distribution and the relationship between us and 2seventy going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time.
The separation agreement provides for indemnification obligations designed to make 2seventy financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation, but we cannot guarantee that 2seventy will be able to satisfy its indemnification obligations. It is also possible that a court would disregard the allocation agreed to between us and 2seventy and require us to assume responsibility for obligations allocated to 2seventy. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover
45
all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to 2seventy, including those related to assets or liabilities allocated to us, may be significant. These risks could negatively affect our business, financial condition or results of operations.
The separation of 2seventy continues to involve a number of additional risks, including, among other things, the potential that management’s and our employees’ attention will be significantly diverted by the provision of transitional services or that we may incur other operational challenges or difficulties as a result of the separation. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If 2seventy is unable to satisfy its obligations under these agreements, we could incur losses and may not have sufficient resources available for such services. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the transition activities and related events could adversely affect our business, financial condition or results of operations.
We may fail to realize some or all of the anticipated benefits of the separation of 2seventy.
The anticipated operational, financial, strategic and other benefits of the separation of 2seventy may not be achieved. The combined value of the common stock of the two publicly-traded companies may not be equal to or greater than what the value of our common stock would have been had the separation not occurred. The combined value of the common stock of the two companies could be lower than anticipated for a variety of reasons, including the failure of either company to operate and compete effectively as an independent company. The common stock price of each company may experience periods of extreme volatility. In addition, following the separation we are smaller and less diversified, with a narrower business focus, and may be more vulnerable to changing market conditions. The separation also presents a number of significant risks to our internal processes, including the failure to maintain an adequate control environment due to changes to our infrastructure technology systems and financial reporting processes.
Completion of the separation of 2seventy resulted in substantial changes in our board of directors and management.
Completion of the separation of 2seventy resulted in substantial changes in our board of directors and management. In particular, our former chief executive officer, Nick Leschly, resigned from that position (although Mr. Leschly continues to serve on our board of directors). In addition, Philip Gregory, our former chief scientific officer, and Chip Baird, our former chief financial officer, resigned from their positions with us to join management positions with 2seventy. Furthermore, Dan Lynch, Ramy Ibrahim, Denice Torres, William Sellers, Sarah Glickman and Marcela Maus resigned as members of our board of directors upon the completion of the separation. These senior officer and board level changes could be disruptive to our operations, present significant management challenges and could harm our business.
The separation may result in disruptions to, and harm our relationships with, our strategic business partners.
Uncertainty related to the separation may lead the suppliers, research organizations, and other parties with which we currently do business or may do business in the future to terminate or attempt to negotiate changes in our existing business relationships, or cause them to delay entering into business relationships with us or consider entering into business relationships with parties other than us. These disruptions could have a material and adverse effect on our business, prospects, financial condition and results of operations.
If the distribution of shares of 2seventy bio, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.
The completion of the distribution was conditioned upon, among other things, our receipt of a private letter ruling from the IRS, and an opinion from Goodwin Procter LLP, both satisfactory to our board of directors and both continuing to be valid, together confirming that the distribution, together with certain related transactions, generally is tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Code. We have received a favorable private letter ruling from the IRS addressing one significant issue of the qualification of the distribution under Section 355 of the Code. However, the private letter ruling does not address the remaining issues that are relevant to determining whether the distribution, together with certain related transactions, qualifies as a transaction that is generally tax-free for U.S. federal income tax purposes. The IRS private letter ruling and opinion of Goodwin Procter LLP were based, among other things, on various facts and assumptions, as well as certain representations, statements and undertakings from us and 2seventy bio (including those relating to the past and future conduct of us and 2seventy bio) and were subject to certain caveats. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if we or 2seventy bio breach any of our respective covenants relating to the separation, the IRS private letter ruling and tax opinion may be invalid. Moreover, the opinion is not
46
binding on the IRS or any courts. Accordingly, notwithstanding receipt of the IRS private letter ruling and an opinion of Goodwin Procter LLP, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.
If the distribution, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain as if we have sold 2seventy bio’s distributed common stock in a taxable sale for its fair market value and our stockholders who receive shares of 2seventy bio common stock in the distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.
In connection with the distribution, we and 2seventy bio entered into a tax matters agreement pursuant to which each party is responsible for certain liabilities and obligations following the distribution. In general, under the terms of the tax matters agreement, if the distribution, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Code, and if and to the extent that such failure results from a prohibited change of control in us under Section 355(e) of the Code, or an acquisition of our stock or assets or certain actions, omissions or failures to act, by us, then we will bear any resulting taxes, interest, penalties and other costs. If and to the extent that such failure results from a prohibited change of control in 2seventy bio under Section 355(e) of the Code or an acquisition of 2seventy bio stock or assets or certain actions by 2seventy bio, then 2seventy bio will be obligated to indemnify us for any resulting taxes, interest, penalties and other costs, including any reductions in our net operating loss carryforwards or other tax assets. If such failure does not result from a prohibited change of control in bluebird bio or 2seventy bio under Section 355(e) of the Code and both we and 2seventy bio are responsible for such failure, liability will be shared according to relative fault. If neither we nor 2seventy bio is responsible for such failure, we will bear any resulting taxes, interest, penalties and other costs.
Risks related to our intellectual property
If we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets.
We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.
If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by a third-party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications.
47
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, and information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.
Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.
Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the U.S. Patent and Trademark Office ("U.S. PTO") and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.
Third parties have asserted and in the future may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.
Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit,
48
would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.
We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our development pipeline through acquisitions and in-licenses.
Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates and commercialize our potential products. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or clinical development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.
In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.
If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. Pursuant to an intellectual property license agreement with 2seventy, we granted sublicenses to 2seventy to certain existing license agreements. If we fail to comply with our obligations under these agreements, we or 2seventy materially breach these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.
We may need to obtain licenses from third parties to advance the development of our product candidates or allow commercialization of our potential products, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidates, approved product, or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.
In many cases, patent prosecution of our licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal,
49
business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:
•the scope of rights granted under the license agreement and other interpretation-related issues;
•the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
•the sublicensing of patent and other rights under our collaborative development relationships;
•our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
•the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
•the priority of invention of patented technology.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved product or product candidates.
We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our potential products. Such a loss of patent protection would have a material adverse impact on our business.
Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.
50
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We have had in the past, and we may also have in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.
Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our potential products.
As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from
51
practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our potential products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
Risks related to ownership of our common stock
The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the price at which you purchase them.
Companies trading in the stock market in general, and The Nasdaq Global Select Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and biotechnology and pharmaceutical industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
The market price of our common stock has been volatile in the past, and may continue to be volatile for the foreseeable future. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:
•adverse results or delays in preclinical or clinical studies;
•reports of adverse events in our product candidates or other gene therapy products, or in clinical studies of such products;
•inability to obtain additional funding;
•any delay in filing an IND or BLA for any of our product candidates, and any adverse development or perceived adverse development with respect to the regulatory authority's review of that IND or BLA;
•failure to successfully manage the commercial launch of beti-cel, eli-cel, or lovo-cel following marketing approval, if and when obtained, including failure to manage our supply chain operations in the coordination and delivery of drug product to patients at qualified treatment centers;
•failure to obtain sufficient pricing and reimbursement for beti-cel, eli-cel, or lovo-cel from private and governmental payers following marketing approval, if and when obtained;
•failure to obtain market acceptance and adoption of beti-cel, eli-cel, or lovo-cel following marketing approval, if and when obtained;
•developments concerning the separation of our programs into two independent, publicly-traded companies;
•failure to maintain our existing strategic collaborations or enter into new collaborations;
•failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;
•changes in laws or regulations applicable to future products;
•inability to obtain adequate product supply for beti-cel, eli-cel, or lovo-cel, or the inability to do so at acceptable prices;
52
•adverse regulatory decisions;
•announcements of clinical trial results or progress in the development of programs by our competitors, and the introduction of new products, services or technologies by our competitors;
•failure to meet or exceed financial projections we may provide to the public;
•failure to meet or exceed the financial projections of the investment community;
•the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;
•the effects of the separation of 2seventy bio;
•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors;
•disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
•additions or departures of key scientific or management personnel;
•significant lawsuits, including patent or stockholder litigation;
•changes in the market valuations of similar companies;
•sales of our common stock by us or our stockholders in the future; and
•trading volume of our common stock.
Actual or potential sales of our common stock by our employees, including our executive officers, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.
In accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and our policies regarding stock transactions, a number of our employees, including executive officers and members of our board of directors, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall or prevent it from increasing for numerous reasons.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.
Pursuant to our 2013 Stock Option and Incentive Plan (the "2013 Plan") our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2013 Plan automatically increases each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors or compensation committee to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2013 Plan each year. If our board of directors or compensation committee elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. We make equity grants to certain new employees joining the company pursuant to an inducement plan, and our compensation committee may elect to increase the number of shares available for future grant without stockholder approval. We also have an Employee Stock Purchase Plan and any shares of common stock purchased pursuant to that plan will also cause dilution.
53
We are subject to securities class action litigation, which may result in substantial costs and a diversion of management's attention and resources, which could harm our business.
In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities, and we are litigating class action complaints in the United States District Court for the District of Massachusetts and for the District of Delaware, filed by purported stockholders against us and certain of our directors and officers. We may face additional securities class action litigation in the future. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years, and we expect to experience continued stock price volatility. Defending against the current litigation and any future litigation could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards ("NOLs") and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We have completed several financings since our inception and prior to our initial public offering in 2013, which we believe have resulted in a change in control as defined by IRC Section 382. We completed a study through December 2020 confirming no ownership changes have occurred since our initial public offering in 2013. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.
We do not intend to pay cash dividends on our common stock so any returns will be limited to the value of our stock.
We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.
Provisions in our amended and restated certificate of incorporation and by-laws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.
Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and by-laws, include provisions that:
•authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;
•create a classified board of directors whose members serve staggered three-year terms;
•specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president;
•prohibit stockholder action by written consent;
•establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
•provide that our directors may be removed only for cause;
•provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
•specify that no stockholder is permitted to cumulate votes at any election of directors;
•expressly authorize our board of directors to modify, alter or repeal our amended and restated by-laws; and
54
•require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.
These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.
In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.
Any provision of our amended and restated certificate of incorporation or amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
Our amended and restated certificate of incorporation and amended and restated by-laws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
Our amended and restated certificate of incorporation and amended and restated by-laws specify that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders, other than suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or any other claim for which the federal courts have exclusive jurisdiction and any action that the Court of Chancery of the State of Delaware has dismissed for lack of subject matter jurisdiction, which may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated by-laws also specify that, unless we consent in writing to the selection of an alternate forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the “Securities Act”). Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated by-laws described above.
We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes or federal judges experienced in resolving Securities Act disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholder’s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents and result in increased costs for stockholders to bring a claim. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation and by-laws has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and amended and restated by-laws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or amended and restated by-laws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.
Changes in tax law could adversely affect our business and financial condition.
The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.
Item 1B. Unresolved Staff Comments
Not applicable.
55
Item 2. Properties
Below is a summary of our material owned and leased properties as of December 31, 2021:
Massachusetts
Our current corporate headquarters encompasses approximately 72,988 square feet of office and laboratory space and is located at 60 Binney Street, Cambridge, Massachusetts. The lease commenced on November 3, 2021 and will continue until December 31, 2023.
In April 2019, we entered into a sublease agreement for approximately 267,278 square feet of office space located at 50 Binney Street, Cambridge, Massachusetts. In December 2021, we entered into a sub-sublease agreement with Meta Platforms, Inc. to sublease the entirety of the 50 Binney Street premises which we have rights to under the sublease. The sub-sublease will commence when the space is available for use, which is anticipated to be in the first half of 2022, and is expected to terminate on December 31, 2030.
In November 2021, we entered into a lease agreement for approximately 61,180 square feet of office space located at 455 Grand Union Boulevard, Somerville, Massachusetts. This space will be our future corporate headquarters. The lease will commence when the space is available for use, which is anticipated to be in the first half of 2022.
We believe that our existing facilities are adequate for our current needs.
Item 3. Legal Proceedings
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, as of December 31, 2021, we were not party to any legal or arbitration proceedings that may have, or have had in the recent past, significant effects on our financial position or profitability. We believe no governmental proceedings are pending or, to our knowledge, contemplated against us. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.
On February 12, 2021, a class action complaint was filed in the United States District Court for the Eastern District of New York, Leung v. bluebird bio, Inc., et. al., Case No. 1:21-cv-00777, by a purported stockholder against us and certain of our officers. The complaint alleges violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5 promulgated thereunder against all defendants and violations of Section 20(a) of the Exchange Act against the officers and seeks unspecified damages. The allegations relate to our disclosure on November 4, 2020 that we were adjusting the expected timing of submission of a BLA to the FDA for LentiGlobin for sickle cell disease to late 2022.

On October 21, 2021, Errant Gene Therapeutics, LLC filed a complaint against us in the United States District Court for the District of Delaware for alleged infringement of U.S. Patents 7,541,179 and 8,058,061. The allegations relate to our use of the BB305 lentiviral vector in the beti-cel program and seeks injunctive relief and money damages. On February 21, 2022, the parties stipulated to amend the case caption, in light of the Plaintiff’s name change, from Errant Gene Therapeutics, LLC to San Rocco Therapeutics, LLC. The Court granted this stipulation and, accordingly, the case is now captioned, San Rocco Therapeutics, LLC v. bluebird bio, Inc. and Third Rock Ventures, LLC, C.A. No. 21-1478-RGA.
Item 4. Mine Safety Disclosures
Not applicable.
56
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock has been traded on the Nasdaq Global Select Market under the symbol “BLUE.”  On February 28, 2022, the last reported sale price for our common stock on the Nasdaq Global Select Market was $6.04 per share.
Stock Performance Graph
The graph set forth below compares the cumulative total stockholder return on our common stock between December 31, 2016 and December 31, 2021, with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period. This graph assumes the investment of $100 on December 31, 2016 of our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any.
The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.
blue-20211231_g1.jpg

57
Holders
As of February 28, 2022, there were approximately 10 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
Dividends
We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.
Securities Authorized for Issuance Under Equity Compensation Plans
Information about our equity compensation plans is provided in Item 12 of Part III of this Annual Report on Form 10-K.
Item 6. Reserved

58
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following information should be read in conjunction with the consolidated financial statements and related notes thereto included in this Annual Report on Form 10-K.
In addition to historical information, this report contains forward-looking statements that involve risks and uncertainties which may cause our actual results to differ materially from plans and results discussed in forward-looking statements. We encourage you to review the risks and uncertainties discussed in the sections entitled Item 1A. “Risk Factors” and “Forward-Looking Statements” included at the beginning of this Annual Report on Form 10-K. The risks and uncertainties can cause actual results to differ significantly from those forecast in forward-looking statements or implied in historical results and trends.
We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Overview
We are a biotechnology company committed to researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases. We have built an integrated product platform with broad therapeutic potential in a variety of indications based on our lentiviral gene addition platform. Our gene therapy programs in severe genetic diseases include programs for β-thalassemia, SCD, and CALD. We also expect to make focused investments in research and development efforts on optimizing our existing programs as well as on pipeline programs in severe genetic diseases. The BLA for beti-cel as a treatment for patients with β-thalassemia who receive regular RBC transfusions was accepted for priority review by the FDA, and the PDUFA goal date is August 19, 2022. The BLA for eli-cel as a treatment for patients less than 18 years of age with early CALD was accepted for priority review by the FDA, and the PDUFA goal date is September 16, 2022. We are developing lovo-cel as a treatment for patients with SCD. Based on our discussions with the FDA, we believe that we may be able to seek approval for lovo-cel in the United States on the basis of clinical data from HGB-206 Group C, with supporting data from HGB-210. We have treated all of the patients who will form the primary basis of efficacy for approval, with the demonstration of analytical comparability and validation of our commercial manufacturing process as the key remaining actions prior to submission of our planned BLA for lovo-cel. In December 2021, the FDA placed a partial clinical hold on our clinical program for lovo-cel for enrolling patients under the age of 18. During the partial clinical hold, we anticipate continuing our clinical study activities as planned for patients 18 and older in HGB-210, as well as follow-up activities for treated patients of all ages in all studies.
We are focusing our development and commercialization efforts in the U.S. market. We have submitted a request for the withdrawal of the marketing authorization for beti-cel in the European Union, to be effective in the first half of 2022. As of December 31, 2021, we have withdrawn the marketing authorization for eli-cel in the European Union. We are continuing the long-term follow-up of patients previously enrolled within the clinical trial programs in Europe as planned but do not intend to initiate any new clinical trials in Europe for β-thalassemia, CALD or SCD. As a result, we anticipate a reduction of selling, general and administrative costs and an impact on our excess inventory analysis as future lots are produced, which is based on forecasted consumption levels driven by sales forecasts.
Since our inception in 1992, we have devoted substantially all of our resources to our development efforts relating to our product candidates, including activities to manufacture product candidates in compliance with good manufacturing practices ("GMP") to conduct clinical studies of our product candidates, to provide selling, general and administrative support for these operations and to protect our intellectual property. We have not generated material revenue from product sales. We have funded our operations primarily through the sale of common stock in our public offerings, private placements of preferred stock and warrants and through collaborations.
As of December 31, 2021, we had cash, cash equivalents and marketable securities of approximately $396.6 million. We have never been profitable and have incurred net losses in each year since inception. Our net loss from continuing operations was $562.6 million for the year ended December 31, 2021 and our accumulated deficit was $3.72 billion as of December 31, 2021. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for at least the next several years, as we:
59
•fund activities related to the potential commercial launches of our late-stage product candidates in the United States;
•seek regulatory approval for our product candidates;
•scale our manufacturing capabilities in support of potential commercialization following any regulatory approvals;
•conduct clinical studies for our clinical programs in β-thalassemia and SCD, and advance our preclinical programs into clinical development; and
•increase research and development-related activities for the discovery and development of product candidates and technologies in severe genetic diseases.
Because of the numerous risks and uncertainties associated with product development and commercialization, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our products, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.
Business update
We continue to experience disruptions and increased risk related to the ongoing COVID-19 pandemic in our operations and those of third parties upon whom we rely, which may materially and adversely affect our business. These include disruptions and risks related to the conduct of our clinical trials, manufacturing, and commercialization efforts, as policies at various clinical sites and federal, state, local and foreign laws, rules and regulations continue to evolve, including quarantines, travel restrictions, and direction of healthcare resources toward pandemic response efforts. The effects of the COVID-19 pandemic impacted the timing of patient treatment in Europe in the commercial context, and the timing of our ongoing clinical studies, with the result of slower patient enrollment and treatment in our clinical studies and delays in post-treatment follow up visits, the impact of which has varied by clinical study and by program. It has also affected our activities with and operations at our third-party manufacturers. It is unknown how long these disruptions could continue. As a result of the demands upon healthcare regulatory authorities, review, inspection, and other activities related to review of regulatory submissions in drug development may be impacted, and may result in delays for an unknown period of time.
We continue to evaluate the impact of the COVID-19 global pandemic on patients, healthcare providers and our employees, as well as our operations and the operations of our business partners and healthcare communities. In response to the COVID-19 pandemic, we have implemented policies to mitigate the risk of exposure to COVID-19 by our personnel, including restrictions on the number of staff in any given research and development laboratory, and a flexible work-from-home policy applicable to the majority of our personnel.
We are working with our clinical study sites to mitigate the impact of the COVID-19 pandemic on activities for our ongoing clinical studies. However, the ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments which are difficult to predict.
In March 2021, we placed a portion of our internal LVV manufacturing facility into service, while still completing qualification of the remaining portion. In September 2021, we completed the sale of this LVV manufacturing facility to National Resilience, Inc. Currently all of our manufacturing activities are contracted out to third parties and we utilize third-party contract research organizations ("CROs") to carry out our clinical development activities. As we seek to obtain regulatory approval for our product candidates and begin commercialization following marketing approval, if obtained, we expect to incur significant commercialization expenses as we prepare for and begin product sales, marketing, commercial manufacturing, and distribution at such time. Accordingly, until we generate significant revenues from product sales at such time, we will continue to seek to fund our operations through public or private equity or debt financings, strategic collaborations, or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our product candidates.
In April 2021, we announced our decision to withdraw ZYNTEGLO from the German market because reimbursement negotiations in Germany did not result in a price for ZYNTEGLO that reflects the value of the one-time gene therapy with potential life-long benefit for people living with transfusion dependent β-thalassemia. A total of approximately 50 employees were impacted by this reduction. During the three months ended June 30, 2021, we substantially completed the implementation of this reduction and, in accordance with ASC 420, Exit and Disposal Activities, and ASC 712, Nonretirement Postemployment
60
Benefits, recorded approximately $4.6 million of costs including severance, the portion of the employees' 2021 retention bonuses to be paid in cash, and the pro rata portion of the employees' 2021 performance bonus.
In July 2021, we made the decision to focus our efforts on the U.S. market for beti-cel, eli-cel, and lovo-cel and are executing an orderly wind down of our European operations. A total of approximately 90 employees were impacted by the reduction in workforce associated with this decision. We recorded $21.2 million of expense, in accordance with the related accounting standards mentioned above, for the affected employees.
All costs associated with the April 2021 and July 2021 reductions are reflected within restructuring expenses in our condensed consolidated statements of operations and comprehensive loss. See Note 17, Reduction in Workforce, in the notes to the consolidated financial statements.
We had cash, cash equivalents and marketable securities of approximately $396.6 million as of December 31, 2021. In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of its plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, the release of restricted cash related to the Company’s 50 Binney Street sublease, and the potential sale of priority review vouchers, if received, cannot be considered probable at this time because none of the plans are entirely within the Company’s control or have been approved by the Board of Directors as of the date of the financial statements.
Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Our plan to alleviate the conditions that raise substantial doubt include reduced 2022 spending, including projected savings through the move of the Company's headquarters to Assembly Row in Somerville, Massachusetts, the orderly wind down of European operations, the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for beti-cel and eli-cel, and the pursuit of additional cash resources through public or private equity or debt financings. We have concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Our legacy business
On November 4, 2021, we completed the separation of our severe genetic disease and oncology programs into two separate, publicly traded companies: bluebird bio, Inc. and 2seventy bio, Inc. ("2seventy bio"), a Delaware corporation and wholly-owned subsidiary prior to the separation (the "Separation"). The Separation was effected by means of a distribution of all of the outstanding shares of common stock of 2seventy bio in which each bluebird stockholder received one share of common stock, par value $0.0001 per share, of 2seventy bio for every three shares of common stock, par value $0.01 per share, of bluebird held as of the close of business on October 19, 2021 (the "Distribution").
We intend to focus on our severe genetic disease programs and 2seventy bio is expected to focus on the separated oncology programs. In collaboration with Bristol-Myers Squibb ("BMS"), 2seventy bio is commercializing idecabtagene vicleucel ("ide-cel") and developing bb21217 as treatments for multiple myeloma, a hematologic malignancy that develops in the bone marrow and is fatal if untreated. 2seventy bio is co-developing and co-promoting ide-cel as ABECMA in the United States with BMS and has exclusively licensed to BMS the development and commercialization rights for ide-cel outside of the United States. It
61
has exclusively licensed the development and commercialization rights for the bb21217 product candidate to BMS, with an option for 2seventy bio to elect to co-develop and co-promote bb21217 within the United States. In March 2021, BMS received marketing approval from the FDA for ide-cel, marketed as ABECMA, as a treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Sales of ABECMA by BMS began in the second quarter of 2021.

In connection with the Separation, we entered into a separation agreement with 2seventy bio, dated as of November 3, 2021, that, among other things, sets forth our agreements with 2seventy bio regarding the principal actions to be taken in connection with the Separation, including the Distribution. In connection with the Separation, we also entered into certain other agreements with 2seventy bio, including transition services agreements. Pursuant to the transition services agreements, we are obligated to provide and are entitled to receive certain transition services related to corporate functions, such as finance, human resources, internal audit, research and development, financial reporting, and information technology. The separation and the aforementioned agreements are more fully described in Note 3, Discontinued operations, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Financial operations overview
Product revenue
Our revenues have primarily been derived from product revenues associated with the sale of ZYNTEGLO in Germany.
Other revenue
We have recognized an immaterial amount of revenue associated with grants and collaboration agreements.
Research and development expenses
Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include:
•employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;
•expenses incurred under agreements with CROs and clinical sites that conduct our clinical studies;
•reimbursable costs to our partners for collaborative activities;
•facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, information technology, insurance, and other supplies in support of research and development activities;
•costs associated with our research platform and preclinical activities;
•milestones and upfront license payments;
•costs associated with our regulatory, quality assurance and quality control operations; and
•amortization of certain intangible assets.
Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. We cannot determine with certainty the duration and completion costs of the current or future clinical studies of our product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may not succeed in achieving regulatory approval for all of our product candidates. The duration, costs, and timing of clinical studies and development of our product candidates will depend on a variety of factors, any of which could mean a significant change in the costs and timing associated with the development of our product candidates, including:
•the scope, rate of progress, and expense of our ongoing as well as any additional clinical studies and other research and development activities we undertake;
•future clinical study results;
62
•uncertainties in clinical study enrollment rates;
•new manufacturing processes or protocols that we may choose to or be required to implement in the manufacture of our LVV or drug product;
•regulatory feedback on requirements for regulatory approval, as well as changing standards for regulatory approval; and
•the timing and receipt of any regulatory approvals.
We plan to increase our research and development expenses for the foreseeable future as we continue to advance the development of beti-cel, eli-cel, and lovo-cel, and conduct research and development activities in our pipeline programs. Our research and development expenses include expenses associated with the following activities:
•for the clinical studies of beti-cel, consisting of HGB-207, HGB-212, and the associated long-term follow-up protocol;
•for the clinical studies of lovo-cel, consisting of HGB-206, HGB-210, and the associated long-term follow-up protocol;
•for the clinical studies of eli-cel, consisting of ALD-104, and the associated long-term follow-up protocol;
•research and development activities for platform technology and our preclinical pipeline programs; and
•for the manufacture of clinical study materials in support of our clinical studies.
We expect that the timing of investment in our ongoing clinical studies will reflect COVID-19 related delays in these studies.
Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical studies, and costs related to acquiring and manufacturing clinical study materials. We allocate salary and benefit costs directly related to specific programs. We do not allocate personnel-related discretionary bonus or stock-based compensation costs, laboratory and related expenses, certain license and other collaboration costs, depreciation or other indirect costs that are deployed across multiple projects under development and, as such, the costs are separately classified as other research and development expenses in the table below:
Year ended December 31,
2021
2020 (2)
2019 (2)
(in thousands)
beti-cel$53,292 $66,141 $73,896 
lovo-cel (formerly LentiGlobin for SCD)
64,861 58,862 50,796 
eli-cel54,581 48,028 40,352 
Preclinical programs7,252 6,644 1,195 
Total direct research and development expense179,986 179,675 166,239 
Employee- and contractor-related expenses48,297 39,255 40,619 
Stock-based compensation expense42,989 49,766 59,378 
Laboratory and related expenses(1)
5,466 8,956 12,208 
License and other collaboration expenses(1)
— 40 1,984 
Facility expenses41,898 37,377 39,291 
Other expenses1,310 4,240 7,400 
Total other research and development expenses139,960 139,634 160,880 
Total research and development expense$319,946 $319,309 $327,119 
(1)Prior to 2020, costs within these categories were disclosed as "platform-related expenses."
(2)Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Selling, general and administrative expenses
63
Selling, general and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation and travel expenses for our employees in executive, operational, finance, legal, business development, commercial, information technology, and human resource functions. Other selling, general and administrative expenses include facility-related costs, professional fees for accounting, tax, legal and consulting services, directors’ fees and expenses associated with obtaining and maintaining patents.
We anticipate that our selling, general and administrative expenses, including payroll and sales and marketing expenses, will continue to increase in the future relative to current levels as we perform commercial readiness activities in the United States for our product candidates.
Cost of product revenue
Cost of product revenue includes costs associated with the sale of ZYNTEGLO in Germany.
Restructuring expenses
We record costs and liabilities associated with exit and disposal activities in accordance with ASC 420, Exit and Disposal Cost Obligations, and other costs and liabilities associated with postemployment nonretirement benefits in accordance with ASC 712, Postemployment Nonretirement Benefits. Such costs are based on the estimate of fair value in the period the liabilities are incurred. We evaluate and adjust costs as appropriate for changes in circumstances as additional information becomes available.
Interest income, net
Interest income, net consists primarily of interest income earned on investments.
Other income (expense), net
Other income (expense), net consists primarily of gains and losses on equity securities held by us, gains and losses on disposal of fixed assets, and gains and losses on foreign currency transactions.
Discontinued operations
Net loss from discontinued operations consists of the results of our oncology business and our manufacturing facility in Durham, North Carolina and is reported as a separate component of income.
Critical accounting policies and significant judgments and estimates
Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.
While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this annual report, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.
Discontinued operations

We determined that the Separation of our oncology business on November 4, 2021 and the sale of our manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, Discontinued Operations. Accordingly,
64
the accompanying consolidated financial statements for all periods have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheet and the results of all discontinued operations reported as a separate component of income in the consolidated statements of operations and comprehensive loss.
For additional information related to discontinued operations, refer to Note 3, Discontinued operations, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
Revenue recognition
Revenue recognition
Under Topic 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.
Once a contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  We assess if these options provide a material right to the customer and if so, they are considered performance obligations.
We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).
The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.
If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.
We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.
Product revenue
65
We recognize product revenue in accordance with ASC 606, Revenue from Contracts with Customers. Product revenue represents sales of ZYNTEGLO. In 2021, we distributed ZYNTEGLO directly to hospitals in Germany. We determined that our contracted sales with hospitals formed a single performance obligation and we recognize revenue from product sales at the point in time that we satisfy our performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue.
Leases
Under ASU 2016-02, Leases (Topic 842), (“ASU 2016-02” or “ASC 842”), at the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. We do not have material financing leases.
Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, we utilize our incremental borrowing rate to discount lease payments, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate our incremental borrowing rate, a credit rating applicable to us is estimated using a synthetic credit rating analysis since we do not currently have a rating agency-based credit rating. Prospectively, we will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.
We have elected not to recognize leases with an original term of one year or less on the balance sheet. We typically only include an initial lease term in our assessment of a lease arrangement. Options to renew a lease are not included in our assessment unless there is reasonable certainty that we will renew.
Assumptions that we made at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.
In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.
Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. We have elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.
ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. We apply the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to our entire portfolio of leases.
Accrued research and development expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time.  
66
We recognize expenses related to clinical studies based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period and adjust accordingly.
Other examples of estimated accrued research and development expenses include fees paid to:
•investigative sites in connection with clinical studies;
•vendors in connection with preclinical development activities; and
•vendors related to the development, manufacturing, and distribution of clinical trial materials.
Stock-based compensation
We issue stock-based awards to employees and non-employees, generally in the form of stock options and restricted stock units. We account for our stock-based awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation ("ASC 718"). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values.  Prior to the adoption of Accounting Standards Update (“ASU”) No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”),  the measurement date for non-employee awards was generally the date the services are completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards.  After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis.
Our stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, non-employees, and directors, with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees and non-employees with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable. We estimate the probability that certain performance criteria will be met and do not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.  
We estimate the fair value of our stock-based awards to employees, non-employees, and directors, using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected volatility of our stock, (ii) the expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, we eliminated the use of a representative peer group and use only our own historical volatility data in our estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of our own stock price. We estimate the expected life of our employee stock options using the “simplified” method, whereby, the expected life equals the average of the vesting term and the original contractual term of the option, unless there are more appropriate indicators of the expected life when measuring the fair value of a modified award. The risk-free interest rates for periods within the expected life of the option were based on the U.S. Treasury yield curve in effect during the period the options were granted.
Conversion and modification of equity awards outstanding at Separation date
In connection with the Separation on November 4, 2021, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution bluebird stock received a number of otherwise-similar awards either in post-Distribution bluebird stock or in a combination of post-Distribution bluebird stock and 2seventy bio stock based on conversion ratios outlined for each group of employees in the Employee Matters Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to 2021 were converted under the shareholder method, wherein employees holding outstanding equity awards received
67
equity awards in both bluebird and 2seventy bio. The conversion ratio for the shareholder method took into consideration a distribution ratio of one share of 2seventy bio common stock for every three shares of bluebird common stock. For equity awards granted in 2021, the number of awards that were outstanding at the Separation were proportionately adjusted to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the volume weighted-average trading price for bluebird common stock for the five trading days before and after the Separation.
These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by 2seventy bio employees and directors. We will incur future compensation cost related to 2seventy bio equity awards held by our employees.
Recent accounting pronouncements
See Note 2, Summary of significant accounting policies and basis of presentation, in the notes to consolidated financial statements for a description of recent accounting pronouncements applicable to our business.

68
Results of Operations
Comparison of the years ended December 31, 2021 and 2020:
Year ended December 31,
20212020Change
(in thousands)
Revenue:
Product revenue$2,850 $— $2,850 
Other revenue812 — 812 
Total revenues3,662 — 3,662 
Operating expenses:
Research and development319,946 319,309 637 
Selling, general and administrative209,969 239,950 (29,981)
Cost of product revenue38,857 — 38,857 
Restructuring expense25,801 — 25,801 
Total operating expenses594,573 559,259 35,314 
Loss from operations(590,911)(559,259)(31,652)
Interest income, net879 5,770 (4,891)
Other income (expense), net27,652 (6,881)34,533 
Loss before income taxes(562,380)(560,370)(2,010)
Income tax (expense) benefit(258)(686)428 
Net loss from continuing operations$(562,638)$(561,056)$(1,582)
Net loss from discontinued operations$(256,740)$(57,639)$(199,101)
Net loss$(819,378)$(618,695)$(200,683)

Revenue. Total revenue was $3.7 million for the year ended December 31, 2021 and is comprised primarily of product revenue from sales of ZYNTEGLO in Germany. For the year ended December 31, 2020 we had no sales of ZYNTEGLO as we had not yet obtained pricing approval in Germany.
Research and development expenses. Research and development expenses were $319.9 million for the year ended December 31, 2021, compared to $319.3 million for the year ended December 31, 2020. The increase of $0.6 million was primarily attributable to the following:
•$13.1 million of increased information technology and facility-related costs;
•$4.8 million of increased material production fees; and
•$2.1 million of increased value-added taxes.
These increased costs were partially offset by:
•$5.5 million of decreased clinical trial costs primarily driven by the clinical hold from February 2021 to June 2021 on our studies of lovo-cel;
•$5.4 million of decreased lab expenses and platform costs;
•$3.1 million of decreased net employee compensation, benefit, and other headcount related expenses, which is primarily driven by a decrease of $6.8 million in stock-based compensation expense due to an overall decrease in the value of awards, offset by an increase due to our employee retention program in 2021.
•$2.5 million of decreased consulting expenses; and
•$2.2 million of decreased medical research costs.
69
Selling, general and administrative expenses. Selling, general and administrative expenses were $210.0 million for the year ended December 31, 2021, compared to $240.0 million for the year ended December 31, 2020. The decrease of $30.0 million was primarily due to the following:
•$17.3 million of decreased employee compensation, benefit, and other headcount related expenses, which is primarily driven by a decrease of $17.1 million in stock-based compensation expense due to an overall decrease in the value of awards, partially offset by an increase primarily driven by our employee retention program in 2021;
•$7.4 million of decreased costs related to consultants;
•$7.2 million of decreased costs related to commercial readiness activities due to delays in commercialization as a result of the COVID-19 pandemic and our decision to focus our efforts on the U.S. market for beti-cel, eli-cel, and lovo-cel; and
•$2.6 million of decreased costs related to professional service costs.
These decreased costs were partially offset by:
•$4.6 million of increased costs related to information technology and facility-related costs.
Cost of product revenue. Cost of product revenue was $38.9 million for the year ended December 31, 2021. We did not have cost of product revenue for the year ended December 31, 2020.  The increase is attributable to costs of sales associated with product sales of ZYNTEGLO in Germany as well as the reserves for excess inventory recognized during the second and third quarters of 2021 based on forecasted consumption levels due to the winddown of our European operations.
Restructuring expenses. Restructuring expenses were $25.8 million for the year ended December 31, 2021. We did not have restructuring expenses for the year ended December 31, 2020. The increase in restructuring expenses is primarily related to the costs associated with the reduction in workforce as a result of our decision to wind down our European operations.
Interest income, net. The decrease in interest income, net was primarily related to decreased interest income earned on investments due to an overall decrease in investments.
Other income (expense), net. The change in other income (expense), net was primarily related to the gain recognized on equity securities.
Comparison of the years ended December 31, 2020 and 2019:
Year ended December 31,
20202019Change
(in thousands)
Operating expenses:
Research and development319,309 327,119 (7,810)
Selling, general and administrative239,950 235,844 4,106 
Total operating expenses559,259 562,963 (3,704)
Loss from operations(559,259)(562,963)3,704 
Interest income, net5,770 17,380 (11,610)
Other expense, net(6,881)(9,984)3,103 
Loss before income taxes(560,370)(555,567)(4,803)
Income tax (expense) benefit(686)545 (1,231)
Net loss from continuing operations(561,056)(555,022)(6,034)
Net loss from discontinued operations(57,639)(234,586)176,947 
Net loss$(618,695)$(789,608)$170,913 
Research and development expenses. Research and development expenses were $319.3 million for the year ended December 31, 2020, compared to $327.1 million for the year ended December 31, 2019. The decrease of $7.8 million was primarily attributable to the following:
•$6.9 million of decreased value-added taxes;
70
•$3.6 million of decreased employee compensation, benefit, and other headcount related expenses, which is primarily driven by a decrease of $9.6 million in stock-based compensation expense offset by an increase in research and development headcount to support overall growth;
•$2.2 million of decreased medical research costs;
•$2.1 million of decreased information technology and facility-related costs;
•$1.6 million of decreased lab costs; and
•$1.3 million of decreased collaboration research funding costs.
These decreased costs were partially offset by:
•$8.7 million of increased material production and non-clinical services costs; and
•$1.8 million of increased consulting costs.
Selling, general and administrative expenses. Selling, general and administrative expenses were $240.0 million for the year ended December 31, 2020, compared to $235.8 million for the year ended December 31, 2019. The increase of approximately $4.1 million was primarily due to the following:
•$8.4 million of increased information technology and facility-related costs primarily due to increased investment in software applications and technology; and
•$5.3 million of increased employee compensation, benefit, and other headcount related expenses, which is primarily driven by an increase in selling, general, and administrative headcount to support overall growth, including an increase of $1.1 million in stock-based compensation expense.
These increased costs were partially offset by:
•$8.3 million of decreased costs related to commercial readiness activities due to delays in commercial launch activities during 2020 as a result of the COVID-19 pandemic; and
•$1.6 million of decreased consulting and professional service fees primarily related to commercial strategy and product marketing.
Interest income, net. The decrease in interest income, net was primarily related to decreased interest income earned on investments due to an overall decrease in interest rates.
Other expense, net. The decrease in other expense, net was primarily related to changes in fair value on equity securities.
Liquidity and Capital Resources
As of December 31, 2021, we had cash, cash equivalents and marketable securities of approximately $396.6 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. As of December 31, 2021, our funds are primarily held in U.S. government agency securities and treasuries, equity securities, corporate bonds, commercial paper, and money market accounts.
We have incurred losses and cumulative negative cash flows from operations since our inception in April 1992, and as of December 31, 2021, we had an accumulated deficit of $3.72 billion. We expect that we will continue to incur significant research and development and selling, general and administrative expenses and, as a result, we will need additional capital to fund our operations within the next twelve months, which we may raise through public or private equity or debt financings, strategic collaborations, or other sources which are not entirely within our control nor have been approved by our Board of Directors as of the date of this filing. Potential additional funding from other sources includes the sale of priority review vouchers, if received.
The likelihood of our long-term success must be considered in light of the expenses, difficulties, and potential delays to be encountered in the development and commercialization of new pharmaceutical products, competitive factors in the marketplace and the complex regulatory environment in which we operate. We may never achieve significant revenue or profitable operations. These factors create substantial doubt about the Company’s ability to continue as a going concern. The
71
accompanying Consolidated Financial Statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The CFS do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
We have funded our operations principally from the sale of common stock in public offerings and through our collaborations with BMS as outlined below:
•In May 2020, we entered into the First Amendment to the Amended and Restated Co-Development, Co-Promote and Profit Share Agreement (as amended, the “Amended Ide-cel CCPS”) and the Second Amended and Restated bb21217 License Agreement (“Amended bb21217 License Agreement”) with BMS (relating to our ide-cel and bb21217 programs which were assigned to 2seventy bio effective upon completion of the Separation), pursuant to which BMS modified its obligations to pay us for future ex-U.S. milestones and royalties on commercial sales by making a one-time up-front payment of $200.0 million.
•In May 2020, we sold 10.5 million shares of common stock (inclusive of shares sold pursuant to an option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $55.00 per share for aggregate net proceeds of $541.5 million.
•On July 2021, we sold our bluebird Research Triangle manufacturing facility in North Carolina as part of an agreement with National Resilience, Inc ("Resilience"). In consideration, upon closing of the transaction we received $110.3 million from Resilience.
•In September 2021, we sold 2.3 million shares of common stock through a private placement offering of securities at a price of $16.50 per share as well as pre-funded warrants to purchase up to 2.3 million shares of common stock at an effective price of $16.49 per share ($16.49 paid to us upon the closing of the offering and $0.01 to be paid upon exercise of such pre-funded warrants) for aggregate gross proceeds of $75.0 million.
Sources of Liquidity
The discussion of our cash flows that follows does not include the impact of any adjustments to remove discontinued operations, unless otherwise noted, and is stated on a total company consolidated basis. The separation of our oncology business may have a negative impact on our cash flows in future periods.
Cash Flows
The following table summarizes our cash flow activity:
Year ended December 31,
202120202019
(in thousands)
Net cash used in operating activities$(635,639)$(470,351)$(564,384)
Net cash provided by (used in) investing activities562,557 (84,345)507,807 
Net cash (used in) provided by financing activities(93,954)546,715 21,187 
Decrease in cash, cash equivalents and restricted cash$(167,036)$(7,981)$(35,390)
Operating Activities. The net cash used in operating activities was $635.6 million for the year ended December 31, 2021 and primarily consisted of a net loss of $819.4 million adjusted for non-cash items including stock-based compensation of $127.9 million, the recognition of a reserve for excess inventories of $29.9 million and depreciation and amortization of $19.6 million, change in net working capital of $18.0 million, and other non-cash items of $17.2 million, offset by an unrealized gain on equity securities of $29.4 million.
The net cash used in operating activities was $470.4 million for the year ended December 31, 2020 and primarily consisted of a net loss of $618.7 million adjusted for non-cash items including stock-based compensation of $156.6 million and depreciation and amortization of $19.4 million, as well as the change in our net working capital.
The net cash used in operating activities was $564.4 million for the year ended December 31, 2019 and primarily consisted of a net loss of $789.6 million adjusted for non-cash items including stock-based compensation of $160.6 million and depreciation and amortization of $17.4 million, as well as the change in our net working capital.
72
Discontinued operations contributed net losses of $256.7 million, $57.6 million and $234.6 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Investing Activities. Net cash provided by investing activities for the year ended December 31, 2021 was $562.6 million and was primarily due to proceeds from the maturities of available-for-sale marketable securities of $895.3 million, proceeds from the sale of the Durham, North Carolina manufacturing facility of $110.3 million, and proceeds from sales of marketable securities of $31.3 million, offset by the purchase of $451.4 million of available-for-sale marketable securities and the purchase of $14.5 million of property, plant and equipment.
Net cash used in investing activities for the year ended December 31, 2020 was $84.3 million and was primarily due to the purchase of $1.00 billion of marketable securities and the purchase of $29.0 million of property, plant and equipment offset by proceeds from the maturities of available-for-sale marketable securities of $918.3 million and proceeds from sales of marketable securities of $29.9 million.
Net cash provided by investing activities for the year ended December 31, 2019 was $507.8 million and was primarily due to proceeds from the maturities of available-for-sale marketable securities of $1.34 billion offset by the purchase of $756.6 million of marketable securities and the purchase of $71.0 million of property, plant and equipment.
Financing Activities: Net cash used in financing activities for the year ended December 31, 2021 was $94.0 million and was primarily due to net cash of $174.3 million transferred to 2seventy bio in connection with the Separation offset by net cash proceeds from our issuance of common stock and warrants of $75.0 million.
Net cash provided by financing activities for the year ended December 31, 2020 was $546.7 million and was primarily due to net cash proceeds from our May 2020 common stock offering.
Net cash provided by financing activities for the year ended December 31, 2019 was $21.2 million and was due to net cash proceeds from employee option exercises and ESPP contributions.
Contractual Obligations and Commitments
Lease commitments
60 Binney Street sublease

In October 2021, we entered into a consent to assignment and amendment to our lease agreement for our 60 Binney Street lease (the "Assignment"). The Assignment transfers our interest in the lease to 2seventy bio and releases us from our obligation to maintain the $13.8 million collateralized letter of credit required under the original 60 Binney Street lease. Although the lease was legally transferred to 2seventy bio, the lessor required that we remain secondarily liable as a guarantor for payment obligations accruing under the 60 Binney Street lease from the date of Assignment until (i) we have completely vacated the premises and (ii) 2seventy bio has reached a market capitalization of $900 million. Upon Separation, the lease assignment was accounted for as the termination of the original lease and we de-recognized the right-of-use asset and lease liability related to the 60 Binney Street lease and recognized the fair value of the guarantee pursuant to ASC 405, Liabilities. The fair value of the guarantee was not material.

Concurrent with the Assignment of the 60 Binney Street lease, we entered into a sublease agreement with 2seventy bio for office, laboratory and storage space located at 60 Binney Street (the "60 Binney Street Sublease") while we construct and outfit our new office and laboratory space. Under the terms of the 60 Binney Street Sublease, we will lease 72,988 square feet for $0.5 million per month in base rent for the period beginning from the Assignment through March 2022 and 58,004 square feet for $0.4 million per month in base rent for the period from April 2022 through March 2024. We will also pay monthly fees for use of the facilities and support personnel, calculated based on our pro-rata share of operating costs during the term of the 60 Binney Street Sublease. We accounted for the 60 Binney Street Sublease as a new lease under ASC 842, and in November 2021, we recognized a right-of-use asset and lease liability related to the 60 Binney Street Sublease.
50 Binney Street sublease
In April 2019, we entered into a sublease agreement for office space located at 50 Binney Street in Cambridge, Massachusetts (the "50 Binney Street Sublease") to supplement our corporate headquarters located at 60 Binney Street in Cambridge, Massachusetts. Under the terms of the 50 Binney Street Sublease, we will lease 267,278 square feet of office space for $99.95 per square foot, or $26.7 million per year in base rent subject to certain operating expenses, taxes and annual rent increases of approximately 3%. The lease will commence when the space is available for use, which is anticipated to be in the
73
first half of 2022, which reflects the sublessor's exercise of its option to postpone the commencement date of the sublease, and end on December 31, 2030, unless other conditions specified in the 50 Binney Street Sublease occur. Upon signing the 50 Binney Street Sublease, we executed a $40.1 million cash-collateralized letter of credit, which may be reduced in the future subject to the terms of the 50 Binney Street Sublease and certain reduction requirements specified therein. The $40.1 million of cash collateralizing the letter of credit is classified as restricted cash and other non-current assets on our consolidated balance sheets. Payments will commence at the earlier of (i) the date which is 90 days following the commencement date and (ii) the date we take occupancy of all or any portion of the premises. In connection with the execution of the 50 Binney Street Sublease, we also entered into a purchase agreement for furniture and equipment (the “Furniture Purchase Agreement”) located on the premises upon lease commencement. Upon execution of the Furniture Purchase Agreement, we made an upfront payment of $7.5 million, all of which was recorded within restricted cash and other non-current assets on our consolidated balance sheets and assessed for recoverability on a recurring basis.
In December 2021, we entered into a sub-sublease agreement with Meta Platforms. Inc. ("Meta"). Under the terms of the sub-sublease, we are subleasing the entirety of the 50 Binney Street premises which we have rights to under the sublease. We are sub-subleasing the premises for $28.0 million in the first year with 3% annual increases in each subsequent year. Meta will receive access to 50 Binney Street at the lease commencement date, which is the same point that we would receive access under the sublease. We remain liable under the sublease, including for the maintenance of the $40.1 million collateralized letter of credit. As a result of the execution of the sub-sublease, we assessed the $7.5 million deposit related to the Furniture Purchase Agreement for recoverability and determined that the amount was not recoverable. As a result, we recorded $7.5 million in our consolidated statements of operations and comprehensive loss as selling, general and administrative expense during the year ended December 31, 2021.
Assembly Row lease
In November 2021, we entered into a lease agreement with Assembly Row 5B, LLC (the "Landlord") for office space located at 455 Grand Union Boulevard in Somerville, Massachusetts to serve as our future headquarters. Under the terms of the arrangement, we will lease approximately 61,180 square feet starting at an annual rate of $45 per square foot, subject to annual increases of 2.5%, plus operating expenses and taxes. In addition, we will be eligible for a tenant work allowance of $160 per rentable square foot of the premises. The lease will commence on the date on which the Landlord tenders possession of the premises to us with any tenant work required to be performed by the Landlord substantially completed, which is anticipated to occur in the first half of 2022.
Embedded leases
In June 2016, we entered into a manufacturing agreement for the future commercial production of our beti-cel and eli-cel drug products with a contract manufacturing organization. Under this 12-year agreement, the contract manufacturing organization will complete the design, construction, validation and process validation of the leased suites prior to anticipated commercial launch of the product candidates. During construction, we paid $12.0 million upon the achievement of certain contractual milestones. We paid $5.0 million for the achievement of the first and second contractual milestones during 2016 and paid $5.5 million for the third and fourth contractual milestones achieved during 2017. In March 2018, $1.5 million of the possible $2.0 million related to the fifth contractual milestone was achieved and was paid in the second quarter of 2018.  Construction was completed in March 2018, and beginning in April 2018 we paid $5.1 million per year in fixed suite fees as well as certain fixed labor, raw materials, testing and shipping costs for manufacturing services. We may terminate this agreement at any time upon payment of a one-time termination fee and up to 24 months of fixed suite and labor fees. We concluded that this agreement contains an embedded lease as the suites are designated for our exclusive use during the term of the agreement. We concluded that we are not the deemed owner during construction nor is it a capital lease under ASC 840-10, Leases – Overall.  As a result, in prior periods we accounted for the agreement as an operating lease under ASC 840 and recognized straight-line rent expense over the non-cancellable term of the embedded lease. As part of our adoption of ASC 842, effective January 1, 2019, we carried forward the existing lease classification under ASC 840. Additionally, we recorded a right-of-use asset and lease liability for this operating lease on the effective date and are recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
In November 2016, we entered into an agreement for clinical and commercial production of our beti-cel, lovo-cel, and eli-cel drug products with a contract manufacturing organization at an existing facility. We concluded that this agreement contains an embedded operating lease as the clean rooms are designated for our exclusive use during the term of the agreement. The term of the agreement is five years with subsequent three-year renewals at the mutual option of each party. As a result, we recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842, and are recognizing rent expense on a straight-line basis throughout the estimated remaining term of the embedded lease. In March 2020, we amended this agreement with the contract manufacturing organization, resulting in a lease modification. Under the terms of the
74
amended arrangement, we may be required to pay annual maintenance and production fees of up to €16.5 million, depending on its production needs, and may terminate this agreement with twelve months’ notice and a one-time termination fee. The amendment also provides for an option to reserve an additional clean room for a one-time option fee plus annual maintenance fees. As a result, we increased the right-of-use asset and lease liability related to this embedded operating lease during the first quarter of 2020. In September 2021, we reassessed the term of this lease in light of the planned orderly wind down of its operations in Europe. As a result, we reduced the right-of-use asset and related lease liability to reflect a shortened expected term of the agreement. In November 2021, we exercised our right to terminate the lease agreement, and such termination will be effective in November 2022. Per the terms of the amended agreement, we were obligated to pay a one-time termination fee of €1.0 million upon termination, which was paid in December 2021. In connection with this termination, we will pay for services properly rendered through the date of termination in accordance with the contract manufacturing agreement, based on work completed and expenses incurred prior to the date of termination.

In July 2020, we entered into an agreement reserving manufacturing capacity with a contract manufacturing organization. We concluded that this agreement contains an embedded lease as a controlled environment room at the facility is designated for our exclusive use during the term of the agreement, with the option to sublease the space if we provide notice that we will not utilize it for a specified duration of time. Under the terms of the agreement, we will be required to pay up to $5.4 million per year in maintenance fees in addition to the cost of any services provided and may terminate this agreement with eighteen months' notice. The term of the agreement is five years, with the option to extend, and the agreement commenced in March 2021. We classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in March 2021 and are recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.

In February 2021, we entered into another agreement reserving manufacturing capacity with a contract manufacturing organization. We concluded that this agreement contains an embedded lease as a controlled environment room at the facility is designated for our exclusive use during the term of the agreement. We also have the option to sublease the space if we provide notice that we will not utilize it for a specified duration of time. Under the terms of the agreement, we are required to pay up to $4.2 million per year in maintenance fees and an immaterial amount of other annual fees as well as per-batch fees for the cost of any services provided. Either party may terminate this agreement with eighteen months’ notice at any time or with eight months’ notice after stage 5 has commenced. The term of the agreement is five years, with the option to extend. The agreement commenced in November 2021 and upon commencement we classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability. We recognize rent expense on a straight-line basis throughout the remaining term of the embedded lease.
Contingent Milestone and Royalty Payments
We also have obligations to make future payments to third parties that become due and payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing of a BLA, approval by the FDA or product launch). We do not recognize these commitments in our financial statements until they become payable or have been paid.
Based on our development plans as of December 31, 2021, we may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with our collaboration and license agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. Because the achievement of these milestones or sales had not occurred as of December 31, 2021, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments and sales-based royalties are not yet considered contractual obligations as they are contingent upon success.
•Under a license agreement with Inserm-Transfert pursuant to which we license certain patents and know-how for use in adrenoleukodystrophy therapy, we will be required to make payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate payments we may be obligated to pay for each of these milestone categories per product is €0.3, €0.2 and €1.6 million, respectively. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits.
•Under a license agreement with Institut Pasteur pursuant to which we license certain patents for use in ex vivo gene therapy, we will be required to make payments per product covered by the in-licensed intellectual property upon the achievement of development and regulatory milestones, depending on the indication and the method of treatment. The maximum aggregate payments we may be obligated to pay for each of these milestone categories per product is €1.5 and €2.0 million, respectively. We will also be required to pay a royalty on net sales of products covered by the in-
75
licensed intellectual property in the low single digits, which varies slightly depending on the indication of the product. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of such license income varying from the low single digits to mid-range double digits depending on the nature of the sublicense and stage of development. We are required to make an annual maintenance payment, which is creditable against royalty payments on a year-by-year basis. On April 1, 2015, we amended this license agreement with Institut Pasteur, which resulted in a payment of €3.0 million that was paid during the second quarter of 2015.  
•Under a license agreement with the Board of Trustees of the Leland Stanford Junior University ("Stanford") pursuant to which we license the HEK293T cell line for use in gene therapy products, we are required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits that varies with net sales. The royalty is reduced for each third-party license that requires payments by us with respect to a licensed product, provided that the royalty to Stanford is not less than a specified percentage that is less than one percent. We have been paying Stanford an annual maintenance fee, which will be creditable against our royalty payments.
•Under a license agreement with the Massachusetts Institute of Technology ("MIT") pursuant to which we license various patents, we will be required to make a payment of $0.1 million based upon a regulatory filing milestone. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property by us or our sublicensees. The royalty is in the low single digits and is reduced for royalties payable to third parties, provided that the royalty to MIT is not less than a specified percentage that is less than one percent. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of such license income varying from the mid-single digits to low double digits. We are required to pay MIT an annual maintenance fee based on net sales of licensed products, which is creditable against our royalty payments.
•Under a license agreement with Research Development Foundation pursuant to which we license patents that involve LVV, we will be required to make payments of $1.0 million based upon a regulatory milestone for each product covered by the in-licensed intellectual property. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits, which is reduced by half if during the ten years following first marketing approval the last valid claim within the licensed patent that covers the licensed product expires or ends.  
•Under a license agreement with SIRION Biotech GmbH ("Sirion") pursuant to which we license certain patents directed to manufacturing related to our LentiGlobin product candidate, we will be required to make certain payments related to certain development milestone obligations and must report on our progress in achieving these milestones on a periodic basis. We may be obligated to pay up to $13.4 million in the aggregate for each product covered by the in-licensed intellectual property. Upon commercialization of our products covered by the in-licensed intellectual property, we will be obligated to pay Sirion a percentage of net sales as a royalty in the low single digits. The royalties payable under this license agreement are subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits.  
Other Funding Commitments
We enter into contracts in the normal course of business with CROs for preclinical research studies and clinical trials, research supplies and other services and products for operating purposes.  We have also entered into multi-year agreements with a manufacturing partner in the United States (Henogen, previously Novasep, and now part of Thermo Fisher Scientific, Inc.), which is partnering with us on production of LVV for lovo-cel. In addition, we have entered into a multi-year agreement with Lonza Houston, Inc. to produce drug product for beti-cel and eli-cel. Currently, SAFC Carlsbad, Inc. ("SAFC", a subsidiary of MilliporeSigma), is the sole manufacturer of the LVV for eli-cel and beti-cel. In our manufacturing agreement with Minaris, we reserve production capacity for the manufacture of our drug product.  Our total non-cancelable contractual obligations arising from these manufacturing agreements is $53.8 million, with $43.9 million of these obligations due within the next twelve months. We believe our team of technical personnel has extensive manufacturing, analytical and quality experience as well as strong project management discipline to effectively oversee these contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions and potential commercial launch. We are engaging with apheresis and infusion centers, which we refer to as qualified treatment centers, that will be the centers for collection of HSCs from the patient and for infusion of drug product to the patient. For the treatment of patients with our drug product in the commercial setting, we are entering into agreements with participating qualified treatment centers in the jurisdictions where we plan to commercialize our products. These contracts generally provide for termination on notice.  Wherever contracts include stipulated commitment payments, we have included such payments in the table of contractual obligations and commitments.
76
Item 7A. Quantitative and Qualitative Disclosures About Market Risks
We are exposed to market risk related to changes in interest rates. As of December 31, 2021 and 2020, we had cash, cash equivalents and marketable securities of $396.6 million and $741.7 million, respectively, primarily invested in U.S. government agency securities and treasuries, equity securities, corporate bonds, commercial paper and money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase. If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at December 31, 2021, the net fair value of our interest-sensitive marketable securities would have resulted in a hypothetical decline of $1.8 million.
Item 8. Financial Statements and Supplementary Data
The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is found in Item 15.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)- 15(e) and 15(d)- 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) under the Exchange Act.
Under the supervision and with the participation of management, including our principal executive and financial officers, we assessed our internal control over financial reporting as of December 31, 2021, based on criteria for effective internal control over financial reporting established in Internal Control — Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management’s assessment of the effectiveness of our internal control over financial reporting included testing and evaluating the design and operating effectiveness of our internal controls.  In our management’s opinion, we have maintained effective internal control over financial reporting as of December 31, 2021, based on criteria established in the COSO 2013 framework.
The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.
77
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
78
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of bluebird bio, Inc.
Opinion on Internal Control over Financial Reporting
We have audited bluebird bio, Inc.’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, bluebird bio, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated March 4, 2022 expressed an unqualified opinion thereon that included an explanatory paragraph regarding the Company’s ability to continue as a going concern.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ Ernst & Young LLP
Boston, Massachusetts
March 4, 2022
79
Item 9B. Other Information
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and certain other persons to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. We have been advised that none of our officers have entered into trading plans covering periods after the date of this annual report on Form 10-K in accordance with Rule 10b5-1 and our policy governing transactions in our securities. Generally, under these trading plans, the individual relinquishes control over the transactions once the trading plan is put into place. Accordingly, sales under these plans may occur at any time, including possibly before, simultaneously with, or immediately after significant events involving our company. We do not undertake to report Rule 10b5-1 trading plans that may be adopted by any officers or directors in the future, or to report any modifications or termination of any publicly announced trading plan, except to the extent required by law.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.
80
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.
Item 11. Executive Compensation
Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.
Item 13. Certain Relationships and Related Transactions and Director Independence
Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.
Item 14. Principal Accountant Fees and Services
Incorporated by reference from the information in our Proxy Statement for our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.
81
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements.
The response to this portion of Item 15 is set forth under Item 8 above.
(a)(2) Financial Statement Schedules.
All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto set forth under Item 8 above.
(a)(3) Exhibits.
See the Exhibit Index immediately before the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.
Item 16. Form 10-K Summary
Not applicable.
82
bluebird bio, Inc.

F-1
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of bluebird bio, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of bluebird bio, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 4, 2022 expressed an unqualified opinion thereon.
The Company's Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company’s ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.




F-2


Accrued Clinical and Contract Research Organization Costs and Manufacturing Costs
Description of the Matter
As discussed in Note 2 to the consolidated financial statements, the Company records costs for clinical trial activities and manufacturing activities based upon estimates of costs incurred through the balance sheet date that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, contract manufacturing organizations or other vendors. The Company’s accruals for clinical and contract research organization costs and manufacturing costs totaled $33.5 million at December 31, 2021.

Auditing the Company’s accruals for clinical and contract research organization costs and manufacturing costs is especially complex due to the fact that information necessary to estimate the accruals is accumulated from multiple sources. In addition, in certain circumstances, the determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the level of services provided and there may be delays in invoicing from clinical study sites and other vendors.

How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that addressed the information used in and the identified risks related to the Company’s process for recording accrued clinical and contract research organization costs and manufacturing costs.


To test the completeness and valuation of the accruals for clinical and contract research organization costs and manufacturing costs, we performed audit procedures that included, among others, reading certain contracts with contract research organizations, contract manufacturing organizations, and clinical study sites to evaluate financial and certain other contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual computations. We also compared the progress of clinical trials and the progress of manufacturing completed through the balance sheet date with information provided by the Company’s operations personnel that oversee the clinical trials and manufacturing activities. Additionally, we obtained information from certain clinical study sites and contract manufacturing organizations which indicated the progress of clinical trials and the progress of manufacturing completed through the balance sheet date and compared that to the Company’s accrual computations.


/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2012.
Boston, Massachusetts
March 4, 2022
F-3
bluebird bio, Inc.
Consolidated Balance Sheets
(in thousands, except per share amounts)
As of December 31,
20212020
Assets
Current assets:
Cash and cash equivalents$161,160 $260,629 
Marketable securities138,343 419,599 
Prepaid expenses25,628 25,718 
Inventory— 10,698 
Receivables and other current assets11,389 3,872 
Current assets of discontinued operations— 495,021 
Total current assets336,520 1,215,537 
Marketable securities97,114 61,445 
Property, plant and equipment, net9,706 17,373 
Intangible assets, net— 4,397 
Goodwill5,646 5,646 
Operating lease right-of-use assets91,532 67,563 
Restricted cash and other non-current assets53,277 65,727 
Non-current assets of discontinued operations— 343,564 
Total assets$593,795 $1,781,252 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$25,883 $13,811 
Accrued expenses and other current liabilities103,958 98,190 
Operating lease liability, current portion23,152 9,711 
Current liabilities of discontinued operations— 81,876 
Total current liabilities152,993 203,588 
Operating lease liability, net of current portion66,432 55,707 
Other non-current liabilities93 5,759 
Non-current liabilities of discontinued operations — 161,142 
Total liabilities$219,518 $426,196 
Commitments and contingencies Note 11
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and
   outstanding at December 31, 2021 and December 31, 2020
$— $— 
Common stock, $0.01 par value, 125,000 shares authorized; 71,115 and 66,432 shares
   issued and outstanding at December 31, 2021 and December 31, 2020, respectively
711 665 
Additional paid-in capital4,096,402 4,260,443 
Accumulated other comprehensive loss(2,911)(5,505)
Accumulated deficit(3,719,925)(2,900,547)
Total stockholders' equity374,277 1,355,056 
Total liabilities and stockholders' equity$593,795 $1,781,252 
See accompanying notes to consolidated financial statements.
F-4
bluebird bio, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
Year ended December 31,
202120202019
Revenue:
Product revenue$2,850 $— $— 
Other revenue812 — — 
Total revenues3,662 — — 
Operating expenses:
Research and development319,946 319,309 327,119 
Selling, general and administrative209,969 239,950 235,844 
Cost of product revenue38,857 — — 
Restructuring expense25,801 — — 
Total operating expenses594,573 559,259 562,963 
Loss from operations(590,911)(559,259)(562,963)
Interest income, net879 5,770 17,380 
Other income (expense), net27,652 (6,881)(9,984)
Loss before income taxes(562,380)(560,370)(555,567)
Income tax (expense) benefit(258)(686)545 
Net loss from continuing operations(562,638)(561,056)(555,022)
Net loss from discontinued operations(256,740)(57,639)(234,586)
Net loss$(819,378)$(618,695)$(789,608)
Net loss per share from continuing operations—basic and diluted$(8.16)$(9.02)$(10.06)
Net loss per share from discontinued operations—basic and diluted$(3.73)$(0.93)$(4.25)
Net loss per share—basic and diluted$(11.89)$(9.95)$(14.31)
Weighted-average number of common shares used in computing net loss per
   share—basic and diluted		68,910 62,178 55,191 
Other comprehensive income (loss):
Other comprehensive income (loss), net of tax benefit (expense) of
  $0.0 million, $0.0 million and $(1.2) million for the years ended
  December 31, 2021, 2020 and 2019, respectively
2,364 (3,612)1,734 
Total other comprehensive income (loss)2,364 (3,612)1,734 
Comprehensive loss$(817,014)$(622,307)$(787,874)
See accompanying notes to consolidated financial statements.
F-5
bluebird bio, Inc.
Consolidated Statements of Stockholders’ Equity
(in thousands)
Common stockAdditional
paid-in
capital		Accumulated
other
comprehensive
loss		Accumulated
deficit		Total
stockholders'
equity
SharesAmount
Balances at December 31, 201854,738 $547 $3,386,958 $(3,627)$(1,498,808)$1,885,070 
Adjustment to beginning
   accumulated deficit from adoption
   of ASU 2016-02
— — — — 6,564 6,564 
Vesting of restricted stock units251 3 (3)— — — 
Exercise of stock options354 4 17,834 — — 17,838 
Purchase of common stock under
   ESPP		25 — 2,766 — — 2,766 
Stock-based compensation— — 160,629 — — 160,629 
Other comprehensive income— — — 1,734 — 1,734 
Net loss— — — — (789,608)(789,608)
Balances at December 31, 201955,368 554 3,568,184 (1,893)(2,281,852)1,284,993 
Issuance of common stock upon
   public offering, net of issuance
   costs of $33,645
10,455 105 541,431 — — 541,536 
Vesting of restricted stock units434 4 (4)— — — 
Exercise of stock options95 1 1,846 — — 1,847 
Purchase of common stock under
   ESPP		80 1 3,774 — — 3,775 
Stock-based compensation— — 145,212 — — 145,212 
Other comprehensive loss— — — (3,612)— (3,612)
Net loss— — — — (618,695)(618,695)
Balances at December 31, 202066,432 665 4,260,443 (5,505)(2,900,547)1,355,056 
Vesting of restricted stock units534 5 (5)— — — 
Exercise of stock options218 2 1,486 — — 1,488 
Purchase of common stock under
   ESPP		120 1 2,580 — — 2,581 
Issuance of common stock for private
   equity placement		2,273 23 37,477 — — 37,500 
Issuance of pre-funded warrants— — 37,477 — — 37,477 
Issuance of unrestricted stock awards
   to settle accrued employee
   compensation		1,538 15 25,059 — — 25,074 
Stock-based compensation— — 110,260 — — 110,260 
Distribution of 2seventy bio— — (378,375)230 — (378,145)
Other comprehensive income— — — 2,364 — 2,364 
Net loss— — — — (819,378)(819,378)
Balances at December 31, 202171,115 $711 $4,096,402 $(2,911)$(3,719,925)$374,277 
See accompanying notes to consolidated financial statements.
F-6
bluebird bio, Inc.
Consolidated Statements of Cash Flows
(in thousands)
Year ended December 31,
202120202019
Cash flows from operating activities:
Net loss$(819,378)$(618,695)$(789,608)
Adjustments to reconcile net loss to net cash used in operating
   activities:
Change in fair value of contingent consideration387 (6,468)2,747 
Depreciation and amortization19,649 19,356 17,434 
Stock-based compensation expense127,915 156,631 160,629 
Unrealized loss (gain) on equity securities(29,356)7,217 9,297 
Excess inventory reserve29,924 — — 
Other non-cash items17,235 458 (11,000)
Changes in operating assets and liabilities:
Prepaid expenses and other assets(5,289)(10,089)(13,913)
Inventory(18,447)— — 
Operating lease right-of-use assets30,148 21,281 22,496 
Accounts payable9,286 (20,100)23,600 
Accrued expenses and other liabilities40,025 4,835 29,617 
Operating lease liabilities(32,142)(17,380)(9,944)
Collaboration research advancement(5,596)(7,397)(5,739)
Net cash used in operating activities(635,639)(470,351)(564,384)
Cash flows from investing activities:
Purchase of property, plant and equipment
(14,503)(28,986)(71,028)
Purchases of marketable securities(451,391)(1,003,525)(756,570)
Proceeds from maturities of marketable securities895,333 918,288 1,340,629 
Proceeds from sales of marketable securities31,318 29,878 — 
Proceeds from sale of Durham, North Carolina manufacturing facility110,300 — — 
Purchase of intangible assets(8,500)— (5,224)
Net cash provided by (used in) investing activities562,557 (84,345)507,807 
Cash flows from financing activities:
Net cash transferred to 2seventy bio at separation(174,284)— — 
Proceeds from public offering of common stock, net of issuance costs— 541,536 — 
Proceeds from issuance of common stock and warrants74,975 — — 
Proceeds from exercise of stock options and ESPP contributions5,355 5,179 21,187 
Net cash provided by (used in) financing activities(93,954)546,715 21,187 
Decrease in cash, cash equivalents and restricted cash(167,036)(7,981)(35,390)
Cash, cash equivalents and restricted cash at beginning of year373,728 381,709 417,099 
Cash, cash equivalents and restricted cash at end of year$206,692 $373,728 $381,709 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$161,160 $317,705 $327,214 
Restricted cash included in receivables and other current assets$2,282 $1,500 $— 
Restricted cash included in restricted cash and other non-current assets$43,250 $54,523 $54,495 
Total cash, cash equivalents and restricted cash$206,692 $373,728 $381,709 
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts
   payable and accrued expenses
$411 $2,854 $5,286 
Right-of-use assets obtained in exchange for operating lease liabilities$202,221 $19,414 $23,939 
Reduction of right of use asset and associated lease liability due to lease reassessment$(9,004)$— $— 
Issuance of unrestricted stock awards to settle accrued employee compensation$25,074 $— $— 
Cash paid during the period for interest$— $— $— 
Cash paid during the period for income taxes$617 $361 $637 
See accompanying notes to consolidated financial statements.
F-7
bluebird bio, Inc.
Notes to Consolidated Financial Statements
For the Years Ended December 31, 2021, 2020 and 2019
1. Description of the business
bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial-readiness activities.
In August 2021, the Company announced its intent to focus its severe genetic disease business on the U.S. market and further invest in research and development for its core programs in β-thalassemia, sickle cell disease ("SCD"), and cerebral adrenoleukodystrophy ("CALD") in that market. As part of the strategy to focus on the U.S. market, it began executing an orderly wind down of its European operations, which will result in a reduction of selling, general and administrative costs and had an impact on the Company's excess inventory analysis, which is based on forecasted consumption levels driven by sales forecasts.
In November 2021, the Company completed the separation of its severe genetic disease and oncology programs into two separate, independent publicly traded companies, bluebird bio, Inc. and 2seventy bio, Inc. ("2seventy bio"), a Delaware corporation and wholly-owned subsidiary of the Company prior to the separation. bluebird intends to retain its severe genetic disease programs, with a focus on the U.S. market. The Company’s programs in severe genetic diseases include programs for β-thalassemia, SCD, and CALD. The Company also expects to make focused investments in research and development efforts on optimizing our existing programs as well as on pipeline programs in severe genetic diseases.
The Company’s programs in severe genetic diseases include betibeglogene autotemcel ("beti-cel", formerly "LentiGlobin for β-thalassemia gene therapy") as a treatment for β-thalassemia; lovotibeglogene autotemcel ("lovo-cel") as a treatment for SCD; and elivaldogene autotemcel ("eli-cel", formerly "Lenti-D gene therapy") as a treatment for CALD.
As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $396.6 million. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from charitable foundations. As of December 31, 2021, the Company had an accumulated deficit of $3.72 billion. During the twelve months ended December 31, 2021, the Company incurred a loss from continuing operations of $562.6 million and used $635.6 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of beti-cel, eli-cel, and lovo-cel, and the achievement of a level of revenues adequate to support its cost structure.
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, the release of restricted cash related to the Company’s 50 Binney Street sublease, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have been approved by the Board of Directors as of the date of these consolidated financial statements.

The Company's expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a
F-8
going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include reduced 2022 spending, including projected savings through the move of the Company's headquarters to Assembly Row in Somerville, Massachusetts, the orderly wind down of European operations, the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for beti-cel and eli-cel, and the pursuit of additional cash resources through public or private equity or debt financings. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
2. Summary of significant accounting policies and basis of presentation
Basis of presentation
The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”).  Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the ASC and the Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).
Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation. The Company has presented its oncology business together with its manufacturing facility in Durham, North Carolina as discontinued operations in its consolidated financial statements for all periods presented (see Note 3, Discontinued operations). The historical financial statements and footnotes have been recast accordingly.
Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding.
Principles of consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. 2seventy bio, Inc. ("2seventy bio") was a wholly-owned subsidiary until it became an independent publicly-traded company on November 4, 2021. All intercompany balances and transactions have been eliminated in consolidation.
Discontinued operations
The Company determined that the separation of its oncology business in November 2021 and the sale of its manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, Discontinued Operations (“ASC 205-20”). Accordingly, the accompanying consolidated financial statements for all periods presented have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheets and the results of all discontinued operations reported as a separate component of loss in the consolidated statements of operations and comprehensive loss (see Note 3, Discontinued operations).
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
F-9
Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.  
Foreign currency translation
The financial statements of the Company’s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in stockholders’ equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.
Segment information
The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.  Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.  All material long-lived assets of the Company reside in the United States.
Cash and cash equivalents
The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value.
Marketable securities
The Company’s marketable securities are maintained by investment managers and consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Equity securities with readily determinable fair values are also carried at fair value with unrealized gains and losses included in other income (expense), net. Realized gains and losses on both debt and equity securities are determined using the specific identification method and are included in other income (expense), net.
The Company classifies equity securities with readily determinable fair values, which would be available for use in its current operations, as current assets even though the Company may not dispose of such marketable securities within the next 12 months. Equity securities are included in the balance of marketable securities on the Company's consolidated balance sheets. The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Marketable securities with a remaining maturity date greater than one year are classified as non-current assets.
Effective January 1, 2020, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements (“ASU 2016-13” or “ASC 326”), using the effective date method. As the Company had never recorded any other-than-temporary-impairment adjustments to its available-for-sale debt securities prior to the effective date, no transition provisions are applicable to the Company.
The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.
F-10
Accrued interest receivable related to the Company's available-for-sale debt securities is presented within receivables and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.
Concentrations of credit risk and off-balance sheet risk
Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.
Fair value of financial instruments
The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:
Level 1—Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2—Fair values are determined utilizing quoted prices for identical or similar assets or liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates.
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Items measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable securities, and Note 5, Fair value measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.
Business combinations
Business combinations are accounted for using the acquisition method of accounting. Using this method, the tangible and intangible assets acquired and the liabilities assumed are recorded as of the acquisition date at their respective fair values. The Company evaluates a business as an integrated set of activities and assets that is capable of being managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits and consists of inputs and processes that provide or have the ability to provide outputs. In an acquisition of a business, the excess of the fair value of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill. In an acquisition of net assets that does not constitute a business, no goodwill is recognized.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. The Company performs a one-step quantitative test and records the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has not recognized any impairment charges related to goodwill to date.
F-11
Upon disposal of a portion of a reporting unit that constitutes a business, goodwill is assigned based on the relative fair values of the portion of the reporting unit being disposed and the portion of the reporting unit remaining. This approach requires a determination of the fair value of both the business to be disposed of and the business (or businesses) within the reporting unit that will be retained. As a result of the separation of the Company's oncology business and the sale of the Company's manufacturing facility in Durham, North Carolina, the Company assigned goodwill based on the relative fair value of the business to be disposed of, and such goodwill has been reclassified to discontinued operations.
Intangible assets, net
Intangible assets, net consist of in-licensed rights with finite lives, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. During the third quarter of 2021, the Company recognized impairment charges related to intangible assets. In accordance with FASB ASC Topic 350, General Intangibles Other than Goodwill (“ASC 350”), the Company reviewed its intangible assets for recoverability. During the third quarter of 2021, the Company determined that the intangible assets were impaired, resulting in the impairment of the remaining carrying value of the intangible assets.
Property, plant and equipment
Property, plant and equipment is stated at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:
AssetEstimated useful life
Building40 years
Computer equipment and software3 years
Furniture and fixtures
2-5 years
Laboratory equipment
2-5 years
Leasehold improvementsShorter of the useful life or remaining lease term
Impairment of long-lived assets
The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.
Leases
Effective January 1, 2019, the Company adopted ASC 842 using the required modified retrospective approach and utilizing the effective date as its date of initial application.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.
Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.
F-12
The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.
In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.
Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.
ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Common stock warrants
The Company's common stock warrants are evaluated pursuant to ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), and ASC 815, Derivatives and Hedging ("ASC 815"). Management classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock.
Inventory
Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company’s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used for the production of clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product.
Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product, which has been produced for the treatment of specific patients, that are owned by the Company.
Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on hand and firm purchase commitments as well as remaining shelf life of on hand inventories. The Company writes-down its inventory that is obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue on the Company’s consolidated statements of operations and comprehensive loss.
Revenue recognition
Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines
F-13
are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.
Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. 
The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).  
The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.
If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.
In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.  The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.  The Company assessed each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.
The Company recognizes revenue within the following financial statement captions:
Product revenue
The Company recognizes product revenue in accordance with Topic 606. Product revenue represents sales of ZYNTEGLO. In 2021, the Company distributed ZYNTEGLO directly to hospitals in Germany. The Company determined that contracted sales with hospitals formed a single performance obligation and it recognizes revenue from product sales at the point in time it satisfies the performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product.
F-14
Other revenue
In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In addition, the Company entered into strategic collaborations and recognized an immaterial amount of revenue associated with those collaboration agreements.
Research and development expenses
Research and development costs are charged to expense as costs are incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, clinical study and related clinical manufacturing costs, license and milestone fees, contract services, manufacturing costs for pre-launch inventory that did not qualify for capitalization, and other related costs. Up-front fees and milestones paid to third parties in connection with technologies which have not reached technological feasibility and do not have an alternative future use are expensed as research and development expense as incurred. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, or other clinical trial vendors that perform the activities. Where amounts owed to a collaboration partner exceed the Company’s collaborative arrangement revenues in each quarterly period, such amounts are classified as research and development expense.
Cost of product revenue
Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue which are associated with the sale of ZYNTEGLO in Germany. Reserves for excess inventories are also included in cost of product revenue.
Stock-based compensation
The Company’s share-based compensation programs grant awards that have included stock options, restricted stock units, restricted stock awards, unrestricted stock awards and shares issued under its employee stock purchase plan.  Grants are awarded to employees and non-employees, including the Company's board of directors.  
The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values.
The Company’s stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable.
The Company estimates the fair value of its option awards using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of its own stock price. For both employee and non-employee awards, the measurement date is the date of grant. The Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
F-15
The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.
Conversion and modification of equity awards outstanding at date of separation of 2seventy bio
In connection with the separation of 2seventy bio on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the separation. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. The Company will recognize future expense for awards denominated in bluebird stock and 2seventy bio stock granted to the Company's employees as a result of the separation of 2seventy bio. Expense related to awards denominated in bluebird stock granted to 2seventy bio employees will be incurred by 2seventy bio.
Stock-based compensation expense related to modified awards is measured based on the fair value for the awards as of the modification date. Any incremental stock-based compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite remaining service period, as appropriate.
Interest income, net
Interest income, net consists primarily of interest income earned on investments, net of amortization of premium and accretion of discount.
Other income (expense), net
Other income (expense), net consists primarily of gains and losses on equity securities held by the Company, gains and losses on disposal of assets, and gains and losses on foreign currency.
Net loss per share
Basic net loss per share is calculated by dividing net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration. Diluted net loss per share is calculated by dividing the net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration as well as any dilutive effect from outstanding stock options, unvested restricted stock, restricted stock units, and employee stock purchase plan stock using the treasury stock method. Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.
The Company follows the two-class method when computing net loss per share in periods when issued shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating securities.
Income taxes
Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if
F-16
based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Comprehensive loss
Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on debt securities, foreign currency translation adjustments and other items.
Restructuring expenses
The Company records costs and liabilities associated with exit and disposal activities in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations ("ASC 420"). Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available. Refer to Note 18, Reduction in workforce, for more information.
Recent accounting pronouncements
Recently adopted
ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity's own equity. The Company early adopted the new standard, effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs (“ASU 2020-08”) to provide further clarification and update the previously issued guidance in ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) (“ASU 2017-08”). ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-10, Codification Improvements
F-17
In October 2020, the FASB issued ASU 2020-10, Codification Improvements ("ASU 2020-10"). The amendments in this ASU represent changes to clarify the ASC, correct unintended application of the guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This new standard was effective beginning January 1, 2021. The adoption of ASU 2020-10 did not have a material impact on the Company's financial position or results of operations upon adoption.
3. Discontinued operations
Sale of bluebird Research Triangle manufacturing facility
In November 2017, the Company acquired a manufacturing facility in Durham, North Carolina ("bRT") for the future manufacture of LVV for the Company’s therapies related to its oncology programs. In July 2021, the Company and Resilience US, Inc., an affiliate of National Resilience, Inc. ("Resilience"), signed an Asset Purchase Agreement (the “Agreement”). As part of the Agreement, and upon the closing of the transaction which occurred in September 2021, Resilience acquired the Company's LVV manufacturing facility located in Durham, North Carolina and retained staff currently employed at the site. As a result of the transaction, the Company disposed of $111.2 million of net assets, primarily consisting of the building and laboratory equipment, that were associated with the Company's oncology programs. The Company recognized a loss on disposal of assets of $2.0 million. As the sale of the bRT manufacturing facility and the separation of 2seventy bio (as described below) were deemed to represent multiple components of a single disposal plan, the assets, liabilities and results of operations related to bRT have been included as a component of discontinued operations.
2seventy bio Separation
On November 4, 2021, the Company completed the previously announced separation of its oncology programs and portfolio, and the certain related assets and liabilities, into a separate, independent publicly traded company (the “Separation”). The Separation was effected by means of a distribution of all of the outstanding shares of common stock of 2seventy bio in which each bluebird stockholder received one share of common stock, par value $0.0001 per share, of 2seventy bio for every three shares of common stock, par value $0.01 per share, of bluebird held as of the close of business on October 19, 2021 (the “Distribution”).
In connection with the Separation, bluebird entered into a separation agreement (the “Separation Agreement”) with 2seventy bio, dated as of November 3, 2021, that, among other things, set forth bluebird’s agreements with 2seventy bio regarding the principal actions to be taken in connection with the Separation, including the Distribution. The effective time of the Distribution was 12:01 a.m. on November 4, 2021. The Separation Agreement identified assets transferred to, liabilities assumed by and contracts assigned to 2seventy bio as part of the Separation, and it provided for when and how these transfers, assumptions and assignments occurred. The purpose of the Separation Agreement was to provide 2seventy bio and bluebird with assets to operate their respective businesses and retain or assume liabilities related to those assets. Each of 2seventy bio and bluebird agreed to releases, with respect to pre-Separation claims, and cross indemnities, with respect to post-Separation claims, that were principally designed to place financial responsibility for the obligations and liabilities allocated to 2seventy bio under the Separation Agreement with 2seventy bio and financial responsibility for the obligations and liabilities allocated to bluebird under the Separation Agreement with bluebird. bluebird and 2seventy bio are also each subject to mutual 12-month employee non-solicit and non-hire restrictions, subject to certain customary exceptions.
The transfer of assets and liabilities to 2seventy bio was effected through a contribution in accordance with the Separation Agreement, as summarized below (in thousands):
F-18
As of November 4, 2021
Assets
Current assets:
Cash and cash equivalents$174,284 
Marketable securities160,447 
Prepaid expenses8,732 
Receivables and other current assets21,637 
Total current assets365,100 
Marketable securities106,826 
Property, plant and equipment, net33,972 
Intangible assets, net10,664 
Goodwill6,410 
Operating lease right-of-use assets255,556 
Restricted cash and other non-current assets5,650 
Total assets$784,178 
Liabilities
Current liabilities:
Accounts payable$2,982 
Accrued expenses and other current liabilities85,659 
Operating lease liability, current portion6,938 
Collaboration research advancement, current portion8,957 
Total current liabilities104,536 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion16,264 
Operating lease liability, net of current portion257,575 
Other non-current liabilities1,896 
Total liabilities$406,033 
Net assets transferred to 2seventy bio$378,145 
bluebird and 2seventy bio also entered into a tax matters agreement, dated as of November 3, 2021, governing bluebird’s and 2seventy bio's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters.
In connection with the Separation, bluebird also entered into an employee matters agreement with 2seventy bio, dated as of November 3, 2021. The employee matters agreement allocates assets, liabilities and responsibilities relating to the employment, compensation and employee benefits of bluebird and 2seventy bio employees, and other related matters, in connection with the Separation, including the treatment of outstanding bluebird incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provides that, unless otherwise specified, 2seventy bio is responsible for liabilities associated with employees who transfer to 2seventy bio and employees whose employment terminated prior to the distribution but who primarily supported the 2seventy bio business, and bluebird is responsible for liabilities associated with other employees, including employees retained by bluebird. Pursuant to the employee matters agreement, the outstanding bluebird equity awards held by 2seventy bio and bluebird employees were adjusted immediately prior to the distribution, with the intent to maintain, immediately following the distribution, the economic value of the awards immediately before the distribution date.
bluebird and 2seventy bio also entered into an intellectual property license agreement on November 3, 2021, pursuant to which each party granted a license to certain intellectual property and technology to the other. bluebird granted 2seventy bio a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property to allow 2seventy bio to use such intellectual property in connection with 2seventy bio's ongoing and future research and development activities and product candidates. 2seventy bio granted bluebird a perpetual, worldwide, non-
F-19
exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property for use in bluebird’s existing products and product candidates. Such licenses between the parties generally allow current or future uses of the intellectual property in connection with each party's respective fields.

Additionally, bluebird entered into two transition services agreements with 2seventy bio, whose President is a member of the Company’s Board of Directors. . Pursuant to the transition service agreements, bluebird is obligated to provide and is entitled to receive certain transition services related to corporate functions, such as finance, human resources, internal audit, research and development, financial reporting, and information technology. Services provided by bluebird to 2seventy bio will continue for an initial term of up to two years, unless earlier terminated or extended according to the terms of the transition services agreement. Services received and performed are paid at a mutually agreed upon rate. Amounts received for services provided to 2seventy bio are recorded as other income and amounts paid for services provided by 2seventy bio are recorded as selling, general and administrative expense and research and development expense, as applicable. During the year ended December 31, 2021, the Company incurred $0.7 million of net expense for services provided by 2seventy bio within Research and development and Selling, general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2021, the Company had an immaterial amount of accounts receivable and accounts payable due from and to 2seventy bio.
Discontinued operations

In connection with the Separation, the Company determined its oncology business, together with the bRT manufacturing facility, qualified for discontinued operations accounting treatment in accordance with ASC 205-20. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Revenue:
Service revenue$18,130 $114,064 $30,729 
Collaborative arrangement revenue18,602 115,594 5,740 
Royalty and other revenue5,762 21,076 8,205 
Total revenues42,494 250,734 44,674 
Operating expenses:
Research and development204,287 268,647 255,294 
Selling, general and administrative82,078 46,945 35,518 
Share of collaboration loss10,071 — — 
Cost of royalty and other revenue2,292 5,396 2,978 
Change in fair value of contingent consideration387 (6,468)2,747 
Total operating expenses299,115 314,520 296,537 
Loss from operations(256,621)(63,786)(251,863)
Interest income, net791 5,770 17,380 
Other income (expense), net(910)377 (103)
Loss before income taxes(256,740)(57,639)(234,586)
Net loss$(256,740)$(57,639)$(234,586)
There were no assets and liabilities related to discontinued operations as of December 31, 2021, as all balances were transferred to 2seventy bio upon Separation. The following table summarizes the assets and liabilities of the discontinued operations as of December 31, 2020 (in thousands):
F-20
As of December 31, 2020
Assets
Current assets:
Cash and cash equivalents$57,076 
Marketable securities413,947 
Prepaid expenses11,754 
Receivables and other current assets12,244 
Total current assets of discontinued operations495,021 
Marketable securities61,446 
Property, plant and equipment, net145,458 
Intangible assets, net5,644 
Goodwill7,482 
Operating lease right-of-use assets116,456 
Restricted cash and other non-current assets7,078 
Total non-current assets of discontinued operations343,564 
Total assets of discontinued operations$838,585 
Liabilities
Current liabilities:
Accounts payable$7,791 
Accrued expenses and other current liabilities48,716 
Operating lease liability, current portion15,313 
Collaboration research advancement, current portion9,236 
Deferred revenue, current portion820 
Total current liabilities of discontinued operations81,876 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion21,581 
Operating lease liability, net of current portion112,290 
Other non-current liabilities1,509 
Total non-current liabilities of discontinued operations161,142 
Total liabilities of discontinued operations$243,018 

The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):
F-21
Year ended December 31,
202120202019
Operating activities:
Change in fair value of contingent consideration$387 $(6,468)$2,747 
Depreciation and amortization14,195 13,730 12,995 
Stock-based compensation expense29,175 34,036 29,545 
Loss on fixed assets disposal569 146 108 
Loss on sale of Durham, North Carolina manufacturing facility 1,986 — — 
Investing activities:
Purchase of property, plant and equipment$(11,256)$(23,159)$(57,196)
Proceeds from sale of Durham, North Carolina manufacturing facility110,300 — — 
Purchase of intangible assets(8,500)— — 
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses$778 $2,039 $3,064 
Right-of-use assets obtained in exchange for operating lease liabilities151,520 4,989 9,745 
4. Marketable securities
The following table summarizes the marketable securities held at December 31, 2021 and 2020 (in thousands):
Amortized cost / costUnrealized gainsUnrealized lossesFair value
December 31, 2021
U.S. government agency securities and treasuries$128,902 $— $(509)$128,393 
Corporate bonds49,366 — (59)49,307 
Commercial paper54,065 — — 54,065 
Equity securities4,305 — (614)3,691 
Total$236,638 $— $(1,182)$235,456 
December 31, 2020 (1)
U.S. government agency securities and treasuries$337,521 $151 $(37)$337,635 
Corporate bonds98,585 216 (20)98,781 
Commercial paper38,975 — — 38,975 
Equity securities20,017 — (14,364)5,653 
Total$495,098 $367 $(14,421)$481,044 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
No available-for-sale debt securities held as of December 31, 2021 or 2020 had remaining maturities greater than five years.
F-22
5. Fair value measurements
The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
TotalQuoted
prices in
active
markets
(Level 1)		Significant
other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)
December 31, 2021
Assets:
Cash and cash equivalents$161,160 $161,146 $14 $— 
Marketable securities:
U.S. government agency securities and treasuries128,393 — 128,393 — 
Corporate bonds49,308 — 49,308 — 
Commercial paper54,065 — 54,065 — 
Equity securities3,691 3,691 — — 
Total assets$396,617 $164,837 $231,780 $— 
December 31, 2020 (1)
Assets:
Cash and cash equivalents$260,629 $260,629 $— $— 
Marketable securities:
U.S. government agency securities and treasuries337,635 — 337,635 — 
Corporate bonds98,781 — 98,781 — 
Commercial paper38,975 — 38,975 — 
Equity securities5,653 5,653 — — 
Total assets$741,673 $266,282 $475,391 $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Cash and cash equivalents
As of December 31, 2021, cash and cash equivalents comprise funds in cash and money market accounts. As of December 31, 2020, cash and cash equivalents comprise funds in cash and money market accounts.
Marketable securities
Marketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At December 31, 2021 and 2020, the balance in the Company’s accumulated other comprehensive loss was composed primarily of activity related to the Company’s available-for-sale debt securities. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended December 31, 2021 or 2020.
Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $1.5 million as of December 31, 2021 and 2020, respectively. No accrued interest receivable was written off during the twelve months ended December 31, 2021 or 2020.
F-23
The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months, and for which an allowance for credit losses has not been recorded at December 31, 2021 and 2020 (in thousands):
Less than 12 months12 months or greaterTotal
DescriptionFair valueUnrealized lossesFair valueUnrealized lossesFair valueUnrealized losses
December 31, 2021
U.S. government agency securities
   and treasuries		$108,695 $(505)$2,496 $(4)$111,191 $(509)
Corporate bonds45,042 (56)3,896 (2)48,938 (58)
Total$153,737 $(561)$6,392 $(6)$160,129 $(567)
December 31, 2020 (1)
U.S. government agency securities
   and treasuries		$105,692 $(37)$— $— $105,692 $(37)
Corporate bonds38,299 (20)603 — 38,902 (20)
Total$143,991 $(57)$603 $— $144,594 $(57)
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
The Company determined that there was no material change in the credit risk of the above investments during the twelve months ended December 31, 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2021, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of their amortized cost bases.
The Company holds equity securities with an aggregate fair value of $3.7 million and $5.7 million at December 31, 2021 and 2020, respectively, within current marketable securities on its consolidated balance sheets. In January 2021, the Company sold a portion of its equity securities for proceeds of $31.3 million. The Company recorded gains of $29.4 million and losses of $7.2 million and $9.3 million related to its equity securities during the years ended December 31, 2021, 2020 and 2019, respectively. Gains and losses related to equity securities are included in other income (expense), net in the consolidated statements of operations and comprehensive loss.
6. Inventory
Inventory consists of the following (in thousands):
As of December 31, 2021As of December 31, 2020
Raw materials$— $8,967 
Finished goods— 1,731 
Inventory$— $10,698 

During the year ended December 31, 2021, the Company recorded a reserve for excess inventories of $29.9 million, which is included within cost of product revenue in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2020, the Company did not record a reserve for excess inventories.

F-24
7. Property, plant and equipment, net
Property, plant and equipment, net, consists of the following (in thousands):
As of December 31,
2021
2020 (1)
Laboratory equipment$29,061 $27,146 
Computer equipment and software421 447 
Office equipment117 1,077 
Leasehold improvements12 5,949 
Construction-in-progress501 895 
Total property, plant and equipment30,112 35,514 
Less accumulated depreciation and amortization(20,406)(18,141)
Property, plant and equipment, net$9,706 $17,373 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Depreciation and amortization expense related to property, plant and equipment was $4.9 million, $5.1 million, and $4.1 million for the years ended December 31, 2021, 2020, and 2019, respectively.
8. Restricted cash
As of December 31, 2021 and 2020, the Company maintained letters of credit of $43.2 million and $54.5 million, respectively, which are collateralized with bank accounts at financial institutions in accordance with the agreements. Total restricted cash as of December 31, 2021 and 2020 consisted of the following (in thousands):
As of December 31,
20212020
50 Binney Street lease$40,072 $40,072 
Assembly Row lease2,753 — 
60 Binney Street lease— 13,763 
Other2,675 2,188 
Total restricted cash$45,500 $56,023 
Refer to Note 10, Leases, for further information on the Company's letters of credit.
9. Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
As of December 31,
2021
2020 (1)
Employee compensation$41,095 $41,192 
Accrued goods and services24,273 14,855 
Accrued clinical and contract research organization costs17,769 20,912 
Accrued manufacturing costs15,722 15,763 
Accrued professional fees1,665 1,541 
Deferred revenue, current portion2,282 1,500 
Other1,152 2,427 
Total accrued expenses and other current liabilities$103,958 $98,190 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
F-25
Accrued employee compensation includes severance costs associated with the Company's orderly wind down of its European operations. As of December 31, 2021, the Company had accrued expenses of $4.7 million related to these restructuring costs. Please refer to Note 17, Reduction in workforce, for further discussion.
10. Leases
The Company leases certain office and laboratory space. Additionally, the Company has embedded leases through its agreements with contract manufacturing organizations.
60 Binney Street lease & sublease
In October 2021, the Company entered into a consent to assignment and amendment to its lease agreement for its 60 Binney Street lease (the "Assignment"). The Assignment transfers the Company's interest in the lease to 2seventy bio and releases the Company from its obligation to maintain the $13.8 million collateralized letter of credit required under the original 60 Binney Street lease. Although the lease was legally transferred to 2seventy bio, the lessor required that the Company remain secondarily liable as a guarantor for payment obligations accruing under the 60 Binney Street lease from the date of Assignment until (i) the Company has completely vacated the premises and (ii) 2seventy bio has reached a market capitalization of $900 million. Upon Separation, the lease assignment was accounted for as the termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 60 Binney Street lease and recognized the fair value of the guarantee pursuant to ASC 405, Liabilities. The fair value of the guarantee was not material.
Concurrent with the Assignment of the 60 Binney Street Lease, the Company entered into a sublease agreement with 2seventy bio for office, laboratory and storage space located at 60 Binney Street (the "60 Binney Street Sublease") while it constructs and outfits its new office and laboratory space. Under the terms of the 60 Binney Street Sublease, the Company will lease 72,988 square feet for $0.5 million per month in base rent for the period beginning from the Assignment through March 2022 and 58,004 square feet for $0.4 million per month in base rent for the period from April 2022 through March 2024. The Company accounted for the 60 Binney Street Sublease as a new lease under ASC 842, and in November 2021, recognized a right-of-use asset and lease liability related to the 60 Binney Street Sublease.
50 Binney Street sublease & sub-sublease
In April 2019, the Company entered into a sublease agreement for office space located at 50 Binney Street in Cambridge, Massachusetts (the “50 Binney Street Sublease”) to supplement the Company’s corporate headquarters located at 60 Binney Street in Cambridge, Massachusetts. Under the terms of the 50 Binney Street Sublease, the Company will lease 267,278 square feet of office space for $99.95 per square foot, or $26.7 million per year in base rent subject to certain operating expenses, taxes and annual rent increases of approximately 3%. The lease will commence when the space is available for use by the Company, which is anticipated to be in the first half of 2022, which reflects the sublessor's exercise of its option to postpone the commencement date of the sublease. The lease term will end on December 31, 2030, unless other specific circumstances specified in the 50 Binney Street Sublease occur. The Company will assess the lease classification of the 50 Binney Street Sublease and commence recognition of the associated rent expense at the lease commencement date.
Upon signing the 50 Binney Street Sublease, the Company executed a $40.1 million cash-collateralized letter of credit, which may be reduced in the future subject to the terms of the 50 Binney Street Sublease and certain reduction requirements specified therein. The $40.1 million of cash collateralizing the letter of credit is classified as restricted cash and other non-current assets on the Company’s consolidated balance sheets. Payments will commence at the earlier of (i) the date which is 90 days following the commencement date and (ii) the date the Company takes occupancy of all or any portion of the premises.
In connection with the execution of the 50 Binney Street Sublease, the Company also entered into a purchase agreement for furniture and equipment (the “Furniture Purchase Agreement”) located on the premises upon lease commencement. Upon execution of the Furniture Purchase Agreement, the Company made an upfront payment of $7.5 million, all of which was recorded within restricted cash and other non-current assets on the Company’s consolidated balance sheets and assessed for recoverability on a recurring basis. The Company will be required to make another $7.5 million payment under the Furniture Purchase Agreement upon lease commencement.
In December 2021, the Company entered into a sub-sublease agreement (the "Sub-Sublease") with Meta Platforms, Inc. (“Meta”). Under the terms of the Sub-Sublease, the Company is subleasing the entirety of the 50 Binney Street premises which it has rights to under the 50 Binney Street Sublease. The Company is sub-subleasing the premises for $28.0 million in the first year with 3% annual increases in each subsequent year. Meta will receive access to 50 Binney Street at the lease commencement date, which is the same point that the Company would receive access under the 50 Binney Street Sublease. The Company remains liable under the 50 Binney Street Sublease, including for maintenance of the $40.1 million collateralized
F-26
letter of credit. As a result of the execution of the Sub-Sublease, the Company assessed the $7.5 million deposit related to the Furniture Purchase Agreement for recoverability and determined that the amount was not recoverable. As a result, the Company recorded $7.5 million in the Company's consolidated statements of operations and comprehensive loss as selling, general and administrative expense during the year ended December 31, 2021.
Assembly Row lease
In November 2021, the Company entered into a lease agreement with Assembly Row 5B, LLC ("Landlord") for office space located at 455 Grand Union Boulevard in Somerville, Massachusetts to serve as the Company's future corporate headquarters. Under the terms of the arrangement, the Company will lease approximately 61,180 square feet starting at an annual rate of $45 per square foot, subject to annual increases of 2.5%, plus operating expenses and taxes. In addition, the Company will be eligible for a tenant work allowance of $160 per rentable square foot of the premises. The lease will commence on the date on which the Landlord tenders possession of the premises to the Company with any tenant work required to be performed by the Landlord substantially completed, which is anticipated to occur in the first half of 2022.
Embedded leases
In June 2016, the Company entered into a manufacturing agreement for the future commercial production of the Company’s beti-cel and eli-cel drug products with a contract manufacturing organization. Under this 12-year agreement, the contract manufacturing organization will complete the design, construction, validation and process validation of the leased suites prior to anticipated commercial launch of the product candidates. During construction, the Company paid $12.0 million upon the achievement of certain contractual milestones. Construction was completed in March 2018 and beginning in April 2018, the Company pays $5.1 million per year, subject to annual inflationary adjustments, in fixed suite fees, as well as certain fixed labor, raw materials, testing and shipping costs for manufacturing services. The Company may terminate this agreement at any time upon payment of a one-time termination fee and up to 24 months of fixed suite and labor fees. The Company concluded in prior periods that this agreement contained an embedded lease as the suites are designated for the Company’s exclusive use during the term of the agreement. The Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
In November 2016, the Company entered into an agreement for clinical and commercial production of the Company’s beti-cel, lovo-cel, and eli-cel drug products with a contract manufacturing organization at an existing facility. The Company concluded that this agreement contains an embedded operating lease as the clean rooms are designated for the Company’s exclusive use during the term of the agreement. The term of the agreement is five years with subsequent three-year renewals at the mutual option of each party. As a result, the Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842, and is recognizing rent expense on a straight-line basis throughout the estimated remaining term of the embedded lease. In March 2020, the Company amended its agreement with the contract manufacturing organization, resulting in a lease modification. Under the terms of the amended agreement, the Company may be required to pay annual maintenance and production fees of up to €16.5 million, depending on its production needs, and may terminate this agreement with twelve months’ notice and a one-time termination fee. In September 2021, the Company reassessed the term of this lease in light of the planned orderly wind down of its operations in Europe. As a result, the Company reduced the right-of-use asset and related lease liability to reflect a shortened expected term of the agreement. In November 2021, the Company exercised its right to terminate the lease agreement, and such termination will be effective in November 2022. Per the terms of the amended agreement, the Company was obligated to pay a one-time termination fee of €1.0 million upon termination, which was paid in December 2021. In connection with this termination, the Company will pay for services properly rendered through the date of termination in accordance with the contract manufacturing agreement, based on work completed and expenses incurred prior to the date of termination.
In July 2020, the Company entered into an agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $5.4 million per year in maintenance fees in addition to the cost of any services provided and may terminate this agreement with eighteen months' notice. The agreement commenced in March 2021, and it has a term of five years with the option to extend. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in March 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
In February 2021, the Company entered into another agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled
F-27
environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $4.2 million per year in maintenance fees and an immaterial amount of other annual fees as well as per-batch fees for the cost of any services provided. Either party may terminate this agreement with eighteen months’ notice at any time or with eight months’ notice after stage 5 has commenced. The term of the agreement is five years, with the option to extend, and it commenced in November 2021. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in November 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
Summary of all lease costs recognized under ASC 842
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the years ended December 31, 2021 and 2020 (in thousands):
For the year ended December 31,
2021
2020 (2)
2019 (2)
Lease cost (1)
Operating lease cost$25,067 $18,660 $20,005 
Total lease cost$25,067 $18,660 $20,005 
Other information
Operating cash flows used for operating leases$22,805 $17,780 $17,205 
Weighted average remaining lease term4.7 years6.3 years7.3 years
Weighted average discount rate5.02 %5.98 %6.66 %
(1) Short-term lease costs and variable lease costs incurred by the Company for the twelve months ended December 31, 2021, 2020 and 2019 were immaterial.
(2) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under all leases, including additional charges for utilities, parking, maintenance, and real estate taxes, was $36.2 million, $24.2 million, and $23.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.
As of December 31, 2021, future minimum commitments under ASC 842 under the Company’s operating leases were as follows (in thousands):
As of
Maturity of lease liabilitiesDecember 31, 2021
2022$27,037 
202321,460 
202418,009 
202514,639 
20268,598 
2027 and thereafter12,356 
Total lease payments102,099 
Less: imputed interest(12,515)
Total operating lease liabilities$89,584 
The above table excludes legally binding minimum lease payments for leases executed but not yet commenced as of December 31, 2021.
F-28
11. Commitments and contingencies
Lease commitments
The Company leases certain office and laboratory space and has embedded leases at contract manufacturing organizations. Refer to Note 10, Leases, for further information on the terms of these lease agreements.
Other funding commitments
The Company is party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specified products.
Additionally, the Company is party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement.
Based on our development plans as of December 31, 2021, the Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with the Company's collaboration and license agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company’s financial statements.
The Company has various manufacturing development and license agreements to support clinical and commercial product needs. The following table presents non-cancelable contractual obligations arising from these arrangements:
Years ended December 31,Purchase
commitment
2022$43,903 
20239,918 
2024 and thereafter— 
Total purchase commitments$53,821 
Litigation
From time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Management does not believe that any ultimate liability resulting from any of these claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, management cannot give any assurance regarding the ultimate outcome of any claims, and their resolution could be material to operating results for any particular period.
The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.
12. Equity
The Company is authorized to issue 125.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s board of directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the
F-29
event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. As of December 31, 2021 and 2020, the Company had 71.1 million and 66.4 million shares of common stock issued and outstanding, respectively.
In September 2021, the Company entered into an equity purchase agreement with certain investors, pursuant to which the Company agreed to sell and issue, in a private placement offering of securities, an aggregate of (i) 2.3 million shares of the Company’s common stock at a purchase price per share of $16.50 and (ii) pre-funded warrants to purchase up to 2.3 million shares of common stock (the “Pre-Funded Warrants”) at an effective price of $16.49 per share ($16.49 paid to the Company upon the closing of the offering and $0.01 to be paid upon exercise of such Pre-Funded Warrants). This resulted in aggregate gross proceeds to the Company of approximately $75.0 million. The Pre-Funded Warrants can be exercised at any time or times on or after September 7, 2021, until exercised in full. The Pre-Funded Warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480 and ASC 815. Based on the terms of the Pre-Funded Warrants, management concluded that they should be classified within stockholders' equity on its consolidated balance sheets, with no subsequent remeasurement as long as the underlying warrant agreements are not modified or amended.
The Company is authorized to issue 5.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of December 31, 2021 and 2020, the Company had no shares of preferred stock issued or outstanding.
Reserved for future issuance
The Company has reserved for future issuance the following number of shares of common stock (in thousands):
As of December 31,
20212020
Options to purchase common stock (1)
5,534 6,262 
Restricted stock units (1)
3,427 1,495 
2013 Stock Option and Incentive Plan2,250 2,545 
Pre-funded warrants2,273 — 
2013 Employee Stock Purchase Plan1,347 67 
14,831 10,369 
(1) Stock options and restricted stock units that are reserved for future issuance include awards outstanding to employees of 2seventy bio.
13. Intangible assets
Intangible assets, net of accumulated amortization, are summarized as follows (in thousands):
As of December 31, 2021
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (1,219)(4,005)— 
Total$5,224 $(1,219)$(4,005)$— 
As of December 31, 2020(1)
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (827)— 4,397 
Total$5,224 $(827)$— $4,397 
F-30
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Amortization expense for intangible assets was $0.4 million, $0.5 million, and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.
In August 2021, the Company announced its decision to focus its efforts on the U.S. market and to execute an orderly wind down of its European operations. In connection with this, in September 2021, the Company recognized an impairment loss of $4.0 million for the remaining unamortized balance of the intangible asset associated with in-licensed rights for the ZYNTEGLO product, which is reflected within cost of product revenue in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

14. Stock-based compensation
In June 2013, the Company’s board of directors adopted its 2013 Stock Option and Incentive Plan (“2013 Plan”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 Plan replaces the 2010 Stock Option and Grant Plan (“2010 Plan”).
The 2013 Plan allows for the granting of incentive stock options, non-qualified stock options, restricted stock units and restricted stock awards to the Company’s employees, members of the board of directors, and consultants of the Company. The Company initially reserved 1.0 million shares of its common stock for the issuance of awards under the 2013 Plan. The 2013 Plan provides that the number of shares reserved and available for issuance under the 2013 Plan will automatically increase each January 1, beginning on January 1, 2014, by four percent of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s compensation committee. In January 2021 and January 2022, the number of common stock available for issuance under the 2013 Plan was increased by approximately 2.7 million and 2.8 million shares, respectively, as a result of this automatic increase provision.
Any options or awards outstanding under the Company’s previous stock option plans, including both the 2010 Plan and the Second Amended and Restated 2002 Employee, Director and Consultant Stock Plan (“2002 Plan”), at the time of adoption of the 2013 Plan remain outstanding and effective. The shares of common stock underlying any awards that are forfeited, canceled, repurchased, expired or are otherwise terminated (other than by exercise) under the 2002 Plan and 2010 Plan are added to the shares of common stock available for issuance under the 2013 Plan. As of December 31, 2021, the total number of common stock that may be issued under all plans is 3.2 million.
The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.
Conversion and modification of equity awards outstanding at the Separation
In connection with the Separation on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units (“RSUs”) and performance restricted stock units (“PRSUs”) denominated in pre-Distribution bluebird stock received a number of otherwise-similar awards either in post-Distribution bluebird stock or in a combination of post-Distribution bluebird stock and 2seventy bio stock based on conversion ratios outlined for each group of employees in the Employee Matters Agreement that the Company entered into in connection with the Distribution. The equity awards that were granted prior to 2021 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both bluebird and 2seventy bio. The conversion ratio for the shareholder method took into consideration a distribution ratio of one share of 2seventy bio common stock for every three shares of bluebird common stock. For equity awards granted in 2021, the number of awards that were outstanding at the Separation were proportionately adjusted to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the volume weighted-average trading price for bluebird common stock for the five trading days before and after the Separation.
These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Due to the modification of the equity awards as a result of the Distribution, the Company compared the fair value of the outstanding equity awards immediately before and after the Distribution. The modification resulted in an incremental fair value of $20.3 million, of which $4.5 million was immediately recognized as of the Distribution date.
F-31
Additionally, bluebird will not incur any future compensation cost related to equity awards held by 2seventy bio employees and directors. The Company will incur future compensation cost related to 2seventy bio equity awards held by bluebird employees.
Stock-based compensation expense
The Company recognized stock-based compensation expense totaling $98.7 million, $122.6 million, and $131.1 million during the years ended December 31, 2021, 2020 and 2019, respectively. Stock-based compensation expense recognized by award type is as follows (in thousands):
Year ended December 31,
202120202019
Stock options$54,660 $75,837 $79,912 
Restricted stock units30,767 38,123 50,158 
Employee stock purchase plan and other13,313 8,636 1,013 
$98,740 $122,596 $131,083 
Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows (in thousands):
Year ended December 31,
202120202019
Research and development$42,989 $49,766 $59,378 
Selling, general and administrative55,751 72,830 71,705 
$98,740 $122,596 $131,083 
Stock-based compensation of $1.0 million was capitalized into inventory during the year ended December 31, 2021. Stock-based compensation of $0.5 million was capitalized into inventory during the year ended December 31, 2020.
Unrestricted stock awards
During the first quarter of 2021, the Company granted 0.4 million unrestricted stock awards to employees as part of its 2020 annual incentive program. In addition, the Company implemented a retention program designed to incentivize and retain employees through the separation of its severe genetic disease and oncology programs. Under the retention program, employees are entitled to a one-time bonus payment, consisting of both a cash payment and unrestricted stock awards, with the condition that the employee remains employed at the end of 2021. For the twelve months ended December 31, 2021, the Company recognized $21.2 million in expense related to this program, which includes $10.6 million in stock compensation expense related to the anticipated grants of stock. During the third quarter of 2021, the Company granted 0.1 million unrestricted stock awards, related to the retention program, to those employees impacted by the orderly wind down of the Company's operations in Europe. During the fourth quarter of 2021, the Company granted 1.0 million unrestricted stock awards to employees as part of its retention program.
As of December 31, 2021, the Company had $34.2 million and $54.3 million of unrecognized compensation expense related to unvested stock options and restricted stock units (exclusive of those with service and performance conditions that have not yet been achieved), respectively, that is expected to be recognized over a weighted-average period of 2.19 years and 2.26 years, respectively.
F-32
Stock options
The fair value of each option issued to employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
Year ended December 31,
202120202019
Expected volatility66.7 %69.5 %70.7 %
Expected term (in years)6.06.06.0
Risk-free interest rate0.8 %1.4 %2.3 %
Expected dividend yield0.0 %0.0 %0.0 %
The following table summarizes the stock option activity under the Company’s equity awards plans:
Shares
(in thousands)		Weighted-
average
exercise price
per share		Weighted-
average
contractual
life
(in years)		Aggregate
intrinsic
value (a)
(in thousands)
Outstanding at December 31, 20206,262 $105.02 
Granted1,238 $27.19 
Exercised(218)$6.82 
Canceled or forfeited(2,357)$81.20 
Conversion and modification of awards (1,339)$42.90 
Outstanding at December 31, 20213,586 $39.23 6.8$631 
Exercisable at December 31, 20211,835 $57.09 5.5$380 
Vested and expected to vest at December 31, 20213,586 $39.23 6.8$631 
(a)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021.
(b)Pursuant to the terms of Employee Matters Agreement, the company granted 4,375 option conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
The weighted-average fair values of options granted during the years ended December 31, 2021, 2020 and 2019 was $16.32, $43.24, and $83.44, respectively. The intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $5.1 million, $4.0 million and $29.0 million, respectively.
Restricted stock units
The following table summarizes the restricted stock unit activity under the Company’s equity award plans:
Shares
(in thousands)		Weighted-average
grant date
fair value
Unvested balance at December 31, 20201,495 $102.34 
Granted3,359 26.43 
Vested(526)112.21 
Forfeited(987)53.58 
Conversion and modification of awards(148)16.84 
Unvested balance at December 31, 20213,193 $16.21 
(a)Pursuant to the terms of Employee Matters Agreement, the company granted 3,327 restricted stock unit conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
F-33
The intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $44.0 million, $30.9 million and $28.4 million, respectively.
Employee Stock Purchase Plan
In June 2013, the Company’s board of directors adopted its 2013 Employee Stock Purchase Plan (“2013 ESPP”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 ESPP authorizes the initial issuance of up to a total of 0.2 million shares of the Company’s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4 million shares of the Company’s common stock available to participating employees. During each of the years ended December 31, 2021 and 2020, approximately 0.1 million shares of common stock were issued under the 2013 ESPP.
15. 401(k) Savings plan
In 1997, the Company established a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. In March 2022, the Company expects to make matching contributions of approximately $2.8 million related to employee contributions made during 2021. At the same time, the Company anticipates making matching contributions to 2seventy bio employees of $2.0 million for their contributions under the 401(k) Plan during 2021 through the Separation. In March 2021, the Company made $6.0 million of matching contributions related to employee contributions made during 2020. The match contribution is included in accrued expenses and other current liabilities as of December 31, 2021 and 2020.  Expense related to the 401(k) Plan from continuing operations totaled $2.8 million, $3.0 million, $2.9 million for the years ended December 31, 2021, 2020, and 2019, respectively.
16. Income taxes
The components of loss before income taxes were as follows (in thousands):
Year ended December 31,
202120202019
U.S.$(487,404)$(431,452)$(414,586)
Foreign(74,976)(128,918)(140,981)
Total$(562,380)$(560,370)$(555,567)
The provision for (benefit from) income taxes were as follows (in thousands):
Year ended December 31,
202120202019
Current:
Federal$— $— $— 
State— 2 7 
Foreign258 684 612 
Deferred:
Federal— — (966)
State— — (198)
Foreign— — — 
Total income tax expense (benefit)$258 $686 $(545)
F-34
A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company’s effective income tax rate as reflected in the financial statements is as follows:
Year ended December 31,
202120202019
Federal income tax expense at statutory rate21.0 %21.0 %21.0 %
State income tax, net of federal benefit3.9 %3.1 %3.7 %
Permanent differences(0.6)%(0.6)%(0.8)%
Stock-based compensation(3.1)%(2.4)%(0.7)%
Research and development credit4.3 %6.0 %5.4 %
Foreign differential(1.9)%(4.6)%(3.7)%
Other— %(0.3)%0.8 %
Change in valuation allowance(23.6)%(22.3)%(25.6)%
Effective income tax rate (expense) benefit— %(0.1)%0.1 %
For the years ended December 31, 2021, 2020 and 2019, the Company recognized an income tax expense (benefit) of $0.3 million or 0.0%, $0.7 million or (0.1)%, and $(0.5) million or 0.1%, respectively.  The Company did not recognize any significant tax expense for the years ended December 31, 2021, 2020, or 2019 as the Company was subject to a full valuation allowance. Tax expense associated with the sale of bRT and the Separation, accounted for as discontinued operations and discussed in Note 3, is $0 for the years ended December 31, 2021, 2020, or 2019 due to the full valuation allowance. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities are composed of the following (in thousands):
Year ended December 31,
2021
2020 (1)
Deferred tax assets:
U.S. net operating loss carryforwards (federal and state)$703,125 $546,098 
Tax credit carryforwards (federal and state)281,687 246,742 
Capitalized license fees and research and development expenses2,237 1,558 
Deferred revenue604 398 
Stock-based compensation25,181 37,164 
Lease liabilities22,916 14,787 
Accruals and other15,598 12,894 
Total deferred tax assets1,051,348 859,641 
Right-of-use assets(23,053)(15,044)
Fixed assets(1,546)(1,212)
Less valuation allowance(1,026,749)(843,385)
Net deferred taxes$— $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets. The valuation allowance increased on a net basis by approximately $183.4 million during the year ended December 31, 2021 due primarily to net operating losses, tax credit carryforwards, and stock-based compensation, offset by the sale of bRT and the Separation. Effective January 1, 2021, the Company adopted ASU 2019-12, which simplifies accounting for income taxes. There was no material impact on the Company's financial position or results of operations upon adoption.
As of December 31, 2021, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of approximately $2.63 billion, $2.03 billion, and $1.62 billion, respectively, which may be available to offset future income tax liabilities. Of the amount as of December 31, 2021, $1.92 billion will carryforward indefinitely while $711.0 million will expire at various dates through 2037. As of December 31, 2021, 2020 and 2019, the Company also had U.S. state net operating loss
F-35
carryforwards of approximately $2.39 billion, $1.89 billion, and $1.56 billion, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2041.
As of December 31, 2021, 2020 and 2019, the Company had federal research and development and orphan drug tax credit carryforwards of approximately $268.3 million, $235.3 million, and $203.1 million, respectively, available to reduce future tax liabilities which expire at various dates through 2041. As of December 31, 2021, 2020 and 2019, the Company had state credit carryforwards of approximately $16.9 million, $14.5 million, and $13.6 million, respectively, available to reduce future tax liabilities which expire at various dates through 2036. During the fourth quarter of 2018, the Company completed an analysis of prior year estimates of U.S. research and development and orphan drug tax credits for the years 2013 through 2017. The analysis resulted in an immaterial adjustment to the Company's income tax benefit, which was offset by an adjustment to the valuation allowance. An analysis of the U.S. research and development and orphan drug credits has not yet been completed for 2019, 2020, or 2021.
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was enacted. This law temporarily suspends and adjusts certain law changes enacted in the Tax Cuts and Jobs Act in 2017. In December 2020, the Consolidated Appropriations Act was enacted. This law modified the employee retention credit under the CARES Act and created credit extenders for certain credits. In March 2021, the American Rescue Plan Act ("ARPA") was enacted and contained extenders to the refundable employee retention credit and provided further limitations to executive compensation effective for tax years beginning after 2026. The Company has concluded that the provisions in the CARES Act, Consolidated Appropriations Act, and ARPA have an immaterial impact on the Company’s income tax expense due to its cumulative losses and full valuation allowance position.
Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which it believes has resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code. The Company completed a study through December 2020 confirming no additional ownership changes; any ownership shifts occurring after December 2020 could result in an ownership change under Section 382.
The Company files Federal income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state or foreign tax authorities to the extent utilized in a future period.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
Unrecognized tax benefits
Balance as of December 31, 2019$15,945 
Increases (decreases) for tax positions related to current period3,149 
Increases (decreases) for tax positions related to prior periods(100)
Balance as of December 31, 202018,994 
Increases (decreases) for tax positions related to current period2,949 
Increases (decreases) for tax positions related to prior periods17 
Balance as of December 31, 202121,960 
The unrecognized tax benefits at December 31, 2021, if recognized, would not affect the Company’s effective tax rate due to its full valuation allowance position. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for income taxes. For the years ended December 31, 2021, 2020 and 2019, the Company’s accrued interest and penalties related to uncertain tax positions were not material.
F-36
17. Reduction in workforce
In April 2021, the Company announced its decision to withdraw ZYNTEGLO from the German market because reimbursement negotiations in Germany did not result in a price for ZYNTEGLO that reflects the value of the one-time gene therapy with potential life-long benefit for people living with β-thalassemia requiring regular transfusions. A total of approximately 50 employees were impacted by this reduction. During the three months ended June 30, 2021, the Company substantially completed the implementation of this reduction and, in accordance with ASC 420, Exit and Disposal Activities, and ASC 712, Nonretirement Postemployment Benefits, recorded approximately $4.6 million of costs including severance, the portion of the employees' 2021 retention bonuses to be paid in cash, and the pro rata portion of the employees' 2021 performance bonus.
In July 2021, the Company made the decision to focus its efforts on the U.S. market for beti-cel, eli-cel, and lovo-cel and is executing an orderly wind down of its European operations. A total of approximately 90 employees were impacted by the reduction in workforce associated with this decision. The Company recorded $21.2 million of expense, in accordance with the related accounting standards mentioned above, for the affected employees. This amount includes expense for severance, the pro rata portion of the employees' 2021 performance bonus, the portion of the European employees' 2021 retention bonuses to be paid in cash, and the portion of retention bonuses to be paid in unrestricted stock awards, which were granted on September 30, 2021. As described in Note 14, Stock-based compensation, the Company recorded $2.5 million of costs associated with the grant of unrestricted stock awards to affected employees as a one-time payment. All costs associated with the April 2021 and July 2021 reductions are reflected within restructuring expense in the Company's consolidated statements of operations and comprehensive loss.
The Company expects that substantially all accrued restructuring charges will be paid in cash by March 31, 2022.
The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):
ChargesAmount paidAmounts accrued
at December 31,
2021
April 2021 reduction$4,625 $(4,625)$— 
July 2021 reduction21,176 (16,503)4,673 
Total$25,801 $(21,128)$4,673 
During the year ended December 31, 2021, the Company recorded approximately $25.8 million in restructuring expenses. During the year ended December 31, 2021, the Company recorded $2.5 million in research and development expenses and selling, general and administrative expenses related to the grant of unrestricted stock awards to affected employees.
18. Net loss per share
The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):
Year ended December 31,
202120202019
Outstanding stock options (1)
5,534 6,262 5,483 
Restricted stock units (1)
3,427 1,495 1,127 
ESPP shares and other— 326 19 
8,961 8,083 6,629 
(1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.

F-37
19. Selected quarterly financial data (unaudited)
The following table contains quarterly financial information for 2021 and 2020. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
2021
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$894 $143 $1,019 $1,606 $3,662 
Total operating expenses146,988 154,844 155,468 137,273 594,573 
Loss from operations(146,094)(154,701)(154,449)(135,667)(590,911)
Net loss from continuing operations(121,504)(155,973)(152,834)(132,327)(562,638)
Net loss from discontinued operations(84,304)(85,729)(63,982)(22,725)(256,740)
Net loss(205,808)(241,702)(216,816)(155,052)(819,378)
Net loss per share from continuing operations
—basic and diluted		(1.81)(2.31)(2.23)(1.83)(8.16)
Net loss per share from discontinued operations—basic and diluted(1.26)(1.27)(0.93)(0.31)(3.73)
Net loss per share—basic and diluted$(3.07)$(3.58)$(3.16)$(2.14)$(11.89)
2020
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$— $— $— $— $— 
Total operating expenses144,479 143,650 131,743 139,387 559,259 
Loss from operations(144,479)(143,650)(131,743)(139,387)(559,259)
Net loss from continuing operations(146,392)(140,665)(137,678)(136,321)(561,056)
Net income (loss) from discontinued operations(56,219)119,200 (57,067)(63,553)(57,639)
Net loss(202,611)(21,465)(194,745)(199,874)(618,695)
Net loss per share from continuing operations
—basic and diluted		(2.63)(2.33)(2.08)(2.05)(9.02)
Net income (loss) per share from discontinued operations—basic and diluted(1.01)1.97 (0.86)(0.96)(0.93)
Net loss per share—basic and diluted$(3.64)$(0.36)$(2.94)$(3.01)$(9.95)

F-38
Exhibit Index
Incorporated by Reference
Exhibit
Number		Exhibit TitleFormFile no.ExhibitFiling Date
2.1*8-K001-359662.1November 4, 2021
3.18-K001-359663.1June 24, 2013
3.210-K001-359663.2February 23, 2021
4.1S-1/A333-1886054.1June 4, 2013
4.210-K001-359664.2February 23, 2021
4.38-K001-359664.1September 8, 2021
10.1#S-1333-18860510.1May 14, 2013
10.2#S-1333-18860510.2May 14, 2013
10.3#S-1/A333-18860510.3June 4, 2013
10.4S-1333-18860510.4May 14, 2013
10.5†S-1333-18860510.6May 14, 2013
10.6†10-K001-3596610.7February 22, 2017
10.7†S-1333-18860510.7May 14, 2013
10.8†S-1333-18860510.8May 14, 2013
10.9†10-Q001-3596610.2November 14, 2013
10.10†10-Q001-3596610.10May 6, 2015
10.11†S-1333-18860510.9May 14, 2013
10.12†S-1333-18860510.10May 14, 2013
10.13††10-Q001-3596610.21August 9, 2021
10.14†10-Q001-3596610.21November 1, 2017
10.15††10-Q001-3596610.23August 9, 2021
10.16†10-K001-3596610.23February 21, 2019
10.17††10-Q001-3596610.25August 1, 2019

Incorporated by Reference
Exhibit
Number		Exhibit TitleFormFile no.ExhibitFiling Date
10.18††8-K001-3596610.1January 21, 2020
10.1910-K001-3596610.28February 23, 2021
10.20#10-Q001-3596610.18May 13, 2014
10.21#10-Q001-3596610.25May 4, 2016
10.22#10-K001-3596610.27February 22, 2017
10.23#———Filed herewith
10.24#———Filed herewith
10.25#———Filed herewith
10.26#———Filed herewith
10.27#———Filed herewith
10.28#S-1/A333-18860510.17June 4, 2013
10.29#10-K001-3596610.38February 21, 2018
10.30#S-8333-25713599.1June 15, 2021
10.31#S-8333-25713599.2June 15, 2021
10.32#S-1333-18860510.18May 14, 2013
10.33††10-Q001-3596610.42August 1, 2019
10.3410-Q001-3596610.43August 1, 2019
10.35*10-Q001-3596610.30November 5, 2021
10.36*———Filed herewith
10.37††*8-K001-3596610.1September 8, 2021
10.388-K001-3596610.2September 8, 2021
10.398-K001-3596610.1November 4, 2021
10.40*8-K001-3596610.2November 4, 2021
10.41*8-K001-3596610.3November 4, 2021
10.42*8-K001-3596610.4November 4, 2021

Incorporated by Reference
Exhibit
Number		Exhibit TitleFormFile no.ExhibitFiling Date
10.43*8-K001-3596610.5November 4, 2021
23.1———Filed herewith
31.1———Filed herewith
31.2———Filed herewith
32.1———Furnished herewith
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
Filed herewith
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
———Filed herewith
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
———Filed herewith
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
———Filed herewith
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
———Filed herewith
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
———Filed herewith
104
Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
———Filed herewith
______________
†    Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the SEC.
††    Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.
#    Indicates a management contract or any compensatory plan, contract or arrangement.
*    Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant will furnish copies of any such schedules and exhibits to the SEC upon request.


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
bluebird bio, Inc.
By:/s/ Andrew Obenshain
Andrew Obenshain
President, Chief Executive Officer and Director
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned directors and officers of bluebird bio, Inc. (the “Company”), hereby severally constitute and appoint Andrew Obenshain and Gina Consylman, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NameTitleDate
/s/ Andrew ObenshainPresident, Chief Executive Officer and DirectorMarch 4, 2022
Andrew Obenshain(Principal Executive Officer and Duly Authorized Officer)
/s/ Gina ConsylmanChief Financial OfficerMarch 4, 2022
Gina Consylman(Principal Financial Officer and Duly Authorized Officer)
/s/ Jessica WhittenVice President, Global Controller and Chief Accounting OfficerMarch 4, 2022
Jessica Whitten(Principal Accounting Officer)
/s/ Mark VachonDirectorMarch 4, 2022
Mark Vachon
/s/ John O. Agwunobi, M.D.DirectorMarch 4, 2022
John O. Agwunobi, M.D.
/s/ Lis Leiderman, M.D.DirectorMarch 4, 2022
Lis Leiderman, M.D.
/s/ Nick LeschlyDirectorMarch 4, 2022
Nick. Leschly
/s/ Najoh Tita-ReidDirectorMarch 4, 2022
Najoh Tita-Reid


 EX-10.23 2 blue-20211231xex1023.htm EX-10.23 Document



Exhibit 10.23

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Andrew Obenshain (the “Executive”) and is made effective as of January 7, 2021 (the “Effective Date”).

WHEREAS, the Company and Employee are parties to that certain letter agreement dated as of December 15, 2016 relating to the Company’s employment of the Executive, that certain letter agreement dated as of December 15, 2016 relating to certain severance arrangements, and that certain letter agreement dated as of February 12, 2019 relating to your return to the United States from Switzerland (collectively, the “Prior Agreement”);

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein, thereby replacing the Prior Agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.Employment.

(a)    Term. The term of this Agreement shall commence on the Effective Date and shall continue until terminated in accordance with the provisions of Section 3 (the “Term”).

(b)    Position and Duties. During the Term, the Executive shall serve as the Company’s President, Severe Genetic Disease, and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the "CEO") or other authorized executive, provided that such duties are consistent with the Executive’s position or other positions that they may hold from time to time. The Executive shall report to the CEO. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on the board of directors of another company, with the prior written approval of the Company’s Board of Directors (the “Board”), and may engage in religious, charitable or other community activities as long as such services and activities do not pose a conflict of interest or interfere with the Executive’s performance of his duties to the Company as provided in this Agreement.

2.Compensation and Related Matters.

(a)    Base Salary. The Executive’s base salary rate shall be $435,000 per year, effective October 19, 2020. The Executive’s base salary shall be re-determined annually by the Board or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The annual base salary rate in effect at any given time is referred to herein as




“Base Salary.” The Executive’s Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.

(b)    Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be forty five percent (45%) of his Base Salary, although any the actual incentive compensation amount shall be discretionary. To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.

(c)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.

(d)    Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms and conditions of such plans.

(e)    Vacations. During the Term, the Executive shall be entitled to accrue paid vacation in accordance with the Company’s applicable policy.

3.Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a)    Death. The Executive’s employment hereunder shall terminate upon his death.

(b)    Disability. The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

2



(c)    Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect to the Company, any affiliate of the Company or any of the Company’s current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Executive’s commission of a felony or any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform his assigned duties to the reasonable satisfaction of the Company, which failure, if curable, continues, in the reasonable judgment of the Company, after written notice given to the Executive by the Company; (iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the Executive’s violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nondisclosure and/or assignment of inventions.

(d)    Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e)    Termination by the Executive. The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events without the Executive’s express written consent: (i) a material diminution in the Executive’s responsibilities, authority and function; (ii) a material reduction in the Executive’s Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated employees and, provided further, that any reduction in the Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change of more than 30 miles in the geographic location at which the Executive must provide services to the Company (except for required travel on Company business to an extent substantially consistent with the Executive’s usual business travel obligations); or (iv) the material breach by the Company of the Company’s equity incentive plan or the stock option agreement governing the stock option granted to the Executive in connection with his hire (as described in the Prior Agreement) or any other material agreement between the Executive and the Company, if any, concerning the terms and conditions of the Executive’s employment, benefits or compensation. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

3



(f)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(g)    Date of Termination. “Date of Termination” shall mean (i) if the Executive's employment is terminated by his death, the date of his death; (ii) if the Executive's employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive's employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive's employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive's employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, (A) in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement, and (B) in the event that the Company terminates the Executive's employment without Cause under Section 3(d), the Company may unilaterally accelerate the Date of Termination to any earlier effective date provided that the Company continues to pay the Executive the Base Salary for the 30-day period immediately following the date on which a Notice of Termination is given to the Executive.

4.Compensation Upon Termination.

(a)    Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements, and unused vacation that accrued through the Date of Termination, such payments to be made on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

(b)    Termination by the Company Without Cause or by the Executive with Good Reason. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:
4




(i)    the Company shall pay the Executive an amount equal to one times the Executive’s Base Salary (the “Severance Amount”); and

(ii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iii)    the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

(iv)    The receipt of any severance payments or benefits pursuant to Section 4 will be subject to Executive not violating the Restrictive Covenant Agreement referenced in Section 7 of this Agreement and attached hereto as Exhibit A, the terms of which are hereby incorporated by reference. In the event Executive breaches the Restrictive Covenant Agreement, in addition to all other legal and equitable remedies, the Company shall have the right to terminate or suspend all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 4 without affecting the Executive’s release or Executive’s obligations under the Separation Agreement and Release.

5.    Change in Control Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control.

(a)    Change in Control. During the Term, if within 12 months after a Change in Control, the Executive’s employment is terminated by the Company without Cause as
5



provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher), plus (B) the Executive’s Target Incentive Compensation. For purposes of this Agreement, “Target Incentive Compensation” shall mean the Executive’s target annual incentive compensation as set forth in Section 2(b); and

(ii)    notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards granted to the Executive after the date of this Agreement shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination. The treatment of stock options and other stock-based awards held by the Executive as of the date of this Agreement shall be governed by the terms of the applicable option agreement or other stock-based award agreement; and

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iv)    The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b)    Additional Limitation.

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Severance Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply:

(A)    If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and
6



employment taxes payable by the Executive on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to the full benefits payable under this Agreement.

(B)    If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order.

(ii)    For the purposes of this Section 5(b), “Threshold Amount” shall mean three times the Executive’s “base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax.

(iii)    The determination as to which of the alternative provisions of Section 5(b)(i) shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining which of the alternative provisions of Section 5(b)(i) shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive’s residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(b)    Definitions. For purposes of this Section 5, the following terms shall have the following meanings:

“Change in Control” shall mean “Sale Event,” as such term is defined in the Company’s 2013 Stock Option and Incentive Plan.

7



6.    Section 409A.

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

(b)    All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

(d)    The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

8



(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

7.    Confidential Information, Noncompetition and Cooperation. The Executive agrees to terms of the Assignment of Invention, Nondisclosure and Noncompetition Agreement (“Restrictive Covenant Agreement”) attached to the Prior Agreement, the terms of which are hereby incorporated by reference as material terms of this Agreement. Nothing in this Agreement or the Restrictive Covenant Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

8.    Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

9.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter.

10.    Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.

11.    Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due his under this Agreement, the Company shall continue such payments to the Executive’s beneficiary
9



designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).

12    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of the Restrictive Covenant Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

13.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

14.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

15.    Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.

16.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

17.    Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

18.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

19.    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.
10




20.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
11




IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.

BLUEBIRD BIO, INC.
By:/s/ Kathy Wilkinson
Kathy Wilkinson
Its:Chief People Officer
/s/ Andrew Obenshain
Andrew Obenshain





Exhibit A

Restrictive Covenant Agreement



 EX-10.24 3 blue-20211231xex1024.htm EX-10.24 Document



Exhibit 10.24

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Gina Consylman (the “Executive”) and is made effective as of June 1, 2021 (the “Effective Date”).

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.Employment.

(a)    Term. The term of this Agreement shall commence on a date to be mutually agreed to by the Executive and the Company, on or before August 2, 2021, and shall continue until terminated in accordance with the provisions of Section 3 (the “Term”). The actual first day of Executive’s employment shall be referred to as the “Start Date”).

(b)    Position and Duties. During the Term, the Executive shall serve as the Company’s Chief Financial Officer, Severe Genetic Diseases, and shall have such powers and duties as may from time to time be prescribed by the President, Severe Genetic Diseases or other authorized executive, provided that such duties are consistent with the Executive’s position or other positions that they may hold from time to time. The Executive shall report to the President, Severe Genetic Diseases. The Executive shall devote their full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on the board of directors of another company, with the prior written approval of the Company’s Board of Directors (the “Board”), and may engage in religious, charitable or other community activities as long as such services and activities do not pose a conflict of interest or interfere with the Executive’s performance of their duties to the Company as provided in this Agreement. The parties acknowledge that as of the Effective Date, the Executive is serving as a member of the board of directors of Verastem, Inc. and as a member of the audit committee and board of directors of Assembly Biosciences, Inc., and the Executive agrees that as of the Start Date, the Executive may serve on the board of directors of no more than one company.

2.Compensation and Related Matters.

(a)    Base Salary. The Executive’s base salary rate shall be $480,000 per year. The Executive’s base salary shall be re-determined annually by the Board or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The annual base salary rate in effect at any given time is referred to herein as “Base Salary.” The Executive’s Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.





(b)    Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be forty five percent (45%) of their Base Salary, although any the actual incentive compensation amount shall be discretionary. To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.

(c)    Equity. Subject to approval by the Board or the Compensation Committee, and as a material inducement to the Executive’s acceptance of employment with the Company, the Executive shall be granted on the first trading day of the first calendar month following the Executive’s Start Date: (i) an option to purchase 85,000 shares of Common Stock of the Company (the “Option”), and (ii) 50,000 restricted stock units (the “RSUs”). The Option shall have an exercise price equal to the closing price of the Company’s common stock on the date of grant, and 25% shall vest and become exercisable on the first anniversary of the Start Date, and in equal monthly installments over the following three years, provided the Executive continues their employment through the applicable vesting date. The RSUs shall vest as follows, provided the Executive continues their employment through the applicable vesting date: 25% on the first anniversary of the date of grant, and in three equal annual installments for the following three years on the anniversaries of the date of grant. In the Company’s sole discretion, the Option and the RSUs may be granted pursuant to the inducement grant exception set forth in NASDAQ Listing Rule 5635(c)(4).

(d)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by then during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.

(e)    Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms and conditions of such plans.

(f)    Vacations. During the Term, the Executive shall be entitled to accrue paid vacation in accordance with the Company’s applicable policy.

3.Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a)    Death. The Executive’s employment hereunder shall terminate upon their death.

(b)    Disability. The Company may terminate the Executive’s employment if they are disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the
2



Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(c)    Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect to the Company, any affiliate of the Company or any of the Company’s current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Executive’s commission of a felony or any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform their assigned duties to the reasonable satisfaction of the Company, which failure, if curable, continues, in the reasonable judgment of the Company, after written notice given to the Executive by the Company; (iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the Executive’s violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nondisclosure and/or assignment of inventions.

(d)    Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e)    Termination by the Executive. The Executive may terminate their employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events without the Executive’s express written consent: (i) a material diminution in the Executive’s responsibilities, authority and function; (ii) a material reduction in the Executive’s Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated employees and, provided further, that any reduction in the Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change of more than 30 miles in the geographic location at which the Executive must provide services to the Company (except for required travel on Company business to an extent substantially consistent with the Executive’s usual business travel obligations); or (iv) the material breach by the Company of the Company’s agreements or equity incentive plan covering the Option or RSUs granted to the Executive in connection with their hire or any other material agreement between the Executive and the Company, if any, concerning the terms
3



and conditions of the Executive’s employment, benefits or compensation. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates their employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

(f)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(g)    Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by their death, the date of their death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, (A) in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement, and (B) in the event that the Company terminates the Executive’s employment without Cause under Section 3(d), the Company may unilaterally accelerate the Date of Termination to any earlier effective date provided that the Company continues to pay the Executive the Base Salary for the 30-day period immediately following the date on which a Notice of Termination is given to the Executive.

4.Compensation Upon Termination.

(a)    Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to their authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements, and unused vacation that accrued through the Date of Termination, such payments to be made on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

4



(b)    Termination by the Company Without Cause or by the Executive with Good Reason. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates their employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive their Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:

(i)    the Company shall pay the Executive an amount equal to one times the Executive’s Base Salary (the “Severance Amount”); and

(ii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iii)    the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

(iv)    The receipt of any severance payments or benefits pursuant to Section 4 will be subject to Executive not violating the Restrictive Covenant Agreement referenced in Section 7 of this Agreement and attached hereto as Exhibit A, the terms of which are hereby incorporated by reference. In the event Executive breaches the Restrictive Covenant Agreement, in addition to all other legal and equitable remedies, the Company shall have the right to terminate or suspend all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 4 without affecting the Executive’s release or Executive’s obligations under the Separation Agreement and Release.

5.    Change in Control Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to their assigned duties and their objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of
5



employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control.

(a)    Change in Control. During the Term, if within 12 months after a Change in Control, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates their employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher), plus (B) the Executive’s Target Incentive Compensation. For purposes of this Agreement, “Target Incentive Compensation” shall mean the Executive’s target annual incentive compensation as set forth in Section 2(b); and

(ii)    notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards granted to the Executive after the date of this Agreement shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination. The treatment of stock options and other stock-based awards held by the Executive as of the date of this Agreement shall be governed by the terms of the applicable option agreement or other stock-based award agreement; and

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iv)    The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b)    Additional Limitation.

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable
6



regulations thereunder (the “Severance Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply:

(A)    If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes payable by the Executive on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to the full benefits payable under this Agreement.

(B)    If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order.

(ii)    For the purposes of this Section 5(b), “Threshold Amount” shall mean three times the Executive’s “base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax.

(iii)    The determination as to which of the alternative provisions of Section 5(b)(i) shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining which of the alternative provisions of Section 5(b)(i) shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive’s residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(b)    Definitions. For purposes of this Section 5, the following terms shall have the following meanings:

7



“Change in Control” shall mean “Sale Event,” as such term is defined in the Company’s 2013 Stock Option and Incentive Plan.

6.    Section 409A.

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

(b)    All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A‑1(h).

(d)    The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A‑2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
8



(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

7.    Confidential Information, Noncompetition and Cooperation. The Executive agrees to terms of the Assignment of Invention, Nondisclosure and Noncompetition Agreement (“Restrictive Covenant Agreement”) attached hereto, the terms of which are hereby incorporated by reference as material terms of this Agreement. Nothing in this Agreement or the Restrictive Covenant Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

8.    Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

9.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter.

10.    Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.

11.    Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after their termination of employment but prior to the completion by the Company of all payments due them under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to their death (or to their estate, if the Executive fails to make such designation).

9



12    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of the Restrictive Covenant Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

13.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

14.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

15.    Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.

16.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

17.    Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

18.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

19.    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.

20.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
10




IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.

BLUEBIRD BIO, INC.
By:/s/ Meredith Willoughby
Meredith Willoughby
Its:Sr. Director, Total Rewards, HRIS and Operations
/s/ Gina Consylman
Gina Consylman





Exhibit A

Restrictive Covenant Agreement

ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION
AND NONSOLICITATION AGREEMENT

This Agreement is made between bluebird bio, Inc., a Delaware corporation (including its subsidiaries and other affiliates and its and their successors and assigns, hereinafter referred to as “bluebird bio” or the “Company’’), and Gina Consylman, an employee or consultant of the Company (the “Service Provider”).

In consideration of the employment of the Service Provider by the Company, the Company’s promise to provide the Service Provider with items of bluebird bio Proprietary Information, specialized training and/or goodwill, and, as applicable, participation by the Service Provider in the Company’s Sale Event Severance Plan, as additional consideration for signing this agreement, the Company and the Service Provider agree as follows:

1.    Noncompetition; Nonsolicitation.
a.    During the term of Service Provider’s provision of services to the Company and for a period of (i) one year after the termination or cessation of such services for any reason or no reason (the “Last Date of Employment”), or (ii) two (2) years following the Last Date of Employment if he or she breaches his or her fiduciary duty to the Company or if he or she has unlawfully taken, physically or electronically, property belonging to the Company (in either case, the “Restricted Period”):
(I) Unless (A) the Company elects to terminate the Service Provider’s employment without Cause (as defined below) or the Service Provider has been laid off; or (B) the Company elects to waive the restrictions upon post-employment activities set forth in this Section 1.a.(I), then, the Company shall make payments to the Service Provider for the post-employment portion of the Restricted Period (but for not more than 12 months following the Last Date of Employment) at the rate of 50% of the highest annualized base salary paid to the Service Provider by the Company within the two-year period preceding the Last Date of Employment, which the Service Provider acknowledges and agrees is consideration mutually agreed upon by the Company and the Service Provider, and in exchange, the Service Provider shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, anywhere in the geographic areas in which, at any time during the two years that immediately preceded the Last Date of Employment (“Two Year Lookback”), the Service Provider provided services or had a material presence or influence, provide any of the types of services that the Service Provider provided to the Company during the Two Year Lookback, in connection with any business that develops, manufactures or markets any products, or performs any services, that are competitive with the products or services of the Company, or products or services that the Company or its affiliates has under development or that are the subject of active planning at any time during the Service Provider’s employment (“Restricted Activity”). For purposes of this Agreement, and notwithstanding anything to the contrary in any other agreement between the Company and the Service Provider, “Cause” shall mean a reasonable and
1



good faith basis for the Company to be dissatisfied with the Service Provider’s job performance, conduct or behavior. The Service Provider acknowledges that this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. The Service Provider further acknowledges and agrees that any payments the Service Provider receives pursuant to this Section 1.a.(I) shall reduce (and shall not be in addition to) any severance or separation pay that the Service Provider is otherwise entitled to receive from the Company pursuant to an agreement, plan or otherwise. Notwithstanding the foregoing, Service Provider shall have the right to own, for investment purposes, not more than one percent of the outstanding capital stock of a publicly held enterprise which competes with bluebird bio and nothing contained in this Section 1 shall prevent Service Provider from being employed by a university or nonprofit research institution.
(II) Service Provider will not solicit, entice or induce any employee or consultant of bluebird bio to terminate his or her employment or consultancy or engage in a Restricted Activity; and
(III) Service Provider will not solicit, entice or induce any vendor, customer or distributor of bluebird bio to terminate or materially diminish its relationship with bluebird bio.
b. Service Provider acknowledges and agrees that, in the event he/she breaches any of the terms described in Section 1.a.(II) or (III) above, the Restricted Period shall be tolled and shall not run during the time that Service Provider is in breach of such obligations; provided that, the Restricted Period shall begin to run again once Service Provider has ceased breaching the terms of Section 1.a.(II) or (III) and is otherwise in compliance with his/her obligations described therein.
c. Service Provider further acknowledges and agrees that (i) the types of employment which are prohibited by Section 1.a(I) are narrow and reasonable in relation to the skills which represent Service Provider’s principal salable assets both to bluebird bio and to other prospective employers, and (ii) the geographical scope of the provisions of Section 1.a(I) is reasonable, legitimate and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited compared to the activities for which Service Provider is qualified to earn a livelihood.
d. Service Provider acknowledges and agrees that (i) the restrictions in Section 1.a are reasonable, legitimate, necessary and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited. Service Provider further acknowledges and agrees that any breach or threatened breach of this Agreement will cause irreparable injury to bluebird bio and that money damages may not provide an adequate remedy to bluebird bio. Service Provider therefore agrees that bluebird bio, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Service Provider of any of the provisions of this Agreement, without having to post bond. Service Provider further acknowledges that a court may render an award extending the Restricted Period as one of the remedies in the event of his or her violation of this Agreement. If the Service Provider violates this Agreement, in
2



addition to all other remedies available to the Company at law (including, without limitation, the Company’s right to discontinue any payments the Service Provider may receive pursuant to Section 1.a.(I)), in equity, and under contract, the Service Provider agrees that he or she is obligated to pay all of the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and expenses.
2.    Confidential Information.
a. Service Provider acknowledges and agrees to abide by bluebird bio’s Confidentiality and Trade Secret Policies.
b. Service Provider acknowledges that bluebird bio would be irreparably damaged if Service Provider’s confidential knowledge of the business of bluebird bio was disclosed to or utilized on behalf of others. Service Provider acknowledges that he or she has learned and will learn bluebird bio Proprietary Information, as defined in Section 2.b. hereof, relating to the business to be conducted by bluebird bio and its subsidiaries and joint ventures and partnerships to which bluebird bio may be a party (together, the “bluebird bio Entities”). Service Provider agrees that he or she will not, except in the normal and proper course of his or her employment or consultancy or as otherwise provided herein, disclose or use or enable anyone else to disclose or use, either during the term of this Agreement or subsequent thereto, any such bluebird bio Proprietary Information without prior written approval of bluebird bio. Service Provider further agrees to comply with all bluebird bio policies that govern the treatment of bluebird bio Proprietary Information and the reporting of any suspected violation of law, including but not limited to the Code of Business Conduct and Ethics, as such policies may be amended or revised from time to time. Service Provider acknowledges receipt of the following notice under 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” In addition, nothing in this Agreement prohibits Service Provider from reporting an event that Service Provider reasonably and in good faith believes is a violation of law to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Opportunity Commission, or Department of Labor), requires notice to or approval from the Company before doing so, or prohibits Service Provider from cooperating in an investigation conducted by such a government agency.
c. For the purpose of this Agreement, “bluebird bio Proprietary Information” shall mean all information, ideas, concepts, improvements, discoveries, and Inventions (defined in 3 a. below) that are both (i) disclosed or made known by bluebird bio to Service Provider, and (ii) identified as “proprietary” by bluebird bio to Service Provider (either orally or in writing) at the time of such disclosure or that should reasonably be known to be proprietary, including, but not limited to, the following types of information: corporate information, including contractual licensing arrangements, plans, strategies, tactics, policies, resolutions, and any litigation or negotiations; intellectual property, including patent applications, trademarks, trade secrets, and secret formulae; marketing information, including sales or product plans, strategies, tactics, methods, customers, prospects, or market research data; financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings; operational information
3



that relates to the technology that bluebird bio has or desires to develop or market, including control and inspection practices, manufacturing processes and methods, suppliers and parts; technical information, including machinery or device designs, drawings, specifications, processes, procedures, scientific or statistical data, research and development information, scientific protocols, clinical data and preclinical data. bluebird bio Proprietary Information does not include information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act such as joining or forming a union, engaging in collective bargaining, or engaging in other concerted activity for mutual aid or protection of laborers. For purpose of clarity, it shall still be a violation of this Agreement for a non-management employee to share Confidential Information with a competitor about other employees’ compensation and benefits which was obtained through the course of employment with the Company for purposes of assisting such competitor in soliciting Company employees.
d. Service Provider agrees that all documents of any nature provided by bluebird bio to Service Provider and pertaining to activities of any bluebird bio entity or to any bluebird bio Proprietary Information, in his or her possession now or at any time during the term of this Agreement, including without limitation memoranda, notebooks, notes, data sheets, records and blueprints, are and shall be the property of bluebird bio, and that they and all copies of them shall be surrendered to bluebird bio upon the earlier of request by bluebird bio or termination of this Agreement.
e. Service Provider shall have none of the obligations set forth above with respect to bluebird bio Proprietary Information (i) that is publicly known or becomes publicly known through no breach of this Agreement by Service Provider, (ii) that is generally or readily obtainable by the public, or within the scientific field, (iii) that is known by Service Provider prior to its disclosure to Service Provider by bluebird bio, as shown by Service Provider’s written records, (iv) that Service Provider received from a source that had the legal right to disclose the information to Service Provider, (v) that is required to be disclosed by law, government regulation or court order, or (vi) involves information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act. Further, nothing herein limits, restricts, or in any other way affects Service Provider communicating with the SEC, the DOL, or any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, or cooperating with or participating in a legal proceeding concerning matters relevant to the governmental agency or entity.
3.    Intellectual Property.
a. Service Provider hereby assigns and agrees to assign to bluebird bio his or her entire right, title and interest in and to all Inventions. “Inventions” means improvements, modifications, know-how, processes, secrets and discoveries made, possessed, discovered or conceived by him or her during the period in which the Service Provider has provided services to the Company (whether or not patentable, whether or not reduced to practice, whether or not made, possessed, discovered or conceived by him or her individually or jointly with any other person or persons, whether made or conceived on or off bluebird bio’s premises, and whether made in or out of working hours), which shall specifically or generally relate to, be applicable to or concern (a) development of therapeutics utilizing ex vivo or in vivo nucleic acid (e.g., gene) transfer utilizing viral vector or virus-based
4



approaches (e.g., lentivirus), (b) methods of manufacturing viral vectors or genetically modified cells for the development of therapeutics, (c) approaches to facilitate proper homing or engraftment of genetically modified cells (d) gene editing, (e) cancer therapy, (f) rare genetic disease therapy, and (g) any other project, field, or line of business in which bluebird bio is engaged (collectively, the “Field”), such Inventions and benefits hereof to immediately become the sole and absolute property of bluebird bio. In the event that any portion of this assignment is prohibited by the terms of a funding agreement under which the work resulting in any Invention was performed or the regulations of the institution where such work was performed (in the event such work was not performed by bluebird bio), Service Provider shall use his or her best efforts to obtain for bluebird bio a license or other consent to use such information on the most advantageous terms that are available to bluebird bio. Service Provider agrees that, upon the request of bluebird bio and at the expense of bluebird bio, Service Provider will execute such further assignments, documents, and other instruments as may be necessary or desirable fully and completely to assign all such Inventions to bluebird bio and to assist bluebird bio in applying for, obtaining, and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. Service Provider shall keep and maintain adequate and current written records of all Inventions, in the form of notes, sketches, drawings or as may be specified by bluebird bio, which records shall be available to and remain the sole property of bluebird bio at all times. Service Provider acknowledges that bluebird bio from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on bluebird bio regarding Inventions made during the course of work under such agreements or regarding the confidential nature of such work. Service Provider agrees to be bound by all such obligations and restrictions which are made known to Service Provider and to take all action necessary to discharge the obligations of bluebird bio under such agreements.
b. This Agreement’s assignment provisions are limited to only those Inventions that can be lawfully assigned by an employee to an employer under applicable law in the state where Service Provider last regularly resided while employed by the Company. Service Provider hereby acknowledges that Service Provider has been notified of the following laws governing the assignment of inventions: Del. Code Title 19 § 805; Ill. 765 ILCS1060/1-3, “Employees Patent Act”; N. C. Gen. Stat. Article 10A, Chp 66, Comm. & Bus., § 66-57.1; Minn. Stat. 13A § 181.78; Kan. Stat. § 44-130; Utah Code §34-39-1 -- 34-39-3, “Employee Inventions Act”; Wash. Rev. Code, Title 49 RCW: Lab. Reg. Chpt. 49.44.140; for example, if Service Provider resides in California, the assignment is limited to comply with Cal. Lab. Code § 2870 which provides: (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or (2) Result from any work performed by the employee for the employer. Service Provider will not, without the Company’s prior written consent, incorporate into any Company product or otherwise deliver to the Company any software code that is subject to any license that by its terms requires, or conditions the use or distribution of such code on, the disclosure, licensing or distribution of such Company
5



product or any source code owned or licensed by the Company (e.g., software code licensed under the GNU GPL, LGPL or AGPL.
4.    Publication.
Anything to the contrary herein notwithstanding, Service Provider may not publish any bluebird bio Proprietary Information or information regarding Inventions, (as defined above) of a scientific (as opposed to business or corporate) nature generated in the Field by Service Provider. Any clinical or research publication request must comport with bluebird bio’s Scientific and Clinical Publication Review and Approval Process. In addition, Service Provider will cooperate with patent counsel for bluebird bio in effecting the intent of this Section by providing a copy of the text and/or data and any other information needed to file any patent applications or other appropriate materials to protect such information prior to any publication request.
5.    Trade Secrets of Others/Obligations to Others.
Service Provider represents that his or her other performance of all the terms of this Agreement does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by him or her in confidence or in trust prior to his or her engagement by bluebird bio, and Service Provider agrees that he or she will not disclose to bluebird bio, or induce bluebird bio to use, any confidential or proprietary information or material belonging to any other person. Service Provider agrees that he or she will not enter into any agreement, either written or oral, in conflict with his or her obligations under this Agreement.
6.    Survival
The terms of this Agreement and Service Provider’s obligations hereunder shall survive any termination of the Services Provider’s employment, contractual or other business relationship with bluebird bio, irrespective of the reason or reasons for such termination. Nothing in this Agreement shall eliminate, reduce, or otherwise remove any legal duties or obligations that Service Provider would otherwise have to the Company through common law or statute.
7.    Agreement Enforceable Upon Material Job Change.
Service Provider acknowledges and agrees that if he or she should transfer between or among any affiliates of bluebird bio, wherever situated, or be promoted, demoted, reassigned to functions other than Service Provider’s present functions, or have his/her job duties changed, altered or modified in any way, all terms of this Agreement shall continue to apply with full force.
8.    Notice of Resignation.
If the Service Provider elects to resign from his or her employment with the Company, the Service Provider agrees to provide the Company with written notification of his or her resignation at least two (2) weeks prior to the intended resignation date. Such notice shall include information in reasonable detail about his or her post-employment job duties and other business activities, including the name and address of any subsequent employer and/or person or entity with whom or which he or she intends to engage in business activities during the Restricted Period and the nature of his or her job duties and other business activities. The Company may elect to waive all or part of the two (2) week notice period in its sole discretion.
6



9.    Disclosure to Future Employers.
Service Provider agrees to provide, and the Company, in its discretion, may provide, a copy of this Agreement to any business or enterprise which Service Provider may directly or indirectly own, manage, operate, finance, join, control or in which Service Provider may participate in the ownership, management, operation, financing, or control, or with which Service Provider may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.
10.    Modification.
This Agreement may not be changed, waived, modified, released, discharged, abandoned, or otherwise amended, in whole or in part, except by an instrument in writing signed by Service Provider and bluebird bio or as provided in Section 17 or Section 1(a)(I)(B), which waiver under Section 1(a)(I)(B) must be in writing. The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
11.    Entire Agreement.
This Agreement constitutes the entire agreement and understanding between the parties hereto and supersedes any previous oral or written communications, representations, understandings, or agreements relating to the subject matter hereof; notwithstanding the foregoing, any Invention that was created prior to execution of this agreement shall also remain subject to the provisions of any intellectual property assignment provisions in existence between bluebird bio and Service Provider.
12.    Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns (including, in the case of Service Provider, his or her heirs, executors, administrators and other legal representatives). Neither party hereto may assign any of its rights or obligations hereunder to any other person, except that bluebird bio may assign all of its rights and obligations under this Agreement to any person or entity controlled by, in control of, or under common control with, bluebird bio, or to any successor or assign of bluebird bio that employs Service Provider subsequent to his or her employment with bluebird bio.
13.    Counterparts.
This Agreement may be signed in two counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement.
14.    Notices.
All notices, requests, consents and other communications required or permitted hereunder shall be in writing and shall be hand delivered or mailed by first-class mail postage prepaid, addressed as follows: If to bluebird bio, at bluebird bio, Inc., 60 Binney Street, Cambridge, MA 02142, Attention: Chief Legal Officer, or to such other address as may have been furnished to Service Provider by bluebird bio in writing as herein provided; or if to Service Provider, at the address set forth below his or her signature hereon, or to such other address as may have been furnished to bluebird bio by Service Provider as herein provided in writing. Any notice or other communication so addressed and so
7



mailed shall be deemed to have been given when mailed, and if hand delivered shall be deemed to have been given when delivered.
15.    Applicable Law.
This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, shall take effect as an instrument under seal within Massachusetts, and the validity, interpretation and performance of this Agreement shall be governed by, and construed in accordance with, the internal law of Massachusetts, without giving effect to conflict of law principles, and specifically excluding any conflict or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties acknowledge that the last act necessary to render this Agreement enforceable is its execution by the Company in Massachusetts, and that the Agreement shall be maintained in Massachusetts.
16.    Jurisdiction, Venue, Service of Process and Jury Trial Waiver.
Any legal action or proceeding with respect to this Agreement must be brought in the courts of the Commonwealth of Massachusetts or in the United States District Court for the District of Massachusetts and shall be subject to the jurisdiction of such courts only. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts and waive any objection to personal jurisdiction or venue in those courts; provided, however, the Company and the Service Provider agree that all civil actions relating to Section 1.a.(I) of this Agreement shall be brought in the county of Suffolk and that the superior court or the business litigation section of the superior court shall have exclusive jurisdiction. Any action, demand, claim or counterclaim arising under or relating to this Agreement will be resolved by a judge alone and each of the Company and the Service Provider waive any right to a jury trial thereof.
17.    Severability.
The parties intend this Agreement to be enforced as written. However, (a) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly-authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law, and (b) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the court making such determination will have the power to modify or reduce the scope, duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-pencilling”), and in its modified, reduced or blue-pencilled form such provision will then be enforceable and will be enforced.
18.    Use of Name or Affiliation.
bluebird bio shall not use Service Provider’s name or affiliation, in publicity, advertising, or securities offering materials without the prior written approval of Service Provider, provided that such approval shall not be unreasonably withheld in cases in which bluebird bio is required by applicable law to disclose Service Provider’s relationship with bluebird bio.
8



19.    Employment At-Will.
This Agreement does not constitute a contract of employment for a definite period or imply that Service Provider’s employment or engagement with the Company shall continue for any definite period of time. Employment with the Company is at-will meaning that the Service Provider or the Company may end the employment relationship at any time with or without notice or cause.

THE SERVICE PROVIDER ACKNOWLEDGES THAT HE OR SHE HAS CAREFULLY READ THIS ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION AND NONSOLICITATION AGREEMENT AND Appendix A and UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. FURTHERMORE, BY SIGNING BELOW, THE SERVICE PROVIDER CERTIFIES THAT (I) HE OR SHE WAS PROVIDED WITH THIS AGREEMENT BY THE EARLIER OF A FORMAL OFFER OF EMPLOYMENT OR TEN (10) BUSINESS DAYS BEFORE THE COMMENCEMENT OF HIS OR HER EMPLOYMENT, AND (II) HE OR SHE HAS BEEN ADVISED BY THE COMPANY THAT HE OR SHE HAS THE RIGHT TO CONSULT WITH COUNSEL PRIOR TO SIGNING THIS AGREEMENT.

bluebird bio, Inc.
By:/s/ Meredith Willoughby
Print Name:Meredith Willoughby
Title:Senior Director, Total Rewards, HRIS, Operations
Date:1-June-2021
SERVICE PROVIDER
By:/s/ Gina Consylman
Print Name:Gina Consylman
Date:1-June-2021

Attachment: Appendix A


9



APPENDIX A

Alabama:

If Service Provider resides in Alabama, and is subject to Alabama law, then the following applies to Service Provider for as long as Service Provider is subject to Alabama law: (i) Paragraph 1(a) shall be further limited to the solicitation or hiring of employees or consultants of the Company who are engaged in a Sensitive Position for the Company. A person is in a “Sensitive Position” if he or she is uniquely essential to the management, organization, or service of the Company’s business; and (ii) Paragraph 1(a)(ii) shall be limited to solicitation of current customers, vendors, or distributors of the Company (i.e., past or inactive customers, vendors, or distributors are not covered by the provision).

Arizona:

If Service Provider resides in Arizona and is subject to Arizona law, then the following applies to Service Provider for as long as Service Provider is subject to Arizona law: the restrictions in Paragraph 1(a)(ii) shall be limited to the geographic region that Service Provider worked in, serviced, managed and/or supervised on behalf of the Company within the one (1) year period immediately preceding the termination of his employment.

California:

If Service Provider resides in California and is subject to California law, then the following applies to Service Provider for so long as Service Provider is subject to California law: (a) Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law); and (b) Paragraphs 14 and 15 shall not apply.

Louisiana:

If Service Provider resides in Louisiana and is subject to Louisiana law, then the following applies to Service Provider for as long as Service Provider is subject to Louisiana law: the restrictions in Paragraph 1(a)(ii) shall be limited to the following parishes in Louisiana and counties outside Louisiana:_____________________________ [each individual Parish and/or County must be named].

Montana:

If Service Provider resides in Montana and is subject to Montana law, then the following applies to Service Provider for as long as Service Provider is subject to Montana law: the last sentence of Paragraph 18 shall not apply.

Nebraska:

If Service Provider resides in Nebraska and is subject to Nebraska law, then the following applies to Service Provider for so long as Service Provider is subject to Nebraska law: Paragraph 1(a)(ii) is further limited to the solicitation of customers, vendors, or distributors, with which
10



Service Provider did business on behalf of the Company and had personal business-related contact during the one (1) year period immediately preceding Service Provider’s termination.
 
Nevada:

If Service Provider resides in Nevada and is subject to Nevada law, then the following applies to Service Provider for so long as Service Provider is subject to Nevada law: Paragraph 1(a)(ii) does not preclude Service Provider from providing services to any former customer of the Company if: (a) Service Provider did not solicit the former customer; (b) the customer voluntarily chose to leave and seek services from Service Provider; and (c) Service Provider is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained.

New York:

If Service Provider resides in New York and is subject to New York law, then the following applies to Service Provider for so long as Service Provider is subject to New York law: Paragraph 1(a)(ii) shall be modified so that it excludes those customers who became a customer of Company as a result of Service Provider’s independent contact and business development efforts with the customer prior to and independent from his/her employment with Company.

North Carolina:

If Service Provider resides in North Carolina and is subject to the laws of North Carolina, then the following applies to Service Provider for so long as Service Provider is subject to North Carolina law: the one (1) year look back period referenced in Paragraph 1(a) shall be calculated looking back one (1) year from the date of enforcement and not from the date employment ends.

North Dakota:

If Service Provider resides in North Dakota and is subject to North Dakota law, then the following applies to Service Provider for so long as Service Provider is subject to North Dakota law: Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).

Wisconsin:

If Service Provider resides in Wisconsin and is subject to Wisconsin law, then the following applies to Service Provider for so long as Service Provider is subject to Wisconsin law: (a) Paragraph 9(g) shall not apply; and (b) Paragraph 5(b) shall be further limited to the solicitation or hiring of employees, independent contractors, sales agents, or sales associates of the Company who are engaged in a Sensitive Position for the Company. “Sensitive Position” refers to an employee of the Company who is in a management, supervisory, sales, research and development, or similar role where the employee is provided Confidential Information or is involved in business dealings with the Company’s customers.

11
 EX-10.25 4 blue-20211231xex1025.htm EX-10.25 Document



Exhibit 10.25

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Thomas Klima (the “Executive”) and is made effective as of April 20, 2021 (the “Effective Date”).

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.Employment.

(a)    Term. The term of this Agreement shall commence on a date to be mutually agreed to by the Executive and the Company, on or before May 10, 2021, and shall continue until terminated in accordance with the provisions of Section 3 (the “Term”). The actual first day of Executive’s employment shall be referred to as the “Start Date”).

(b)    Position and Duties. During the Term, the Executive shall serve as the Company’s Chief Commercial Officer, Severe Genetic Disease, and shall have such powers and duties as may from time to time be prescribed by the President, Severe Genetic Disease or other authorized executive, provided that such duties are consistent with the Executive’s position or other positions that he may hold from time to time. The Executive shall report to the President, Severe Genetic Disease. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on boards of directors of another company, with the prior written approval of the Company’s Board of Directors (the “Board”), and may engage in religious, charitable or other community activities as long as such services and activities do not pose a conflict of interest or interfere with the Executive’s performance of his duties to the Company as provided in this Agreement.

2.Compensation and Related Matters.

(a)    Base Salary. The Executive’s base salary rate shall be $400,000 per year. The Executive’s base salary shall be re-determined annually by the Board or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The annual base salary rate in effect at any given time is referred to herein as “Base Salary.” The Executive’s Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.

(b)    Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be forty five percent (45%) of his




Base Salary, although any the actual incentive compensation amount shall be discretionary. To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.

(c)    Equity. Subject to approval by the Board or the Compensation Committee, and as a material inducement to the Executive’s acceptance of employment with the Company, the Executive shall be granted on the first trading day of the first calendar month following the Executive’s Start Date: (i) an option to purchase 50,000 shares of Common Stock of the Company (the “Option”), and (ii) 25,000 restricted stock units (the “RSUs”). The Option shall have an exercise price equal to the closing price of the Company’s common stock on the date of grant, and 25% shall vest and become exercisable on the first anniversary of the Start Date, and in equal monthly installments over the following three years, provided the Executive continues his employment through the applicable vesting date. The RSUs shall vest as follows, provided the Executive continues his employment through the applicable vesting date: 25% on the first anniversary of the date of grant, and in three equal annual installments for the following three years on the anniversaries of the date of grant. In the Company’s sole discretion, the Option and the RSUs may be granted pursuant to the inducement grant exception set forth in NASDAQ Listing Rule 5635(c)(4).

(d)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.

(e)    Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms and conditions of such plans.

(f)    Vacations. During the Term, the Executive shall be entitled to accrue paid vacation in accordance with the Company’s applicable policy.

3.Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a)    Death. The Executive’s employment hereunder shall terminate upon his death.

(b)    Disability. The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician
2



in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(c)    Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect to the Company, any affiliate of the Company or any of the Company’s current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Executive’s commission of a felony or any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform his assigned duties to the reasonable satisfaction of the Company, which failure, if curable, continues, in the reasonable judgment of the Company, after written notice given to the Executive by the Company; (iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the Executive’s violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nondisclosure and/or assignment of inventions.

(d)    Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e)    Termination by the Executive. The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events without the Executive’s express written consent: (i) a material diminution in the Executive’s responsibilities, authority and function; (ii) a material reduction in the Executive’s Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated employees and, provided further, that any reduction in the Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change of more than 30 miles in the geographic location at which the Executive must provide services to the Company (except for required travel on Company business to an extent substantially consistent with the Executive’s usual business travel obligations); or (iv) the material breach by the Company of the Company’s agreements or equity incentive plan covering the Option or RSUs granted to the Executive in connection with his hire or any other material agreement between the Executive and the Company, if any, concerning the terms and conditions of the Executive’s employment, benefits or compensation. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good
3



Reason condition continues to exist; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

(f)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(g)    Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, (A) in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement, and (B) in the event that the Company terminates the Executive’s employment without Cause under Section 3(d), the Company may unilaterally accelerate the Date of Termination to any earlier effective date provided that the Company continues to pay the Executive the Base Salary for the 30-day period immediately following the date on which a Notice of Termination is given to the Executive.

4.Compensation Upon Termination.

(a)    Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements, and unused vacation that accrued through the Date of Termination, such payments to be made on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

(b)    Termination by the Company Without Cause or by the Executive with Good Reason. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the “Separation
4



Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:

(i)    the Company shall pay the Executive an amount equal to one times the Executive’s Base Salary (the “Severance Amount”); and

(ii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iii)    the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

(iv)    The receipt of any severance payments or benefits pursuant to Section 4 will be subject to Executive not violating the Restrictive Covenant Agreement referenced in Section 7 of this Agreement and attached hereto as Exhibit A, the terms of which are hereby incorporated by reference. In the event Executive breaches the Restrictive Covenant Agreement, in addition to all other legal and equitable remedies, the Company shall have the right to terminate or suspend all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 4 without affecting the Executive’s release or Executive’s obligations under the Separation Agreement and Release.

5.    Change in Control Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control.

(a)    Change in Control. During the Term, if within 12 months after a Change in Control, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section
5



3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher), plus (B) the Executive’s Target Incentive Compensation. For purposes of this Agreement, “Target Incentive Compensation” shall mean the Executive’s target annual incentive compensation as set forth in Section 2(b); and

(ii)    notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards granted to the Executive after the date of this Agreement shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination. The treatment of stock options and other stock-based awards held by the Executive as of the date of this Agreement shall be governed by the terms of the applicable option agreement or other stock-based award agreement; and

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iv)    The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b)    Additional Limitation.

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Severance Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply:

(A)    If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes payable by the Executive on the amount of the Severance Payments which are in
6



excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to the full benefits payable under this Agreement.

(B)    If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order.

(ii)    For the purposes of this Section 5(b), “Threshold Amount” shall mean three times the Executive’s “base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax.

(iii)    The determination as to which of the alternative provisions of Section 5(b)(i) shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining which of the alternative provisions of Section 5(b)(i) shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive’s residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(b)    Definitions. For purposes of this Section 5, the following terms shall have the following meanings:

“Change in Control” shall mean “Sale Event,” as such term is defined in the Company’s 2013 Stock Option and Incentive Plan.

6.    Section 409A.

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the
7



Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

(b)    All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A‑1(h).

(d)    The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A‑2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

7.    Confidential Information, Noncompetition and Cooperation. The Executive agrees to terms of the Assignment of Invention, Nondisclosure and Noncompetition Agreement (“Restrictive
8



Covenant Agreement”) attached hereto, the terms of which are hereby incorporated by reference as material terms of this Agreement. Nothing in this Agreement or the Restrictive Covenant Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

8.    Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

9.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter.

10.    Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.

11.    Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due his under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).

12    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of the Restrictive Covenant Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.
9




13.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

14.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

15.    Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.

16.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

17.    Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

18.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

19.    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.

20.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
10




IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.

BLUEBIRD BIO, INC.
By:/s/ Meredith Willoughby
Its:Sr. Director, HR Operations & Rewards
/s/ Thomas Klima
Thomas Klima





Exhibit A

Restrictive Covenant Agreement

ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION
AND NONSOLICITATION AGREEMENT

This Agreement is made between bluebird bio, Inc., a Delaware corporation (including its subsidiaries and other affiliates and its and their successors and assigns, hereinafter referred to as “bluebird bio” or the “Company’’), and Thomas Klima, an employee or consultant of the Company (the “Service Provider”).

In consideration of the employment of the Service Provider by the Company, the Company’s promise to provide the Service Provider with items of bluebird bio Proprietary Information, specialized training and/or goodwill, and, as applicable, participation by the Service Provider in the Company’s Sale Event Severance Plan, as additional consideration for signing this agreement, the Company and the Service Provider agree as follows:

1.    Noncompetition; Nonsolicitation.
a.    During the term of Service Provider’s provision of services to the Company and for a period of (i) one year after the termination or cessation of such services for any reason or no reason (the “Last Date of Employment”), or (ii) two (2) years following the Last Date of Employment if he or she breaches his or her fiduciary duty to the Company or if he or she has unlawfully taken, physically or electronically, property belonging to the Company (in either case, the “Restricted Period”):
(I) Unless (A) the Company elects to terminate the Service Provider’s employment without Cause (as defined below) or the Service Provider has been laid off; or (B) the Company elects to waive the restrictions upon post-employment activities set forth in this Section 1.a.(I), then, the Company shall make payments to the Service Provider for the post-employment portion of the Restricted Period (but for not more than 12 months following the Last Date of Employment) at the rate of 50% of the highest annualized base salary paid to the Service Provider by the Company within the two-year period preceding the Last Date of Employment, which the Service Provider acknowledges and agrees is consideration mutually agreed upon by the Company and the Service Provider, and in exchange, the Service Provider shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, anywhere in the geographic areas in which, at any time during the two years that immediately preceded the Last Date of Employment (“Two Year Lookback”), the Service Provider provided services or had a material presence or influence, provide any of the types of services that the Service Provider provided to the Company during the Two Year Lookback, in connection with any business that develops, manufactures or markets any products, or performs any services, that are competitive with the products or services of the Company, or products or services that the Company or its affiliates has under development or that are the subject of active planning at any time during the Service Provider’s employment (“Restricted Activity”). For purposes of this Agreement, and notwithstanding anything to the contrary in any other agreement between the Company and the Service Provider, “Cause” shall mean a reasonable and good faith basis for the Company to be dissatisfied with the Service Provider’s job
1



performance, conduct or behavior. The Service Provider acknowledges that this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. The Service Provider further acknowledges and agrees that any payments the Service Provider receives pursuant to this Section 1.a.(I) shall reduce (and shall not be in addition to) any severance or separation pay that the Service Provider is otherwise entitled to receive from the Company pursuant to an agreement, plan or otherwise. Notwithstanding the foregoing, Service Provider shall have the right to own, for investment purposes, not more than one percent of the outstanding capital stock of a publicly held enterprise which competes with bluebird bio and nothing contained in this Section 1 shall prevent Service Provider from being employed by a university or nonprofit research institution.
(II) Service Provider will not solicit, entice or induce any employee or consultant of bluebird bio to terminate his or her employment or consultancy or engage in a Restricted Activity; and
(III) Service Provider will not solicit, entice or induce any vendor, customer or distributor of bluebird bio to terminate or materially diminish its relationship with bluebird bio.
b. Service Provider acknowledges and agrees that, in the event he/she breaches any of the terms described in Section 1.a.(II) or (III) above, the Restricted Period shall be tolled and shall not run during the time that Service Provider is in breach of such obligations; provided that, the Restricted Period shall begin to run again once Service Provider has ceased breaching the terms of Section 1.a.(II) or (III) and is otherwise in compliance with his/her obligations described therein.
c. Service Provider further acknowledges and agrees that (i) the types of employment which are prohibited by Section 1.a(I) are narrow and reasonable in relation to the skills which represent Service Provider’s principal salable assets both to bluebird bio and to other prospective employers, and (ii) the geographical scope of the provisions of Section 1.a(I) is reasonable, legitimate and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited compared to the activities for which Service Provider is qualified to earn a livelihood.
d. Service Provider acknowledges and agrees that (i) the restrictions in Section 1.a are reasonable, legitimate, necessary and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited. Service Provider further acknowledges and agrees that any breach or threatened breach of this Agreement will cause irreparable injury to bluebird bio and that money damages may not provide an adequate remedy to bluebird bio. Service Provider therefore agrees that bluebird bio, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Service Provider of any of the provisions of this Agreement, without having to post bond. Service Provider further acknowledges that a court may render an award extending the Restricted Period as one of the remedies in the event of his or her violation of this Agreement. If the Service Provider violates this Agreement, in addition to all other remedies available to the Company at law (including, without
2



limitation, the Company’s right to discontinue any payments the Service Provider may receive pursuant to Section 1.a.(I)), in equity, and under contract, the Service Provider agrees that he or she is obligated to pay all of the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and expenses.
2.    Confidential Information.
a. Service Provider acknowledges and agrees to abide by bluebird bio’s Confidentiality and Trade Secret Policies.
b. Service Provider acknowledges that bluebird bio would be irreparably damaged if Service Provider’s confidential knowledge of the business of bluebird bio was disclosed to or utilized on behalf of others. Service Provider acknowledges that he or she has learned and will learn bluebird bio Proprietary Information, as defined in Section 2.b. hereof, relating to the business to be conducted by bluebird bio and its subsidiaries and joint ventures and partnerships to which bluebird bio may be a party (together, the “bluebird bio Entities”). Service Provider agrees that he or she will not, except in the normal and proper course of his or her employment or consultancy or as otherwise provided herein, disclose or use or enable anyone else to disclose or use, either during the term of this Agreement or subsequent thereto, any such bluebird bio Proprietary Information without prior written approval of bluebird bio. Service Provider further agrees to comply with all bluebird bio policies that govern the treatment of bluebird bio Proprietary Information and the reporting of any suspected violation of law, including but not limited to the Code of Business Conduct and Ethics, as such policies may be amended or revised from time to time. Service Provider acknowledges receipt of the following notice under 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” In addition, nothing in this Agreement prohibits Service Provider from reporting an event that Service Provider reasonably and in good faith believes is a violation of law to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Opportunity Commission, or Department of Labor), requires notice to or approval from the Company before doing so, or prohibits Service Provider from cooperating in an investigation conducted by such a government agency.
c. For the purpose of this Agreement, “bluebird bio Proprietary Information” shall mean all information, ideas, concepts, improvements, discoveries, and Inventions (defined in 3 a. below) that are both (i) disclosed or made known by bluebird bio to Service Provider, and (ii) identified as “proprietary” by bluebird bio to Service Provider (either orally or in writing) at the time of such disclosure or that should reasonably be known to be proprietary, including, but not limited to, the following types of information: corporate information, including contractual licensing arrangements, plans, strategies, tactics, policies, resolutions, and any litigation or negotiations; intellectual property, including patent applications, trademarks, trade secrets, and secret formulae; marketing information, including sales or product plans, strategies, tactics, methods, customers, prospects, or market research data; financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings; operational information that relates to the technology that bluebird bio has or desires to develop or market,
3



including control and inspection practices, manufacturing processes and methods, suppliers and parts; technical information, including machinery or device designs, drawings, specifications, processes, procedures, scientific or statistical data, research and development information, scientific protocols, clinical data and preclinical data. bluebird bio Proprietary Information does not include information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act such as joining or forming a union, engaging in collective bargaining, or engaging in other concerted activity for mutual aid or protection of laborers. For purpose of clarity, it shall still be a violation of this Agreement for a non-management employee to share Confidential Information with a competitor about other employees’ compensation and benefits which was obtained through the course of employment with the Company for purposes of assisting such competitor in soliciting Company employees.
d. Service Provider agrees that all documents of any nature provided by bluebird bio to Service Provider and pertaining to activities of any bluebird bio entity or to any bluebird bio Proprietary Information, in his or her possession now or at any time during the term of this Agreement, including without limitation memoranda, notebooks, notes, data sheets, records and blueprints, are and shall be the property of bluebird bio, and that they and all copies of them shall be surrendered to bluebird bio upon the earlier of request by bluebird bio or termination of this Agreement.
e. Service Provider shall have none of the obligations set forth above with respect to bluebird bio Proprietary Information (i) that is publicly known or becomes publicly known through no breach of this Agreement by Service Provider, (ii) that is generally or readily obtainable by the public, or within the scientific field, (iii) that is known by Service Provider prior to its disclosure to Service Provider by bluebird bio, as shown by Service Provider’s written records, (iv) that Service Provider received from a source that had the legal right to disclose the information to Service Provider, (v) that is required to be disclosed by law, government regulation or court order, or (vi) involves information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act. Further, nothing herein limits, restricts, or in any other way affects Service Provider communicating with the SEC, the DOL, or any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, or cooperating with or participating in a legal proceeding concerning matters relevant to the governmental agency or entity.
3.    Intellectual Property.
a. Service Provider hereby assigns and agrees to assign to bluebird bio his or her entire right, title and interest in and to all Inventions. “Inventions” means improvements, modifications, know-how, processes, secrets and discoveries made, possessed, discovered or conceived by him or her during the period in which the Service Provider has provided services to the Company (whether or not patentable, whether or not reduced to practice, whether or not made, possessed, discovered or conceived by him or her individually or jointly with any other person or persons, whether made or conceived on or off bluebird bio’s premises, and whether made in or out of working hours), which shall specifically or generally relate to, be applicable to or concern (a) development of therapeutics utilizing ex vivo or in vivo nucleic acid (e.g., gene) transfer utilizing viral vector or virus-based approaches (e.g., lentivirus), (b) methods of manufacturing viral vectors or genetically
4



modified cells for the development of therapeutics, (c) approaches to facilitate proper homing or engraftment of genetically modified cells (d) gene editing, (e) cancer therapy, (f) rare genetic disease therapy, and (g) any other project, field, or line of business in which bluebird bio is engaged (collectively, the “Field”), such Inventions and benefits hereof to immediately become the sole and absolute property of bluebird bio. In the event that any portion of this assignment is prohibited by the terms of a funding agreement under which the work resulting in any Invention was performed or the regulations of the institution where such work was performed (in the event such work was not performed by bluebird bio), Service Provider shall use his or her best efforts to obtain for bluebird bio a license or other consent to use such information on the most advantageous terms that are available to bluebird bio. Service Provider agrees that, upon the request of bluebird bio and at the expense of bluebird bio, Service Provider will execute such further assignments, documents, and other instruments as may be necessary or desirable fully and completely to assign all such Inventions to bluebird bio and to assist bluebird bio in applying for, obtaining, and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. Service Provider shall keep and maintain adequate and current written records of all Inventions, in the form of notes, sketches, drawings or as may be specified by bluebird bio, which records shall be available to and remain the sole property of bluebird bio at all times. Service Provider acknowledges that bluebird bio from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on bluebird bio regarding Inventions made during the course of work under such agreements or regarding the confidential nature of such work. Service Provider agrees to be bound by all such obligations and restrictions which are made known to Service Provider and to take all action necessary to discharge the obligations of bluebird bio under such agreements.
b. This Agreement’s assignment provisions are limited to only those Inventions that can be lawfully assigned by an employee to an employer under applicable law in the state where Service Provider last regularly resided while employed by the Company. Service Provider hereby acknowledges that Service Provider has been notified of the following laws governing the assignment of inventions: Del. Code Title 19 § 805; Ill. 765 ILCS1060/1-3, “Employees Patent Act”; N. C. Gen. Stat. Article 10A, Chp 66, Comm. & Bus., § 66-57.1; Minn. Stat. 13A § 181.78; Kan. Stat. § 44-130; Utah Code §34-39-1 -- 34-39-3, “Employee Inventions Act”; Wash. Rev. Code, Title 49 RCW: Lab. Reg. Chpt. 49.44.140; for example, if Service Provider resides in California, the assignment is limited to comply with Cal. Lab. Code § 2870 which provides: (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or (2) Result from any work performed by the employee for the employer. Service Provider will not, without the Company’s prior written consent, incorporate into any Company product or otherwise deliver to the Company any software code that is subject to any license that by its terms requires, or conditions the use or distribution of such code on, the disclosure, licensing or distribution of such Company
5



product or any source code owned or licensed by the Company (e.g., software code licensed under the GNU GPL, LGPL or AGPL.
4.    Publication.
Anything to the contrary herein notwithstanding, Service Provider may not publish any bluebird bio Proprietary Information or information regarding Inventions, (as defined above) of a scientific (as opposed to business or corporate) nature generated in the Field by Service Provider. Any clinical or research publication request must comport with bluebird bio’s Scientific and Clinical Publication Review and Approval Process. In addition, Service Provider will cooperate with patent counsel for bluebird bio in effecting the intent of this Section by providing a copy of the text and/or data and any other information needed to file any patent applications or other appropriate materials to protect such information prior to any publication request.
5.    Trade Secrets of Others/Obligations to Others.
Service Provider represents that his or her other performance of all the terms of this Agreement does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by him or her in confidence or in trust prior to his or her engagement by bluebird bio, and Service Provider agrees that he or she will not disclose to bluebird bio, or induce bluebird bio to use, any confidential or proprietary information or material belonging to any other person. Service Provider agrees that he or she will not enter into any agreement, either written or oral, in conflict with his or her obligations under this Agreement.
6.    Survival
The terms of this Agreement and Service Provider’s obligations hereunder shall survive any termination of the Services Provider’s employment, contractual or other business relationship with bluebird bio, irrespective of the reason or reasons for such termination. Nothing in this Agreement shall eliminate, reduce, or otherwise remove any legal duties or obligations that Service Provider would otherwise have to the Company through common law or statute.
7.    Agreement Enforceable Upon Material Job Change.
Service Provider acknowledges and agrees that if he or she should transfer between or among any affiliates of bluebird bio, wherever situated, or be promoted, demoted, reassigned to functions other than Service Provider’s present functions, or have his/her job duties changed, altered or modified in any way, all terms of this Agreement shall continue to apply with full force.
8.    Notice of Resignation.
If the Service Provider elects to resign from his or her employment with the Company, the Service Provider agrees to provide the Company with written notification of his or her resignation at least two (2) weeks prior to the intended resignation date. Such notice shall include information in reasonable detail about his or her post-employment job duties and other business activities, including the name and address of any subsequent employer and/or person or entity with whom or which he or she intends to engage in business activities during the Restricted Period and the nature of his or her job duties and other business activities. The Company may elect to waive all or part of the two (2) week notice period in its sole discretion.
6



9.    Disclosure to Future Employers.
Service Provider agrees to provide, and the Company, in its discretion, may provide, a copy of this Agreement to any business or enterprise which Service Provider may directly or indirectly own, manage, operate, finance, join, control or in which Service Provider may participate in the ownership, management, operation, financing, or control, or with which Service Provider may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.
10.    Modification.
This Agreement may not be changed, waived, modified, released, discharged, abandoned, or otherwise amended, in whole or in part, except by an instrument in writing signed by Service Provider and bluebird bio or as provided in Section 17 or Section 1(a)(I)(B), which waiver under Section 1(a)(I)(B) must be in writing. The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
11.    Entire Agreement.
This Agreement constitutes the entire agreement and understanding between the parties hereto and supersedes any previous oral or written communications, representations, understandings, or agreements relating to the subject matter hereof; notwithstanding the foregoing, any Invention that was created prior to execution of this agreement shall also remain subject to the provisions of any intellectual property assignment provisions in existence between bluebird bio and Service Provider.
12.    Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns (including, in the case of Service Provider, his or her heirs, executors, administrators and other legal representatives). Neither party hereto may assign any of its rights or obligations hereunder to any other person, except that bluebird bio may assign all of its rights and obligations under this Agreement to any person or entity controlled by, in control of, or under common control with, bluebird bio, or to any successor or assign of bluebird bio that employs Service Provider subsequent to his or her employment with bluebird bio.
13.    Counterparts.
This Agreement may be signed in two counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement.
14.    Notices.
All notices, requests, consents and other communications required or permitted hereunder shall be in writing and shall be hand delivered or mailed by first-class mail postage prepaid, addressed as follows: If to bluebird bio, at bluebird bio, Inc., 60 Binney Street, Cambridge, MA 02142, Attention: Chief Legal Officer, or to such other address as may have been furnished to Service Provider by bluebird bio in writing as herein provided; or if to Service Provider, at the address set forth below his or her signature hereon, or to such other address as may have been furnished to bluebird bio by Service Provider as herein provided in writing. Any notice or other communication so addressed and so
7



mailed shall be deemed to have been given when mailed, and if hand delivered shall be deemed to have been given when delivered.
15.    Applicable Law.
This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, shall take effect as an instrument under seal within Massachusetts, and the validity, interpretation and performance of this Agreement shall be governed by, and construed in accordance with, the internal law of Massachusetts, without giving effect to conflict of law principles, and specifically excluding any conflict or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties acknowledge that the last act necessary to render this Agreement enforceable is its execution by the Company in Massachusetts, and that the Agreement shall be maintained in Massachusetts.
16.    Jurisdiction, Venue, Service of Process and Jury Trial Waiver.
Any legal action or proceeding with respect to this Agreement must be brought in the courts of the Commonwealth of Massachusetts or in the United States District Court for the District of Massachusetts and shall be subject to the jurisdiction of such courts only. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts and waive any objection to personal jurisdiction or venue in those courts; provided, however, the Company and the Service Provider agree that all civil actions relating to Section 1.a.(I) of this Agreement shall be brought in the county of Suffolk and that the superior court or the business litigation section of the superior court shall have exclusive jurisdiction. Any action, demand, claim or counterclaim arising under or relating to this Agreement will be resolved by a judge alone and each of the Company and the Service Provider waive any right to a jury trial thereof.
17.    Severability.
The parties intend this Agreement to be enforced as written. However, (a) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly-authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law, and (b) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the court making such determination will have the power to modify or reduce the scope, duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-pencilling”), and in its modified, reduced or blue-pencilled form such provision will then be enforceable and will be enforced.
18.    Use of Name or Affiliation.
bluebird bio shall not use Service Provider’s name or affiliation, in publicity, advertising, or securities offering materials without the prior written approval of Service Provider, provided that such approval shall not be unreasonably withheld in cases in which bluebird bio is required by applicable law to disclose Service Provider’s relationship with bluebird bio.
8



19.    Employment At-Will.
This Agreement does not constitute a contract of employment for a definite period or imply that Service Provider’s employment or engagement with the Company shall continue for any definite period of time. Employment with the Company is at-will meaning that the Service Provider or the Company may end the employment relationship at any time with or without notice or cause.

THE SERVICE PROVIDER ACKNOWLEDGES THAT HE OR SHE HAS CAREFULLY READ THIS ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION AND NONSOLICITATION AGREEMENT AND Appendix A and UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. FURTHERMORE, BY SIGNING BELOW, THE SERVICE PROVIDER CERTIFIES THAT (I) HE OR SHE WAS PROVIDED WITH THIS AGREEMENT BY THE EARLIER OF A FORMAL OFFER OF EMPLOYMENT OR TEN (10) BUSINESS DAYS BEFORE THE COMMENCEMENT OF HIS OR HER EMPLOYMENT, AND (II) HE OR SHE HAS BEEN ADVISED BY THE COMPANY THAT HE OR SHE HAS THE RIGHT TO CONSULT WITH COUNSEL PRIOR TO SIGNING THIS AGREEMENT.

bluebird bio, Inc.
By:/s/ Meredith Willoughby
Print Name:Meredith Willoughby
Title:Senior Director, Total Rewards, HRIS, Operations
Date:20-April-2021
SERVICE PROVIDER
By:/s/ Thomas Klima
Print Name:Thomas Klima
Date:20-April-2021

Attachment: Appendix A


9



APPENDIX A

Alabama:

If Service Provider resides in Alabama, and is subject to Alabama law, then the following applies to Service Provider for as long as Service Provider is subject to Alabama law: (i) Paragraph 1(a) shall be further limited to the solicitation or hiring of employees or consultants of the Company who are engaged in a Sensitive Position for the Company. A person is in a “Sensitive Position” if he or she is uniquely essential to the management, organization, or service of the Company’s business; and (ii) Paragraph 1(a)(ii) shall be limited to solicitation of current customers, vendors, or distributors of the Company (i.e., past or inactive customers, vendors, or distributors are not covered by the provision).

Arizona:

If Service Provider resides in Arizona and is subject to Arizona law, then the following applies to Service Provider for as long as Service Provider is subject to Arizona law: the restrictions in Paragraph 1(a)(ii) shall be limited to the geographic region that Service Provider worked in, serviced, managed and/or supervised on behalf of the Company within the one (1) year period immediately preceding the termination of his employment.

California:

If Service Provider resides in California and is subject to California law, then the following applies to Service Provider for so long as Service Provider is subject to California law: (a) Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law); and (b) Paragraphs 14 and 15 shall not apply.

Louisiana:

If Service Provider resides in Louisiana and is subject to Louisiana law, then the following applies to Service Provider for as long as Service Provider is subject to Louisiana law: the restrictions in Paragraph 1(a)(ii) shall be limited to the following parishes in Louisiana and counties outside Louisiana:_____________________________ [each individual Parish and/or County must be named].

Montana:

If Service Provider resides in Montana and is subject to Montana law, then the following applies to Service Provider for as long as Service Provider is subject to Montana law: the last sentence of Paragraph 18 shall not apply.

Nebraska:

If Service Provider resides in Nebraska and is subject to Nebraska law, then the following applies to Service Provider for so long as Service Provider is subject to Nebraska law: Paragraph 1(a)(ii) is further limited to the solicitation of customers, vendors, or distributors, with which
10



Service Provider did business on behalf of the Company and had personal business-related contact during the one (1) year period immediately preceding Service Provider’s termination.
 
Nevada:

If Service Provider resides in Nevada and is subject to Nevada law, then the following applies to Service Provider for so long as Service Provider is subject to Nevada law: Paragraph 1(a)(ii) does not preclude Service Provider from providing services to any former customer of the Company if: (a) Service Provider did not solicit the former customer; (b) the customer voluntarily chose to leave and seek services from Service Provider; and (c) Service Provider is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained.

New York:

If Service Provider resides in New York and is subject to New York law, then the following applies to Service Provider for so long as Service Provider is subject to New York law: Paragraph 1(a)(ii) shall be modified so that it excludes those customers who became a customer of Company as a result of Service Provider’s independent contact and business development efforts with the customer prior to and independent from his/her employment with Company.

North Carolina:

If Service Provider resides in North Carolina and is subject to the laws of North Carolina, then the following applies to Service Provider for so long as Service Provider is subject to North Carolina law: the one (1) year look back period referenced in Paragraph 1(a) shall be calculated looking back one (1) year from the date of enforcement and not from the date employment ends.

North Dakota:

If Service Provider resides in North Dakota and is subject to North Dakota law, then the following applies to Service Provider for so long as Service Provider is subject to North Dakota law: Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).

Wisconsin:

If Service Provider resides in Wisconsin and is subject to Wisconsin law, then the following applies to Service Provider for so long as Service Provider is subject to Wisconsin law: (a) Paragraph 9(g) shall not apply; and (b) Paragraph 5(b) shall be further limited to the solicitation or hiring of employees, independent contractors, sales agents, or sales associates of the Company who are engaged in a Sensitive Position for the Company. “Sensitive Position” refers to an employee of the Company who is in a management, supervisory, sales, research and development, or similar role where the employee is provided Confidential Information or is involved in business dealings with the Company’s customers.

11
 EX-10.26 5 blue-20211231xex1026.htm EX-10.26 Document



Exhibit 10.26

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and Anne-Virginie Eggimann (the “Executive”) and is made effective as of June 14, 2021 (the “Effective Date”).

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1.Employment.

(a)    Term. The term of this Agreement shall commence on the Effective Date and shall continue until terminated in accordance with the provisions of Section 3 (the “Term”).

(b)    Position and Duties. During the Term, the Executive shall serve as the Company’s Chief Regulatory Officer, and shall have such powers and duties as may from time to time be prescribed by the President, Severe Genetic Diseases or other authorized executive, provided that such duties are consistent with the Executive’s position or other positions that they may hold from time to time. The Executive shall report to the President, Severe Genetic Diseases. The Executive shall devote their full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on the board of directors of another company, with the prior written approval of the Company’s Board of Directors (the “Board”), and may engage in religious, charitable or other community activities as long as such services and activities do not pose a conflict of interest or interfere with the Executive’s performance of their duties to the Company as provided in this Agreement.

2.Compensation and Related Matters.

(a)    Base Salary. The Executive’s base salary rate shall be $405,000 per year. The Executive’s base salary shall be re-determined annually by the Board or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The annual base salary rate in effect at any given time is referred to herein as “Base Salary.” The Executive’s Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.

(b)    Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be forty five percent (45%) of their Base Salary, although any the actual incentive compensation amount shall be discretionary. To earn




incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.

(c)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by then during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.

(d)    Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms and conditions of such plans.

(e)    Vacations. During the Term, the Executive shall be entitled to accrue paid vacation in accordance with the Company’s applicable policy.

3.Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a)    Death. The Executive’s employment hereunder shall terminate upon their death.

(b)    Disability. The Company may terminate the Executive’s employment if they are disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(c)    Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect to the Company, any affiliate of the Company or any of the Company’s current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Executive’s commission of a felony or any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform their assigned duties to the reasonable satisfaction of the Company, which failure, if curable, continues, in the reasonable judgment of the Company, after written notice given to the Executive by
2



the Company; (iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the Executive’s violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nondisclosure and/or assignment of inventions.

(d)    Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e)    Termination by the Executive. The Executive may terminate their employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events without the Executive’s express written consent: (i) a material diminution in the Executive’s responsibilities, authority and function; (ii) a material reduction in the Executive’s Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated employees and, provided further, that any reduction in the Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change of more than 30 miles in the geographic location at which the Executive must provide services to the Company (except for required travel on Company business to an extent substantially consistent with the Executive’s usual business travel obligations); or (iv) the material breach by the Company of the Company’s agreements or equity incentive plan covering the Option or RSUs granted to the Executive in connection with their hire or any other material agreement between the Executive and the Company, if any, concerning the terms and conditions of the Executive’s employment, benefits or compensation. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates their employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

(f)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(g)    Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by their death, the date of their death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s
3



employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, (A) in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement, and (B) in the event that the Company terminates the Executive’s employment without Cause under Section 3(d), the Company may unilaterally accelerate the Date of Termination to any earlier effective date provided that the Company continues to pay the Executive the Base Salary for the 30-day period immediately following the date on which a Notice of Termination is given to the Executive.

4.Compensation Upon Termination.

(a)    Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to their authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements, and unused vacation that accrued through the Date of Termination, such payments to be made on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

(b)    Termination by the Company Without Cause or by the Executive with Good Reason. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates their employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive their Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:

(i)    the Company shall pay the Executive an amount equal to one times the Executive’s Base Salary (the “Severance Amount”); and

(ii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

4



(iii)    the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

(iv)    The receipt of any severance payments or benefits pursuant to Section 4 will be subject to Executive not violating the Restrictive Covenant Agreement referenced in Section 7 of this Agreement, the terms of which are hereby incorporated by reference. In the event Executive breaches the Restrictive Covenant Agreement, in addition to all other legal and equitable remedies, the Company shall have the right to terminate or suspend all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 4 without affecting the Executive’s release or Executive’s obligations under the Separation Agreement and Release.

5.    Change in Control Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to their assigned duties and their objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control.

(a)    Change in Control. During the Term, if within 12 months after a Change in Control, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates their employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination,

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher), plus (B) the Executive’s Target Incentive Compensation. For purposes of this Agreement, “Target Incentive Compensation” shall mean the Executive’s target annual incentive compensation as set forth in Section 2(b); and

(ii)    notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards
5



granted to the Executive after the date of this Agreement shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination. The treatment of stock options and other stock-based awards held by the Executive as of the date of this Agreement shall be governed by the terms of the applicable option agreement or other stock-based award agreement; and

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

(iv)    The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b)    Additional Limitation.

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Severance Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions shall apply:

(A)    If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes payable by the Executive on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to the full benefits payable under this Agreement.

(B)    If the Threshold Amount is less than (x) the Severance Payments, but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment is to be
6



made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order.

(ii)    For the purposes of this Section 5(b), “Threshold Amount” shall mean three times the Executive’s “base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and any interest or penalties incurred by the Executive with respect to such excise tax.

(iii)    The determination as to which of the alternative provisions of Section 5(b)(i) shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining which of the alternative provisions of Section 5(b)(i) shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive’s residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(b)    Definitions. For purposes of this Section 5, the following terms shall have the following meanings:

“Change in Control” shall mean “Sale Event,” as such term is defined in the Company’s 2013 Stock Option and Incentive Plan.

6.    Section 409A.

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

7



(b)    All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A‑1(h).

(d)    The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A‑2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

7.    Confidential Information, Noncompetition and Cooperation. The Executive agrees to and reaffirms the terms of the Assignment of Invention, Nondisclosure and Noncompetition Agreement (“Restrictive Covenant Agreement”), as previously executed on June 21, 2018, the terms of which are hereby incorporated by reference as material terms of this Agreement. Nothing in this Agreement or the Restrictive Covenant Agreement, and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly
8



liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

8.    Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

9.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter.

10.    Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.

11.    Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after their termination of employment but prior to the completion by the Company of all payments due them under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to their death (or to their estate, if the Executive fails to make such designation).

12    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of the Restrictive Covenant Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

13.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

14.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

9



15.    Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.

16.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company..

17.    Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

18.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

19.    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.

20.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
10




IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.

BLUEBIRD BIO, INC.
By:/s/ Kathy Wilkinson
Kathy Wilkinson
Its:Chief People Officer
/s/ Anne Virginie-Eggimann
Anne-Virginie Eggimann


 EX-10.27 6 blue-20211231xex1027.htm EX-10.27 Document



Exhibit 10.27

October 1, 2019

Dear Jessica:

Woo hoo! We are SO excited to extend this offer to join the nest! Read on for all the legal requirements of a traditional offer, but know we are so pumped that you’re potentially going to be a bluebird- this is NOT your typical company! We are all about our WHY and we hope that you will help us continue to build a meaningful company that helps the lives of many patients in need! Here comes the official stuff…

Officially, we extend this offer of employment with bluebird bio, Inc. (the “Company”), in the position of Vice President, Internal Audit reporting to Chip Baird, Chief Financial Officer. If you accept this offer, pursuant to the terms outlined herein, your employment with the Company will begin on November 4, 2019 (the “Commencement Date”).

This offer and your employment relationship with the Company will be subject to the terms and conditions of this letter. Please note, however, that no provision of this letter shall be construed to create an express or implied employment contract or a promise of employment for any specific period of time. Rather, your employment with the Company is at-will, meaning that such employment may be terminated by you or the Company, at any time, for any reason, and with or without advance notice. The Company expects that you will devote substantially all of your working time to the performance of your job duties, and that you will do so in a satisfactory manner and to the best of your abilities at all times.

Should you accept the Company’s offer of employment, your initial salary will be $260,000.00 (the “Base Salary”). As an exempt employee, you are paid for the job and not by the hour. Accordingly, you will not receive overtime pay. Rather, your salary is intended to compensate you for all hours worked. Your Base Salary shall be payable in substantially equal bi-weekly installments in accordance with Company’s normal payroll practices as in effect from time-to-time. The Base Salary listed above is before taxation or other withholdings required or permitted by law. The Company reserves the right to withhold all applicable federal, state and local income, Social Security and other employment taxes, along with any other amounts of required withholding, from all amounts of compensation and other remuneration payable to you, whether as direct compensation or pursuant to any of the compensation or benefit plans in which you may participate.

You understand and agree that the Base Salary listed above is set forth as a matter of convenience and does not constitute nor will be deemed to constitute an agreement by the Company to employ you for any specific period of time. You also understand that your Base Salary may be adjusted occasionally throughout your employment, including through increases, in the Company’s sole discretion.

You also will be eligible to participate in the bluebird bio cash bonus plan (the “Bonus Plan”). Pursuant to the Bonus Plan, your initial bonus target will be set at 30% of your Base Salary. The determination of whether a bonus will be granted, and the actual amount of any such bonus to be paid, will be determined by the Company in its sole discretion, taking into account, without limitation, the Company’s performance and your individual performance. This means that your bonus may go up or down from year-to-year and/or that receipt of a bonus in one year does not guarantee a bonus the following year. In other words, the Bonus Plan is truly discretionary. Your bonus, if any, will be payable no later than March 15 of the year following the applicable bonus year. Please note that to be eligible to participate in the Bonus Plan, you must be employed in good standing on the date the Company pays any bonuses pursuant to the Bonus Plan.





Subject to approval by the Compensation Committee of the Company’s Board of Directors (or other appropriate Committee or designee as appointed by the Compensation Committee), the Company will grant you (i) an option to purchase 7900 shares of common stock in the Company at the then-current fair market value (which presently is calculated using the closing price of the Company’s common stock on the first trading day of the month following the Commencement Date) and (ii) restricted stock units for 1975 shares of common stock in the Company. You may be considered annually for additional equity grants, subject to the company’s sole discretion. Any and all grants shall be pursuant and subject to the terms of the Company’s 2013 Stock Option and Incentive Plan and appropriate stock option and restricted stock unit agreements, in the Company’s standard form, as amended from time to time, which you will need to sign and which, together with the Stock Plan, constitute the “Equity Documents.”

You will also be eligible to participate fully in employee benefit plans that the Company provides or may establish for the benefit of its employees generally. Your eligibility to participate in these plans and receive benefits thereunder will be subject to the plan documents governing such benefits. Notwithstanding the foregoing, you understand and agree that nothing contained herein will require the Company to establish or maintain any fringe benefits and any such benefits may be modified, amended, terminated or cancelled at any time by the Company in its sole and absolute discretion.

As a condition of your employment, you certify to the Company that you are free to enter into and fully perform the duties of your position and that you are not subject to any employment, confidentiality, noncompetition or other agreement that would restrict your performance for the Company. You further certify that your signing this letter of employment does not violate any order, judgment or injunction applicable to you, or conflict with or breach any agreement to which you are a party or by which you are bound. If you are subject to any such agreement or order, please forward it to Jason Cole, our Chief Legal Officer JCole@bluebirdbio.com, along with a copy of this letter.

Additionally, as a condition of your employment, you also certify that all facts you have presented to the Company in furtherance of your potential employment are accurate and true. This includes, but is not limited to, all oral and written statements you have made (including those pertaining to your education, training, qualifications, licensing and prior work experience), resume or curriculum vitae, or in any interview or discussion with the Company regarding your potential employment.

The Company considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. Accordingly, you will be required to sign, return and comply with an agreement relating to confidentiality, nonsolicitation and work product on or before your first day of work, as a condition of this offer of employment (the “Assignment of Invention, Nondisclosure, Noncompetition and Nonsolicitation Agreement”). A copy of the Assignment of Invention, Nondisclosure, Noncompetition and Nonsolicitation Agreement is enclosed for your consideration and signature.

In addition, you will comply at all times with all Company policies, rules and procedures as they may be established, stated and/or modified from time-to-time at the Company’s sole discretion. In this regard, among other things, you will be expected to comply at all times to the Company’s standards of professionalism, loyalty, integrity, honesty, reliability, and respect for others. You will also comply at all times with all laws and regulations applicable to the Company’s business and performance of your duties for the Company. As and when requested, you will sign periodic forms to certify your continuing understanding of and full compliance with the Company’s policies. You also agree that, during the term of your employment with the Company and at all times thereafter, upon reasonable request, you will fully cooperate with the Company and/or its representatives, without additional compensation (to the extent permitted by law), concerning any business matters or disputes of any kind about which you have, or may have, any relevant information.
2




Your employment with the Company is conditioned on your eligibility to work in the United States. Should you commence employment with the Company, on your first day, you must complete an I-9 Form and provide us with any of the accepted forms of identification specified on the I-9 Form.

This letter, along with the Equity Documents and the Assignment of Invention, Nondisclosure
Noncompetition and Nonsolicitation Agreement, constitute the Company’s entire offer regarding the terms and conditions of your prospective employment with the Company, and supersede any prior agreements, or other promises or statements (whether oral or written) regarding the offered terms of employment. Nothing in this letter should be read to alter the at-will nature of your anticipated employment with the Company.

The terms of your employment shall be governed by the law of Massachusetts. By accepting this offer of employment, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be resolved in a court of competent jurisdiction in Massachusetts by a judge alone, and you waive and forever renounce your right to a trial before a civil jury.

You may accept this offer of employment and the terms and conditions hereof by electronically signing this letter. Your electronic submission of your signature will evidence your agreement with the terms and conditions set forth herein. This offer will expire on October 2, 2019 unless accepted by you prior to such date by directing the signed offer letter to my attention with the Assignment of Invention, Nondisclosure and Nonsolicitation Agreement

Jessica, we are pleased to offer you the opportunity to join the Company, and we look forward to having you aboard. We are confident that you will continue to make important contributions to our unique and exciting opportunity to make a difference in bringing important new therapies to patients who need them.

Sincerely

/s/ Kathy Wilkinson
Kathy Wilkinson
Chief People Officer


3




By signing below, I acknowledge that I have been furnished with a copy of this offer and that I understand and agree to the terms set forth above. I understand that I will be an at-will employee and that nothing in this document is intended to create a contract of employment or alter the at-will nature of my employment.

Acknowledged And Agreed:
/s/ Jessica Whitten
Jessica Whitten
1/10/2019
Date
Enclosures: Offer Letter (2)
Assignment of Invention, Nondisclosure Noncompetition and Nonsolicitation Agreement (2)

4



ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION

AND NONSOLICITATION AGREEMENT

This Agreement is made between bluebird bio, Inc., a Delaware corporation (including its subsidiaries and other affiliates and its and their successors and assigns, hereinafter referred to as “bluebird bio” or the “Company’’), and Jessica Whitten, an employee or consultant of the Company (the “Service Provider”).

In consideration of the employment of the Service Provider by the Company, the Company’s promise to provide the Service Provider with items of bluebird bio Proprietary Information, specialized training and/or goodwill, and, as applicable, participation by the Service Provider in the Company’s Sale Event Severance Plan, as additional consideration for signing this agreement, the Company and the Service Provider agree as follows:

1.    Noncompetition; Nonsolicitation.
a.    During the term of Service Provider’s provision of services to the Company and for a period of (i) one year after the termination or cessation of such services for any reason or no reason (the “Last Date of Employment”), or (ii) two (2) years following the Last Date of Employment if he or she breaches his or her fiduciary duty to the Company or if he or she has unlawfully taken, physically or electronically, property belonging to the Company (in either case, the “Restricted Period”):
(I) Unless (A) the Company elects to terminate the Service Provider’s employment without Cause (as defined below) or the Service Provider has been laid off; or (B) the Company elects to waive the restrictions upon post-employment activities set forth in this Section 1.a.(I), then, the Company shall make payments to the Service Provider for the post-employment portion of the Restricted Period (but for not more than 12 months following the Last Date of Employment) at the rate of 50% of the highest annualized base salary paid to the Service Provider by the Company within the two-year period preceding the Last Date of Employment, which the Service Provider acknowledges and agrees is consideration mutually agreed upon by the Company and the Service Provider, and in exchange, the Service Provider shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, anywhere in the geographic areas in which, at any time during the two years that immediately preceded the Last Date of Employment (“Two Year Lookback”), the Service Provider provided services or had a material presence or influence, provide any of the types of services that the Service Provider provided to the Company during the Two Year Lookback, in connection with any business that develops, manufactures or markets any products, or performs any services, that are competitive with the products or services of the Company, or products or services that the Company or its affiliates has under development or that are the subject of active planning at any time during the Service Provider’s employment (“Restricted Activity”). For purposes of this Agreement, and notwithstanding anything to the contrary in any other agreement between the Company and the Service Provider, “Cause” shall mean a reasonable and good faith basis for the Company to be dissatisfied with the Service Provider’s job performance, conduct or behavior. The Service Provider acknowledges that this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. The Service Provider further
1



acknowledges and agrees that any payments the Service Provider receives pursuant to this Section 1.a.(I) shall reduce (and shall not be in addition to) any severance or separation pay that the Service Provider is otherwise entitled to receive from the Company pursuant to an agreement, plan or otherwise. Notwithstanding the foregoing, Service Provider shall have the right to own, for investment purposes, not more than one percent of the outstanding capital stock of a publicly held enterprise which competes with bluebird bio and nothing contained in this Section 1 shall prevent Service Provider from being employed by a university or nonprofit research institution.
(II) Service Provider will not solicit, entice or induce any employee or consultant of bluebird bio to terminate his or her employment or consultancy or engage in a Restricted Activity; and
(III) Service Provider will not solicit, entice or induce any vendor, customer or distributor of bluebird bio to terminate or materially diminish its relationship with bluebird bio.
b. Service Provider acknowledges and agrees that, in the event he/she breaches any of the terms described in Section 1.a.(II) or (III) above, the Restricted Period shall be tolled and shall not run during the time that Service Provider is in breach of such obligations; provided that, the Restricted Period shall begin to run again once Service Provider has ceased breaching the terms of Section 1.a.(II) or (III) and is otherwise in compliance with his/her obligations described therein.
c. Service Provider further acknowledges and agrees that (i) the types of employment which are prohibited by Section 1.a(I) are narrow and reasonable in relation to the skills which represent Service Provider’s principal salable assets both to bluebird bio and to other prospective employers, and (ii) the geographical scope of the provisions of Section 1.a(I) is reasonable, legitimate and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited compared to the activities for which Service Provider is qualified to earn a livelihood.
d. Service Provider acknowledges and agrees that (i) the restrictions in Section 1.a are reasonable, legitimate, necessary and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited. Service Provider further acknowledges and agrees that any breach or threatened breach of this Agreement will cause irreparable injury to bluebird bio and that money damages may not provide an adequate remedy to bluebird bio. Service Provider therefore agrees that bluebird bio, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Service Provider of any of the provisions of this Agreement, without having to post bond. Service Provider further acknowledges that a court may render an award extending the Restricted Period as one of the remedies in the event of his or her violation of this Agreement. If the Service Provider violates this Agreement, in addition to all other remedies available to the Company at law (including, without limitation, the Company’s right to discontinue any payments the Service Provider may receive pursuant to Section 1.a.(I)), in equity, and under contract, the Service Provider
2



agrees that he or she is obligated to pay all of the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and expenses.
2.    Confidential Information.
a. Service Provider acknowledges and agrees to abide by bluebird bio’s Confidentiality and Trade Secret Policies.
b. Service Provider acknowledges that bluebird bio would be irreparably damaged if Service Provider’s confidential knowledge of the business of bluebird bio was disclosed to or utilized on behalf of others. Service Provider acknowledges that he or she has learned and will learn bluebird bio Proprietary Information, as defined in Section 2.b. hereof, relating to the business to be conducted by bluebird bio and its subsidiaries and joint ventures and partnerships to which bluebird bio may be a party (together, the “bluebird bio Entities”). Service Provider agrees that he or she will not, except in the normal and proper course of his or her employment or consultancy or as otherwise provided herein, disclose or use or enable anyone else to disclose or use, either during the term of this Agreement or subsequent thereto, any such bluebird bio Proprietary Information without prior written approval of bluebird bio. Service Provider further agrees to comply with all bluebird bio policies that govern the treatment of bluebird bio Proprietary Information and the reporting of any suspected violation of law, including but not limited to the Code of Business Conduct and Ethics, as such policies may be amended or revised from time to time. Service Provider acknowledges receipt of the following notice under 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” In addition, nothing in this Agreement prohibits Service Provider from reporting an event that Service Provider reasonably and in good faith believes is a violation of law to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Opportunity Commission, or Department of Labor), requires notice to or approval from the Company before doing so, or prohibits Service Provider from cooperating in an investigation conducted by such a government agency.
c. For the purpose of this Agreement, “bluebird bio Proprietary Information” shall mean all information, ideas, concepts, improvements, discoveries, and Inventions (defined in 3 a. below) that are both (i) disclosed or made known by bluebird bio to Service Provider, and (ii) identified as “proprietary” by bluebird bio to Service Provider (either orally or in writing) at the time of such disclosure or that should reasonably be known to be proprietary, including, but not limited to, the following types of information: corporate information, including contractual licensing arrangements, plans, strategies, tactics, policies, resolutions, and any litigation or negotiations; intellectual property, including patent applications, trademarks, trade secrets, and secret formulae; marketing information, including sales or product plans, strategies, tactics, methods, customers, prospects, or market research data; financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings; operational information that relates to the technology that bluebird bio has or desires to develop or market, including control and inspection practices, manufacturing processes and methods, suppliers and parts; technical information, including machinery or device designs,
3



drawings, specifications, processes, procedures, scientific or statistical data, research and development information, scientific protocols, clinical data and preclinical data. bluebird bio Proprietary Information does not include information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act such as joining or forming a union, engaging in collective bargaining, or engaging in other concerted activity for mutual aid or protection of laborers. For purpose of clarity, it shall still be a violation of this Agreement for a non-management employee to share Confidential Information with a competitor about other employees’ compensation and benefits which was obtained through the course of employment with the Company for purposes of assisting such competitor in soliciting Company employees.
d. Service Provider agrees that all documents of any nature provided by bluebird bio to Service Provider and pertaining to activities of any bluebird bio entity or to any bluebird bio Proprietary Information, in his or her possession now or at any time during the term of this Agreement, including without limitation memoranda, notebooks, notes, data sheets, records and blueprints, are and shall be the property of bluebird bio, and that they and all copies of them shall be surrendered to bluebird bio upon the earlier of request by bluebird bio or termination of this Agreement.
e. Service Provider shall have none of the obligations set forth above with respect to bluebird bio Proprietary Information (i) that is publicly known or becomes publicly known through no breach of this Agreement by Service Provider, (ii) that is generally or readily obtainable by the public, or within the scientific field, (iii) that is known by Service Provider prior to its disclosure to Service Provider by bluebird bio, as shown by Service Provider’s written records, (iv) that Service Provider received from a source that had the legal right to disclose the information to Service Provider, (v) that is required to be disclosed by law, government regulation or court order, or (vi) involves information lawfully acquired by a non-management employee about wages, hours or other terms and conditions of employment when used for purposes protected by §7 of the National Labor Relations Act. Further, nothing herein limits, restricts, or in any other way affects Service Provider communicating with the SEC, the DOL, or any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, or cooperating with or participating in a legal proceeding concerning matters relevant to the governmental agency or entity.
3.    Intellectual Property.
a. Service Provider hereby assigns and agrees to assign to bluebird bio his or her entire right, title and interest in and to all Inventions. “Inventions” means improvements, modifications, know-how, processes, secrets and discoveries made, possessed, discovered or conceived by him or her during the period in which the Service Provider has provided services to the Company (whether or not patentable, whether or not reduced to practice, whether or not made, possessed, discovered or conceived by him or her individually or jointly with any other person or persons, whether made or conceived on or off bluebird bio’s premises, and whether made in or out of working hours), which shall specifically or generally relate to, be applicable to or concern (a) development of therapeutics utilizing ex vivo or in vivo nucleic acid (e.g., gene) transfer utilizing viral vector or virus-based approaches (e.g., lentivirus), (b) methods of manufacturing viral vectors or genetically modified cells for the development of therapeutics, (c) approaches to facilitate proper homing or engraftment of genetically modified cells (d) gene editing, (e) cancer therapy,
4



(f) rare genetic disease therapy, and (g) any other project, field, or line of business in which bluebird bio is engaged (collectively, the “Field”), such Inventions and benefits hereof to immediately become the sole and absolute property of bluebird bio. In the event that any portion of this assignment is prohibited by the terms of a funding agreement under which the work resulting in any Invention was performed or the regulations of the institution where such work was performed (in the event such work was not performed by bluebird bio), Service Provider shall use his or her best efforts to obtain for bluebird bio a license or other consent to use such information on the most advantageous terms that are available to bluebird bio. Service Provider agrees that, upon the request of bluebird bio and at the expense of bluebird bio, Service Provider will execute such further assignments, documents, and other instruments as may be necessary or desirable fully and completely to assign all such Inventions to bluebird bio and to assist bluebird bio in applying for, obtaining, and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. Service Provider shall keep and maintain adequate and current written records of all Inventions, in the form of notes, sketches, drawings or as may be specified by bluebird bio, which records shall be available to and remain the sole property of bluebird bio at all times. Service Provider acknowledges that bluebird bio from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on bluebird bio regarding Inventions made during the course of work under such agreements or regarding the confidential nature of such work. Service Provider agrees to be bound by all such obligations and restrictions which are made known to Service Provider and to take all action necessary to discharge the obligations of bluebird bio under such agreements.
b. This Agreement’s assignment provisions are limited to only those Inventions that can be lawfully assigned by an employee to an employer under applicable law in the state where Service Provider last regularly resided while employed by the Company. Service Provider hereby acknowledges that Service Provider has been notified of the following laws governing the assignment of inventions: Del. Code Title 19 § 805; Ill. 765 ILCS1060/1-3, “Employees Patent Act”; N. C. Gen. Stat. Article 10A, Chp 66, Comm. & Bus., § 66-57.1; Minn. Stat. 13A § 181.78; Kan. Stat. § 44-130; Utah Code §34-39-1 -- 34-39-3, “Employee Inventions Act”; Wash. Rev. Code, Title 49 RCW: Lab. Reg. Chpt. 49.44.140; for example, if Service Provider resides in California, the assignment is limited to comply with Cal. Lab. Code § 2870 which provides: (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or (2) Result from any work performed by the employee for the employer. Service Provider will not, without the Company’s prior written consent, incorporate into any Company product or otherwise deliver to the Company any software code that is subject to any license that by its terms requires, or conditions the use or distribution of such code on, the disclosure, licensing or distribution of such Company product or any source code owned or licensed by the Company (e.g., software code licensed under the GNU GPL, LGPL or AGPL.
5



4.    Publication.
Anything to the contrary herein notwithstanding, Service Provider may not publish any bluebird bio Proprietary Information or information regarding Inventions, (as defined above) of a scientific (as opposed to business or corporate) nature generated in the Field by Service Provider. Any clinical or research publication request must comport with bluebird bio’s Scientific and Clinical Publication Review and Approval Process. In addition, Service Provider will cooperate with patent counsel for bluebird bio in effecting the intent of this Section by providing a copy of the text and/or data and any other information needed to file any patent applications or other appropriate materials to protect such information prior to any publication request.
5.    Trade Secrets of Others/Obligations to Others.
Service Provider represents that his or her other performance of all the terms of this Agreement does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by him or her in confidence or in trust prior to his or her engagement by bluebird bio, and Service Provider agrees that he or she will not disclose to bluebird bio, or induce bluebird bio to use, any confidential or proprietary information or material belonging to any other person. Service Provider agrees that he or she will not enter into any agreement, either written or oral, in conflict with his or her obligations under this Agreement.
6.    Survival
The terms of this Agreement and Service Provider’s obligations hereunder shall survive any termination of the Services Provider’s employment, contractual or other business relationship with bluebird bio, irrespective of the reason or reasons for such termination. Nothing in this Agreement shall eliminate, reduce, or otherwise remove any legal duties or obligations that Service Provider would otherwise have to the Company through common law or statute.
7.    Agreement Enforceable Upon Material Job Change.
Service Provider acknowledges and agrees that if he or she should transfer between or among any affiliates of bluebird bio, wherever situated, or be promoted, demoted, reassigned to functions other than Service Provider’s present functions, or have his/her job duties changed, altered or modified in any way, all terms of this Agreement shall continue to apply with full force.
8.    Notice of Resignation.
If the Service Provider elects to resign from his or her employment with the Company, the Service Provider agrees to provide the Company with written notification of his or her resignation at least two (2) weeks prior to the intended resignation date. Such notice shall include information in reasonable detail about his or her post-employment job duties and other business activities, including the name and address of any subsequent employer and/or person or entity with whom or which he or she intends to engage in business activities during the Restricted Period and the nature of his or her job duties and other business activities. The Company may elect to waive all or part of the two (2) week notice period in its sole discretion.
6



9.    Disclosure to Future Employers.
Service Provider agrees to provide, and the Company, in its discretion, may provide, a copy of this Agreement to any business or enterprise which Service Provider may directly or indirectly own, manage, operate, finance, join, control or in which Service Provider may participate in the ownership, management, operation, financing, or control, or with which Service Provider may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.
10.    Modification.
This Agreement may not be changed, waived, modified, released, discharged, abandoned, or otherwise amended, in whole or in part, except by an instrument in writing signed by Service Provider and bluebird bio or as provided in Section 17 or Section 1(a)(I)(B), which waiver under Section 1(a)(I)(B) must be in writing. The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
11.    Entire Agreement.
This Agreement constitutes the entire agreement and understanding between the parties hereto and supersedes any previous oral or written communications, representations, understandings, or agreements relating to the subject matter hereof; notwithstanding the foregoing, any Invention that was created prior to execution of this agreement shall also remain subject to the provisions of any intellectual property assignment provisions in existence between bluebird bio and Service Provider.
12.    Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns (including, in the case of Service Provider, his or her heirs, executors, administrators and other legal representatives). Neither party hereto may assign any of its rights or obligations hereunder to any other person, except that bluebird bio may assign all of its rights and obligations under this Agreement to any person or entity controlled by, in control of, or under common control with, bluebird bio, or to any successor or assign of bluebird bio that employs Service Provider subsequent to his or her employment with bluebird bio.
13.    Counterparts.
This Agreement may be signed in two counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement.
14.    Notices.
All notices, requests, consents and other communications required or permitted hereunder shall be in writing and shall be hand delivered or mailed by first-class mail postage prepaid, addressed as follows: If to bluebird bio, at bluebird bio, Inc., 60 Binney Street, Cambridge, MA 02142, Attention: Chief Legal Officer, or to such other address as may have been furnished to Service Provider by bluebird bio in writing as herein provided; or if to Service Provider, at the address set forth below his or her signature hereon, or to such other address as may have been furnished to bluebird bio by Service Provider as herein provided in writing. Any notice or other communication so addressed and so
7



mailed shall be deemed to have been given when mailed, and if hand delivered shall be deemed to have been given when delivered.
15.    Applicable Law.
This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, shall take effect as an instrument under seal within Massachusetts, and the validity, interpretation and performance of this Agreement shall be governed by, and construed in accordance with, the internal law of Massachusetts, without giving effect to conflict of law principles, and specifically excluding any conflict or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties acknowledge that the last act necessary to render this Agreement enforceable is its execution by the Company in Massachusetts, and that the Agreement shall be maintained in Massachusetts.
16.    Jurisdiction, Venue, Service of Process and Jury Trial Waiver.
Any legal action or proceeding with respect to this Agreement must be brought in the courts of the Commonwealth of Massachusetts or in the United States District Court for the District of Massachusetts and shall be subject to the jurisdiction of such courts only. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts and waive any objection to personal jurisdiction or venue in those courts; provided, however, the Company and the Service Provider agree that all civil actions relating to Section 1.a.(I) of this Agreement shall be brought in the county of Suffolk and that the superior court or the business litigation section of the superior court shall have exclusive jurisdiction. Any action, demand, claim or counterclaim arising under or relating to this Agreement will be resolved by a judge alone and each of the Company and the Service Provider waive any right to a jury trial thereof.
17.    Severability.
The parties intend this Agreement to be enforced as written. However, (a) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly-authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law, and (b) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the court making such determination will have the power to modify or reduce the scope, duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-pencilling”), and in its modified, reduced or blue-pencilled form such provision will then be enforceable and will be enforced.
18.    Use of Name or Affiliation.
bluebird bio shall not use Service Provider’s name or affiliation, in publicity, advertising, or securities offering materials without the prior written approval of Service Provider, provided that such approval shall not be unreasonably withheld in cases in which bluebird bio is required by applicable law to disclose Service Provider’s relationship with bluebird bio.
8



19.    Employment At-Will.
This Agreement does not constitute a contract of employment for a definite period or imply that Service Provider’s employment or engagement with the Company shall continue for any definite period of time. Employment with the Company is at-will meaning that the Service Provider or the Company may end the employment relationship at any time with or without notice or cause.

THE SERVICE PROVIDER ACKNOWLEDGES THAT HE OR SHE HAS CAREFULLY READ THIS ASSIGNMENT OF INVENTION, NONDISCLOSURE, NONCOMPETITION AND NONSOLICITATION AGREEMENT AND Appendix A and UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. FURTHERMORE, BY SIGNING BELOW, THE SERVICE PROVIDER CERTIFIES THAT (I) HE OR SHE WAS PROVIDED WITH THIS AGREEMENT BY THE EARLIER OF A FORMAL OFFER OF EMPLOYMENT OR TEN (10) BUSINESS DAYS BEFORE THE COMMENCEMENT OF HIS OR HER EMPLOYMENT, AND (II) HE OR SHE HAS BEEN ADVISED BY THE COMPANY THAT HE OR SHE HAS THE RIGHT TO CONSULT WITH COUNSEL PRIOR TO SIGNING THIS AGREEMENT.

bluebird bio, Inc.
By:/s/ Kathy Wilkinson
Print Name:Kathy Wilkinson
Title:Chief People Officer
Date:1/10/2019
SERVICE PROVIDER
By:/s/ Jessica Whitten
Print Name:Jessica Whitten
Date:1/10/2019

Attachment: Appendix A


9



APPENDIX A

Alabama:

If Service Provider resides in Alabama, and is subject to Alabama law, then the following applies to Service Provider for as long as Service Provider is subject to Alabama law: (i) Paragraph 1(a) shall be further limited to the solicitation or hiring of employees or consultants of the Company who are engaged in a Sensitive Position for the Company. A person is in a “Sensitive Position” if he or she is uniquely essential to the management, organization, or service of the Company’s business; and (ii) Paragraph 1(a)(ii) shall be limited to solicitation of current customers, vendors, or distributors of the Company (i.e., past or inactive customers, vendors, or distributors are not covered by the provision).

Arizona:

If Service Provider resides in Arizona and is subject to Arizona law, then the following applies to Service Provider for as long as Service Provider is subject to Arizona law: the restrictions in Paragraph 1(a)(ii) shall be limited to the geographic region that Service Provider worked in, serviced, managed and/or supervised on behalf of the Company within the one (1) year period immediately preceding the termination of his employment.

California:

If Service Provider resides in California and is subject to California law, then the following applies to Service Provider for so long as Service Provider is subject to California law: (a) Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law); and (b) Paragraphs 14 and 15 shall not apply.

Louisiana:

If Service Provider resides in Louisiana and is subject to Louisiana law, then the following applies to Service Provider for as long as Service Provider is subject to Louisiana law: the restrictions in Paragraph 1(a)(ii) shall be limited to the following parishes in Louisiana and counties outside Louisiana:_____________________________ [each individual Parish and/or County must be named].

Montana:

If Service Provider resides in Montana and is subject to Montana law, then the following applies to Service Provider for as long as Service Provider is subject to Montana law: the last sentence of Paragraph 18 shall not apply.

Nebraska:

If Service Provider resides in Nebraska and is subject to Nebraska law, then the following applies to Service Provider for so long as Service Provider is subject to Nebraska law: Paragraph 1(a)(ii) is further limited to the solicitation of customers, vendors, or distributors, with which
10



Service Provider did business on behalf of the Company and had personal business-related contact during the one (1) year period immediately preceding Service Provider’s termination.
 
Nevada:

If Service Provider resides in Nevada and is subject to Nevada law, then the following applies to Service Provider for so long as Service Provider is subject to Nevada law: Paragraph 1(a)(ii) does not preclude Service Provider from providing services to any former customer of the Company if: (a) Service Provider did not solicit the former customer; (b) the customer voluntarily chose to leave and seek services from Service Provider; and (c) Service Provider is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained.

New York:

If Service Provider resides in New York and is subject to New York law, then the following applies to Service Provider for so long as Service Provider is subject to New York law: Paragraph 1(a)(ii) shall be modified so that it excludes those customers who became a customer of Company as a result of Service Provider’s independent contact and business development efforts with the customer prior to and independent from his/her employment with Company.

North Carolina:

If Service Provider resides in North Carolina and is subject to the laws of North Carolina, then the following applies to Service Provider for so long as Service Provider is subject to North Carolina law: the one (1) year look back period referenced in Paragraph 1(a) shall be calculated looking back one (1) year from the date of enforcement and not from the date employment ends.

North Dakota:

If Service Provider resides in North Dakota and is subject to North Dakota law, then the following applies to Service Provider for so long as Service Provider is subject to North Dakota law: Paragraph 1(a)(ii) shall be limited to situations where Service Provider is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).

Wisconsin:

If Service Provider resides in Wisconsin and is subject to Wisconsin law, then the following applies to Service Provider for so long as Service Provider is subject to Wisconsin law: (a) Paragraph 9(g) shall not apply; and (b) Paragraph 5(b) shall be further limited to the solicitation or hiring of employees, independent contractors, sales agents, or sales associates of the Company who are engaged in a Sensitive Position for the Company. “Sensitive Position” refers to an employee of the Company who is in a management, supervisory, sales, research and development, or similar role where the employee is provided Confidential Information or is involved in business dealings with the Company’s customers.

11
 EX-10.36 7 blue-20211231xex1036.htm EX-10.36 Document



Exhibit 10.36
SUB-SUBLEASE AGREEMENT

This SUB-SUBLEASE AGREEMENT (this “Sub-Sublease”) is made as of the 29th day of December, 2021 (the “Effective Date”), by and between BLUEBIRD BIO, INC., a Delaware corporation (hereinafter referred to as “Sub-Sublandlord”), and META PLATFORMS, INC., a Delaware corporation (hereinafter referred to as “Sub-Subtenant”).
W I T N E S S E T H :
WHEREAS, by that certain Sublease, dated as of April 16, 2019 (the “Sublease”), AVENTIS INC., a Pennsylvania corporation (hereinafter referred to as “Sublandlord”), subleased to Sub-Sublandlord, as subtenant, certain premises containing approximately 267,278 rentable square feet located on the first (1st) through tenth (10th) floors and together with certain areas of the Garage (the “Premises”) in the building known as and located at 50 Binney Street, Cambridge, Massachusetts (the “Building”), upon and subject to the terms and conditions set forth in the Sublease; and
WHEREAS, by that certain Lease Agreement, dated as of March 25, 2015 (the “Original Lease”), as amended by that certain First Amendment to Lease, dated as of October 27, 2015 (the “First Amendment”), as further amended by that certain Second Amendment to Lease, dated as of June 30, 2018 (the “Second Amendment”), and as further amended by that certain Consent to Sublease and Third Amendment to Lease, dated as of April 22, 2019 (the “Consent / Third Amendment” and together with the Original Lease, the First Amendment and the Second Amendment, collectively, the “Master Lease”), between ARE-MA REGION NO. 40, LLC, a Delaware limited liability company (“Master Landlord”), as landlord, leased to Sublandlord, as tenant, the entire Premises, upon and subject to the terms and conditions set forth in the Master Lease; and
WHEREAS, Sub-Sublandlord desires to sublease to Sub-Subtenant and Sub-Subtenant desires to sublease from Sub-Sublandlord the entire Premises on the terms and conditions set forth in this Sub-Sublease. A redacted copy of the Sublease is attached hereto as Exhibit A.
A G R E E M E N T :
NOW, THEREFORE, the parties hereto, for themselves, their successors and assigns, mutually covenant and agree as follows:
1.Capitalized Terms; References to Master Lease and Sublease. Any capitalized terms not otherwise defined in this Sub-Sublease shall have the meanings ascribed thereto in the Master Lease. Unless expressly set forth in this Sub-Sublease to the contrary, references in this Sub-Sublease to (i) the Master Lease or the Sublease (for example, where a party hereto is required to perform in accordance with the terms of the Master Lease and/or Sublease), as applicable, are only made in each case to the extent the Master Lease or the Sublease, as applicable, are incorporated into this Sub-Sublease pursuant to the express terms hereof and (ii) this Sub-Sublease shall include those provisions of the Master Lease and the Sublease incorporated into this Sub-Sublease pursuant to the express terms hereof.




2.Subleasing. Sub-Sublandlord hereby subleases to Sub-Subtenant and Sub-Subtenant hereby subleases from Sub-Sublandlord the Premises, together with the right to use the common areas as set forth in the Master Lease.
3.Delivery of the Premises. Sub-Sublandlord shall deliver the Premises to Sub-Subtenant on the Sub-Sublease Term Commencement Date (i) in broom clean condition, (ii) free and clear of all tenants and occupants, (iii) free of all personal property (including signage), except for Sub-Sublandlord’s Furniture (as hereinafter defined), (iv) otherwise in the delivery condition required to be delivered to Sub-Sublandlord under the Sublease, and (v) except as set forth in the foregoing clauses (i) through (iv), in as-is, where-is condition (collectively, the “Delivery Condition”). In the event of any material change in the condition of the Premises between November 15, 2021, and the Sub-Sublease Term Commencement Date, upon Sub-Subtenant’s request Sub-Sublandlord shall exercise its rights and remedies under Section 3.01 of the Sublease to cure such material change, and, for the avoidance of doubt, the Delivery Condition shall not be deemed satisfied until such material change has been cured. Sub-Sublandlord has made no representations, warranties or undertakings as to the present or future condition of the Premises or the fitness and availability of the Premises for any particular use, except as expressly set forth in this Sub-Sublease.
4.Term. This Sub-Sublease is effective as of the Effective Date. The term of this Sub-Sublease (the “Sub-Sublease Term”) shall commence on the later date to occur of (i) the date Sub-Sublandlord delivers to Sub-Subtenant a fully executed copy of this Sub-Sublease and the Consent to Sub-Sublease (as hereinafter defined), and (ii) the date possession of the Premises is delivered to Sub-Subtenant in the Delivery Condition (such later date, the “Sub-Sublease Term Commencement Date”) and shall end on December 31, 2030, or on such earlier date upon which said Sub-Sublease Term may expire or be terminated pursuant to any of the conditions or limitations or other provisions of this Sub-Sublease (which date for the termination of the term hereof shall hereafter be called the “Sub-Sublease Termination Date”). Notwithstanding the foregoing, in no event shall Sub-Subtenant be obligated to accept delivery of the Premises prior to April 1, 2022. Sub-Subtenant shall surrender the Premises upon the Sub-Sublease Termination Date in the condition required under this Sub-Sublease; provided, however, (A) in no event shall Sub-Subtenant be obligated to restore any alterations or improvements existing in the Premises as of the Sub-Sublease Term Commencement Date, and (B) Sub-Sublandlord acknowledges that it shall not require Sub-Subtenant to remove any alterations, additions or improvements (including with respect to the roof) if Master Landlord and Sublandlord shall not require or Master Landlord or Sublandlord is not entitled to require removal of the same in accordance with the terms and conditions of the Master Lease or Sublease, as applicable. Notwithstanding anything to the contrary contained in this Sub-Sublease, if the Sub-Sublease Term Commencement Date has not occurred by December 31, 2022, which date shall not be subject to extension for any reason (including Force Majeure), then Sub-Subtenant shall have the right to terminate this Sub-Sublease by delivering written notice to Sub-Sublandlord at any time thereafter until the Sub-Sublease Term Commencement Date occurs. Sub-Sublandlord shall not consent to or otherwise permit any further extensions of the delivery of the Premises from Sublandlord to Sub-Sublandlord under the Sublease without the prior written consent of Sub-Subtenant in Sub-Subtenant’s sole and absolute discretion.
2



5.Rent.
(a)Fixed Annual Rent. From and after the Sub-Sublease Term Commencement Date, Sub-Subtenant shall pay to Sub-Sublandlord, as fixed annual rent (“Fixed Annual Rent”), the monthly amounts set forth below, in advance on the first (1st) day of each calendar month during the Sub-Sublease Term, without set-off, abatement, deduction or demand, except as set forth in this Sub-Sublease. Fixed Annual Rent due for any partial month at the beginning or end of the Sub-Sublease Term shall be pro-rated on a per diem basis.
DATESFIXED ANNUAL RENTMONTHLY INSTALLMENTS OF FIXED ANNUAL RENT
Sub-Sublease Year 1$28,064,190.00*$2,338,682.50*
Sub-Sublease Year 2$28,906,115.70$2,408,842.98
Sub-Sublease Year 3$29,772,096.42$2,481,008.04
Sub-Sublease Year 4$30,667,477.72$2,555,623.14
Sub-Sublease Year 5$31,586,914.04$2,632,242.84
Sub-Sublease Year 6$32,533,078.16$2,711,089.85
Sub-Sublease Year 7$33,511,315.64$2,792,609.64
Sub-Sublease Year 8$34,516,280.92$2,876,356.74
Sub-Sublease Year 9 (partial year)$35,550,646.78$2,962,553.90

For purposes of this Sub-Sublease, “Sub-Sublease Year” shall mean each successive twelve (12) month period during the Sub-Sublease Term, with the first such Sub-Sublease Year commencing on the Sub-Sublease Rent Commencement Date (as hereinafter defined) and each successive Sub-Sublease Year commencing on the next succeeding anniversary of the Sub-Sublease Rent
3



Commencement Date; provided, however, (i) the final Sub-Sublease Year shall expire on the Sub-Sublease Termination Date, (ii) if the Sub-Sublease Rent Commencement Date does not occur on the first day of a calendar month, then the first Sub-Sublease Year shall include the partial calendar month in which the Sub-Sublease Term Rent Commencement Date occurs and the following twelve (12) full calendar months thereafter, and (iii) the remaining Sub-Sublease Years shall be the successive twelve (12) month periods following the end of the first Sub-Sublease Year.
*Notwithstanding anything to the contrary contained in this Sub-Sublease, the payment of Fixed Annual Rent and those items of Additional Rent set forth in Section 5(b)(ii) below (as hereinafter defined) due under this Sub-Sublease will be abated for the first ninety (90) days following the Sub-Sublease Term Commencement Date, with such ninety-first (91st) day following the Sub-Sublease Term Commencement Date being the “Sub-Sublease Rent Commencement Date” for purposes of this Sub-Sublease. If an event of Default by Sub-Subtenant occurs at any time from and after the Sub-Sublease Term Commencement Date through the Sub-Sublease Rent Commencement Date, then Sub-Subtenant’s right to abate the Fixed Annual Rent and those items of Additional Rent set forth in Section 5(b)(ii) below shall toll (and Sub-Subtenant shall be required to pay such sums during any such period) until Sub-Subtenant has cured such event of Default, and thereafter the abatement shall continue until Sub-Subtenant receives the full abatement including any tolled amounts.
As used herein, “Construction Force Majeure Delay” shall mean an actual delay in the completion of any construction, development or permitting contemplated as part of Sub-Subtenant’s initial occupancy of the Premises, which is caused solely as a result of (a) any governmental actions, including governmental guidelines or mandates, concerning the imposition of limitations on construction activities as a result of an actual or threatened public health emergency (including, without limitation, epidemic, pandemic, and other significant public health risk, including COVID-19), or (b) government or regulatory agency delay with respect to approval or permit process, all of which are beyond the reasonable control of Sub-Subtenant. Notwithstanding anything to the contrary set forth in this Sub-Sublease, if Sub-Subtenant encounters any Construction Force Majeure Delay that prohibits or delays the performance of Sub-Subtenant’s construction, development or permitting of the Premises, then the Sub-Sublease Rent Commencement Date (to the extent the same shall not then have previously occurred) shall be extended by one (1) day for every day of such Construction Force Majeure Delay, in an amount not to exceed sixty (60) days; in each instance commencing from and after the date such Construction Force Majeure Delay occurs until the date on which such Construction Force Majeure Delay ceases.
(b)Additional Rent.
i.All amounts other than Fixed Annual Rent that are due to Sub-Sublandlord from Sub-Subtenant under this Sub-Sublease are hereinafter referred to collectively as “Additional Rent”. Fixed Annual Rent and Additional Rent may be referred to collectively as “Rent”. The obligation of Sub-Subtenant to pay Rent and other sums to Sub-Sublandlord and the obligations of Sub-Sublandlord are independent obligations. Except as expressly provided in this Sub-Sublease, Sub-Subtenant shall have no right at any time to abate, withhold, reduce or set off any Rent due hereunder.
ii.From and after the Sub-Sublease Rent Commencement Date and during the remainder of the Sub-Sublease Term, Sub-Subtenant shall pay to Sub-Sublandlord, as Additional Rent, one
4



hundred percent (100%) of Sub-Sublandlord’s obligations to make payments to Sublandlord pursuant to Section 4.04 of the Sublease of (i) Operating Expenses, (ii) Taxes, (iii) Landlord’s Property Management Fee, and (iv) Tenant’s Share of Operating Expenses for the Garage, the Project, the Campus and the Premises, which is allocable to the Premises, in the manner and at the same time as set forth in Section 5(a) above with respect to Fixed Annual Rent.
iii.Sub-Sublandlord shall, within a reasonable period of time after Sub-Sublandlord receives corresponding notices or statements from Sublandlord of the estimated monthly payments of Additional Rent due under Section 4 of the Sublease for the Premises, provide to Sub-Subtenant a good faith estimate of the Additional Rent payable from Sub-Subtenant under this Section 5(b) for any calendar year (or part thereof) during the Sub-Sublease Term that such amounts are due, and Sub-Subtenant shall pay to Sub-Sublandlord, at the times and in the manner set forth in Section 5(a) above with respect to Fixed Annual Rent, an amount equal to 1/12th of such good faith estimate (to the extent provided) Additional Rent due for such calendar year or part thereof. Within thirty (30) days following receipt by Sub-Sublandlord of any annual reconciliation statement of the Additional Rent, as applicable, Sub-Sublandlord will send to Sub-Subtenant a statement together with relevant, non-confidential documentation, establishing the actual Additional Rent payments, as applicable, for such year. If Sub-Subtenant has paid more in estimated Additional Rent under this Section than the actual amount due from Sub-Subtenant for the applicable year, Sub-Sublandlord shall credit such excess against subsequent obligations of Sub-Subtenant for Additional Rent (or refund such excess to Sub-Subtenant within thirty (30) days if the Sub-Sublease Term has ended and Sub-Subtenant has no further obligation to Sub-Sublandlord). If Sub-Subtenant has paid less than the actual Additional Rent due under this Section 5(b), Sub-Subtenant shall pay any deficiency to Sub-Sublandlord within thirty (30) days following receipt of the reconciliation documentation from Sub-Sublandlord.
(c)Utilities. Commencing on the Sub-Sublease Term Commencement Date, and continuing throughout the remainder of the Sub-Sublease Term or such later date as Sub-Subtenant or anyone claiming by, through or under Sub-Subtenant remains in occupancy of the Premises, Sub-Subtenant shall be responsible for payment on all utility charges as Operating Expenses or otherwise in accordance with the Master Lease. For the avoidance of doubt, as of the Effective Date of this Sub-Sublease, all utilities are separately metered for the Premises.
(d)Additional Charges. Sub-Subtenant shall also be responsible for its own services, including telephone, facsimile transmitter, internet access, photocopier, and its other business expenses. In addition, if Sub-Subtenant shall procure any additional services from Sublandlord or Master Landlord, or if additional rent or other sums are incurred for Sub-Subtenant’s sole benefit, including, without limitation, repairs and replacements to the Premises caused or permitted by Sub-Subtenant, Sub-Subtenant shall make such payment to Sub-Sublandlord within thirty (30) days after Sub-Subtenant’s receipt of an invoice. Any rent or other sums payable by Sub-Subtenant to Sub-Sublandlord under this Section 5(d) shall constitute and be due as Rent.
(e)Audit Right. Sub-Subtenant shall be entitled to all rights of “Lessee” under Section 4.10 of the Sublease to cause Sublandlord to exercise Sublandlord’s audit rights under the Master Lease.
(f)    Late Charge; Interest. If any Rent due from Sub-Subtenant is not received by Sub-Sublandlord when due, Sub-Subtenant shall pay to Sub-Sublandlord a late payment charge of four
5



percent (4%) of the past-due amount; provided, however, Sub-Sublandlord agrees to waive such late charge two (2) times in any twelve (12) month period, provided that the late payment is made within five (5) business days of Sub-Sublandlord’s written notice demanding payment. Following Sub-Sublandlord’s second (2nd) waiver of late payment in any twelve (12) month period, Sub-Sublandlord shall provide Sub-Subtenant with written notice that the two (2) waivers have been exhausted for the ensuing twelve (12-) month period prior to Sub-Sublandlord’s assessment of any late charge(s). Notwithstanding the foregoing, Sub-Sublandlord’s failure to provide such notice shall not be a waiver of Sub-Sublandlord’s right to impose late charge(s), however, Sub-Subtenant shall not be responsible for the payment of any late charge(s) until such notice is received. Acceptance of any late charge shall not constitute a waiver of Sub-Subtenant’s default with respect to the overdue amount, or prevent Sub-Sublandlord from exercising any of the other rights and remedies available to Sub-Sublandlord under this Sub-Sublease or under applicable law. In addition to the late charge, Rent not paid when due shall bear interest at the Default Rate from the date of expiration of the applicable cure period for Default set forth in Section 15 below until paid.
6.Insurance. Sub-Subtenant shall obtain and maintain all insurance types and coverage as specified in the Sublease or Master Lease, as applicable, to be obtained and maintained by Sub-Sublandlord, as subtenant, in amounts not less than those specified in the Sublease or Master Lease, as applicable. All such policies of insurance shall name Master Landlord, Sublandlord and Sub-Sublandlord as additional insureds thereunder. Sub-Subtenant’s insurance shall be primary over Master Landlord’s, Sublandlord’s and Sub-Sublandlord’s insurance. Notwithstanding the foregoing or anything to the contrary contained in this Sub-Sublease, Sub-Subtenant shall not be required to obtain and maintain any type of insurance to the extent Master Landlord and Sublandlord do not require such insurance pursuant to the Consent to Sub-Sublease.
7.Indemnification.
(a)Subject to any applicable waiver of subrogation and/or release provisions applicable to the parties, and except to the extent resulting from the negligence or willful misconduct of Sub-Sublandlord, Sublandlord and Master Landlord or any of their employees, agents, contractors or invitees, Sub-Subtenant shall indemnify, defend and hold harmless Sub-Sublandlord and its employees and agents from and against any and all loss, cost, liability, claim, damage and expense, including, without limiting the generality of the foregoing, reasonable attorneys’ fees and expenses and court costs, penalties and fines incurred in connection with or arising from any injury, damage or loss (by theft or otherwise) occurring in or about the Premises during the Sub-Sublease Term and arising from any acts, omissions or negligence of Sub-Subtenant, its employees, licenses or agents occurring in or about the Building. Notwithstanding the foregoing or anything to the contrary contained in this Sub-Sublease, Sub-Subtenant shall not be responsible or otherwise liable for any acts, omissions or negligence occurring in or about the Building, or any injury, damage or loss (by theft or otherwise) occurring in or about the Premises, in each case, for any period of time prior to the Sub-Sublease Term Commencement Date. Subject to any applicable waiver of subrogation and/or release provisions applicable to the parties, and except to the extent resulting from the negligence or willful misconduct of Sub-Subtenant or any of its employees, agents, contractors or invitees, Sub-Sublandlord shall indemnify, defend and hold harmless Sub-Subtenant and its employees and agents, from and against any and all loss, cost, liability, claim, damage and expense, including, without limiting the generality of the foregoing, reasonable attorneys’ fees and expenses and court costs,
6



penalties and files incurred in connection with or arising from any negligence or willful misconduct of Sub-Sublandlord or its employees, agents, contractors or invitees.
(b)Sub-Subtenant shall neither do nor permit anything to be done which would cause a default under the Master Lease or Sublease, or termination or forfeiture by reason of any right of termination or forfeiture, reserved or vested in the Master Landlord under the Master Lease or the Sublandlord under the Sublease. Sub-Sublandlord shall neither do nor permit anything to be done which would cause a default under the Master Lease or Sublease, or termination or forfeiture by reason of any right of termination or forfeiture, reserved by or vested in the Master Landlord under the Master Lease or the Sublandlord under the Sublease. Sub-Subtenant shall indemnify and hold Sub-Sublandlord harmless from and against all claims of any kind whatsoever by reason of a Default on the part of Sub-Subtenant under this Sub-Sublease. Sub-Sublandlord shall indemnify and hold Sub-Subtenant harmless from and against all claims of any kind whatsoever by reason of (i) a default beyond notice and cure periods on the part of Sub-Sublandlord under this Sub-Sublease, (ii) any termination of the Master Lease or Sublease resulting solely from a default beyond notice and cure periods on the part of Sub-Sublandlord under the Sublease, except if such default results from the acts or omissions of Sub-Subtenant in violation of the first sentence of this Section 7(b) above, and (iii) any voluntary termination of the Sublease in violation of Section 8(a) of this Sub-Sublease below.
8.Sub-Sublandlord Covenants and Representations.
(a)Sub-Sublandlord covenants and agrees that Sub-Sublandlord: (i) shall cause all rent to be paid under the Sublease as and when due and payable under the Sublease; (ii) shall observe and perform the other terms, provisions, covenants and conditions of the Sublease to be observed and performed by Sub-Sublandlord, except and to the extent that such terms, provisions, covenants and conditions are assumed by Sub-Subtenant hereunder; (iii) shall not terminate the Sublease under any circumstances (including with respect to voluntary rights of termination arising out of casualty or condemnation set forth in the Sublease) except to the extent permitted by Sub-Subtenant in Sub-Subtenant’s sole discretion and shall not amend the Sublease except to the extent permitted by Sub-Subtenant in Sub-Subtenant’s sole discretion; (iv) shall not take any action or fail to perform any act that results in a breach or default under the Sublease; (v) shall, upon written request from and at the direction of Sub-Subtenant and at Sub-Subtenant’s sole cost and expense, enforce Sub-Sublandlord’s rights and remedies under the Sublease and/or Master Lease (but in no event shall Sub-Sublandlord in the exercise of such request be obligated to commence litigation as against Sublandlord or Master Landlord); (vi) shall not extend or renew the term of the Sublease or permit the extension or renewal of the Master Lease; (vii) shall not expand or permit the expansion of the Premises; and (viii) shall not purchase or otherwise acquire any portion of the Premises.
(b)Sub-Sublandlord represents and warrants to Sub-Subtenant that:
i.Sub-Sublandlord has not received any written notice of default under the Sublease, except for any defaults that Sub-Sublandlord has cured and Sublandlord is no longer claiming to exist, and Sub-Sublandlord is not in default under the Sublease;
ii.Sub-Sublandlord has not sent to Sublandlord any written notice stating that Sublandlord is in default under the Sublease, and to the actual knowledge, without any investigation, of Sub-Sublandlord, Sublandlord is not in default under the Sublease;
7



iii.Sub-Sublandlord has not received from Master Landlord or Sublandlord, any written notice of default by either Master Landlord or Sublandlord under the Master Lease, and to the actual knowledge, without any investigation, of Sub-Sublandlord, neither Master Landlord nor Sublandlord is in default under the Master Lease;
iv.Sub-Sublandlord has not received any written notice that any work is required under the Sublease or by applicable law to be done in the Premises;
v.Sub-Sublandlord has not assigned, granted a security interest in or encumbered in any way whatsoever its rights, duties or interests in the Sublease, and the Sublease is in full force and effect;
vi.To the actual knowledge, without any investigation, of Sub-Sublandlord, as of the Effective Date, no party other than (x) Sub-Sublandlord pursuant to the Sublease, (y) Sublandlord pursuant to the Master Lease, and (z) Sub-Subtenant pursuant to this Sub-Sublease, has a right to lease, sublease, or otherwise occupy all or any portion of the Premises; provided, however, notwithstanding the foregoing, the parties acknowledge Sub-Sublandlord holds a current right of first offer to lease the Premises pursuant to a Lease Agreement by and between Sub-Sublandlord, as tenant, and Master Landlord, as landlord for space in that certain building located at and known as 60 Binney Street, Cambridge Massachusetts. Sub-Sublandlord hereby agrees not to exercise such right of first offer with respect to the Premises during the term of this Sub-Sublease or Sub-Subtenant’s occupancy of the Premises;
vii.Attached hereto as Exhibit A is a true, correct and complete (except for redactions) copy of the Sublease with all Exhibits attached, including the redacted Master Lease; and
viii.Sub-Sublandlord has not received any written notice of violation of any laws, ordinances, codes, rules, regulations or requirements affecting the Premises.
Sub-Sublandlord shall not be deemed to have made any representation made by Master Landlord or Sublandlord in any of the incorporated provisions.
(c)Sub-Sublandlord’s Performance. If Sub-Sublandlord shall fail to pay any sum of money required to be paid by it under the Sublease, or shall fail to perform any other act on its part to be performed thereunder, and such failure could reasonably be expected to adversely impact Sub-Subtenant’s rights or use of the Premises and such failure continues for ten (10) days after notice thereof by Sub-Subtenant to Sub-Sublandlord for failures relating to the payment of money, or such failure continues for thirty (30) days after notice thereof by Sub-Subtenant to Sub-Sublandlord for other failures, Sub-Subtenant may, but shall not be obligated to do so, and without waiving or releasing Sub-Sublandlord from any obligations of Sub-Sublandlord, make any such payment or perform any such other act on Sub-Sublandlord’s part to be made or performed as provided in the Sublease. Sub-Sublandlord shall reimburse Sub-Subtenant for all actual costs incurred in connection with such payment or performance within thirty (30) days following demand. All unpaid amounts shall bear interest at the Default Rate from the date Sub-Subtenant incurs such sum.
8



9.Incorporation of the Master Lease and Sublease by Reference.
(a)Except to the extent such terms and provisions are inconsistent with or are specifically contrary to the express written provisions of this Sub-Sublease and except as provided in this Section 9, all of the terms, covenants and conditions of the Sublease, and the Master Lease to the extent incorporated into the Sublease, are by this reference incorporated herein and made a part of this Sub-Sublease with the same force and effect as if fully set forth herein, provided, however, that for purposes of such incorporation, (i) the term “Sublease” as used in the Sublease shall refer to this Sub-Sublease; (ii) the term “Lessor” as used in the Sublease shall refer to Sub-Sublandlord; (iii) the term “Lessee” as used in the Sublease shall refer to Sub-Subtenant; (iv) the term “Term” as used in the Sublease shall refer to the Sub-Sublease Term; (v) the term “Expiration Date” as used in the Sublease shall refer to the Sub-Sublease Termination Date; (vi) the term “Subleased Premises” as used in the Sublease shall refer to the Premises; (vii) the term “Base Rent” as used in the Sublease shall refer to the Fixed Annual Rent; (viii) the term “Prime Landlord” or “Prime Lessor” as used in the Sublease shall refer to Master Landlord; (ix) the term “Prime Lease” as used in the Sublease shall refer to the Master Lease; (x) the term “Commencement Date” as used in the Sublease shall refer to the Sub-Sublease Term Commencement Date; (xi) the term “Effective Date” as used in the Sublease shall refer to the Effective Date. In the event of any inconsistency between the provisions set forth in this Sub-Sublease and the provisions of the Sublease and/or Master Lease, as incorporated herein, the provisions of this Sub-Sublease shall control as between Sub-Sublandlord and Sub-Subtenant. Notwithstanding the foregoing, the following provisions of the Sublease and the Master Lease, as applicable, are expressly not incorporated into this Sub-Sublease: (1) all redacted provisions of the Master Lease and Sublease or provisions of the Master Lease and Sublease not otherwise included on Exhibit A attached hereto; (2) all within the Sublease: Section 1.01, Section 1.02, Section 1.03, Section 2.01, Section 2.02, the final three (3) sentences of Section 3.01, Section 3.03 (as Section 3.03 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 3.03 shall remain in effect as to Sublandlord), Section 4.01, Section 4.02, Section 4.03, Section 4.04 (provided that Sub-Subtenant is responsible for the payments described in Section 4.04 as set forth in Section 5(b)(ii) of this Sub-Sublease), Section 4.08, Section 4.09, Section 5.02, Section 5.04 (as Section 5.04 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 5.04 shall remain in effect as to Sublandlord), Section 8, Section 9.01 (as Section 9.01 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 9.01 shall remain in effect as to Sublandlord), Section 9.02 (as Section 9.02 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 9.02 shall remain in effect as to Sublandlord), Section 9.03 (as Section 9.03 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 9.03 shall remain in effect as to Sublandlord), Section 9.04, Section 9.05 (as Section 9.05 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 9.05 shall remain in effect as to Sublandlord), Section 9.06 (as Section 9.06 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 9.06 shall remain in effect as to Sublandlord), Section 10.01, Section 10.02, Section 11, Section 12, Section 13.01, Section 13.02, Section 14, Section 15.01, Section 15.02, Section 18.01, Section 21.01, Section 21.02, Section 22.08, Schedule 1 and Exhibit C; (2) any excluded Primary Lease Provisions in accordance with Section 5 of the Sublease; and (3) all within the Master Lease: Basic Lease Provisions: Address for Rent Payment, Landlord’s Notice Address, Tenant’s Notice Address and Work Letters, Section 23, Section 30(c) (as Section 30(c) shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 30(c) shall remain in effect as to Sublandlord and Master Landlord), Section 31(d) (as Section 31(d) shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 31(d) shall remain in effect as to Master Landlord), Section 32
9



(as Section 32 shall relate to Sub-Subtenant and Sub-Sublandlord only, which Section 32 shall remain in effect as to Sublandlord and Master Landlord), Section 42, Section 43(a), Section 43(b), Section 43(c), the “provided, however” clause in the first sentence of Section 43(d), Section 43(j), Section 43(m), all Schedules, Exhibit D, Exhibit F, Exhibit G, Exhibit H (and all references to Exhibit H in Section 27) and Exhibit I, the entire First Amendment (except with respect to provisions in the First Amendment that amend provisions of the Original Lease that are incorporated into this Sub-Sublease), and the entire Consent / Third Amendment. Notwithstanding anything to the contrary contained in this Sub-Sublease, under no circumstances shall Sub-Subtenant be responsible or have any liability with respect to any redacted provisions from the Sublease or the Master Lease or other provisions not otherwise set forth on Exhibit A attached hereto.
(b)Sub-Sublandlord shall have all of the same rights and remedies with respect to the Premises as Sublandlord and Master Landlord have with respect thereto under the Sublease and Master Lease.
(c)With respect to any of Sub-Subtenant’s obligations to be performed under this Sub-Sublease, when the Sublease grants Sub-Sublandlord a specific number of days to perform its obligations thereunder, Sub-Subtenant shall perform such obligation not later than the date that is three (3) business days prior to the date Sub-Sublandlord is obligated under the Sublease to perform such obligation; provided, however, in no event shall Sub-Subtenant have less than five (5) business days with which to perform any monetary obligations prior to a Default being claimed in accordance with Section 15 hereof. As between Sub-Subtenant and Sub-Sublandlord, in the event of any conflict between the provisions of the Sublease and/or Master Lease, on the one hand, and this Sub-Sublease, on the other hand, this Sub-Sublease shall govern and control.
10.Benefits of the Sublease and Master Lease. Sub-Sublandlord agrees that Sub-Subtenant shall be entitled to receive all warranties, indemnifications, abatements, waivers, guaranties, releases, rights, services, utilities, repairs and restorations to be provided by Master Landlord and/or Sublandlord under the Master and/or Sublease, as applicable, and Sub-Sublandlord shall enforce any of the foregoing upon Sub-Subtenant’s written request therefor at Sub-Subtenant’s sole cost and expense (but in no event shall Sub-Sublandlord in the exercise of such request be obligated to commence litigation as against Sublandlord or Master Landlord). Notwithstanding the foregoing, Sub-Subtenant may pursue on behalf of Sub-Sublandlord any remedies that may be available against Master Landlord or Sublandlord under the Master Lease and/or Sublease to the extent permitted in the Consent to Sub-Sublease, and Sub-Sublandlord shall diligently and in good faith cooperate with Sub-Subtenant in connection with the foregoing at Sub-Subtenant’s expense. Sub-Subtenant shall look solely to Master Landlord for all services, utilities, repairs and restorations under the Master Lease and shall not require Sub-Sublandlord or Sublandlord to perform any such services, utilities, repairs and restorations. Sub-Sublandlord shall not be obligated to (i) directly provide any of the services or utilities, including cleaning, that Master Landlord has agreed to provide in the Master Lease and as incorporated into the Sublease, (ii) directly make any of the repairs or restorations that Master Landlord has agreed in the Master Lease to make and as incorporated into the Sublease, or (iii) take any action that Master Landlord has agreed in the Master Lease to take, or take any action that Sublandlord has agreed in the Sublease to take, and Sub-Sublandlord shall have no liability to Sub-Subtenant on account of any failure of Master Landlord or Sublandlord, as applicable, to do so. Sub-Sublandlord agrees, upon Sub-Subtenant’s request, to use reasonable efforts at Sub-
10



Subtenant’s expense, to (a) cause Master Landlord or Sublandlord to provide the services or utilities or make the repairs or restorations described in the Master Lease or Sublease, as applicable, or (b) to obtain Master Landlord’s or Sublandlord’s consent or approval wherever required by the Master Lease or Sublease, as applicable. Sub-Sublandlord agrees that if under the Master Lease or Sublease any right or remedy of Sub-Sublandlord or any duty or obligation of Master Landlord or Sublandlord is subject to or conditioned upon Sub-Sublandlord making any demand upon Master Landlord or Sublandlord or giving any notice or request to Master Landlord or Sublandlord then, if Sub-Subtenant shall so request, Sub-Sublandlord, at Sub-Subtenant’s expense, shall make such demand or give such notice or request on Sub-Sublandlord’s behalf, except that Sub-Sublandlord shall not be required to do so with respect to any act or thing as to which Sub-Sublandlord shall have determined in accordance with this Sub-Sublease to withhold its consent or approval. Notwithstanding anything to the contrary contained in this Sub-Sublease, if Sub-Sublandlord shall actually receive an abatement of any rent (including, without limitation, Base Rent, Additional Rent, Rental, Operating Expenses, Operating Expense Payments (as defined in the Sublease), Taxes and/or Landlord’s Property Management Fee), for any reason under the Sublease and/or Master Lease with respect to the Sub-Sublease Term, then Sub-Subtenant shall be entitled to receive from Sub-Sublandlord such abatement.
11.Direct Performance. At any time by written notice to Sub-Subtenant, Sub-Sublandlord may elect to require Sub-Subtenant to perform its obligations under this Sub-Sublease directly to Sublandlord, and Sub-Subtenant shall do so on Sub-Sublandlord’s election, in which event Sub-Subtenant shall send to Sub-Sublandlord from time to time copies of all notices and other communications that it shall send to and receive from Sublandlord. Sub-Subtenant may also perform Sub-Sublandlord’s obligations if directed in writing by Master Landlord or Sublandlord and thereafter shall be released of the obligation to perform such obligations to Sub-Sublandlord until directed in writing by Master Landlord or Sublandlord, as applicable.
12.Repairs; Alterations.
(a)Approval Required. Sub-Subtenant at its own cost shall keep the Premises in good condition and repair and in accordance with the applicable terms of the Sublease and Master Lease. Sub-Subtenant shall not perform or cause to be performed any interior or exterior improvements to the Premises (“Sub-Subtenant Alterations”) without the prior written consent of Sublandlord and Master Landlord to the extent required under the terms of the Sublease and Master Lease, as applicable, and the Consent to Sub-Sublease. Notwithstanding the foregoing or anything to the contrary contained in this Sub-Sublease, for the avoidance of doubt, Sub-Subtenant shall not be required to obtain Sub-Sublandlord’s consent with respect to any Sub-Subtenant Alterations. Sub-Subtenant shall reimburse Sublandlord and/or Master Landlord, if applicable, in accordance with the terms and conditions of the Sublease and/or Master Lease, for costs Sub-Sublandlord may be liable for under the Master Lease or Sublease in connection with reviewing Sub-Subtenant’s proposed Sub-Subtenant Alterations. For the avoidance of doubt, in no event shall Sub-Sublandlord charge a separate construction management or oversight fee or for any of its third party costs or expenses in connection with this Sub-Sublease.
(b)Removal. Prior to expiration of the Sub-Sublease Term or earlier termination of this Sub-Sublease, if Sublandlord or Master Landlord so directs in accordance with the terms of the
11



Sublease or Master Lease, as applicable, Sub-Subtenant shall remove all of the Sub-Subtenant Alterations and restore the Premises to the same condition as of the Sub-Sublease Term Commencement Date, ordinary wear and tear excepted. Notwithstanding the foregoing or anything to the contrary contained in this Sub-Sublease, Sub-Sublandlord shall not be permitted to require Sub-Subtenant to remove or restore any Sub-Subtenant Alterations, including any computer, security, roof equipment or installations, and telecommunications wiring and cable and other related wiring, unless either Master Landlord or Sublandlord requires such removal or restoration of such Sub-Subtenant Alterations in accordance with the terms of the Sublease or Master Lease, as applicable. For the avoidance of doubt, notwithstanding anything to the contrary contained in this Sub-Sublease, Sub-Subtenant shall not be required to remove or otherwise restore any alterations, improvements or additions existing as of the Sub-Sublease Term Commencement Date, and Sub-Subtenant shall not assume any restoration obligations of Sub-Sublandlord or Sublandlord with respect to such alterations, improvements or additions.
13.Assigning and Subletting.
(a)Consent Required. Sub-Sublandlord shall have all of the rights of Master Landlord under Section 22 of the Master Lease, as if Sub-Sublandlord were the “Landlord” and Sub-Subtenant were the “Tenant”. Notwithstanding the foregoing or anything to the contrary contained in this Sub-Sublease, Sub-Sublandlord shall have no right to recapture or otherwise terminate this Sub-Sublease in connection with any assignment, sublease or other transfer by Sub-Subtenant as described in Section 9.05 of the Sublease except if Sublandlord elects to recapture in accordance with the terms of the Sublease.
(b)No Release of Sub-Subtenant. Regardless of Sub-Sublandlord’s, Sublandlord’s and Master Landlord’s consent, no subletting or assignment shall release Sub-Subtenant of Sub-Subtenant’s obligation or alter the primary liability of Sub-Subtenant to pay the Rent and to perform all other obligations to be performed by Sub-Subtenant under this Sub-Sublease. The acceptance of Rent by Sub-Sublandlord from any other person shall not be deemed to be a waiver by Sub-Sublandlord of any provision of this Sub-Sublease. In the event of Default by Sub-Subtenant or any successor or assignee which remains uncured after any applicable notice and cure periods, if any, Sub-Sublandlord may proceed directly against Sub-Subtenant without the necessity of exhausting remedies against such assignee or successor.
14.Use. Sub-Subtenant shall use and occupy the Premises solely for those uses permitted by the Master Lease, the Sublease and the Consent to Sub-Sublease; provided, however, notwithstanding anything to the contrary contained in Section 1.03 of the Sublease, the parties acknowledge it is Sub-Subtenant’s intent to use the Premises for laboratory, assembly space, a full cooking kitchen(s)/café(s), and food delivery areas in addition to general office use, all as consistent with class A buildings of similar nature in the Cambridge market and in compliance with applicable laws. Sub-Sublandlord shall not object to Sub-Subtenant’s use of the Premises for any purpose provided that Sublandlord and Master Landlord shall agree to the same in writing.
15.Default. The occurrence of any of the following shall constitute a material breach of this Sub-Sublease and a “Default” by Sub-Subtenant: (a) failure to pay Rent within five (5) business days after written notice from Sub-Sublandlord to Sub-Subtenant of such late payment; and (b) all of
12



those items of default set forth in the Master Lease, which remain uncured after the cure period provided in the Master Lease, less the number of days set forth in Section 9(c) above.
16.Intentionally Omitted.
17.Confidentiality. Except as expressly permitted in this Section 17, neither party nor its agents, servants, employees, invitees and contractors will, without the prior written consent of the other party, disclose any Confidential Information (as hereinafter defined) of the other party to any third party. Information will be considered “Confidential Information” of a party if either: (a) it is disclosed by the party to the other party in tangible form and is conspicuously marked “Confidential”, “Proprietary” or the like; or (b) it is disclosed by one party to the other party in non-tangible form and is identified as confidential at the time of disclosure. In addition, notwithstanding anything in this Sub-Sublease to the contrary, the terms of this Sub-Sublease (but not its mere existence) will be deemed Confidential Information of each party. Other than the terms and conditions of this Sub-Sublease, information will not be deemed Confidential Information hereunder if such information: (i) is known to the receiving party prior to receipt from the disclosing party directly or indirectly from a source other than one having an obligation of confidentiality to the disclosing party; (ii) becomes known (independently of disclosure by the disclosing party) to the receiving party directly or indirectly from a source other than one having an obligation of confidentiality to the disclosing party; (iii) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Sub-Sublease by the receiving party; or (iv) is independently developed by the receiving party. The terms and conditions of this Sub-Sublease will cease being confidential if, and only to the extent that, they become publicly known, except through a breach of this Sub-Sublease by the receiving party. Each party will secure and protect the Confidential Information of the other party (including, without limitation, the terms of this Sub-Sublease) in a manner consistent with the steps taken to protect its own trade secrets and confidential information, but not less than a reasonable degree of care. Each party may disclose the other party’s Confidential Information where: (A) the disclosure is required by law or by an order of a court or other governmental body having jurisdiction after giving reasonable notice to the other party with adequate time for such other party to seek a protective order; (B) if in the opinion of counsel for such party, disclosure is advisable or necessary under any applicable securities laws regarding public disclosure of business information; (C) the disclosure is reasonably necessary and is to that party’s or its affiliates’ employees, officers, directors, attorneys, accountants, consultants and other advisors, or the disclosure is otherwise necessary for a party to exercise its rights and perform its obligations under this Sub-Sublease, so long as in all cases the disclosure is no broader than necessary and the party who receives the disclosure agrees prior to receiving the disclosure to keep the information confidential; (D) the disclosure is reasonably necessary for a party to conclude a business transaction; or (E) the disclosure is to Sublandlord or Master Landlord and their representatives and legal counsel in connection with obtaining the Consent to Sub-Sublease. Each party is responsible for ensuring that any Confidential Information of the other party that the first party discloses pursuant to this Section 17 is kept confidential by the person receiving the disclosure. Without limiting the generality of this Section 17, neither party will, directly or indirectly issue any press release or advertising, or otherwise use the other party’s name for any commercial purposes or use any of the other party’s trademarks, in each case, without the express prior written consent of the other party, to be granted or withheld in such party’s sole and absolute discretion.
13



18.Quiet Enjoyment. So long as Sub-Subtenant is not in Default under this Sub-Sublease, its quiet enjoyment of the Premises shall not be disturbed or interfered with by Sub-Sublandlord or anyone claiming by, through or under Sub-Sublandlord.
19.Notices. Sub-Sublandlord shall deliver to Sub-Subtenant copies of all written notices that Sub-Sublandlord shall send to, or receive from, Sublandlord or Master Landlord that are related to the Premises, simultaneously with sending such notices to Sublandlord or Master Landlord and promptly following Sub-Sublandlord’s receipt of any other written notice relating to the Premises. Whenever any notice or any other communication is required or permitted to be given under any provision of this Sub-Sublease (as, for example, where a party is permitted or required to “notify” another party), such notice or other communication shall be in writing, signed by or on behalf of the party giving the notice or other communication, and shall be deemed to have been given on the earliest to occur of (i) the date of the actual delivery, (ii) if mailed, three (3) business days after the date mailed by certified or registered mail, return receipt requested, with postage prepaid, or (iii) if sent with a reputable air or ground courier service, fees prepaid, the date on which such courier represents such notice will be available for delivery, in each case to the respective address(es) of the party to whom such notice is to be given as set forth below, or at such other address of which such party shall have given notice to the other parties as provided in this Section 19. Legal counsel for any party may give notice on behalf of such party. The parties intend that the requirements of this Section 19 cannot be waived or varied by course of conduct.
If to Sub-Sublandlord:
bluebird bio, Inc.
60 Binney Street
Cambridge, MA 02142
Attn: Chief Operating and Legal Officer

If to Sub-Subtenant:
Meta Platforms, Inc.
1 Hacker Way
Menlo Park, CA 94025
Attn: Director of Real Estate
with a copy to:
Meta Platforms, Inc.
1 Hacker Way
Menlo Park, CA 94025
Attn: Real Estate Counsel
with a copy to:
Paul Hastings LLP
101 California Street, 48th Floor
14




San Francisco, CA 94111
Attn: Stephen I. Berkman, Esq.
and a digital copy (for courtesy purposes only) to:
recelegal@fb.com
20.Signage. Sub-Subtenant shall be entitled to all signage in accordance with the terms and conditions of the Sublease and the Master Lease; provided, however, for purposes of Section 18.02 of the Sublease, Sub-Sublandlord shall request Sublandlord request that Master Landlord remove Sublandlord’s name from the monument sign located on the exterior of the Building (the “Monument Sign”), and if Sub-Subtenant elects in its sole and absolute discretion, replace with Sub-Subtenant’s signage on the Monument Sign at any time thereafter, all of which shall be at the sole cost of Sub-Subtenant.
21.Parking. Sub-Subtenant shall have the right to use Two Hundred Sixteen (216) parking spaces in the Garage at the then applicable monthly market rate, subject to the terms and conditions as set forth in the Master Lease, Consent to Sub-Sublease and the Sublease (the “Sublease Parking Rights”). If permitted by Master Landlord in the Consent to Sub-Sublease, Sub-Subtenant shall have the right to two (2) access cards per one (1) parking space to allow for a “spot sharing” plan with its employees. Sub-Subtenant shall have all rights and remedies available under the Sublease and Master Lease with respect to the Sublease Parking Rights. Notwithstanding anything to the contrary contained in Section 10(a) and Section 10(b) of the Master Lease, as between Sub-Sublandlord and Sub-Subtenant, Sub-Sublandlord shall have no obligations or liabilities to Sub-Subtenant relating in any way to Sub-Subtenant’s rights to park in the Garage, except as expressly set forth in Section 8(a) and Section 10 of this Sub-Sublease.
22.Successors and Assigns. This Sub-Sublease and everything herein contained shall extend to and bind and inure to the benefit of Sub-Sublandlord and its successors and assigns and Sub-Subtenant and its heirs, executors, administrators and permitted successors and assigns. No rights shall inure to the benefit of any assignee, sub-sub-subtenant or occupant unless the provisions of Section 13 of this Sub-Sublease are complied with.
23.Miscellaneous.
(a)Time of Essence. Time is of the essence with respect to the performance of every provision of this Sub-Sublease in which time of performance is a factor, including, without limitation, the giving of any notice required to be given under this Sub-Sublease or by law, the time periods for giving any such notice and for taking of any action with respect to any such notice.
(b)Partial Invalidity. If any term, provision or condition contained in this Sub-Sublease shall, to any extent, be invalid or unenforceable, the remainder of this Sub-Sublease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Sub-Sublease shall be valid and enforceable to the fullest extent possible permitted by law; provided that, if a material provision is adjudged void or unenforceable, the parties shall negotiate, in good faith, an equitable adjustment to such other provisions of this Sub-
15



Sublease as may be necessary or appropriate to effectuate as closely as possible the parties’ intent as evidenced by this Sub-Sublease.
(c)Entire Agreement. There are no oral agreements between the parties hereto affecting this Sub-Sublease and this Sub-Sublease constitutes the parties’ entire agreement with respect to the subleasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements, letters of intent, agreements and understandings, if any, between the parties, and none thereof shall be used to interpret or construe this Sub-Sublease. None of the terms, covenants, conditions or provisions of this Sub-Sublease can be modified, deleted or added to except in writing signed by the parties.
(d)Execution. Each party executing this Sub-Sublease represents and warrants to the other that it has been duly authorized to do so.
(e)Interpretation. Preparation of this Sub-Sublease has been a joint effort of the parties and the resulting document shall not be construed more severely against one of the parties than against the other.
(f)Exhibits. All Exhibits to this Sub-Sublease are a part hereof.
(g)Counterparts. This Sub-Sublease may be executed in counterparts with the same effect as if both parties had executed the same document. Both counterparts shall be construed together and shall constitute a single sublease. The signature pages of counterpart copies may be assembled to form one instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Sub-Sublease and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.
(h)Limited Liability. In no event shall the partners, principals, members, officers, stockholders, directors, employees or agents of either Sub-Sublandlord or Sub-Subtenant be personally liable under this Sub-Sublease. Notwithstanding anything in this Sub-Sublease to the contrary (for the avoidance of doubt, including any provisions incorporated into this Sub-Sublease), under no circumstances shall either party be liable to the other party hereunder for punitive, indirect or consequential damages, each of which is excluded by agreement of the parties.
24.Sub-Sublandlord’s Consent. In any instance when Sub-Sublandlord’s consent or approval is required under this Sub-Sublease, Sub-Sublandlord’s refusal to consent to or approve any matter or thing shall be deemed reasonable if, inter alia, such consent or approval has not been obtained from Master Landlord (if required under the Master Lease), or Sublandlord (if required under the Sublease). Notwithstanding anything to the contrary contained herein, in the event Master Landlord agrees to provide its consent where necessary pursuant to the Master Lease, and Sublandlord agrees to provide its consent where necessary pursuant to the Sublease, Sub-Sublandlord agrees it shall not unreasonably withhold, condition or delay its consent hereunder.
16



25.Brokers. Sub-Sublandlord and Sub-Subtenant each hereby represents and warrants that it has not dealt with any broker other than Jones Lange LaSalle and Cushman & Wakefield, in connection with this Sub-Sublease for the Premises. Each party shall indemnify the other against any cost or liability resulting from the indemnifying party’s breach of the foregoing representation and warranty. Sub-Sublandlord shall be responsible for any commissions owed to the foregoing named brokers, subject to and in accordance with the provisions of separate agreements. This provision shall survive the expiration or sooner termination of this Sub-Sublease.
26.Master Landlord’s and Sublandlord’s Consent. Master Landlord and Sublandlord have each provided written consent to this Sub-Sublease pursuant to that certain Consent to Sub-Sublease dated as of the Effective Date by and among Master Landlord, Sublandlord, Sub-Sublandlord and Sub-Subtenant (the “Consent to Sub-Sublease”). Sub-Sublandlord shall pay the fees and costs charged by Master Landlord and Sublandlord in connection with the request for their consent to this Sub-Sublease.
27.Furniture. On the Sub-Sublease Term Commencement Date, Sub-Sublandlord shall deliver the Premises with the furniture identified on Exhibit B attached hereto (the “Sub-Sublandlord’s Furniture”) in its “AS IS,” where is, condition. As of the Sub-Sublease Term Commencement Date, Sub-Sublandlord’s Furniture shall be sold to Sub-Subtenant for One Dollar ($1.00) under a bill of sale in the form provided in Exhibit C attached hereto (the “Bill of Sale”), and Sub-Subtenant shall be required to remove Sub-Sublandlord’s Furniture at the end of the Sub-Sublease Term. Sub-Sublandlord shall deliver title to the Sub-Sublandlord’s Furniture free and clear of all liens, judgments, security interests and encumbrances. Sub-Sublandlord shall deliver the Bill of Sale to Sub-Subtenant within ten (10) business days following the Sub-Sublease Term Commencement Date. Sub-Subtenant acknowledges and agrees that Sub-Sublandlord is not obligated to provide any other furniture, furnishings, or equipment in the Premises other than Sub-Sublandlord’s Furniture, and Sub-Subtenant agrees that it will be solely responsible for providing any other furniture, furnishings, and equipment necessary for Sub-Subtenant’s occupancy.
28.OFAC.
(a)Representations and Warranties. Each of Sub-Sublandlord and Sub-Subtenant represents and warrants that Sub-Sublandlord or Sub-Subtenant: (i) is not a person that is the target of any economic sanctions administered or enforced by the United States (including the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) and the U.S. Department of State), the United Nations, the European Union, and/or the United Kingdom; and (ii) is not owned or controlled by such a person.
(b)Compliance with Laws. Each of Sub-Sublandlord and Sub-Subtenant covenants and agrees (i) to comply with all requirements of applicable law relating to money laundering, anti-terrorism, trade embargos and economic sanctions, now or hereafter in connection with this Sub-Sublease, and (ii) to immediately notify the other party in writing if any of the representations, warranties, or covenants set forth in this paragraph or the preceding Section 28(a) are no longer true or have been breached or if Sub-Sublandlord or Sub-Subtenant has a reasonable basis to believe that they may no longer be true or have been breached.
17



(c)Event of Default; Indemnity. Sub-Sublandlord and Sub-Subtenant hereby agree to indemnify, defend (with counsel reasonably acceptable to the indemnified party) and hold the other party harmless against any and all claims, losses, damages (for the avoidance of doubt, expressly excluding indirect, special, incidental, punitive, or consequential damages (including loss of profits, production, anticipated savings, goodwill or business opportunities or business interruption)), and expenses arising out of or related to a breach of any of the representations, warranties or obligations set forth in Section 28(a) or Section 28(b) above. If either Sub-Sublandlord or Sub-Subtenant breaches any of the representations, warranties, or obligations set forth in Section 28(a) or Section 28(b) above, the non-breaching party may terminate this Sub-Sublease upon delivery of written notice to the breaching party.
29.Non-Discrimination. Sub-Subtenant is a federal contractor and maintains an equal opportunity/affirmative action program in accordance with applicable law. As a result, Sub-Sublandlord may be a covered subcontractor. In such a case, it must, in accordance with applicable law, afford equal employment opportunity to all of its applicants and employees, regardless of their race, color, national origin, sex, age, religion, marital status, sexual orientation, gender identity and gender expression, protected veteran status, disability, or other basis protected by law. If applicable, Sub-Sublandlord and Sub-Subtenant shall abide by the requirements of 41 CFR 60–1.4(a), 60–300.5(a) and 60–741.5(a). These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, sexual orientation, gender identity or national origin. Moreover, these regulations require that covered prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
30.U.S. Foreign Corrupt Practices Act. In connection with the negotiation and performance of this Sub-Sublease, Sub-Sublandlord, on behalf of itself and Sub-Sublandlord’s affiliates, all entities that it owns or controls, and all of Sub-Sublandlord’s owners, directors, officers, employees, representatives, and agents, represents and warrants that they have not engaged in and covenants that they shall refrain from offering, promising, paying, giving, authorizing the paying or giving of, soliciting, or accepting money or anything of value, which includes, but is not limited to, cash or a cash equivalent (including “grease”, “expediting” or facilitation payments), discounts, rebates, gifts, meals, entertainment, hospitality, use of materials, facilities or equipment, transportation, lodging, or promise of future employment), directly or indirectly, to or from (a) any Government Official (as hereinafter defined) to (i) influence any act or decision of a Government Official in his or her official capacity, (ii) induce a Government Official to use his or her influence with a government or instrumentality thereof, or (iii) otherwise secure any improper advantage; or (b) any person in any manner that would constitute bribery or an illegal kickback, or would otherwise violate applicable anti-corruption law and commercial bribery laws. As used in this Sub-Sublease, “Government Official” shall refer to any official or employee of any multinational, national, regional, or local government in any country, including any official or employee of any government department, agency, commission, or division; any official or employee of any government-owned or government-controlled enterprise; any official or employee of any public educational, scientific, or research institution; any political party or official or employee of a political party; any candidate for
18



public office; any official or employee of a public international organization; and any person acting on behalf of or any relatives, family, or household members of any of those listed above.
31.Estoppel Certificate. Sub-Subtenant shall, within ten (10) business days of written notice from Sub-Sublandlord, execute, acknowledge and deliver a statement in writing reasonably requested by Sub-Sublandlord and reasonably acceptable to Sub-Subtenant, (i) certifying that this Sub-Sublease is unmodified and in full force or effect (or, if modified, stating the nature of such modification and certifying that this Sub-Sublease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii) acknowledging to Sub-Subtenant’s actual knowledge that there are not any uncured defaults on the part of Sub-Sublandlord hereunder, or specifying such defaults if any are claimed, and (iii) setting forth such further factual information with respect to the status of this Sub-Sublease or the Premises as may be reasonably requested thereon. Sub-Sublandlord shall, within ten (10) business days of written notice from Sub-Subtenant, execute, acknowledge and deliver a statement in writing reasonably requested by Sub-Subtenant and reasonably acceptable to Sub-Sublandlord, (a) certifying that this Sub-Sublease and the Sublease are unmodified and in full force or effect (or, if modified, stating the nature of such modification and certifying that this Sub-Sublease and the Sublease as so modified are in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (b) acknowledging to Sub-Sublandlord’s actual knowledge that there are not any uncured defaults on the part of Sub-Subtenant hereunder or Sublandlord under the Sublease, or specifying such defaults if any are claimed, and (c) setting forth such further factual information with respect to the status of this Sub-Sublease, the Sublease or the Premises as may be reasonably requested thereon.
32.Health Policy. Notwithstanding anything to the contrary contained in this SubSublease, except in the event of an emergency, Sub-Landlord shall ensure that each of its employees, agents, contractors, subcontractors, laborers, visitors, guests and invitees and others under its control or direction accessing any portion of the Premises (collectively, “Visitors”) shall comply with Sub-Subtenant’s health requirements and policies as set forth in this Section 32 (“Health Policy”) when accessing the Premises. As of the Effective Date, the Health Policy requires (without limitation) that all persons accessing the Premises be fully vaccinated for COVID-19 (with no option for testing in lieu of). As used in this Section 32, “fully vaccinated” means that two (2) weeks have passed since the person (a) for persons vaccinated inside the United States, received their second dose in a 2-dose series (such as the Pfizer or Moderna vaccines) or received a single-dose vaccine (such as Johnson & Johnson’s Janssen vaccine) with a COVID-19 vaccine currently approved or authorized for emergency use by the U.S. Food and Drug Administration; or (b) for persons who were vaccinated outside of the United States, received a World Health Organization (WHO)-listed vaccine in accordance with manufacturer’s instructions. Sub-Subtenant may adjust the Health Policy from time to time in Sub-Subtenant’s sole but reasonable discretion and will provide Sub-Landlord with any applicable updates (individually and collectively, “Updates”). Except in the event of an emergency, any Visitor accessing the Premises will be required to (i) verify to Sub-Subtenant that such Visitor fully complies with the Health Policy as amended by Updates and (ii) provide Sub-Subtenant with evidence to Sub-Subtenant’s satisfaction that such Visitor complies with the Health Policy as amended by Updates (including, as of the Effective Date, an image of such Visitor’s COVID-19 vaccination record card or health document showing vaccination status together with official identification for such Visitor). Sub-Sublandlord and Sub-Subtenant agree that any failure of Master Landlord and Sublandlord to perform under the Master Lease or Sublease due to their
19



compliance with Section 32 of the Consent to Sub-Sublease shall not be breach or default of Sub-Sublandlord and Sub-Subtenant under this Sub-Sublease.
[Remainder of Page Intentionally Left Blank]

20



IN WITNESS WHEREOF, Sub-Sublandlord and Sub-Subtenant have duly executed this Sub-Sublease, as an instrument under seal, to be effective as of the Effective Date.

SUB-SUBLANDLORD:
BLUEBIRD BIO, INC.,
a Delaware corporation
By:/s/ Thomas Provencher
Name:Thomas Provencher
Title:Vice President, Operations Excellence
SUB-SUBTENANT:
META PLATFORMS, INC.,
a Delaware corporation
By:/s/ Nicholas Raby
Name:Nicholas Raby
Title:Director, N.A. Real Estate

[Signature Page to Sub-Sublease Agreement]
 EX-23.1 8 blue-20211231xexx231.htm EX-23.1 Document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
1.Registration Statement (Form S-3 No. 333-236489) of bluebird bio, Inc.,
2.Registration Statement (Form S-8 No. 333-189560) pertaining to the Second Amended and Restated 2002 Employee, Director and Consultant Plan, 2010 Stock Option and Grant Plan, 2013 Stock Option and Incentive Plan, and 2013 Employee Stock Purchase Plan of bluebird bio, Inc., and
3.Registration Statement (Form S-8 Nos. 333-194340, 333-202283, 333-209715, 333-216179, 333-223132, 333-229768, 333-236490, 333-253398 and 333-257135) pertaining to the 2013 Stock Option and Incentive Plan of bluebird bio, Inc.;

of our reports dated March 4, 2022, with respect to the consolidated financial statements of bluebird bio, Inc. and the effectiveness of internal control over financial reporting of bluebird bio, Inc., included in this Annual Report (Form 10-K) of bluebird bio, Inc. for the year ended December 31, 2021.

/s/ Ernst & Young LLP

Boston, Massachusetts
March 4, 2022

 EX-31.1 9 blue-20211231xexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS
I, Andrew Obenshain, certify that:
1.I have reviewed this Annual Report on Form 10-K of bluebird bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 4, 2022By:/s/ Andrew Obenshain
Andrew Obenshain
President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 10 blue-20211231xexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS
I, Gina Consylman, certify that:
1.I have reviewed this Annual Report on Form 10-K of bluebird bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 4, 2022By:/s/ Gina Consylman
Gina Consylman
Chief Financial Officer
(Principal Financial Officer and Duly Authorized Signer)


 EX-32.1 11 blue-20211231xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of bluebird bio, Inc. (the “Company”) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 4, 2022By:/s/ Andrew Obenshain
Andrew Obenshain
President, Chief Executive Officer and Director (Principal Executive Officer and Duly Authorized Signer)
Date: March 4, 2022By:/s/ Gina Consylman
Gina Consylman
Chief Financial Officer
(Principal Financial Officer and Duly Authorized Signer)


 EX-101.SCH 12 blue-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 1001003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004006 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1105101 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101102 - Disclosure - Description of the business link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Description of the business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2103103 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of significant accounting policies and basis of presentation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - Discontinued operations link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Discontinued operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Discontinued operations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Discontinued operations - Revenue and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Marketable securities link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Marketable securities - Summary of Marketable Securities Held (Detail) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Marketable securities - Summary of Marketable Securities Held (Detail) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Marketable securities - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Fair value measurements - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Fair value measurements - Schedule of Unrealized Loss on Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Property, plant and equipment, net link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - Property, plant and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2428414 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Property, plant and equipment, net - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2130109 - Disclosure - Restricted cash link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Restricted cash (Tables) link:presentationLink link:calculationLink link:definitionLink 2432416 - Disclosure - Restricted cash - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail) link:presentationLink link:calculationLink link:definitionLink 2134110 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 2335308 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - Accrued expenses and other current liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2138111 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2339309 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2143112 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2344310 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2445423 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) link:presentationLink link:calculationLink link:definitionLink 2146113 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2347311 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2448424 - Disclosure - Equity - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2449425 - Disclosure - Equity - Summary of Future Issuance of Common Stock Shares (Detail) link:presentationLink link:calculationLink link:definitionLink 2150114 - Disclosure - Intangible assets link:presentationLink link:calculationLink link:definitionLink 2351312 - Disclosure - Intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2452426 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2453427 - Disclosure - Intangible assets - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2154115 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2355313 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2456428 - Disclosure - Stock-based compensation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2457429 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) link:presentationLink link:calculationLink link:definitionLink 2458430 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail) link:presentationLink link:calculationLink link:definitionLink 2459431 - Disclosure - Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 2460432 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 2461433 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Detail) link:presentationLink link:calculationLink link:definitionLink 2162116 - Disclosure - 401(k) Savings plan link:presentationLink link:calculationLink link:definitionLink 2463434 - Disclosure - 401(k) Savings plan - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2164117 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2365314 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2466435 - Disclosure - Income taxes - Schedule of Components of Loss Before Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2467436 - Disclosure - Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2468437 - Disclosure - Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail) link:presentationLink link:calculationLink link:definitionLink 2469438 - Disclosure - Income taxes - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2470439 - Disclosure - Income taxes - Components of Deferred Tax Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2471440 - Disclosure - Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail) link:presentationLink link:calculationLink link:definitionLink 2172118 - Disclosure - Reduction in workforce link:presentationLink link:calculationLink link:definitionLink 2373315 - Disclosure - Reduction in workforce (Tables) link:presentationLink link:calculationLink link:definitionLink 2474441 - Disclosure - Reduction in workforce - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2475442 - Disclosure - Reduction in workforce - Accrued Liabilities Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2176119 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 2377316 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2478443 - Disclosure - Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2179120 - Disclosure - Selected quarterly financial data (unaudited) link:presentationLink link:calculationLink link:definitionLink 2380317 - Disclosure - Selected quarterly financial data (unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2481444 - Disclosure - Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 blue-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 blue-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 blue-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Goodwill Disposal Group, Including Discontinued Operation, Goodwill Federal income tax expense at statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Letter of Credit Letter of Credit [Member] Net loss per share Earnings Per Share, Policy [Policy Text Block] State Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Conversion and modification of awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modification of Awards Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modification of Awards Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Common stock warrants Common Stock Warrants [Policy Text Block] Common Stock Warrants Operating lease right-of-use assets Operating Lease, Right-of-Use Asset U.S. net operating loss carryforwards (federal and state) Deferred Tax Assets, Operating Loss Carryforwards Restructuring expenses Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Preferred stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Employee compensation Employee-related Liabilities, Current Income Statement Location Income Statement Location [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Research And Development And Selling, General And Administrative Expenses Research And Development And Selling, General And Administrative Expenses [Member] Research And Development And Selling, General And Administrative Expenses Segment information Segment Reporting, Policy [Policy Text Block] Operating lease right-of-use assets Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset Security Exchange Name Security Exchange Name Equity securities Investment at fair value Equity Securities, FV-NI, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Research and development Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Distribution of Assets, Liabilities and Stockholders' Equity Distribution of Assets, Liabilities and Stockholders' Equity [Table Text Block] Distribution of 2seventy bio Adjustments to Additional Paid In Capital, Separation Of Assets Adjustments to Additional Paid In Capital, Separation Of Assets Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Foreign currency transaction Foreign Currency Transactions and Translations Policy [Policy Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period Shares Vesting Of Restricted Stock Units Stock issued during period shares vesting of restricted stock units. Restricted cash and other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Computer equipment and software Computer Equipment And Software [Member] Computer equipment and software. Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Retirement Benefits [Abstract] Retirement Benefits [Abstract] Decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Interest receivable, write-off Interest Receivable, Write-Off Interest Receivable, Write-Off Entity File Number Entity File Number Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Collaboration research advancement Increase Decrease In Collaboration Research Advancement Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Canceled or forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Loss on fixed assets disposal Loss on fixed assets disposal Gain (Loss) on Disposition of Assets Discontinued operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Assembly Row lease Assembly Row Lease [Member] Assembly Row Lease Marketable securities, amortized cost / cost Marketable Securities Amortized Cost Marketable securities amortized cost. Subsequent Event Type Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense Amortization of Intangible Assets Increases (decreases) for tax positions related to prior periods Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Variable lease, cost Variable Lease, Cost Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Impairment Finite-Lived Intangible Assets, Accumulated Impairment Finite-Lived Intangible Assets, Accumulated Impairment Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Cost of royalty and other revenue Disposal Group, Including Discontinued Operation, Costs of Goods Sold Research and development Research and Development Expense [Member] Sale of Stock Sale of Stock [Axis] Building Building [Member] Private Placement Private Placement [Member] Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value Debt Securities, Available-for-sale, Fair Value [Abstract] Debt Securities, Available-for-sale, Fair Value Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Disposal Group Name [Axis] Disposal Group Name [Axis] Limitations on use of net operating losses and tax credit carryforwards, period Net Operating Losses And Tax Credit Carryforwards Limitations On Use Ownership Change Period Net operating losses and tax credit carry forwards limitations on use ownership change period. Equity Award Award Type [Domain] Outstanding stock options Equity Option [Member] Local Phone Number Local Phone Number Credit Facility Credit Facility [Domain] Assets Assets [Abstract] Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Goodwill, impaired, accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Research and development credit Effective Income Tax Rate Reconciliation Tax Credits Research And Development Effective income tax rate reconciliation tax credits research and development. Vested and expected to vest at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and    outstanding at December 31, 2021 and December 31, 2020 Preferred Stock, Value, Issued Property, plant and equipment Property, Plant and Equipment, Policy [Policy Text Block] Unrestricted Stock Unrestricted Stock [Member] Unrestricted Stock Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued expenses and other current liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Line Items] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Line Items] Schedule of share-based compensation arrangement by share-based payment award equity instruments other than options activity. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Number of transition services agreements Number of Transition Services Agreements Number of Transition Services Agreements Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Income tax expense, discontinued operations Discontinued Operation, Tax Effect of Discontinued Operation Purchases of property, plant and equipment included in accounts    payable and accrued expenses Capital Expenditures Incurred but Not yet Paid 50 Binney Street lease Fifty Binney Street Lease [Member] Fifty Binney Street Lease Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Tenant work allowance (in dollars per sq ft) Lease Arrangements, Tenant Work Allowance Per Square Foot Lease Arrangements, Tenant Work Allowance Per Square Foot Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Stock-based compensation capitalized into inventory Share-based Payment Arrangement, Amount Capitalized Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Number of operating segments Number of Operating Segments Loss on sale of Durham, North Carolina manufacturing facility Gain (Loss) on Disposition of Business Net loss per share applicable to common stockholders - basic (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Operating lease, expense Operating Lease, Expense Retention Program Retention Program [Member] Retention Program U.S. government agency securities and treasuries US Treasury and Government [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Deferred revenue, current portion Disposal Group, Including Discontinued Operation, Deferred Revenue, Current Unvested restricted stock awards outstanding (in shares) Unvested balance at beginning of period (in shares) Unvested balance at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Operating lease liability, net of current portion Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent Estimated Useful Lives of Assets Schedule Of Property Plant And Equipment Estimated Useful Lives Table [Text Block] Schedule of property plant and equipment, estimated useful lives. Other income (expense), net Disposal Group, Including Discontinued Operation, Other Expense 2seventy bio 2seventy bio [Member] 2seventy bio Prepaid expenses Prepaid Expense, Current Raw materials Inventory, Raw Materials, Gross ESPP shares and other Employee Stock Purchase Plan And Other [Member] Employee Stock Purchase Plan And Other Expenses related to 401(k) plan Defined Contribution Plan, Cost Shares (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Tax credit carryforwards (federal and state) Deferred Tax Assets, Tax Credit Carryforwards Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Marketable securities, unrealized gains Marketable Securities Unrealized Gains Marketable securities unrealized gains. Commercial paper Commercial Paper [Member] Net deferred taxes Deferred Tax Liabilities, Net Common shares reserved for future issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating cash flows used for operating leases Operating Lease, Payments Other non-cash items Other Noncash Income (Expense) Lease building space (in sq ft) Area Of Leased Space Area of leased space. Stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Restricted cash balance Total restricted cash Restricted Cash and Cash Equivalents Number of employees impacted Restructuring and Related Cost, Number of Positions Eliminated Stock based compensation Employee Benefits and Share-based Compensation Lease rent, annual increase percentage Lease Arrangements Annual Increase Percentage Lease arrangements annual increase percentage. Other revenue Other Revenue [Member] Other Revenue Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Schedule of Capitalization [Table] Schedule of Capitalization [Table] Research and development expenses Research and Development Expense, Policy [Policy Text Block] Annual lease rent per square foot (in dollars per sq ft) Lease Arrangements, Annual Lease Payment Per Square Foot Lease arrangements annual lease payment per square foot. Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Entity Voluntary Filers Entity Voluntary Filers Net loss per share from continuing operations - diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Plan Name Plan Name [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Limitations on use of net operating losses and tax credit carryforwards, percentage Net Operating Losses And Tax Credit Carryforwards Limitations On Change In Ownership Minimum Percentage Net operating losses and tax credit carryforwards limitations on change In ownership minimum percentage. Total assets Assets, Fair Value Disclosure Discontinued operations Discontinued Operations, Policy [Policy Text Block] Quoted prices in active markets (Level 1) Fair Value, Inputs, Level 1 [Member] Other income (expense), net Other Nonoperating Expense Income Net Policy Policy [Policy Text Block] Other nonoperating (expense) income net policy. Cash flows from investing activities: Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Collaborative arrangement revenue Collaboration Arrangement [Member] Collaboration arrangement. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Increases (decreases) for tax positions related to current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders' equity Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Net income (loss) per share from discontinued operations - diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Deferred revenue, current portion Contract with Customer, Liability, Current 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Scenario Scenario [Axis] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Service revenue Service [Member] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule of share-based compensation arrangement by share-based payment award equity instruments other than options activity. Additional paid-in capital Additional Paid in Capital U.S. government agency securities and treasuries US Government Agencies Debt Securities [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] 60 Binney Street lease 60 Binney Street lease Sixty Binney Street Lease [Member] Sixty Binney street lease. Cash and cash equivalents Cash Equivalents, at Carrying Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets Net loss per share Earnings Per Share [Text Block] Total assets Disposal Group, Including Discontinued Operation, Assets Receivables and other current assets Disposal Group, Including Discontinued Operation, Receivables and Other Current Assets Disposal Group, Including Discontinued Operation, Receivables and Other Current Assets Operating expenses: Operating Expenses [Abstract] Unrealized loss (gain) on equity securities Equity Securities, FV-NI, Gain (Loss) Entity Interactive Data Current Entity Interactive Data Current Interest income, net Interest Expense, Policy [Policy Text Block] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Marketable securities Marketable Securities, Current 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Unrestricted Stock Awards Unrestricted Stock Awards [Member] Unrestricted Stock Awards Selling, general and administrative Selling, General and Administrative Expense Canceled or forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Balance as of beginning of period Balance as of end of period Unrecognized Tax Benefits Total deferred tax assets Deferred Tax Assets, Gross Income Tax Authority Income Tax Authority [Domain] Restricted cash Cash and Cash Equivalents Disclosure [Text Block] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt securities, unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Loss from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) 12 months or greater Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Annual base rent of sub-sublease Lessor, Operating Lease, Payment to be Received, Year One Deferred revenue, net of current portion Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent Current liabilities: Liabilities, Current [Abstract] Lease arrangements annual rent increase percentage Lessee, Operating Lease, Annual Rent Increase Percentage Lessee, Operating Lease, Annual Rent Increase Percentage Issuance of common stock Stock Issued During Period, Value, New Issues Restructuring Plan [Domain] Restructuring Plan [Domain] Summary of Provision for (Benefit from) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock-based compensation Share-based Payment Arrangement [Text Block] Option Conversion Awards Option Conversion Awards [Member] Option Conversion Awards Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Inventory Inventory Disclosure [Text Block] Leases Lessee, Leases [Policy Text Block] Selling, general and administrative expense related to transition services agreement Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Accounting Policies [Abstract] Accounting Policies [Abstract] Outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues July 2021 reduction July 2021 Reduction [Member] July 2021 Reduction Accrued professional fees Accrued Professional Fees, Current Marketable securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Federal Current Federal Tax Expense (Benefit) Total operating lease liabilities Operating Lease, Liability Document Transition Report Document Transition Report Net loss from continuing operations Net loss from continuing operations Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Common stock, $0.01 par value, 125,000 shares authorized; 71,115 and 66,432 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Total liabilities Disposal Group, Including Discontinued Operation, Liabilities Expected weighted-average period related to unvested stock options, restricted stock awards and employee stock purchase plan Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unvested balance at beginning of period (in dollars per share) Unvested balance at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies Note 11 Commitments and Contingencies Leases Lessee, Operating Leases [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Royalty and other revenue Royalty And Other Revenue [Member] Royalty And Other Revenue Entity Emerging Growth Company Entity Emerging Growth Company Excess inventory reserve Inventory Write-down Vesting of restricted stock units Stock Issued During Period Value Vesting Of Restricted Stock Units Stock issued during period value vesting of restricted stock units. ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Foreign Deferred Foreign Income Tax Expense (Benefit) Auditor Name Auditor Name Cover [Abstract] Total operating expenses Total operating expenses Costs and Expenses Marketable securities Marketable Securities, Policy [Policy Text Block] Interest income, net Disposal Group, Including Discontinued Operation, Interest Income Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Income Tax Authority Income Tax Authority [Axis] Proceeds from stock offering Sale of Stock, Consideration Received on Transaction Milestone paid Contractual Obligation Milestone Paid Contractual obligation milestone paid. Financial Instrument [Axis] Financial Instrument [Axis] Selling, general and administrative Selling, General and Administrative Expenses [Member] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Income tax examination, penalties and interest accrued Income Tax Examination, Penalties and Interest Accrued Total operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Warrant price per share (in dollars per share) Class Of Warrant Or Right, Effective Price Per Share Class Of Warrant Or Right, Effective Price Per Share 2023 Purchase Obligation, to be Paid, Year Two Office equipment Office Equipment [Member] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Pre-funded warrants Pre-funded Warrants [Member] Pre-funded Warrants Options to purchase common stock Share-based Payment Arrangement, Option [Member] Upfront payment for purchase of furniture and equipment Upfront Payment for Purchase of Furniture and Equipment Upfront Payment for Purchase of Furniture and Equipment Costs from public offering Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Comprehensive loss Comprehensive Income, Policy [Policy Text Block] Amount paid Payments for Restructuring Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common stock Common Stock [Member] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Loss from operations Loss from operations Operating Income (Loss) Contributions to the 401(k) plan Defined Contribution Plan, Employer Discretionary Contribution Amount Property, Plant and Equipment Property, Plant and Equipment [Table] In-licensed rights In-licensed Rights [Member] In-licensed Rights Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Operating lease liability, current portion Operating Lease, Liability, Current Debt securities, unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Summary of significant accounting policies and basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Realized gain (loss) recognized on sale Debt Securities, Available-for-sale, Realized Gain (Loss) Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Reduction in workforce Restructuring and Related Activities Disclosure [Text Block] Additional paid-in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash paid during the period for income taxes Income Taxes Paid Number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Restricted stock unit conversion awards Restricted Stock Unit Conversion Awards [Member] Restricted Stock Unit Conversion Awards 2013 Stock Option and Incentive Plan Two Thousand Thirteen Stock Option And Incentive Plan [Member] Two thousand thirteen stock option and incentive plan Other income (expense), net Other Nonoperating Income (Expense) Operating loss carryforwards, without expiration dates Operating Loss Carryforwards, Without Expiration Dates Operating Loss Carryforwards, Without Expiration Dates Accrued manufacturing costs Accrued Manufacturing Costs Current Accrued manufacturing costs current. Issuance of unrestricted stock awards to settle accrued employee compensation Stock Issued Purchase of property, plant and equipment Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Deferred revenue Deferred Tax Assets, Deferred Income Maximum Maximum [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Deferred tax assets: Deferred Tax Assets, Net [Abstract] Summary of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value 2024 and thereafter Purchase Obligation, to be Paid, After Year Two Purchase Obligation, to be Paid, After Year Two Other Other [Member] Other Summary of Future Minimum Commitments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Operating loss carryforwards Operating Loss Carryforwards Conversion and modification of awards (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modifications in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modifications in Period, Weighted Average Exercise Price Increase in shares authorized (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Net assets transferred to 2seventy bio Net assets transferred to 2seventy bio Disposal Group, Including Discontinued Operation, Net Assets Transferred Disposal Group, Including Discontinued Operation, Net Assets Transferred Exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Increase in common stock available for issuance under 2013 plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period Operating lease liabilities Lessee, Increase (Decrease) In Operating Lease, Liabilities Lessee, Increase (Decrease) In Operating Lease, Liabilities Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Cost of product revenue Cost of Product Revenue Policy [Policy Text Block] Cost of Product Revenue Policy Intangible assets Intangible Assets Disclosure [Text Block] Estimated useful lives of assets Property, Plant and Equipment, Useful Life Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Retirement Plan Type Retirement Plan Type [Axis] Supplemental cash flow disclosures: Noncash Investing and Financing Items [Abstract] Reconciliation of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Concentrations of credit risk and off-balance sheet risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Fair Value, Measurement Frequency Measurement Frequency [Domain] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Payment of termination fee Lessee, Operating Lease, Termination Fee Lessee, Operating Lease, Termination Fee Rate of area for sublease per square feet (in dollars per sq ft) Rate of Area for Sublease Per Square Feet Rate of Area for Sublease Per Square Feet Discontinued Operations and Disposal Groups [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Lease period Lessee, Operating Lease, Term of Contract Marketable securities, unrealized losses Marketable Securities Unrealized Loss Marketable securities unrealized loss. Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchase of common stock under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Schedule of collateralized bank account of financial institution Restrictions on Cash and Cash Equivalents [Table Text Block] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Proceeds from exercise of stock options and ESPP contributions Proceeds from Stock Options Exercised Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax (expense) benefit Total income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Amendment Flag Amendment Flag Equity securities, unrealized losses Equity Securities Unrealized Loss Equity securities unrealized loss. Equity Components Equity Components [Axis] Lessee, operating lease, annual expense Lessee, Operating Lease, Annual Expense Lessee, Operating Lease, Annual Expense Selling, general and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Entity Tax Identification Number Entity Tax Identification Number Accumulated other comprehensive loss Accumulated Other Comprehensive Income Net Gain Loss [Member] Accumulated other comprehensive income net gain loss. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities Antidilutive Securities [Axis] Investment Type Investment Type [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Initial term of transition services agreement Transition Services Agreement, Initial Term Transition Services Agreement, Initial Term Sale of Stock Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventory Inventory, Net Stock-based compensation Share-based Payment Arrangement [Policy Text Block] Issuance of pre-funded warrants Adjustments to Additional Paid in Capital, Warrant Issued Federal Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] 2027 and thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Approximately valuation allowance increased Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Product and Service Product and Service [Axis] Property, Plant and Equipment, Type Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Preferred stock, par value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2020 Annual Incentive Program 2020 Annual Incentive Program [Member] 2020 Annual Incentive Program Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Collaboration research advancement, current portion Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Current Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Current Change in fair value of contingent consideration Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration, Liability Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration, Liability Weighted average grant date fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component Equity Component [Domain] Short-term lease, cost Short-term Lease, Cost Issuance of unrestricted stock awards to settle accrued employee compensation (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Audit Information [Abstract] Audit Information 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Share-based compensation arrangement by share-based payment award, shares issued in period (less than) (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Disposal Group Name [Domain] Disposal Group Name [Domain] Incremental fair value from modification Share-based Payment Arrangement, Plan Modification, Incremental Cost Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Marketable securities Marketable Securities, Noncurrent Statement [Line Items] Statement [Line Items] Lessee, operating lease, termination notice period, after stage 5 commencement Lessee, Operating Lease, Termination Notice Period, After Stage 5 Commencement Lessee, Operating Lease, Termination Notice Period, After Stage 5 Commencement Intangible asset impairment Impairment of Intangible Assets, Finite-lived Accruals and other Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Restricted cash included in restricted cash and other non-current assets Restricted Cash, Noncurrent Weighted- average exercise price per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Debt securities, available-for-sale, noncurrent Debt Securities, Available-for-sale, Noncurrent Issuance of unrestricted stock awards to settle accrued employee compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture U.S. Domestic Tax Authority [Member] Retirement Plan Type Retirement Plan Type [Domain] Liabilities Liabilities [Abstract] Summary of Stock-Based Compensation Expense by Award Type Share-based Payment Arrangement, Cost by Plan [Table Text Block] Debt securities, fair value Marketable securities Debt Securities, Available-for-sale Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Loss on unrecoverable upfront payment Loss on Unrecoverable Upfront Payment Loss on Unrecoverable Upfront Payment 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Non-cancelable Contractual Obligations Long-term Purchase Commitment [Table Text Block] Prepaid expenses Disposal Group, Including Discontinued Operation, Prepaid Expenses Disposal Group, Including Discontinued Operation, Prepaid Expenses Common stock, number of votes (in votes per share) Common Stock, Number Of Votes, Per Common Share Common Stock, Number Of Votes, Per Common Share Purchases of marketable securities Payments to Acquire Marketable Securities Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Percentage of automatic increase in shares reserved and available for issuance determined based on shares outstanding Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Percentage Share-based compensation arrangement by share-based payment award number of shares authorized increase percentage. Property, Plant and Equipment, Type Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] Less valuation allowance Deferred Tax Assets, Valuation Allowance Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Auditor Location Auditor Location Current liabilities of discontinued operations Total current liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Total Debt Securities, Available-for-sale, Unrealized Loss Position Debt securities, amortized cost / cost Debt Securities, Available-for-sale, Amortized Cost Total revenues Disposal Group, Including Discontinued Operation, Revenue Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] 401(k) Savings plan Retirement Benefits [Text Block] Use of estimates Use of Estimates, Policy [Policy Text Block] Unrestricted stock awards granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Document Annual Report Document Annual Report Schedule of Stock-Based Compensation Expense by Classification Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Forecast Forecast [Member] Title of 12(b) Security Title of 12(b) Security 401 (k) Four Hundred And One K [Member] Four hundred and one k. Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Total assets Assets Plan Name Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Document Type Document Type Lessee, operating lease, termination notice period Lessee, Operating Lease, Termination Notice Period Lessee, Operating Lease, Termination Notice Period Summary of Restricted Common Stock Awards Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Research and development Research and Development Expense Product and Service Product and Service [Domain] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Lease extension terms Lessee, Operating Lease, Renewal Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity securities, amortized cost / cost Equity Securities, FV-NI, Cost Operating lease right-of-use assets Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Assets Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Assets Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Measurement Frequency Measurement Frequency [Axis] Marketable securities Disposal Group, Including Discontinued Operation, Marketable Securities, Current Disposal Group, Including Discontinued Operation, Marketable Securities, Current Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Tax credit carryforward amount Tax Credit Carryforward, Amount Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and fixtures Furniture and Fixtures [Member] Lease, Cost Lease, Cost [Table Text Block] Corporate bonds Corporate Bond Securities [Member] Collateralized letter of credit Letter Of Credit Related To New Lease Agreement Letter of credit related to new lease agreement. Tax Credit Carryforward Tax Credit Carryforward [Axis] Equity securities, unrealized gains Equity Securities Unrealized Gain Equity securities unrealized gain. Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Net loss per share applicable to common stockholders - diluted (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted State and Local Jurisdiction State and Local Jurisdiction [Member] Common stock price per share (in dollars per share) Sale of Stock, Price Per Share Product revenue Product [Member] Intangible assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Lessee, operating lease, termination fees, term Lessee, Operating Lease, Termination Fees, Term Lessee, Operating Lease, Termination Fees, Term Components Of Income Tax Expense Benefit [Line Items] Components Of Income Tax Expense Benefit [Line Items] Components of income tax expense benefit. Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Selected quarterly financial data (Unaudited) Quarterly Financial Information [Text Block] Accrued restructuring charges Amounts accrued at December 31, 2021 Restructuring Reserve, Current Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Lessee, operating lease, maximum potential annual maintenance fees Lessee, Operating Lease, Maximum Potential Annual Maintenance Fees Lessee, Operating Lease, Maximum Potential Annual Maintenance Fees Operating lease liability, current portion Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current Net loss per share from continuing operations - basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Accrued clinical and contract research organization costs Accrued Clinical And Contract Research Organization Costs Current Accrued clinical and contract research organization costs current. Reconciliation of Income Tax Provision (Benefit) Computed at the Statutory Federal Income Tax Rate to Effective Income Tax Rate (Provision) Benefit as Reflected in the Financial Statements Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Fair value measurements Fair Value Disclosures [Text Block] Restructuring expense Charges Restructuring Charges Accounts payable Accounts Payable, Current 50 Binney Street sublease Fifty Binney Street Sublease [Member] Fifty Binney Street Sublease Schedule of Capitalization [Line Items] Schedule of Capitalization [Line Items] Depreciation and amortization Depreciation, Depletion and Amortization Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Net loss per share from discontinued operations - diluted (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Business combinations Business Combinations Policy [Policy Text Block] Inventory Increase (Decrease) in Inventories Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Capitalized license fees and research and development expenses Deferred Tax Assets Capitalized License Fee And Research And Development Expenses Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Collaboration research advancement, net of current portion Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Noncurrent Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Noncurrent Cost of product revenue Cost of Goods and Services Sold Revenue: Revenues [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Restructuring and Related Activities [Abstract] Document Period End Date Document Period End Date Accrued goods and services Accrued Goods and Services, Current Accrued Goods and Services, Current Stock-based compensation Deferred Tax Assets Stock Based Compensation Purchase of intangible assets Purchase of intangible assets Payments to Acquire Intangible Assets Proceeds from sale of Durham, North Carolina manufacturing facility Proceeds from Divestiture of Businesses Entity Central Index Key Entity Central Index Key 2013 Employee Stock Purchase Plan Two Thousand Thirteen Employee Stock Purchase Plan E S P P [Member] Two thousand thirteen employee stock purchase plan ESPP. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Quarterly Financial Information Quarterly Financial Information [Table Text Block] Shares (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] State income tax, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State Deferred State and Local Income Tax Expense (Benefit) Total lease cost Lease, Cost Summary of Property, Plant and Equipment Net Property, Plant and Equipment [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Market capitalization required for release of liability Market Capitalization Required for Release of Liability Market Capitalization Required for Release of Liability Income Statement Location Income Statement Location [Domain] Increases (decreases) for tax positions related to prior periods Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Interest receivable Interest Receivable Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Property, plant and equipment, net Property, Plant and Equipment Disclosure [Text Block] Public Offering Public Offering [Member] Public Offering Other non-current liabilities Other Liabilities, Noncurrent Unrealized losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract] Cash, cash equivalents and marketable securities Investments and Cash Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Marketable securities, fair value Marketable Securities Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Net loss per share from discontinued operations - basic (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Total property, plant and equipment Property, Plant and Equipment, Gross Inventory, Total Inventory, Gross Unrealized gain (loss) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Discontinued Operations, Disposed of by Means Other than Sale, Spinoff Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] Total Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Total revenues Total revenues Revenues Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Marketable securities Disposal Group, Including Discontinued Operation, Marketable Securities, Noncurrent Disposal Group, Including Discontinued Operation, Marketable Securities, Noncurrent Vested and expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Finished goods Inventory, Finished Goods, Gross Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-sale Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Net income (loss) per share from discontinued operations - basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Stock options Employee And Non Employee Stock Option [Member] Employee and non employee stock option. Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Permanent differences Effective Income Tax Rate Reconciliation Permanent Differences Effective income tax rate reconciliation permanent differences. Stock-based compensation expense Share-based Payment Arrangement, Expense Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Entity Current Reporting Status Entity Current Reporting Status Weighted-average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Components Of Income Tax Expense Benefit [Table] Components Of Income Tax Expense Benefit [Table] Components of income tax expense benefit. Effective income tax rate (expense) benefit Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Lentiviral Vector Manufacturing Facility Lentiviral Vector Manufacturing Facility [Member] Lentiviral Vector Manufacturing Facility Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Investments Investments [Domain] Restricted cash included in receivables and other current assets Restricted Cash, Current Proceeds from sale of equity securities Proceeds from Sale and Maturity of Marketable Securities Payables and Accruals [Abstract] Payables and Accruals [Abstract] Reserve for excess inventory Inventory Valuation Reserves Schedule Components of Loss Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Construction-in-progress Construction in Progress [Member] Cash, cash equivalents and restricted cash at beginning of year Cash, cash equivalents and restricted cash at end of year Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Current assets: Assets, Current [Abstract] Payment for purchase of furniture and equipment, upon lease commencement Payment for Purchase of Furniture and Equipment, Upon Lease Commencement Payment for Purchase of Furniture and Equipment, Upon Lease Commencement Number of companies Number Of Companies Number Of Companies Cost Finite-Lived Intangible Assets, Gross Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Interest income, net Interest Income (Expense), Nonoperating, Net Leases [Abstract] Leases [Abstract] Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income taxes Income Tax, Policy [Policy Text Block] Impairment of long-lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Disposal Group Classification [Domain] Disposal Group Classification [Domain] Net income (loss) from discontinued operations Net loss from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue recognition Revenue from Contract with Customer [Policy Text Block] Exercise of stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 2022 Purchase Obligation, to be Paid, Year One Intrinsic value of restricted stock units vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Conversion and modification of awards (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Conversions and Modifications, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Conversions and Modifications, Weighted Average Grant Date Fair Value Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Fair value, measurements, recurring Fair Value, Recurring [Member] Other income (expense), net Disposal Group, Including Discontinued Operation, Other Income Lessee, operating lease, monthly expense Lessee, Operating Lease, Monthly Expense Lessee, Operating Lease, Monthly Expense Income taxes Income Tax Disclosure [Text Block] Non-current liabilities of discontinued operations Non-current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Non-current assets of discontinued operations Non-current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Summary of Stock Option Activity Under Plan Share-based Payment Arrangement, Option, Activity [Table Text Block] Receivables and other current assets Receivables And Other Current Assets Receivables and other current assets. Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Revenue and Expenses for Discontinued Operations Summary of Significant Non-Cash Items and Capital Expenditures for Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Weighted-average number of common shares used in computing net loss per share - basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Lessee, operating lease, maximum potential annual maintenance and production fees Lessee, Operating Lease, Maximum Potential Annual Maintenance And Production Fees Lessee, Operating Lease, Maximum Potential Annual Maintenance And Production Fees Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Total purchase commitments Purchase Obligation Credit Facility Credit Facility [Axis] Entity Address, Address Line One Entity Address, Address Line One Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Purchase of common stock under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Cash flows from operating activities: Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Principles of consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Aggregate intrinsic value (in thousands) Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Share based compensation arrangement by share based payment award options aggregate intrinsic value. Weighted- average contractual life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term Employee stock purchase plan and other Employee Stock Purchase Plan [Member] Employee stock purchase plan. Defined Contribution Plan [Table] Defined Contribution Plan [Table] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date Conversion and modification of awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Converted and Modified in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Converted and Modified in Period Current assets of discontinued operations Total current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Operating loss carryforwards, with expiration dates Operating Loss Carryforwards, With Expiration Dates Operating Loss Carryforwards, With Expiration Dates Summary of Marketable Securities Held Marketable Securities [Table Text Block] Statement [Table] Statement [Table] Lessee, operating sublease, payment commencement, term Lessee, Operating Sublease, Payment Commencement, Term Lessee, Operating Sublease, Payment Commencement, Term Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Unrecognized stock- based compensation expense related to unvested stock options, restricted stock awards and employee stock purchase plan Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Summary of Future Issuance of Common Stock Shares Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of common stock reserved for future issuance. Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Restricted cash and other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Reduction of right of use asset and associated lease liability due to lease reassessment Reduction Of Right-of-Use Asset And Associated Lease Liability Due To Reassessment Reduction Of Right-of-Use Asset And Associated Lease Liability Due To Reassessment Subsequent Event Subsequent Event [Member] Loss before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Net Finite-Lived Intangible Assets, Net Net cash transferred to 2seventy bio at separation Payments of Distributions to Affiliates Goodwill Goodwill April 2021 reduction April 2021 Reduction [Member] April 2021 Reduction Foreign differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Inventory Inventory, Policy [Policy Text Block] Foreign Current Foreign Tax Expense (Benefit) Scenario, Unspecified Scenario [Domain] Description of the business Nature of Operations [Text Block] Adjustments to reconcile net loss to net cash used in operating    activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type Subsequent Event Type [Axis] Operating lease cost Operating Lease, Cost Conversion ratio Common Stock, Convertible, Conversion Ratio Common Stock, Convertible, Conversion Ratio Manufacturing Facility Manufacturing Facility [Member] 12 months or greater Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Share of collaboration loss Disposal Group, Including Discontinued Operation, Share of Collaboration Loss Disposal Group, Including Discontinued Operation, Share of Collaboration Loss Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Accounting Standards Update 2016-02 [Member] EX-101.PRE 16 blue-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 17 blue-20211231_g1.jpg begin 644 blue-20211231_g1.jpg M_]C_X 02D9)1@ ! 0$!2@%* #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" R?#S,# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKF? M'/Q-\(?#'3?[0\7^*-'\,61^[-JU]';*WLN]AN/L.:\ULOVX/@%J&H&RB^+G MA19@=NZ;44BCSG'$C84_G0![A15+1M;T[Q%IL&HZ3?VNJ:?.-T5W9S+-%(/5 M74D$?0U=H ***YGQS\3/"/PQTW^T/%WB?1_#%EVFU:^CME;V7>PW'V'- '34 M5X;%^W)\ )KY[1?BYX5$J#)9M058^W1S\IZ]CZ^AKUWPWXJT7QEI<>I^']8L M-'[.63R8[C5+R. MVC=R"0@9V +8!..N : -FBO/_P#AH3X6?]%+\'_^#ZU_^.5W-C?6VIV5O>6= MQ%=VEQ<-Q X>.1&&596'!!!!!'!!H GHJKJ>J6>BZ?@45D>&/&&@^-M M/:_\.ZWIVO6*R&%KK2[N.YB#@ E"R$C< P..O(]:Q==^,WP_\+ZK/I>L^.?# M>D:G;D":SOM7MX9H\@,-R,X(R"#R.A% '8T5Y_\ \-"?"S_HI?@__P 'UK_\ MM.H M **H:[K^F>%]*GU36=1M-(TRW ,UY?3K##'DA1N=B ,D@BBB@ HKS_\ X:$^ M%G_12_!__@^M?_CE'_#0GPL_Z*7X/_\ !]:__'* /0**XC3_ (Y?#?5KE;>Q M^(/A:\N&^[#;ZU;.Y^@#YKM8Y%EC5T8.C#*LIR"/44 .HILDB0QM)(RHB@LS M,< =237"0_'[X87$R11?$?PC++(P5(TUVU+,Q. !)R: .]HHK \9?$#PQ\ M.=+.I^*O$6E>&]/Y_P!*U:\CMHR1V#.0"?84 ;]%>%']NK]G\7PM/^%M^%_- M_O?;1Y?3/^L^[^OMUKUGPCXZ\-_$#2_[3\+^(-+\2:=NV_;-(O8[J+.,XWQL M1G\: -RBBB@ HK'\5>,M \#:3)JGB37--\/Z;'R]YJEW';0K]7<@?K7DC?MR M_ ".]2U/Q<\*F5QN#"_4Q]^KCY0>.A/IZB@#W.BN>\%_$3PM\2-+_M'PGXDT MGQ+8<9N-)O8[E!GL2C'!]CZ5T- !16?KWB'2O"NDSZIK>IV>CZ9;[?.O;^=( M(8]S!5W.Y"C+, ,GDD#O7/:%\9? 'BC58-,T;QSX;U?4I\B*SL=7MYYI, L= MJ*Y)P 3P.@- '8T45G>(/$FD^$]*FU37-4LM&TR$J);S4+A((4W$*NYW( R2 M ,GDD4 :-%,= UV_$9E-KIFJ07$H0$ MM1R< D<^X MKJJ "BBB@ HHKS_Q]^T%\,OA;>):>+O'_ASP[>M]VUU#4X8IC[^66W8]\=QZ MT >@45XOX=_;0^!7BJZBMM-^+'A5[B5_+CBGU*.!G;&< 2%<]>/7I7LEO<17 MEO'/!*DT,BATDC8,K*1D$$=0: )***Y?Q1\4_!?@?4(['Q'XOT'0+Z2(3I;: MIJ<%M(T9)4.%=@2I*L,],J?2@#J**\__ .&A/A9_T4OP?_X/K7_XY1_PT)\+ M/^BE^#__ ?6O_QR@#T"BN/T'XR> ?%6K0:7HGCCPWK&IW&[R;*PU:WGFDVJ M6;:B.6.%4DX' !/:NPH ***9+*D,;R2.L<: LSLM_XBUO3M!L6D$*W6J7<=M$7()"!G(&XA2<=> M#Z5A:/\ &OX>>(M3M]-TKQYX9U/4;AMD-I9ZQ;RRRMZ*BN23[ 4 =I1110 4 M5P,O[0'POAD>.3XD>$8Y$)5D;7;4%2.H(\SK6UJ7Q,\(:-X?LM>U#Q5HECH= M\0MKJ=SJ,,=M<$@D".4L%8D*QX)X!]* .DHKS_\ X:$^%G_12_!__@^M?_CE M'_#0GPL_Z*7X/_\ !]:__'* /0**\_\ ^&A/A9_T4OP?_P"#ZU_^.5U_A_Q) MI/BS2H=4T/5++6=,F+"*\T^X2>%]I*MM="0<$$'!X(- &C1161XG\8:#X)T] M;_Q%K>G:#8M((5NM4NX[:(N02$#.0-Q"DXZ\'TH UZ*Y#P_\8O 7BS58=+T/ MQOX?_ M /#0GPL_Z*7X/_\ !]:__'*OZ/\ &;X?^(KH6NE>.?#>IW)( AL]7MY7.>G" MN30!V-%%% !1110 445QGQ ^-'@'X4QQMXR\::#X7,G^K35=1BMWD_W59@6_ M 4 =G17BF@_MK? ?Q)?"SL?BSX4-PS;%6XU*.#WK7LMI=P7]K% M_$/PK:7EO(T,UO M/K=LDD3J2&1E+Y# @@@\@B@#N:*@L;ZVU2QM[VRN(KNSN(UFAN('#QRHP!5U M8<%2"""."#4] !17!3?'[X86\SQ2_$?PC%+&Q5XWUVU#*P.""#)P:[N.1)HU MDC971@&5E.00>A!H =17#7WQV^&NEWUQ97OQ#\*VEY;R-#-;SZW;))$ZDAD9 M2^0P(((/((K2\+_%#P;XXO9;/PYXMT+Q!=Q1^=);Z7J4-S(B9 W%48D#) ST MR10!T]%%G!H MZFBN(TWXY?#C6M0MK#3_ (@>%KZ^NI%A@M;;6K:265V.%155R68D@ #DUTWB M#Q)I/A/2IM4US5++1M,A*B6\U"X2"%-Q"KN=R ,D@#)Y)% &C17(>'_C%X"\ M6:K#I>A^-_#FLZG,&,5GI^K6\\S[06;:B.2< $G X -=?0 45E>)/%FB>#=- M_M'Q!K.GZ%I^\1_:M2NDMXMQZ+O<@9.#QGM65X9^*_@CQIJ)T_P]XQT#7;\1 MF4VNF:I!<2A 0"VU')P"1S[B@#JJ*JZIJMEHEC+>ZC>6]A9Q8,EQ=2K'&F2 M,LQ ') _&LC2_B)X4UN^BLM.\3:/?WDN1';VM_%)(^ 2<*K$G@$_A0!T-%%% M !1110 45S'BCXH^#/ ]]%9>(_%VA>'[R6/SH[?5-2AMI'0D@.%=@2N01GID M&K'A3X@>%_'BW+>&O$FD>(EM2HG.DW\5T(MV=N_RV.W.UL9ZX/I0!OT50UW7 M],\+Z5/JFLZC::1IEN 9KR^G6&&/)"C<[$ 9) Y/4BN._P"&A/A9_P!%+\'_ M /@^M?\ XY0!Z!17G_\ PT)\+/\ HI?@_P#\'UK_ /'*/^&A/A9_T4OP?_X/ MK7_XY0!Z!17*>&_BSX'\9:E_9WA_QEX?UW4-AD^RZ;JD%Q+M'5MB.3@9'..] M6?%7Q&\)^!)+:/Q+XHT;P\]R&:!=5U"&U,H7&XJ)&&[&1G'J* .BHKD[/XN> M!=2T._UFT\:>'KK1]/*+>:A#JL#V]L7(""20/M0DD 9(R3572_C?\.=G^//#6K^&Y_$-CXBTF] MT"!7>75;>]BDM8U09N#Z4 =#1110 45Q& MI?'+X<:+J%S8:A\0/"UC?6LC0SVMSK5M'+$ZG#(RLX*L"""#R*K?\-"?"S_H MI?@__P 'UK_\F4450UW7],\+Z5/J MFLZC::1IEN 9KR^G6&&/)"C<[$ 9) Y/4B@"_17G_P#PT)\+/^BE^#__ ?6 MO_QRC_AH3X6?]%+\'_\ @^M?_CE 'H%%>?\ _#0GPL_Z*7X/_P#!]:__ !RM M7PW\6? _C+4O[.\/^,O#^NZAL,GV73=4@N)=HZML1R<#(YQWH ZNBBN8\4?% M'P9X'OHK+Q'XNT+P_>2Q^=';ZIJ4-M(Z$D!PKL"5R",],@T =/16!X4^('A? MQXMRWAKQ)I'B);4J)SI-_%="+=G;O\MCMSM;&>N#Z5OT %%9^M>(-+\-VBW6 MKZE9Z7:LXC$U[.D*%B"0NYB!G /'L:IZ+XY\-^)+MK72/$&EZI=*AD,-E>QS M.%! +;58G&2.?<4 ;E%%% !1110 45C^*/&6@>!]/COO$>N:;H%C)*($N=4N MX[:-I""P0,Y +$*QQUPI]*Y?_AH3X6?]%+\'_P#@^M?_ (Y0!Z!17G__ T) M\+/^BE^#_P#P?6O_ ,'_ ]C%>^(]=TSP_9RR>3'<:I>1VT;N02$#.P!; )QUP#0!LT5Y__ M ,-"?"S_ **7X/\ _!]:_P#QRC_AH3X6?]%+\'_^#ZU_^.4 >@45Y_\ \-"? M"S_HI?@__P 'UK_\*/&GA_P/8Q7OB/7=,\/V11^=);Z7J4 M-S(B @%RJ,2%R0,],D4 =/116%XJ\>>&? L-O+XE\1:3X>BN&*PR:K?16RRL M!DA3(PR1D=/6@#=HKG?"OQ&\)^.Y+F/PUXHT;Q"]L%:==*U"&Z,0;.TL(V.W M.#C/H:M>*/&6@>!]/COO$>N:;H%C)*($N=4NX[:-I""P0,Y +$*QQUPI]* - MBBO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\,V*^'_$^C:ZV"<:;?Q7!XZ_<8UT- !16/XH\9:!X'T^.^\1ZYIN@6,DH M@2YU2[CMHVD(+! SD L0K''7"GTK.\,?%3P5XVU![#P[XPT'7[Y(S,UMI>IP M7,JH" 6*HQ. 2!GIR* .IHHK&\4>-/#_ ('L8KWQ'KNF>'[.63R8[C5+R.VC M=R"0@9V +8!..N : -FBN=\*_$;PGX[DN8_#7BC1O$+VP5IUTK4(;HQ!L[2P MC8[.2 L)E M(QC*%&SSVKTR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "OD#_@H=^W"G[)_@NSTCPX+>\^(NO1LU MC'.N^.QMQE6NI%_B.[Y44\,P8G(0J?K^OYW/V_\ XF7/Q4_:Z^(^H33M-;:= MJ6&,RRVFC:@D] MRH!.0(SM+M@9VIN)R,9/%?J5_P $W?@QIOP?_9.\&2P6B1ZQXFM(]>U*ZV8D MF:==\0)ZX2)HU Z<,>K&OJ&@#^<+]FS]JCX@_LG>/(]0\/WURNG+&1P#PRL&4CL5-?*OQH_X)5_#7XY?'#6?B#J^N:QI%OJWERW6CZ(D,"O<*H5 MY?,9'^_@%@%!+%CG+5],_!/X*^%_V??A[9>"_!\%U;Z%9O)+%'>73W#AG8LY MW,3@%B3A<#))QR: /F[_ (*,?MTG]E?PK9^'/"C07'Q'UR%I;?SE#IIMMDK] MI=3]YBP*HIX)5BOV2_X)P_ G3/@G^RUX2GBM$37O%%G%KNJ717$DC3H'AC)Z@1Q,B[ M>F=YP"QH _,B\_X)&_M$VND&\CT;0[NX"D_V?#K$0GX .,MB/)SC[_8^U>$^ M$_'GQ:_8[^*%PFGW6L>!/%%A*HO=,N T:3@?,$FA/RRQD'(R""""IZ&OZ3Z_ M/_\ X+$? K3?&'P#@^),%HD?B#PG=0QRW2*-\MC/((FC8]2%E>)AG.W+X^\: M />_V)_VN=)_:Z^%0UN.&'3/%.F,MKKFDQ,2L$I!*R1YY\J0 E<]"&7)*Y/S MU_P6P_Y-M\&_]C;#_P"D=U7QE_P23^*%SX$_:WTS0C.R:;XLL;C3;B//R&1( MVGA8CU#1%0?^FA]37V;_ ,%L/^3;?!O_ &-L/_I'=4 ?C#[]J_?O_@F%\3/^ M%E?L<>#1))YE[X?,V@W'.=OD-F(?A \-?C'\-_AO_P )G^SO\8->ABWW7A6Y MT34"RC+>3))]? M&'Q8^&__ @?P1^#>I2Q>7>>*+74M8DW#YMGVD01?@4@5A_O^] 'ZJ?\$8?^ M34-;_P"QMO/_ $EM*_.O_@II_P GQ_$__KM8_P#I!;5^BG_!&'_DU#6_^QMO M/_26TK\Z_P#@II_R?'\3_P#KM8_^D%M0!2^%/_!/'XW_ !J^'^D^-/"?ANSO MO#^J+(UK<2ZK;0LX21XVRCN&'S(PY':L3XO?L,_'#X%^'Y]>\7^ [JST*!L2 MZE9W,%[#&,X#/Y,CF-2<RM(FF.YVQSP9/[M0Q&]1P5).,@&OW5K M^6/1K>\O-8L8-/#M?RSQI;K&"6,A8!<8[YQ7]3*DQQ R.N57YGQ@>Y]J /S2 M_P""TWQR_L7P/X4^%.GW&VYUJ;^V-413R+6$E8$8=P\NYOK;BOR3T76;WP[K M%AJVFW#VFHV-Q'=6UQ&<-%*C!D<>X8 _A7LO[9_QLD_:)_:8\8^*;:5KK2WO M/[/TA5R1]CA_=PE1_MX,F/[TAKW#]O7]BU/V<_@G\$_$%G:"*[.F?V/XD=%X M.HMNN@Q/6.P)K6GQSS11G(AN!\D M\7_ )5=?^ UZ%7YTE6//EL5CN4'L&\IP!_ MST"W0=6=(G+A0.2VW:!R2*ZO]@7]M;Q3^SK\4= T+4M9N;W MX;:I=I9W^E74K/#9"1@OVF$$_NV0D,P7AE# C.TC]E_CQ^T3\-/A#\.M!@#)) !(_G+\%^%=0\<^+]%\.Z5! M)YH _IY\6?\BKK/_7E-_Z+:OYC?A[_ ,C]X9_[ M"=M_Z-6OZ*O'UQ MW/IMN%LK5\[9[J1A'"C8YV[V7<1R%#5^!4EQ\ M6_VVOC*(]VH^.O&FIEWC@,H$=O$"6(7<1'!"N>F549]3S^S_ /P4Z^&^J?$K M]COQ?!HT,EU?:3);ZQ]FB!+2Q0R S<#KMC+OC_8]<5^-?[(O[3FJ?LF_&&W\ M;Z=I<.MP26DFGW^G32&(SVSLC,$DP=C!HT8-@_=P1@T >\7'_!'?X_PZ*UZA M\*SW(0L--CU5A.2 #MRT0CR2$_&GQ)_9-^+DTVF7.H>#O&.A MW/D7EFY(#%3EH9DSMEC/H!M0DPIAU MRR9HMWH)H=ZA?]I]GX5I_$+]BS]GO]M#QO+\3SKDGB2>X@BMKB;PSK,36LOE MIM0N8U8APNT?>'"*,<4 >U_LQ_'*R_:.^!_A;Q_9PK:2:G;D7=FK9%O=1L8Y MHQWVAU;:3R5*GO7!?MR?M?Z;^R+\*QJD<4.H^,-79K;0]+F)V/(H!>:0 @^5 M&&4G')+(O&[(](^ OP#\*?LW^ _^$0\&QWD6B_:I+P)?7!G<2.%#88CI\HX^ MM?C/_P %8OB5<^._VP-ON+_@C_P# G3/!'[/9 M^(LUHC^(_&%Q-MNG7YXK*&5HDB7T#21R.<8W93.=HK[WH _FLUC1/BY^QW\3 MDBNTUSX<^,+5=\<95T)2:(D$'!9#@@YY%?LE_P $\_VYXOVL?"5Y MHOB-;:Q^(VAQ*][#;C9'?V^0HNHU_A^8A74< E2,!P!K?\%+/@5IOQF_98\5 M7TEHC:]X3M9-=TV["CS(Q"N^>//4J\2N-O3<$/)45^/W[!_Q0N?A+^UE\.=7 MBG:"UO-4BTF]"GY7M[EA"VX=PI=7^J ]J /V"_X*C_\ )B?Q-_[AG_ITM*_! MKP;XPU?X?^+-(\2Z#>/I^LZ3=1WEI? M]E6/;% ']%G[+7[06D?M-_!70?'.E[(;BX3R-2L5;)L[U !-$>^,D,I/)1T/ M>O)/^"JG_)CGC[_KMIO_ *7V]?FG_P $R?VLO^&=?C0F@Z]>^3X%\6/'9WS2 MMB.SN?]BS>_\ HVWK]OZ_$#_@C;_R=Q>?]BS>_P#HVWK]OZ "BBN$^/'Q ?X4 M_!7QUXQB7=<:'HMW?0*<8:5(F,8Y]6VB@#\VO^"E'_!1C7+'Q9JGPF^%>KR: M3!IS-;:[XAL7*W$EP.'MH) 6!ED(\Q^02J;F&X$C!S7!_#?P??\ Q>^*OAKPPES( MVH^)-8M[ W4F78//,J&1LGG&XL23V-?TM_#_ ,!Z'\+_ 7HWA3PW8QZ=H>D MVR6MK;QC[J*,9)[L3DECR223R: /PM^(7_!+/]H3X?Z%/JW_ B]IXCMH$\R M:+0+Y;F=5QDXB(5W(Z80,?PYKE?V5/VW_B+^RCXFMH[*^N=8\("7;?>%;^9C M;E2WSF$'_4R]?F4=?O!AQ7]#E?BK_P %B?@5IOPW^.&@^-M&M$LK3QI:S27< M,2A4-] R"60 ="Z2PD^K!VY)- '[ _"_XE:!\8OA_H?C/PQ>"^T/6+87-M+C M##DAD8=G5@RL.S*1VK\?_P#@M7_R=-X6_P"Q,M?_ $NOJ]\_X(F_%"YUCX=^ M/O 5W.TD>B7T&I62.<[8[A7615] 'A#8]9">YKP/_@M7_P G3>%O^Q,M?_2Z M^H ^=_@/^Q'\6_VE/"%YXF\!:%:ZIH]I?/ILLT^HP6Y$ZQQR,NV1@2-LJ'/3 MGVKTC_AT_P#M)?\ 0H:?_P"#NT_^.5]:_P#!(GXW?#KX:_LV^)-,\7>/O"_A M74IO%MSMZS;6_QM^!W[57@CQMXO\ #EG8>'=+^W?:KB+5+>9D\RQN M(4PB.6.7D0<#OFOUOKF_!'Q*\(?$RRN+SP?XJT3Q7:6TGDSW&AZC#>1Q/C.U MFB9@IP0<'G%=)0 5\Z?\%#/&_P#P@/[&OQ0OA)YG_!:CQO_ &-^SYX3\,QR;)M%RPQ_ORPG\* /R M,^'?PJ\8_%O5KC3/!?AG4_%&H6\!N9K;2[9IY(X@P7>0HX&649]Q7H'_ Q3 M\>_^B0^,/_!3+_A7J'_!/_\ :^\(?L>S^/-=U[0M4\0ZYJ\%I9Z=;:?Y:1K& MK2/,9)'.5R?)QM5LX.<<5]R?##_@L_\ ##Q7KD.G^+O"^M>"8)G"+J0D2_MH ML_Q2[ LBC_=1J .J_P""2?PK\8?"3X">*M+\:>&M3\+ZE<>)I;F*UU2V:"1X MC:VRAP&'*[E89]0:^X*IZ/K%CX@TFSU/2[R#4=-O(EGMKNUD$D4T;#*NC#AE M((((JY0!PWQN^#^@_'KX6^(/ OB2+?IFKVYB\U0"]O(/FCF3/\:.%8?3!X)K M^=+XA>!_%_[,?QIO]!OI)=(\5^%]162WO+?*_,C!X;B(G^%AL=3Z$9]*_IFK MX _X*Q_LC_\ "VOALOQ1\-V7F>+?"=NWV^.%?GO=-!+/]6A)9Q_LF0X->5_ M\%,?VJ/^&=/@5/I6BWGD>-_%BR:?IQC?$EK!C%Q O$H2SU?=DI:N"?)NL#^X20V/X';@D"O/\ ]K+X M_P"L?M;_ +06I^(X8;F6SN)UTSP_I:J6>.U#%84"C^-RQ=@,_-(0.,4 6_V) M/V7[W]JKXX:;X;*2Q>&;'%_KUXF1Y5HK#,:MVDD.$7N,EL$*:_17_@LQI-EX M?_97\ :9IMK%8Z=9>)K:VMK6!0L<4:6-TJ(H'0 #VKZ'_8/_97MOV5?@?8 MZ1=11MXOU?;?Z_=)@YG*_+ #W2)3M'8G>PQNQ7@?_!;#_DVWP;_V-L/_ *1W M5 'Y5_ 7]G7QS^TKXIOO#O@'38=4U6RLFOYHI[N.W"PATC+;I& )W2+QUYKW M7_AT_P#M)?\ 0H:?_P"#NT_^.5L?\$H?C%X+^"OQV\4:QXY\16?AK3+GPW+: M0W5\Q"/,;JV<(, \[48_@:_5'_AOS]GG_HK'A_\ [^O_ /$T ?DM_P .G_VD MO^A0T_\ \'=I_P#'*_6?]@OX0^)_@5^RYX3\%^,+./3_ !!I\MZUQ;Q3I,JB M2[FD3#H2IRKJ>#WIW_#?G[//_16/#_\ W]?_ .)KW;2]4M=/[LD;J&5A[$$'\: +5?CU_P6A^.7_"1?$KPS\+;"XW67AVW_M/4D4\& M\G7]VK#U2'##_KX-?K?XL\4:=X(\+:QXBU><6NE:39S7UW,?X(HD+N?P"FOY MM_$VM>(_VI/VA+N_$9F\1^-M>"00$EA&\\H2*//]U 54>BK0!D?!?XGZC\%_ MBOX4\<:66-YH>H17@C4X\U <21$^CH60^S&OZ8?"WB;3O&GAG2?$&D7"W>E: MK:17UI.O22&1 Z-^*L*_#/\ X*;?LLZ=^S7\4/"C^'+;R?#&L:';PQ,%V@W5 MI&D$Q/\ M,HAE8]VE8U]W?\ !('X[?\ "QOV>[KP/?W DU?P5<^1&&/S-8S% MGA/OM83)[!$]: /IW]K'_DUGXR?]B9K/_I#-7\X_@CP;JOQ$\9:)X7T.!;G6 M=9O8;"SA>18U>:5PB*68@ %B.3Q7]''[6/\ R:S\9/\ L3-9_P#2&:OP(_9! MFCM_VJOA#+*ZQ1)XKTQF=R J@7,>22>@H ]C_P"'3_[27_0H:?\ ^#NT_P#C ME>9_&S]B/XS_ +/>@G7?&O@N>RT$.L;:I9W,-W!&S'"B0Q.QCR2%!< $D 9R M*_H?_P"$LT/_ *#.G_\ @5'_ (U\S_\ !0']H3X;^#/V9_'^A:MXATN^UK7M M)N-,T[1X+A)KB2XEC(C?8I)54++)N; &T\4-R51G/EQ@>BIM4#T4"OZ) M_P!FOX-:9\ _@CX2\%:;:QV[:?8QF]D50&N+ME#3RMZEG+?08 X H _$KXK_ M /!,_P"/?PC\,W/B"_\ "]OK>E6D?G74N@W:W3P(%RS-%PY"\Y*J0,$YQS5; M]BS]N/Q=^ROXVT^WGU"\U;X=7,ZKJF@2.9$CC)PTUN"?W#R*^$-9_X(^_"7Q-\4/$7BK5-;UR/3=4OY+Z'P_I/DVEO;;VW-%NV,Q3); M 79@8';D ^Y-&UBS\0:/8ZIIUPEWI]]!'Q!!_&OYK?VFO^ M3DOBO_V-NK?^EDM?T>_#[P)I'PP\$Z+X3T"*:#1='M4L[.*XG>=TB4852[DL M<#@9/ X K^<+]IK_DY+XK_ /8VZM_Z62T ?T)_LR_\FV_"C_L4M)_](XJ] M+KS3]F7_ )-M^%'_ &*6D_\ I'%7I= '\N_Q"_Y'[Q-_V$[G_P!&M7].7A/_ M )%71O\ KRA_]%K7\QOQ"_Y'[Q-_V$[G_P!&M7].7A/_ )%71O\ KRA_]%K0 M!_-O^TU_RO-+H%QSC=Y MZXB'_?\ 6&O(?VFO^3DOBO\ ]C;JW_I9+72_M+>$[OX ?M4>((M,'V273]3M M]7_ (*'?$S_ (6I^V#\1-0AE,MEIU\- M%M1G("VJB%MOLTB2-_P.OW/U_P"-NEZ9^SG>?%F(K_92^&3XB@5CD,IMO.C3 MW)RJ_4U^!/[+_@>X^,WQ]LX[_=>"&*_UZ^FD&=WV>WEN,M_O2(B_\#H K_L= M_P#)U_P>_P"QMTO_ -*HZ_93_@JI_P F.>/O^NVF_P#I?;U^-?['?_)U_P ' MO^QMTO\ ]*HZ_93_ (*J?\F.>/O^NVF_^E]O0!^8'_!*O_D^/P#_ -<=2_\ M2"XK]]*_ O\ X)5_\GQ^ ?\ KCJ7_I!<5^^E 'Q!_P %A?\ DS]_^Q@L?Y2U M\/\ _!&W_D[B\_[%F]_]&V]?<'_!87_DS]_^Q@L?Y2U\/_\ !&W_ ).XO/\ ML6;W_P!&V] 'Z/\ _!33_DQSXG_]<;'_ -+[:OR6_P""9?\ R?'\,/\ KM?? M^D%S7ZT_\%-/^3'/B?\ ]<;'_P!+[:OR6_X)E_\ )\?PP_Z[7W_I!W/DZ'XTB_L6=6.%%R3NM7^OF?NQ_UV-^%OB+XU?LN>.?!?A.T MCOO$&J16JVMO+,D*N4NX9&R[D*/E1CR>U?D3_P .G_VDO^A0T_\ \'=I_P#' M*_9G]F7XS6_[0'P(\&^.X#&)]5L5-Y''TBNT)CG0#L!(KX]L'O7J% '\P/Q2 M^&7B#X-^/M7\&^*;6.RU_2I%CN[>.9951F17&'4E3\K+T->U_"W_ ()V?'+X MR> =(\9>%O#5G>Z!JL;26EQ)JMM$SJKLARC.&'S(W4=J3_@I#_R>U\4O^OVW M_P#22"OU_P#^";W_ "9+\+?^O*X_]*YZ /DO_@G/^PG\8OV>?VBE\6>./#]I MINB#2+JT\^'4K>=O,>>:0X6.-5+,Q]@ 3^%?!W_!''XQ_\)O^SOJ?@BZFWZAX M-U!DB5CD_8[DM+&?7B07 ]@%KTG_ (*??&'_ (5)^R+XGBMY_)U7Q0R>'K7: M<';,"9S]/(289]66@#\1OC9\1K_XZ?&SQ9XP>*66Z\0ZM+<6]N 6=8V?;#$! MWVIL0?[HK]NO$WP?B^ O_!-/Q5X&1$6YTKP%J O6CQA[M[:22X8>H,KOCVQ7 MY7_\$T/@N?C+^UIX6%S;^=H_ALGQ!?;ERO[@KY*GL18U>:5PB*68@ M%B.3Q7U)_P .G_VDO^A0T_\ \'=I_P#'*\-_9@\2:9X/_:.^&&NZU>1Z=I&F M^)-/N[N[F.$AA2X1G=O8 $_A7[M_\-^?L\_]%8\/_P#?U_\ XF@#\EO^'3_[ M27_0H:?_ .#NT_\ CE?=O_!+;]DGXE_LPW_Q(E^(.CV^E)K46GK9&"^AN=YB M-P7SY;';CS$Z]8N-R\@&6=W1BK.""5(X/-?-GQZ_8N^*W[-/AS3]=\?: M':Z7IM_=_8H)(-0@N"TNQGQMC8D?*COSJ_P""VG_) O O_8S#_P!) M9Z /RY^ O[.'CO\ :6\1ZAH7@'3(=4U*PM/ML\<]W%;A8MZIG=(P!^9UX'K7 MN7_#I_\ :2_Z%#3_ /P=VG_QRO5?^")?_)??'7_8LG_TJ@K]E* .8L+^U^'O MPTM;SQ#=0Z99:)I*2:AVO-?NEM/.0X(=8SF0H000VS# Y4FL+XZ?L)_&C]G/1_[=\5>%F;08R- M^L:3<)=6\)) 'F%#NC&2 &=0"2 "37]$W3@<"JVJ:79ZWIMUI^H6L-]87430 M7%M<('CEC8$,C*>"""00?6@#\;/V ?\ @I7XC^'?BK2O ?Q3UN;7/!%_*MM; MZSJ4K27.D.<*A:1B2T&< AON Y! !4_I5^VY\+?$7QL_9;\<^"_"5I'?^(-5 MBM5M+>29(5Y98U;/^U0!^3/_ Z?_:2_Z%#3_P#P=VG_ ,AK^GZOYZ_\ @I#_ ,GM?%+_ *_;?_TD M@H 7X6_\$[/CE\9/ .D>,O"WAJSO= U6-I+2XDU6VB9U5V0Y1G##YD;J.U?9 M7_!.?]A/XQ?L\_M%+XL\<>'[33=$&D75IY\.I6\[>8Y3:-J.3_"><5]:?\$W MO^3)?A;_ ->5Q_Z5SU]*T )G')X%?SI?MR?'(_M!?M->,O$\$_GZ-!'-,U2R6^\.:,KZUJL,J[HY(H<>7&PZ$/, MT2D'JI:@#L/^"5'QT_X5#^U%IVB7MSY.A^-(O[%G5CA11Q](KM"8YT [ 2*^/;![T ?+7_!9[_DU#1/^ MQML__26[KY _X(P_\G7ZW_V*5Y_Z56E?7_\ P6>_Y-0T3_L;;/\ ]);NOD#_ M ((P_P#)U^M_]BE>?^E5I0!^VE%%% !1110!\ ?\%J_^36?"W_8YVO\ Z0WU M?E!\!?V=?'/[2OBF^\.^ =-AU35;*R:_FBGNX[<+"'2,MND8 G=(O'7FOU?_ M ."U?_)K/A;_ +'.U_\ 2&^KY7_X(NZE::9^T;XPDO+J&TC;PI,H>>0("?ME MKQDGK0!Y[_PZ?_:2_P"A0T__ ,'=I_\ '*\+^+'P+^)O[,OBG3[;QIH&H>$- M6?\ TBQNDF5EGZ_XIL]6_M.X?3I5G%G;^1(FQY%RH9V=#MSG$8) M!&0#U?\ X)4_MCZ_\?/"^N>!?'&H2:MXK\-Q)=6NJ7#%I[ZR9MI\T_Q/&Y4% MSRPD7.2"30_X+8?\FV^#?^QMA_\ 2.ZKYW_X(G^$=0O/COXV\3)%,-*L/#K6 M$LRJ?+,T]S"Z(3Z[8)#CVKZ(_P""V'_)MO@W_L;8?_2.ZH _*OX"_LZ^.?VE M?%-]X=\ Z;#JFJV5DU_-%/=QVX6$.D9;=(P!.Z1>.O->Z_\ #I_]I+_H4-/_ M /!W:?\ QRMC_@E#\8O!?P5^.WBC6/'/B*S\-:9<^&Y;2&ZOF(1YC=6SA!@' MG:C'\#7ZH_\ #?G[//\ T5CP_P#]_7_^)H _);_AT_\ M)?]"AI__@[M/_CE M?IC^SW^SWXW^'_\ P3SU+X4ZUIL-OXUGT37;)+)+J.1#+:K%.1*G.> M,\]*[C_AOS]GG_HK'A__ +^O_P#$U[MI>J6NN:79ZC83K=6-Y"EQ!/']V2-U M#*P]B"#^- 'X0?\ #I_]I+_H4-/_ /!W:?\ QRO ?CC\!O&7[.OC1/"OCG3X M=-UI[2.]6&&YCN%\IV95.Y"1U1N,]J_IGK\0/^"R7_)W%G_V+-E_Z-N* /$_ M@=^PQ\8/VBO!;^*O V@6NI:*EW)9---J4%NWFHJLPVNX/1UYQWKZE_8]_P"" M<_QT^$/[2W@+QAXG\-65GH.DWS3W<\>K6TK(AB=,O!'A#P-H.MZ?K_ (IL]6_M.X?3I5G%G;^1(FQY%RH9 MV=#MSG$8) !&?/\ _@B?X1U"\^._C;Q,D4PTJP\.M82S*I\LS3W,+HA/KM@D M./:@#Z3_ ."U?_)K/A;_ +'.U_\ 2&^K\E/@/\9]<_9^^+'A[QWX>?\ T[2K M@.]NS%4NH2-LL+_[+H67VR".0*_6O_@M7_R:SX6_['.U_P#2&^K\>-$\ ZWX MB\(^(_$NG6;76E>'C;?VE(G+0).[)'(1_=WJ%)[%U]> #^ESX5_$O0OC%\.] M \:>&[G[5HNM6JW5NYQN7/#1N!T=&#*P[,I%?#__ 6P_P"3;?!O_8VP_P#I M'=5\^_\ !(?]K+_A!?&TWP<\27NS0O$4QFT269OEM]0QS"">BS # _OJ !F0 MU]!?\%L/^3;?!O\ V-L/_I'=4 >/_P#!#G_D:OBW_P!>6F_^C+BO8OVKO^"F MFO?LQ_M02^#F\&QZYX)M;&V%T\HDMKJ2X<&1Y+>4Y1T5)(U*E3\R$;EYKQW_ M ((<_P#(U?%O_KRTW_T9<5]4?\%-/VC+_P" OP/2WTSP@OB&]\02-9IJ6H:> MMUINF?+_ *R4.I1I3DB-&&"0Q.0NU@#\Y_@Y^UM\/?AE^W!\0_C9>7RQ(4F$TIPK-EX2H5%Z/U[?G%XK_ &-?'WP)_9Z\ M ?M!O'#++?PA)X(:\C(FTHV9MH?,& TL' WPOP5<=1P>0: /9:*** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ K^9/X_6\UK\=_B/#<9^T1^)-223.<[A=2 _K7]-E?@O_ ,%2O@7>_"'] MJ;7-:6 _V#XS+:W93A2%\YB!P:C^S9\*;FV*^ M1)X4THJ%/ _T2+C\.GX5Z;7YY_\ !*C]L3PSXL^$FD?"7Q'J]OIGC'P_OM]- MCO90@U*T+%HQ$3@&2,,4,8YVJK#/S;?O/Q?XRT+X?^';W7O$NKV>A:+9ION+ MZ_F6**,>[,>I/ '4D@#F@#9HK^?[]J3]N+Q?\2?VFM=\??#[Q3KOA72H4CTW M2?L-Y);LUI%G#.JD AW:23:P./,P+I&UZPN F$=Y3FY3/3?PKZ:N+J&SMY+B>6.&"-2[RR,%55'4D MG@"OR%_X*N?MN>'/BI8V/PF\ :I%K6DV5X+W6M7LW#V\\R B.WB<<2*I8NS# M*[@@!.#0!\N_\$];6:[_ &T/A2D&=XU4R';G[JPR,W_CH-?HO_P6P_Y-M\&_ M]C;#_P"D=U7SI_P1G^!MYXF^,NL_$^ZMF31O#-I)96D[)\LE[<+M(5N^R$ON MQT\U/6OHO_@MA_R;;X-_[&V'_P!([J@#YG_X)6?#V/XL^!?VD?!KJK-K?ANW ML8BW197%T(V^JOM;\*\._P"">/Q&D^$O[9'@"XNBUO;ZA?-H-Y&_R\7(,*AO M3;*T;'/]VOJG_@AS_P C5\6_^O+3?_1EQ7R#^VUX#G^"/[87Q!T[3]UB(=8_ MM?3Y(^/+2?;V&;T/K']BZ>D9R)$M M]MM'L]G,>[ZO7OO_ 5J\#V_PRN/@3X1M-IM]"\(C3491PWE,B;OJ2N?QKP_ M_@GO\.F^+?[8_P /K2[1KFVLK]M?\ I+:5^=?_ 4T_P"3X_B?_P!=K'_T@MJ /,?! M_P 9OC5X7\-V>E^%?'/CW2- MPPM;/1]7O8;6,%BS;$C<*,L6)P.I/>IM:3X=N<&YGN5.8YIU!_= M+&P#!#\S,!D ##?97_!1GXY?\**_95\57MI<>1KFNJ-!TPJ<,))U82.#V*0B M5@?55]:^FZ_%G_@L=\M 'SS^PMX9\*>(OVGO!DWCCQ!HOASPMH]Q_;%Y=:[?16D$A@^>*(-*RJQ:7 MRP5SDKN..#7ZU?MG?$;X(?'_ /9J\;^$8/B[\/Y]6DLS>:6H\3V);[9 ?-B5 M?WO&\KY9/HYK\L_@G_P3K^,WQ]^'>G^-O"VF:;_8.H/*EM)?7ZP/)Y;F-F"D M?=W*PS_LFNZ_X=#_ +0W_0-\/_\ @X3_ H \!_99^-,_P"S[\?O!OCE&?[) MIUZJW\-98IHVW*Z,,JP M/<$$&OYJ/C_^SQXT_9G\;0^%?'-E#9ZI-9I?0FUF$T4D+,RAE<=?F1@?0BOV M;_X)9_'3_A<7[+.DZ7>W'G:[X.?^P[H,V6:!5!M7^GE$1^YA:@#\&X8GGE2- M!N=V"J/4G@5[SX^_8-^/OPST.^UCQ!\,]5@TRQ4R7-Q9R0WJQ(!EG/D2.=H' M);H "2:\.TG_ )"ME_UV3_T(5_4[UX/(H _EQ\&Z'8^)?%&G:9J6NV?AFQNI MA'+JVH1RO!;*?XF$2.Y'T7ZX'-?MO^P[_P $Y_ ?[/=Q9>/Y?$,/Q%\4SP^; MIFLP1A+&UAD3&^W4.V]F5B/-)^Z?E"Y.?AK_ (*C_L9Q_ 7X@Q^/O"5AY'@/ MQ-.WF6\"XCTV^.6:( <+'( 70= 0ZC 5:[3_ ()+?MD3>!_%T7P9\6:A_P 4 MWK4I.@37#<6=\QR8 3T28]!T$F,#,A- 'ZY^+/\ D5=9_P"O*;_T6U?S&_#W M_D?O#/\ V$[;_P!&K7].7BS_ )%76?\ KRF_]%M7\QOP]_Y'[PS_ -A.V_\ M1JT ?U#LH92",@\$&OS\_:8_X)"^"/BGK%]XB^'6K_\ " :S=.99M+:#SM,E M<]2B@AH,G).W/\ XH?"GX1^%?%?P[\4:CX;LX-4>RU879BI("M&RY!',HZ\8^7/^":W[?.K:7\7-9\._&/X@:IJ6E^)((ET_4_ M$6HO+;V-U$6PNZ1ML*2*Y!(P"R)GUH \6^)O_!+']H/X<+--;^%[;QC8QYS< M^&[Q9V(]H7"2G\$-?/OA7QAX^_9[\??;='O=9\#^+--EVRQE7MIXV!R8Y8F MRI[HX((Z@U_3?#,EQ$DL3K)$ZAE=#D,#R"#W%?B[_P %C/BAX%\??&/PIIGA M:YL=4US0K&>#6M2L&612SNABMVD7AFCVR$C)VF7'!R ?HW^PG^U0O[6'P/M M_$5[##9^*--G.FZS;0'">>JJPF1>H216# =B&7)VYK\8O^"@$,]O^V7\6%N& M+2'6&<$C^%HT*#_ODBOO3_@A_HNH6_P_^*.K2HXTN[U.RMK=BI"F6**1I<'N M<319_"O$O^"R/P-O/"/QRTWXE6ULS:+XLM([>XN%3Y8[ZW01[6/0%H5C*YZ[ M'_NF@#]#/^"<%];ZA^Q/\+9+9@R)93PMCLZ74RN/^^@:^E*_(?\ X)1_MO>' M?AGIMU\(_'^J1:-IES=M>:%J]Y($MX9),>9;2N3B-68;U8\;F<$C*U^N<%U# M=6R7$,L [>WS]HFUZPCCVYSN-Q&!C\:_4G_ (*G?MQ^%[?X MU 'Z@?\%1_^3$_ MB;_W#/\ TZ6E?FY_P2!@CNOVNC#-&LL,GAV_1XY%#*RDQ @@]017Z1_\%1_^ M3$_B;_W#/_3I:5^<'_!'K_D\!/\ L7[[^<5 ' _\%"?V4I?V7?CC=0Z9;,G@ MCQ 9-0T.0 [8EW?O+7/K$S #OL:,GDFO>KS]K'_A??\ P2Y\>^$-?O/.\;># MSI-M*TK9DO;+[?;K!/SRS+CRW//(5CR]?HS^V9^S/I_[5'P/U;PI*(H=>@_T M[1+Z08^SWB*=H)[(X)1O9LXRHK^=_5;'6/!VJZSH=_'?]BS>_\ HVWK]OZ_$#_@C;_R=Q>? M]BS>_P#HVWK]OZ "O ?V^(9[C]C?XLK;L5D&B2.2!_"K*7'_ 'R#7OU87CSP MA9_$'P/XA\+ZC_QX:UIUQIMQQG]W-&T;-/"?B3X#_%C4M"OQ+I?B?PQJ>P2*"I26)PT MX0+:@G\21^5? MI9XU\=>'?AQX=NM>\4ZW8Z!H]JI:6]U"=8HU]LD\D]E')/ !-?@9_P % /VJ MH/VK/CE)K&CK-%X1T:W_ +-T=)E*/+&&+/<,I^Z9&/0\A50'D&@#Z9_X(?VL MS?$3XHW"Y^SQZ59QOUQN:9ROZ*U<;_P6K_Y.F\+?]B9:_P#I=?5]??\ !(7X M&WGPQ_9VO?%NJVS6NH^-KM;V*.1-KBRB4I;DY_O%II!ZK(I'6OD'_@M7_P G M3>%O^Q,M?_2Z^H ^=_@/^Q'\6_VE/"%YXF\!:%:ZIH]I?/ILLT^HP6Y$ZQQR M,NV1@2-LJ'/3GVKTC_AT_P#M)?\ 0H:?_P"#NT_^.5]U?\$5/^36?%/_ &.= MU_Z0V-??] 'QA_P3#_9K\>_LS_#7QAH_C_2X-+O]1U=+NVC@NXK@-&(50DF- MB!R#P:^SZ** "OB__@H-^PSXK_;$U#PC=:%XMTS1(/#]O<1I8ZE!(5DDF9"[ M[TSCB)!C:>G6OM"OBW]M3_@HQC Y&: /*OV??^",OA/0=):[^,.LR>)M;:0[=/\/W4D%A%'VS M(4661CPM?,7_!23]@W0_V56\/>*_!-W>2^$=9N&L9;&_D$DEE3D8_4;]B_]K#3OVN?A0_B>*SM]%UNSNY+34M&AN?/-L028 MFR54E70@@XQD,.=IKY3_ ."V7Q*TFV^%O@;P MQ')KEYK/\ ;;6ZX9XK>&": M$,W]W,OA;JEW)=6NCI'JVCK(2Q@BD,&MY5T^VTV#24N""(WDEE$K*#T)4 M0H3Z;U]:_7.@ ILD:RQLCJ'1AAE89!'H:=10!_/U_P %&/V:;']FC]HB]T[0 MS&GAG7X/[:TRU3K:(\CJ\'T5T;;_ +!4=0:]X_X(\_LQV'Q \%;@6FE6;#=F_9 QF8>D:,NW_:<'@IS!_P %M/\ DOO@7_L61_Z53U[_ /\ M!$O_ )(%XZ_[&8_^DL% 'Z*U^>O_ 6P_P"3;?!O_8VP_P#I'=5^A5?GK_P6 MP_Y-M\&_]C;#_P"D=U0!^7G[-?[,7C#]JKQEJ/AGP7+ID6I6%@VI2G5+AH8_ M*62.,X*HV6W2+QCIFOH[_AS;\>_^?SP?_P"#27_XQ6Q_P1=U*TTS]HWQA)>7 M4-I&WA290\\@0$_;+7C)/6OV1_X2S0_^@SI__@5'_C0!^*W_ YM^/?_ #^> M#_\ P:2__&*_9SX;^'[KPG\._"VB7IC-YINE6ME.8FW)YD<*HVTX&1E3CBKO M_"6:'_T&=/\ _ J/_&KUEJ%KJ4)EM+F&ZB!VEX9 ZY],COS0!\+_ /!7_P". M7_"N?V=[7P38W'E:OXUN_L[JIPRV,)62<_\ F,*>X=Z^#?^"6FG^!M/_:._ MX3/Q]XL\.^%M-\,6,EQ9?V_J<%F+B\E!B0()77?L0RL2,[2$]16-_P %-/CE M_P +K_:L\1):3^=H?A:DL4IAD4,C,A'&5(/T(H ^Y_^"G7C#X/?'G]F6^_L M'XH>!]6\5>'+N/5=.M+/Q%9RW%PO^KFB15D+,3&Y;: 23&HKX(_X)L_'7_A1 MO[5'AN6\N/)T'Q(?[ U'M ']$ M7[6/_)K/QD_[$S6?_2&:OYQ/!WA'5O'WBS1_#6@VGV_6]7NXK&RM?,2/S9I& M"(FYR%7+$#+$ =S7[FZ!\?V._\ DZ_X/?\ 8VZ7_P"E4= $_P 4OV-_C3\%] EUSQC\/=5T MG1H6VS7Z>7%G" G !; )('>N/^#?P_TKXH?$#3/#FL>,M)\"VEZ_ MEC5]964P*Q( 4E%(4DGJY51W85_31JFEV>MZ;=Z=J%K#?6%W$\%Q:W"!XY8V M!5D93P5()!!Z@U^ '_!0#]D>?]E/XQRP:9#*_@77=]YH=PY+>6N1YEJS'JT1 M8 9Y*,A)R3@ _6K]C/\ 8,\%?LCZ?/J5G>/XI\:7\/DW7B*XB$0$)(;RH(@S M"-"54GYF9B,DXPH^GZ_,O_@D?^V1-XJTL_!3Q?J'FZGIT)E\-75PV7FME&9+ M3)ZF,#K64\RAHHIT=U/0J&!(_*OZFHI4FC22-@\;@,K*<@@]"*_G%_;*^!=[^ MSQ^T5XO\)SP&/3C=-?Z5+M(66RF8O$5]=H)C/^U&P[5^PW_!/?\ ;$\,_M!? M!_P]X?O-7M[;XAZ'8QV.HZ7$O%VO>%Y]>U)KB+3K.\9HEB&$@B>+_5R;8U1>5.<=* /Z)Z_FF_:E M@^R_M.?%V$G<8_&&KIN]<7LPK^B'X'Q^,8_A!X0/Q!O!?>-I--AEU>401PXN M77OP+_;T\)W/@W]L+XKV=U"T+7.N3:C'N&-T=SB=6'J M"): /WA_9E_Y-M^%'_8I:3_Z1Q5Z77RE_P $Y?VC?"_QD_9P\&:#::M:KXL\ M,:7#I&HZ/)*HN46W18HY@A.61T5#O QDD9R#7M_QN^-WA/X _#_4_%GBW5;; M3K.UA=X()90LMY*!E885ZN[' P <9R< $T ?S:_$+_D?O$W_ &$[G_T:U?TY M>$_^15T;_KRA_P#1:U_,1H^FZE\0O&UEI]NK7.KZYJ"6\:J,F2>:0* ![LU? MU$V\"6MO%#&,1QJ$4>@ P* /YI?VFO\ DY+XK_\ 8VZM_P"EDM?7_P#P6#^& M_P#8WC7X6^-X8ML.N>'%T^9E'!FMBK;C[E+A!](_:OD#]IK_ ).2^*__ &-N MK?\ I9+7ZV_\%3/AF/&W[$6G:]%%OO/"D]AJ(91EO)D46\B_3]\C'_KGGM0! M\K:U^TS]I_X)#Z7X6%R#K,FO_P#"(2C=^\^SQ/\ ;0P']T1>3%^/Y1?\$H/A MO]NT?X[>/)HODTWPM-H]L[#@O.CRR8]U$$8^DGO7P VK7C:5'IIN9#81S-<+ M;[OD$C*JE\>I"J/PK]K?^"?'PT'P_P#^"=6K:C)#Y5[XHL]6UF;%_%6C>-M M"M-:\/ZK9ZWI%VGF6]]I\ZS0RKZJZD@T ?&O_!87_DS]_P#L8+'^4M?#_P#P M1M_Y.XO/^Q9O?_1MO7T5_P %F/CYX9F^'&A?"S2M7MK_ ,2R:Q'J6I6MK*)# M9P112JJ2X^Z[/(I"GG"$D8()\:_X(H^%[F__ &A/&?B 1,UCIOAIK5Y,<+-/ MPN-^G>$[3[1>HIX-]<*K8/KLA$6/0R.*_77QO\ M0=&\!_#_ %WQEJ%U&^B:/83ZA/-"X8-'$C,P4]"3MP!Z\5_-IK>I^)/VB/C1 M=7@B-_XJ\9:V3' IX:XN9L)&OHH+A1V ]* /TC_ ."1VN_"KX-_"WQ/XJ\7 M?$7P=X>\4>(KX6Z6.JZ[:6US#9P A2T6@[BN,_X= M#_M#?] WP_\ ^#A/\*AO/^"1_P"T-9V<]Q_9&B3^5&TGE0ZLC.^!G:HQR3V% M 'T#_P $5?CKY=QXP^$>HW'$@_M_25=NXVQW,8SZCR7 'I(:_5FOYH/V=?B[ M>_ 'XY>#_'-N) =%U!'NH4X:6W;*7$7U:)G7ZFOZ5-)U2TUS2[/4K"X2[L+R M%+BWN(SE9(W4,K ^A!!_&@#^?;_@I#_R>U\4O^OVW_\ 22"OU_\ ^";W_)DO MPM_Z\KC_ -*YZ_(#_@I#_P GM?%+_K]M_P#TD@K]?_\ @F]_R9+\+?\ KRN/ M_2N>@#Z5K\E?^"XW_(U?"3_KRU+_ -&6]?K57Y*_\%QO^1J^$G_7EJ7_ *,M MZ .V_P""'W_(@_%/_L)V7_HJ2O5?^"N7P7_X63^S"_B>T@\W5O!=XNHJRC+& MUDQ%<*/89CD/M#7E7_!#[_D0?BG_ -A.R_\ 14E?H_XL\,Z?XT\+ZQX>U:$7 M&EZM9S6%W"?XX94*.OXJQH _#+_@E-\8_P#A5O[66D:5=3^3I/B^WDT28,?E M$S8DMSC^\946,?\ 74UZ=_P6A^,'_"3?&CPQ\/+2?=:>%]/-W=HI_P"7NZPV MUAWVPI$1_P!=37Q'XV\,Z[\ ?C-JVBO*UKX@\):TT<5PHQ^]@ES'*OL=JN/8 MBK_CWQ9XB_:>^/FI:T;7S?$?C+6@MM91L6"/-((X8%)Y(4%$!]%% 'ZJ_P#! M&?X+GPC\#]>^(5[;[+[Q;?>1:.R\_8[8L@(/;=,TV?7RUKZL_;$_Y-0^,/\ MV*6J?^DLE=K\)_AY8?"7X9^%_!FE@?8="TZ"PC<+@R>6@5I"/5F!8^[&N*_; M$_Y-0^,/_8I:I_Z2R4 ?SL?#SP/J/Q-\>>'O".CM NJZ[?P:;:M_^?SP?_X-)?\ XQ7SE^R#-';_ +57PAEE=8HD\5Z8 MS.Y 50+F/))/05_1M_PEFA_]!G3_ /P*C_QH _%;_AS;\>_^?SP?_P"#27_X MQ7Z6?\$__P!GOQ1^S+\ 5\&>+Y-/EU<:K*?\$2[ZWC^/7CNT=@+J;PUYD8[E4NH0WZNM?> M7_!2+X&WGQV_95\1:?I-LUYKNAR)KUA;QIO>5X0PD10.2S0O* !R6P.]?BQ^ MR7^T'=_LQ_'7P]X[@@DO+&V9K;4K*,X:XLY!ME49XW#AUSQN1<\4 ?TD45QG MPG^,?@WXW^$[7Q'X)U^SU[3)T5BUO(#) Q&=DL?WHW'=6 -\=+ M P8V\&GPR%?[XLH21^ ('X5^DW_!)"UFM_V+]">7.R;5=0DBSG[OG%>/^!*U M?BSX^\8>(?C]\7]8\0W%M)?^)/%6JM*EG:J79I9I,1P1CJ0,JBCK@"OZ)OV9 M_A(/@3\!? _@0LCW&CZ:D5T\?W6N7)DG8>QE=R/K0!Z;7\]?_!2'_D]KXI?] M?MO_ .DD%?T*5_/7_P %(?\ D]KXI?\ 7[;_ /I)!0!^O_\ P3>_Y,E^%O\ MUY7'_I7/7TK7S5_P3>_Y,E^%O_7E#? M7"JV#Z[(1%CT,CBO3?\ @D=KOPJ^#?PM\3^*O%WQ%\'>'O%'B*^%NECJNNVE MM"(W_BKQEK9,<"GAKBY MFPD:^B@N%'8 #TKZ<_X=#_M#?] WP_\ ^#A/\* .S_X*\2?#KQUXZ\'_ !!\ M!^-_"_BB[O+1]*U:VT/6+:[E1HCO@E9(G8X*NZ%B,#RT'<5Z1_P15^.OEW'C M#X1ZC<<2#^W])5V[C;'DAKY^O/^"1_[0UG9SW']D:)/Y4;2>5# MJR,[X&=JC')/85\]?LZ_%V]^ /QR\'^.;<2 Z+J"/=0IPTMNV4N(OJT3.OU- M 'ZU?\%GO^34-$_[&VS_ /26[KY _P"",/\ R=?K?_8I7G_I5:5]:_\ !8G5 M+37/V._#&I6%PEW87GB:QN+>XC.5DC>TNF5@?0@@_C7R%_P1MU"UTW]JK6I; MNYAM8CX4NU#S2!%S]IM.,GOQ0!^WE%9/_"6:'_T&=/\ _ J/_&C_ (2S0_\ MH,Z?_P"!4?\ C0!K44R*5)HTDC=9(W 974Y# ]"#Z4^@#X _X+5_\FL^%O\ ML<[7_P!(;ZOR4^#?P'\=_M Z]?Z+\/\ 0'\1:I8V;7]Q;1W,,++ '1"P\UU# M?-(@P,GGI@&OUK_X+5_\FL^%O^QSM?\ TAOJ^7_^")__ "^$=2\,R70)MY+N,&&;'W@DJDHQ&1D DC(SUKTO] MC;]D_1_VKO&$OA^[^)FD^#-13YXM,N+62:]O(P,N80=D;8&>/,+ G;@9K]V M/V@O@3X;_:.^%>L^!_$\ :TO4W6]VJ@RV5PH/ESQD]&4G\064\,17\[7Q*^' M_BW]F_XOZEX;U1IM(\4>&[Y3%=VKLAW*0\-Q"W!PPVNK=<$=#0!_1#^S_P#L M]^#?V:?A[;^#_!5B]M8JYGN;JX??<7DY #32O@98A0. !BOC_\ X+8? M\FV^#?\ L;8?_2.ZKW3]@G]K&W_:L^"MMJ-]+"GC71=MCKUK& N9<'9<*HZ) M*H+<# 8.H^[7A?\ P6P_Y-M\&_\ 8VP_^D=U0!^7G[-?[,7C#]JKQEJ/AGP7 M+ID6I6%@VI2G5+AH8_*62.,X*HV6W2+QCIFOH[_AS;\>_P#G\\'_ /@TE_\ MC%;'_!%W4K33/VC?&$EY=0VD;>%)E#SR! 3]LM>,D]:_9'_A+-#_ .@SI_\ MX%1_XT ?BM_PYM^/?_/YX/\ _!I+_P#&*_9SX;^'[KPG\._"VB7IC-YINE6M ME.8FW)YD<*HVTX&1E3CBKO\ PEFA_P#09T__ ,"H_P#&KUEJ%KJ4)EM+F&ZB M!VEX9 ZY],COS0!8K\0/^"R7_)W%G_V+-E_Z-N*_;^OQ _X+)?\ )W%G_P!B MS9?^C;B@#[5_X(V_\FCWG_8S7O\ Z*MZ^ZJ^%?\ @C;_ ,FCWG_8S7O_ **M MZ^ZJ /SZ_P""UT&[]F/PC-GA/&%NFWZV5X?_ &7]:^9?^")__)R7C+_L4IO_ M $LM:^Q_^"OGA.Y\2?L>W5Y;PM,NAZY9:C-M&=L9\R M] ;@5^;W_!,SX^:# M^S]^T[::CXHO(]-\/Z[ITVAW6H3-B*U,CQ21R.>R^9"BECPH&=7MM8D\-B[N-5ELY1+%'/-Y2I%N'!=%C< ML 3C> <$$4 =!_P0Y_Y&KXM_]>6F_P#HRXKVO_@M7_R:SX6_['.U_P#2&^KS MG_@AWX7N8-!^+7B.2)A9W5SIVGP2XX+Q)/)*N?83P_F*]&_X+5_\FL^%O^QS MM?\ TAOJ /R4^#?P'\=_M Z]?Z+\/] ?Q%JEC9M?W%M'>F :7XM? 'XB? F^M;3Q[X1U+PS)= FWDNXP89L?>"2J2C$9&0"2,C/ M6OLK_@B?_P G)>,O^Q2F_P#2RUK]6?V@O@3X;_:.^%>L^!_$\ :TO4W6]VJ@ MRV5PH/ESQD]&4G\064\,10!^$_[&W[)^C_M7>,)?#]W\3-)\&:BGSQ:9<6LD MU[>1@986 !.W S7[J?L_\ [/?@W]FGX>V_@_P58O;6*N9[FZN' MWW%Y.0 TTKX&6(4#@ 8K^=[XE?#_P 6_LW_ !?U+PWJC3:1XH\-WRF* M[M79#N4AX;B%N#AAM=6ZX(Z&OW5_8)_:QM_VK/@K;:C?2PIXUT7;8Z]:Q@+F M7!V7"J.B2J"W P&#J/NT >+?\%J_^36?"W_8YVO_ *0WU?.?_!&OPII/CK5_ MC1X=UVRCU'1M4T*VL[NUE'RRQ.\JLOMP>HY'45]&?\%J_P#DUGPM_P!CG:_^ MD-]7A7_!#[_D?OBG_P!@RR_]&R4 ?&/[3WP%U_\ 9+^/&I^%99[A!93+?Z)J MR$H]Q;%BT$RL,8<%2IQT=&QT!KZN_;"_:CMOVJ/^"?/P]UNYEC'BW2O%MOIV MO6RX!%PMC=8F"]DE7YQV!WJ/NFOMC_@I/^R8/VE/@K+J>B6?F^._"R27NF>6 MO[R[BQF:U]RP4,H_OJHX#&OP:6\N8;.:R$TB6TDB2R6^XA&= P5BOM 'Z;_ /!#G_D:OBW_ ->6F_\ HRXK]6]>T#3/%.CW>DZSIUKJVEW:&*XL MKZ%9H9D/\+HP(8>Q%?E)_P $.?\ D:OBW_UY:;_Z,N*_6J@"EJVB:=KVESZ9 MJ=A:ZCILZ>7+9W<*RPR+_=9&!!' X([5<50BA5 50, #H*6B@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "O*?VD_V;O"/[47PVN?"/BR!U7=Y]CJ5O@7%A< $++&3UX)!4\,"1Z$> MK44 ?@9\3_ +2G[-/@_P#:D^',WA/Q=;NH1_/L M-2ML"XL9]I DC)ZC!P5/##KR 1^-GQN_X);_ !S^$NI73:1X?;X@Z$GS1:EX M=Q)*R^C6I/FAO90X]&-?O710!_-PW[/'Q_OK==%?X:?$B:WB (L'T*_*1@X M.PQX ^5>R./.YY&)R\DC=6 M=F))/J>PP*^5_P#@J]\'?&GQJ^!/A?1_ WAV\\2ZG;>)(KN:UL5!=(1:W*%S MDCC>$-1\,1:C:V*6CWR*HF9' MF+A<$] R_G7._P#!5W]D'Q]\6OB]X4\8_#WPC?>)3L:WH-_+:-;7]K&ICE"V4 M"-C+=F5A^%?M/10!\^_L"^!-?^&?[(_P^\->*-*N-$UZPBNUN;"Z $D1:]G= MTMI)X[&U&9;AE0L(T_VF(P/(]9^&.N?VMK^I2WEU<2HBQK)-(68D[OE0%OP ]J_H M&HH Y/X2_#K3_A'\,?"_@O2\&QT+3H;!'VX,A1 &D(_O,V6/NQKK*** /A'_ M (*M_LJ:_P#'[X?>%?$/@G1)M<\7:!>-;M9VH'FSVKB'Q1\.]=TGP9XDL7L]0N9XU\FWFC!DMYFPV>"'C]O.)]Q M^L]% '\[^F_L#_M"0ZC:N_PH\0*BRJQ)B3@ C_:K^B"BB@#COC!\*?#_ ,;_ M (;Z]X)\3VWVG1]7MS#)MQOB;JDJ$]'1@K ^JBOPG\7_ /!.O]H+P-XXU/3] M)\":OK4.FWC+9ZWI8417"JV8YHSNRN1AO4'CJ*_H)HH \._9U\6?$#X@_LYP M_P#"Q_"^H>'/'MO9RZ=?6]Y&%-Y(L>%N$P<8D!!(XPV\8P 3^,/@G]@_]H#3 M_&>@75S\*]>AMX-0MY9)&B3"JLBDD_-V K^@^B@#E_B=\-] ^+_@'6_!OB>S M^WZ%K%NUM#=-?XC>% MFEZ9&0993F6XE8[I) MI#W9F))[#@ 6OC!\(?"_QT^'^J>#/&&G#4M$U! '4';)$X.4EC;JKJ>0? MP.02#V=% 'X<_M!?\$E_B[\,=8NKGP-:#XC>&"S/#+8ND=]"F>%E@8CSA!_M5^R/[- M_P"S?X/_ &7OAS;^$?"%M)Y1?S[W4+DAKF^G( ,LA Z *,!0,#N3ZI10!\ MZ_\ !0KP!XB^*'['_C[PQX4TFXUS7[[^S_LUA:@&279J%M(^ 3V1&;Z U\*_ M\$P_V5OBU\'_ -IQ?$'C/P)JWAW1O[%N[?[9>(H3S&,>U>">3@_E7ZZ44 %? MEU_P5!_8%\2?$#QYI_Q,^%OAR;6]1U;%KKVEV 42>:J_N[H*2,[E78^.ZH>2 MS&OU%HH _)3_ ()<_LM?%CX.?M+76O>-? NJ^'-';0+JV%Y>(H0RM)"53@GD MA6_*OUKHHH **** /DC]N+_@GWX=_:ULX]=TV[B\,_$.SA$,&JLA:"[B!)$5 MPHY(&3MD'S+GHPP*_)CXA?\ !/\ _:$^%>K>7/\ #?7-7$)_C@]O;V%NPFC\(V,XFDG8'(6YF0E M GJD98MG[R\@_K%10!';V\5G;Q001)!!$H2..-0JHH& !P !VK\J?\ @JW^ MS#\5/C5^T1X=UOP/X(U3Q+I-OX6M[*6[L44HDRW=XY0Y(Y"R(?\ @0K]6J* M/B__ ()2?"'QE\%?V=_$6B>./#UYX:U:X\4W%[%:7R@.\+6EF@<8)X+1N/\ M@)K[0HHH **** "OFG]NC]C73/VO/AM#9P30:5XUTZ)X1\<:)?P!HGU;P>9YE>/J3 MYMJ3E"!DAOQ /%;'P[_8+_:._:4\;F\\1>'_ !!I!N)5_M#Q)X[\Z"15Q]XB M?]],<# VJ>P) Y'[\T4 >8?LW_L_^'?V9?A/I7@7PV9)[>U+3W5]. );RY?' MF3.!P"< =E51DXS7I]%% !1110!^6__ 5B_9I^*'QL^,WA#5? W@O4_$VG MVF@"VGN+%%*QR_:)FV')'.&!_&O9_P#@D[\&?&WP3^#/B_2O'/AN]\,ZA=Z^ M;F"WOE :2+[/"N\8)XRI'X5]PT4 %?$__!5[X.^-/C5\"?"^C^!O#MYXEU.V M\217KVUBHWA8SO@E()&>'D0G_ &4%?IG10!^3'[%OP>^. M?PW^!_[0?PR\3?#O7;#3/$_A'4I]&\^-=AU(VDD/DKAN&F5TZ\?N0,\\^%_L MP?L3_'/P?^T=\,-=UKX9ZYIVD:;XDT^[N[N:-0D,*7",[M\W0 $_A7[MT4 % M>/?M6_LXZ+^U'\&M7\%ZIY=O>L/M.E:BRY-E>*#YB7RW%I?6JHRB6-\AE.[#*2/H0?0U^[7P MA\6ZUXY^&WA_6_$GAVZ\)^(+JV4ZAHUXN'M;@9611R][=FQF.1VD6>."8'*RW,@RK,IY5$)&0I+'&VOTU MHH *^,_^"@'_ 3]M?VL+*S\3>&;NUT7XB:;!]G2:ZRMMJ-N"2(92H)5E).U MP#U(((P5^S** /YS_%/[$/[0GPZUH6]Q\*_%DMU&3LN-"L9-0CX[B6VWJ.OJ M#5#3_P!E;X__ !$U*#'PQ\=:C/-D)=:EI5S'&>>K>M?T?T4 ?FM^ MP!_P3!U7X1^,-.^)7Q7-I_;^G_O=)\.VTJSK:38($T\@RC.O550L <-NR !^ ME-%% 'X)?'[]A_X[^)OCM\1]8TOX8:Y>Z9J'B34KNUNHHT*30R74CHX^;H5( M/XU^U'Q&^&__ LS]G_7_ ]W&$EUCP]+IN)/^67<0,M&@ ^IW5^[\?PY'@O]G4^!='B^T'3/"YT>UCC',K M):>4N/=B!^)KTBB@#\)/V8/V)_CGX/\ VCOAAKNM?#/7-.TC3?$FGW=W=S1J M$AA2X1G=OFZ G\*_=>XMXKJ"2">-)H9%*/'(H964C!!!Z@CM4E% 'XY_M=_ M\$D_&7ASQ5J/B+X-64?B3PM=RM,/#_GI'>Z?G)*)YA"RQ@_=P=X! (;&X_(J M_LX?'[PJTMM#\,_B)IPFD\AEMM#OE25\\*"J8?..,9SBOZ1J* /YZ?A=_P $ M[?V@/BMJT-O#\/M4\-VKR;9M1\41-IT4(SRS+*!(P_W$8^U?L[^QS^R;H7[( MOPM_X1S3[G^U=O7\5HMM86H!DE*WL#MC)[*K'\*_%C_ (8#_:&_Z)/X M@_[])_\ %5_1310!_.M_PP'^T-_T2?Q!_P!^D_\ BJ/^& _VAO\ HD_B#_OT MG_Q5?T4T4 ?EY\0OA;\:M,_X)E?#;X0>'O .M7/B?4KFX77K2&-=]G:1WLTZ MH_S<&1F@(P>55QWK@O\ @FW^PK\1/"O[2=CXP^)'@R_\.:1X,/*C4 $_=#O)GL47UK]@** "BBB@#\0OVS/^">OQ1M_VD/&=[\// >I:_X1 MU:Z_M2SN-/13'&TPWRQ8)&-LA< ?W=M?I+_P3Q3X@Z/^S3HGA?XE>'-1\/:_ MX;E?3(%U%0&N+-<- ZD$C"JWE8_Z9#UR?IBB@#\3_P!NO]COXT_$C]K+XA^) M/#/PZUG6="O[J%[6^MHU,:* "OS9_X*X?L\_$?XX>(OAK/X#\(: MCXGBTZUODNWL45A"SO"4#9(ZA6_*OTFHH ^!/^"27P-\>_!#P9\0[7QWX7OO M#%Q?ZA:2VL=\H4RJL;AB,$]"1^=??=%% 'Y-?\%0?V(O'WC_ ./UIXY^''A" M]\26VO:=&-473U4F*[AQ'N8$C :+RL>I1JYS_@G'^PE\1_#/[3&E>+/B/X*O M_#FB>'+::_MGU%%"SWA CB0 $G*[VDSV,8]:_8BB@ KS']I_PWJ?C#]G'XGZ M%HMG)J.KZEX;U"TM+2$9>:9[=U1%]R2!^->G44 ?SK?\,!_M#?\ 1)_$'_?I M/_BJ/^& _P!H;_HD_B#_ +])_P#%5_1310!_.M_PP'^T-_T2?Q!_WZ3_ .*K M[8_X)0_LR_%+X*_';Q1K'CGP3JGAK3+GPW+:0W5\BA'F-U;.$&">=J,?P-?J MC10 4444 %?#W_!6+X,^-OC9\&?"&E>!O#=[XFU"TU\7,]O8J"T<7V>9=YR1 MQE@/QK[AHH _+?\ X)._LT_%#X)_&;Q?JOCGP7J?AG3[O0#;07%\BA9)?M$+ M;!@GG"D_A7ZD444 %?FE^VQ_P2>_X6)X@U+QS\'9;/3=7O'>YO\ PQ=OY5O< MS,W#)U /#=A5WP?\ L/?M"_%#6O*M_AAXHAGD*[[SQ!:/I\>,8W&2 MYV!@!Z$G X%?T5T4 ?"W[#/_ 3,TG]FW5+?QOXWO;7Q-\0(U/V2.U!-EI>Y M<%H]P!DEP2-Y !X7/S'[IHHH *_$_\ ;K_8[^-/Q(_:R^(?B3PS\.M9UG0K M^ZA>UOK:-3'*HMHE)&6_O*1^%?MA10!X-^PIX(UWX;_LF_#SPWXFTR?1M=L+ M69+JQN0!)$QN96 ./]E@?QKS?_@I[H_Q*\<_ .W\"_#7PKJ?B.Y\07Z#5)-/ M0$0VD)$FUB2,%Y/*QZA''>OL&B@#\?\ _@FW^PK\1/"O[2=CXP^)'@R_\.:1 MX,/*C4 $_=#O)GL47UK]@*** "OQ"_;,_X)Z_%&W_:0\9WO MP\\!ZEK_ (1U:Z_M2SN-/13'&TPWRQ8)&-LA< ?W=M?M[10!^4'Q$^$7QQ^) MW_!-OP?\.M4^'NNMXV\+>*8;>.RDC7S9M-CM[CR9A\V-J"58>N1Y8XYS7QK_ M ,,!_M#?]$G\0?\ ?I/_ (JOZ*:* /YUO^& _P!H;_HD_B#_ +])_P#%4?\ M# ?[0W_1)_$'_?I/_BJ_HIHH X+X Z'?^&?@3\.-'U2UDLM3T_PWIMI=6LHP M\,T=K&CH?<,"/PKO:** /B__ (*M_"'QE\:OV=_#NB>!_#UYXEU:W\4V][+: M6*@ND*VEXA=J,?P-?JC10 5\-?\%.OV*;G]HKP3:>,_!FF_:OB'H"B+ M[+#@/J=F6R8N>KH6+KD]"XY)&/N6B@#\2_V,O@[^TM^RO\;]*\51_"CQ+/H% MQ_H.MV,<:?O[-V&X@;N70@.ONN,X8U]M_P#!5SX/^-/C;\!_"ND^!O#E[XEU M*W\217DMK9H"Z0BUN%+D$C W.H_&OMFB@#^=;_A@/]H;_HD_B#_OTG_Q5'_# M ?[0W_1)_$'_ 'Z3_P"*K^BFB@#^=;_A@/\ :&_Z)/X@_P"_2?\ Q5?K%_P2 MN^$OC#X,_LXZMH7C;P_>>&]7E\27-VEI>J [0M;VRJ_!/!*,/P-?8]% !7Y* M?\%1OV6OBQ\8_P!I:UU[P5X%U7Q'HZZ!:VQO+-%*"59)BR$])\>>%]6\.:]91ZEHVJ6TEG>6LH^66)U*L/;@]1R#R*_%;]I3_@DY\4_ MAEXBO;SX>6$GQ \(.[26WV61!J%LF>(Y825\QATW1;LXR0N<5^X%% '\V\?[ M._Q]TV :7'\,_B1:P7.[%FF@WZ++@'=A!'AL G/'>O3?@M_P3*^.WQ=U:U2\ M\)W'@717(,^J>)D-J8E[XMS^^9L9P-H&>K+UK]^Z* /-?V=_@+X<_9K^%.D> M!?#*O):68:2XO)@!+>7#\R3/CN3@ =E55Z"OGG_@JW\(?&7QJ_9W\.Z)X'\/ M7GB75K?Q3;WLMI8J"Z0K:7B%SDC@-(@_X$*^T** /RN_X)0_LR_%+X*_';Q1 MK'CGP3JGAK3+GPW+:0W5\BA'F-U;.$&">=J,?P-?JC110!\-?\%.OV*;G]HK MP3:>,_!FF_:OB'H"B+[+#@/J=F6R8N>KH6+KD]"XY)&/C#]C+X._M+?LK_&_ M2O%4?PH\2SZ!(/#WB7??75EIJKG3[S=^]7:2,(Y(=<="77 "C/[%44 ?F MS_P2/_9Y^(_P/\1?$J?QYX0U'PQ%J-K8I:/?(JB9D>8N%P3T#+^=?I-110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?G7^UU_P %/?$_ MP+^.^N>"_!GA+2?$NB>&K>V;6KZ[\XO%-(R[U5D8*H EB3D'#EA[5]^>#_%> MF^._">C>)-'G%UI.KV<-]:3+_'%(@=#^1% &Q1110 4444 %%%% !1110 44 M44 %%%% !1110 445\D?L9_MC>)OVDOBM\6_"VN:+I.EV?@Z[%O:3:>)?,F4 MSSQYDWN1G$2G@#DF@#ZWHHK%\::Y+X9\&Z]K$$:2SZ?87%W'')G:S1QLX!QV M)% &U17S#_P3_P#VJO$/[7'PIU[Q3XCTC3-&O-/UI],CATL2>6R+!#(&.]F. M[,I'7& *^GJ "BBB@ HHHH **S/%&J2:'X:U;4HD626SM)KA$?.UF1"P!QVX MKYN_X)^_M8^(OVNOAKXC\2>)-'TO1KK3-7.GQQ:6)-C)Y,/_LG_%;Q?\:/@EI'BOQSX:_X1'Q)=37$<^E?9IK?RE29D0[)27&Y0#SZ M\5[!0 4444 %%?)W_#7WB3_AX'_PH/\ L;2O^$;^P?:_[3Q+]LW?8OM&/O[, M;N/N]*^L: "BO.?VBOB7??!OX&^-O&^F6MO>ZAH6F2WT%O=[O*D91P&VD''T M(KD_V+OCUJ_[2W[/NA^/M=T^QTO4K^XNHGMM/W^2HBG>-2-[,>0H)YH ]RHH MKQK]K;XM>,?@G\%M0\5>!/"__"8>(H+JWABTO[--<;T>0*[;(2'.!SQ^- 'L MM%<5\%/&&M?$#X1^$/$GB/2O[#U[5=,@N[[3?*>+[-,Z M'L?YEP3C#&_MH_'K5_V:?V?=<\?:%I]CJFI6%Q:Q);:AO\ )82SI&Q. MQE/ 8D/-6L[6PU'6[1KB:VLMWDQL)'3"[B3C"CJ: M /4J*** "BBB@ HHHH **** "BBLWQ)X@L?"7AW5=W4JH7*1 M1H7=@HY.%4\#F@#2HKQK]EK]IK1?VK? ^M>+?#NEWFF:-9:U-I-O]O9?.N%C MBAD\UE7(3)EP%RW"YSS@>6_#']L;Q-XX_;J\=? ^[T728/#^@6DUQ!J,(E^U MR,@@(#9] 'J]%8OC37)?#/@W7M8@C26?3[" MXNXXY,[6:.-G ..Q(KY[_P""?_[57B']KCX4Z]XI\1Z1IFC7FGZT^F1PZ6)/ M+9%@AD#'>S'=F4CKC % 'T]117YJ^-_^"LFK^%_VCM3\.V_AC2;GX4Z7XDBT M&\\1L)C.B[BDL@43\: /TJHIL9I]K%3B9I88F.>JH&*D8W58L_\ @I/\ M:_@'XDTS3OVCO@Y_8NC7KB-=9T6&2(@=RNZ22*9@,DHKH6=Y"Q!'7FOS$^&O_!2_P#:5^-%YKD/ M@'X-:!XI71Y$2\-C'\M_P#ODT ?J=17YK:I^W?^UWX0\V[U M_P#9G9M.MQOG:ST^^.U<9)\Q6D4 #J<$#O7T1^Q[^W]X'_:X6YTJUM)O"OC2 MTB\Z;0+V99?,C!P9()0%\U1D9RJL,],)=2U&'3M+T^\WF.1CEY&8(0Q"QHW0CYF3UQ0!]$T5\N?L'_M@:A^U7X6 M\5Q^)](L_#GC3PSJ7V2_TNSWA5B8'RWVNQ8'>DR$9X,?OBOJ.@ HKYV_:\_; M>\#_ +(>AVW]LI)KOBJ_C,FG^';.0)+*@.#+(Y!$4>01N())!"J<-CY>T?\ M:R_;C^*ENFO>"_@7HNG^')%%U:KJ4#QR30D K\T]U$9,CD&-%R#QZT ?I517 MYY_#3_@J-KGA#X@6W@7]H_X=2_#+5IVVC6;>.5+1?F\E#&8T.#M>65,_P!VL?6OVR/VSO@;8CQ%\3_@9H]]X1AQ M->3:4#YL$1YRTD-Q.L2@ Y,D?!(R1TH _2JBO(_V9_VG/!O[5'P]3Q1X2N'C M>)A#J&E71 N;";&=D@!Y!'*L.&'N"!ZY0 4444 %%%% !1110 4444 %%%% M!1110 4444 %%9_B*^N-+\/ZG>6D/VFZM[66:&':3YCJA*K@"_L2_ M'SXB?M!> ==UGXC^"?\ A!M4LM3^R6UG]BN+7SH?*1_,VSDL?F9AD<<4 ?15 M%>$_LW_M>>%_VH/%7Q!T[PE87L>E^$IK6V.I7H$?VV24SABD7547R>"QRV[[ MJXY]VH **** "BBN _: ^(E[\(_@EXX\::=;6]Y?Z#I%QJ$%O=;O*D>-"P5M MI!P2.Q% '?T5\]?L,?M'ZW^U-\#5\;^(-,T_2=0.IW%C]GTT/Y6V,)@_.S') MW'O7T+0 4444 %%%?)W[>7[7WB3]E'_A77_"/:-I6K_\)+?SVES_ &F)?W2I MY."FQUY_>'KGH* /K&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH *Y;XJ?$/3?A+\-_$WC/5SC3M"T^:_E4' M!DV(6"+_ +3$!1[L*ZFOSM_X+)?&:;0?A3X9^%NDL\NJ^+KT7%U;P L[6L#* M43:.27F:/'KY3"@#S3]B']F[4OVF?V:_VA?&?BA4G\0?$VXF@T^XF7'^D0.U MP)@>R&[=!C_I@17LO_!(/XV3>+O@GK'PTUEVCU_P->M%'!-Q)]CF9F4$'DE) M1,A_NCRQZ5Y[\"_^"AUA\#O@_P"$O FF_ 3Q]);Z'I\=JTRVVWSY<;I9<;." M\C.Y'JU?/WP7_:0M_AC_ ,%$_P#A8$7AK5_ ?@WQY?M:ZAINM1&)HUNBGF29 MP 46ZVRY X7(H _4/]MC]H+6?V8_@'J?CS0=.L=5U&UN[:W6VU'?Y)660(2= MC*<@'CFOFBU_;T^/7Q\T?3G_ &>_A#:>(XK>P@76M?U@-#9+J!A5[B"V\R>( M$1LV 6=B>/EP06]%_P""MG_)EOB#_L)Z?_Z/%>F?L#^';/PS^QW\*;:RA2&. M?18KV38,;I9R9G8^I+.: /EWX:_\%9M2T7_A,/#'QD^'TVC?$K12(K#1=!AE M']IW1D6,6@C%-28!AGD6SD'\" ?PH Z3X"_&; M1?V@OA+X<\?: LD.G:Q 9/L\W^LMY58I+$WJ4=67(X.,C@U\Z_M6?\%!#\(_ MB3:_"?X9>$9OB-\5+DQJUC'N^SVC. RHX3YG?9ABH*JJL"6X(JM_P2)F>3]C M32E9BRQZQ?JH/8>8#@?B2?QKPG_@EK8)X^_:R_:#\>:XBS>)+>Z=(VFY>+[3 M=SM+M!Z8\A%]@<#@F@#L_%'[8W[7WP'TV/Q7\5_@9X?E\%+(C7DWA^X)FM(R M<'>R7,^SM\SKMR<;N<#[8^!WQL\,?M"?#32?''A&YDGTC4%8>7.H2>WE4[7B ME4$[74CU((P02"">PUK1K'Q'H]]I.IVL=]IM]!):W-K,NY)HG4JZ,.X()!^M M?FS_ ,$:;^;1]8^.W@R*9Y])TK5+2:V;=E Q:YB9OJRPQ<]]GTH OZ#_ ,%4 M?&.K>*/'?@NP^&T/BOQ];:VVD^&-&T-9@+B-'G6:XN6);"H(XCA=N=S9*@%A MG>,_V]_VK?V=;K3]<^,WP5T&T\'7DZ1%]+9D9"RY""9+F=$:?Z%XTT2Y\S0M8L8]0@EEPI2 M-EW$/SA67D,,\%2.U?"NM_\ !1#XL_'3XG:OX2_9@^&EAXNTW26,=UXCUTL( M)!DJ)%_>PI$I()3>[,X&=@Y ;\,?$.H^&_\ @C%/?Z=(ZW@\-ZI;B1>65)+^ MXB/?$S_@IQ\8/@'X>U'0OBE\(K/PO\2?W4VE.I>72-0AWA9L,DK89 M0<@K(X[-M.-WWW\%O&UU\3/@YX$\7WT$-K?>(-!L-6G@M\^7')/;QRLJ9).T M%R!DDX%?)'_!8OPCIFM?LI0ZUU M?2O[)W_)K/P;_P"Q,T;_ -(8: /5:_$[]EW]I36/@%\?/CIIGA'P9>>._'WB MS76LM$TF $1%H[NZ:225AR%56!XQWRR@$U^V-?F#_P $K_!^G:C^U!^TAXFG M@CDU/2M1-C:R,,M&EQ>7;2;?3/V9!GKV[F@#IO$W[=/[3/[.-[INL_';X*:1 M:>!KRY6&2_\ #<^^2VW?PEQ/CBUNC(8-+NM9L[7>21Y1M(Y MCM]!OFD_'- $W_!$_P#Y-M\9?]C;-_Z1VM>I_!_]L;Q-\1OVX/B)\%+W1=)M MM \-6ES<6^H6XE^U2M');J ^7*X(F;HHZ"O+/^")_P#R;;XR_P"QMF_]([6N M3_9==5_X*]?'$%@"VFWX )ZGSK(X'X _E0!^B'Q.\4W'@?X:^+/$EI%'<76C MZ1=ZA%%-G8[Q0O(JM@@X)4 X->-?L(_M+:[^U9\$I_&GB'2]/TB_CU>XT\6^ MF"3RMD:1,&^=F.29#W["O2OVAF"_ 'XF$G 'AC4R2?\ KUDKY"_X)+ZN_A_] MA_Q)JD<1FDL=:U.Y6-1DN4MH& 'UQ0!T'Q^_X*#^(=)^-TWP<^!OP_\ ^%E^ M.K,E-0GED(M+60 ;TPI&=A8!W9T5&^4Y.<<;K'[4O RAI#$66)SEFDWMDC/R\<5](?&+]J+]H;XS?"OQ5X' MU7]D?7H[+7M.FL6F+7$A@9E.R95-O@LC[7'NHH ^]K[QEH_Q"^"=]XFT"]CU M'1=6T*:\M+J/H\;P,P..QYP0>000>17Y$_\ !//]J+QO\,?AQK/PW^$_P\E^ M('Q'UO6WU)([AO+L;.T6WB0R2OO7DNN/F9%''S9(!^T_^"?/A;QOX%_8@\2^ M&_'?A_5O#>HZ7<:I%:6>KPO%(;9X$E#(K?P&224<<9#5Y]_P1*\'Z=:_!7QY MXJ6"/^U[[Q#_ &9)-CY_)@MH9$7V&ZY<^_X"@"XW_!0CXT_L[^-M&TO]IGX4 MV/AWP[JSM'#K_ADF1$(_BP)IDDVY&Y RN%.<'H?L7X^?%F;X7_L_^+OB'H"6 M>KRZ5I#ZG9+,Q:WN %#(25()4@@Y!KR#_@J!X3TWQ1^Q7X\FOX8GGTDVFHV4 MT@YAF6YC3G?#G]L;Q-XR_8+UKXZW6BZ3!XBL;2_N$TV$2_9&:"9HU!R^_!"C/ MS5\YZ;_P4]^-_P 8?#N@VOP?^$UIXH\46]HUUXFFBT^[NK.T^!/\ RAD\6?\ 8,UG_P!*I*]<_P""0OAFUT3]CVQU&&*- M;G6=8O;J>15 9BCB%0Q[X$7'UH [_7?VQ)?@W^R3H'Q7^+OAX^'_ !1J4"JO MA:SWI++=.7,4($HW1DQJ'?=DH-P^8@ ^ >&/VMOVT_B#H*>/_#?P&\/3> Y5 M-Q;6,SNM_B+^&X^M?IU!!':PQPPQK%#&H1(XU"JJ@8 '0 4 ?DC^SO\ M;K#]HC_@JYH_CC3]+O=$6\T>6"XTW4 !-:W$6FM%+&2.H#HV#@$C&0IR!^N5 M?F-HO@^P\'_\%JYUTZ%+>'4]/GU.2./H)I=-8RL?=G#.?=Z_3F@#PK]NK_DS M_P"+?_8OW'\J_/O]B']JSXL6?P'\.?"GX$_#&/QIXHTM[R[UC5M:?RM.LEFN M9&B4'S8P6*G/S.I."%5L$C]!/VZO^3/_ (M_]B_:#IUCJNHVMW;6ZVVH[_)*RR!"3L93D \O+G MS22_FR)"[[B>^2/7AT:RN-"M]5O8;)68>;*J[8 M858Y9F=@J@GJ1D@9-?*WAC]MS]JG]HR.\U_X(_!'11X*BF9+:^\37&)+G9U" MNUS C$D$'8&"DX+9&:\._;>\07]G_P $X?V8='A9TTZ_M;6>YVG 9HK/$:GU M'[USCU4'M7ZO_"KPAIO@#X9^%?#>CQ10Z9I>F6]I L/W2JQJ-WN3U)/)))/6 M@#Y6_9K_ ."@FI^,_BY)\'_C-X)?X:_$MG*V<:[OL=V0I8(-Y)5F )0AG1^S M9(#?:=?F+_P6>TVW\+7GP<^(.FA+3Q18:A/!'=QG;*R1F.>+D=D<,1Z&0^M? MII9W'VNT@GV-'YJ*^QNJY&<'WH FHHHH ^/_ /@K!_R9+XO_ .OW3O\ TKBK M/_9[^)=]\&_^"7>@>-],M;>]U#0O#-Q?06]WN\J1EFDP&VD''T(K0_X*P?\ M)DOB_P#Z_=._]*XJX#PU_P H;9O^Q,N__1TE '/>"?\ @I)\8_CUX1T33O@Y M\(K3Q;X^6 S^(+J;S(](TUC-(L4(+RIEFC5&RTRC). V#ML_#;_@HU\5/AY\ M;M!^&G[2'PZL?",^M2106VK:;NB6(R/Y:2N#++')&7X9T3@XQ7H/_ 2' M\-V>C?L=:;J$$,:7.KZM?7-Q(J ,[))Y*[CWPL0Q]:\>_P""UT*+9_!2X"@3 MIJ5^JR#[P!%J2 ?J!^5 'Z&_%+XG>'O@W\/];\9^*KT6&A:1 9[B7&6/("H@ M_B=F*JH[E@*^#O"W[;O[5/[2#76N_!'X)Z&G@B&5HX;[Q+.=]R4)X61KB!&S MC:0@8*Y8DL3U))/>@#YN_95_;T MU7XH?%;4/@]\6?!O_"O/BG:*[16L;,;>]**9'5%;)1A'\X^=U=02&Z _9->< M>(/V=_AWXH^+6D_$[5/#,-UXZTJ%(+/6//F5HD0N5&Q7"$CS'Y*DX.,X ]' MH **** "OG+]N[Q)\3_#WP)UH?#?PGI_BF*[L;Z#7FOKI(38Z>;63S)X]TL> MYAS\HW'_ &37T;7G_P"T)_R0+XE_]BSJ?_I+)0!^<'_!)GQE\;=-\(V6B>&? M 6DZK\)KGQ-,VL>);B]C2ZM)#!")%2(SJS *L1XC;[YZXXY/4_CY!^SI_P % M/_C%XE.@:CXJU.Z@ETO2M%TM-TU[>2K:>5'G!(!VG) 8^BDX%?2W_!&'_DU# M6_\ L;;S_P!);2O+/@IX=L]<_P""RWQ(N;N%)9-*@N[VWWC.R7[/;P[A[[9G M_.@#I/B!^V5^V;\(M'?QQXQ^!'ARP\!Q;'N$BE:6X@C/>1H[MVB.2 6>+ X! M -?:O[-WQ]T/]ICX0Z-X]T&&6SM[[?%<6,[!I+2X1MLD3$<'!Y#<95E.!G T MOC]8P:I\"?B-9W,8EMY_#FHQR(W0J;:0$5\6?\$@]=FT3]B[Q[J2H9VTWQ+J M,\<2C);9I]F^T>N3G\Z .R^/W_!0?Q#I/QNF^#GP-^'_ /PLOQU9DIJ$\LA% MI:R #>F%(SL+ .[.BHWRG)SCC=8_;F_:1_9PNM.U/]H+X+:;;>";JX$,NL>% M)@[6V_D XN)DW Y 5RF['#'J?D__ ()\?'#XH?"FW\=>(O!7P2U3XMZCKEY& ME_KL#REX&4-(8BRQ."_&6C_$+PCH_B;0+V/4=%U:UCO+2 MZCZ/&ZA@<=CS@@\@@@\BMJOD+_@EOX6\;^!?V7_^$;\=^']6\-ZCI>MW<5I9 MZO"\4AMG6*4,BM_ 9))1QQD-7U[0!^7G_!:JWCN_$7[/T$R"2&6ZU9'1NC*7 MTX$?E7+^%;[4/^"6'[9L_A_4IKA_@AXZ<-!:)J M,@_X]KM5.T$]?+<91QZ-G&5% 'HOQ2FCN/A+XOEB=98I-$O&21""K*8'(((Z MBOB/_@B?_P FV^,O^QMF_P#2.UKE_P!A/]I[5+[X0?$3]G_XB^;8>.O!VC:A M;Z='>G$LUK%$ZO;'/5X",#'6/&.$)KJ/^")__)MOC+_L;9O_ $CM: /J/]L7 MXV+^S[^SCXU\91S"+5(+,VNE^IO9OW<) [[68.1_=1J_/?X<_L> O@WI4 M=YJ$=I_Q/-5M=-0RS/(X9(45!_&L0F?'I*IKTK0O^"H6G>&_#FGZ#I_[/'CR M#2=/M([&WM1;Y1(40(B8V= H H ]I_X)J?'C_A>7[+/ATWESY^O^&?\ B0ZC MN/SGR57R9#W.Z$QY;NP?T-+X1_MB^(/!/7ECT_2]60QR MVLJ.\ED'R!D[#)#D#YF=:_6OQY\6/ WPW:RMO&/BW0O#DFI;DM+?6-0AMWN\ M%581H[ R8+J#M!QN&>M 'RG^Q7^WE\$-8^"7@;PG>^*=+\#>(-%TFUTRXTO6 M7%G$9(HUC+QS/B-@Y!8?-N^;D9Y/OW[07P9\-?M:? W5?!\VJ6YT[5/*FL]9 MLU2Z^S2QR!EEB(;!/#*<,,J[#/)KR7XP?\$NO@+\6[RZU!/#]UX,U6X)=[KP MQ<"V0L3G/D,KQ#D\[4&?6OD?XH?\$Z_B[^QSI.J?$CX(_%*_O;71XFO[W3U5 MK2Z\F,%G)0,T5R%4%BKA<@$!6. 0#])/V<_@K!^SO\'=!^'UKK5UK]GH_G+! M>WJ*DI229Y=I"\84R$#V K\__P#@B/\ \A7X\_\ 7;1__0M0K[#_ &$_VG)_ MVK/@'9^*]2M(K+Q!8WS^19KF MW>,3L1T GAG",!][#D\L2?UKK\N?^"W.J1W\/P>\-VJBXU:XN=0N%A09<*1; MQH/^!,2!Z[#Z4 ?J#;7$=Y;Q3PL'BE0.C#H5(R#^5?F9^T5J$O[6'_!3?X<_ M#"S;[3X6^'C)?ZH/O1>:FRYN-V.S!;:W]F)K[[\<>-K'X$_!'5?$VLOOM/#& MBFXE!?F9HHL*@/\ >=@%'NPK\?OV'?VJ)_@GXP^(/Q*U_P"&GBKQ]XE\8SEA MJNDVY\J-6F>6X 8J$-9\-77*V.VX@2 >DBT ?!O[#^BV'[;'[<7Q.^+WC"#^VM+\/2+/I%A> 210^ M9(\=D"I^4B.&%R!C&_#]1S^LU?E;_P $5;H^%_&'QL\%ZE&MKK<)L9'MWP)! MY$ES%,".N%:1![%O>OU2H ^J@CR[_ ()'?&B_^)_[,C:#JUQ)=7_@^_.EQ32MN8V; M(LD S_LY>,#LL:U]8?%[Q)9^#OA3XRUW4'6.RTW1KR[F9NFU(78CWZ=*^ O^ M"(>A7EM\+_B7K,B,+&\UBVM(7/W3)#"6D ^@GC_,4 ?I77P-_P %C?B]?>!/ MV>='\):;-+;3>+]2,%U)&VW=:0*'DCXY^9VA![%0P/6OOFOS&_X+A^';JZ\$ M_"C741S966H7]E*XSM$D\<+H#[D6\F/H: /LO]C?X#Z3^SS^S[X3\.6-E%!J MZQR(&E9VZD*3L7/1445[5<6\5Y;RP3Q)/!*I22.10RNI&""# MP01VK&\">([7QCX'\/:_8NLEEJNG6]] Z#"M'+$KJ1[885NT ?+7[+_[".F? MLM?%[QQXO\/>+;N;1?$AD2/PPMFL5M9Q&;S(EW[V+F(%T5L+\KGCO2?ME?MW M:+^RU<:5X8TK0[CQI\2-:C#Z?H-J2 BLQ2-Y2H+' M -;^(FH^ K+Q?I$_C33VVW&A?:E6[4^6)#MC."^%()VYQSGYW_!>P3XF? M\%COB/J'B%%GG\.6]U-I\<_(0PI;VL14=,A)&<>^6Z\T =OK7[4O[;W@/P_- MXR\2_ 3PW-X5AC\^>ST^1FO8(AR69$NY''RDY_=';MR0N.?JW]EG]J3PG^UA M\.!XJ\,":RFMY?LNHZ3=E?/LI]H;:<<,A!RKCAAG@$,H]CZ\'D5^8'["=K;_ M U_X*6_'WP-H48M_#,/B9\$- TWP%,$G"M*ES+Y3GIF2, D# &:RO@IX= ML]<_X++?$BYNX4EDTJ"[O;?>,[)?L]O#N'OMF?\ .OJ__@I1!'S+>0$'\"!0!Y)KG[?WQ+^.5P+']EOX5MXWBM[:&;4=?\ $/\ H]G: MS21JYM0&EB4RH&P?WO4'"LN&-S]E#]O[QEX[^.5Q\%OC5X(MO!/C\H[6CV*R M1Q2ND?FF)XW=\$QAG617*L!@ 9&>X_X):Z%::+^Q#X!EMHDCFU![^\N750#) M(;V9 Q]2$C1<^BBOGK]IO_1?^"OGP1DA'E/)IEEO9>"V9;U3G_@/'TH ^O?V MV/V@M9_9C^ >I^/-!TZQU74;6[MK=;;4=_DE99 A)V,IR >.:^9_#?[=G[0? M[2EG WP!^%&D:E8V%G;+K/B#Q [16IOVA5YX;97FBX1R5'S.V,$A=P->C?\ M!6S_ ),M\0?]A/3_ /T>*]4_87\(:=X+_9#^%%GIL4445UX?M=3F,?\ '-1B>YW2$?ACM0!XO^SG^W]XGUGXU?\ "F/CQX'A^'?Q$G;;8S6;,+*[<@E8 MP&=\%@#L=9'1SP"#@'Z*_:3_ &CO"?[+OPRNO&7BQYI(1*MM9Z?:@&>]N&!* MQ1@D <*S%BQO;J.*YC&)7$3030\^B M/O(]#(?6HO\ @JLLGCO]IC]G7P+J>Z/PYJ%U&)HW8JI-S>PPR[L'J$1>>VXX MZT =AX8_:V_;.^,.BIXR^'_P(\-P^"YB9[./6+@K=74.>"ADNH2XV\AUC ;' M&>A]A_8]_;RM?VA_$FJ?#_QAX;N/ /Q4TA9'NM%N0RQSJC .8M^'5UR"T;#( M'(+ -M^KK6UAL;6&VMHD@MX46..*-0JHH& H Z 8Q7YB?MR6MO\./\ @I9^ MSYXMT6,6VJZS<:=!J M_E>X'VS[,S-ZEH9/+]P@% 'T[^V3^VA-^SCJGA?P9 MX1\+2>.?B;XI;&F:,K,L<:%BBR/M&7W."H0$9VN2R@<^&^+OVI?VV_@YX>G\ M9>.?@IX1N?"=JOGW\6DSEI[2( 9),=W*5&,DL4<+SG KH/\ @H'^RK\4O%GQ M8\$_'+X,.MYXT\,6R6LFF-)&LA2.222.6(2D(_\ KI5>,D9&W ))KS*'_@JI MXV\ ^9X9_:&^!%[IL%Y&UM=26MO+:>?&P*N!;70*RJRD])0"/8T ?;OP1_:8 MT3]H']GX_$WPS;O;A;6X,^FW9W/:W4*$O"Y&-P^Z0PQE64X!.!\]?L\_MI?& MG]I/]FWQ=XR\&_#_ ,.ZOX\TK78M-M-%2X:WMIH#'$\DC/-.OS .?XQT'!KV M?X+?$#X2?$C]FOQ!JWP:L-+TCPPUI>"?3=,T^.P-M=>1\ZS0H !)MV9;G<-I M!(P:^;?^")?_ "0+QU_V,Q_])8* /F[_ ()H^-?CKX=\5?$&/X9?#[2/%=A? M:K8#Q+-?WT4#:@6SE3MW!!))M#-@N=JJJDNP8#&"1\S_P#!&'_D*_'W_L)Z?_Z%>UX] M\5?B5XNL?^"JGB_Q/X?^'E[\4-9\-8AT_P /1E\PI':1Q>O? #P]+X2BA^T3:?9S,=0@A #%F5;IY <$Y_=$ MKMY48Y^K/V7?VGO"O[5OPUC\6^&!-9O#,;74-+NROGV5P%#%&P<,I!!5QPP[ M @@?,'_#=_[2_P#T:-X@_P"_US_\CUR'_!,WP+\3/!W[2GQ8U3Q)\,]<^'7A M3Q3:3:G!9WEM)':6\XO%:.W1F502J3RA> =J&@#]+J\4_;6_Y-'^+W_8LWW_ M **:O:Z\4_;6_P"31_B]_P!BS??^BFH ^>/^"4.J2:'^PSJ>I1(LDMGJFIW" M(^=K,D:, <=N*\^^&/\ P5.^)GQD\&QZ+X'^%-MXM^+ES=SD6&GK,NFV%BB1 M;)YV9\DL[2+CS$4;1E@2 >T_X)>_\H__ !'_ -?NK_\ HA*Y/_@B+X;LX?A; M\1]?$,?V^YUF&Q:;8-_EQ0!PN>N,S$XH BOO^"B_Q^_9S\<:-8_M%_"33-&\ M.ZI,RK?:'N$B*"-[1N)YHI=@9?DRK$?Q9.:_136O&VA^'_!EYXLO]3MX/#EI M8MJ4VH[LQ"V5/,,@(ZC;SQU[5\6_\%EK>.7]DO3W=%9XO%%FR,1RI,%R"1^! M(_&N?_;*\27VB_\ !)_P;':NZ_VIH?ANSN'7KY9AAD.3Z$Q@'ZX[T 4='_;V M_:+_ &EO$&KS?L[?!_2KWP;IDQB.J^)Y-K3D'(&XW$,:LPQF-3(RAP2PZU\S M_MS?M-^)?C1>?#+P?\1/ USX!^)?A3696U2PP3:3QS>1Y4T#%B=IV-QEAT(= MLG'Z;?L$^%=/\'_L>_"JUTZ*...ZT2'493'_ !S7 \Z0D]SND(]L8Z"OD3_@ MLIX/L%U[X*>*DA1-4;4)M,FF_BDA#Q21J?96,A_[:&@#]$_B5\1-"^$O@/7/ M&/B:\%CH6C6K75U-C)VCHJC^)V8A57NS =Z^#O"_[<7[47[2$-[K?P.^!^C_ M /"'PSLD&I>)KGFY"$Y56:>!&8D;2$W!22"W&ZK?_!:KQ->:;^SUX0T:W>6. MWU3Q$KW+(2%=8K>4K&WJ"S*V/6,'M6'\*_VNOV@/AO\ #7POX7T']D;7&T?2 M=-@L[:2*2X42HB >9Q;XR_WB>Y8GO0!Z[^S=^WQJWC+XN2?![XR^"'^&GQ-; M)LXE8FSO<*6VJ6)*L5!*D,ZO@X;. >@_;P_:4^*'[*_AO1O&7A/PMHGB?P<9 M1;:P;T3BXLY&;]V^Y'"B-_N;BOROMSG> /AW]IWQ!^T)^TC\1/ASXS7]FWQ1 MX/USP=<^&_$%C M%J>BZI;/:7=I,/EDC<8(]0?0CD$ CD4 <-X?_:4\":]^S_#\8QJR6O@LZ<=1 MFN)B-\&WY7A8#K*) 8]HZO@#.17C7[#_ .U5\2?VMK[Q/XFU'PCI/ACX9V<\ MEMI=QB9KV\EW9"[B^PA$QO8+@LP"]&Q^5.O:>/#/QCU']FA?BH(_@T_C6,SZ MH.8$;(C,C'&-R A&_P"6?F1AN@#5^]GP_P# >A?##P5HWA3PS81Z9H.DVRVU MI;1=%0=R?XF))8L>222>30!T-%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 5^5GPKF_X;0_X*I:WXP;%[X,^'*L+%C\T;"V8Q6^T M_P"WA^&&G.C:-I^DF?;YIL;6.'S,9QNV@9QDXSZF@#6 MKX0_X*_? _\ X6-^SI;>-;&W\W5_!5W]I=E&6-C,5CG ^C"%\]EC:ON^H+VR MM]2LYK6[@BNK69#'+#,@='4C!5E/!!]#0!^77Q\^.W_#0G_!)&R\175P;C7+ M.^T_2=79CES=P3(K.WO(GER_]M*^X?V*?^31_A#_ -BS8_\ HI:],C\ >%X= M+FTR/PWI$>FS.)9;-;&(0NXZ,R;<$C Y([5L6-C;:;9PVEG;Q6EK"H2*"! B M(HZ!5' 'L* /S2O/^4WMA_V##_Z9'K[4_;$_Y-0^,/\ V*6J?^DLE>F'POHQ MUP:T=(L3K &T:A]F3[1C;MQYF-WW>.O3BKUY9V^HVDUK=P1W5K,ACEAF0.CJ M1@JRG@@CL: /C#_@D-_R9MIW_8:O_P#T-:^>_$=SK_\ P31_;8\5^/-1T/4M M9^#?CZ662>_L80PMGFE,VS/"B6*3S J,PWQMD<]/U+T?0].\/68L]*T^UTRT M#%A;V<*Q1@GJ=J@#)J74M-L]8L9;._M(+ZSF&)+>YC$D;C.<%2"#R!UH ^%O MC5_P5L^$^E_#^\3X8WNH>,?'%_";?3;)-,G@2WN'!5'E,J+N"G!V)N+'"\9+ M#?\ ^"6_[,?B#X _!_6]=\96DNG>+O&5W'>7%E<9$UO;1*P@24'[LA,LSD=0 M)%!P00/J'PU\%_A]X,U=M5\/^!/#.A:HQ)-]INCV]O.NRH _,K M_@E1_P G)?M-?]A-?_2R\KZ@_P""D/\ R9+\4O\ KRM__2N"OH'2?"^C:#(-'O-)\ :QI_@N"STG54L+A=)C2%$MX;DHQB)3&W;YA M!(Q@\U\%_ G_ (*5>&K[3]<\#?M36EOX5\:Z3?M"R76ARR6DJC: KQHLA216 MWDD@(05(- 'S_P#\%"OVQ[_]K+X6P1^ /"VM6?PHT/4XGU/Q%JD*PK>7S*RP MPH 3PJEV(R22RDJH4%OU#_91C:/]EOX.HZE77P;HX*GJ#]AAK\\_VU/VF-)_ M;J'@_P"!'P!T^\\3B?4XK^\U1;*6UMHD1&15VN@98D\TN[LJ@;% W9K]1? _ MA>W\#^"_#_ANU8O:Z/I]OI\3'J4BC6-3^2B@#;K\3/V4_P!I._\ V7?VFOC' MXIU/0]0U3X:7>NRZ9XBO=/B\QM.E>ZN6LYB._*3KCC(8X.X*K?MG6+#X*\/6 MT&I0PZ#ID4.I#%]&EG&%NASQ* OS_>;[V?O'UH _/?\ :S_X*/>$/C!\+[[X M7_ Q-5\<^,O&D#:1_HVF3Q"VAE&V90LB*SR,A=!M&U,$<$(-L>>^S/?%>\>$?A/X(^'\\LWA M?P;X?\-S2DF232-+@M6?/)R8T&,+,XOK2#<1'+ M%&LFW.%9XYH02N<[&!ZL*_5#1/#ND^&;9[?1]+L]*MW?S&AL;=(49L ;B% ! M. !GV%)K_AO2?%6G/I^MZ79:Q8..O&'BG3IK&2:.PEMK?3[1X\7,LC2A3E8V89 V@_,6P & MZ+_@CG"EQ^R%?Q2*'C?Q+>JRMT(,-N"*^Q_"/PQ\'?#^UN+7POX2T/PW;7 Q M-#I&FPVJ2CGAA&H!ZGKZUKZ-H.F>'+,VFDZ=::7:EBY@LX%A3<<9.U0!G@<^ MU 'Y0?!?QKJG_!*G]H+QAX,^(&DZI=?"3Q/<+)I?B*VMC(/D)\J88X8B.39+ M&/F!52H(QN]D_:2_X*L>![GX?W&@_ R^U+Q;\0]:06FGS6VDSQK8NYP7V31@ MR2@?=558%B"3@8/WWK>@:9XFT][#6--M-5L7.6MKZ!9HF^JL"#7/^$_@_P" MO 5\][X9\$>'/#MX^XM<:3I-O:R-N^]EHT!.>_K0!Y?\$]-^)^G?LHSM\8=: M;6?'EUI=Y(M3:.V\0V=NTT=GJD4,1EC=5Y(:&2$G'(VK@,-VW]J9(TFC:.1 M5=&!5E89!!Z@BL"3X>>%9O#]SH3^&='?1+I_,GTUK"(VTKW:Q^5>2.P M]* /S8_;,_;'M/VT-#LO@/\ L_6&H^,KKQ!=0RZIJ?V.2WA6WBD$@0"55=5$ MBQN\C!54)CG<)?B=X#\+?$;P+;37?BWP'-?XFB>)'"XY!?N "WX=_\ !7KX+ZI\-;?4_&%SJ7A[QA!; M@7F@0Z;-.9IP/F\B15\O:2./,9",X/3-?==<1J'P.^'&K>(_^$@OOA_X6O-? M\SS?[5N-%MI+K?\ WO-*;L^^: /RR_9;^)/B+XQ_\%4]/\<^)-%N?#TNOV%W M>6&G7:[9(K#[ Z6N1QUB16S@;L[AP17["5FGPSI!UL:R=*L3JX78-0^S)]HV MXQCS,;L8XZ]*TJ /"OVZO^3/_BW_ -B_H27&H^%_$L=G)<6\L)G>.XB98PS?).DARH8_,P('REOUCOK"UU2SFM M+VVAN[29=DD$Z!T=3U#*>"/K6#K/PQ\'>(O#D?A_5O">AZGH,3%DTN\TV&:U M1B221$RE026;MW/K0!^9'[37QFN/^"F_Q(\'?![X/6.HW7@;3-134]=\3W%H MT<4>08Q-M?!5(XWFP'PTCM@ ;03]!_\ !4S0[7PS^P??:/8H8['3[K2[2!6. M2(XY411^0%?8?AGP?H/@K3Q8>'M$T[0;$'(M=,M([:+IC[J "K6KZ+I_B"R: MSU2PM=2M&(9K>\A66,D<@E6!'% 'Y]?$G]FO5/VEO^"7OPJT[P[&T_BC0=$T M_6=.M%QF\*6Q22 $]V21BOJR(. 2:F_9I_X*D?#_ ,._#/3?"7QGFU7P3X[\ M-VZZ9>K=:7<2BZ:%=@?;&C-'(0HW*ZJ V<''3]!;&QMM-LX;2SMXK2UA4)%! M @1$4= JC@#V%,#\A0 M!^87Q&\3:I_P56_:<\':/X/T/4+?X->#;@MJ.L7T1C657=6G8X^Z\B1I''&2 M6ZN0H+!?T1_:@_:$T_\ 9@^$=]X]U32;K6[2UN(+=K.TD5)&,KA 06XXS7I> MBZ%IOAK3(-.TC3[72M/@&V*TLH%ABC'HJ* !^ KSK]IW3?$^M?!'Q+IO@WPK M8^,/$E]"+.TL-2FCBAC:4B/[0QD&#Y08R8X)V8!S0!K? GXM6GQV^$?AKQ[8 M6$VEVFN6YN([.X=DDV-TK+D [=[-C/.,5Z-0!\?\ _!6#_DR7Q?\ ]?NG?^E<5L7LM3L;;4;-R"UO=PK+&Q!R"58$'!J-?#VE1Z-_ M9"Z99KI.PQ_8!;H(-AZKY>-N/;% 'R?_ ,$G_P#DR7PA_P!?NH_^E%_\ M!:__ )!7P7_["=]_Z#;5^E&DZ-I^@V*66F6-MIUFA)6WM(5BC4DY)"J !DU7 MUOPOHWB98!K&D6.JB EHA?6R3>63C)7<#C.!T]* /GO_ (*&_LZ:C^TM^S;J MF@Z&IE\1Z3=1ZWI=L,?Z3-$DB&')Z%XY9 /]K;GBO!_V7_\ @IW\/O!WPMTO MP3\9Y]4\$>.O"ULNE7B7>DW$@N?)&Q3MB1F23:H#*ZK\V2#@\?HA7)>*_A'X M%\>7B7?B7P7X>\172,K+/JVE073J5QM(:1"01@8^@H ^"OA?\8_'W[*:SGCC6';(B?,&Z\N#QZ5]':3H]AH&G0:? MI=C;:;80#;%:VD*Q11CKA54 ?2JNM>$="\1S03:MHNGZI-!Q%)>VLV4VHVN@V,E]):P,%>55'W5)X!^M_$J;4;?X?^(9M(\. M0>+M4CL97M=!N94BCOY I*PL[@JH8X&6&*\P_8O^".L_ 7X%V.A>)6M?^$FO M[ZZUG5(K YMX)[B0N8H_9%V+QQD'!(Q0![I7)_%K0[CQ1\*O&>C6D1GNM1T6 M]LX8@<%WD@=%7\217644 ?DU_P $J_VMO"'P=\/R_!7Q;:ZMI_B_6?%Q6Q'V M0>4))D@MQ%*2P:-UDB;(*_Q =1BNP_9[_P"4Q7QA_P"P9=?^@V=?H=-\+_!E MQXE7Q%+X1T*7Q L@F75GTV$W8<='$NW=N'KG-:=OX7T:SUB;5X-(L8=6F!66 M^CMD6>0'&0T@&X]!U/84 <]\;O\ DB_C[_L7]0_])I*^,O\ @BS"EQ^RGXMB MD4/&_C&[5E;H0;&Q!%??T\$=U#)#-&LL,BE'CD4,K*1@@@]015/1/#VE>&K5 M[72-,L]*MG![GX?W& M@_ R^U+Q;\0]:06FGS6VDSQK8NYP7V31@R2@?=558%B"3@8/WWK>@:9XFT][ M#6--M-5L7.6MKZ!9HF^JL"#7/^$_@_X"\!7SWOAGP1X<\.WC[BUQI.DV]K(V M[[V6C0$Y[^M ''_LHZ;\3].^!^@M\8=:;6?'ET&N;P-!!$;1&/[NW/DHJLRH M 6)!.YF&X@"O7Z** /S _P""T7_(U?L]?]?NJ_\ HS3J_3^LO6O"NB^)&MVU M?1[#56MB3 U[;),8B<9*[@=N=J]/0>E:E 'YH_\ !53]F#4M)N+7]H?X=K+8 M:]I2K#XA%DN'DA*^6EW@==JGRI,YRA4GA6SL_P#!&75;30OV6?'VI:A<):6% MGXFN;BXN)#A8XTL;5F8^P )_"OT0NK6&^M9K:YACN+:9&CEAE4,CJ1@JP/!! M!P0:SM/\):'I&F7.FV&BZ?9:=<[O/M+>UCCBEW+M;<@&&RO!R.1Q0!^9G_!. M+3[O]IK]L+XL_M#ZS QM;65[;2EF&3%).-D:@^L5I&(S_P!=17ZDUG:)X=TK MPS:O;:1IEGI5L[^8T-C;I"C,0!N(4 $X &?85HT ?F7_ ,%BOA;?Z#-\.OCG MX;W6FL:#>1Z;=7<(^>,AS/9R^VR191D]Y$%=C^U]\*[K_@H-^QW\/_B7X!@^ MT>*]-MSJMKI\;X:0.@2]M4]9%EA7;SR82!RPK[WU;1[#7K%[+4[&VU&SD(+V M]W"LL;8.1E6!!P0#2:3HNGZ!8K9Z786VFV:DE;>TA6*,$G)(50!R: /SA^!G M_!7[0M!T"V\+_&WPSK^A^,-*06=YJ%I:B1)W0;2\T+LLD4I_B4!AG)^7.T5? MV@_^"KGA_P"*'@O5OA[\%_"/B/Q'XL\26\NE07%U9*J(LJ%&:&%&>263:6PI M50#@G< 5/Z&>,/A5X*^(3*WBGP?H/B5E78#K&F079"^G[Q3Q[4>#?A7X*^'6 M_P#X13P?H/AC>NQO[&TR"TW+G.#Y:C(S0!XA_P $\_V;=2_9C_9SL-!UX+'X MGU:[DUG5;=7#K;32(B+"&'!*1Q1AL9&[?@D8-?F=_P $]?VUO!'['NJ_%#_A M,M*\0:G_ ,)%-8_9/["MX)=GV=KK?YGFS1XSYZ8QGHV<<9_$=$:&?1M)N87B$YB;?;111R?, M85C^!_#GA^8S:7X?TO39WB=1%&1_TTG9"/>$U]I?L_?" M>U^!OP5\&^!+381HFG16\TD8PLMP1NGD_P"!RL[?\"KJ]0\)Z'J^J6VI7VC: M?>ZC;;?(O+BUCDFBVMN7:Y&5PQ)&#P3FM:@#&\:>$M-\?>$-;\-:Q#]HTG6+ M*:PNXO[T4J%' ]#ACS7Y@?\ !++QGJ7P#_:,^)?[.WBB8I+)=3S6(;A&O+;* MR%!Z2P!9 ?[L(]:_5BL<^#= ;7/[9.AZ:=8W;O[0^R1_:,XVY\S&[...O2@# M\Y/VM/V>?B+^R_\ M*+^TQ\%])DU[3[F5[CQ%H, >1@\F1<,T:_,\,O#DC)C MDR^, 8N_$+_@J/\ "#XY? KQ!X:N-<\7?"KQ+J=H(C=6>G?;)K60.C$0O'(N MX$ KDF,X)^Z<5^DU<-X@^!/PU\6:H=2UOX>^%=9U$R>:;S4-$MIYM_\ >WNA M.??- 'X8>-/VS?C1\1O@EK'PWU'Q-J'B7P!_:$,=SXJU'3W%X8 ^8X;B92_R MLP5\,6D.W;N(^6OV-_8?T/X;^$_V=/"^A?#'Q-8>+-&LX=]UJEFP$D]U(2\K MRQ_>B8L3A'^95"KVKUX>!?#:^%IO#*^']+7PY-$T$FD+9QBT>-OO(8@NTJ?3 M%<'\#OV6?AO^SCJ7B>\^'^@_V&?$,D4EY%Y[RHOEAMJ1[R2BY=SMSC+<8 M!ZS7D'[6'[/EA^TY\#?$'@:[D2UO;A!29VVUY'DQ.<<[-C MA2%P0!CUWXI_\%BOACIOAV6#X<:/K7C'Q9=*(K&WN+,VULLK#"^82=[88CY$ M7YB,!AG=7W7XE\(Z%XSL!8^(-%T[7;(-O%MJ5I'<1AO7:X(S[UB>%O@O\/O M]Z+SPWX$\,^'[L,7%QI>CV]M)N.\4>*/CS M\6H9K?QUXL\X6VGWT/EW%O'+())IY4P/+>1@ J8!5 >F[ X3]KKPOXN_8Y_; M4T_]ICP_HEYXC\#:O&L7B*&T3/V7,2P2HYP=@=5CD1VP#("I(&,_IY4=Q;Q7 M4$D$\:30R*4>.10RLI&""#U!':@#XI\5?\%>/@'I'@>;5]&U#5M?UWR=T/AY M=-FMYC(0,))*Z^4HR>65GP 1_X)@_ KQK_PE?Q!_: ^(^GR:5X@\<-( M+"UN(S%*8)IA<32F,\JCNL00'G;&3T*D_:&G_ OX;Z3KRZW8_#[PK9ZTK!QJ M-OHMLEP&!)!\P)NSR><]Z[B@#\ROV>_^4Q7QA_[!EU_Z#9U]0?\ !2'_ ),E M^*7_ %Y6_P#Z5P5] V_A?1K/6)M7@TBQAU:8%9;Z.V19Y <9#2 ;CT'4]A5K M4M+L]9L9;+4+2"^LYAB2WN8UDC< YP58$'D#\J /FG_@F7_R8Y\,/^N-]_Z7 MW-?-7[4?_*7CX&?]@RQ_]'WU?I7I>EV6B6,5EIUG;V%G%D1V]K$L<:9))PJ@ M #4M.<%[=U\I&8$*=F=NTA0=V=P'M7_ 5L_P"3+?$'_83T_P#]'BN^_99^ M'/A/XB?L>_!VV\5>&-&\36\?AFQV0ZQI\5VB_NEZ"12!0!\5^+O$E_\ \%2? MVN/!-MX5T:_C^"_@2;S;[5;Z QI-ETDFSZ-,(HHTCY8 %R -P7WC_@J=^S;X MJ^*W@OPE\0O -O=7_B[P+=/.MA91^9/-;NT;%XUP2SQ/$C!0.59^I !^V-#\ M/Z7X7TN'3=&TVSTG3H$/%L,02_T=M,N+@-..'\EXT9=I.2-Y4CH??Q/X/V_B7_@HA^W)HOQ MJD\/WNA_";P.\7]ES7Z[3,]NS20QJ1\KRF=O-<*2$50I8G:6_1SQ!\$?AUXN MU3^TM<\ >%]:U'<7^V:AHUM/-N.Z$YY/.>]=?9V=OIUK#:VD$=K;0J$CA MA0(B*. %4< #T% 'PO\ MN?M ?&#]E;X_>!/',4]]K7P(F58-7TBSLX#Y4YW MI(&EV;P2K1R1[G"ET9<@9J]\1O\ @J1^S)KGPSU);F\G\8O=6K*WA2YT.?=. MQ!Q'(TL?D@9QD[SC.1GI7VU=VD%_:RVUS#'(M/GTBV\5PM-IMC=*4D-O#;RCSMIY"N9"!GDB,-T()N?\ !$O_ )(% MXZ_[&8_^DL%?HG)&DT;1R*KHP*LK#((/4$5GZ'X;TCPS;R0:/I=EI4$C;WCL M;=(59L8R0H&3@#GVH _(']B/]IKPQ^Q'\9OC5X0^)EAJ^F7&JZO!%;_9[7?Y M3PRW((D#,I"NL\;*W((&>A%>K_MG>#_&/[)?[96C_M/^&-%NO$?A&^2./Q'; MV\9(ML0K;2*Y ^19(PC)(>!(I![!OT2\0?"_P9XLU6/4]<\(Z%K.I1A0EYJ& MFPSS*%.5 =U)&#TYKI)H4N(GBE19(G4JR.,A@>"".XH ^+M9_P""N?[/MCX( MEUFPU?5M3UKR=\?AU=*GBN3(5R$:5E\E0#P6$C=R W>S_P $[O&7QY^+NG^* M?B'\5]4GMO"FKS%O#?A^:Q@AV(SEGE5A&)?*4!(X]S$,-[8/RL?I"'X"_#*W MUD:O%\.O"<>K @B^30[43C!R/WGE[NO/6N[H *\4_;6_Y-'^+W_8LWW_ **: MO:Z@OK&VU*SFM+RWBN[692DL$Z!T=3U#*>"/8T ? _\ P2]_Y1_^(_\ K]U? M_P!$)63_ ,$2_P#D@7CK_L9C_P"DL%?H+I?A[2M#T]K#3=,L]/L6+%K6UMTB MB)/!)50!SWINA^&](\,V\D&CZ79:5!(V]X[&W2%6;&,D*!DX Y]J /B?_@LE M_P FCV?_ &,UE_Z*N*[[7O@:?VC?^"='A?P)#)'!J5]X*T>;3YI>%2ZBMH)8 MLGLK,@0GLKGK7T[K.@Z9XCLQ::MIUIJEJ&#B"\@69-PS@[6!&>3S[U:M;6&Q MMHK>WACM[>%!''#$H5$4# 4 < <8% 'YD?L6_\ !0+PY^SS\/U^#?QXAU3P M3XA\(2265O=W&GRSJ\ 8LL3K$K.K+G:K!2K+L.[U\!_;Y_:H;]JSQ_X"U3PO MH^HVWPQT'4C8V&K7T!A&HWSO&TS*#V5$B 7J,Y;;O K]C_&GPF\#_$B2&3Q; MX-\/^*)(1MB;6M+@O#&,YPID1L#//%76\ ^&)-+L--;PYI+:=8?\>EF;&(PV MW_7--N$_ "@#Y^_X**_LWZE^TQ^SC?Z/H"F7Q-HMVFMZ9:C ^UR1I(CP9/0O M'(^W_;"9P,FO"_V6?^"GG@3PC\-M,\#?&V74_ OC?PO"FDW3W>E7$J7(B78C M,D2,\<@55#JRCYN0<'"_HG7)^+OA+X&^($PE\4>#/#_B248P^KZ5!=-QTYD0 M],4 ? B_MD_%+]L;]I_PUX:_9ZOM4\,_#C2&#:_X@N=.@<31%U,LC":-PGR# M;$APS,Q) 'W?5?\ @I-^UY=? _P/:_#[P3++E6.C:>A++::?;I!$I/4A$ _*H; MKP?H-]K$>K7.B:;<:K&59+Z6TC:="OW2'(W#';GB@#X+T#_@E?HC?L5W'@C4 M(K5/BQ?;=<;7& )@U (?+M=XY\@*QB;J"6:0#. -O_@F7^U=J7C71;_X)_$5 MIK+XD^"P]K$M^<3W=K$VPHV>LL)&QNY7:W)#FOO&L>/P=H$.MG64T/34U@DL M=06TC%P21M)\S&[)''7I0!L4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWCO MX-^ OBCL/C'P5X?\4O&ACCDUC3(;IXUYX1G4E>IZ$=:[&B@#F_!7PU\(_#:S MEM/"/A71/"UK,V^2#1=.ALT=O4K&J@GW-=)110 4444 %%%% !1110 4444 M%%%% !117Q3^S!^TU\0/B9^V]\;?AQX@U2"Z\)^%_M?]EVD=G%&\6R[CB7,B MJ&;Y6(Y)H ^UJ**\^^/_ ,8K/X _!WQ/\0+_ $^?5K70[=9C96SJCS,TBQJN MX\*-SC)YP,\'I0!Z#17D?[)_QHO_ -H;X ^%OB%J>GVVE7FM_:I#96C,T<*Q MW4T2+N;ECLC7)XR M&O#W@C5K*VT*?P];:I<65W813B:5KNZ1@79=X!2%!A2,2)951PRC)5@0>IZBN9_8+^+WB?XZ_LN>$_&GC" M\CU#Q!J$MZMQ<10)"K".[FC3"( HPJ*.!VH ^@J*H:_KECX7T'4M9U.X6TTW M3K:2[NKA_NQQ1J7=C[!03^%?E-\#?^"EGQ:UCX\>#=3\=36UI\'_ !CKUYI= MC$UC#&8%#(J?OE7<1"UQ;AF).1NSZT ?K1117@/[:'[6FD_LB?"I?$=S9?VQ MKNH3_8M(TKS-@FFVEF=SU$: 98@9R57C=D 'OU%?F/H=G_P4*^.FEV_BFV\0 MZ+\/-,OD6>STF>.VMF$;C(.SR9I5XQQ*VX>@J"/]M3]H_P#8U\?:'HO[2>B6 M?B;PAJDGEQ^(M-BA67:" [Q/"%1R@8$QNBN1CD9R0#]/Z*X#XN>.9=#^ GC3 MQEX:O89)[/PS>ZOIEZ@66-F2U>6&0 Y#+D*>>"*_-K]GGXZ?MR_M/>"[WQ3X M'\2>&Y])L]0?3)6O;.R@?SDCCD("F+D;9DY^OI0!^LE%?F=K7CG_ (*)_#*W MGUK4/#NB>,-.L\O+:V=M97!=%Y)6*!TF;/H@W>PKZ'_8@_;RT/\ :XTV_P!) MO=.7PQ\0-)C\V^T;S"\4+*,G(- 'U5117Q-_P4._:J\? M_"'Q#\.?AW\(98C\0?$]R\[(UK'<,+8?NT79("!OCSK9;@#D[=L=I)&<9QEW)X')H _2 M2BOS@^%?_!1+XD_!?XJ67PR_:F\+0^'KFZVI;^)[2)8T^9MJRRA&,3Q$Y!DB MP%QRO!(_1Y6#J&4AE(R".AH 6BBOD?\ X*9_M">-_P!FOX#Z#XF\!:E#I>L7 M?B6WTV6:>UCN 8&M;J1EVR*0#NB0YZ\>] 'UQ17YH>%=4_X*%^-/!FC^)](U MOPK/ VG:[ MX.OIQ"]_91PJ_J5CGMW,:2 9(25!N"'&.6 !^I%%"[ MZ+3M>M[ZT@CGFMTG4))*%8;'!'(/I0!](T5YE^S+XWU?XE?L]_#OQ5K\ZW6M M:QHEK>WDR1K&KRO&&8A5 Y/0"O3: "BBB@ HHHH **** "BOB'QE^U!\0M' M_P""FGA/X.VNJP)X"U"Q$]Q8&SB,C-]BGER)2N\?/&IX/;%?;U !1110 444 M4 %%%% !1110 445\)?\%%OVJOB/^SS\2_A%H_@C5[?3;#Q%+,NHQS644YD" MS0(,%U)7B1NGK0!]VT444 %%%% &9XB\+Z-XPTM]-U[2;'6].=E9K/4;9+B% MF!R"4<$$@].*LZ7I=EH>G6VGZ=9V^GV%M&(H+6UB6**) ,!550 H [ 5:KXI M_9@_::^('Q,_;>^-OPX\0:I!=>$_"_VO^R[2.SBC>+9=QQ+F15#-\K$
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

222>36_110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !17'?$GXQ>!O@[IL5_XW\6:1X6MIMP@. MJ7B0M.5QN$:D[G(R,A03S7RI\0?^"OGP#\'3F#1Y]?\ &L@;:9-'T[RHASR= MURT1..?N@@\=N: /MRBO%_B)\:-Z+'J>B:?- QDD M\S:3F('+.B%F\L'+%-HSD5^69L_V]?VI6=)O^$VL=-F8JZRE?#MH4]"O[GS% M'T8G'N^.O%-G>3:];QQ_V+IMQ+/&)%?= MY\SNJ@R 94;0>';YJ]7^)/\ P3\^!WQ<^*%YX]\5>$7U+7+T(;I%OYX+>X=5 M"K(\<;KEMJJ#@X..03DT ?$FH?\ !;#Q5K?BS3[3PM\)K%K&:X2+[' M7.6 VQF-%"N>@&U^2.M?;_[;WP[^*?Q<_9]FT?X2:S-X=\4R7<%Q/"MW]DFN MK7:PDMA,"/+;G?#WX%_#OX3QHG@[P1H/AME&WSM.T^**9NW MS2!=['W8DUV4U];V\T,,L\44TQ(BC=P&?'7:#UQGM0!^/7@/_@C!\4/%US]O M\?>.M&\.M.=\HMA+JEV3WWY\M,^X=J_17]D7]D/PQ^R#X)U+0M U*_UJZU2Y M6ZO]0U#:ID=5VJJ(HPB@9XR3ECDG@#W>N4^*WQ"M/A-\,_%'C2_M;B^LM TV M?4IK:T7,LJQ(7*KV!..IX'4\"@"2S^%W@S3_ !1=>);7PCH5MXCNG\RXUB'3 M84NYF'\3S!=['W)KIZ_'GQG_ ,%L/B)K$QA\'_#WP_H@D;:G]I33ZA+R>,;# M",_@:Y)?V@/V\/C]M&AVOC"VT^;_ %E>4>,_VMO@M\/]XU[XH^%K.9!EK:/5(IYP/^N499_P!. MU?E5:_\ !,_]K#XU30W'CO6H[0L=YD\7>)9+Z1??$1G.3]1[XKUOP3_P0]/[ MN7Q?\5 /[]IHFD_RFDD_]IT ?;'PD_;L^"?QR^(2^"O!?C'^U=?DCDE@ADL+ MFW6X"+N<1M+&H8JH)QU(4D9 S7OM?+/[-_\ P3B^$O[,OC*U\7:#_;6M^)[6 M&2*WU#6KM'\CS$*2-&D:(H)5F7D$@,1GO7U-0!\X_MY>-_C+X!^"*ZC\$=(N M-5\3MJ,4-TUCIXO[NWM2K[I(;Z_FY_P *]_;_ /CH,W:HFAQ8_P!J'?#GZ;2?;BOVQHH _&+0?^".7QP\97GV[Q=XO\.: M7)(?WDEQ>W%]=>N3B/:>O_/2O:/!O_!$'PM:^6WBOXGZQJG0O'HVG166/4!I M&FS]=OX5^FM% 'QWX/\ ^"3O[.GA8(;SPUJ?B>51Q)K&KS]<]2L)B4_B,>U? M2OPU^$7@OX.Z-)I7@GPQIGABPE?S)8=-MUB\UNFYV'+G'&6)KKZ* "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_%'PM\%^-U<>(_"&@Z^ M) 0XU33(;G=G@YWJ<]3^==110!\]^*/^"??[._BYG-]\*-#@+G)_LL2Z?^7V M=TQ^%>0^*/\ @CQ\ =>W'3_^$H\.,>G]G:JL@' _Y[QR<<>O<^V/N*B@#\P/ M%'_!#W0[C>WASXK:A8GJL>J:1'.>(OV?_ /@DK\0/@O\ M'KP?XT_X61I)TG0]2BO9CI\4\=U7_M M.>//%_PQ^ WC'Q1X#T'_ (27Q9IMHLMCIOE/+O)D17?8A#/Y<;/)M')V8[UZ MA10!^+^E_P#!8SXZ^$;H67BCPCX8OI(_]8EUI]S9W/! .<2[1T;^#K],5Z=X M9_X+BH=D?B'X2,O]^XTS7,^G2-X![_Q_XU^HVJ:/8:Y:FUU*QMM0MFZPW4*R MH>,=&!'0FO,?$W[)'P4\8;CJWPI\(7$K?>GCT:"*4_\ ;1%#?K0!\P>&?^"S MWP3U;:FJZ'XOT*7^)I+*">(?0I,6/_?->I^'?^"G7[-OB/8B_$6/3IF_Y9ZC MIEY!CZN8MG_CU4O$O_!+/]F[Q$6>/P--HTS=9--U:[3TZ(TC(.G9>YKRWQ%_ MP17^#NH!GTCQ5XQTB4]%DN;:XB'X&!6_\>H ^ROAO\>/AU\8'GC\$^-]!\47 M$""6:VTR_CFFB0XPSQ@[E&2!DC&>.M=W7Q?^R7_P3-\/_LJ_%:7QU;^-M2\2 M7:V^$.G0_ F M[NK?6UU)6U*/3;B.WO)+78V/+D=EP ^W<%(8C';(/YY+\6_^"A'P['[VQ\>W M4,?W_.\,Q:FNW[QR_D2$#'4Y&.F10!^U5%?BO_P\Z_:P^'__ ",GARSD\KYG M_MWPQ-;<#YCNV&+ P1GIQ^=;^@_\%N/B+;[?[:^'GA>_Z;OL$US:YZYQN>7' M;Z>] '[$T5^7&A?\%QM.DV+K/PBNK8C :2QUY9L\+:1^VI\ M!=;"FW^+W@Z/<"1]LU>&VZ''/FLN/ZUVFD_&[X=:]@:9X^\+ZB3MQ]DUFVE^ M]]W[KGKV]: .UHJ"SOK;48?.M+B*ZBSCS(7#KGTR*GH **** "BBB@ HHHH M**** "BBB@# \=^//#_PR\):GXG\4ZM;:)H.FQ&:ZOKIMJ(O0#U+$D * 2Q( M !) KY+L_P!L#XX?'D2WOP&^"L+/'EW]C@O< X:*W5E=D)Z,KL#T M.TU6^-FD#]K#]M_0_A!JC&?X;?#W2X_$_B#3LD)J%_(0+:"3U4))&^.A4RCN M*^U[:VAL[>*WMXD@@B01QQ1J%5% P% ' ':@#XTO_VC/VI?@W"=5^)OP0T7 MQ;X9A)^V7_PYOW>XMD!.9!;2N[R#;SCY0,$EEKZ1^"/QT\&?M#> [7Q;X(U9 M-3TN8^7+&PV3VLH +0S1]4<9''0@@@D$$]U#-6O=.'B+4M=N;.5X9 M#I.F2R1ET."%=]BL,YPP)!QG.,$^7:]_P6P^$UHSKH_@OQAJ14X#74=K;(W/ M4$3.<8YY /L* /T/HK\J->_X+CN5*:+\(%5NTU_K^1T/&Q;<=\?Q>OUKSO6? M^"TWQAU680:%X+\(6#2G:@EM[JZER<8"XF4$YS_">M '[-T5^/?PL_;P_;'^ M(_Q%\.II_A&;5]*GOX5N+&U\,M%:R0LXW![@HQB7;G]YNX R&-"=#AEU+6+>W(/'&'<<\C\Q5SXJ^"[CXC?#/Q7X5M-6G MT*YUK2[G3XM3ML^9:M+&R"08()P3G (/N.M?EEX?_P""'_BVYEQKGQ1T73H\ MGYM/TR:[..QP[Q?SH ^Z?$G_ 44_9R\*[OMGQ3TFX([:;#<7V?IY$;CO7E' MB;_@L5\ ]#5_[/3Q3XBH MA,8[C\A[Y /G_P 7?\%PM/C\R/PO\*;FYSG9<:OK"PX]"8XXFS_WV/QK=_8_ M_P""GGQ,_:0_:(T;P3?^ =%3PYJ"S&:XTA+C[18*D;N)9)'D9"F5"D;5R6&# MG"G[%\)_L9_ SP2$.E?"CPHDD?W)KO3([J5>,9$DP9@<>]>M:7H]AH=FMKIM MC;:?:J[T4 ?D?X0_X(?^)+HHWBGXHZ5IH'+1 MZ/IDMWGV#2/%CZ[3]*]S\&_\$8?@SHGER:]K_BKQ),OWHVNH;6!O^ I'O'_? M=??M% 'SKX-_X)Y_L[>!]AL?A;H][(N,OK)EU'<1W*W#NO/H!CVKV[PQX'\- M^";;[/X=\/Z7H%OC'E:791VR8],(H%;E% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110!\R_M0?\ !/GX5_M/1W.HW^G?\(QXQ<$KXDT:-4FD;M]HC^[..F2V M'P,!UK\T/%?P1_:8_P"":?BBX\3^%]0N;OPD9!YNKZ2IN-,N4!X%Y;-GRSCC M>*7P@O))"=*NF]5E;F _[,AVC^^3Q7WE!/'=0QS0R++#(H=)(V#*R MD9!!'4$5\)_M3?\ !)OX??&#[9KOP\>'X=^*Y,R&WAC)TJZ<\X:%>82?[T7 MY^1C7Q/X1^-G[2O_ 3/\50>&?%&G7%[X2:0^5I.JLUQIERF>6L[E<^6V.=J MG@D%XR>* /W(HKYL_9?_ &^_A;^U#;V]CI>I?\(]XO9&M7=4G+=_(?[LX MZ_=^; R56OI.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#P#_R6WXJ_P#<*_\ 29J] M/KS#P#_R6WXJ_P#<*_\ 29J]/H *^9/V^/VN;3]E'X.S75A+%+XYUL/::%:. M VU\?/>K%%Z$D>\_$+Q]H?PM\$:UXM\2WR:=H6D6S75UP'\ M3,<*JCDLP Y-?BAX5T7QA_P50_;*N=1U(7&G^$K9EDNMIRNDZ3&Y\N!#T\V0 MDCW=W?&U2 >T_\ !*']DB[\=>*)OC_X]BEOHH[J5]!%\2[WEX6/FWSEOO;& MW!2&?#>E^#?#NF:#HEE#IND:;;QVEI9P+M2&)%"JH'H !6 MG0 4444 %%%% !1110 4444 %%%% !117Q+\:?\ @K5\&_A/X@U70--M=;\9 MZSIT[VLW]FP)%:"5"5=?.E8$@,"-RHP.."1S0!]M45^8OPB_X*]>*/C!\?/! MW@_3_A;:VVAZYJ<.GRI%?275[$LCA3,&"(FU 2[ KC:I^8=:]^_X**?!+XV_ M&SP;X7T[X0>()--@ANI1K.FPZ@;![M'51&[2[AN1,/F//.\'!*C !] ?$/X] M?#CX2JQ\8^.= \.2 9^SZAJ$4)/AQ+X[T#58?$/A ME;.:]2\TMA,)DB#%PF.K HR[3@Y&#BORR^'O_!$[QEJTBW7C[XB:3HRL?,D@ MT:WDOY6SR09)/*56]\,/K7W%\+?$'P"_8A^%6G^ Q\3M#L[:Q>267^U-8@DO M9YG.Z1S$AW=>RK@# Z\D ^$_B)_P6?\ B/XIU*73_AQX%TG1(II#';2:@)-1 MO7&?E(52B!B/X=K@=,GK7K_[!?Q _; ^)'QR@UKXFP:Q'\-[BTF^VC7-*BT^ M('8Q@-M'Y:,6\S:"P!!3=N).TUV6H?\ !2;]DSX-W%[-X,TO[?>3NS3MX1\, MI:&9RGIIMQ9KIXNTEC21W4QDRIY39D;/# \' M YS5^&__ 2-^ ?@?RI=8L-8\;W: -!2U);Y4\)^&'OV4 ]S,)_Q.!^%?K'^SGJGCS6O@CX/OOB=91Z?X[F ML@VJ6\:*F)-S;2RKPKE-C,HX#%@ ,8H [K1=&L/#ND66E:590:=IEE"EO;6= MK&(XH8D 5411PJ@ =,5\V?%W_@I+\!O@UX@U+0-4\53ZMKVFS/;W>GZ+8R MW#0R*<,ADPL6X$$$;\@@@XKZ@KXO\2_\$E_@9XL^(NM>+M1;Q,[ZM>2WT^DQ MZDD=FLDC%GV8B\P L2<>8<9P..* /'/&W_!;[PI9[U\(_#+6-5ZA9=:OXK+' MH2L:S9^FX?6O#]9_X*Z_M _$:^&G>"?"^AZ9.^?+BTK2Y]0NSG_?=E/X1U^D M?@C]@7]GSX?^4=,^%>A7,D?(DUB-]2;/K_I+2<_R[8KW#0_#VE>&;%;+1],L M])LU^[;V-ND,8^BJ * /Q<73/^"@/[0.SS&\?V5O-G/FRIX: M_8FB@ J.XMXKJ"2">-)H9%*/'(H964C!!!Z@CM4E% '+>$OA5X*\ L6\,>#] M!\.,2QSI.F06IR>I_=J.N3GZUU-%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %<_KWP^\+>*=W]M>&M'U?=G=]OL(I\YZYW* M>N!^5=!10!X[KW['/P,\2;S??"/P:7?.Z2WT:"W=B3DDM&JDGWS71_"3X!_# MWX#V>I6W@'PI8>&8M2E6:[^QJQ:9ESMW,Q)PNYL+G W' &37?T4 %?,O[7G[ M!/@O]L#4-%U77-8U;0-;TFW>TAN]-*,DD+-NVR1NISAB2"I4_,@I/@8Y!VSIGGZ5QNJ?\$/?%$.?[-^*FD78R M?^/K298..WW9'Z_I[U^N=% 'XO7W_!%'XR1R*+/QAX%GCQRT]W>1$'TP+5N/ MQJ"3_@DW^TOICDVGB?P_(;[%C;LD86 2N,M\ZR/@?*#)@>M?1= M%% 'YT?M[>$_VPM:^-*W/PBN];'@)+"+[)'X=U*&U*R@?OO.4NK,Y;IU7;M MYW"OFS_C89_U4#_R#7[544 ?BK_:'_!0S2O]+V?$!_+YV_9X9\]ON;6W=?0T MO_"RO^"AG_/G\0/_ G(?_C%?M310!^*Z_$G_@H:S!1:>/\ )..?#L('_HBO MU3_9;N/B1=? 7PC+\6XTB^(#6[G4E545O]:_E%PGRB0Q>66"\;B>!TKU6B@ MK\L_VL/AE^W'XH^/7BH^!M2\2?\ "%W5S_Q)SX>\00Z=;I; #8I'G1LCCHQ; M!)SR017ZF44 ?@*O[/\ ^U1;_M!/X0OM4U[2OBIXATL:F9+OQ8HN-3M8LQKF MZ6=A*46-@$+EE6,\ "O55_X)O_M?:[)_Q,/$P0W*_OGOO%DLG4?'32?#_B'P?K \*_%/P?N-$8M+M))#I]K$ UQ=,'92RJNXJ/EW[&Y7%?H?KG M_!3SX>^(&?2?@_H'B7XQ>+)<+;:=HVE7%O"&/1II94#1IGJVPXP>@YKHOV6? MV=/&5AX_UOXV_&FZM;[XK:];"SMM-LFW6GA^PSD6L/)&[^\P)_B^9B[LP!]" M_#OP;!\.?A_X:\*6MU<7UMH>F6VF1W5TVZ6988EC#N?[Q"Y/N:Z&BB@#XWOO M^"37[/6H^(K[59M$U@+=SM.;&/59$MX]Q)*H%PP7)Z;CCZ5UV@_\$UOV;?#Z MKY'PQL[EP.7O[^[N2QQC)$DQ'Y #TKZ:HH \KT']E/X,>&2K:9\*/!EK(O28 M:%;-)V_C*%NP[]J]"T?PWI'AV+R]*TNRTR/&-EG;I$,9SC"@=R36E10 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 5A^-/ _A_P"(WAN\\/\ BC1K+7M%NUVS6-_"LL;^AP>A'4$< M@\@BMRB@#\JOVH/^"/=S8W$_BCX$:DZR1MYX\+:E<[9$8'(^RW+'J#C"RD8P M3YG05Y]\!?\ @IU\5_V:O$'_ @GQPT35?$FGV+B&4ZDAAUNQ7UW/CSQCD>8 M=QSD28P*_9:O+/CU^S'\.?VE/#W]E>._#T.HO&I6UU*']U>VA/>*8?,!GG:< MJ>ZF@"]\$_VA/ '[0WAE=<\!^([76K=0/M%LIV7-HQ_AFA/S(>O48.,@D4/JT0(R?N*!F@ M#]0J*R_#/BG1_&FA6>M:!JEGK6D7B>9;WUA.LT,J^JNI(-:E !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !117"K\;_!,GQ@?X6KK8/CM-/\ [5;2?LTW M_'MD#?YNSR^I'R[MWM0!W5%%% !1110 4444 %%%% !1110 4444 >8> ?\ MDMOQ5_[A7_I,U>GUYAX!_P"2V_%7_N%?^DS5\T?\%/?VU/\ AG_P#_P@?A*_ M\KX@^)+[;S7=2C&?M%T5Y13U\N,?(HXX!; +-7RC_ ,$G/V*_^$-T.#XU>,[' M&O:I"1X=L[A/FM+5QAKH@]'E!POI&2>?,X_2F@ HHHH ***@O+ZWTVUEN;N> M*UMHANDFF<(B#U)/ % $]%>#^._V[/@#\-YC#K7Q3T$SAMK1:7*^HNASC#+; M+(5_'&*ZSXJ?'72OA]\ M:^*VDVS^,-&L]*&JVL>EN"+R)@I5E?!PF&#%L': MH8X.,4 >F45^(WQ&_P""Q'QP\7+.GAFST'P3:=%EL[(W=PF?[SSED)^D8KZ" M_P""5'[2WQ(^*_Q,\8Z3\0_B/;^(89[!;NQTK4+J-[PSAUW/ %&%C"%MR CD MJ0O#&@#[D^+7[4GPG^!DYMO'/CS1]!O@@D.GR3&6[V'HWD1AI,'L=O/:OF3Q M!_P62^!FDZY;V.GV/BG6[1I5274K?3XXH8T)P7"R2+(V!SC8*E_:!_X)2^%? MV@/COJ_Q#OO'.KZ/;:QY]\8ZGXFT3P_-_KY/%&JIH-@H/=K8M&/7I&:UFU MC_@H)\?,F&/Q[I\$QW)Y,,?AR/:>FUR(,KCODYZDGK5S2O\ @DG^T/\ $R\6 M_P#'/BO1M/ES\TFL:M/J%USUQL5U/OF0=J /H']BGQK\+?V"_AKK^B?$/X^> M$]=O]2OA=C3/#5Y)JEO8;4VL%$2,Q=SC=\@^XO7DUX=\1/C9^P=;?$+6?%EI M\-_%'CG5=1N'O&MXS)::8)F.YF$;S(0&))VE&49. .!7K/@O_@B!X:M?+?Q= M\3]5U/D%X=%TZ*SP.X#R-+GZ[1]*]]\$_P#!*G]G3P=Y;W'A.]\3W$9R)];U M29_S2)HXS^*F@"7_ ()\?'KX7_'GPEXBE^'OPRLOAI-H4\5O=V5G:P*LB2JQ MC<2QHN\GRWW C((')S7UM7-> /AKX4^%>@KHO@[P[IOAK2@YD^RZ9;)"C.>K M-M'S-[G)KI: /SY_X*%_L4_&S]IWXI:+>>#/%-BG@P:,?BC96>"-]MH>F/<;O4"65TQ_W MP:_66B@#X=\$?\$>O@)X9V-K*^(_%\G!==2U/R(S[ 6ZQ,!_P(GWKZ#\$?L@ M_!3X=;6T#X7^&+6=?NW,VG1W,Z_264,X_.O7Z* &0PQV\*111K%$@"JB !5 MZ =!3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH *CN+>*[A>&>))HG&&CD4,K#T(/6I** *]G8 M6NFP^5:6T-K%G=Y<*!%SZX%6*** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH *^5_VI_\ @G3\+_VFENM5-H/!_C:0$CQ#I,*CSG];F'A9O][* MOP/GP,5]444 ?AAJW@[]IK_@E_XLDU/3;B:;P?-.-UY:A[O0[_G"B>,X\F0C MCG8_4(Q'-??G[*__ 5(^&OQZ%IHGBIX_A[XTDP@M=0F'V&[?I^XN#@ D_P2 M;3R "_6OLK4=.M-8L+BQO[6&]LKF-HI[:XC$D?;/$'P@N8?!FNMF1]!NBQTRX/I&0"UN2>PW)T 5!S0!^C%%?B'\+?VQ MOV@_^"?_ (J@\"?$G1+_ %?P[;\+H6O.=Z0CC=978W IQ@ %X^" ')H(?&7AR>2 M[TR.Z?9'=(Z 36Y;HA?9&0QXR@!P"6'Y3^!/CM\8/V(OV@K/5/&>@S7GB;2- M%&A?V7XF9R1IQ8,BQ2HW*C9A'!=0!@ @ _5[_@GC?_ !PC^$M[H7QOT34K M+4M)G1-*U35IDDN;VV8'*R8=F+1LN-SX)#KUP37CG[,]6TS6+Z76M6D$\L#3Q3.ZP+@)$/G*Y5=Q7@L: /CC_@B Q?X@?%1 MF)9CIED23U/[V2OO/]N;]HRX_9?_ &=]:\7::L3^(;B6/2](6==R"ZEW$.P[ M[$223!X.P ]:^"_^"'W_ "/WQ3_[!EE_Z-DKU+_@MS?S1_!OX=V2L1;S:]+, MZYX+);L%/Y2-^= 'RQ\*_P!CSXZ?M+/ MF>4Z_+""P9$ XRI&% !KZQ_X)*_M@^)?C%8Z]\,_&^J2ZWK&A6:7^E:E=/ON M)K,.(Y(Y7/+E&>+#'+$2$$_**]\_X)HVT=K^P_\ "](\;6MKR0X 'S-?7#'] M2:_-O_@E3,VF?MUS6MJICMY=/U2W9$Z",$, ?;*+^E 'H/[:GQ\^)/[5/[7* M?L^_#O7)=%T&TU/^QS';SO MU=(I-S-<.GS&.+$@V#(Q$3@DUYMX]T'XS_\ M!*OXP>%+FT\8_P#"0:%JD37"V\4DHL;^-'47%O+"Y(5QN7#KDC>I!!R*M_L( MS-KG_!4)]0NVWW+ZMX@NBSIBEC61"??#"MJO ?V! MKR:__8W^$TL^XNNBQQ#=UVHS(OX;5&/:O?J /SD_X*G3^"_^%R? *+XE?:KC MP!'#KUUJ=G:S/&\WEP0-&J;6'SLX55Y'+8R 37D/P;_X)E^'_B?H>H?%GXCQ MS_!_X;M:OJ5CX8T^Z>>]BL54R">ZN;C?LR@W$!,DG[06B_%+3?"/P+\& M>(TBG\;WZ#7]3BC<#3](B8-*QRH)+E3@#.1&ZG[PH _+N/P=X%TK4-8\2>)_ M#WB33_AYKEOJ!\*'3[I/MD,\9)M%N&=&4K(!M8[60^&+ %I&+'B%0.3[ 5Z!XT^*'@[X;VWVCQ9XKT3PS#C<'U?4(K M4$>V]AG\*_"/3_CK^T]\7OAGX3\!>#;7Q8?"^@V:6%K#X+TZZC-Q&J!1Y\L( M)DP%S@G;R3CT;X;_ .";_P"TK\0;K[7)\/[ZT\\AI;S7;^"V?)[LLDGF$_\ M 2: /W=F^)WA6/P:WBJ'7K"]T#[#+J4=]97"SI/;QH7>2,H3O 52?ESTK\WO MB5_P6ZLX)KFV\ _#:6[0,PBU'Q!?"($ \$V\2D\]?]8,5Q_P%_X(]_%/0?B! MX:\1^*_&&@^';/3;Z&]>/2)IKJ]_=L'V#,:1J3@+G_P!$^%OA:SO6;>+@Z9%*\9_V"X)3_@.* /@S]FW_ (*;?&;QAK_B7Q7X M[\&V]Y\+M'T>ZU"^NM!TJ6%;1XU_+:SGB5X9(B-I1D(P5(X((QBN-\'_ /X9_#YD?PS\/O M#&@RJ(4D *R:;I,\Z8 M/0[E0@#W)Q7U=X7_ &+?VT/B%X;T[0+C^W]"\*VD M+:PUGQ(+:T@B QM%JL MI8#'_3/GWK]Q** /R!\$_P#!$7QMJ'EOXN^)&A:*#R\>CVLO$6D2\^3=I\T3?WXW&&C?_:0@^]?EE^TC M_P $F?&OPHU1O&GP(UB^UNVLY#=1:3Y_D:O9$<@V\J[1-CG&-LG0 .>:_7VB M@#\BOV:O^"MWBOX:M#:2?9I-;BM_)U.T8'!6Y@(428[D;7&#D M.:_4KX:?%7PC\8O"]OXB\%^(+'Q'H\W N+*3=L;&=CK]Z-QGE6 8=Q7F7[2O M[%?PO_:DT]SXJT86?B!4VV_B/2PL-]%@84,^")4']R0,!SC!YK\M?B5^RA^T M1_P3O\53^-_ .M7NJ>&83NDU[04)C\H'A;ZT.X!?]X/&,CY@>* /W"HK\\/V M5O\ @KOX/^(OV/P_\6H+?P/XA;$:ZU"3_95RW3+$DM;D_P"T63@DNO K]"+* M]M]2LX;NTGBNK6=!)%/"X=)%(R&5AP01W% $]%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$/_ M 4@_:^^+'[)C>$KSP5HN@WGAS6DF@N-1U2SGG>WNT(8("DR*H9"2 RDG8^. MG'S;H?[6WP>^)_[9=_\ $OQA=V4/@C4/AC]BU33M3@,G^E>8AELQ&1F5\@[= MH.X8(]OU(^)7PQ\+?&#P??>%O&.B6NOZ%>#$MI=+D9'1U889''9E(([&OSEM M?^"3OA=?VN9M.E\/Z\_P571?M:7C:G'EM0W@?9]P_>[-N3TS_MT <=/,'J*_33XW?\D7\??\ M8OZA_P"DTE7_ (=?#7PO\)/"-EX8\'Z):^']"LUQ#9VBX7/=F)RSL>[,2Q/) M)K5\1:#:^*?#^J:+?!FL=1M9;.<1MM8QR(4;!['!/- 'Y.?\$/O^1^^*?_8, MLO\ T;)7T7_P6$^&-YXX_9T^W:>?PKK$-_<;%W,MK(CPR''H'>)B>P4G MW'NG[.?[&/PV_99U36K_ ,"6VI6]QJ\,<%T;Z]:<%48LN 1QRQKVZ^L;;5+& MXL[VWBN[.XC:*:WG0/'(C##*RG@@@D$'KF@#\V?V!OV[/A9\*OV+[71/%GB6 MUTKQ'X1%\JZ3,&^T7ZO-)/#Y*@?/DR^7QT*Y; YKQW_@C+\.=2\4?'KQA\0[ MJ%FTW2=+>T^TE^(XY<@=-Z^HKZY\5?\$A_@!XF\4/K$-MXAT&& M25I9-)TK442S8L.=$::^L@ M1::M8R^1>0*)]*L-3\1Z]9DO M:7GB2YCN?LSYR)$1(T0..S%21U!!YH ]D_9S^'K-:1] M988&M)9E/HOE))D]AD]J])_8&\.GXW>+?B%^TMX@LHQ/XNO)-)\-64BJWV#2 M;=]@7 X5G= &]3$6_CJ'_@I7^Q[\1/VHI? -_P##ZYTV.XT*+4+>[AOKMK=W M2Y$*_(0I!&V-PP)'##KDUX-\+?V3/VR_@7XJO=5^')\(^#=+O762X\,V>JR7 M&E.P4*6\FY,K!FVC+*P;L"!@4 ?4]]^QW\'?C%^TI\3_ !!XR\$VVN:I"=** M237=PD8S:!3F))!&>(TZKV]S7PW^WYX7TC]CGXB>.]!\&Z-H'8?(L M(XHO.T.>&9$F:)<%HXY8O- Q@,TK8_U6*]PL;K]N?7/&GCVST>Q\ :!XAD2R M74KZW<,4/DD0M%YCR+DIDG*D9]*\:UW_ ()T_M+^,-'\3Q^)] \$^*?$OB"X MBN)_&&LZS<3ZM!Y; B.%R_EHA *D>6?E.,X5=H!^D7[$ZA?V1_A" ,#_ (1F MQ/'_ %R6O:Z\Z_9S^'^I_"GX#^ ?!VLR6\NK:'HUM8736C%HC(D85MI(!(R. MN!FO1: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH *1E#*01D'@@TM% 'Q!^U5_P2L^'7QQ M^V:[X*\GX>>,I-TC-9PYTZ\<\_O8!]PD_P <>.I)5S7P?X?^)7[3'_!,7Q9% MH>M6E?N?6/XN\'Z%X^\/W>A M>)-(LM=T:[79/8ZA LT4@]U8$9'4'J#R* /G?]EG_@H9\+OVGH[73+:]_P"$ M4\:2 !_#FK2*KR-Z6\O"SCKP,/QDH!7U!7Y8_M2?\$=PKW/B7X%Z@UO,I\X^ M%-4N#C(YQ:W+'(/3"RGU/F#@5Y;\#?\ @I-\8_V4?$?_ @7QHT/5/$NF6+" M*2WU<-#K-DG8I*_^N3&2!)G<,;9 * /V@HKS#X$_M*?#O]I#PZ-7\">(K?5- MBJUSI[GR[RS)[30GYEYR-W*G!P37I] !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 >8> ?^2V_%7_N%?^DS5Z?7F'@'_DMOQ5_[A7_I,U>G MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YG\J/+N[0G^*&9?F7G!(SM.!N!'%>F44 ?C%\=O^":/Q>_9;\1 MCQY\%-;U3Q+IM@QGBETMC#K-DHY(:-,>>N.#Y8^;G,8%>F?LN_\ !8=X9K;P MS\==.,4J'R?^$JTRW((8'!-U;*.#URT0]O+ZFOU1KYE_:B_X)]_"S]J".YU& M_P!/_P"$8\9./D\2:/&J3.V./M$?W9QTY;#X& ZT >_^#?&V@?$+P[9Z]X8U MFRU[1KM=T%]I\ZS1/ZC0>#6W7X:>*/A#^TO\ \$S/%4_B'PY?W%SX M1>4&35-,5KG2;MA_$%8?A MWXLD(C$\\F=+NF/&4F/,))_AEX' WL: /NZBF0S)<1)+$ZR1.H970Y# \@@] MQ3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/ /_);?BK_ -PK_P!) MFKT^O,/ /_);?BK_ -PK_P!)FKT^@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH BN;:&\MY;>XB2>"5#')%(H974C!4@\$$=J^#/VHO^ M"2?@#XL?:]<^&TL/P\\4/ES9(A.DW+^\0&8">.8_E'_/,DYK[XHH _#;PK\: M_P!IG_@FGXFM_#?B?3KFZ\)&0B'2=69KG3+E1U-G//%?I;^ MR_\ \%"?A7^TY':Z=9:C_P (MXQD #>'-8D5)9']+>3A9QUP%P^!DH*^@O&' M@O0?B!X?N]"\2Z/8Z]HUTNV>QU"!9HG'NK C(['J#R*_-']I[_@CG#,]SXA^ M!VI_8KA29?\ A%=6N#LSUQ;7+'*GT67/_70=* /U(HK\6_@S_P %%OC=^R'X MF7P'\9=#U/Q)I=F0DEGK@:+5K6/. T,[?ZY."1OW!L *ZBOU)^ '[5'PU_:8 MT/[?X&\10WMU&@>ZTBYQ#?VG_72$G.,\;URA/1C0!ZW1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 >8> ?\ DMOQ5_[A7_I,U>GUYAX!_P"2V_%7_N%?^DS5Z?0 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110! MY_\ &;X"> OV@/#+:'X\\-6>O6@#>1+*NVXMF/5H95P\9X'W2,XP&4U[P+XEL?$>FG =K63]Y Q&0DL9P\;8_A< UQ'[17[ M''PM_:>T]E\9>'T&LK'L@\0:<1!J$'&!B0 [U'9) R^U?E_\6/\ @G_\?/V, M?$TGCGX1ZYJ7B+2;3+C4O#H:/4((LY*W%J"?,3CG;O4@995'% '[6T5^7'[, MG_!9"VN6MM ^-VD_8;@$1CQ1H\!,9/3-Q;#E3W+19&3Q&M?I5X+\=>'OB/X= MM=?\+:U8^(-&NAF&^T^=9HF]1E3PP[J>0>" : -VBBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / M,/ /_);?BK_W"O\ TF:O3Z\P\ _\EM^*O_<*_P#29J]/H **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YA_ M:;_X)Y_"C]IA;K4;S3?^$5\82Y8>(M%18Y9']9X_N3#.,DX? P'%?FIXT_9V M_:8_X)Q^)+CQ5X/U2\O/"ZMNFUK00T]C+&.@O;5@=G'=U*@GY7SS7[DTC*'4 MJP#*1@@]#0!^=7[-/_!8;P;XX%IHOQ9TX>"=:?$?]M6:M+IDK=,L.9(,GUWJ M.2645^@^@Z_IGBC2+75=&U&TU;2[I/,M[VQG6:&53_$CJ2&'N#7R%^TI_P $ MM/A/\=/M6J^'K8?#GQ7)E_MNCP#['.Y[RVN0O7)W1E"2$/.WRWNG$WVB78R #<0D?NF(PNYU1N<*W>@#]SJ*_/W]FO_ M (*^?#_XD_9='^)MHOP]\0-A/[05FETN=O7?]Z#)[/E1W>OOC3=4L]:T^WO] M/NX+^QN$$D-S;2+)%*AY#*RD@@^HH M4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 >8> ?^2V_%7_ +A7_I,U M>GUYAX!_Y+;\5?\ N%?^DS5Z?0 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/!'=0R0S1K+#(I1 MXY%#*RD8((/4$5)10!\0?M+?\$HOA;\9OM>K^#5'PW\4R9?.FPAM.G?_ *:6 MW 3/3,14#DE6-?!TVE_M4_\ !,O7&F@>X_X1!ILM)%NU#0+S)_B7@PLQ]?*D M..#BOW0J&\L[?4;2:UNX([JUF0QRPS('1U(P593P01V- 'PQ^S3_ ,%:_AI\ M6OLND>/D7X;^)7PGG7F8R%'78:^()M+_:Q_X)JZHTL#WH\'++S)#G4M N?F_B4_ZAF/NAZ[IOB;2;;5-'U"UU73+I/,@O+&=9H95/\2.I(8>X- %ZBBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \P\ _\ );?B MK_W"O_29J]/KS#P#_P EM^*O_<*_])FKT^@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "H[BWBO+>6">))X)5*21R*&5U(P00>"".U244 ?%'[1?\ P2C^$GQE^TZG MX5B/PU\22?-YVD0AK"1O]NUR%7_MD4]2#7P5KGP?_:K_ ."<>KW&L^'KN^?P MJC^9-J.ADWVD3+W-S;LO[LXP-SHN,_*_>OW,I&4.I5@&4C!!Z&@#\W_V=?\ M@LIX2\5_9M)^+FC-X/U-L(=;TM'N-/<^KQ\RQ?AY@[DBOT(\(^,M!\?:#;:W MX:UFQU[2+D9BOM.N$GA?V#*2,^HZBOEW]HS_ ()B?![X\_:M2L-//@#Q1-E_ M[4T"-5AE<]YK;A'YY)78Q/5J_/GQ5^R#^U-^PKKESXF^'^H:CJ6CQG=)JGA% MVGCD0RACWR+9S?O8>"0LL9 >(G'1 MU!H [VBO@'X&_M&?MA_M&?#JR\=>#_#GP?@T"^FGBMX]4_M%+A?+D:,A@LQ' M53R.OH.E=]_;/[=7_0!^!_\ W\U/_P".T ?8%%?'_P#;/[=7_0!^!_\ W\U/ M_P".TOP/_:*^.$G[53_!WXPZ+X'M9I?"[^(;>Y\(BZ^4"<1*&::1@HH ^OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/ /\ R6WXJ_\ M<*_])FKT^O,/ /\ R6WXJ_\ <*_])FKT^@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** /GS]H']@_X.?M'++6]W?WG( M!64_]=%;VQ7YR_%K_@E?\:OV?M6E\5_"'Q++XGMK16D272KAM.U:!.I&S<%< M8_N.2V/N=J_9VJFK?\@J]_ZXO_Z": /P[_8S_P""FGB']EOPC8>!]7\*VGB; MP3!-)-$;>0VU_!YDA9RKG*2#<6(4J#G(W@=/U-^ ?[=WP:_:*6VMO#GBJ'3M M>FP/[ US%I>[O[J*QVRG_KDSUX-_P3W^!/P_^.G[!GA#3/'GA/3?$MLMWJ2Q MO=PXGAS=RY,4RXDC/NC"O,?CU_P19M;@W&I_"#Q:UG)RXT+Q(2\?KMCN47]?!-C\=/VP/V!;R'3_ !5;ZK=>&HG$ M<=OXEC.I:9(.@6*[5B4XZ(DJXSRM>A?!7_@H=X/^('[<.D?%/Q];+\/]/_X0 MQO#4S>9)>0"Y^TF57W)'N5Y'RD$O&F@>/M$AUCPUK>G^( M-)F_U=]IETEQ"WL'0D9]JV: "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/ M/_);?BK_ -PK_P!)FKT^O,/ /_);?BK_ -PK_P!)FKT^@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "JNJ*7TR[5068PN !U/RFK5% 'YC?\$^ M?VZ/@?\ O\ 9=\.^#_''C8Z'XCL[J]>>Q.D7TY0/OH_ M_AZ-^S%_T4S_ ,H&J?\ R-7TM)X6T661G?2+!W8Y9FMD))]3Q3?^$3T/_H#: M?_X"Q_X4 ?,>H?\ !3?]EC5K&>SO?B)#>6^'?A'J/_ CW@^3P>VI27F@Z9):PQ:FESM8FWGC3Y-DD M>50(I.,$'-?K[_PB>A_] ;3_ /P%C_PJS8Z+I^F2,]G86UH[##-!"J$CT.!0 M!^+?C#]@']IW]D+7)O$GPMUB^\064?S&^\'7#QW3(#PLUF3NDS_<7S5]:[3X M-_\ !9#QYX&OAH7QA\()XA%L_DW%_I\8L-2B(/S&2 @1NP_N@1?6OU]KS#XS M?LS?#']H"P:W\=^#M-UN;9LCU Q^5>0CMLN$Q(H]MV#CD&@#F/@;^V[\&_VA M%@A\+>,;2+69<#^P]6(L[X-_=6-SB0^\9<>]>[5^5/QO_P""*;JUQJ'PE\:; MNKKHOB<8([X2YB7\ &C^K=Z\1M?C5^V)^P3""#P0?2I:* / MDCXW?\$O?@9\9//N[30'\":U)S]N\,%;>,MVW6Q!BQZ[54G^]7PI\0O^"6WQ M^_9[UIO$OPF\2/XG6VRT5UH%V^F:HBCDYB+@-VX21B?[M?M%10!^,?PY_P"" MK'QU^ ^LCPU\6_#'_"3FU(6:#6;5M*U:,9(^^$VGH?OQDG'WNIK[G^"__!4# MX$?&#R+:Y\1OX&UB3 ^P^*$%LF>^+@$PXSTW.I.>E?1'Q&^$O@OXO:.=*\:> M%]*\36.#LCU*U24QD]2C$;D;W4@^]?#7QH_X(Q_#GQ5]HO?ASXAU'P/?-EDL M+S.H6/J%&XB5/3)=\>E 'Z%V-];:E9PW=G<17=K,H>*>!PZ.IZ%6'!'N*GK\ M0+S]FG]L3]A^\FU#P7<:Q=Z)"QD>X\(W!U&QDQ@EI+)E)X[L\.!SSC->I?!S M_@M-XAT.9-,^+'@>+55B;RY=3\/G[-=+C@[[>0[';/H\8'I0!^MM%>#?!?\ M;E^"GQX,%OX:\<6,&KRX T?5S]BO-Q_A5),"0_\ 7,L*]YH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/ /\ MR6WXJ_\ <*_])FKT^O,/ /\ R6WXJ_\ <*_])FKT^@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ KR?XQ_LJ?"?X^12?\)QX'TO5[QEVC4DC-O>KCIBXC*R8']TL1[5ZQ10!^ M6GQJ_P"")]K-Y][\*O'#VS\LFC^*$WIGT6YB7('H#&W;+=Z\)77OVT?V#ODN MUU]_"MKQB[4:SH_E@< 2#?Y"D#. T;<=.M?N#2=>#R* /S"^#?\ P6PT>^\B MS^*/@:?2I3P^J^&9//ASZFWE(9%'M(Y]J^Z?A!^U-\)_CQ''_P (/XYTG6;M MAN_LXR^1>@=R;>0+)CWVX]ZY'XR?L$_ [XX^?/KO@:RT_5I>3JVA#[!=;O[S M&/"R'_KHK?H*^%OC!_P15\0:/-)J/PJ\=0ZFL;>9%IOB%3;7*XY&VXB!5FST MRD8]Z /ULHK\0H/CU^V;^P]-':^+(-RB0T ?I'17 MGOPK_:$^&WQNM5G\#>-='\1MLWM;6MR!ZOXN\0:=8WB6(_LS_M>?#_]I[PK8WWA_5[*S\02Q/+<^&)[R-K^T57* MY:,8)7 !W 8^8:GJ=Y;Z=IMG"]S1W8@*JJ M"2Q. 2: +=%>5?\-8_!#_HLGP__ /"HL?\ X[72^!_C)X!^)MU\>)"^'O$M]$&9[/3M1BEG"J<% M_+#;MO/WL8]Z /0**** "BBB@#S#P#_R6WXJ_P#<*_\ 29J]/KS#P#_R6WXJ M_P#<*_\ 29J]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG@CNH9(9 MHUEAD4H\%V%C)N/ M5C& 86.>JQ)], M)-CD<=*_;JH[BWBO+>2">))H9%*/'(H964C!!!Z@T ?F[\'_ /@M5X+USR;3 MXC^#=1\+W!^5M1T:07UJ3_>:,[9$'LOF'^GVY\)_VE/A=\<85;P-XYT?Q!,1 MN-G#<>7=J,9RUN^V51]5'0UYA\8/^";%8ZRC6-TA!R DR;D9 MO*HO$%SH5N=FWQ1;'5=.;T5;Q22!CHJ3#CM MTKZ)^$?_ 6Q\-ZEY-K\2? M]HDQPK:EX>F%U"3W8PR%70?1G- 'Z:T5Y%\( M_P!K7X0?'(0IX,\?:/J=[+C;ILLWV:\)/;R)0LAYXR%(]Z]=H **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP*ATN'] MK;]I+XY:Y\1M=N+2_P!(T+7M:TZP:4))++9HPM[-,@@)&HW%5Y*Q-ZDU^^M? MEC_P4!_X)DW%YJWC'XQ_#C5;.PMA;W.MZYH5ZS1[61&DGEMG52#O 9C&V/F+ M8;!"@ \O_9]_X)S^//'/@GX/_&/X2>+M,\-:I);-?WLFLW$P:"\BNI45H%CA M;-I? _[$_Q$N9&6*^U"SATI4C8E6:XFCBD4$CD> M6TAYZ@5^8W[-7[>7QF_9'T/P;8Z[I,VM_"F^C>73M/U"T$/F6_FL)6L[D*"2 MK[LJQ=03C"YS7Z0?MQ?!/Q/^VU^S?X4L/ACJVCQ65_>6OB$3:Q++ MU:&VD, M2KMB<[B9D;#!>G44 ?G9^R+_ ,$[_#G[1?PCM/&/B3XGQ^"+J_U"XM+'3I+: M*1KB*+8ID4O,A/SEUP!_#7Z*_L7_ + &G_L<^)_$>LV?C.Y\4-K-G':-#/IZ MVPB"OOW B1LYZ8KY-T?_ ((DZK-\-Y+C5OB-#!XZ,#21:?:V1DT^.3!*Q-*S M!V!.,N%&,GY6QS/_ ,$B?VE/%EO\0M8^!_BF]N-0TV&TEN-)2[E+OI\T# 2V MZ$_\LV4EMN<*8S@?,: /./VT/%&N_MC?\% M/^#\&KSVGAC3=7AT"UA4EHX& M !O+G9T:0'S0"?X8U''-8W[=7['\/[!/B/X>>-?ACXIUQ4NII$2ZO)D^U6=Y M"$8.KQH@*NK-\NWC:P)(; ;^SM()?^"NUT]V26;QQXB))SG?B]QT_P!K%?4/ M_!;C_DC'P\/?_A()/_29Z /MS]G?XI#XU_ WP/XX*+'/K>E0W-S'&/E2XV[9 ME7V$BN!["O1*^6_^"89E/[#/PQ\[[_EZAC_=_M&ZV_IBOJ2@ HHKS#_A9GC; M_HE]_P#^#.#_ H / /_ "6WXJ_]PK_TF:O3Z\<^#>IWVL?%+XFWFHZ7)HMY M)_9GF6,LJR-'B!P,LO!R #^->QT %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 -DC2:-HY%5T8%65AD$'J"*^=OB[_ ,$^O@/\9O.G MU;P'9:1J$=O=U:OHNB@#\FOBY_P $3=4LS->?##Q] M#?*HW1Z;XFA,,O'87$(*L3[QJ,]_3R+_ (2+]MK]B/B\_P"$G;PY:<'[8HUO M2A&.0!)^\$*GK@-&>O3FOW"HH _*WX1_\%ME/D6OQ.^'Y7M)JGA6?/\ Y+3- M^OG?A7VO\)?V[/@9\:/(B\/_ !!TNWU&4#&F:PYL+G=_<59MHD/_ %S+#KS5 MKXN?L2_!/XW>=-XG^'^EG49@#]1E8,H(.0>012U^'Y^#?[;'[% MY,GAQ_$LN@VO*_\ "/7 UC3MHZL;0A]HQW>)>*]$^%O_ 6E\<>&YUT[XE^! M-/UX0MY4UWI+OI]VA!Y+Q/O1F!R,#RQ_4 _7RBOE#X2_\%/OV?\ XJ^3!)XL M;P;J4A ^Q^*8?L@'UG!:$#ZR#Z5]1Z3K%AK^GPW^F7UMJ-C,-T5U:2K+%(/5 M64D$?2@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/&9H9 M(P[1%U*B2/&Y?B%\6OAG\:=7USQ?::MH&H^'UCNYO MDB>:)UMKZ $ %&!YQC*N?XE"U^X%>4_M%_L]^%_V@OAWKNC:OX>T74M=DTRZ MMM'U35+19'T^XDC81R))M+H ^UCMZ[>AH _%#QA\8I/V@O@#\"O@'X*\*7^K M>*- FN&FN5B#/---)(1%"%)/EA'W.S8&4'9E>\LH=2K ,I&"#T- ' MYD?"?_@LGX6TOX%VR>.=*UK5/B;I]KY#BV@B%MJ:S)IL<:.VL?L9_\ !1*S^*8TN:Z\ M.ZEK$?B2TD0;5NE? O8 ^-HDW-*,=A)&Q^]57]OK]L/3?VZ=<^'G@[X7^'-> MG6SFE<6][;H+F\NY@BI'''&[\(JMDD\EST R?V<\:^ /#/Q)T5M'\6>'M+\3 M:4S"0V6K6<=S%N&<,%<$!ADX(Y%%/\ =!QP.* %_9S^%A^"?P*\#^!W=9+G1=+AM[F2,Y5K@C=, MR^QD9R/8BO1Z** "BBB@#S#P#_R6WXJ_]PK_ -)FKT^O,/ /_);?BK_W"O\ MTF:O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "O._BE^SO\,_C7;O'XW\#Z+XBD9=GVJZM5%T@QC"3KB1/ M^ L.E>B44 ?G?\6O^"+WPS\3>=<^ O$VL>";I@2EI=@:C9CT #%91]3(WT]? MES5O^"?O[6/[+VH3ZI\.-4NM3ME.][CP5J[Q2.!T$ELY1I#_ +(5Q7[9T4 ? MBYX1_P""K'[0WP2U9=$^)_AJW\020\2VVO::^E:B .,;D55'U:)C[U]:?"G_ M (+$_!CQKY-OXLM-9\ 7S<,]U ;VT!/82P@OU[F-1_3[3\7>!_#GQ TE]+\3 MZ!IGB+37^]9ZK9QW,1_X"X(KY,^*W_!)GX#?$4S7&CZ;J7@/4),GS-!NR8"W MJ89@Z@?[*;.E 'U#\/?B]X(^+%B;SP9XMT;Q/ J[G.EWL<[1C_;53E#[, :Z MZOQO^(7_ 1T^+?P\O\ ^U_AGXST[Q+);L7@'F/I.H*>VPEFCSVR95^GIRD/ M[4W[9_['\T=MXTM]U_:28["]4[F]/EF[T ?MW17YD?"G_@MI MX=U PVWQ%\ 7VCR<*^H>'[A;J(G^\89-C(/H[GZU]C?"K]MOX(?&;RH_#7Q% MTXT4F<\CD4M !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'@'_DMOQ5_[A7_I,U>G MUYAX!_Y+;\5?^X5_Z3-7I] !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)H4N(GBE19( MG4JR.,A@>"".XI]% 'SS\5?^"?\ \!?B_P";+J_P]TW3=0DY_M#00=.FW?WC MY)57/^^K5\=<_#?XBR0'GR].\46P<>V;F$ @?]LC7ZFT4 ?B$ M?@E^VY^QV-_AJ3Q-/H=KR@\-W0U>PP/XOLAW[1CNT0XKN/AO_P %G/B1X0O! MIOQ)\#:9XA\AO+FELB^F7JGN75@Z$C^Z%3\*_86N'^)'P/\ A]\8+7[/XU\& M:)XF7;M634;*.26,?[$A&]#[J10!\X_"K_@JY\ OB1Y4&I:U?>!M0? ^S^(K M0I&6[XFB+Q@>[E?I7U;X5\9:!XZTF/5/#>N:;X@TV3[EYI=W'$-3UOP%>-G9##+]OLU^L4V!7/<1+F'/N8 MS7U%10!^2WQ4_P"").LV?G77PX^(=IJ"C+1Z?XDMFMW ';SXMP8_]LU&>X[> M5M8_MR_LT4 ?D=\+?\ @MCX METMH[/XC_#^QU<*=CWV@3M:2KCJ3#)O5F^C(*^POA9_P4_\ V??B@(8G\7-X M/OY,?Z)XHMS:;?K,"T(_[^5['\4/V9_A7\:%D_X37P%H>O7#C!O9K14NP/07 M";9!^#"OCWXJ_P#!%WX8^)O-N/ WB?6O!5TV2MM= :C:#T #%91]3(WT]0#[ M_P!#U[3/$VFPZCH^HVFK:?,-T5W8SK-%(/574D'\#5^OQ2UK_@FU^U+^SIJ4 MNK_#76VU54._[3X0UI[*Y91_?BD,9;_=4OG/>C0O^"EW[4/[/&J0Z/\ $K1/ M[7"?*;7Q=HSV-V5']R5!&6_WF5\Y[T ?M;17YZ_"O_@M!\+?$_E6_C?PWK?@ MBZ;&ZX@ U&T7U)9 LOX"(_X_8/PO_:2^%OQHCC/@KQYH>OSN,BS@NU6Z ]6@ M?$B_BHH ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@#S#P#_R6WXJ_P#<*_\ 29J]/KS# MP#_R6WXJ_P#<*_\ 29J]/H **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "L[7O#ND^*M+ETW6]+L]8TZ;B2SO[=)X7^J. M"#^(K1HH ^3?BI_P2\_9]^)WG2Q>$Y/!VH29_P!+\+W!M0/I"P:$#Z1BOCSX MH?\ !%'Q7H\TEY\-_B!I^L(A\R.SUV%[*=,= LL>]6;W*H/YU^NM% 'XA_VU M^W/^Q[\MR/%T^AVO7[0BZ]IRQCH-_P"]$2^P9"/8UZK\*_\ @MMJ]JT-M\1_ MAY:WR=)-0\-7#0.,=_(F+!C_ -M%%?K/7E'Q2_93^$/QI\YO&7P^T/5[J;.^ M_%L+>\.?^GB+;)_X]0!YI\*_^"EG[/WQ6:&"'QM'X7U"3_ER\41&P*Y[&5LP MY]A(:^F-+U6RUNPAOM.O+>_LIEW17-K*LD;CU5E)!'TK\[OBK_P16^'VO^;< M> ?&&L>$KELL+34HUU"U]E7E)%'N6?Z5\S:G^P'^UK^R_?2ZE\.]3N]2M5;S M&N/!.L/&SCMYELYC:0^JA7'UH _;2BOQ<\)_\%6/VB/@EJR:)\3O#5OX@DA. M);;7],?2M1 '& R*JCZM$QKZP^%7_!8WX->,O*@\76&M> ;UL!I+B#[=: GT MDA!?\X@* /O.BN,^'7QF\!_%RR^U>"_&&B^)X@NYUTR]CFDC'^V@.Y#[, :[ M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** /,/ /\ R6WXJ_\ <*_])FKT^O,/ /\ R6WXJ_\ <*_])FKT^@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** ,3Q9X)\.^/M)?2_$V@Z9XBTU_O6>JV<=S$?^ ."*^3_ M (K?\$G?@)\1O.GTK2=0\":B^6\[P_=D1%O>&4.@'L@2OLNB@#\=/B-_P1I^ M*/@>].J_#7QMIOB1K=O,@CG+Z7?J>P1LM'D?WC(GX5QR_M$?MK_L>L(_%T/B M*YT:W(5O^$KLCJEDV.@%ZI)_!9OZ5^WE-=5D5E90RL,%6&01Z4 ?E]\*?^"V M^E7 AMOB1\/+JQ?@2:CX9N5F0GU^SS%2H_[:L?:OLCX4_MV? OXQF&'0/B)I M4&H2X T[5W-A<;O[JK,%WG_<+4?%;]A/X%_&0S3:_P##O2H-0ER3J.D(;"XW M?WF:$KO/^^&KXW^*W_!$C2K@37/PW^(=U8OR8].\36RS(3Z?:(0I4?\ ;)C[ MT ?J"CK(JLK!E89#*<@CUIU?B&W[._[:_P"QZQD\(S>(KG1K3;ZEK=YX%U*0A?L_B*V*1;O:>,O&%]W9?I7 MUAX:\5Z)XSTF+5/#^L:?KNF2_P"KO--NDN(7[\.A(/7UH U:*** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@#S#P#_R6WXJ_P#<*_\ 29J]/KS# MP#_R6WXJ_P#<*_\ 29J]/H **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ KB_B1\%O 7Q@L#9^-?"&C>)HMNU6U*S262,?[$A&Y#[J0:[2B@#X%^+7_! M&WX0^,O.N?!FJZSX O6!V0QR?VA9*?4QRGS.OI*!7R?XE_X)D_M,_L\ZK+K? MPQU_^V]G(NO"FJOI][M']^-V3/4_*K/UK]JJ* /Q3\-_\%+OVG/V==4BT3XF MZ$VM*GR_9/%NDO87A4=TE14+?[S*^(_"^C>,-)ETO7](L=;TR7_ %EGJ5LEQ"_;E'!! MZGMWKY2^+7_!*KX!_$[S[BPT&[\#:E)S]I\-W/E1Y[?N) \0'LBK]10!]%_# M7XV> ?C%8_:_!/C#1O$T07))+&/]N/.]#R.& /-=M7XZ_$G_@C?\4O M-]_;'PO\:6'B5K9O,MXY7;2M01NP1MS1DC^\9$^G:N-M?VKOVROV.IX[/QO; M:U>:1 P0)XSL&O;60],+>J=S?\!F(Z4 ?M1XH\3:7X+\-:KX@UN\33]'TNUE MO;R[D!*PPQJ7=R "3A03@ GTKYI_X>C?LQ?]%,_\H&J?_(U?'OBW_@KSH7Q@ M^ OCWP5XK\#7V@:_KF@7VFVU[I5PMU:-/+ Z(75]CQKD@<>9C^7UK^P;\4/A M+XU_9Y^&_ANPUWPQJ'BNPT2UM+W27>$7R3)& X,3X=N0?F (/8T 7?\ AZ-^ MS%_T4S_R@:I_\C4?\/1OV8O^BF?^4#5/_D:OI3_A$]#_ .@-I_\ X"Q_X4?\ M(GH?_0&T_P#\!8_\* //O@;^U-\+OVDFU=/ASXJ3Q%)I(B-[']BN;5HA)NV' M$\:%@=CKU\8?LR6L-C_ ,%!OVJ(+>&.WA6#0-L<2A5'^B \ 5]G MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 >8> ?^2V_%7_N%?^DS5Z?7F'@'_DMOQ5_[A7_I M,U>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 5%=6L-[;RV]Q#'/!*I22*50RNIZ@@\$5+10!\5?MM?L0?!34O@?\1?&UMX$ MT_0O$^CZ'>ZG;7VB V0,T4+R*7BC(C<%@,[E)/K7Q3X8_P""2?BSXE?!3P7\ M0? GC;39[W7-)MM3DT?6(7MC"[QABL]?J7^V)_R:A\8?^Q2U M3_TEDJI^Q3_R:/\ "'_L6;'_ -%+0!^:'PS3]O']FGQWHOA^WT/Q9XETQKJ. M!=/OA_;&E21E@-IN5+BVC/7<'CVC)..:_9JBB@#XU_9M_P"4AG[5?_7'0/\ MTC%?95?&O[-O_*0S]JO_ *XZ!_Z1BOLJ@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#P#_R M6WXJ_P#<*_\ 29J]/KS#P#_R6WXJ_P#<*_\ 29J]/H **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YSXD>!;#XH?#[Q+X/ MU62>'3=>TZXTRYDMF"RI'-&T;,A((# -D9!&>QKY5T3_ ()PW?AK2+/2M(_: M/^,VE:79Q+!;6-CXC,,$$:C"HB*H55 Z # K[-HH ^/_ /AWYKG_ $<]\ M.?$'BA+9+[4O%-XMS.1 '"?/M#,<,!EB>$4#&*]\HHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH \P\ _P#);?BK_P!PK_TF:O3Z\P\ _P#);?BK_P!PK_TF:O3Z "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** /,/ /\ R6WXJ_\ <*_])FKT^O,/ /\ MR6WXJ_\ <*_])FKT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#P#_ M ,EM^*O_ '"O_29J]/KS#P#_ ,EM^*O_ '"O_29J]/H **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL?QA MXPT7P!X9U'Q%XCU.WT;1-.A,]W?7;[(XD'&M+NM2^&BK*NNW\^F%=09]K>4UH#<(NS=LW>8@.-V!G%?=/P M2^.W@G]H;P3%XJ\"ZS'J^ELYAE7:8YK:4 $Q2QMRC $=>""""00: ._HKQ?] MHC]K[X8?LO6MF?'.NF#4;U2]KI-C$;B\E0<%_+'W4R"-SE02" 217'? '_@H ME\&/VBO$T/AO0-9O-(\17"DVVFZ];"VDN".JQL&9&?OL#;B,D X. #Z9HHHH M **** /,/ /_ "6WXJ_]PK_TF:O3Z\P\ _\ );?BK_W"O_29J]/H **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "O@;_@L]=:S!^RWH<=@95TR;Q-;IJ7E9P4$%PT8?'\'F*IYXW!.^*^^:YC MXE_#OPW\6/ VK^%/%^FPZMX=U*'R[JVG)4$ A@P8$%65@&# @@J".E 'XQ_L M[^"/@W\5OBU^S%X2T[3++5(M2T?5[;QC9S*?/>^-O<'=(3SP C1,IPH"D88& MOTB_8W_83TG]CJ^\076D>,]7\0_VW#'%=6MW#'%;[HV)20*N3N&Z09W='Z<5 M^;'[2G_!/&Y^%W[27@7X??"SQ+-J]YXNM+G4-*_M9U@>V:!7DV&>/AB5C.UM MJC)&<#FOHG_@EW^UI\1]6^+&N? [XG:A>:S=6-O<-97&JR>;>V=Q;N%FMI)" M2TBXWD;B2ICP#@\ 'SOX'TFT_;<_X*=:A!XO\S4_#-QK-^[VID8 V%G'(+>' M(((5A%$K;*/AKIP\(Q:O#/*MOI[LJ07EI) M$PFCR24;$T? P 4!')-9'_!-.%]-_P""AQM+DD7$?]LPMOR&+JDF?QX->X_\ M%S+B/R?@Q!\IFW:P_;*KBR'ZG_T&@#]&_@AX\?XI?!OP-XPE54GUW1+/49D0 M8"22PH[J/HQ(_"NVKQ']B*SEL?V1/A%',,.WANSE'^Z\8=?T85[=0 445YA_ MQ>?_ *D3_P G: #P#_R6WXJ_]PK_ -)FKT^O$]'\&_%K1?%/B#7H)?!;WFM_ M9_M"2-=F-/)0HFP C(/.2>?2MW_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R= MH_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$ M_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?1 M7F'_ !>?_J1/_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T M>GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+ MS_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)V MC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G M_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z? M17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ M ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC M_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ M ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%> M8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z M?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/ M_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/ M^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ M *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M 'I]% M>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ MD[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^ M+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ MR=H_XO/_ -2)_P"3M 'I]>=?!_5+W4[SQVMY>7%VMMXDNH(!/*S^5& F$7)^ M51DX XJK_P 7G_ZD3_R=K"\+>#?BUX1EUF2SE\%R-JM_)J,_GM=G;(^,A< 8 M7@8SD^] 'ME%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G: M/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%>8?\ M%Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F M'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/_P!2 M)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ M /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ *D3 M_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M 'I]%>8?\ M7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ D[0! MZ?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^+S_] M2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_ MXO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7 MG_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8? M\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G M_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ M]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ M "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q> M?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I M]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U( MG_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B M\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>? M_J1/_)VC_B\__4B?^3M %K]G_5+W6OA7I=WJ%Y<7UT\MR&GN96D=@)W RS$D MX _"O1:\3\$>#?BUX!\-V^B:?+X+FM8&D=7N6NVGT5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/ M_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ MZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M ' MI]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D M[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ M (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_ M\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_ MQ>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M M'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4 MB?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\ MG:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J M1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >G MT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ MB\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R M=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_% MY_\ J1/_ "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T > MGT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2) M_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R= MH_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M '8^/KF:S\">([BW ME>">+3;F2.6-BK(PB8A@1R"#WJM\+[R?4/AQX8N;J:2YN9M-MY))IG+N[&-2 M68GDDGN:XK6])^,.O:-?Z9<-X'2"]MY+:1HS>!@KJ5)&01G!]*C\.Z'\8/#. M@Z=I%J_@B2VL;=+:-IC>%RJ*%!8@ 9P.P% 'L%%>8?\ %Y_^I$_\G:/^+S_] M2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_ MXO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7 MG_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8? M\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G M_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ M]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ M "=H_P"+S_\ 4B?^3M 'I]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q> M?_J1/_)VC_B\_P#U(G_D[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I M]%>8?\7G_P"I$_\ )VC_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U( MG_D[0!Z?17F'_%Y_^I$_\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B M\_\ U(G_ ).T >GT5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>? M_J1/_)VC_B\__4B?^3M 'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q M>?\ ZD3_ ,G:/^+S_P#4B?\ D[0!Z?17F'_%Y_\ J1/_ "=H_P"+S_\ 4B?^ M3M 'I]%>8?\ %Y_^I$_\G:/^+S_]2)_Y.T >GT5YA_Q>?_J1/_)VC_B\_P#U M(G_D[0!Z?17F'_%Y_P#J1/\ R=H_XO/_ -2)_P"3M 'I]%>8?\7G_P"I$_\ M)VC_ (O/_P!2)_Y.T >GT5YA_P 7G_ZD3_R=H_XO/_U(G_D[0!Z?17F'_%Y_ M^I$_\G:/^+S_ /4B?^3M 'I]%>8?\7G_ .I$_P#)VC_B\_\ U(G_ ).T >GT M5YA_Q>?_ *D3_P G:/\ B\__ %(G_D[0!Z?17F'_ !>?_J1/_)VC_B\__4B? M^3M 'I]%>8?\7G_ZD3_R=H_XO/\ ]2)_Y.T >GT5YA_Q>?\ ZD3_ ,G:/^+S M_P#4B?\ D[0!Z?7GWQ\U.\T?X1^(+S3[N>QNXDA,=Q;2-'(F9HP<,""."1^- M4?\ B\__ %(G_D[6'XV\(_%OQYX7OM"U"3P7#:7@42/;-=K(-KJXP2".JCM0 M![-;,6MXB3DE 23]*EKRZ-/C-'&J#_A!<*,#/VVG?\7G_P"I$_\ )V@#T^BO M,/\ B\__ %(G_D[1_P 7G_ZD3_R=H ]/HKS#_B\__4B?^3M'_%Y_^I$_\G: M/3Z*\P_XO/\ ]2)_Y.T?\7G_ .I$_P#)V@#T^BO,/^+S_P#4B?\ D[1_Q>?_ M *D3_P G: /3Z*\P_P"+S_\ 4B?^3M'_ !>?_J1/_)V@#T^BO,/^+S_]2)_Y M.T?\7G_ZD3_R=H ]/HKS#_B\_P#U(G_D[1_Q>?\ ZD3_ ,G: /3Z*\P_XO/_ M -2)_P"3M'_%Y_\ J1/_ "=H ]/HKS#_ (O/_P!2)_Y.T?\ %Y_^I$_\G: / M3Z*\P_XO/_U(G_D[1_Q>?_J1/_)V@#T^BO,/^+S_ /4B?^3M'_%Y_P#J1/\ MR=H ]/HKS#_B\_\ U(G_ ).T?\7G_P"I$_\ )V@#T^BO,/\ B\__ %(G_D[1 M_P 7G_ZD3_R=H ]/HKS#_B\__4B?^3M'_%Y_^I$_\G: /3Z*\P_XO/\ ]2)_ MY.T?\7G_ .I$_P#)V@#T^BO,/^+S_P#4B?\ D[1_Q>?_ *D3_P G: /3Z*\P M_P"+S_\ 4B?^3M'_ !>?_J1/_)V@#T^BO,/^+S_]2)_Y.T?\7G_ZD3_R=H ] M/HKS#_B\_P#U(G_D[1_Q>?\ ZD3_ ,G: /3Z*\P_XO/_ -2)_P"3M'_%Y_\ MJ1/_ "=H ]/HKS#_ (O/_P!2)_Y.T?\ %Y_^I$_\G: /3Z*\P_XO/_U(G_D[ M1_Q>?_J1/_)V@#T^BO,/^+S_ /4B?^3M'_%Y_P#J1/\ R=H ]/HKS#_B\_\ MU(G_ ).T?\7G_P"I$_\ )V@#T^BO,/\ B\__ %(G_D[1_P 7G_ZD3_R=H ]/ MHKS#_B\__4B?^3M'_%Y_^I$_\G: /3Z*\P_XO/\ ]2)_Y.T?\7G_ .I$_P#) MV@#T^BO,/^+S_P#4B?\ D[1_Q>?_ *D3_P G: /3Z*\P_P"+S_\ 4B?^3M'_ M !>?_J1/_)V@#T^BO,/^+S_]2)_Y.T?\7G_ZD3_R=H ]/HKS#_B\_P#U(G_D M[1_Q>?\ ZD3_ ,G: /3Z*\P_XO/_ -2)_P"3M'_%Y_\ J1/_ "=H ]/HKS#_ M (O/_P!2)_Y.T?\ %Y_^I$_\G: /3Z*\P_XO/_U(G_D[1_Q>?_J1/_)V@#T^ MBO,/^+S_ /4B?^3M'_%Y_P#J1/\ R=H M?&;5+W2_P#A!OL5Y<6GVCQ38V\W MD2LGFQ-OW1M@\J<#(/!Q7HM>0WW@OXC^,]8\.#Q-<^%[;2]*U6'56;25N6G9 MHMVU )/EP"- ?6/"MYJLVJVT\,32PQ/.C_ &JUN G,8/F3!6Z;2"#E2!Q7 MC;6_BQ_P5<^.GADZ=X0;P]X=T^$6GVB+?+9Z=;F7,\\D[!1))T^1<%MB@+G) MK]RJ* ,OPKX;L?!OAC2- TN+R-,TJSAL;6+KLBB0(B_@JBM2BB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBOSN_;T_X*;>%?!/@_6? ?PJUJ/Q#XRU"%[. MXUS39=UKI2,"KM',IP\^#A=A(0G);*[2 ?HC17YT?\$:/'GB;QUX&^),/CY\"_@WX:UJ^T>ZU>Y66[;3KEX7(NKE+>)F*D<*(YSSZD]J^P_P!H M3]JSX9_LI^&4G\7:U'#??9PUAX?LV$M_=J,JNR/.0N5(\QR%R#\V>* /:**_ M#KX-?M??$/\ :"_;^\$ZY?>(-5TC1=8\16\:^&[/4IA8PVX 5(C&&"O\H!8E M?F8L<#.*_:3XA>.M*^&/@77_ !;KDK0Z1HEC-?W3( 6\N-"Q"C/+'& .Y(% M'0T5^+OA_P"(W[5'_!2?X@>)'\#>*9O!'A72RK&TMM5FTZPM$ !0!9HK\ MH_\ @HC_ ,%,M,\0:%/\-_@UK=Q-YLJG5?%NFS/" J,&$-K(I#'+ ;I!P0-J M[@Q(^DO^"3WBS6_&7[**:CX@UC4-=U#^W;R/[5J5T]Q+M CPN]R3@9/&>] ' MV517Y?\ _!1?]M?XE6?QRLO@1\'[VXT?5&:UM;V\T\J+R[O+H(T-O%(>8@%D MCRRD,2Y&0%Y\6^,'@3]L?]B71=*^(VM?%;4=7TZ:[CCN%@\0W6IPPS,,JMU! M*?L=?M"#]I[X ^'O',UHEAJDV^SU*VB/[M+J) MMLA3DD*W#@'D!P"3C-?'7QZ\4ZU\8?\ @J]\./AYIFLWUKH?AF*UFU"TM+F1 M(9&B1]0D\P*<':C!KWCI8O]%\+ MV4H:?>R[D:X(SY$>"K9;YB#E0U?GM_P3@_: ^(7Q>_;F@NO$_BW6-0MM5@U. M]FTQ[^8V2.T;.%2 L555)PH X &* /V,/ /A>W^ T^J6 M^N0ZFTFH'2]6AT]S;^4P&YI98PPWXX!)]J^"M8^$W_!0KP_I-[JFIZYXJL=. MLH'N;FZG\;V"QPQ(I9W8F[X ))]J /V@HK\>_\ @F/\4OC_ /'#]I+3+S5O M&WB;Q'X"T&&XFUQ=1U&22U_>6TT=NA#'#.961@OI&S?PU^PE !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !161XL\7Z'X#\/7NO>(]7LM"T6R3?<7 M^H3K##$"0!N9B ,D@ =R0!R:_'C_ (*"?\%*I_C!J%GX0^$6KZKHOA?3+C[1 M<>(+.:6SN-2F 95";2KK Q.&P6;!(&T9 /V>HKPO]AO6=0\0_LD_"_4=5OK MG4]0N-(1YKN\F:665M[VCM+1A+;Z9+RI>Y<<;D.?W0RV1AMH.: /M"BORF M_P""./Q.\8^/_BA\1H_$_BO6_$4<6DP2QQZKJ,URJ.9SEE#L0"?:OIW_ (*5 M?M9:]^RU\']+;PCY4/BSQ'=M9V=[,BR"SC10TLH1@0S8_B[K7V0Z6=;32_^$GO1>O8A?-+B(#R=I0"01[N1VSA3 M]K?\$R/VNO$/[4?PQU^S\9/'=^+/"UQ!#C1-L^TWTNWS'P2(XU^](Y"L0B@L<' XH ZRBOPB_;<_X M*(>)_C]\2(/^$!UG7/!W@O1ED@L5LKV6TGOF8C?/,(V'7:H5#G: >[$5^V?P MUOF?X6^%;V\N"S'1K6::XF?))\A"S,Q_$DF@#JJ*_&'5OVDOVB/^"A/Q^U+P ME\(_$U]X+\,0"6>V@L[^33HK>S1E3S[N>$>:Y;"(3M7RXX(UZ9 ?W- 'Z6T5^;W_!0#_@I MIX9\.^#=6^'_ ,(]=CUWQ1J436EYXBTN8FVTV)AA_)F4_O)B"0&0X3).[< * MT_\ @C9XZ\2>.OAI\1)_$GB'5?$,\&KVZ0R:K>RW+1J822%+L<#/84 ?H=17 MYT_\%-OVWO&7PJ\5:-\(?A;/)8>*-4MTFU#4[>,->(;?2(W5C:V0.^[O67&5AA'S.?MS>//VB/VN/"VMZ;K6M>$_"SZUI]A8Z%8ZE+%']E%RO,RHP5Y'W,6.#U M"\A10!^[]%-" SK%&S[%S_ !-C ]R* M_'GP+XV_:N_X*0>//$L_A'QS/X.T#3<-);V^JSZ9IMFDC,8H";=3).Y"-\S* MQ^7)*@@4 ?M917X\? ?]K;XY_LF_M26GPC^-&O7WBK2;K4+?3[W^U+PWTEO] MHVB&Z@N7.\Q_.C%6.-NX;58"Q.U3-=-NV\[8CZ"O+/A)H/[8O[>EOK?CG1/B?>Z%I5C=>3%NUNYTFT>X10 M_E6\-LI&Y R_.P'7ER6%]$&.QI\DS1N49026.60J=N:[/_@II^V[XW\ ^/M*^#/PJO)=-\07 MD4,FI:E9 &[$DS 06L#?P,1ABPYPZ $?-D _2>BOQ0^(FJ?M??\ !/\ U7PK MXO\ %GCZ\\0Z;JTYW6=[K4^K63RA=SV]PDN-KE2?FC/\)*OE:_7;X'_%C3?C ME\(_"OCS2D,-GKEBEUY!8,8).5EB)'4I(KH3ZK0!W-%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%>'_M,?MB_#?]EG099_%6LQ3Z^\!ELO#=DX>^ MNLY"G9_RS0D$>8^%X.,D8H ]PHK\0/V8?VJOB-\=O^"@?A#6-9\2ZM:Z;K>M M.[>'[;49A80Q"!PD*Q;MI50J\DL45^*WPA\-_MB_MWV>M>.M%^*-]H>E M6=V8HC)KESI5K).@#>7;0VJ%I_L!_MH_%3PY^T4_P%^,>H M7>NS2W5SIL-WJ?),T;^6R@DLU?'GP[_ &@M>_8Y M_P""9?A[QH]Q/K7COQOJEP=-;59FG^SM(75)F#DED2&V5PO0M(N>": /U#HK M\7?AI\&_VU?VG/A^WQ9TGXIZQ;6]PTTVG6T4A4%6NF7 M_4I@AL'YV!&T"Q.5C!X+!BXU<7DD]EX"?%OBCP MGXJL/$NE>%[.2\U.2PW]]9:5I$&EQ M^'K8B&":4?.RGS]NQ-A^7.XYP/G'_ ((U>&;KQ#9?%WXKZJOF:CX@ MUA;(3$8^90UQ/CV9KB/_ +XK]*: /P^M]%T_PW_P5SL-*TFQM]-TRS\:006U MG:1+%%#&JJ%1%4 * .PK]$/^"IFL3Z3^Q#X]$#%&NY+"V9AU"M>PEA^(!'XU M^?FI?\IBD_['F+_T%:_2S_@H-\.[WXH?L>?$G1M-@:YU"*QCU*&*,9=OLTT= MPRJ.[%(G Y).!0!^6O["GQ>^/\ IO@+Q!\/_P!GSP;;:GKDFHG6-6URX\D^ M3"T4<4,(\]DA0[HY6^8L6W84#:2?K;]CW_@HYXVUSXU_\*9^.^BVVC>*YKEK M&UU*.'[*ZW8'RV\\7*DOT1TP"2HP=P8>:_\ !&7XU>"?!NG_ ! \(>(-:T[0 M=+S F1NV[\XR,XZBNIHH _*W]MC]B;X:_LH?L3ZNWA:QFU'Q#=:M81W7B M'5"LEY(N\YC0@!8X\C.U0,X&XM@&O<_^"/7_ "9^G_8P7W\HJM?\%>?^3-M1 M_P"PU8?^AM57_@CU_P F?I_V,%]_**@#ZOO?@WX!U+Q5!XGN_ _ANZ\2P3BY MBUF;2+=[R.88Q(LQ3>&&T?,#G@5^9W_!6/\ ;&T7QU:Q_ SP0XUNYAU&.77+ MZU_>(LT9(CLXL9WN'(+D?=*JO)W!?1_^"HW[>5_\(XY/A)\/[UK/Q9>VRR:U MJ\)(DTZWD7*0Q'M,ZG<7_@5ACYF!3Q+_ ()VZ!^SC\&[:P^)7Q,^)7AVZ^($ MH\[3])GD9TT8'H[?*0UP1SGHF>/FY !^@7[!GP*OOV=?V8?"WAC6E6'7IA)J MFIQ@8\F><[_*/^TB;$)Z90XXKY#_ .":R#XX?MG_ ![^,TF9[-)9;>P=^=J7 M5RS1;3W*P6P7Z/[U]:_'3]ISPC>?L?\ Q-^(O@CQ%::]I]GIES86]_9,2B7D MBK#&O('(>>(_C7E7_!'_ .'(\'_LFQZ_)%MNO%6KW5_O88;R8B+9%^F89&'^ M_0!WOB3_ ()Y?#;X@?M+:_\ &/QJ;CQ1>ZA+:R6V@7*JNGP&"UA@!D7DSDF' M=AB%^;!5L9/YV_\ !.:-(?\ @I!?QQHL<:2ZXJHHP% $F !Z5^VU?B7_ ,$Z M_P#E))J7_7;7/_:E '[:5^:__!8/]HR_T?0?#_P4\+W,C:MXDVW>L16N3*;; M>%M[?C_GK(&)'4B-1T?G]**_&/P+C]J;_@KM=ZA>QFXTC1]>N+@*W*K#IL92 MW..F&EAA)'^V: /TL_8T_9TL_P!F+X!^'_"*0Q#7)(Q?:W6T0DD58;B.8JH) RWE["?#6E^($60G6K;2;>&[56SO_?! P!W-GGG)S7F/[ ?_ "9M\)_^ MP,G_ *&]?!7_ 5,_;NU#7/$&K?!3P'?O::+8NUKXDU&!MKWDXX:T5ATB0\/ M_>8%?NJ=P!R?_!1S]IJ+]L7XN>$_A-\+;5O$6GZ5J#007EK\PU._EQ'^Z_Z9 M( 0'Z'<[?= 8_J%X'T&S_91_97L+"\GCNK?P/X9::[G0%4F>"!I)F4'D!G#D M#KR*^'_V##^RY^ROX=@\0Z]\5/#&L?$Z_@'VN^+L\>G*P^:WMSMXZX:3JW., M+Q7M?_!1_P"/6AM^P?J^M>&-6@U/3_&0O+MSU!B@F6@#S+ M_@B]X,N+GP/\3?B5J1:;4?$.M)8^?(/F;R4,TC#V9[GGWC]J].D_X)U?#/X? MZA\5/BAJXF\8^+-4&KZO;?VE&HM-.>;S95\J$9RZ;L"1RW(!4(:]-_X)^_#D M?#']C_X::8T7EW5YIHU>XR,,7NF-P WNJR(O_ 17K?Q9_P"25^,O^P+>_P#H MAZ /RK_X(A_\E4^)?_8%M_\ T>:^K?\ @JU\.? 7C3]G6/5/&7BF/PCJ6B79 MFT2Z>)IC=7#H0UIY2_,PD"@Y'W-@8_*&!^4O^"(?_)5/B7_V!;?_ -'FNC_X M+B6VK_VA\);@O(=!,6HQJBYV+< P$ENV2A&/]UO>@#YRT_\ ;T^/5E^RDWP\ M@T6V;P.FGG0!XJ_LJ2#L/E@[=P'?=S7W_\ \$C? OP\\,_ M;4]7\'^*/^$F\1:Q<0MXB#0F!K"9$/EVWEMSM422$2V0BSX[X8^] 'Z_T444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 5X?^UA^RKHG[6_A'P[X9\0ZS?:/I.F:PFJS? MV=X44 ?B!_P %6/@QX.^ _C/X9>%?!&B0 M:)I$'A^1F6,;I)Y/M#@RRN?FD?"/PE!/$D\$NAVB M21R*&5U-N@((/!!':ORE_P""W'_):/AY_P!B_)_Z4O7ZO?"+++PUX7\$1QVI?4M8L].M[$^0@W'S94525&T'!. M.!7XW_M*_$?5/^"EG[8'A_PW\/;"9=#MT&E:=U']I[XD'X;^$]8ATCX9V-^MK]JFF\J'4IU?:;J=QG]PIY1 M>>!O()P%^O?V//&?[)G[(O@95M82ONID4_\!KRC_@D M[\,1X1_8ULK^1/)N_%E_>:F[,OS!-WV:/\-L&X#_ &_>O.O^"QWQ1ANO@'\/ M/"^BS_;/^$PU5=0@:#)^T6T,0*@#N&>Y@(^E?=?P=\ P_"OX3^#O!T 79H6D MVNGEEZ.T<2JS?5F!/XT ? GQC_X)Z_#/]E?]C7XI:S8QS^*?&7]D*AU_5D7= M#F:,,+>(#;"".,Y9\$C=@XI?^"(?_)+/B7_V&;?_ -$&OJ#_ (*'?\F6_%7_ M +!B_P#H^*OE_P#X(A_\DL^)?_89M_\ T0: /#_^"G6B:G\'/VZ_"GQ0O=/F MN]"O'TW5+9L_),]DT:S0*3P& 2,D?]-0>]>Y?\%$/VYO@]\3/V2M5\+>#O%- MOXEUSQ0UGY-G;Q.'M(X[B*=WF#*/+($6W:?FRW P"1ZW^WK^U-\$?AS=67PR M^,?@'6O&-KJUK'J,1M[2(VT:&1H]ZS&9)(Y%V/\ ZL;L$<_-7S/^U_\ #?\ M91^ ?[->N:E\+H=#U7QEXLCCL=(N;?67U.6&!I4>:1 TCB-1&KIOP&S)MSR1 M0!V7_!#_ %.6;X?_ !2TXD^1;ZI97"#/&Z2*16X^D2U^F=?G_P#\$9?AO>^% M?V==?\3WT#P?\)-K+/:;@1YEM!&(PX]C(9A_P&OT H **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH ^7@A0"=W#+7YC_ +97@G0?AS_P42\(^'/#&DVNAZ'87/A^ M*VL;.,)'&NZ+MW).22>22222:_<6OQ6_;^_Y2=:#_P!?OA__ -"BH _9S6-% MT_Q%IEQINJV%MJ>G7"[)K2\A66*5>N&1@01[$5P&M/\ "S]E?P'XA\4G2O#_ M ,/_ ]'_I6HS:7I\-H+B3HN5B4&60D[5'+$G KNO$GB+3?!_AW4]=UB[CL- M)TRVDO+NZE^[##&I=W/L%!/X5^#_ .TE^U!J?[=WQ\TW2M4\36W@/X9V]XT> MF_VHQ6WLH!G==SJI/F3LH.%'3(0$#+$ [3X=G7/^"C7_ 4+MO&%OH\EAX5L M+^UU"[60;EM--M"OEQR-T\R8IMP,_-(Q&54D?>7_ 5H^(P\#_L>ZQID"? WQ'T%I9Y$^TWL MLC-=:E"/LMWAZ'9Q6IOKIAD M1PQ1A5+MCEL8 !+' KLOBQ\3O#?P$^%NM>,?$#_8] T&T\QHX5&YL82.&->! MN9BJ*.!EAR!S7X7:Y\59OV\?VDXM5^+GCVR^'_@Z+>R&XD)BTZS##%O;)@[I MGXRY')!8\*%H ]L_X)[^"?$O[5G[<&L_&_5]/%KHFE:AV7C'4XWBT237=(\4)(5)\RW#1>>1])(IUX]* /LW_ (+,6D5Q^R;IA,%RI_1C70?\$C-4FU#]C+1X)&9DL=7O[>($!I^G6D%A86OC6^AM[6VC$<44:I,%15 PJ@ <"OVI\2^$]$\9Z8=.\0:-I M^NZ>7$AM-2M4N(BPZ-L<$9&3SBOQ@\#_ /*8JY_['G4/_09J_8'XQ?%C0?@= M\,_$'CGQ+,T6CZ-;&>58\%Y6)"QQ(#U=W94&>,L,XH X?XN?%/X6_L1_!ZZU M>72]+\+Z)$[_ �-"M(K4WUTPSY<,2!5W-C+-C ))P*_-'_@G5X%\3_M0_ MML:U\<=7L%M]%TO4+O5[R0*?)-Y<)(L%M&>Y3S _L(US]X9\3UCXJ2_MY?M) M1:M\7_'MC\/O!T(9D\Z0F+3[,,,6UJF#NF?C+L.2"QX54K](M::\\B,\NL"")%/LSW*X]T]J^VM#^!'@V'X6^$O ^O>&M&\3:7X> MTRWTZWAU;3XKJ,".%8BP612 6"\^O>O@+X[@?M ?\%=OAWX0QYVF>"8+6>Y7 M&4#PQOJ#$_[S/#&?H!7W!^U;^TAHW[+/P;U7QMJL7VRZ5A::9IV[:;R\<$QQ MY[+A69CV5&(R< @''?M5?M/^!/V'OA!#%96.GVNK20/;^&_"FFQ)!&S#HWEH M (X$)RQ 'H.2*^*?^"-_P/U[6OB!XJ^-6M0,NE&UFTNPGF3:;NZEE1YY4_V4 M5"A/0F4@H!XRS%A^ROP3_ &B/@;XKFTSP#\,?%N@W;V5IMLM%TG*B*",#.U=H M % '"W'_!._X:>)/VC/$/Q@\8"X\6:KJ5U'=6VC7B*NGVI2)(P6CY,S?)GY MCMY^X<9K\[_^"4BA/VZ-550%4:7J@ '0?O4K]M:_$O\ X)3?\GU:M_V#-4_] M&I0!^VE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 5Q?QF^%NG_&SX6^)/ VJW=S8Z?KEJ;2:XL]OFQJ2#E=P(SQW!KM** / M OV2?V.?#/['^B^(M-\-:UJVM1:U<17$SZJ8MR-&K* OEHO!W'K7G?[2W_!- M/P9^U!\5+OQUXD\8^)+"]FMH;2.SL#;^1!'&N J[XV/+%F.3U8U]@T4 ?G5_ MPY+^%G_0]>,/^^K7_P",UZS\._\ @G-X=^$GP1^)_P .O"OC76H4\>6\5M=Z MGJ$,4[VT:AE8(B",'>DCJ8H V?ZO=MX_O9KZPZ\'D4M% 'P/\;O^"/?PQ^)OBZYU_P +:[J' MP_>\E::YTZTMTN;+<223%&Q4Q9)SM#%1T55%>O\ [*/[ /PW_9.O+G6-&-YX MA\5W$9A;7-6*F2&(XW1PHH"Q@XY/+'INQQ7TS10 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 >4?M,_L[Z+^U#\+9_ VOZE?Z3I\UU#=FXTW M9YH:,D@?.K#!SZ5'^S#^SAHG[+/PQ'@CP_J>H:MIXO9K[[1J6SS=T@7(^15& M!M':O6Z* /AOXP?\$F_ /QI^)_B7QSK?CCQ5%J>N7KWDT5N;;RXL\+&FZ(G: MJA5&2> *X[_AR7\+/^AZ\8?]]6O_ ,9K]%:* /CN_P#^"<&B6_[*]W\#=!\= M:MINBWNN+K5UJ5Y:Q7,TN O[G:IC4+NCC;/7Y??CZ3^#OPTL?@W\*_"G@?39 M6N+/0=.AL%N&0(T[(H#2E0>"[;F(]6-=C10 5\G? _\ X)T>"O@3\=Y_BGI' MB77M0UB9[QS9WI@^SC[1NW_=C#<;CCFOK&B@ KY8_9U_X)\^#OV"WFD5Y+*.XFO6<_*SD,BJ5#2 8!^_P"W/V+10!6TW3[?2=/M;&TB6"TM M8EAAB7HB* JJ/8 "JWB30XO$WAW5-'GD>*#4+66TDDCQN59$*$C/&0#6E10! M\Q_LE_L%>$/V0?$6O:QX;\0ZWK,^L6J6DL>JF':BJ^\%=B* ;WP=XVTL:GHURRRC:YCE@E7[LL3CE'&3R.H)!!!(/=T4 ?FK-_P1#\# MMK)EB^)7B"/2=Q(M6LH&GQN.!YN0N<8&=G7GVK[B^ ?[/O@O]FOP##X2\$:< MUEIXD,]Q<3OYEQ=S$ -+*_\ $Q"@< #%>D44 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% 'R_\ M9_L!^#_ -KSQ5HFO>)/$6N:-<:5 M9-8Q1Z68=CJ9"^6WHQSD]J]UU#X?PWGPLN?!$.H75E;RZ,VC)J$.W[1$A@\D M2KD;=X'S#C&1TKJZ* /SJ_XO&'_?5K_\9H_XO&'_ 'U: M_P#QFOT5HH ^5/BM^P3I?Q8^)GPB\27_ (ONXM&^'5K96UMH;62R+>_9Y5E^+([FSU#3V>33M9T]E6YM6889?F!#(V%RA' M.T8(/-?*_@/_ ((J?#G0?$T=]XF\:ZWXITJ)PZZ5' ED),'[LLBLS%2.#LV' MT(K]%Z* ,_P_X?TWPIH=AHVC6,&F:580);6MG:H$BAC4 *BJ. !6A110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 5\I?&C_@G?X+^-G[0%G\6= M5\2:]8:U:RV4JV-F8/LY-L5* [HRW.T9Y^E?5M% ' ?'CX067Q[^$WB#P#J. MJ7VC:?K4<<,]YII03JBRI(57<",-LVG(Z,:^*?\ AR7\+/\ H>O&'_?5K_\ M&:_16B@#\]]$_P""+_PPT/6K#4HO&_BZ26SN([A$PA6&R\.M9*(8-MJ8%/F[\G#.\GW?O-[5]+44 >/?M2 M_LTZ1^U9\-X/!>NZWJFAZ;'J$6H/)I)C$DIC1U5&WJPVY?=TSE5KY+_XO&'_ 'U:_P#QFOT5HH ^&OA!_P $EOAU\&_B=X:\;Z9XP\47NH:%>I?0 M6]V;;RI&4\!ML0./H17O/[3W[(GP_P#VL/#-MIOC"TFM]1LB38:WIS+'>6F2 M"RJS*0R-CE&!'<8(!'ME% 'Y\_"__@C/\,?!OBRVU?Q-XFU?QI96L_FQZ1/! M':V\H'W5FVDLXSR0"H.,$8R#^@-M;0V=O%;V\2001((XXHU"JB@8"@#@ #M4 MM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\G:3_P3H\%: M/^U!)\<(O$NO/X@?5Y]9.G,8/LGF2AP4_P!7NVC>^U#0[H7<-O>&W\J1@",-MB M!QSV(K[AHH ^:?@W^Q79?"O]IKQ[\:;SQ7<>(M:\4"Y1+.:R6%+%)IDDVHV] MBVU8TC!P. ?6M']KC]C'P]^V%:^&;7Q)XDUK1+30GN)8H=),069Y1&"S^8C9 M*B/ QC[[>M?0M% 'YU?\.2_A9_T/7C#_ +ZM?_C->K_LS?\ !-/P-^R]\4H/ M'.@>*/$.K:A#:S6@M]2,'E%9 3\D:G(QZU]?44 %?)W[.?_ 3H\%?LU_%^ MY^(>A^)=>U34Y[>XMVM=0,'DA9F#,1LC#9&WCFOK&B@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN$^/7B_4 M?A]\#/B+XITAXX]6T/PYJ.IV;2H'030VLDD993U&Y1D=Z^9?A/\ #']IWXH? M"OP;XR_X:K_LS_A(M&L]7^Q?\*ZTN7[/]H@27R]^Y=VW?C=M&<9P.E 'VK17 MRK_PSO\ M._]'<_^8UTO_P".5Y=^TW8?M-_LR_!'Q%\2W_:83Q4FA-:,VCR> M --M%N1+=0P;3*K,5 \W/ R<8R,Y !]]T444 %%%% !1110 5POQ>^./@;X" M^'[37/'WB"'PYI5U="RAN9XI) \Q1G"8C5CG:C'ICBNZK\]?^"V'_)MO@W_L M;8?_ $CNJ /MOX6_%KPE\:_"-!#+'Y3.&* ^8BYR%;IGI7DO_!33_DQSXG_ M /7&Q_\ 2^VKY@_X(<_\BK\6_P#K]TW_ -%W% 'Z?T5XMXY_;,^#/PU^(-SX M'\2^.K32O%=O)#%+ILEM<,ZM*B/&-RQE?F61#U_BKV2ZN8K.VEN)G\N&)#([ M'LH&2?RH EHKQOX5?MA?!WXW>*AX;\#^-[37];,#W/V.&VN(V\M,;FR\:CC( M[]Z]*\8>,]"^'WAN]U_Q+J]GH6BV2>9<7U],L448]R>Y/ Y)( R: -JBOF" MU_X*8?LUW6N_V4OQ,MDF+!%GETV]2W+'/'G&'8 ,?>) Y')YQ])Z/K%AX@TN MUU+2[ZVU+3KJ,2V]Y9RK+#,AY#(ZDA@?4&@#R+QA^V9\&? /Q$F\":_XZM-- M\60SPVTFF26UPSK)*J-&NY8RO(D0]>]>TU^$'[;G_*3;7O\ L8-%_P#2:SK] M7?B!^WY\ /AAXFD\/Z_\2=.CU6*4P3PV,$]ZL#CJLCP1NJD'@@G(/7&#@ ^@ MJ\D^+W[6'PF^ OB"TT/Q]XRM?#FJW5J+V&VGMYY"\)=D#YCC88W(PZYXKM?A MW\2_"WQ:\+V_B/P=KUEXBT2X)5+RQE#KN'56'56'=6 (]*^(O^"AWPE_9T\? M?%O0+[XP_%;4_ GB&+0XX;6PL8"Z2VPN)R)2?(DY+M(O4?='% 'WKH6MV/B; M0]/UC3+A;O3=0MX[NUN%! DBD4,C $ C*D'D=ZO5Y?;^/_ ?P,_9_P##VOZG MXC%MX#TK2=/@@UNZB=O,@9(XH)&5$W9?K=!7*W'[=GP)M?AS-XZ;XAV+ M>&8KXZ9]J2WN#))="-9#$D7E^8Y".I)52 &&2* />J*\[^"?[0?P_P#VB?#U MUK?P]\11^(-/M9OL]PRV\T#PR8SM9)45AQSTP>U;1/&GCV MRTW64"F33[>">\GBWZ_#X M=T>YNUL8KJ>*20-.R.ZIB-6.2L;GICY:G^%7Q?\ !_QN\*CQ)X'UN+7]$\][ M;[9#')&OF)C0,;&^($D; /&2,X# 9Q7K'_!'K_DS]/^Q@OOY14 ?;]>/_%K]KGX1? G MQ-#X>\=^-;7P]K,UJMZEK-;SR,T+,RJ^4C88+(XZYXKV"OQ+_P""SW_)U^B? M]BE9_P#I5=T ?M5I>I6VLZ;::A92B>SNX4GAE4$!T90RMSSR"*M5\RR_MK_! M/X%^!_!^B^,_']AIVL1Z-8"73[6*:\GAW0)CS$@1RG'.&P<8]1GV'X2_'#P' M\==#FUCP%XHL/$MA"_E3-:.0\+$9 DC8!T)'(W 9[4 4/C)^T9\.?V?8])D^ M(/BBW\-)JIE6R,\,LGG&/9OQY:-C'F)UQUKI_ 'Q \/_ !2\'Z;XI\+:E'J^ M@:DC26E[&C(LJJQ0D!@&'S*PY':OE+_@H]\./@A\0K+P"OQG^(FH> (K22^. MEM8P^9]J+"#S0W[F3&W;'Z?>/7M[C^R7X?\ !OA7]G?P9I7P^U^?Q1X.MK>5 M=.U:Y3;)<(9Y"Q(V)C#EA]T=* /7:*\Z^,7[1'PW^ .FPWOQ \7Z=X;2<%H( M)V:2XF ."8X(PTC@=RJG&>:\Q\%_\%'/V=/'NM1Z5IOQ+LK:]ED\N,:K:7-A M&YS@$2SQ(@SV!8'VH ^DZ*:CK(JLK!E89#*<@CUIU !1110!XE\-?VU/@I\8 M/&5EX4\'^/+/6_$%Z)&M[&*UN$:0(C2/@O&%X56/)[5[;7X%_P#!*O\ Y/C\ M _\ 7'4O_2"XK]E_B]^UI\)/@-XDMM \>^,[7P[K%S:+?16L]O/(6@9W17S' M&PP6C<=<_+0!Z[17B/Q>_;4^"WP+O(++QEX[LM.U*:))TT^WAFN[@(PW(7CA M1VC!'(WAC44C,$4LQ"J!DD]!7SEXT_X*)_LZ^ M4DT[4_B=IT]W&_ENNEVU MQJ"*0<'+V\;KQ]>U 'T=17G?PA_:&^''Q[T^:[\ >+]-\2I ,S0V[E+B$$X! MDA<+(@)Z%E /:O1* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHJ*ZNH;&UFN;F5+>WA1I))9&"JB@9+$GH !G- $M M%? O[-W[?GB;XG_M.3Z5XDL1IWPI\;2WEKX OY+=8O.ELW"N"_5C*,DAB=K[ M$7K7WU0 4444 %%%% !1110 5P'Q@^/7@+X!Z38:IX_\1P>&["^G-M;33Q2R M"20*6*@1JQZ GFN_K\X/^"W'_)%_AY_V,$G_ *3/0!]S_"/XW>!OCQX>N-<\ M!>([7Q)I=O<&TFGMU=#'*%5BK*ZJP.&4\CG-;/COQWH/PS\(ZGXH\3ZBFDZ# MIL8EN[V1&98E+!OPB_X)S_ +5S?LQ_'"WCU>Z,?@;Q*8]/UE68 M[+<[OW-WCUC9CG_8=^"<5^N'_!0N19?V*OBFZ,'1M+0JRG((\^+D4 >@_!K] MI#X;?M!_VQ_PKWQ3;^)?[(\G[=Y$,T?D^;O\O/F(N=WE2=,_=KTNORK_ ."& M/_-;/^X)_P"W]?J9J&H6VDZ?P !- 'DGQ6_; M ^#OP/\ %(\-^./'-EH.MFW2Z^QR03RL(W)"L3&C 9VG@G/0]Q7H7P_^('A[ MXI>#]-\4^%-4AUKP_J2,]K?6X8)*%=D;A@""&5@00""#7\\_Q>\0>)_VP/CY M\2O&ND64U\/+O-<,1ZVNEVJ )G_0JEP@]ED\MOK,U 'Z=UYW\8/VAOAQ\ ]/AO/'_B_3O#23@M! M#<,SW$P'4QPH&D<#U537HE?SYQ1S?MG?MT2:=\1_%#^&8-?UNYM)+RX91]AA MB$AAM(@YVJ?D2%<_Q/D[B3D _5S2O^"I7[-6J7AMS\0)+,YPLEUHU\B-_P " M\DX_X%BOI?PAXST'X@>'[77?#6L6.O:/=+NAOM/G6:)_HRDC([CJ.]?!WQ"_ MX(R?"F]\$WT/@[6?$6F>)XX':RNM0O(YX)9@"569!$ORDX!*$$=>>A\>_P"" M6OPW^//P+^.UQI'B+P+XET+P%KMK*NI-J-D\=M%<1HSP3 MT;(,>5ZB09Z @ M _1GXQ?M/?"_X 7VFV?Q \6VWANYU*-Y;2.>":0RHI 8CRT;&"1U]:\\_P"' MD/[-O_14M/\ _ *[_P#C-?$'_!<'_D?OA9_V#+W_ -&QUM_LX?\ !*#X9?&[ MX ^!?'%_XJ\6:;JVMZ>+N[AMYK5H Q8C$:F#]TRY WQ>8R''.UMLB[>5Q@$KG],_^" MOS_:/%WA^X_LK59R,&Y(4-%<$>KH0&]71S@ @4 ?5->%>/OVY/@7\,/%^I>% M_$_Q#L-+U[37$5W9M;W$AB8J&VEDC*YPPZ'CH>17I?Q5^(FF_"3X:^)O&>KG M&G:'I\U_*N<&38I(C'^TQPH]V%?S>ZII7C#XRR?$+XDSV[Z@EE<+JNO7RYVQ M/=W.U3_P*1S@=@#Z4 ?TO:%KEAXFT/3]8TJZCOM+U"WCN[2ZA.4FAD4.CJ?0 MJ01]:O5\,_\ !(KXZ?\ "SOV;W\'WT_FZSX(N?L.&.6:REW26S'Z$2QCVB6O MM3Q-XBL/"/AS5==U2;[-IFEVDM[=3$9\N&-"[M^"J30!F^/OB1X5^%?AZ77? M&'B#3O#>D1G:;O4KA84+=E7)^9CV49)["OF^Z_X*H_LU6NH&U_X3RXF0,%:Y MBT2^,0YP3GRFP3L)-3N9(=)L)W;['HUBN M69F SC"+N=@,NWU45]^:+_P11^%,'AM;?5?&?BZ\UPHN^^M)+:" .!\Q2%H7 M(4GL7)P!SU) /M'X2_'SX>?';39;[P%XNTSQ+%" 9H[67$\(/0R0L!(F?]I1 M7?U_/M\=O@S\1/\ @G'^T%I%SHOB)S,%^WZ)K]FK1+=0!RKQ31DXSP!)'EE( M9>H:OV]_9M^-5G^T-\#_ E\0+.%;8ZQ:;KFU0DB"Y1C'/&">2%D1P">HP>] M 'IE(S!%+,0J@9)/04M?EK_P6 _:TU?0+RQ^"WA;4)M/2YM!>^(KBW8H\L2 M-R792#M4+MR 23D#R']M;_@FWKO[-.L>'=;^&,^O^,="U*[%M!#';F;4[*[5 M2Z F!!O#!&*LJJ05((Z$@'[@45X7^Q5XL^(WB[]GGP]-\5M"U'0_&MGOLKK^ MU(3#/>(F/*N&0\AF0J&S@EU^*].\,VDF[R1=R9 MFGVXW"*)09)",C(121F@#NZ*^9?"O_!2C]F_QAK*:79?$NTMKF1]D;ZG87=E M"_3GS9HE11DX^9@>#VYKZ5MKF&\MXKBWE2>"5!)'+&P974C(8$<$$=Z ):*\ M#?%#Z#J/Q+LI+Z)S'+)86=U>6\; XP9H8FC//'#''?% 'TG17FWB[] MI#X8>!?AS8^/=;\;Z/9^$;]0]EJBS^:EWGM"J9:1N#E4!(P)]132=!TV,2W=[(C,L2E@N2%!)Y(Z#O7F_AW]LKX*^*?!6M^+ MM/\ B'I3>&]%EC@OM0N/,MXXI'!*1CS%4NS!3A5!)QTH ]GHKYZ^'/\ P4 ^ M 'Q6\30>'_#OQ%LY=7N91#;V]]:7-D)W/14:>-%8D\!^%G[/L<)^('C73O#T\RAXK-]\]VZ$D;UMXE>0KD$;MN..M<-\.?^"A'[ M/OQ2UN#1]#^(]BFJ3OY<5OJEM<6'F,20H5YXT1B<< -GD#&>* /HFBBO%_B[ M^V5\%_@3JQTKQKX_TW2M54;GT^!);RXCZ8WQP([)G/&X#(YZ4 >T55U34K;1 MM-N]0O91!9VD+SS2L"0B*I9FXYX ->"_#/\ ;_\ @#\7->M=#\/?$:Q.L715 M8;/4K:XL&D=CA8T:>-$=R> JL23C&!/&MKXAUF&U:]>UAMYXV6%65 M6?+QJ,!G0=<\UZ^S!%+,0J@9)/05^=__ 3\^$/[-G@/XW:CJ/PB^+6J>.?$ M[Z'/#+IM[ 41+8S0%Y<^1'R&6,=?XCQ7D_\ P5V_:LBUN\T/X<^!/'-QY%G- M?VOBW2+#S( 9D:%8HIF*C>O^N^4$J<9(.!0!^KFC:WI_B+38-1TJ^MM3T^<$ MQ75I*LL4@!()5E)!&01QZ5=KXY_X)Q?M$?#OQ5\"OA[\-M*\3V]YXWTK0_,O M=(6&4/"J288EB@0XWKT8]:][^,?[27PR_9_@M9/B!XQT_P -O=*TD%O-OEN) M5'!988U:1@#QD+C/% 'I=%>#_"7]NCX&?&[7H-#\)?$"QNM:G.V'3[Z">QEF M;LL8G1!(W^RA)KWB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **^8OBK^U+XLUCXG:A\*O@3X6L_&GC;354ZWKFKSM M%HF@;ONK.Z?-++U_=H01@]2K**#?#7]KRTC_ +1@^,G@6_U# 8:+=^%VBL2W M&4\]&,VWWQGGI0!]645\Z_ O]J74_$WQ G^%?Q6\,+\/_BO;P&Z@M(YO-T_6 MK<9S/8RG[P&&)C)+*%/)VN%^BJ "BBB@ HHHH **** .0^*7Q:\)?!3PG)XF M\;:U%H.A1S) UY-'(ZAW.%7"*QYQZ5C_ <_:+^''[0$.IR_#[Q79^)5TQHU MO%MTDC>'>&*$K(JG!VM@XQ\I]*^"WGC*1;E7=F1%'WF4<'O5SXTZU8>)/V:?'FKZ7=Q7^F7_A&_NK6Z@; M='-$]G(R.I[@J01]:_+C_@B7_P E]\=?]BR?_2J"@#]E*\K^,7[47PL^ .I: M=I_C_P 86GAR]U")I[:":*61I(U;:6Q&C8&>.<9P<=#7JE?@'^UWXOUW]M#] MM+Q%:>$(7UH1/+I&AV\1SYEM9QR.[)[.R3RC_?H _!=0J%F11W+Q;6^EO7Z]T <9\4OC-X(^">@C6?'/B?3O#.G,2L< ME]+AIF')6-!EI&QV4$UX!:?\%3OV:;O43:_\)_-"N=JW,VB7ZQ,<@#GR%/BUX;A\0>#?$&G^)-'FX6ZT^82*K=U8#E&'=6 M([BL+XQ?M!_#WX 6.FWGQ \2P>&[;4I'BM))X99!*R %@/+1L8!'7UK\K_V# M_@E^T%^S-^UE903>"/$4/A"\O)-'UV\%DXL+BW#,J7 =@ 55]LBN.=I;'#$' MV#_@N#_R(/PL_P"PG>_^BHZ /I__ (>0_LV_]%2T_P#\ KO_ .,UU_PY_;)^ M"?Q9U>/2O"WQ)T/4-4E;9%92S&VFF;TC28(7/LH-?G-^QC_P3)^'7[2_[..@ M>/-;\2>*-*UR^NKJ*:.PFMOLP2*=XUVH\)8$A022Y[\>G"_MN?\ !,6]_9C\ M%/X^\(>(KKQ/X6M9HXKZ"\@"7=B'.U92R?*Z;RJD@*077@C) !^W-%?"_P#P M2C_:IUCX\_"?5O"GBR_DU/Q1X0>*-=0N&+37=E*&\II&/WG1D="W4C83DDD_ M;>M:Q9^'='OM5U&X2TT^Q@DNKFXD^[%$BEG8^P )_"@#R;XI_MC?!KX*>+'\ M,^-?'=EH6NQPI.]E)!/*RHX)4DQQL!D#."XKTKP1XWT/XD>$],\3>&M2 MAU?0M3A$]I>P9V2IDC(! (Y!!! (((-?SK?$[5_%7[6?QF^)_C[3[&:]98[K MQ%^.G_"1?#CQ-\*]0N-UYX>G_M3348\ MFSG;$JJ/1)OF/O<"@#])JQ_%GC#0O >@W.M^)-8L=!T>V&Z:^U&X2"%/JS$# M/MWK79@JDDX Y)-?@;^U)\>/&O[?'[3-KX6\-2S76@2:K_9?A?1T=A!MW%/M M<@'1G ,C.1\B<=%H _4+6O\ @J5^S9HVH/:?\)[+?,APTMEI%Y)&#GH&\H!O MJN1[U[!\'_VG_A7\?/,7P%XWTSQ!R1FANE7^\8)560+[[<5\:>!_P#@ MBC\.+7PK%'XN\9^)=1\120CSKC1Y(+:UBDSD^6CPNQ Z99N1DX7/'Q-^U[^R M3XN_8%^)WA[7O#GB2[N-'NYGGT+Q#:Y@NK::/!,4I7@2 ,,$'#KG@890 ?OK M17@?[#_[1Y_:B_9[T3Q=>+''X@MY'TS68X5VH+R(*691V#H\WGD,D88J6!C1AU!'-?]B_)_Z4O7H/[-O_ 2=^$?QB^ _ M@;QMK/B+QK;:KKFEQ7MS#8WUHD".PY"!K5F ^K$^] 'VWX _;6^!GQ/UJ+2? M#GQ,T.[U.9MD-K<2M:R3-_=03*F\\]%R>OI7MM?A?_P4(_8!T?\ 9"TOPYXC M\+^);_6="U>\DL6M-66/[3;R*F]2)(PHD4@-GY%VE1UWW)9@,YQSUKVFOS4\1_!C]EZ MX_;@A\17OQCU:W^*(\:6MXOAI;<^2=16YC:.VW?9_NM(%7._OU[U^E,DB0QM M)(RHB@LS,< =230 ZBOFGQC_P %(?V#/0R0N%D0 M'MN49P?0T >A51BUS39]8GTF/4+635;>))YK%9E,T<;$A'9,[@K%6 )&#M.. ME?/_ .W9^T=I'[/_ ,#]?0^*E\,^-M:TN\7PWMB9Y9KB-4#;"$95*^:G+8^\ M,=./SL_X)=?M3>#?A/XX^*6O?%GQNUA?:_#9&/4-4\^ZFNY$>8N6=5=B0&7E MO6@#]H:*Q_$GC#1/!OAJ[\0Z[JMIH^AVD7GSZA?2B*&-/4LV,=OJ2!7SPO\ MP4R_9K;7/[*_X69;B;(43G3+T6Y8]O-\G9@?WB=O/7K0!]/T50T'7],\4Z/: M:MHVHVNK:5>1B6VO;&99H9D/1D=20P]P:S?'?Q"\,_"_P[/KWBW7M/\ #FC0 MG#WNI7"PQ[CT4$GYF..%&2>PH Z&BOF"'_@IC^S5/K']FK\3;99LA1,^F7JP M$G/'FF#8,>I..>O7'T;X=\2:3XNT2SUG0M3L]9TF\3S+:^L)UF@F7.,HZDAA MD'H>U 'E%Y^V9\&=/^)R_#NX\=6D7C-M2CT@:2;:XW_:W<1I%N\O;DLP&*Y/#FM?$BQ&J0R^3.M MC:W-Y% W.0\L,;H"#P1NR#U P< 'T517.?#_ .(WACXJ^%[;Q'X0URR\0Z)< MDB.]L)1(A8?>4]U8=U.".XKC/C!^U/\ "OX!ZO8:7X_\86WAN_OH# S0RJL M@7/&=N,\=: /3J*;)(D,;22,J(H+,S' '4DU\U^,?\ @I#^SEX'UJ72K_XE MV=U>1.$D.E65U?PKDX)\Z")XVQCD*Q/M0!]+5QWQ5^+_ (/^"/A4^)/'&MQ: M!HGGI;?;)HY)%\Q\[5PBL><'MVK.^$'[07PZ^/FES7_@#Q=IWB6&#'GQ6[E) MX,]#)"X61 >VY1G!]#7S%_P6%_Y,_?\ [&"Q_E+0!]3_ A^-G@CX\^&[G7_ M %K\/B+1[:[:QENH(I(PLZHCLF)%4Y"R(>F/FKN*^ /^"*G_)K/BG_L<[K_ M -(;&OK_ .+WQ^^'GP%T>/4O'_BW3O#5O,&,,=RY:>?;][RH4#228R,[5.,C MUH ] HKYG\(_\%)/V(O&>OV/AS186 M"-=WTNP,QZ(HZNQP<*H).#Q7DOPU_;Z^ GQ:\61^&_#?Q$LI]9FD\JWM[ZVN M+(7#'HL;SQHKL3P%!W$]!TH ^@J*\=\&_M??!_X@_$C_ (0#P]XVM=3\7^=/ M!_9<=O.K[X5=I5W-&%^41OW[<9JFW[:WP3C^(_\ P@,GCVSA\7_VG_8_]ES6 MMPCB[\SRA%N,87)?C.<<]: /;J**\3\(_MH?!;QY\0;?P/X>\=VFK>*KBXDM M8M.M[6X+/)&&+@-Y>W ",V4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>-/%5IX%\':[XDOT MFDL-'L)]1N$MTWR-'%&TC!5[MA3@=S7YDWG_ 7,@2ZE6U^"\DUN&/ER3>)Q M&[+V)46C 'VR?K7ZFR1K+&R.H=&&&5AD$>AKRV3]E'X)2R,[_!WP"[L& M+$DGU/[J@#\__P#A^=_U1/\ \NO_ .XJ/^'YW_5$_P#RZ_\ [BK[_P#^&3O@ MA_T1OX?_ /A+V/\ \:H_X9.^"'_1&_A__P"$O8__ !J@#X _X?G?]43_ /+K M_P#N*C_A^=_U1/\ \NO_ .XJ^_\ _AD[X(?]$;^'_P#X2]C_ /&J/^&3O@A_ MT1OX?_\ A+V/_P :H _-7XL?\%E/^%H?"OQEX-_X5!_9G_"1:->:1]M_X2;S M?L_VB!XO,V?8UW;=^=NX9QC(ZT?"?_@LI_PJ_P"%?@WP;_PJ#^T_^$=T:STC M[;_PDWE?:/L\"1>9L^QMMW;,[=QQG&3UK[?_ &FOV9?@]H/[-OQ7U/3/A/X' MT[4K+PEJUS:WEIX_9M^%&IZ MG\)_ ^HZE>^$M)N;J\N_#EG+-/*]G$SR.[1DLS,22Q.222: /DO_ (?G?]43 M_P#+K_\ N*O*OVI/^"K7_#2GP)\3?#C_ (5=_P (Y_;7V7_B9_\ "0_:O)\F MZBG_ -5]E3=GRMOWAC=GG&#^JG_#)WP0_P"B-_#_ /\ "7L?_C5?-7_!1[]G MOX6>!_V,?B'K?AOX:>#_ _K5K_9WD:CI>@VMM<0[M1M4;9(D89Q_^-4 ? '_#\[_JB?\ Y=?_ -Q4 M?\/SO^J)_P#EU_\ W%7W_P#\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P M_P#_ E['_XU0!\ ?\/SO^J)_P#EU_\ W%6EX;_X+A:9J&N65MK'P@NM-TV6 M54FNK+Q +J6-20"RQ&U3>0.<;AFONW_AD[X(?]$;^'__ (2]C_\ &JL:;^S! M\&]'U"VO[#X2^!K&^MI%F@N;;PW9QRQ.IRK*PB!4@\@CD4 >FU^>O_!;#_DV MWP;_ -C;#_Z1W5?H57YZ_P#!;#_DVWP;_P!C;#_Z1W5 'SW_ ,$U_P!@'P=^ MT=\/]4\>_$AK[4M)AO'TO2])MKMX$^0*\DKLN&QNDPJJ0,AR3_M\?LRP M_L1?'3PQJ/P_U2^M-)U"(:KI$TTNZYL;F&0!T#X^8*3&RD\X;!SC)^L/^"0? M[3'@G1?A#JWPU\2>(M/T#7K+59;^RCU.Y6W2[MY5CR(V<@,ZNKY4'.&! QG' M@_\ P5Z^/7A;XP?%[PEX>\(ZK;Z_;^&+*=+J^L)!+ ;F=T)B1UX?"_P#X)#R^&-2MVM-3T_PYI"WEN_WH MIVO+9Y4/NKLP_"O./^"'/_(J_%O_ *_=-_\ 1=Q0!\P?\%!/^4E7B?\ [">A M?^D-E7[D>+/^15UG_KRF_P#1;5^&7_!2J23PO_P4)\5:O=0O]G\[1[Z/@CS( MTLK53CU^:-A]17ZT_&C]J[X8^%?V>];\<)XSTF]TV\TN7^S19W:/->3218CB MCC!W%\LN1@%>2V #@ _+#_@CU_R> G_8OWW\XJVO^"KWQHU?XI?M11_"]=2B MT[PQX8:UM4\Z?9;-=7$< G_8OWW\XJ MP/\ @I-X%_X0#]NCQ%?>(;"XE\.:Y/9:PGEMAKJU:.-)PC=COCF3VP* /HKX M@_L7_L=6_P $]2L_#7QG\,_\)[9Z>\UMK,GC*SD^UW2(6"/ )=@1V&W" , 1 MR2.6?\$6/CMJTWB#Q9\)=1O)+G2%L3KFE13,2+5UE2.=$ST#^:C[>@*,>K'/ M6>*?V._V)?"_P=G^)3>(+N^\.BR:[MA:^(P9[M@FY8(XS@F8G"[#@@GYL8.. MF_X)OZ/^S3XB^(VM>(O@OH?C;3?$&FZ88+UO$A#0Q0S2+A=R.Z;V,>0-V<(Y M[4 ?"'_!1RUNK[]OGXA6UB6%[->Z=' 4)!\PV-J%P1T.2*_032_^".?PA7X5 M1:/J%WJ\GC=K3][XDBO&VK=%@_MI?!K7/A/'\01X^T2UT86@N9[>:]C M%W;MMR8&@SYGF@@@(%RW;((- 'Y4_P#!,?XC>(?@7^VYP?LT9,KH6(_Z:RPIQW:N^_P""V'_)R7@W_L4H M?_2RZH ^JOVS_P#E$_9?]B_X:_\ 1MG7PI_P3N_8NL/VP]4\3)XJUW5=,\'^ M&/*D^S:8Z+)-=7.1\I=65!LMQN.TDXC':ONO]L__ )1/V7_8O^&O_1MG7#_\ M$0857X9_$V4??;5[53]!"Q'\S0![?J_@#2?^";_[$7Q#D\#W<]_=6/VB_@O] M35#*UUC_MA>.O%^O>/[Z_N] T/R MGN88;@I/J%W<-(1OEY;:!&[,00Q++SUK]4?V^/A[??%#]D+XEZ!I=I)?:BVG MI>P6\(S)(UO-'<;5'=B(B !R)T9OF(9!*"&)((X.&P/M#_@CU_R9^G_ &,% M]_**O!?^"QW[1G@OQEX/\(?#CPUKUCX@U6VU4ZQJ#:;.L\=H$ADBC1W4D;V\ MYSM!R G(&5S[U_P1Z_Y,_3_L8+[^45 'V_7XE_\ !9[_ ).OT3_L4K/_ -*K MNOVTK\2_^"SW_)U^B?\ 8I6?_I5=T ?3'[.G_!*'X7>)O@7H.L_$(ZQJ_C'Q M#81ZE/>V^H/"+(S('5(U PQ4,,F0-EL]L"OB[X,7VO?L-_\ !02V\,0:D;BS MM/$$?A_4';Y$O-/N)$4.Z]F"21R@=F4 MCZEI&D6]IK-EJ6H16\UK-#$J2,5<@E&*[E8#!!QG(('Y5ZWJL7[7O_!22&_\ M+P37VE:[XMM3"^TJ6L;8QJ\Y!Y \F!I,'D#CK0!]4_\ !K1PS7,C >^%-?-7_!!YOB;_P2_P!(\(VQ5;K7?"NK:;"SG 62:2Z1"?HS M _A0!^:W[/'PP\2_\%)/VKM4NO&VO7$,$D4FKZQ>6^"\-JKJB6UNK9"#+HB] M0JY;#$8/T[^VG_P2K\"_#7X'ZUXY^&E[JUKJ/ARV-Y>V&I7(N(KNV7_6L#M! M215RW7:0I& 3FOGO_@F3\>-$_9E_:4U:Q\?RMX=TW6+&71;JZO5,:Z?=I,C+ MYX(RB[D>,DXVE@6P 2/T*_;_ /VP_AIX5_9G\8Z'I/C#1?$?B/Q1IDNE6&G: M1?1W3E)U\MY7\LL$18V=@6P&( ')X /+/^"-W[1>N>//!_B;X8^(;V74/^$9 MBAN]'FG)9TM'9D> M_=C8)MSG D(& H _2.ORE_X(D_"W4XK[X@_$2YMWATF M2"+1+.5EP)Y-XEFV^R!81]7]C7W%8_MS?!'4OBTWPRMO&WF>-UU631#I?]DW MP_TR.1HWB\TP>7PZL-V[;QP<4 >\4444 ?@7_P $J_\ D^/P#_UQU+_T@N*] M+_X+5_\ )TWA;_L3+7_TNOJ\T_X)5_\ )\?@'_KCJ7_I!<5Z7_P6K_Y.F\+? M]B9:_P#I=?4 ?1?[/G_!+'X./%FFQZMT]5'H!;1U^+'[.O\ RE.M?^QYU7_T M.YH ^Z_^"OWQXUCX6_ C2/"6AW#65SXUN9K6ZN8W*R"SA5&FC7'3>9(U)_NE MA_%QXG_P3]_X)J_#KXQ? 6Q^(7Q'CU#5;K7Y)_[/L;6\>VCM8(Y7B#G9AF=F M1VY)7;MXSFNX_P""VGP[U'7/AI\/?&5I:23V6@7]U9WLL8R(5NEAV,WH-\ 7 M/3+@=Q78?\$O_P!J;X>3?LNZ#X,UOQ9I'A_Q)X7:Y@N+35KV.U:6%IY)HYH] MY 90DFTX)P4.< C(!YI\)/\ @F5\6_V?_P!JN#QC\//%.CVW@C2]14PMJU[* MMW?Z>X4RVTD<415C@LF25&4#@#@5^H=?GCK7_!66.X_:7_X5OX%\#VOQ T*\ MU.VTC3=8M-5:V:YFD*([K^Z=6C61F 88!5=V<'-?7?QR_:>^&?[-L6C2?$?Q M+_PCJ:PTRV)^P75UYQBV&3_41/MQYB?>QG/&<&@#U.BN:^&_Q(\._%SP3I7B M_P ):C_:WAW5$:2TO/(DA\U5=D)V2*KCYE8<@=*Z6@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@#&\:>*K3P+X.UWQ)?I-)8:/83ZC<);IOD:.*-I M&"KW;"G [FOS)O/^"YD"74JVOP7DFMPQ\N2;Q.(W9>Q*BT8 ^V3]:_4V2-98 MV1U#HPPRL,@CT->6R?LH_!*61G?X.^ 7=CEF;PQ8DD^I_=4 ?,W[)?\ P5.T MS]ISXPZ;\/;KX=W7A2_U.*=[.[BU47\1:*)I660>3$4!1'P>>0!WKK_VVO\ M@H=IG['7B?0O#O\ PA5UXNU?4[+^T"/MXLH(H?,:-?WGE2%F)1_E"C YYKZ M'\&_ WX;_#G5FU3PG\/O"WAC4VC,)O-&T6VM)BAQE=\:*<' XSCBKGCCX3^" M/B=]D_X3'P;X?\6?9-WV;^W-+@O?)W8W;/-1MN<#..N!0!^:Z?\ !2OBK) ^GV*OO;X7_ +26A_$S]FNW^,T.FW]AHC:5=ZI/8.H>XC%L95F1 M0.'.Z%]IXW#:>,U8_P"&3O@A_P!$;^'_ /X2]C_\:KT;2=!TS0='MM(TS3K3 M3M*MHA!!8VD"Q011@8"+&H"JN.P&* /R_O/^"YD"74JVOP7DFMPQ\N2;Q.(W M9>Q*BT8 ^V3]:Q?%G_!2WQ1^VEX=;X)>"?A[)X0\2^-KB+1QJ:ZQ]M6&T=O] M)8J((R!Y0?<><)O/7%?HA??LN? RUAN+R\^$7P]BBC5I9IYO#5B J@$LS,8N M!C))-?+G[ OPO\-?$SXU?$3]H71_"6D^&/"DES)X?\$Z?I>FQ6<2VL7R3W@C M10-\F-N[J"TRYP!0!Y;_ ,%,?&W@S]G/X7_"GX->&M"OH?$_AJ*TUSP]XAAE M6(::T,IC\PG:3*\A21F4;?FV.2>!5/3?^"Y4\=I:QWWP:2>Y5%6>>'Q-L5VP M-S*AM#M!.2%+''3)ZU^E_CCX3^"/B=]D_P"$Q\&^'_%GV3=]F_MS2X+WR=V- MVSS4;;G SCK@5\)>'/@1\-/@#^W7JO@/Q7\//"FL> OBA;G5/"DVKZ);7":= MJ$63/8Q&1#L1LL0B\#= H&2: /KOX7_M):'\3/V:[?XS0Z;?V&B-I5WJD]@Z MA[B,6QE69% X<[H7VGC<-IXS7P;>?\%S($NI5M?@O)-;ACYNO_ &VO^"AVF?L=>)]"\._\(5=> M+M7U.R_M C[>+*"*'S&C7]YY4A9B4?Y0HP .>:^A_!OP-^&_PYU9M4\)_#[P MMX8U-HS";S1M%MK28H<97?&BG!P.,XXJYXX^$_@CXG?9/^$Q\&^'_%GV3=]F M_MS2X+WR=V-VSS4;;G SCK@4 ?FNG_!2OBK) ^GV*OT/_ &>_ MC1IW[0WP;\,_$+2K"YTRRUJ&1Q9W>#)"\-L-QD8.!G%9W_ R= M\$/^B-_#_P#\)>Q_^-5Z1HNBZ?XS?"W]K+_A+O"&BQ):O*V7O--%Q$L;>[1';&W M^R8CR2:^O_\ @F%I-GKW[ _@[3-1M8KW3[W^U;:YM9U#1S1/?7"NC ]002"/ M0U^3W[9G[.NL?LA_'37/#=E-=1^&]4ADGT>\#'%Q82D@PN?XF0@HP/4JK8&X M4 ?9O_!#'_FMG_<$_P#;^OH__@JE\5KGC&7^Q+<*V&6!@ M6NGQZ>4#&?0S+7SA_P $,?\ FMG_ '!/_;^O#O\ @JQ\8;GXU?M5Q>"=$+WU MCX31=%MK>'YO.OY65I]H_O;C'$1ZPT ?17_!&7X#6W_"N?'GQ#UJQ6=/$+GP M_:),O#V:#=_L!_M[^3=R3)IOAO77LKICG=<:5/QYA' MZ.T^F1#7AW[67_!/WQW^R M+X5T7Q%X@U;2-=TK4KQK'SM),Q^SR["Z!]Z+]X*^,?W#0!_0)!/'=0QS0R++ M#(H=)(V#*RD9!!'4$5^6O[OV.;+3X=6^Q^+_#=O+X17PY^SS_P4;^*GPJ_:4&G_ !Y\3ZMJ'AZ% MI]&UBRGM8T.G2A^)_*BC4DHZX.!G8S8!P!0!XU;_ !&_:N_8[G2"YO\ QSX. ML;_^C8Z^C/V,_VS?@EX!_9; M^&_A[Q#\2-%TG6M/TI8;JRN)&$D+[F.TX7KR* .Y_P""IEK%9\9K;+&WQI$F.<*W^F#\R/_01Z5G? M\%.OV_/ /Q:^&*?"_P"&^IMXB6[OHKG5M6CA=+58HCO2&,L 78R;&+ ;0$QD MD\>]?\$A/@3J'PM_9_U+Q;K-JUGJ/C:[CO((9$*N+&%66!F!_O%YG'JKJ>] M')_\%G/CE_PBWPG\._#*PN-M]XGNOMVH(K3:5D^>*U"M#:L/7:0\R_P#705\'_M3>+=6_;;_; MGO-*\,RK=0WVJ1>&="9V)A2WB#_^ M^KK_ .,T >9?\$\?B=J'[+_[:4'A?Q&QT^VU6ZF\):Q"[?+%<>;LB8YX^6X1 M%W'&%=Z_6O\ ;KNKBS_8]^+OS7_ M &P/VU/$_P"VI>>![6\T"'1_['MVA&G:<[3"ZOIG >1 1N 8)$JQG<0=WS-F MOV6_8=^!MU^SS^S+X.\(ZG$(=>\E[_5%!!*W4[F1D)!P2@*QY'!\O- 'O%?S M\?\ !0B277_V\?B%#J#NJ/JEI:Y8_=B%O BX]!M -?T#U^+O_!8KX W_ (.^ M.%K\3[.S=O#WBNWB@NKE%^2+4(8_+*-V&^%(V']XK)Z&@#]H(XUCC5$4*BC M4= *=7QE^RO_ ,%*OA3\4/AGI">-/%VG^#?&=E:QV^IV^N3+;13RJ@#30RL= MK*Y!.W.X$D$="?F3_@HQ_P %(K?7+K0/"/P/\8WT+:9>?VAJ7B;19W@25PK( MEM&XP9$^=F?JA^0#=@X /U;UO6+;P_HM_JEZQ2SL;>2YF8#)"(I9C^0-?@GX M!T+Q3_P4O_;*E77]7FL+?4FFO+B52&SFC,< D6-5#$I^\W8R1(,\BOR ME_8+^*]G^R#^V!(GQ"230[3RKOPWJTLJG_07,B$.X R5$D* D= 2W:@#ZU_: MM_X)+?#[P?\ _Q#XH^&][K5KXA\.V,FHO;:E=+<17T,2EY5/RJ5DV!F4KP2 M-NWYLBI_P1G_ &D-:UZ3Q%\'M,OB%) Z:)IFDG1XYF7"R74TL4A53W*Q MQ'('3S$]: /F?XU>$]2\?_M_>-_"NCWS:;J.O^/[S2(KM6(\K[1>O"2<$$KB M0Y&>1D=Z^Q/VYO\ @F[\*O@/^RGJGC3PBFJ0^(O#KV7GWEU>M*+]9;B*W??& M?E4YE#C8%QMQTKYWT^-9/^"LS!E##_A:DIY]1J#$?K7Z;?\ !4?_ ),3^)O_ M '#/_3I:4 ?G+_P34_9)TG]K;6-?E\?ZAJ-[X(\'QHEMHL-Y)&KW-T7)*D'] MV@$)9MFTLQ3G (/G?[>GP-TC]DO]I\:1X"N[VPT];2TUO32\Y>:QD+-@+)]X M[7B+*3R,CDD9K[4_X(??\B#\4_\ L)V7_HJ2OG3_ (+)?\G<6?\ V+-E_P"C M;B@#](/VXM2FUK]@3Q[J%QM\^[\/VT\FT8&YI(6./;)K\M/^"='[)UK^UMXZ MUK2_$VJWUMX$\.QQW][8V,Q1KFYEW)$HR"%^5),MC=A<#&[(_4#]LS_E'?XP M_P"Q9L__ $*"OSW_ ."17[17A?X+_%?Q7X<\7:K;Z%IWBRTMUM]1O91';K=6 M[OLC=CPNY9Y,,Q RH'\0H UO^"E/_!/WPA^S9X-T/Q[\/)+VUT:>_73+_2[R MX,_E2.CO'+&[?-C]VRL"3R5([U]:?L?_ +7FHW?_ 3QUKXB>)&_M36/ =O> M:8\LC%FO)+>*-K;S"3G9?\ !8+]H[P7K'P@T+X=>']?T_7M M=OM5CU&Z33;E+A;6WB20#S"A(5G=UPO7"L>F,L_8[_9[UWQ%_P $LOB-HB6$ MJ:MXR;4-6TR"0'=Y_M^?\$R?!OP1^#= MW\1OAM=ZI%'HTL0U32]2N!<*\$CK&)8VP&#*[KE3D$,3\NWGSK_@D[^TAX6^ M 7Q<\5:!XWU&+P[IOBBU@A34KYO+@M[J!WV),QXC#"60;F( ( /7(^P/^"G7 M[7'P[L?V:]=\#Z!XITGQ+XG\4"&VBM=(O8[G[- )4DDFE*$A053:H)!)<$9" MG !4_P""6?[2GBKXN_L\^,O"=]%U MR?X2@[<_FC^SSXL^%D'QIU75/VC=%U_Q7I=XLQG%K/(LZW[2J6EN LD6>Y%[[P3^S?J?A_4M//\ @G-::KXKN)[W4?["U6UBO+ELRSV\)GBB M9CU)"H%R>2%!).A2:@^J>.;G5-2U5;R=7C657@(\H!057,S\$GM5?_ ((P_P#)U^M_]BE> M?^E5I7J__!J_L#?LU_#_P"!OP'TC]HB MW?5I?$LWA&ZN]0AN+M/LGE@&20*HCRO$*\ECCFO@/X$VWAW]LC]JS5_$'QW\ M>6/AC1+I)]7O[K4=4BL%GPZ+%9023'"@;QA1R(XFQ@\C]*?V6?$WA7XK_P#! M/W1_ACI'B?1[SQ=JO@K4=*&B1ZA%]M5VCFB;=%NWJ 77+$ #_"OQI\>)O!GQOEN=$TVZMIK6TF:\-D(-121-L[/'Y;'W8U\ M3?M(? ']B/\ 9ENM%M->7Q1K]]J4C!K+PWK4=U/:QA0?-F4NNU26 '.3S@'! MK[F_8>\+_#?P[^S_ *7<_"BTUFS\&:SBGRACL1R.#0 M![]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^87B[_@MYIFC M>)=2L-'^$5UJ>G6T[PQ7=YKXM)90K$;FB%K)LSCIN.*R/^'YW_5$_P#RZ_\ M[BK]"=6_9E^#VO:G=:CJ?PG\#ZCJ%U(TUQ=W?ARSEEFD8Y9W=HR68GDDG)JK M_P ,G?!#_HC?P_\ _"7L?_C5 'P!_P /SO\ JB?_ )=?_P!Q4?\ #\[_ *HG M_P"77_\ <5??_P#PR=\$/^B-_#__ ,)>Q_\ C5'_ R=\$/^B-_#_P#\)>Q_ M^-4 ?"7AO_@N%IFH:Y96VL?""ZTW39952:ZLO$ NI8U) ++$;5-Y YQN&:_1 MOXH^*I? OPS\7>)8(Q+-HVD7FHI&P)#-#"\@! Z\K7,Z;^S!\&]'U"VO[#X2 M^!K&^MI%F@N;;PW9QRQ.IRK*PB!4@\@CD5WOB#0[3Q/H.I:-?H9;#4+:6TN$ M!P6CD0HP_(F@#YJ_8STW3/@K^Q7IOCG4O.U"^U72KCQQX@OXT\RZOIIHVN9& M/]YPFU /]GW-?*MY_P %S($NI5M?@O)-;ACYC_ !V^%/PA^-WQH\+?!#X5?#GP=#<:?J4.K>./$F@Z#:PKI-C"V[[&9XT& M)IF&PH#D="/O;?KC_AD[X(?]$;^'_P#X2]C_ /&J /@#_A^=_P!43_\ +K_^ MXJ[WX$_\%B-,^+OQ9\+^"M3^%UUX>77]0ATR"_M=;%]Y9*S2+&B@G@ NZY;L,GM7?U4U;2;'7M,NM.U.RM]1T^ZC:&XM+N)9 M8IHV&&1T8$,I'!!�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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 28, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-35966    
Entity Registrant Name bluebird bio, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 13-3680878    
Entity Address, Address Line One 60 Binney Street    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02142    
City Area Code 339    
Local Phone Number 499-9300    
Title of 12(b) Security Common Stock, $0.01 par value per share    
Trading Symbol BLUE    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 1,398,973,030
Entity Common Stock, Shares Outstanding   71,433,275  
Documents Incorporated by Reference Portions of the registrant’s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001293971    
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
 12 Months Ended
Dec. 31, 2021
Audit Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location Boston, Massachusetts
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 161,160 $ 260,629
Marketable securities 138,343 419,599
Prepaid expenses 25,628 25,718
Inventory 0 10,698
Receivables and other current assets 11,389 3,872
Current assets of discontinued operations 0 495,021
Total current assets 336,520 1,215,537
Marketable securities 97,114 61,445
Property, plant and equipment, net 9,706 17,373
Intangible assets, net 0 4,397
Goodwill 5,646 5,646
Operating lease right-of-use assets 91,532 67,563
Restricted cash and other non-current assets 53,277 65,727
Non-current assets of discontinued operations 0 343,564
Total assets 593,795 1,781,252
Current liabilities:    
Accounts payable 25,883 13,811
Accrued expenses and other current liabilities 103,958 98,190
Operating lease liability, current portion 23,152 9,711
Current liabilities of discontinued operations 0 81,876
Total current liabilities 152,993 203,588
Operating lease liability, net of current portion 66,432 55,707
Other non-current liabilities 93 5,759
Non-current liabilities of discontinued operations 0 161,142
Total liabilities 219,518 426,196
Commitments and contingencies Note 11
Stockholders' equity:    
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and    outstanding at December 31, 2021 and December 31, 2020 0 0
Common stock, $0.01 par value, 125,000 shares authorized; 71,115 and 66,432 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively 711 665
Additional paid-in capital 4,096,402 4,260,443
Accumulated other comprehensive loss (2,911) (5,505)
Accumulated deficit (3,719,925) (2,900,547)
Total stockholders' equity 374,277 1,355,056
Total liabilities and stockholders' equity $ 593,795 $ 1,781,252
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value per share (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 125,000,000 125,000,000
Common stock, shares issued (in shares) 71,115,000 66,432,000
Common stock, shares outstanding (in shares) 71,115,000 66,432,000
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue:      
Total revenues $ 3,662 $ 0 $ 0
Operating expenses:      
Research and development 319,946 319,309 327,119
Selling, general and administrative 209,969 239,950 235,844
Restructuring expense 25,801 0 0
Total operating expenses 594,573 559,259 562,963
Loss from operations (590,911) (559,259) (562,963)
Interest income, net 879 5,770 17,380
Other income (expense), net 27,652 (6,881) (9,984)
Loss before income taxes (562,380) (560,370) (555,567)
Income tax (expense) benefit (258) (686) 545
Net loss from continuing operations (562,638) (561,056) (555,022)
Net income (loss) from discontinued operations (256,740) (57,639) (234,586)
Net loss $ (819,378) $ (618,695) $ (789,608)
Net loss per share from continuing operations - basic (in dollars per share) $ (8.16) $ (9.02) $ (10.06)
Net loss per share from continuing operations - diluted (in dollars per share) (8.16) (9.02) (10.06)
Net loss per share from discontinued operations - basic (in dollars per share) (3.73) (0.93) (4.25)
Net loss per share from discontinued operations - diluted (in dollars per share) (3.73) (0.93) (4.25)
Net loss per share applicable to common stockholders - basic (in dollars per share) (11.89) (9.95) (14.31)
Net loss per share applicable to common stockholders - diluted (in dollars per share) $ (11.89) $ (9.95) $ (14.31)
Weighted-average number of common shares used in computing net loss per share - basic and diluted (in shares) 68,910 62,178 55,191
Other comprehensive income (loss):      
Other comprehensive income (loss) $ 2,364 $ (3,612) $ 1,734
Comprehensive loss (817,014) (622,307) (787,874)
Product revenue      
Revenue:      
Revenue 2,850 0 0
Operating expenses:      
Cost of product revenue 38,857 0 0
Other revenue      
Revenue:      
Revenue $ 812 $ 0 $ 0
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Other Comprehensive Income (Loss), Tax $ 0.0 $ 0.0 $ (1.2)
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Statement of Financial Position [Abstract]  
Costs from public offering $ 33,645
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Cash flows from operating activities:      
Net loss $ (819,378) $ (618,695) $ (789,608)
Adjustments to reconcile net loss to net cash used in operating    activities:      
Change in fair value of contingent consideration 387 (6,468) 2,747
Depreciation and amortization 19,649 19,356 17,434
Stock-based compensation expense 127,915 156,631 160,629
Unrealized loss (gain) on equity securities (29,356) 7,217 9,297
Excess inventory reserve 29,924 0 0
Other non-cash items 17,235 458 (11,000)
Changes in operating assets and liabilities:      
Prepaid expenses and other assets (5,289) (10,089) (13,913)
Inventory (18,447) 0 0
Operating lease right-of-use assets 30,148 21,281 22,496
Accounts payable 9,286 (20,100) 23,600
Accrued expenses and other liabilities 40,025 4,835 29,617
Operating lease liabilities (32,142) (17,380) (9,944)
Collaboration research advancement (5,596) (7,397) (5,739)
Net cash used in operating activities (635,639) (470,351) (564,384)
Cash flows from investing activities:      
Purchase of property, plant and equipment (14,503) (28,986) (71,028)
Purchases of marketable securities (451,391) (1,003,525) (756,570)
Proceeds from maturities of marketable securities 895,333 918,288 1,340,629
Proceeds from sales of marketable securities 31,318 29,878 0
Proceeds from sale of Durham, North Carolina manufacturing facility 110,300 0 0
Purchase of intangible assets (8,500) 0 (5,224)
Net cash provided by (used in) investing activities 562,557 (84,345) 507,807
Cash flows from financing activities:      
Net cash transferred to 2seventy bio at separation (174,284) 0 0
Proceeds from exercise of stock options and ESPP contributions 5,355 5,179 21,187
Net cash provided by (used in) financing activities (93,954) 546,715 21,187
Decrease in cash, cash equivalents and restricted cash (167,036) (7,981) (35,390)
Cash, cash equivalents and restricted cash at beginning of year 373,728 381,709 417,099
Cash, cash equivalents and restricted cash at end of year 206,692 373,728 381,709
Reconciliation of cash, cash equivalents and restricted cash:      
Cash and cash equivalents 161,160 317,705 327,214
Restricted cash included in receivables and other current assets 2,282 1,500 0
Restricted cash included in restricted cash and other non-current assets 43,250 54,523 54,495
Total cash, cash equivalents and restricted cash 206,692 373,728 381,709
Supplemental cash flow disclosures:      
Purchases of property, plant and equipment included in accounts    payable and accrued expenses 411 2,854 5,286
Right-of-use assets obtained in exchange for operating lease liabilities 202,221 19,414 23,939
Reduction of right of use asset and associated lease liability due to lease reassessment (9,004) 0 0
Issuance of unrestricted stock awards to settle accrued employee compensation 25,074 0 0
Cash paid during the period for interest 0 0 0
Cash paid during the period for income taxes 617 361 637
Private Placement      
Cash flows from financing activities:      
Proceeds from issuance of common stock 74,975 0 0
Public Offering      
Cash flows from financing activities:      
Proceeds from issuance of common stock $ 0 $ 541,536 $ 0
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2018     54,738,000        
Beginning balance at Dec. 31, 2018 $ 1,885,070 $ 6,564 $ 547 $ 3,386,958 $ (3,627) $ (1,498,808) $ 6,564
Vesting of restricted stock units (in shares)     251,000        
Vesting of restricted stock units 0   $ 3 (3)      
Exercise of stock options (in shares)     354,000        
Exercise of stock options 17,838   $ 4 17,834      
Purchase of common stock under ESPP (in shares)     25,000        
Purchase of common stock under ESPP 2,766     2,766      
Stock-based compensation 160,629     160,629      
Other comprehensive income (loss) 1,734       1,734    
Net loss (789,608)         (789,608)  
Ending balance (in shares) at Dec. 31, 2019     55,368,000        
Ending balance at Dec. 31, 2019 $ 1,284,993   $ 554 3,568,184 (1,893) (2,281,852)  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-02 [Member]            
Issuance of common stock (in shares)     10,455,000        
Issuance of common stock $ 541,536   $ 105 541,431      
Vesting of restricted stock units (in shares)     434,000        
Vesting of restricted stock units 0   $ 4 (4)      
Exercise of stock options (in shares)     95,000        
Exercise of stock options 1,847   $ 1 1,846      
Purchase of common stock under ESPP (in shares)     80,000        
Purchase of common stock under ESPP 3,775   $ 1 3,774      
Stock-based compensation 145,212     145,212      
Other comprehensive income (loss) (3,612)       (3,612)    
Net loss $ (618,695)         (618,695)  
Ending balance (in shares) at Dec. 31, 2020 66,432,000   66,432,000        
Ending balance at Dec. 31, 2020 $ 1,355,056   $ 665 4,260,443 (5,505) (2,900,547)  
Issuance of common stock (in shares)     2,273,000        
Issuance of common stock 37,500   $ 23 37,477      
Vesting of restricted stock units (in shares)     534,000        
Vesting of restricted stock units $ 0   $ 5 (5)      
Exercise of stock options (in shares) 218,000   218,000        
Exercise of stock options $ 1,488   $ 2 1,486      
Purchase of common stock under ESPP (in shares)     120,000        
Purchase of common stock under ESPP 2,581   $ 1 2,580      
Issuance of pre-funded warrants 37,477     37,477      
Issuance of unrestricted stock awards to settle accrued employee compensation (in shares)     1,538,000        
Issuance of unrestricted stock awards to settle accrued employee compensation 25,074   $ 15 25,059      
Stock-based compensation 110,260     110,260      
Distribution of 2seventy bio 378,145     378,375 (230)    
Other comprehensive income (loss) 2,364       2,364    
Net loss $ (819,378)         (819,378)  
Ending balance (in shares) at Dec. 31, 2021 71,115,000   71,115,000        
Ending balance at Dec. 31, 2021 $ 374,277   $ 711 $ 4,096,402 $ (2,911) $ (3,719,925)  
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of the business
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of the business Description of the business
bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial-readiness activities.
In August 2021, the Company announced its intent to focus its severe genetic disease business on the U.S. market and further invest in research and development for its core programs in β-thalassemia, sickle cell disease ("SCD"), and cerebral adrenoleukodystrophy ("CALD") in that market. As part of the strategy to focus on the U.S. market, it began executing an orderly wind down of its European operations, which will result in a reduction of selling, general and administrative costs and had an impact on the Company's excess inventory analysis, which is based on forecasted consumption levels driven by sales forecasts.
In November 2021, the Company completed the separation of its severe genetic disease and oncology programs into two separate, independent publicly traded companies, bluebird bio, Inc. and 2seventy bio, Inc. ("2seventy bio"), a Delaware corporation and wholly-owned subsidiary of the Company prior to the separation. bluebird intends to retain its severe genetic disease programs, with a focus on the U.S. market. The Company’s programs in severe genetic diseases include programs for β-thalassemia, SCD, and CALD. The Company also expects to make focused investments in research and development efforts on optimizing our existing programs as well as on pipeline programs in severe genetic diseases.
The Company’s programs in severe genetic diseases include betibeglogene autotemcel ("beti-cel", formerly "LentiGlobin for β-thalassemia gene therapy") as a treatment for β-thalassemia; lovotibeglogene autotemcel ("lovo-cel") as a treatment for SCD; and elivaldogene autotemcel ("eli-cel", formerly "Lenti-D gene therapy") as a treatment for CALD.
As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $396.6 million. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from charitable foundations. As of December 31, 2021, the Company had an accumulated deficit of $3.72 billion. During the twelve months ended December 31, 2021, the Company incurred a loss from continuing operations of $562.6 million and used $635.6 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of beti-cel, eli-cel, and lovo-cel, and the achievement of a level of revenues adequate to support its cost structure.
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, the release of restricted cash related to the Company’s 50 Binney Street sublease, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have been approved by the Board of Directors as of the date of these consolidated financial statements.

The Company's expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a
going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include reduced 2022 spending, including projected savings through the move of the Company's headquarters to Assembly Row in Somerville, Massachusetts, the orderly wind down of European operations, the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for beti-cel and eli-cel, and the pursuit of additional cash resources through public or private equity or debt financings. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of significant accounting policies and basis of presentation
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of significant accounting policies and basis of presentation Summary of significant accounting policies and basis of presentation
Basis of presentation
The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”).  Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the ASC and the Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).
Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation. The Company has presented its oncology business together with its manufacturing facility in Durham, North Carolina as discontinued operations in its consolidated financial statements for all periods presented (see Note 3, Discontinued operations). The historical financial statements and footnotes have been recast accordingly.
Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding.
Principles of consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. 2seventy bio, Inc. ("2seventy bio") was a wholly-owned subsidiary until it became an independent publicly-traded company on November 4, 2021. All intercompany balances and transactions have been eliminated in consolidation.
Discontinued operations
The Company determined that the separation of its oncology business in November 2021 and the sale of its manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, Discontinued Operations (“ASC 205-20”). Accordingly, the accompanying consolidated financial statements for all periods presented have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheets and the results of all discontinued operations reported as a separate component of loss in the consolidated statements of operations and comprehensive loss (see Note 3, Discontinued operations).
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.  
Foreign currency translation
The financial statements of the Company’s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in stockholders’ equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.
Segment information
The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.  Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.  All material long-lived assets of the Company reside in the United States.
Cash and cash equivalents
The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value.
Marketable securities
The Company’s marketable securities are maintained by investment managers and consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Equity securities with readily determinable fair values are also carried at fair value with unrealized gains and losses included in other income (expense), net. Realized gains and losses on both debt and equity securities are determined using the specific identification method and are included in other income (expense), net.
The Company classifies equity securities with readily determinable fair values, which would be available for use in its current operations, as current assets even though the Company may not dispose of such marketable securities within the next 12 months. Equity securities are included in the balance of marketable securities on the Company's consolidated balance sheets. The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Marketable securities with a remaining maturity date greater than one year are classified as non-current assets.
Effective January 1, 2020, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements (“ASU 2016-13” or “ASC 326”), using the effective date method. As the Company had never recorded any other-than-temporary-impairment adjustments to its available-for-sale debt securities prior to the effective date, no transition provisions are applicable to the Company.
The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.
Accrued interest receivable related to the Company's available-for-sale debt securities is presented within receivables and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.
Concentrations of credit risk and off-balance sheet risk
Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.
Fair value of financial instruments
The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:
Level 1—Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2—Fair values are determined utilizing quoted prices for identical or similar assets or liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates.
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Items measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable securities, and Note 5, Fair value measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.
Business combinations
Business combinations are accounted for using the acquisition method of accounting. Using this method, the tangible and intangible assets acquired and the liabilities assumed are recorded as of the acquisition date at their respective fair values. The Company evaluates a business as an integrated set of activities and assets that is capable of being managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits and consists of inputs and processes that provide or have the ability to provide outputs. In an acquisition of a business, the excess of the fair value of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill. In an acquisition of net assets that does not constitute a business, no goodwill is recognized.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. The Company performs a one-step quantitative test and records the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has not recognized any impairment charges related to goodwill to date.
Upon disposal of a portion of a reporting unit that constitutes a business, goodwill is assigned based on the relative fair values of the portion of the reporting unit being disposed and the portion of the reporting unit remaining. This approach requires a determination of the fair value of both the business to be disposed of and the business (or businesses) within the reporting unit that will be retained. As a result of the separation of the Company's oncology business and the sale of the Company's manufacturing facility in Durham, North Carolina, the Company assigned goodwill based on the relative fair value of the business to be disposed of, and such goodwill has been reclassified to discontinued operations.
Intangible assets, net
Intangible assets, net consist of in-licensed rights with finite lives, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. During the third quarter of 2021, the Company recognized impairment charges related to intangible assets. In accordance with FASB ASC Topic 350, General Intangibles Other than Goodwill (“ASC 350”), the Company reviewed its intangible assets for recoverability. During the third quarter of 2021, the Company determined that the intangible assets were impaired, resulting in the impairment of the remaining carrying value of the intangible assets.
Property, plant and equipment
Property, plant and equipment is stated at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:
AssetEstimated useful life
Building40 years
Computer equipment and software3 years
Furniture and fixtures
2-5 years
Laboratory equipment
2-5 years
Leasehold improvementsShorter of the useful life or remaining lease term
Impairment of long-lived assets
The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.
Leases
Effective January 1, 2019, the Company adopted ASC 842 using the required modified retrospective approach and utilizing the effective date as its date of initial application.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.
Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.
The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.
In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.
Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.
ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Common stock warrants
The Company's common stock warrants are evaluated pursuant to ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), and ASC 815, Derivatives and Hedging ("ASC 815"). Management classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock.
Inventory
Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company’s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used for the production of clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product.
Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product, which has been produced for the treatment of specific patients, that are owned by the Company.
Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on hand and firm purchase commitments as well as remaining shelf life of on hand inventories. The Company writes-down its inventory that is obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue on the Company’s consolidated statements of operations and comprehensive loss.
Revenue recognition
Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines
are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.
Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. 
The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).  
The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.
If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.
In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.  The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.  The Company assessed each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.
The Company recognizes revenue within the following financial statement captions:
Product revenue
The Company recognizes product revenue in accordance with Topic 606. Product revenue represents sales of ZYNTEGLO. In 2021, the Company distributed ZYNTEGLO directly to hospitals in Germany. The Company determined that contracted sales with hospitals formed a single performance obligation and it recognizes revenue from product sales at the point in time it satisfies the performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product.
Other revenue
In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In addition, the Company entered into strategic collaborations and recognized an immaterial amount of revenue associated with those collaboration agreements.
Research and development expenses
Research and development costs are charged to expense as costs are incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, clinical study and related clinical manufacturing costs, license and milestone fees, contract services, manufacturing costs for pre-launch inventory that did not qualify for capitalization, and other related costs. Up-front fees and milestones paid to third parties in connection with technologies which have not reached technological feasibility and do not have an alternative future use are expensed as research and development expense as incurred. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, or other clinical trial vendors that perform the activities. Where amounts owed to a collaboration partner exceed the Company’s collaborative arrangement revenues in each quarterly period, such amounts are classified as research and development expense.
Cost of product revenue
Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue which are associated with the sale of ZYNTEGLO in Germany. Reserves for excess inventories are also included in cost of product revenue.
Stock-based compensation
The Company’s share-based compensation programs grant awards that have included stock options, restricted stock units, restricted stock awards, unrestricted stock awards and shares issued under its employee stock purchase plan.  Grants are awarded to employees and non-employees, including the Company's board of directors.  
The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values.
The Company’s stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable.
The Company estimates the fair value of its option awards using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of its own stock price. For both employee and non-employee awards, the measurement date is the date of grant. The Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.
Conversion and modification of equity awards outstanding at date of separation of 2seventy bio
In connection with the separation of 2seventy bio on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the separation. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. The Company will recognize future expense for awards denominated in bluebird stock and 2seventy bio stock granted to the Company's employees as a result of the separation of 2seventy bio. Expense related to awards denominated in bluebird stock granted to 2seventy bio employees will be incurred by 2seventy bio.
Stock-based compensation expense related to modified awards is measured based on the fair value for the awards as of the modification date. Any incremental stock-based compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite remaining service period, as appropriate.
Interest income, net
Interest income, net consists primarily of interest income earned on investments, net of amortization of premium and accretion of discount.
Other income (expense), net
Other income (expense), net consists primarily of gains and losses on equity securities held by the Company, gains and losses on disposal of assets, and gains and losses on foreign currency.
Net loss per share
Basic net loss per share is calculated by dividing net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration. Diluted net loss per share is calculated by dividing the net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration as well as any dilutive effect from outstanding stock options, unvested restricted stock, restricted stock units, and employee stock purchase plan stock using the treasury stock method. Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.
The Company follows the two-class method when computing net loss per share in periods when issued shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating securities.
Income taxes
Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if
based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Comprehensive loss
Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on debt securities, foreign currency translation adjustments and other items.
Restructuring expenses
The Company records costs and liabilities associated with exit and disposal activities in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations ("ASC 420"). Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available. Refer to Note 18, Reduction in workforce, for more information.
Recent accounting pronouncements
Recently adopted
ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity's own equity. The Company early adopted the new standard, effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs (“ASU 2020-08”) to provide further clarification and update the previously issued guidance in ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) (“ASU 2017-08”). ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-10, Codification Improvements
In October 2020, the FASB issued ASU 2020-10, Codification Improvements ("ASU 2020-10"). The amendments in this ASU represent changes to clarify the ASC, correct unintended application of the guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This new standard was effective beginning January 1, 2021. The adoption of ASU 2020-10 did not have a material impact on the Company's financial position or results of operations upon adoption.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued operations Discontinued operations
Sale of bluebird Research Triangle manufacturing facility
In November 2017, the Company acquired a manufacturing facility in Durham, North Carolina ("bRT") for the future manufacture of LVV for the Company’s therapies related to its oncology programs. In July 2021, the Company and Resilience US, Inc., an affiliate of National Resilience, Inc. ("Resilience"), signed an Asset Purchase Agreement (the “Agreement”). As part of the Agreement, and upon the closing of the transaction which occurred in September 2021, Resilience acquired the Company's LVV manufacturing facility located in Durham, North Carolina and retained staff currently employed at the site. As a result of the transaction, the Company disposed of $111.2 million of net assets, primarily consisting of the building and laboratory equipment, that were associated with the Company's oncology programs. The Company recognized a loss on disposal of assets of $2.0 million. As the sale of the bRT manufacturing facility and the separation of 2seventy bio (as described below) were deemed to represent multiple components of a single disposal plan, the assets, liabilities and results of operations related to bRT have been included as a component of discontinued operations.
2seventy bio Separation
On November 4, 2021, the Company completed the previously announced separation of its oncology programs and portfolio, and the certain related assets and liabilities, into a separate, independent publicly traded company (the “Separation”). The Separation was effected by means of a distribution of all of the outstanding shares of common stock of 2seventy bio in which each bluebird stockholder received one share of common stock, par value $0.0001 per share, of 2seventy bio for every three shares of common stock, par value $0.01 per share, of bluebird held as of the close of business on October 19, 2021 (the “Distribution”).
In connection with the Separation, bluebird entered into a separation agreement (the “Separation Agreement”) with 2seventy bio, dated as of November 3, 2021, that, among other things, set forth bluebird’s agreements with 2seventy bio regarding the principal actions to be taken in connection with the Separation, including the Distribution. The effective time of the Distribution was 12:01 a.m. on November 4, 2021. The Separation Agreement identified assets transferred to, liabilities assumed by and contracts assigned to 2seventy bio as part of the Separation, and it provided for when and how these transfers, assumptions and assignments occurred. The purpose of the Separation Agreement was to provide 2seventy bio and bluebird with assets to operate their respective businesses and retain or assume liabilities related to those assets. Each of 2seventy bio and bluebird agreed to releases, with respect to pre-Separation claims, and cross indemnities, with respect to post-Separation claims, that were principally designed to place financial responsibility for the obligations and liabilities allocated to 2seventy bio under the Separation Agreement with 2seventy bio and financial responsibility for the obligations and liabilities allocated to bluebird under the Separation Agreement with bluebird. bluebird and 2seventy bio are also each subject to mutual 12-month employee non-solicit and non-hire restrictions, subject to certain customary exceptions.
The transfer of assets and liabilities to 2seventy bio was effected through a contribution in accordance with the Separation Agreement, as summarized below (in thousands):
As of November 4, 2021
Assets
Current assets:
Cash and cash equivalents$174,284 
Marketable securities160,447 
Prepaid expenses8,732 
Receivables and other current assets21,637 
Total current assets365,100 
Marketable securities106,826 
Property, plant and equipment, net33,972 
Intangible assets, net10,664 
Goodwill6,410 
Operating lease right-of-use assets255,556 
Restricted cash and other non-current assets5,650 
Total assets$784,178 
Liabilities
Current liabilities:
Accounts payable$2,982 
Accrued expenses and other current liabilities85,659 
Operating lease liability, current portion6,938 
Collaboration research advancement, current portion8,957 
Total current liabilities104,536 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion16,264 
Operating lease liability, net of current portion257,575 
Other non-current liabilities1,896 
Total liabilities$406,033 
Net assets transferred to 2seventy bio$378,145 
bluebird and 2seventy bio also entered into a tax matters agreement, dated as of November 3, 2021, governing bluebird’s and 2seventy bio's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters.
In connection with the Separation, bluebird also entered into an employee matters agreement with 2seventy bio, dated as of November 3, 2021. The employee matters agreement allocates assets, liabilities and responsibilities relating to the employment, compensation and employee benefits of bluebird and 2seventy bio employees, and other related matters, in connection with the Separation, including the treatment of outstanding bluebird incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provides that, unless otherwise specified, 2seventy bio is responsible for liabilities associated with employees who transfer to 2seventy bio and employees whose employment terminated prior to the distribution but who primarily supported the 2seventy bio business, and bluebird is responsible for liabilities associated with other employees, including employees retained by bluebird. Pursuant to the employee matters agreement, the outstanding bluebird equity awards held by 2seventy bio and bluebird employees were adjusted immediately prior to the distribution, with the intent to maintain, immediately following the distribution, the economic value of the awards immediately before the distribution date.
bluebird and 2seventy bio also entered into an intellectual property license agreement on November 3, 2021, pursuant to which each party granted a license to certain intellectual property and technology to the other. bluebird granted 2seventy bio a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property to allow 2seventy bio to use such intellectual property in connection with 2seventy bio's ongoing and future research and development activities and product candidates. 2seventy bio granted bluebird a perpetual, worldwide, non-
exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property for use in bluebird’s existing products and product candidates. Such licenses between the parties generally allow current or future uses of the intellectual property in connection with each party's respective fields.

Additionally, bluebird entered into two transition services agreements with 2seventy bio, whose President is a member of the Company’s Board of Directors. . Pursuant to the transition service agreements, bluebird is obligated to provide and is entitled to receive certain transition services related to corporate functions, such as finance, human resources, internal audit, research and development, financial reporting, and information technology. Services provided by bluebird to 2seventy bio will continue for an initial term of up to two years, unless earlier terminated or extended according to the terms of the transition services agreement. Services received and performed are paid at a mutually agreed upon rate. Amounts received for services provided to 2seventy bio are recorded as other income and amounts paid for services provided by 2seventy bio are recorded as selling, general and administrative expense and research and development expense, as applicable. During the year ended December 31, 2021, the Company incurred $0.7 million of net expense for services provided by 2seventy bio within Research and development and Selling, general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2021, the Company had an immaterial amount of accounts receivable and accounts payable due from and to 2seventy bio.
Discontinued operations

In connection with the Separation, the Company determined its oncology business, together with the bRT manufacturing facility, qualified for discontinued operations accounting treatment in accordance with ASC 205-20. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Revenue:
Service revenue$18,130 $114,064 $30,729 
Collaborative arrangement revenue18,602 115,594 5,740 
Royalty and other revenue5,762 21,076 8,205 
Total revenues42,494 250,734 44,674 
Operating expenses:
Research and development204,287 268,647 255,294 
Selling, general and administrative82,078 46,945 35,518 
Share of collaboration loss10,071 — — 
Cost of royalty and other revenue2,292 5,396 2,978 
Change in fair value of contingent consideration387 (6,468)2,747 
Total operating expenses299,115 314,520 296,537 
Loss from operations(256,621)(63,786)(251,863)
Interest income, net791 5,770 17,380 
Other income (expense), net(910)377 (103)
Loss before income taxes(256,740)(57,639)(234,586)
Net loss$(256,740)$(57,639)$(234,586)
There were no assets and liabilities related to discontinued operations as of December 31, 2021, as all balances were transferred to 2seventy bio upon Separation. The following table summarizes the assets and liabilities of the discontinued operations as of December 31, 2020 (in thousands):
As of December 31, 2020
Assets
Current assets:
Cash and cash equivalents$57,076 
Marketable securities413,947 
Prepaid expenses11,754 
Receivables and other current assets12,244 
Total current assets of discontinued operations495,021 
Marketable securities61,446 
Property, plant and equipment, net145,458 
Intangible assets, net5,644 
Goodwill7,482 
Operating lease right-of-use assets116,456 
Restricted cash and other non-current assets7,078 
Total non-current assets of discontinued operations343,564 
Total assets of discontinued operations$838,585 
Liabilities
Current liabilities:
Accounts payable$7,791 
Accrued expenses and other current liabilities48,716 
Operating lease liability, current portion15,313 
Collaboration research advancement, current portion9,236 
Deferred revenue, current portion820 
Total current liabilities of discontinued operations81,876 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion21,581 
Operating lease liability, net of current portion112,290 
Other non-current liabilities1,509 
Total non-current liabilities of discontinued operations161,142 
Total liabilities of discontinued operations$243,018 

The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Operating activities:
Change in fair value of contingent consideration$387 $(6,468)$2,747 
Depreciation and amortization14,195 13,730 12,995 
Stock-based compensation expense29,175 34,036 29,545 
Loss on fixed assets disposal569 146 108 
Loss on sale of Durham, North Carolina manufacturing facility 1,986 — — 
Investing activities:
Purchase of property, plant and equipment$(11,256)$(23,159)$(57,196)
Proceeds from sale of Durham, North Carolina manufacturing facility110,300 — — 
Purchase of intangible assets(8,500)— — 
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses$778 $2,039 $3,064 
Right-of-use assets obtained in exchange for operating lease liabilities151,520 4,989 9,745 
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable securities
 12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Marketable securities Marketable securities
The following table summarizes the marketable securities held at December 31, 2021 and 2020 (in thousands):
Amortized cost / costUnrealized gainsUnrealized lossesFair value
December 31, 2021
U.S. government agency securities and treasuries$128,902 $— $(509)$128,393 
Corporate bonds49,366 — (59)49,307 
Commercial paper54,065 — — 54,065 
Equity securities4,305 — (614)3,691 
Total$236,638 $— $(1,182)$235,456 
December 31, 2020 (1)
U.S. government agency securities and treasuries$337,521 $151 $(37)$337,635 
Corporate bonds98,585 216 (20)98,781 
Commercial paper38,975 — — 38,975 
Equity securities20,017 — (14,364)5,653 
Total$495,098 $367 $(14,421)$481,044 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
No available-for-sale debt securities held as of December 31, 2021 or 2020 had remaining maturities greater than five years.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair value measurements Fair value measurements
The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
TotalQuoted
prices in
active
markets
(Level 1)		Significant
other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)
December 31, 2021
Assets:
Cash and cash equivalents$161,160 $161,146 $14 $— 
Marketable securities:
U.S. government agency securities and treasuries128,393 — 128,393 — 
Corporate bonds49,308 — 49,308 — 
Commercial paper54,065 — 54,065 — 
Equity securities3,691 3,691 — — 
Total assets$396,617 $164,837 $231,780 $— 
December 31, 2020 (1)
Assets:
Cash and cash equivalents$260,629 $260,629 $— $— 
Marketable securities:
U.S. government agency securities and treasuries337,635 — 337,635 — 
Corporate bonds98,781 — 98,781 — 
Commercial paper38,975 — 38,975 — 
Equity securities5,653 5,653 — — 
Total assets$741,673 $266,282 $475,391 $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Cash and cash equivalents
As of December 31, 2021, cash and cash equivalents comprise funds in cash and money market accounts. As of December 31, 2020, cash and cash equivalents comprise funds in cash and money market accounts.
Marketable securities
Marketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At December 31, 2021 and 2020, the balance in the Company’s accumulated other comprehensive loss was composed primarily of activity related to the Company’s available-for-sale debt securities. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended December 31, 2021 or 2020.
Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $1.5 million as of December 31, 2021 and 2020, respectively. No accrued interest receivable was written off during the twelve months ended December 31, 2021 or 2020.
The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months, and for which an allowance for credit losses has not been recorded at December 31, 2021 and 2020 (in thousands):
Less than 12 months12 months or greaterTotal
DescriptionFair valueUnrealized lossesFair valueUnrealized lossesFair valueUnrealized losses
December 31, 2021
U.S. government agency securities
   and treasuries		$108,695 $(505)$2,496 $(4)$111,191 $(509)
Corporate bonds45,042 (56)3,896 (2)48,938 (58)
Total$153,737 $(561)$6,392 $(6)$160,129 $(567)
December 31, 2020 (1)
U.S. government agency securities
   and treasuries		$105,692 $(37)$— $— $105,692 $(37)
Corporate bonds38,299 (20)603 — 38,902 (20)
Total$143,991 $(57)$603 $— $144,594 $(57)
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
The Company determined that there was no material change in the credit risk of the above investments during the twelve months ended December 31, 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2021, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of their amortized cost bases.
The Company holds equity securities with an aggregate fair value of $3.7 million and $5.7 million at December 31, 2021 and 2020, respectively, within current marketable securities on its consolidated balance sheets. In January 2021, the Company sold a portion of its equity securities for proceeds of $31.3 million. The Company recorded gains of $29.4 million and losses of $7.2 million and $9.3 million related to its equity securities during the years ended December 31, 2021, 2020 and 2019, respectively. Gains and losses related to equity securities are included in other income (expense), net in the consolidated statements of operations and comprehensive loss.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventory
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists of the following (in thousands):
As of December 31, 2021As of December 31, 2020
Raw materials$— $8,967 
Finished goods— 1,731 
Inventory$— $10,698 

During the year ended December 31, 2021, the Company recorded a reserve for excess inventories of $29.9 million, which is included within cost of product revenue in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2020, the Company did not record a reserve for excess inventories.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property, plant and equipment, net
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property, plant and equipment, net Property, plant and equipment, net
Property, plant and equipment, net, consists of the following (in thousands):
As of December 31,
2021
2020 (1)
Laboratory equipment$29,061 $27,146 
Computer equipment and software421 447 
Office equipment117 1,077 
Leasehold improvements12 5,949 
Construction-in-progress501 895 
Total property, plant and equipment30,112 35,514 
Less accumulated depreciation and amortization(20,406)(18,141)
Property, plant and equipment, net$9,706 $17,373 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Depreciation and amortization expense related to property, plant and equipment was $4.9 million, $5.1 million, and $4.1 million for the years ended December 31, 2021, 2020, and 2019, respectively.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restricted cash
 12 Months Ended
Dec. 31, 2021
Other Assets, Noncurrent [Abstract]  
Restricted cash Restricted cash
As of December 31, 2021 and 2020, the Company maintained letters of credit of $43.2 million and $54.5 million, respectively, which are collateralized with bank accounts at financial institutions in accordance with the agreements. Total restricted cash as of December 31, 2021 and 2020 consisted of the following (in thousands):
As of December 31,
20212020
50 Binney Street lease$40,072 $40,072 
Assembly Row lease2,753 — 
60 Binney Street lease— 13,763 
Other2,675 2,188 
Total restricted cash$45,500 $56,023 
Refer to Note 10, Leases, for further information on the Company's letters of credit.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued expenses and other current liabilities
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued expenses and other current liabilities Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
As of December 31,
2021
2020 (1)
Employee compensation$41,095 $41,192 
Accrued goods and services24,273 14,855 
Accrued clinical and contract research organization costs17,769 20,912 
Accrued manufacturing costs15,722 15,763 
Accrued professional fees1,665 1,541 
Deferred revenue, current portion2,282 1,500 
Other1,152 2,427 
Total accrued expenses and other current liabilities$103,958 $98,190 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Accrued employee compensation includes severance costs associated with the Company's orderly wind down of its European operations. As of December 31, 2021, the Company had accrued expenses of $4.7 million related to these restructuring costs. Please refer to Note 17, Reduction in workforce, for further discussion.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Leases Leases
The Company leases certain office and laboratory space. Additionally, the Company has embedded leases through its agreements with contract manufacturing organizations.
60 Binney Street lease & sublease
In October 2021, the Company entered into a consent to assignment and amendment to its lease agreement for its 60 Binney Street lease (the "Assignment"). The Assignment transfers the Company's interest in the lease to 2seventy bio and releases the Company from its obligation to maintain the $13.8 million collateralized letter of credit required under the original 60 Binney Street lease. Although the lease was legally transferred to 2seventy bio, the lessor required that the Company remain secondarily liable as a guarantor for payment obligations accruing under the 60 Binney Street lease from the date of Assignment until (i) the Company has completely vacated the premises and (ii) 2seventy bio has reached a market capitalization of $900 million. Upon Separation, the lease assignment was accounted for as the termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 60 Binney Street lease and recognized the fair value of the guarantee pursuant to ASC 405, Liabilities. The fair value of the guarantee was not material.
Concurrent with the Assignment of the 60 Binney Street Lease, the Company entered into a sublease agreement with 2seventy bio for office, laboratory and storage space located at 60 Binney Street (the "60 Binney Street Sublease") while it constructs and outfits its new office and laboratory space. Under the terms of the 60 Binney Street Sublease, the Company will lease 72,988 square feet for $0.5 million per month in base rent for the period beginning from the Assignment through March 2022 and 58,004 square feet for $0.4 million per month in base rent for the period from April 2022 through March 2024. The Company accounted for the 60 Binney Street Sublease as a new lease under ASC 842, and in November 2021, recognized a right-of-use asset and lease liability related to the 60 Binney Street Sublease.
50 Binney Street sublease & sub-sublease
In April 2019, the Company entered into a sublease agreement for office space located at 50 Binney Street in Cambridge, Massachusetts (the “50 Binney Street Sublease”) to supplement the Company’s corporate headquarters located at 60 Binney Street in Cambridge, Massachusetts. Under the terms of the 50 Binney Street Sublease, the Company will lease 267,278 square feet of office space for $99.95 per square foot, or $26.7 million per year in base rent subject to certain operating expenses, taxes and annual rent increases of approximately 3%. The lease will commence when the space is available for use by the Company, which is anticipated to be in the first half of 2022, which reflects the sublessor's exercise of its option to postpone the commencement date of the sublease. The lease term will end on December 31, 2030, unless other specific circumstances specified in the 50 Binney Street Sublease occur. The Company will assess the lease classification of the 50 Binney Street Sublease and commence recognition of the associated rent expense at the lease commencement date.
Upon signing the 50 Binney Street Sublease, the Company executed a $40.1 million cash-collateralized letter of credit, which may be reduced in the future subject to the terms of the 50 Binney Street Sublease and certain reduction requirements specified therein. The $40.1 million of cash collateralizing the letter of credit is classified as restricted cash and other non-current assets on the Company’s consolidated balance sheets. Payments will commence at the earlier of (i) the date which is 90 days following the commencement date and (ii) the date the Company takes occupancy of all or any portion of the premises.
In connection with the execution of the 50 Binney Street Sublease, the Company also entered into a purchase agreement for furniture and equipment (the “Furniture Purchase Agreement”) located on the premises upon lease commencement. Upon execution of the Furniture Purchase Agreement, the Company made an upfront payment of $7.5 million, all of which was recorded within restricted cash and other non-current assets on the Company’s consolidated balance sheets and assessed for recoverability on a recurring basis. The Company will be required to make another $7.5 million payment under the Furniture Purchase Agreement upon lease commencement.
In December 2021, the Company entered into a sub-sublease agreement (the "Sub-Sublease") with Meta Platforms, Inc. (“Meta”). Under the terms of the Sub-Sublease, the Company is subleasing the entirety of the 50 Binney Street premises which it has rights to under the 50 Binney Street Sublease. The Company is sub-subleasing the premises for $28.0 million in the first year with 3% annual increases in each subsequent year. Meta will receive access to 50 Binney Street at the lease commencement date, which is the same point that the Company would receive access under the 50 Binney Street Sublease. The Company remains liable under the 50 Binney Street Sublease, including for maintenance of the $40.1 million collateralized
letter of credit. As a result of the execution of the Sub-Sublease, the Company assessed the $7.5 million deposit related to the Furniture Purchase Agreement for recoverability and determined that the amount was not recoverable. As a result, the Company recorded $7.5 million in the Company's consolidated statements of operations and comprehensive loss as selling, general and administrative expense during the year ended December 31, 2021.
Assembly Row lease
In November 2021, the Company entered into a lease agreement with Assembly Row 5B, LLC ("Landlord") for office space located at 455 Grand Union Boulevard in Somerville, Massachusetts to serve as the Company's future corporate headquarters. Under the terms of the arrangement, the Company will lease approximately 61,180 square feet starting at an annual rate of $45 per square foot, subject to annual increases of 2.5%, plus operating expenses and taxes. In addition, the Company will be eligible for a tenant work allowance of $160 per rentable square foot of the premises. The lease will commence on the date on which the Landlord tenders possession of the premises to the Company with any tenant work required to be performed by the Landlord substantially completed, which is anticipated to occur in the first half of 2022.
Embedded leases
In June 2016, the Company entered into a manufacturing agreement for the future commercial production of the Company’s beti-cel and eli-cel drug products with a contract manufacturing organization. Under this 12-year agreement, the contract manufacturing organization will complete the design, construction, validation and process validation of the leased suites prior to anticipated commercial launch of the product candidates. During construction, the Company paid $12.0 million upon the achievement of certain contractual milestones. Construction was completed in March 2018 and beginning in April 2018, the Company pays $5.1 million per year, subject to annual inflationary adjustments, in fixed suite fees, as well as certain fixed labor, raw materials, testing and shipping costs for manufacturing services. The Company may terminate this agreement at any time upon payment of a one-time termination fee and up to 24 months of fixed suite and labor fees. The Company concluded in prior periods that this agreement contained an embedded lease as the suites are designated for the Company’s exclusive use during the term of the agreement. The Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
In November 2016, the Company entered into an agreement for clinical and commercial production of the Company’s beti-cel, lovo-cel, and eli-cel drug products with a contract manufacturing organization at an existing facility. The Company concluded that this agreement contains an embedded operating lease as the clean rooms are designated for the Company’s exclusive use during the term of the agreement. The term of the agreement is five years with subsequent three-year renewals at the mutual option of each party. As a result, the Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842, and is recognizing rent expense on a straight-line basis throughout the estimated remaining term of the embedded lease. In March 2020, the Company amended its agreement with the contract manufacturing organization, resulting in a lease modification. Under the terms of the amended agreement, the Company may be required to pay annual maintenance and production fees of up to €16.5 million, depending on its production needs, and may terminate this agreement with twelve months’ notice and a one-time termination fee. In September 2021, the Company reassessed the term of this lease in light of the planned orderly wind down of its operations in Europe. As a result, the Company reduced the right-of-use asset and related lease liability to reflect a shortened expected term of the agreement. In November 2021, the Company exercised its right to terminate the lease agreement, and such termination will be effective in November 2022. Per the terms of the amended agreement, the Company was obligated to pay a one-time termination fee of €1.0 million upon termination, which was paid in December 2021. In connection with this termination, the Company will pay for services properly rendered through the date of termination in accordance with the contract manufacturing agreement, based on work completed and expenses incurred prior to the date of termination.
In July 2020, the Company entered into an agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $5.4 million per year in maintenance fees in addition to the cost of any services provided and may terminate this agreement with eighteen months' notice. The agreement commenced in March 2021, and it has a term of five years with the option to extend. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in March 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
In February 2021, the Company entered into another agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled
environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $4.2 million per year in maintenance fees and an immaterial amount of other annual fees as well as per-batch fees for the cost of any services provided. Either party may terminate this agreement with eighteen months’ notice at any time or with eight months’ notice after stage 5 has commenced. The term of the agreement is five years, with the option to extend, and it commenced in November 2021. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in November 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.
Summary of all lease costs recognized under ASC 842
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the years ended December 31, 2021 and 2020 (in thousands):
For the year ended December 31,
2021
2020 (2)
2019 (2)
Lease cost (1)
Operating lease cost$25,067 $18,660 $20,005 
Total lease cost$25,067 $18,660 $20,005 
Other information
Operating cash flows used for operating leases$22,805 $17,780 $17,205 
Weighted average remaining lease term4.7 years6.3 years7.3 years
Weighted average discount rate5.02 %5.98 %6.66 %
(1) Short-term lease costs and variable lease costs incurred by the Company for the twelve months ended December 31, 2021, 2020 and 2019 were immaterial.
(2) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under all leases, including additional charges for utilities, parking, maintenance, and real estate taxes, was $36.2 million, $24.2 million, and $23.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.
As of December 31, 2021, future minimum commitments under ASC 842 under the Company’s operating leases were as follows (in thousands):
As of
Maturity of lease liabilitiesDecember 31, 2021
2022$27,037 
202321,460 
202418,009 
202514,639 
20268,598 
2027 and thereafter12,356 
Total lease payments102,099 
Less: imputed interest(12,515)
Total operating lease liabilities$89,584 
The above table excludes legally binding minimum lease payments for leases executed but not yet commenced as of December 31, 2021.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Lease commitments
The Company leases certain office and laboratory space and has embedded leases at contract manufacturing organizations. Refer to Note 10, Leases, for further information on the terms of these lease agreements.
Other funding commitments
The Company is party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specified products.
Additionally, the Company is party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement.
Based on our development plans as of December 31, 2021, the Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with the Company's collaboration and license agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company’s financial statements.
The Company has various manufacturing development and license agreements to support clinical and commercial product needs. The following table presents non-cancelable contractual obligations arising from these arrangements:
Years ended December 31,Purchase
commitment
2022$43,903 
20239,918 
2024 and thereafter— 
Total purchase commitments$53,821 
Litigation
From time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Management does not believe that any ultimate liability resulting from any of these claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, management cannot give any assurance regarding the ultimate outcome of any claims, and their resolution could be material to operating results for any particular period.
The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Equity EquityThe Company is authorized to issue 125.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s board of directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the
event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. As of December 31, 2021 and 2020, the Company had 71.1 million and 66.4 million shares of common stock issued and outstanding, respectively.
In September 2021, the Company entered into an equity purchase agreement with certain investors, pursuant to which the Company agreed to sell and issue, in a private placement offering of securities, an aggregate of (i) 2.3 million shares of the Company’s common stock at a purchase price per share of $16.50 and (ii) pre-funded warrants to purchase up to 2.3 million shares of common stock (the “Pre-Funded Warrants”) at an effective price of $16.49 per share ($16.49 paid to the Company upon the closing of the offering and $0.01 to be paid upon exercise of such Pre-Funded Warrants). This resulted in aggregate gross proceeds to the Company of approximately $75.0 million. The Pre-Funded Warrants can be exercised at any time or times on or after September 7, 2021, until exercised in full. The Pre-Funded Warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480 and ASC 815. Based on the terms of the Pre-Funded Warrants, management concluded that they should be classified within stockholders' equity on its consolidated balance sheets, with no subsequent remeasurement as long as the underlying warrant agreements are not modified or amended.
The Company is authorized to issue 5.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of December 31, 2021 and 2020, the Company had no shares of preferred stock issued or outstanding.
Reserved for future issuance
The Company has reserved for future issuance the following number of shares of common stock (in thousands):
As of December 31,
20212020
Options to purchase common stock (1)
5,534 6,262 
Restricted stock units (1)
3,427 1,495 
2013 Stock Option and Incentive Plan2,250 2,545 
Pre-funded warrants2,273 — 
2013 Employee Stock Purchase Plan1,347 67 
14,831 10,369 
(1) Stock options and restricted stock units that are reserved for future issuance include awards outstanding to employees of 2seventy bio.
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets Intangible assets
Intangible assets, net of accumulated amortization, are summarized as follows (in thousands):
As of December 31, 2021
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (1,219)(4,005)— 
Total$5,224 $(1,219)$(4,005)$— 
As of December 31, 2020(1)
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (827)— 4,397 
Total$5,224 $(827)$— $4,397 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Amortization expense for intangible assets was $0.4 million, $0.5 million, and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively.
In August 2021, the Company announced its decision to focus its efforts on the U.S. market and to execute an orderly wind down of its European operations. In connection with this, in September 2021, the Company recognized an impairment loss of $4.0 million for the remaining unamortized balance of the intangible asset associated with in-licensed rights for the ZYNTEGLO product, which is reflected within cost of product revenue in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
In June 2013, the Company’s board of directors adopted its 2013 Stock Option and Incentive Plan (“2013 Plan”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 Plan replaces the 2010 Stock Option and Grant Plan (“2010 Plan”).
The 2013 Plan allows for the granting of incentive stock options, non-qualified stock options, restricted stock units and restricted stock awards to the Company’s employees, members of the board of directors, and consultants of the Company. The Company initially reserved 1.0 million shares of its common stock for the issuance of awards under the 2013 Plan. The 2013 Plan provides that the number of shares reserved and available for issuance under the 2013 Plan will automatically increase each January 1, beginning on January 1, 2014, by four percent of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s compensation committee. In January 2021 and January 2022, the number of common stock available for issuance under the 2013 Plan was increased by approximately 2.7 million and 2.8 million shares, respectively, as a result of this automatic increase provision.
Any options or awards outstanding under the Company’s previous stock option plans, including both the 2010 Plan and the Second Amended and Restated 2002 Employee, Director and Consultant Stock Plan (“2002 Plan”), at the time of adoption of the 2013 Plan remain outstanding and effective. The shares of common stock underlying any awards that are forfeited, canceled, repurchased, expired or are otherwise terminated (other than by exercise) under the 2002 Plan and 2010 Plan are added to the shares of common stock available for issuance under the 2013 Plan. As of December 31, 2021, the total number of common stock that may be issued under all plans is 3.2 million.
The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.
Conversion and modification of equity awards outstanding at the Separation
In connection with the Separation on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units (“RSUs”) and performance restricted stock units (“PRSUs”) denominated in pre-Distribution bluebird stock received a number of otherwise-similar awards either in post-Distribution bluebird stock or in a combination of post-Distribution bluebird stock and 2seventy bio stock based on conversion ratios outlined for each group of employees in the Employee Matters Agreement that the Company entered into in connection with the Distribution. The equity awards that were granted prior to 2021 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both bluebird and 2seventy bio. The conversion ratio for the shareholder method took into consideration a distribution ratio of one share of 2seventy bio common stock for every three shares of bluebird common stock. For equity awards granted in 2021, the number of awards that were outstanding at the Separation were proportionately adjusted to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the volume weighted-average trading price for bluebird common stock for the five trading days before and after the Separation.
These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Due to the modification of the equity awards as a result of the Distribution, the Company compared the fair value of the outstanding equity awards immediately before and after the Distribution. The modification resulted in an incremental fair value of $20.3 million, of which $4.5 million was immediately recognized as of the Distribution date.
Additionally, bluebird will not incur any future compensation cost related to equity awards held by 2seventy bio employees and directors. The Company will incur future compensation cost related to 2seventy bio equity awards held by bluebird employees.
Stock-based compensation expense
The Company recognized stock-based compensation expense totaling $98.7 million, $122.6 million, and $131.1 million during the years ended December 31, 2021, 2020 and 2019, respectively. Stock-based compensation expense recognized by award type is as follows (in thousands):
Year ended December 31,
202120202019
Stock options$54,660 $75,837 $79,912 
Restricted stock units30,767 38,123 50,158 
Employee stock purchase plan and other13,313 8,636 1,013 
$98,740 $122,596 $131,083 
Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows (in thousands):
Year ended December 31,
202120202019
Research and development$42,989 $49,766 $59,378 
Selling, general and administrative55,751 72,830 71,705 
$98,740 $122,596 $131,083 
Stock-based compensation of $1.0 million was capitalized into inventory during the year ended December 31, 2021. Stock-based compensation of $0.5 million was capitalized into inventory during the year ended December 31, 2020.
Unrestricted stock awards
During the first quarter of 2021, the Company granted 0.4 million unrestricted stock awards to employees as part of its 2020 annual incentive program. In addition, the Company implemented a retention program designed to incentivize and retain employees through the separation of its severe genetic disease and oncology programs. Under the retention program, employees are entitled to a one-time bonus payment, consisting of both a cash payment and unrestricted stock awards, with the condition that the employee remains employed at the end of 2021. For the twelve months ended December 31, 2021, the Company recognized $21.2 million in expense related to this program, which includes $10.6 million in stock compensation expense related to the anticipated grants of stock. During the third quarter of 2021, the Company granted 0.1 million unrestricted stock awards, related to the retention program, to those employees impacted by the orderly wind down of the Company's operations in Europe. During the fourth quarter of 2021, the Company granted 1.0 million unrestricted stock awards to employees as part of its retention program.
As of December 31, 2021, the Company had $34.2 million and $54.3 million of unrecognized compensation expense related to unvested stock options and restricted stock units (exclusive of those with service and performance conditions that have not yet been achieved), respectively, that is expected to be recognized over a weighted-average period of 2.19 years and 2.26 years, respectively.
Stock options
The fair value of each option issued to employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
Year ended December 31,
202120202019
Expected volatility66.7 %69.5 %70.7 %
Expected term (in years)6.06.06.0
Risk-free interest rate0.8 %1.4 %2.3 %
Expected dividend yield0.0 %0.0 %0.0 %
The following table summarizes the stock option activity under the Company’s equity awards plans:
Shares
(in thousands)		Weighted-
average
exercise price
per share		Weighted-
average
contractual
life
(in years)		Aggregate
intrinsic
value (a)
(in thousands)
Outstanding at December 31, 20206,262 $105.02 
Granted1,238 $27.19 
Exercised(218)$6.82 
Canceled or forfeited(2,357)$81.20 
Conversion and modification of awards (1,339)$42.90 
Outstanding at December 31, 20213,586 $39.23 6.8$631 
Exercisable at December 31, 20211,835 $57.09 5.5$380 
Vested and expected to vest at December 31, 20213,586 $39.23 6.8$631 
(a)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021.
(b)Pursuant to the terms of Employee Matters Agreement, the company granted 4,375 option conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
The weighted-average fair values of options granted during the years ended December 31, 2021, 2020 and 2019 was $16.32, $43.24, and $83.44, respectively. The intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $5.1 million, $4.0 million and $29.0 million, respectively.
Restricted stock units
The following table summarizes the restricted stock unit activity under the Company’s equity award plans:
Shares
(in thousands)		Weighted-average
grant date
fair value
Unvested balance at December 31, 20201,495 $102.34 
Granted3,359 26.43 
Vested(526)112.21 
Forfeited(987)53.58 
Conversion and modification of awards(148)16.84 
Unvested balance at December 31, 20213,193 $16.21 
(a)Pursuant to the terms of Employee Matters Agreement, the company granted 3,327 restricted stock unit conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
The intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $44.0 million, $30.9 million and $28.4 million, respectively.
Employee Stock Purchase Plan
In June 2013, the Company’s board of directors adopted its 2013 Employee Stock Purchase Plan (“2013 ESPP”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 ESPP authorizes the initial issuance of up to a total of 0.2 million shares of the Company’s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4 million shares of the Company’s common stock available to participating employees. During each of the years ended December 31, 2021 and 2020, approximately 0.1 million shares of common stock were issued under the 2013 ESPP.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
401(k) Savings plan
 12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
401(k) Savings plan 401(k) Savings planIn 1997, the Company established a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. In March 2022, the Company expects to make matching contributions of approximately $2.8 million related to employee contributions made during 2021. At the same time, the Company anticipates making matching contributions to 2seventy bio employees of $2.0 million for their contributions under the 401(k) Plan during 2021 through the Separation. In March 2021, the Company made $6.0 million of matching contributions related to employee contributions made during 2020. The match contribution is included in accrued expenses and other current liabilities as of December 31, 2021 and 2020.  Expense related to the 401(k) Plan from continuing operations totaled $2.8 million, $3.0 million, $2.9 million for the years ended December 31, 2021, 2020, and 2019, respectively.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The components of loss before income taxes were as follows (in thousands):
Year ended December 31,
202120202019
U.S.$(487,404)$(431,452)$(414,586)
Foreign(74,976)(128,918)(140,981)
Total$(562,380)$(560,370)$(555,567)
The provision for (benefit from) income taxes were as follows (in thousands):
Year ended December 31,
202120202019
Current:
Federal$— $— $— 
State— 2 7 
Foreign258 684 612 
Deferred:
Federal— — (966)
State— — (198)
Foreign— — — 
Total income tax expense (benefit)$258 $686 $(545)
A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company’s effective income tax rate as reflected in the financial statements is as follows:
Year ended December 31,
202120202019
Federal income tax expense at statutory rate21.0 %21.0 %21.0 %
State income tax, net of federal benefit3.9 %3.1 %3.7 %
Permanent differences(0.6)%(0.6)%(0.8)%
Stock-based compensation(3.1)%(2.4)%(0.7)%
Research and development credit4.3 %6.0 %5.4 %
Foreign differential(1.9)%(4.6)%(3.7)%
Other— %(0.3)%0.8 %
Change in valuation allowance(23.6)%(22.3)%(25.6)%
Effective income tax rate (expense) benefit— %(0.1)%0.1 %
For the years ended December 31, 2021, 2020 and 2019, the Company recognized an income tax expense (benefit) of $0.3 million or 0.0%, $0.7 million or (0.1)%, and $(0.5) million or 0.1%, respectively.  The Company did not recognize any significant tax expense for the years ended December 31, 2021, 2020, or 2019 as the Company was subject to a full valuation allowance. Tax expense associated with the sale of bRT and the Separation, accounted for as discontinued operations and discussed in Note 3, is $0 for the years ended December 31, 2021, 2020, or 2019 due to the full valuation allowance. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities are composed of the following (in thousands):
Year ended December 31,
2021
2020 (1)
Deferred tax assets:
U.S. net operating loss carryforwards (federal and state)$703,125 $546,098 
Tax credit carryforwards (federal and state)281,687 246,742 
Capitalized license fees and research and development expenses2,237 1,558 
Deferred revenue604 398 
Stock-based compensation25,181 37,164 
Lease liabilities22,916 14,787 
Accruals and other15,598 12,894 
Total deferred tax assets1,051,348 859,641 
Right-of-use assets(23,053)(15,044)
Fixed assets(1,546)(1,212)
Less valuation allowance(1,026,749)(843,385)
Net deferred taxes$— $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets. The valuation allowance increased on a net basis by approximately $183.4 million during the year ended December 31, 2021 due primarily to net operating losses, tax credit carryforwards, and stock-based compensation, offset by the sale of bRT and the Separation. Effective January 1, 2021, the Company adopted ASU 2019-12, which simplifies accounting for income taxes. There was no material impact on the Company's financial position or results of operations upon adoption.
As of December 31, 2021, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of approximately $2.63 billion, $2.03 billion, and $1.62 billion, respectively, which may be available to offset future income tax liabilities. Of the amount as of December 31, 2021, $1.92 billion will carryforward indefinitely while $711.0 million will expire at various dates through 2037. As of December 31, 2021, 2020 and 2019, the Company also had U.S. state net operating loss
carryforwards of approximately $2.39 billion, $1.89 billion, and $1.56 billion, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2041.
As of December 31, 2021, 2020 and 2019, the Company had federal research and development and orphan drug tax credit carryforwards of approximately $268.3 million, $235.3 million, and $203.1 million, respectively, available to reduce future tax liabilities which expire at various dates through 2041. As of December 31, 2021, 2020 and 2019, the Company had state credit carryforwards of approximately $16.9 million, $14.5 million, and $13.6 million, respectively, available to reduce future tax liabilities which expire at various dates through 2036. During the fourth quarter of 2018, the Company completed an analysis of prior year estimates of U.S. research and development and orphan drug tax credits for the years 2013 through 2017. The analysis resulted in an immaterial adjustment to the Company's income tax benefit, which was offset by an adjustment to the valuation allowance. An analysis of the U.S. research and development and orphan drug credits has not yet been completed for 2019, 2020, or 2021.
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was enacted. This law temporarily suspends and adjusts certain law changes enacted in the Tax Cuts and Jobs Act in 2017. In December 2020, the Consolidated Appropriations Act was enacted. This law modified the employee retention credit under the CARES Act and created credit extenders for certain credits. In March 2021, the American Rescue Plan Act ("ARPA") was enacted and contained extenders to the refundable employee retention credit and provided further limitations to executive compensation effective for tax years beginning after 2026. The Company has concluded that the provisions in the CARES Act, Consolidated Appropriations Act, and ARPA have an immaterial impact on the Company’s income tax expense due to its cumulative losses and full valuation allowance position.
Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which it believes has resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code. The Company completed a study through December 2020 confirming no additional ownership changes; any ownership shifts occurring after December 2020 could result in an ownership change under Section 382.
The Company files Federal income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state or foreign tax authorities to the extent utilized in a future period.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
Unrecognized tax benefits
Balance as of December 31, 2019$15,945 
Increases (decreases) for tax positions related to current period3,149 
Increases (decreases) for tax positions related to prior periods(100)
Balance as of December 31, 202018,994 
Increases (decreases) for tax positions related to current period2,949 
Increases (decreases) for tax positions related to prior periods17 
Balance as of December 31, 202121,960 
The unrecognized tax benefits at December 31, 2021, if recognized, would not affect the Company’s effective tax rate due to its full valuation allowance position. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for income taxes. For the years ended December 31, 2021, 2020 and 2019, the Company’s accrued interest and penalties related to uncertain tax positions were not material.
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reduction in workforce
 12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Reduction in workforce Reduction in workforce
In April 2021, the Company announced its decision to withdraw ZYNTEGLO from the German market because reimbursement negotiations in Germany did not result in a price for ZYNTEGLO that reflects the value of the one-time gene therapy with potential life-long benefit for people living with β-thalassemia requiring regular transfusions. A total of approximately 50 employees were impacted by this reduction. During the three months ended June 30, 2021, the Company substantially completed the implementation of this reduction and, in accordance with ASC 420, Exit and Disposal Activities, and ASC 712, Nonretirement Postemployment Benefits, recorded approximately $4.6 million of costs including severance, the portion of the employees' 2021 retention bonuses to be paid in cash, and the pro rata portion of the employees' 2021 performance bonus.
In July 2021, the Company made the decision to focus its efforts on the U.S. market for beti-cel, eli-cel, and lovo-cel and is executing an orderly wind down of its European operations. A total of approximately 90 employees were impacted by the reduction in workforce associated with this decision. The Company recorded $21.2 million of expense, in accordance with the related accounting standards mentioned above, for the affected employees. This amount includes expense for severance, the pro rata portion of the employees' 2021 performance bonus, the portion of the European employees' 2021 retention bonuses to be paid in cash, and the portion of retention bonuses to be paid in unrestricted stock awards, which were granted on September 30, 2021. As described in Note 14, Stock-based compensation, the Company recorded $2.5 million of costs associated with the grant of unrestricted stock awards to affected employees as a one-time payment. All costs associated with the April 2021 and July 2021 reductions are reflected within restructuring expense in the Company's consolidated statements of operations and comprehensive loss.
The Company expects that substantially all accrued restructuring charges will be paid in cash by March 31, 2022.
The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):
ChargesAmount paidAmounts accrued
at December 31,
2021
April 2021 reduction$4,625 $(4,625)$— 
July 2021 reduction21,176 (16,503)4,673 
Total$25,801 $(21,128)$4,673 
During the year ended December 31, 2021, the Company recorded approximately $25.8 million in restructuring expenses. During the year ended December 31, 2021, the Company recorded $2.5 million in research and development expenses and selling, general and administrative expenses related to the grant of unrestricted stock awards to affected employees.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net loss per share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net loss per share Net loss per share
The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):
Year ended December 31,
202120202019
Outstanding stock options (1)
5,534 6,262 5,483 
Restricted stock units (1)
3,427 1,495 1,127 
ESPP shares and other— 326 19 
8,961 8,083 6,629 
(1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Selected quarterly financial data (unaudited)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]  
Selected quarterly financial data (Unaudited) Selected quarterly financial data (unaudited)
The following table contains quarterly financial information for 2021 and 2020. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
2021
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$894 $143 $1,019 $1,606 $3,662 
Total operating expenses146,988 154,844 155,468 137,273 594,573 
Loss from operations(146,094)(154,701)(154,449)(135,667)(590,911)
Net loss from continuing operations(121,504)(155,973)(152,834)(132,327)(562,638)
Net loss from discontinued operations(84,304)(85,729)(63,982)(22,725)(256,740)
Net loss(205,808)(241,702)(216,816)(155,052)(819,378)
Net loss per share from continuing operations
—basic and diluted		(1.81)(2.31)(2.23)(1.83)(8.16)
Net loss per share from discontinued operations—basic and diluted(1.26)(1.27)(0.93)(0.31)(3.73)
Net loss per share—basic and diluted$(3.07)$(3.58)$(3.16)$(2.14)$(11.89)
2020
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$— $— $— $— $— 
Total operating expenses144,479 143,650 131,743 139,387 559,259 
Loss from operations(144,479)(143,650)(131,743)(139,387)(559,259)
Net loss from continuing operations(146,392)(140,665)(137,678)(136,321)(561,056)
Net income (loss) from discontinued operations(56,219)119,200 (57,067)(63,553)(57,639)
Net loss(202,611)(21,465)(194,745)(199,874)(618,695)
Net loss per share from continuing operations
—basic and diluted		(2.63)(2.33)(2.08)(2.05)(9.02)
Net income (loss) per share from discontinued operations—basic and diluted(1.01)1.97 (0.86)(0.96)(0.93)
Net loss per share—basic and diluted$(3.64)$(0.36)$(2.94)$(3.01)$(9.95)
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of significant accounting policies and basis of presentation (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of presentation
Basis of presentation
The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”).  Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the ASC and the Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).
Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation. The Company has presented its oncology business together with its manufacturing facility in Durham, North Carolina as discontinued operations in its consolidated financial statements for all periods presented (see Note 3, Discontinued operations). The historical financial statements and footnotes have been recast accordingly.
Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding.
Principles of consolidation
Principles of consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. 2seventy bio, Inc. ("2seventy bio") was a wholly-owned subsidiary until it became an independent publicly-traded company on November 4, 2021. All intercompany balances and transactions have been eliminated in consolidation.
Discontinued operations
Discontinued operations
The Company determined that the separation of its oncology business in November 2021 and the sale of its manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, Discontinued Operations (“ASC 205-20”). Accordingly, the accompanying consolidated financial statements for all periods presented have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheets and the results of all discontinued operations reported as a separate component of loss in the consolidated statements of operations and comprehensive loss (see Note 3, Discontinued operations).
Use of estimates
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.
Foreign currency transaction
Foreign currency translation
The financial statements of the Company’s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in stockholders’ equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.
Segment information
Segment information
The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.  Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.  All material long-lived assets of the Company reside in the United States.
Cash and cash equivalents
Cash and cash equivalents
The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value.
Marketable securities
Marketable securities
The Company’s marketable securities are maintained by investment managers and consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Equity securities with readily determinable fair values are also carried at fair value with unrealized gains and losses included in other income (expense), net. Realized gains and losses on both debt and equity securities are determined using the specific identification method and are included in other income (expense), net.
The Company classifies equity securities with readily determinable fair values, which would be available for use in its current operations, as current assets even though the Company may not dispose of such marketable securities within the next 12 months. Equity securities are included in the balance of marketable securities on the Company's consolidated balance sheets. The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Marketable securities with a remaining maturity date greater than one year are classified as non-current assets.
Effective January 1, 2020, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements (“ASU 2016-13” or “ASC 326”), using the effective date method. As the Company had never recorded any other-than-temporary-impairment adjustments to its available-for-sale debt securities prior to the effective date, no transition provisions are applicable to the Company.
The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.
Accrued interest receivable related to the Company's available-for-sale debt securities is presented within receivables and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.
Concentrations of credit risk and off-balance sheet risk
Concentrations of credit risk and off-balance sheet risk
Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.
Fair value of financial instruments
Fair value of financial instruments
The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:
Level 1—Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2—Fair values are determined utilizing quoted prices for identical or similar assets or liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates.
Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Items measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable securities, and Note 5, Fair value measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.
Business combinations
Business combinations
Business combinations are accounted for using the acquisition method of accounting. Using this method, the tangible and intangible assets acquired and the liabilities assumed are recorded as of the acquisition date at their respective fair values. The Company evaluates a business as an integrated set of activities and assets that is capable of being managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits and consists of inputs and processes that provide or have the ability to provide outputs. In an acquisition of a business, the excess of the fair value of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill. In an acquisition of net assets that does not constitute a business, no goodwill is recognized.
Goodwill
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. The Company performs a one-step quantitative test and records the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has not recognized any impairment charges related to goodwill to date.
Upon disposal of a portion of a reporting unit that constitutes a business, goodwill is assigned based on the relative fair values of the portion of the reporting unit being disposed and the portion of the reporting unit remaining. This approach requires a determination of the fair value of both the business to be disposed of and the business (or businesses) within the reporting unit that will be retained. As a result of the separation of the Company's oncology business and the sale of the Company's manufacturing facility in Durham, North Carolina, the Company assigned goodwill based on the relative fair value of the business to be disposed of, and such goodwill has been reclassified to discontinued operations.
Intangible assets Intangible assets, netIntangible assets, net consist of in-licensed rights with finite lives, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. During the third quarter of 2021, the Company recognized impairment charges related to intangible assets. In accordance with FASB ASC Topic 350, General Intangibles Other than Goodwill (“ASC 350”), the Company reviewed its intangible assets for recoverability. During the third quarter of 2021, the Company determined that the intangible assets were impaired, resulting in the impairment of the remaining carrying value of the intangible assets.
Property, plant and equipment
Property, plant and equipment
Property, plant and equipment is stated at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:
AssetEstimated useful life
Building40 years
Computer equipment and software3 years
Furniture and fixtures
2-5 years
Laboratory equipment
2-5 years
Leasehold improvementsShorter of the useful life or remaining lease term
Impairment of long-lived assets
Impairment of long-lived assets
The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.
Leases
Leases
Effective January 1, 2019, the Company adopted ASC 842 using the required modified retrospective approach and utilizing the effective date as its date of initial application.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.
Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.
The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.
Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.
In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.
Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.
ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Common stock warrants Common stock warrantsThe Company's common stock warrants are evaluated pursuant to ASC 480, Distinguishing Liabilities from Equity ("ASC 480"), and ASC 815, Derivatives and Hedging ("ASC 815"). Management classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock.
Inventory
Inventory
Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company’s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used for the production of clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product.
Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product, which has been produced for the treatment of specific patients, that are owned by the Company.
Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on hand and firm purchase commitments as well as remaining shelf life of on hand inventories. The Company writes-down its inventory that is obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue on the Company’s consolidated statements of operations and comprehensive loss.
Revenue recognition
Revenue recognition
Under ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines
are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.
Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. 
The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).  
The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.
If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.
In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.  The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.  The Company assessed each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.
The Company recognizes revenue within the following financial statement captions:
Product revenue
The Company recognizes product revenue in accordance with Topic 606. Product revenue represents sales of ZYNTEGLO. In 2021, the Company distributed ZYNTEGLO directly to hospitals in Germany. The Company determined that contracted sales with hospitals formed a single performance obligation and it recognizes revenue from product sales at the point in time it satisfies the performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product.
Other revenue
In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, Revenue Recognition Not-for-Profit Entities, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In addition, the Company entered into strategic collaborations and recognized an immaterial amount of revenue associated with those collaboration agreements.
Research and development expenses
Research and development expenses
Research and development costs are charged to expense as costs are incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, clinical study and related clinical manufacturing costs, license and milestone fees, contract services, manufacturing costs for pre-launch inventory that did not qualify for capitalization, and other related costs. Up-front fees and milestones paid to third parties in connection with technologies which have not reached technological feasibility and do not have an alternative future use are expensed as research and development expense as incurred. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, or other clinical trial vendors that perform the activities. Where amounts owed to a collaboration partner exceed the Company’s collaborative arrangement revenues in each quarterly period, such amounts are classified as research and development expense.
Cost of product revenue Cost of product revenue Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue which are associated with the sale of ZYNTEGLO in Germany. Reserves for excess inventories are also included in cost of product revenue.
Stock-based compensation
Stock-based compensation
The Company’s share-based compensation programs grant awards that have included stock options, restricted stock units, restricted stock awards, unrestricted stock awards and shares issued under its employee stock purchase plan.  Grants are awarded to employees and non-employees, including the Company's board of directors.  
The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values.
The Company’s stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable.
The Company estimates the fair value of its option awards using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of its own stock price. For both employee and non-employee awards, the measurement date is the date of grant. The Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.
Conversion and modification of equity awards outstanding at date of separation of 2seventy bio
In connection with the separation of 2seventy bio on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the separation. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. The Company will recognize future expense for awards denominated in bluebird stock and 2seventy bio stock granted to the Company's employees as a result of the separation of 2seventy bio. Expense related to awards denominated in bluebird stock granted to 2seventy bio employees will be incurred by 2seventy bio.
Stock-based compensation expense related to modified awards is measured based on the fair value for the awards as of the modification date. Any incremental stock-based compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite remaining service period, as appropriate.
Interest income, net Interest income, netInterest income, net consists primarily of interest income earned on investments, net of amortization of premium and accretion of discount.
Other income (expense), net
Other income (expense), net
Other income (expense), net consists primarily of gains and losses on equity securities held by the Company, gains and losses on disposal of assets, and gains and losses on foreign currency.
Net loss per share
Net loss per share
Basic net loss per share is calculated by dividing net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration. Diluted net loss per share is calculated by dividing the net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration as well as any dilutive effect from outstanding stock options, unvested restricted stock, restricted stock units, and employee stock purchase plan stock using the treasury stock method. Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.
The Company follows the two-class method when computing net loss per share in periods when issued shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating securities.
Income taxes
Income taxes
Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if
based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Comprehensive loss
Comprehensive loss
Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on debt securities, foreign currency translation adjustments and other items.
Restructuring expenses
Restructuring expenses
The Company records costs and liabilities associated with exit and disposal activities in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations ("ASC 420"). Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available. Refer to Note 18, Reduction in workforce, for more information.
Recent accounting pronouncements
Recent accounting pronouncements
Recently adopted
ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity's own equity. The Company early adopted the new standard, effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs (“ASU 2020-08”) to provide further clarification and update the previously issued guidance in ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) (“ASU 2017-08”). ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.
ASU No. 2020-10, Codification Improvements
In October 2020, the FASB issued ASU 2020-10, Codification Improvements ("ASU 2020-10"). The amendments in this ASU represent changes to clarify the ASC, correct unintended application of the guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This new standard was effective beginning January 1, 2021. The adoption of ASU 2020-10 did not have a material impact on the Company's financial position or results of operations upon adoption.
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of significant accounting policies and basis of presentation (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Estimated Useful Lives of Assets Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:
AssetEstimated useful life
Building40 years
Computer equipment and software3 years
Furniture and fixtures
2-5 years
Laboratory equipment
2-5 years
Leasehold improvementsShorter of the useful life or remaining lease term
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations (Tables)
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Distribution of Assets, Liabilities and Stockholders' Equity The transfer of assets and liabilities to 2seventy bio was effected through a contribution in accordance with the Separation Agreement, as summarized below (in thousands):
As of November 4, 2021
Assets
Current assets:
Cash and cash equivalents$174,284 
Marketable securities160,447 
Prepaid expenses8,732 
Receivables and other current assets21,637 
Total current assets365,100 
Marketable securities106,826 
Property, plant and equipment, net33,972 
Intangible assets, net10,664 
Goodwill6,410 
Operating lease right-of-use assets255,556 
Restricted cash and other non-current assets5,650 
Total assets$784,178 
Liabilities
Current liabilities:
Accounts payable$2,982 
Accrued expenses and other current liabilities85,659 
Operating lease liability, current portion6,938 
Collaboration research advancement, current portion8,957 
Total current liabilities104,536 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion16,264 
Operating lease liability, net of current portion257,575 
Other non-current liabilities1,896 
Total liabilities$406,033 
Net assets transferred to 2seventy bio$378,145 
The following table summarizes the assets and liabilities of the discontinued operations as of December 31, 2020 (in thousands):
As of December 31, 2020
Assets
Current assets:
Cash and cash equivalents$57,076 
Marketable securities413,947 
Prepaid expenses11,754 
Receivables and other current assets12,244 
Total current assets of discontinued operations495,021 
Marketable securities61,446 
Property, plant and equipment, net145,458 
Intangible assets, net5,644 
Goodwill7,482 
Operating lease right-of-use assets116,456 
Restricted cash and other non-current assets7,078 
Total non-current assets of discontinued operations343,564 
Total assets of discontinued operations$838,585 
Liabilities
Current liabilities:
Accounts payable$7,791 
Accrued expenses and other current liabilities48,716 
Operating lease liability, current portion15,313 
Collaboration research advancement, current portion9,236 
Deferred revenue, current portion820 
Total current liabilities of discontinued operations81,876 
Deferred revenue, net of current portion25,762 
Collaboration research advancement, net of current portion21,581 
Operating lease liability, net of current portion112,290 
Other non-current liabilities1,509 
Total non-current liabilities of discontinued operations161,142 
Total liabilities of discontinued operations$243,018 
Summary of Revenue and Expenses for Discontinued Operations The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Revenue:
Service revenue$18,130 $114,064 $30,729 
Collaborative arrangement revenue18,602 115,594 5,740 
Royalty and other revenue5,762 21,076 8,205 
Total revenues42,494 250,734 44,674 
Operating expenses:
Research and development204,287 268,647 255,294 
Selling, general and administrative82,078 46,945 35,518 
Share of collaboration loss10,071 — — 
Cost of royalty and other revenue2,292 5,396 2,978 
Change in fair value of contingent consideration387 (6,468)2,747 
Total operating expenses299,115 314,520 296,537 
Loss from operations(256,621)(63,786)(251,863)
Interest income, net791 5,770 17,380 
Other income (expense), net(910)377 (103)
Loss before income taxes(256,740)(57,639)(234,586)
Net loss$(256,740)$(57,639)$(234,586)
The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Operating activities:
Change in fair value of contingent consideration$387 $(6,468)$2,747 
Depreciation and amortization14,195 13,730 12,995 
Stock-based compensation expense29,175 34,036 29,545 
Loss on fixed assets disposal569 146 108 
Loss on sale of Durham, North Carolina manufacturing facility 1,986 — — 
Investing activities:
Purchase of property, plant and equipment$(11,256)$(23,159)$(57,196)
Proceeds from sale of Durham, North Carolina manufacturing facility110,300 — — 
Purchase of intangible assets(8,500)— — 
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses$778 $2,039 $3,064 
Right-of-use assets obtained in exchange for operating lease liabilities151,520 4,989 9,745 
Summary of Significant Non-Cash Items and Capital Expenditures for Discontinued Operations The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Revenue:
Service revenue$18,130 $114,064 $30,729 
Collaborative arrangement revenue18,602 115,594 5,740 
Royalty and other revenue5,762 21,076 8,205 
Total revenues42,494 250,734 44,674 
Operating expenses:
Research and development204,287 268,647 255,294 
Selling, general and administrative82,078 46,945 35,518 
Share of collaboration loss10,071 — — 
Cost of royalty and other revenue2,292 5,396 2,978 
Change in fair value of contingent consideration387 (6,468)2,747 
Total operating expenses299,115 314,520 296,537 
Loss from operations(256,621)(63,786)(251,863)
Interest income, net791 5,770 17,380 
Other income (expense), net(910)377 (103)
Loss before income taxes(256,740)(57,639)(234,586)
Net loss$(256,740)$(57,639)$(234,586)
The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):
Year ended December 31,
202120202019
Operating activities:
Change in fair value of contingent consideration$387 $(6,468)$2,747 
Depreciation and amortization14,195 13,730 12,995 
Stock-based compensation expense29,175 34,036 29,545 
Loss on fixed assets disposal569 146 108 
Loss on sale of Durham, North Carolina manufacturing facility 1,986 — — 
Investing activities:
Purchase of property, plant and equipment$(11,256)$(23,159)$(57,196)
Proceeds from sale of Durham, North Carolina manufacturing facility110,300 — — 
Purchase of intangible assets(8,500)— — 
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses$778 $2,039 $3,064 
Right-of-use assets obtained in exchange for operating lease liabilities151,520 4,989 9,745 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable securities (Tables)
 12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Summary of Marketable Securities Held The following table summarizes the marketable securities held at December 31, 2021 and 2020 (in thousands):
Amortized cost / costUnrealized gainsUnrealized lossesFair value
December 31, 2021
U.S. government agency securities and treasuries$128,902 $— $(509)$128,393 
Corporate bonds49,366 — (59)49,307 
Commercial paper54,065 — — 54,065 
Equity securities4,305 — (614)3,691 
Total$236,638 $— $(1,182)$235,456 
December 31, 2020 (1)
U.S. government agency securities and treasuries$337,521 $151 $(37)$337,635 
Corporate bonds98,585 216 (20)98,781 
Commercial paper38,975 — — 38,975 
Equity securities20,017 — (14,364)5,653 
Total$495,098 $367 $(14,421)$481,044 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
TotalQuoted
prices in
active
markets
(Level 1)		Significant
other
observable
inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)
December 31, 2021
Assets:
Cash and cash equivalents$161,160 $161,146 $14 $— 
Marketable securities:
U.S. government agency securities and treasuries128,393 — 128,393 — 
Corporate bonds49,308 — 49,308 — 
Commercial paper54,065 — 54,065 — 
Equity securities3,691 3,691 — — 
Total assets$396,617 $164,837 $231,780 $— 
December 31, 2020 (1)
Assets:
Cash and cash equivalents$260,629 $260,629 $— $— 
Marketable securities:
U.S. government agency securities and treasuries337,635 — 337,635 — 
Corporate bonds98,781 — 98,781 — 
Commercial paper38,975 — 38,975 — 
Equity securities5,653 5,653 — — 
Total assets$741,673 $266,282 $475,391 $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value
The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months, and for which an allowance for credit losses has not been recorded at December 31, 2021 and 2020 (in thousands):
Less than 12 months12 months or greaterTotal
DescriptionFair valueUnrealized lossesFair valueUnrealized lossesFair valueUnrealized losses
December 31, 2021
U.S. government agency securities
   and treasuries		$108,695 $(505)$2,496 $(4)$111,191 $(509)
Corporate bonds45,042 (56)3,896 (2)48,938 (58)
Total$153,737 $(561)$6,392 $(6)$160,129 $(567)
December 31, 2020 (1)
U.S. government agency securities
   and treasuries		$105,692 $(37)$— $— $105,692 $(37)
Corporate bonds38,299 (20)603 — 38,902 (20)
Total$143,991 $(57)$603 $— $144,594 $(57)
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventory (Tables)
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventory Inventory consists of the following (in thousands):
As of December 31, 2021As of December 31, 2020
Raw materials$— $8,967 
Finished goods— 1,731 
Inventory$— $10,698 
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property, plant and equipment, net (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Summary of Property, Plant and Equipment Net
Property, plant and equipment, net, consists of the following (in thousands):
As of December 31,
2021
2020 (1)
Laboratory equipment$29,061 $27,146 
Computer equipment and software421 447 
Office equipment117 1,077 
Leasehold improvements12 5,949 
Construction-in-progress501 895 
Total property, plant and equipment30,112 35,514 
Less accumulated depreciation and amortization(20,406)(18,141)
Property, plant and equipment, net$9,706 $17,373 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restricted cash (Tables)
 12 Months Ended
Dec. 31, 2021
Other Assets, Noncurrent [Abstract]  
Schedule of collateralized bank account of financial institution Total restricted cash as of December 31, 2021 and 2020 consisted of the following (in thousands):
As of December 31,
20212020
50 Binney Street lease$40,072 $40,072 
Assembly Row lease2,753 — 
60 Binney Street lease— 13,763 
Other2,675 2,188 
Total restricted cash$45,500 $56,023 
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued expenses and other current liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Summary of accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
As of December 31,
2021
2020 (1)
Employee compensation$41,095 $41,192 
Accrued goods and services24,273 14,855 
Accrued clinical and contract research organization costs17,769 20,912 
Accrued manufacturing costs15,722 15,763 
Accrued professional fees1,665 1,541 
Deferred revenue, current portion2,282 1,500 
Other1,152 2,427 
Total accrued expenses and other current liabilities$103,958 $98,190 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Lease, Cost
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the years ended December 31, 2021 and 2020 (in thousands):
For the year ended December 31,
2021
2020 (2)
2019 (2)
Lease cost (1)
Operating lease cost$25,067 $18,660 $20,005 
Total lease cost$25,067 $18,660 $20,005 
Other information
Operating cash flows used for operating leases$22,805 $17,780 $17,205 
Weighted average remaining lease term4.7 years6.3 years7.3 years
Weighted average discount rate5.02 %5.98 %6.66 %
(1) Short-term lease costs and variable lease costs incurred by the Company for the twelve months ended December 31, 2021, 2020 and 2019 were immaterial.
(2) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Summary of Future Minimum Commitments
As of December 31, 2021, future minimum commitments under ASC 842 under the Company’s operating leases were as follows (in thousands):
As of
Maturity of lease liabilitiesDecember 31, 2021
2022$27,037 
202321,460 
202418,009 
202514,639 
20268,598 
2027 and thereafter12,356 
Total lease payments102,099 
Less: imputed interest(12,515)
Total operating lease liabilities$89,584 
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Non-cancelable Contractual Obligations The following table presents non-cancelable contractual obligations arising from these arrangements:
Years ended December 31,Purchase
commitment
2022$43,903 
20239,918 
2024 and thereafter— 
Total purchase commitments$53,821 
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Future Issuance of Common Stock Shares
The Company has reserved for future issuance the following number of shares of common stock (in thousands):
As of December 31,
20212020
Options to purchase common stock (1)
5,534 6,262 
Restricted stock units (1)
3,427 1,495 
2013 Stock Option and Incentive Plan2,250 2,545 
Pre-funded warrants2,273 — 
2013 Employee Stock Purchase Plan1,347 67 
14,831 10,369 
(1) Stock options and restricted stock units that are reserved for future issuance include awards outstanding to employees of 2seventy bio.
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net of accumulated amortization, are summarized as follows (in thousands):
As of December 31, 2021
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (1,219)(4,005)— 
Total$5,224 $(1,219)$(4,005)$— 
As of December 31, 2020(1)
CostAccumulated amortizationImpairmentNet
In-licensed rights$5,224 (827)— 4,397 
Total$5,224 $(827)$— $4,397 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of Stock-Based Compensation Expense by Award Type Stock-based compensation expense recognized by award type is as follows (in thousands):
Year ended December 31,
202120202019
Stock options$54,660 $75,837 $79,912 
Restricted stock units30,767 38,123 50,158 
Employee stock purchase plan and other13,313 8,636 1,013 
$98,740 $122,596 $131,083 
Schedule of Stock-Based Compensation Expense by Classification Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows (in thousands):
Year ended December 31,
202120202019
Research and development$42,989 $49,766 $59,378 
Selling, general and administrative55,751 72,830 71,705 
$98,740 $122,596 $131,083 
Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted The fair value of each option issued to employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
Year ended December 31,
202120202019
Expected volatility66.7 %69.5 %70.7 %
Expected term (in years)6.06.06.0
Risk-free interest rate0.8 %1.4 %2.3 %
Expected dividend yield0.0 %0.0 %0.0 %
Summary of Stock Option Activity Under Plan
The following table summarizes the stock option activity under the Company’s equity awards plans:
Shares
(in thousands)		Weighted-
average
exercise price
per share		Weighted-
average
contractual
life
(in years)		Aggregate
intrinsic
value (a)
(in thousands)
Outstanding at December 31, 20206,262 $105.02 
Granted1,238 $27.19 
Exercised(218)$6.82 
Canceled or forfeited(2,357)$81.20 
Conversion and modification of awards (1,339)$42.90 
Outstanding at December 31, 20213,586 $39.23 6.8$631 
Exercisable at December 31, 20211,835 $57.09 5.5$380 
Vested and expected to vest at December 31, 20213,586 $39.23 6.8$631 
(a)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021.
(b)Pursuant to the terms of Employee Matters Agreement, the company granted 4,375 option conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
Summary of Restricted Common Stock Awards The following table summarizes the restricted stock unit activity under the Company’s equity award plans:
Shares
(in thousands)		Weighted-average
grant date
fair value
Unvested balance at December 31, 20201,495 $102.34 
Granted3,359 26.43 
Vested(526)112.21 
Forfeited(987)53.58 
Conversion and modification of awards(148)16.84 
Unvested balance at December 31, 20213,193 $16.21 
(a)Pursuant to the terms of Employee Matters Agreement, the company granted 3,327 restricted stock unit conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table.
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule Components of Loss Before Income Taxes The components of loss before income taxes were as follows (in thousands):
Year ended December 31,
202120202019
U.S.$(487,404)$(431,452)$(414,586)
Foreign(74,976)(128,918)(140,981)
Total$(562,380)$(560,370)$(555,567)
Summary of Provision for (Benefit from) Income Taxes The provision for (benefit from) income taxes were as follows (in thousands):
Year ended December 31,
202120202019
Current:
Federal$— $— $— 
State— 2 7 
Foreign258 684 612 
Deferred:
Federal— — (966)
State— — (198)
Foreign— — — 
Total income tax expense (benefit)$258 $686 $(545)
Reconciliation of Income Tax Provision (Benefit) Computed at the Statutory Federal Income Tax Rate to Effective Income Tax Rate (Provision) Benefit as Reflected in the Financial Statements A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company’s effective income tax rate as reflected in the financial statements is as follows:
Year ended December 31,
202120202019
Federal income tax expense at statutory rate21.0 %21.0 %21.0 %
State income tax, net of federal benefit3.9 %3.1 %3.7 %
Permanent differences(0.6)%(0.6)%(0.8)%
Stock-based compensation(3.1)%(2.4)%(0.7)%
Research and development credit4.3 %6.0 %5.4 %
Foreign differential(1.9)%(4.6)%(3.7)%
Other— %(0.3)%0.8 %
Change in valuation allowance(23.6)%(22.3)%(25.6)%
Effective income tax rate (expense) benefit— %(0.1)%0.1 %
Components of Deferred Tax Assets and Liabilities The significant components of the Company’s deferred tax assets and liabilities are composed of the following (in thousands):
Year ended December 31,
2021
2020 (1)
Deferred tax assets:
U.S. net operating loss carryforwards (federal and state)$703,125 $546,098 
Tax credit carryforwards (federal and state)281,687 246,742 
Capitalized license fees and research and development expenses2,237 1,558 
Deferred revenue604 398 
Stock-based compensation25,181 37,164 
Lease liabilities22,916 14,787 
Accruals and other15,598 12,894 
Total deferred tax assets1,051,348 859,641 
Right-of-use assets(23,053)(15,044)
Fixed assets(1,546)(1,212)
Less valuation allowance(1,026,749)(843,385)
Net deferred taxes$— $— 
(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Reconciliation of Unrecognized Tax Benefits A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
Unrecognized tax benefits
Balance as of December 31, 2019$15,945 
Increases (decreases) for tax positions related to current period3,149 
Increases (decreases) for tax positions related to prior periods(100)
Balance as of December 31, 202018,994 
Increases (decreases) for tax positions related to current period2,949 
Increases (decreases) for tax positions related to prior periods17 
Balance as of December 31, 202121,960 
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reduction in workforce (Tables)
 12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):
ChargesAmount paidAmounts accrued
at December 31,
2021
April 2021 reduction$4,625 $(4,625)$— 
July 2021 reduction21,176 (16,503)4,673 
Total$25,801 $(21,128)$4,673 
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net loss per share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share
The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):
Year ended December 31,
202120202019
Outstanding stock options (1)
5,534 6,262 5,483 
Restricted stock units (1)
3,427 1,495 1,127 
ESPP shares and other— 326 19 
8,961 8,083 6,629 
(1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Selected quarterly financial data (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information
The following table contains quarterly financial information for 2021 and 2020. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
2021
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$894 $143 $1,019 $1,606 $3,662 
Total operating expenses146,988 154,844 155,468 137,273 594,573 
Loss from operations(146,094)(154,701)(154,449)(135,667)(590,911)
Net loss from continuing operations(121,504)(155,973)(152,834)(132,327)(562,638)
Net loss from discontinued operations(84,304)(85,729)(63,982)(22,725)(256,740)
Net loss(205,808)(241,702)(216,816)(155,052)(819,378)
Net loss per share from continuing operations
—basic and diluted		(1.81)(2.31)(2.23)(1.83)(8.16)
Net loss per share from discontinued operations—basic and diluted(1.26)(1.27)(0.93)(0.31)(3.73)
Net loss per share—basic and diluted$(3.07)$(3.58)$(3.16)$(2.14)$(11.89)
2020
First
quarter		Second
quarter		Third
quarter		Fourth
quarter		Total
(in thousands, except per share data)
Total revenues$— $— $— $— $— 
Total operating expenses144,479 143,650 131,743 139,387 559,259 
Loss from operations(144,479)(143,650)(131,743)(139,387)(559,259)
Net loss from continuing operations(146,392)(140,665)(137,678)(136,321)(561,056)
Net income (loss) from discontinued operations(56,219)119,200 (57,067)(63,553)(57,639)
Net loss(202,611)(21,465)(194,745)(199,874)(618,695)
Net loss per share from continuing operations
—basic and diluted		(2.63)(2.33)(2.08)(2.05)(9.02)
Net income (loss) per share from discontinued operations—basic and diluted(1.01)1.97 (0.86)(0.96)(0.93)
Net loss per share—basic and diluted$(3.64)$(0.36)$(2.94)$(3.01)$(9.95)
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of the business - Additional Information (Detail)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Nov. 04, 2021
company
Organization, Consolidation and Presentation of Financial Statements [Abstract]                        
Number of companies | company                       2
Cash, cash equivalents and marketable securities $ 396,600               $ 396,600      
Accumulated deficit 3,719,925       $ 2,900,547       3,719,925 $ 2,900,547    
Net loss from continuing operations $ 132,327 $ 152,834 $ 155,973 $ 121,504 $ 136,321 $ 137,678 $ 140,665 $ 146,392 562,638 561,056 $ 555,022  
Net cash used in operating activities                 $ 635,639 $ 470,351 $ 564,384  
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail)
 12 Months Ended
Dec. 31, 2021
Building  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 40 years
Computer equipment and software  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 3 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 2 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 5 years
Laboratory equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 2 years
Laboratory equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 5 years
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of significant accounting policies and basis of presentation - Narrative (Detail)
 12 Months Ended
Dec. 31, 2021
USD ($)
target
Accounting Policies [Abstract]  
Number of operating segments | target 1
Goodwill, impaired, accumulated impairment loss | $ $ 0
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
Nov. 03, 2021
agreement
Oct. 19, 2021
Dec. 31, 2020
$ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Conversion ratio     0.3333  
Common stock, par value (in dollars per share) | $ / shares $ 0.01     $ 0.01
Number of transition services agreements | agreement   2    
Initial term of transition services agreement   2 years    
Selling, general and administrative expense related to transition services agreement $ 0.7      
Lentiviral Vector Manufacturing Facility        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net assets transferred to 2seventy bio 111.2      
Loss on fixed assets disposal $ 2.0      
2seventy bio        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Common stock, par value (in dollars per share) | $ / shares $ 0.0001      
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations - Revenue and Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Net loss from discontinued operations $ (22,725) $ (63,982) $ (85,729) $ (84,304) $ (63,553) $ (57,067) $ 119,200 $ (56,219) $ (256,740) $ (57,639) $ (234,586)
2seventy bio | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff                      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Total revenues                 42,494 250,734 44,674
Research and development                 204,287 268,647 255,294
Selling, general and administrative                 82,078 46,945 35,518
Share of collaboration loss                 10,071 0 0
Change in fair value of contingent consideration                 387 (6,468) 2,747
Total operating expenses                 299,115 314,520 296,537
Loss from operations                 (256,621) (63,786) (251,863)
Interest income, net                 791 5,770 17,380
Other income (expense), net                 910   103
Other income (expense), net                   377  
Loss before income taxes                 (256,740) (57,639) (234,586)
Net loss from discontinued operations                 (256,740) (57,639) (234,586)
2seventy bio | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Service revenue                      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Total revenues                 18,130 114,064 30,729
2seventy bio | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Collaborative arrangement revenue                      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Total revenues                 18,602 115,594 5,740
2seventy bio | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Royalty and other revenue                      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Total revenues                 5,762 21,076 8,205
Cost of royalty and other revenue                 $ 2,292 $ 5,396 $ 2,978
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Nov. 04, 2021
Dec. 31, 2020
Current assets:      
Total current assets of discontinued operations $ 0   $ 495,021
Non-current assets of discontinued operations 0   343,564
Current liabilities:      
Total current liabilities 0   81,876
Non-current liabilities of discontinued operations $ 0   161,142
2seventy bio | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff      
Current assets:      
Cash and cash equivalents   $ 174,284 57,076
Marketable securities   160,447 413,947
Prepaid expenses   8,732 11,754
Receivables and other current assets   21,637 12,244
Total current assets of discontinued operations   365,100 495,021
Marketable securities   106,826 61,446
Property, plant and equipment, net   33,972 145,458
Intangible assets, net   10,664 5,644
Goodwill   6,410 7,482
Operating lease right-of-use assets   255,556 116,456
Restricted cash and other non-current assets   5,650 7,078
Non-current assets of discontinued operations     343,564
Total assets   784,178 838,585
Current liabilities:      
Accounts payable   2,982 7,791
Accrued expenses and other current liabilities   85,659 48,716
Operating lease liability, current portion   6,938 15,313
Collaboration research advancement, current portion   8,957 9,236
Deferred revenue, current portion     820
Total current liabilities   104,536 81,876
Deferred revenue, net of current portion   25,762 25,762
Collaboration research advancement, net of current portion   16,264 21,581
Operating lease liability, net of current portion   257,575 112,290
Other non-current liabilities   1,896 1,509
Non-current liabilities of discontinued operations     161,142
Total liabilities   406,033 $ 243,018
Net assets transferred to 2seventy bio   $ 378,145  
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities:      
Change in fair value of contingent consideration $ 387 $ (6,468) $ 2,747
Depreciation and amortization 4,900 5,100 4,100
Stock-based compensation expense 127,915 156,631 160,629
Investing activities:      
Purchase of property, plant and equipment (14,503) (28,986) (71,028)
Proceeds from sale of Durham, North Carolina manufacturing facility 110,300 0 0
Purchase of intangible assets (8,500) 0 (5,224)
Supplemental cash flow disclosures:      
Purchases of property, plant and equipment included in accounts    payable and accrued expenses 411 2,854 5,286
Right-of-use assets obtained in exchange for operating lease liabilities 202,221 19,414 23,939
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | 2seventy bio      
Operating activities:      
Change in fair value of contingent consideration 387 (6,468) 2,747
Depreciation and amortization 14,195 13,730 12,995
Stock-based compensation expense 29,175 34,036 29,545
Loss on fixed assets disposal 569 146 108
Loss on sale of Durham, North Carolina manufacturing facility 1,986 0 0
Investing activities:      
Purchase of property, plant and equipment (11,256) (23,159) (57,196)
Proceeds from sale of Durham, North Carolina manufacturing facility 110,300 0 0
Purchase of intangible assets (8,500) 0 0
Supplemental cash flow disclosures:      
Purchases of property, plant and equipment included in accounts    payable and accrued expenses 778 2,039 3,064
Right-of-use assets obtained in exchange for operating lease liabilities $ 151,520 $ 4,989 $ 9,745
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable securities - Summary of Marketable Securities Held (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Equity securities, amortized cost / cost $ 4,305 $ 20,017
Marketable securities, amortized cost / cost 236,638 495,098
Equity securities, unrealized gains 0 0
Marketable securities, unrealized gains 0 367
Equity securities, unrealized losses (614) (14,364)
Marketable securities, unrealized losses (1,182) (14,421)
Equity securities 3,691 5,653
Marketable securities, fair value 235,456 481,044
U.S. government agency securities and treasuries    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost / cost 128,902 337,521
Debt securities, unrealized gains 0 151
Debt securities, unrealized losses (509) (37)
Debt securities, fair value 128,393 337,635
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost / cost 49,366 98,585
Debt securities, unrealized gains 0 216
Debt securities, unrealized losses (59) (20)
Debt securities, fair value 49,307 98,781
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost / cost 54,065 38,975
Debt securities, unrealized gains 0 0
Debt securities, unrealized losses 0 0
Debt securities, fair value $ 54,065 $ 38,975
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable securities - Narrative (Detail) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]    
Debt securities, available-for-sale, noncurrent $ 0 $ 0
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Assets:    
Equity securities $ 3,691 $ 5,653
Corporate bonds    
Assets:    
Marketable securities 49,307 98,781
Commercial paper    
Assets:    
Marketable securities 54,065 38,975
Fair value, measurements, recurring    
Assets:    
Cash and cash equivalents 161,160 260,629
Equity securities 3,691 5,653
Total assets 396,617 741,673
Fair value, measurements, recurring | U.S. government agency securities and treasuries    
Assets:    
Marketable securities 128,393 337,635
Fair value, measurements, recurring | Corporate bonds    
Assets:    
Marketable securities 49,308 98,781
Fair value, measurements, recurring | Commercial paper    
Assets:    
Marketable securities 54,065 38,975
Fair value, measurements, recurring | Quoted prices in active markets (Level 1)    
Assets:    
Cash and cash equivalents 161,146 260,629
Equity securities 3,691 5,653
Total assets 164,837 266,282
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | U.S. government agency securities and treasuries    
Assets:    
Marketable securities 0 0
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | Corporate bonds    
Assets:    
Marketable securities 0 0
Fair value, measurements, recurring | Quoted prices in active markets (Level 1) | Commercial paper    
Assets:    
Marketable securities 0 0
Fair value, measurements, recurring | Significant other observable inputs (Level 2)    
Assets:    
Cash and cash equivalents 14 0
Equity securities 0 0
Total assets 231,780 475,391
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | U.S. government agency securities and treasuries    
Assets:    
Marketable securities 128,393 337,635
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Corporate bonds    
Assets:    
Marketable securities 49,308 98,781
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Commercial paper    
Assets:    
Marketable securities 54,065 38,975
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)    
Assets:    
Cash and cash equivalents 0 0
Equity securities 0 0
Total assets 0 0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | U.S. government agency securities and treasuries    
Assets:    
Marketable securities 0 0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Corporate bonds    
Assets:    
Marketable securities 0 0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Commercial paper    
Assets:    
Marketable securities $ 0 $ 0
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value measurements - Narrative (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Fair Value Disclosures [Abstract]        
Realized gain (loss) recognized on sale   $ 0 $ 0  
Interest receivable   300,000 1,500,000  
Interest receivable, write-off   0 0  
Investment at fair value   3,691,000 5,653,000  
Proceeds from sale of equity securities $ 31,300,000      
Unrealized gain (loss) on equity securities   $ 29,400,000 $ (7,200,000) $ (9,300,000)
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair value measurements - Schedule of Unrealized Loss on Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair value    
Less than 12 months $ 153,737 $ 143,991
12 months or greater 6,392 603
Total 160,129 144,594
Unrealized losses    
Less than 12 months (561) (57)
12 months or greater (6) 0
Total (567) (57)
U.S. government agency securities and treasuries    
Fair value    
Less than 12 months 108,695 105,692
12 months or greater 2,496 0
Total 111,191 105,692
Unrealized losses    
Less than 12 months (505) (37)
12 months or greater (4) 0
Total (509) (37)
Corporate bonds    
Fair value    
Less than 12 months 45,042 38,299
12 months or greater 3,896 603
Total 48,938 38,902
Unrealized losses    
Less than 12 months (56) (20)
12 months or greater (2) 0
Total $ (58) $ (20)
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 0 $ 8,967
Finished goods 0 1,731
Inventory, Total 0 10,698
Reserve for excess inventory $ 29,900 $ 0
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 30,112 $ 35,514
Less accumulated depreciation and amortization (20,406) (18,141)
Property, plant and equipment, net 9,706 17,373
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 29,061 27,146
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 421 447
Office equipment    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 117 1,077
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 12 5,949
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 501 $ 895
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property, plant and equipment, net - Narrative (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Abstract]      
Depreciation and amortization $ 4.9 $ 5.1 $ 4.1
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restricted cash - Narrative (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt and Equity Securities, FV-NI [Line Items]    
Restricted cash balance $ 45,500 $ 56,023
Letter of Credit    
Debt and Equity Securities, FV-NI [Line Items]    
Restricted cash balance $ 43,200 $ 54,500
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt and Equity Securities, FV-NI [Line Items]    
Total restricted cash $ 45,500 $ 56,023
50 Binney Street lease    
Debt and Equity Securities, FV-NI [Line Items]    
Total restricted cash 40,072 40,072
Assembly Row lease    
Debt and Equity Securities, FV-NI [Line Items]    
Total restricted cash 2,753 0
60 Binney Street lease    
Debt and Equity Securities, FV-NI [Line Items]    
Total restricted cash 0 13,763
Other    
Debt and Equity Securities, FV-NI [Line Items]    
Total restricted cash $ 2,675 $ 2,188
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Employee compensation $ 41,095 $ 41,192
Accrued goods and services 24,273 14,855
Accrued clinical and contract research organization costs 17,769 20,912
Accrued manufacturing costs 15,722 15,763
Accrued professional fees 1,665 1,541
Deferred revenue, current portion 2,282 1,500
Other 1,152 2,427
Total accrued expenses and other current liabilities $ 103,958 $ 98,190
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued expenses and other current liabilities - Narrative (Details)
Dec. 31, 2021
USD ($)
Payables and Accruals [Abstract]  
Accrued restructuring charges $ 4,673,000
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Narrative (Details)
€ in Millions
 1 Months Ended 12 Months Ended 22 Months Ended
Apr. 30, 2022
USD ($)
ft²
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Nov. 30, 2021
ft²
$ / ft²
Oct. 31, 2021
USD ($)
ft²
Feb. 28, 2021
USD ($)
Jul. 31, 2020
USD ($)
Mar. 31, 2020
EUR (€)
Apr. 30, 2019
USD ($)
ft²
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Nov. 30, 2016
Jun. 30, 2016
Lessee, Lease, Description [Line Items]                              
Lease arrangements annual rent increase percentage                 3.00%            
Operating lease, expense                   $ 36,200,000 $ 24,200,000 $ 23,300,000      
60 Binney Street lease                              
Lessee, Lease, Description [Line Items]                              
Collateralized letter of credit         $ 13,800,000                    
Market capitalization required for release of liability         $ 900,000,000                    
Lease building space (in sq ft) | ft²         72,988                    
Lessee, operating lease, monthly expense         $ 500,000                    
60 Binney Street lease | Forecast                              
Lessee, Lease, Description [Line Items]                              
Lease building space (in sq ft) | ft² 58,004                            
Lessee, operating lease, monthly expense $ 400,000                            
50 Binney Street sublease                              
Lessee, Lease, Description [Line Items]                              
Collateralized letter of credit   $ 40,100,000             $ 40,100,000            
Lease building space (in sq ft) | ft²                 267,278            
Rate of area for sublease per square feet (in dollars per sq ft)                 99.95            
Lessee, operating lease, annual expense                 $ 26,700,000            
Lease arrangements annual rent increase percentage   3.00%               3.00%          
Lessee, operating sublease, payment commencement, term                 90 days            
Upfront payment for purchase of furniture and equipment   $ 7,500,000             $ 7,500,000 $ 7,500,000          
Payment for purchase of furniture and equipment, upon lease commencement                 $ 7,500,000            
Annual base rent of sub-sublease   28,000,000               28,000,000          
50 Binney Street sublease | Selling, general and administrative                              
Lessee, Lease, Description [Line Items]                              
Loss on unrecoverable upfront payment   $ 7,500,000                          
Assembly Row lease                              
Lessee, Lease, Description [Line Items]                              
Lease building space (in sq ft) | ft²       61,180                      
Annual lease rent per square foot (in dollars per sq ft) | $ / ft²       45                      
Lease rent, annual increase percentage       2.50%                      
Tenant work allowance (in dollars per sq ft) | $ / ft²       160                      
Manufacturing Facility                              
Lessee, Lease, Description [Line Items]                              
Lessee, operating lease, annual expense                   $ 5,100,000          
Lease period           5 years 5 years             5 years 12 years
Milestone paid                         $ 12,000,000    
Lease extension terms                           3 years  
Lessee, operating lease, termination fees, term                   24 months          
Lessee, operating lease, maximum potential annual maintenance and production fees | €               € 16.5              
Lessee, operating lease, termination notice period           18 months 18 months 12 months              
Payment of termination fee | €     € 1.0                        
Lessee, operating lease, maximum potential annual maintenance fees           $ 4,200,000 $ 5,400,000                
Lessee, operating lease, termination notice period, after stage 5 commencement           8 months                  
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]      
Operating lease cost $ 25,067 $ 18,660 $ 20,005
Total lease cost 25,067 18,660 20,005
Operating cash flows used for operating leases $ 22,805 $ 17,780 $ 17,205
Weighted average remaining lease term 4 years 8 months 12 days 6 years 3 months 18 days 7 years 3 months 18 days
Weighted average discount rate 5.02% 5.98% 6.66%
Short-term lease, cost $ 0 $ 0  
Variable lease, cost $ 0 $ 0  
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Leases [Abstract]  
2022 $ 27,037
2023 21,460
2024 18,009
2025 14,639
2026 8,598
2027 and thereafter 12,356
Total lease payments 102,099
Less: imputed interest (12,515)
Total operating lease liabilities $ 89,584
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail)
$ in Thousands
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2022 $ 43,903
2023 9,918
2024 and thereafter 0
Total purchase commitments $ 53,821
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity - Narrative (Detail)
$ / shares in Units, $ in Millions
 1 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2021
vote
shares
Dec. 31, 2020
shares
Subsidiary, Sale of Stock [Line Items]      
Common stock, shares authorized (in shares)   125,000,000 125,000,000
Common stock, number of votes (in votes per share) | vote   1  
Common stock, shares issued (in shares)   71,115,000 66,432,000
Common stock, shares outstanding (in shares)   71,115,000 66,432,000
Preferred stock, shares authorized (in shares)   5,000,000 5,000,000
Preferred Stock, shares issued (in shares)   0 0
Preferred stock, shares outstanding (in shares)   0 0
Private Placement      
Subsidiary, Sale of Stock [Line Items]      
Number of shares issued in transaction (in shares) 2,300,000    
Common stock price per share (in dollars per share) | $ / shares $ 16.50    
Proceeds from stock offering | $ $ 75.0    
Private Placement | Pre-funded warrants      
Subsidiary, Sale of Stock [Line Items]      
Number of securities called by warrants 2,300,000    
Warrant price per share (in dollars per share) | $ / shares $ 16.49    
Exercise price of warrants (in dollars per share) | $ / shares $ 0.01    
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity - Summary of Future Issuance of Common Stock Shares (Detail) - shares
shares in Thousands
Dec. 31, 2021
Dec. 31, 2020
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 14,831 10,369
2013 Stock Option and Incentive Plan    
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 2,250 2,545
2013 Employee Stock Purchase Plan    
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 1,347 67
Options to purchase common stock    
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 5,534 6,262
Restricted stock units    
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 3,427 1,495
Pre-funded warrants    
Schedule of Capitalization [Line Items]    
Common shares reserved for future issuance (in shares) 2,273 0
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Cost $ 5,224 $ 5,224
Accumulated amortization (1,219) (827)
Impairment (4,005) 0
Net 0 4,397
In-licensed rights    
Finite-Lived Intangible Assets [Line Items]    
Cost 5,224 5,224
Accumulated amortization (1,219) (827)
Impairment (4,005) 0
Net $ 0 $ 4,397
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible assets - Narrative (Detail) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]        
Amortization expense   $ 0.4 $ 0.5 $ 0.3
In-licensed rights        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset impairment $ 4.0      
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Narrative (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 04, 2021
Jan. 31, 2022
Jan. 31, 2021
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2021
Jun. 24, 2013
Jun. 03, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Increase in common stock available for issuance under 2013 plan (in shares)     2,700,000                
Number of shares available for issuance (in shares)       3,200,000   3,200,000          
Incremental fair value from modification $ 4,500         $ 20,300          
Stock-based compensation expense           98,740 $ 122,596 $ 131,083      
Stock-based compensation capitalized into inventory           $ 1,000 $ 500        
Unrestricted stock awards granted (in shares)           1,238,000          
Weighted average grant date fair value of options granted (in dollars per share)           $ 16.32 $ 43.24 $ 83.44      
Intrinsic value of stock options exercised           $ 5,100 $ 4,000 $ 29,000      
Subsequent Event                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Increase in common stock available for issuance under 2013 plan (in shares)   2,800,000                  
Stock options                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Stock-based compensation expense           54,660 75,837 79,912      
Unrecognized stock- based compensation expense related to unvested stock options, restricted stock awards and employee stock purchase plan       $ 34,200   $ 34,200          
Expected weighted-average period related to unvested stock options, restricted stock awards and employee stock purchase plan           2 years 2 months 8 days          
Restricted stock units                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Stock-based compensation expense           $ 30,767 $ 38,123 50,158      
Unvested restricted stock awards outstanding (in shares)       3,193,000   3,193,000 1,495,000        
Unrecognized stock- based compensation expense related to unvested stock options, restricted stock awards and employee stock purchase plan       $ 54,300   $ 54,300          
Expected weighted-average period related to unvested stock options, restricted stock awards and employee stock purchase plan           2 years 3 months 3 days          
Intrinsic value of restricted stock units vested           $ 44,000 $ 30,900 28,400      
Employee stock purchase plan and other                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common shares reserved for future issuance (in shares)                     200,000
Stock-based compensation expense           $ 13,313 $ 8,636 $ 1,013      
Increase in shares authorized (in shares)                 1,400,000    
Employee stock purchase plan and other | Maximum                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Share-based compensation arrangement by share-based payment award, shares issued in period (less than) (in shares)           100,000 100,000        
2013 Stock Option and Incentive Plan                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Common shares reserved for future issuance (in shares)                   1,000,000  
Percentage of automatic increase in shares reserved and available for issuance determined based on shares outstanding       4.00%   4.00%          
2020 Annual Incentive Program | Unrestricted Stock Awards                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Stock-based compensation expense     $ 10,600                
Unrestricted stock awards granted (in shares)     400,000                
Stock based compensation     $ 21,200                
Retention Program | Unrestricted Stock Awards                      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                      
Unrestricted stock awards granted (in shares)       1,000,000 100,000            
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 98,740 $ 122,596 $ 131,083
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense 54,660 75,837 79,912
Restricted stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense 30,767 38,123 50,158
Employee stock purchase plan and other      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 13,313 $ 8,636 $ 1,013
XML 93 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 98,740 $ 122,596 $ 131,083
Research and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense 42,989 49,766 59,378
Selling, general and administrative      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 55,751 $ 72,830 $ 71,705
XML 94 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]      
Expected volatility 66.70% 69.50% 70.70%
Expected term (in years) 6 years 6 years 6 years
Risk-free interest rate 0.80% 1.40% 2.30%
Expected dividend yield 0.00% 0.00% 0.00%
XML 95 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Shares (in thousands)  
Outstanding at beginning of period (in shares) 6,262,000
Granted (in shares) 1,238,000
Exercised (in shares) (218,000)
Canceled or forfeited (in shares) (2,357,000)
Conversion and modification of awards (in shares) 1,339,000
Outstanding at end of period (in shares) 3,586,000
Exercisable at end of period (in shares) 1,835,000
Vested and expected to vest at end of period (in shares) 3,586,000
Weighted- average exercise price per share  
Outstanding at beginning of period (in dollars per share) $ 105.02
Granted (in dollars per share) 27.19
Exercised (in dollars per share) 6.82
Canceled or forfeited (in dollars per share) 81.20
Conversion and modification of awards (in dollars per share) 42.90
Outstanding at end of period (in dollars per share) 39.23
Exercisable at end of period (in dollars per share) 57.09
Vested and expected to vest at end of period (in dollars per share) $ 39.23
Weighted- average contractual life (in years)  
Outstanding at end of period 6 years 9 months 18 days
Exercisable at end of period 5 years 6 months
Vested and expected to vest at end of period 6 years 9 months 18 days
Aggregate intrinsic value (in thousands)  
Outstanding at end of period $ 631
Exercisable at end of period 380
Vested and expected to vest at end of period $ 631
Option Conversion Awards  
Shares (in thousands)  
Conversion and modification of awards (in shares) 4,375
XML 96 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based compensation - Summary of Restricted Stock Units (Detail)
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Restricted stock units  
Shares (in thousands)  
Unvested balance at beginning of period (in shares) 1,495,000
Granted (in shares) 3,359,000
Vested (in shares) (526,000)
Forfeited (in shares) (987,000)
Conversion and modification of awards (in shares) 148,000
Unvested balance at end of period (in shares) 3,193,000
Weighted-average grant date fair value  
Unvested balance at beginning of period (in dollars per share) | $ / shares $ 102.34
Granted (in dollars per share) | $ / shares 26.43
Vested (in dollars per share) | $ / shares 112.21
Forfeited (in dollars per share) | $ / shares 53.58
Conversion and modification of awards (in dollars per share) | $ / shares 16.84
Unvested balance at end of period (in dollars per share) | $ / shares $ 16.21
Restricted stock unit conversion awards  
Shares (in thousands)  
Conversion and modification of awards (in shares) 3,327
XML 97 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
401(k) Savings plan - Additional Information (Detail) - 401 (k) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Contribution Plan Disclosure [Line Items]          
Contributions to the 401(k) plan   $ 6.0      
Expenses related to 401(k) plan     $ 2.8 $ 3.0 $ 2.9
Forecast          
Defined Contribution Plan Disclosure [Line Items]          
Contributions to the 401(k) plan $ 2.8        
Forecast | 2seventy bio          
Defined Contribution Plan Disclosure [Line Items]          
Contributions to the 401(k) plan $ 2.0        
XML 98 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Schedule of Components of Loss Before Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
U.S. $ (487,404) $ (431,452) $ (414,586)
Foreign (74,976) (128,918) (140,981)
Loss before income taxes $ (562,380) $ (560,370) $ (555,567)
XML 99 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current:      
Federal $ 0 $ 0 $ 0
State 0 2 7
Foreign 258 684 612
Deferred:      
Federal 0 0 (966)
State 0 0 (198)
Foreign 0 0 0
Total income tax expense (benefit) $ 258 $ 686 $ (545)
XML 100 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Federal income tax expense at statutory rate 21.00% 21.00% 21.00%
State income tax, net of federal benefit 3.90% 3.10% 3.70%
Permanent differences (0.60%) (0.60%) (0.80%)
Stock-based compensation (3.10%) (2.40%) (0.70%)
Research and development credit 4.30% 6.00% 5.40%
Foreign differential (1.90%) (4.60%) (3.70%)
Other 0.00% (0.30%) 0.80%
Change in valuation allowance (23.60%) (22.30%) (25.60%)
Effective income tax rate (expense) benefit 0.00% (0.10%) 0.10%
XML 101 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Narrative (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Components Of Income Tax Expense Benefit [Line Items]      
Income tax expense (benefit) $ 258,000 $ 686,000 $ (545,000)
Income tax expense, discontinued operations $ 0 $ 0 $ 0
Effective income tax rate 0.00% (0.10%) 0.10%
Approximately valuation allowance increased $ 183,400,000    
Operating loss carryforwards, without expiration dates 1,920,000,000    
Operating loss carryforwards, with expiration dates 711,000,000    
Income tax examination, penalties and interest accrued $ 0 $ 0 $ 0
Research Tax Credit Carryforward      
Components Of Income Tax Expense Benefit [Line Items]      
Limitations on use of net operating losses and tax credit carryforwards, period 3 years    
Limitations on use of net operating losses and tax credit carryforwards, percentage 50.00%    
U.S.      
Components Of Income Tax Expense Benefit [Line Items]      
Operating loss carryforwards $ 2,630,000,000 2,030,000,000.00 1,620,000,000
U.S. | Research Tax Credit Carryforward      
Components Of Income Tax Expense Benefit [Line Items]      
Tax credit carryforward amount 268,300,000 235,300,000 203,100,000
State and Local Jurisdiction      
Components Of Income Tax Expense Benefit [Line Items]      
Operating loss carryforwards 2,390,000,000 1,890,000,000 1,560,000,000
State and Local Jurisdiction | Research Tax Credit Carryforward      
Components Of Income Tax Expense Benefit [Line Items]      
Tax credit carryforward amount $ 16,900,000 $ 14,500,000 $ 13,600,000
XML 102 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
U.S. net operating loss carryforwards (federal and state) $ 703,125 $ 546,098
Tax credit carryforwards (federal and state) 281,687 246,742
Capitalized license fees and research and development expenses 2,237 1,558
Deferred revenue 604 398
Stock-based compensation 25,181 37,164
Lease liabilities 22,916 14,787
Accruals and other 15,598 12,894
Total deferred tax assets 1,051,348 859,641
Right-of-use assets (23,053) (15,044)
Fixed assets (1,546) (1,212)
Less valuation allowance (1,026,749) (843,385)
Net deferred taxes $ 0 $ 0
XML 103 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Balance as of beginning of period $ 18,994 $ 15,945
Increases (decreases) for tax positions related to current period 2,949 3,149
Increases (decreases) for tax positions related to prior periods 17  
Increases (decreases) for tax positions related to prior periods   (100)
Balance as of end of period $ 21,960 $ 18,994
XML 104 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reduction in workforce - Narrative (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Jul. 31, 2021
USD ($)
employee
Apr. 30, 2021
USD ($)
employee
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Restructuring Cost and Reserve [Line Items]            
Restructuring expense       $ 25,801 $ 0 $ 0
Stock-based compensation expense       98,740 $ 122,596 $ 131,083
April 2021 reduction            
Restructuring Cost and Reserve [Line Items]            
Number of employees impacted | employee     50      
Restructuring expense     $ 4,600 4,625    
July 2021 reduction            
Restructuring Cost and Reserve [Line Items]            
Number of employees impacted | employee   90        
Restructuring expense   $ 21,200   21,176    
July 2021 reduction | Unrestricted Stock            
Restructuring Cost and Reserve [Line Items]            
Stock-based compensation expense $ 2,500          
July 2021 reduction | Unrestricted Stock | Research And Development And Selling, General And Administrative Expenses            
Restructuring Cost and Reserve [Line Items]            
Stock-based compensation expense       $ 2,500    
XML 105 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reduction in workforce - Accrued Liabilities Activity (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2021
Apr. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]          
Charges     $ 25,801,000 $ 0 $ 0
Amount paid     (21,128,000)    
Amounts accrued at December 31, 2021     4,673,000    
April 2021 reduction          
Restructuring Cost and Reserve [Line Items]          
Charges   $ 4,600,000 4,625,000    
Amount paid     (4,625,000)    
Amounts accrued at December 31, 2021     0    
July 2021 reduction          
Restructuring Cost and Reserve [Line Items]          
Charges $ 21,200,000   21,176,000    
Amount paid     (16,503,000)    
Amounts accrued at December 31, 2021     $ 4,673,000    
XML 106 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 8,961 8,083 6,629
Outstanding stock options      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 5,534 6,262 5,483
Restricted stock units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 3,427 1,495 1,127
ESPP shares and other      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Common stock equivalents excluded from the calculation of diluted net loss per share (in shares) 0 326 19
XML 107 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 1,606 $ 1,019 $ 143 $ 894 $ 0 $ 0 $ 0 $ 0 $ 3,662 $ 0 $ 0
Total operating expenses 137,273 155,468 154,844 146,988 139,387 131,743 143,650 144,479 594,573 559,259 562,963
Loss from operations (135,667) (154,449) (154,701) (146,094) (139,387) (131,743) (143,650) (144,479) (590,911) (559,259) (562,963)
Net loss from continuing operations (132,327) (152,834) (155,973) (121,504) (136,321) (137,678) (140,665) (146,392) (562,638) (561,056) (555,022)
Net income (loss) from discontinued operations (22,725) (63,982) (85,729) (84,304) (63,553) (57,067) 119,200 (56,219) (256,740) (57,639) (234,586)
Net loss $ (155,052) $ (216,816) $ (241,702) $ (205,808) $ (199,874) $ (194,745) $ (21,465) $ (202,611) $ (819,378) $ (618,695) $ (789,608)
Net loss per share from continuing operations - basic (in dollars per share) $ (1.83) $ (2.23) $ (2.31) $ (1.81) $ (2.05) $ (2.08) $ (2.33) $ (2.63) $ (8.16) $ (9.02) $ (10.06)
Net loss per share from continuing operations - diluted (in dollars per share) (1.83) (2.23) (2.31) (1.81) (2.05) (2.08) (2.33) (2.63) (8.16) (9.02) (10.06)
Net income (loss) per share from discontinued operations - basic (0.31) (0.93) (1.27) (1.26) (0.96) (0.86) 1.97 (1.01) (3.73) (0.93)  
Net income (loss) per share from discontinued operations - diluted (0.31) (0.93) (1.27) (1.26) (0.96) (0.86) 1.97 (1.01) (3.73) (0.93)  
Net loss per share - basic (in dollars per share) (2.14) (3.16) (3.58) (3.07) (3.01) (2.94) (0.36) (3.64) (11.89) (9.95) (14.31)
Net loss per share - diluted (in dollars per share) $ (2.14) $ (3.16) $ (3.58) $ (3.07) $ (3.01) $ (2.94) $ (0.36) $ (3.64) $ (11.89) $ (9.95) $ (14.31)
XML 108 blue-20211231_htm.xml IDEA: XBRL DOCUMENT 0001293971 2021-01-01 2021-12-31 0001293971 2021-06-30 0001293971 2022-02-28 0001293971 2021-12-31 0001293971 2020-12-31 0001293971 us-gaap:ProductMember 2021-01-01 2021-12-31 0001293971 us-gaap:ProductMember 2020-01-01 2020-12-31 0001293971 us-gaap:ProductMember 2019-01-01 2019-12-31 0001293971 blue:OtherRevenueMember 2021-01-01 2021-12-31 0001293971 blue:OtherRevenueMember 2020-01-01 2020-12-31 0001293971 blue:OtherRevenueMember 2019-01-01 2019-12-31 0001293971 2020-01-01 2020-12-31 0001293971 2019-01-01 2019-12-31 0001293971 us-gaap:CommonStockMember 2018-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2018-12-31 0001293971 us-gaap:RetainedEarningsMember 2018-12-31 0001293971 2018-12-31 0001293971 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001293971 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001293971 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2019-01-01 2019-12-31 0001293971 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001293971 us-gaap:CommonStockMember 2019-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2019-12-31 0001293971 us-gaap:RetainedEarningsMember 2019-12-31 0001293971 2019-12-31 0001293971 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2020-01-01 2020-12-31 0001293971 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001293971 us-gaap:CommonStockMember 2020-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2020-12-31 0001293971 us-gaap:RetainedEarningsMember 2020-12-31 0001293971 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2021-01-01 2021-12-31 0001293971 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001293971 us-gaap:CommonStockMember 2021-12-31 0001293971 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001293971 blue:AccumulatedOtherComprehensiveIncomeNetGainLossMember 2021-12-31 0001293971 us-gaap:RetainedEarningsMember 2021-12-31 0001293971 blue:PublicOfferingMember 2021-01-01 2021-12-31 0001293971 blue:PublicOfferingMember 2020-01-01 2020-12-31 0001293971 blue:PublicOfferingMember 2019-01-01 2019-12-31 0001293971 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001293971 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001293971 us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001293971 2021-11-04 0001293971 us-gaap:BuildingMember 2021-01-01 2021-12-31 0001293971 blue:ComputerEquipmentAndSoftwareMember 2021-01-01 2021-12-31 0001293971 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001293971 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001293971 srt:MinimumMember blue:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001293971 srt:MaximumMember blue:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001293971 blue:LentiviralVectorManufacturingFacilityMember 2021-12-31 0001293971 blue:LentiviralVectorManufacturingFacilityMember 2021-01-01 2021-12-31 0001293971 blue:A2seventyBioMember 2021-12-31 0001293971 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2021-11-04 0001293971 2021-11-03 0001293971 us-gaap:ServiceMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2021-01-01 2021-12-31 0001293971 us-gaap:ServiceMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2020-01-01 2020-12-31 0001293971 us-gaap:ServiceMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2019-01-01 2019-12-31 0001293971 blue:CollaborationArrangementMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2021-01-01 2021-12-31 0001293971 blue:CollaborationArrangementMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2020-01-01 2020-12-31 0001293971 blue:CollaborationArrangementMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2019-01-01 2019-12-31 0001293971 blue:RoyaltyAndOtherRevenueMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2021-01-01 2021-12-31 0001293971 blue:RoyaltyAndOtherRevenueMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2020-01-01 2020-12-31 0001293971 blue:RoyaltyAndOtherRevenueMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2019-01-01 2019-12-31 0001293971 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2021-01-01 2021-12-31 0001293971 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2020-01-01 2020-12-31 0001293971 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2019-01-01 2019-12-31 0001293971 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember blue:A2seventyBioMember 2020-12-31 0001293971 2021-10-19 0001293971 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0001293971 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:CommercialPaperMember 2021-12-31 0001293971 us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0001293971 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 us-gaap:CommercialPaperMember 2020-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001293971 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001293971 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001293971 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001293971 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001293971 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001293971 2021-01-01 2021-01-31 0001293971 blue:LaboratoryEquipmentMember 2021-12-31 0001293971 blue:LaboratoryEquipmentMember 2020-12-31 0001293971 blue:ComputerEquipmentAndSoftwareMember 2021-12-31 0001293971 blue:ComputerEquipmentAndSoftwareMember 2020-12-31 0001293971 us-gaap:OfficeEquipmentMember 2021-12-31 0001293971 us-gaap:OfficeEquipmentMember 2020-12-31 0001293971 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001293971 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001293971 us-gaap:ConstructionInProgressMember 2021-12-31 0001293971 us-gaap:ConstructionInProgressMember 2020-12-31 0001293971 us-gaap:LetterOfCreditMember 2021-12-31 0001293971 us-gaap:LetterOfCreditMember 2020-12-31 0001293971 blue:FiftyBinneyStreetLeaseMember 2021-12-31 0001293971 blue:FiftyBinneyStreetLeaseMember 2020-12-31 0001293971 blue:AssemblyRowLeaseMember 2021-12-31 0001293971 blue:AssemblyRowLeaseMember 2020-12-31 0001293971 blue:SixtyBinneyStreetLeaseMember 2021-12-31 0001293971 blue:SixtyBinneyStreetLeaseMember 2020-12-31 0001293971 blue:OtherMember 2021-12-31 0001293971 blue:OtherMember 2020-12-31 0001293971 blue:SixtyBinneyStreetLeaseMember 2021-10-01 2021-10-31 0001293971 blue:SixtyBinneyStreetLeaseMember 2021-10-31 0001293971 srt:ScenarioForecastMember blue:SixtyBinneyStreetLeaseMember 2022-04-01 2022-04-30 0001293971 blue:FiftyBinneyStreetSubleaseMember 2019-04-01 2019-04-30 0001293971 blue:FiftyBinneyStreetSubleaseMember 2019-04-30 0001293971 2019-04-30 0001293971 blue:FiftyBinneyStreetSubleaseMember 2021-12-31 0001293971 blue:FiftyBinneyStreetSubleaseMember 2021-12-01 2021-12-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember blue:FiftyBinneyStreetSubleaseMember 2021-12-01 2021-12-31 0001293971 blue:AssemblyRowLeaseMember 2021-11-01 2021-11-30 0001293971 blue:AssemblyRowLeaseMember 2021-11-30 0001293971 us-gaap:ManufacturingFacilityMember 2016-06-30 0001293971 us-gaap:ManufacturingFacilityMember 2016-06-01 2018-03-31 0001293971 us-gaap:ManufacturingFacilityMember 2021-01-01 2021-12-31 0001293971 us-gaap:ManufacturingFacilityMember 2016-11-30 0001293971 us-gaap:ManufacturingFacilityMember 2020-03-31 0001293971 us-gaap:ManufacturingFacilityMember 2020-03-01 2020-03-31 0001293971 us-gaap:ManufacturingFacilityMember 2021-12-01 2021-12-31 0001293971 us-gaap:ManufacturingFacilityMember 2020-07-31 0001293971 us-gaap:ManufacturingFacilityMember 2020-07-01 2020-07-31 0001293971 us-gaap:ManufacturingFacilityMember 2021-02-28 0001293971 us-gaap:ManufacturingFacilityMember 2021-02-01 2021-02-28 0001293971 us-gaap:PrivatePlacementMember 2021-09-01 2021-09-30 0001293971 us-gaap:PrivatePlacementMember 2021-09-30 0001293971 blue:PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2021-09-30 0001293971 us-gaap:EmployeeStockOptionMember 2021-12-31 0001293971 us-gaap:EmployeeStockOptionMember 2020-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001293971 blue:TwoThousandThirteenStockOptionAndIncentivePlanMember 2021-12-31 0001293971 blue:TwoThousandThirteenStockOptionAndIncentivePlanMember 2020-12-31 0001293971 blue:PreFundedWarrantsMember 2021-12-31 0001293971 blue:PreFundedWarrantsMember 2020-12-31 0001293971 blue:TwoThousandThirteenEmployeeStockPurchasePlanESPPMember 2021-12-31 0001293971 blue:TwoThousandThirteenEmployeeStockPurchasePlanESPPMember 2020-12-31 0001293971 blue:InLicensedRightsMember 2021-12-31 0001293971 blue:InLicensedRightsMember 2020-12-31 0001293971 blue:InLicensedRightsMember 2021-09-01 2021-09-30 0001293971 blue:TwoThousandThirteenStockOptionAndIncentivePlanMember 2013-06-24 0001293971 us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0001293971 2021-11-04 2021-11-04 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2021-01-01 2021-12-31 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2020-01-01 2020-12-31 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2019-01-01 2019-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001293971 blue:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001293971 blue:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001293971 blue:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001293971 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001293971 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001293971 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001293971 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001293971 blue:UnrestrictedStockAwardsMember blue:A2020AnnualIncentiveProgramMember 2021-01-01 2021-01-31 0001293971 blue:UnrestrictedStockAwardsMember blue:RetentionProgramMember 2021-07-01 2021-09-30 0001293971 blue:UnrestrictedStockAwardsMember blue:RetentionProgramMember 2021-10-01 2021-12-31 0001293971 blue:EmployeeAndNonEmployeeStockOptionMember 2021-12-31 0001293971 blue:OptionConversionAwardsMember 2021-01-01 2021-12-31 0001293971 blue:RestrictedStockUnitConversionAwardsMember 2021-01-01 2021-12-31 0001293971 blue:EmployeeStockPurchasePlanMember 2013-06-03 0001293971 blue:EmployeeStockPurchasePlanMember 2021-06-30 0001293971 srt:MaximumMember blue:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001293971 srt:MaximumMember blue:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001293971 srt:ScenarioForecastMember blue:FourHundredAndOneKMember 2022-03-01 2022-03-31 0001293971 srt:ScenarioForecastMember blue:A2seventyBioMember blue:FourHundredAndOneKMember 2022-03-01 2022-03-31 0001293971 blue:FourHundredAndOneKMember 2021-03-01 2021-03-31 0001293971 blue:FourHundredAndOneKMember 2021-01-01 2021-12-31 0001293971 blue:FourHundredAndOneKMember 2020-01-01 2020-12-31 0001293971 blue:FourHundredAndOneKMember 2019-01-01 2019-12-31 0001293971 us-gaap:DomesticCountryMember 2021-12-31 0001293971 us-gaap:DomesticCountryMember 2020-12-31 0001293971 us-gaap:DomesticCountryMember 2019-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001293971 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-12-31 0001293971 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2020-12-31 0001293971 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2019-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2021-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2020-12-31 0001293971 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0001293971 us-gaap:ResearchMember 2021-01-01 2021-12-31 0001293971 blue:April2021ReductionMember 2021-04-01 2021-04-30 0001293971 blue:July2021ReductionMember 2021-07-01 2021-07-31 0001293971 blue:UnrestrictedStockMember blue:July2021ReductionMember 2021-09-30 2021-09-30 0001293971 blue:April2021ReductionMember 2021-01-01 2021-12-31 0001293971 blue:April2021ReductionMember 2021-12-31 0001293971 blue:July2021ReductionMember 2021-01-01 2021-12-31 0001293971 blue:July2021ReductionMember 2021-12-31 0001293971 blue:UnrestrictedStockMember blue:ResearchAndDevelopmentAndSellingGeneralAndAdministrativeExpensesMember blue:July2021ReductionMember 2021-01-01 2021-12-31 0001293971 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001293971 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001293971 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001293971 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2021-01-01 2021-12-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2020-01-01 2020-12-31 0001293971 blue:EmployeeStockPurchasePlanAndOtherMember 2019-01-01 2019-12-31 0001293971 2021-01-01 2021-03-31 0001293971 2021-04-01 2021-06-30 0001293971 2021-07-01 2021-09-30 0001293971 2021-10-01 2021-12-31 0001293971 2020-01-01 2020-03-31 0001293971 2020-04-01 2020-06-30 0001293971 2020-07-01 2020-09-30 0001293971 2020-10-01 2020-12-31 iso4217:USD shares iso4217:USD shares blue:company blue:target blue:agreement pure utr:sqft iso4217:USD utr:sqft iso4217:EUR blue:vote blue:employee false 2021 FY 0001293971 http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member 1 0.3333 0 0 0 0 10-K true 2021-12-31 --12-31 false 001-35966 bluebird bio, Inc. DE 13-3680878 60 Binney Street Cambridge MA 02142 339 499-9300 Common Stock, $0.01 par value per share BLUE NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 1398973030 71433275 Portions of the registrant’s definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. 42 Ernst & Young LLP Boston, Massachusetts 161160000 260629000 138343000 419599000 25628000 25718000 0 10698000 11389000 3872000 0 495021000 336520000 1215537000 97114000 61445000 9706000 17373000 0 4397000 5646000 5646000 91532000 67563000 53277000 65727000 0 343564000 593795000 1781252000 25883000 13811000 103958000 98190000 23152000 9711000 0 81876000 152993000 203588000 66432000 55707000 93000 5759000 0 161142000 219518000 426196000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 125000000 125000000 71115000 71115000 66432000 66432000 711000 665000 4096402000 4260443000 -2911000 -5505000 -3719925000 -2900547000 374277000 1355056000 593795000 1781252000 2850000 0 0 812000 0 0 3662000 0 0 319946000 319309000 327119000 209969000 239950000 235844000 38857000 0 0 25801000 0 0 594573000 559259000 562963000 -590911000 -559259000 -562963000 879000 5770000 17380000 27652000 -6881000 -9984000 -562380000 -560370000 -555567000 258000 686000 -545000 -562638000 -561056000 -555022000 -256740000 -57639000 -234586000 -819378000 -618695000 -789608000 -8.16 -8.16 -9.02 -9.02 -10.06 -10.06 -3.73 -3.73 -0.93 -0.93 -4.25 -4.25 -11.89 -11.89 -9.95 -9.95 -14.31 -14.31 68910000 62178000 55191000 0 0 -1200000 2364000 -3612000 1734000 2364000 -3612000 1734000 -817014000 -622307000 -787874000 54738000 547000 3386958000 -3627000 -1498808000 1885070000 6564000 6564000 251000 3000 -3000 0 354000 4000 17834000 17838000 25000 2766000 2766000 160629000 160629000 1734000 1734000 -789608000 -789608000 55368000 554000 3568184000 -1893000 -2281852000 1284993000 33645000 10455000 105000 541431000 541536000 434000 4000 -4000 0 95000 1000 1846000 1847000 80000 1000 3774000 3775000 145212000 145212000 -3612000 -3612000 -618695000 -618695000 66432000 665000 4260443000 -5505000 -2900547000 1355056000 534000 5000 -5000 0 218000 2000 1486000 1488000 120000 1000 2580000 2581000 2273000 23000 37477000 37500000 37477000 37477000 1538000 15000 25059000 25074000 110260000 110260000 378375000 -230000 378145000 2364000 2364000 -819378000 -819378000 71115000 711000 4096402000 -2911000 -3719925000 374277000 -819378000 -618695000 -789608000 387000 -6468000 2747000 19649000 19356000 17434000 127915000 156631000 160629000 29356000 -7217000 -9297000 29924000 0 0 -17235000 -458000 11000000 5289000 10089000 13913000 18447000 0 0 30148000 21281000 22496000 9286000 -20100000 23600000 40025000 4835000 29617000 -32142000 -17380000 -9944000 5596000 7397000 5739000 -635639000 -470351000 -564384000 14503000 28986000 71028000 451391000 1003525000 756570000 895333000 918288000 1340629000 31318000 29878000 0 110300000 0 0 8500000 0 5224000 562557000 -84345000 507807000 174284000 0 0 0 541536000 0 74975000 0 0 5355000 5179000 21187000 -93954000 546715000 21187000 -167036000 -7981000 -35390000 373728000 381709000 417099000 206692000 373728000 381709000 161160000 317705000 327214000 2282000 1500000 0 43250000 54523000 54495000 206692000 373728000 381709000 411000 2854000 5286000 202221000 19414000 23939000 9004000 0 0 25074000 0 0 0 0 0 617000 361000 637000 Description of the business<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial-readiness activities.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company announced its intent to focus its severe genetic disease business on the U.S. market and further invest in research and development for its core programs in β-thalassemia, sickle cell disease ("SCD"), and cerebral adrenoleukodystrophy ("CALD") in that market. As part of the strategy to focus on the U.S. market, it began executing an orderly wind down of its European operations, which will result in a reduction of selling, general and administrative costs and had an impact on the Company's excess inventory analysis, which is based on forecasted consumption levels driven by sales forecasts. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed the separation of its severe genetic disease and oncology programs into two separate, independent publicly traded companies, bluebird bio, Inc. and 2seventy bio, Inc. ("2seventy bio"), a Delaware corporation and wholly-owned subsidiary of the Company prior to the separation. bluebird intends to retain its severe genetic disease programs, with a focus on the U.S. market. The Company’s programs in severe genetic diseases include programs for β-thalassemia, SCD, and CALD. The Company also expects to make focused investments in research and development efforts on optimizing our existing programs as well as on pipeline programs in severe genetic diseases. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s programs in severe genetic diseases include betibeglogene autotemcel ("beti-cel", formerly "LentiGlobin for β-thalassemia gene therapy") as a treatment for β-thalassemia; lovotibeglogene autotemcel ("lovo-cel") as a treatment for SCD; and elivaldogene autotemcel ("eli-cel", formerly "Lenti-D gene therapy") as a treatment for CALD. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $396.6 million. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from charitable foundations. As of December 31, 2021, the Company had an accumulated deficit of $3.72 billion. During the twelve months ended December 31, 2021, the Company incurred a loss from continuing operations of $562.6 million and used $635.6 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of beti-cel, eli-cel, and lovo-cel, and the achievement of a level of revenues adequate to support its cost structure.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, the release of restricted cash related to the Company’s 50 Binney Street sublease, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have been approved by the Board of Directors as of the date of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company's expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support its planned operations raise substantial doubt regarding the Company’s ability to continue as a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">going concern for a period of one year after the date that these consolidated financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include reduced 2022 spending, including projected savings through the move of the Company's headquarters to Assembly Row in Somerville, Massachusetts, the orderly wind down of European operations, the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for beti-cel and eli-cel, and the pursuit of additional cash resources through public or private equity or debt financings. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></div> 2 396600000 -3720000000 -562600000 -635600000 Summary of significant accounting policies and basis of presentation<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”).  Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the ASC and the Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation. The Company has presented its oncology business together with its manufacturing facility in Durham, North Carolina as discontinued operations in its consolidated financial statements for all periods presented (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The historical financial statements and footnotes have been recast accordingly. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. 2seventy bio, Inc. ("2seventy bio") was a wholly-owned subsidiary until it became an independent publicly-traded company on November 4, 2021. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the separation of its oncology business in November 2021 and the sale of its manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 205-20”). Accordingly, the accompanying consolidated financial statements for all periods presented have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheets and the results of all discontinued operations reported as a separate component of loss in the consolidated statements of operations and comprehensive loss (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of the Company’s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in stockholders’ equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.  Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.  All material long-lived assets of the Company reside in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s marketable securities are maintained by investment managers and consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Equity securities with readily determinable fair values are also carried at fair value with unrealized gains and losses included in other income (expense), net. Realized gains and losses on both debt and equity securities are determined using the specific identification method and are included in other income (expense), net.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity securities with readily determinable fair values, which would be available for use in its current operations, as current assets even though the Company may not dispose of such marketable securities within the next 12 months. Equity securities are included in the balance of marketable securities on the Company's consolidated balance sheets. The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Marketable securities with a remaining maturity date greater than one year are classified as non-current assets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2016-13” or “ASC 326”), using the effective date method. As the Company had never recorded any other-than-temporary-impairment adjustments to its available-for-sale debt securities prior to the effective date, no transition provisions are applicable to the Company.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable related to the Company's available-for-sale debt securities is presented within receivables and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and off-balance sheet risk</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Fair values are determined utilizing quoted prices for identical or similar assets or liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items measured at fair value on a recurring basis include marketable securities (see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business combinations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting. Using this method, the tangible and intangible assets acquired and the liabilities assumed are recorded as of the acquisition date at their respective fair values. The Company evaluates a business as an integrated set of activities and assets that is capable of being managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits and consists of inputs and processes that provide or have the ability to provide outputs. In an acquisition of a business, the excess of the fair value of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill. In an acquisition of net assets that does not constitute a business, no goodwill is recognized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. The Company performs a one-step quantitative test and records the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has not recognized any impairment charges related to goodwill to date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal of a portion of a reporting unit that constitutes a business, goodwill is assigned based on the relative fair values of the portion of the reporting unit being disposed and the portion of the reporting unit remaining. This approach requires a determination of the fair value of both the business to be disposed of and the business (or businesses) within the reporting unit that will be retained. As a result of the separation of the Company's oncology business and the sale of the Company's manufacturing facility in Durham, North Carolina, the Company assigned goodwill based on the relative fair value of the business to be disposed of, and such goodwill has been reclassified to discontinued operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible assets, net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of in-licensed rights with finite lives, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. During the third quarter of 2021, the Company recognized impairment charges related to intangible assets. In accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Intangibles Other than Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 350”), the Company reviewed its intangible assets for recoverability. During the third quarter of 2021, the Company determined that the intangible assets were impaired, resulting in the impairment of the remaining carrying value of the intangible assets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:48.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated useful life</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC 842 using the required modified retrospective approach and utilizing the effective date as its date of initial application. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock warrants</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's common stock warrants are evaluated pursuant to ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 480"), and ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815"). Management classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company’s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used for the production of clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product, which has been produced for the treatment of specific patients, that are owned by the Company. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on hand and firm purchase commitments as well as remaining shelf life of on hand inventories. The Company writes-down its inventory that is obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue on the Company’s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.  The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.  The Company assessed each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue within the following financial statement captions:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes product revenue in accordance with Topic 606. Product revenue represents sales of ZYNTEGLO. In 2021, the Company distributed ZYNTEGLO directly to hospitals in Germany. The Company determined that contracted sales with hospitals formed a single performance obligation and it recognizes revenue from product sales at the point in time it satisfies the performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue Recognition Not-for-Profit Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In addition, the Company entered into strategic collaborations and recognized an immaterial amount of revenue associated with those collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as costs are incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, clinical study and related clinical manufacturing costs, license and milestone fees, contract services, manufacturing costs for pre-launch inventory that did not qualify for capitalization, and other related costs. Up-front fees and milestones paid to third parties in connection with technologies which have not reached technological feasibility and do not have an alternative future use are expensed as research and development expense as incurred. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, or other clinical trial vendors that perform the activities. Where amounts owed to a collaboration partner exceed the Company’s collaborative arrangement revenues in each quarterly period, such amounts are classified as research and development expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of product revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue which are associated with the sale of ZYNTEGLO in Germany. Reserves for excess inventories are also included in cost of product revenue. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s share-based compensation programs grant awards that have included stock options, restricted stock units, restricted stock awards, unrestricted stock awards and shares issued under its employee stock purchase plan.  Grants are awarded to employees and non-employees, including the Company's board of directors.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation—Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its option awards using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of its own stock price. For both employee and non-employee awards, the measurement date is the date of grant. The Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion and modification of equity awards outstanding at date of separation of 2seventy bio </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the separation of 2seventy bio on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the separation. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. The Company will recognize future expense for awards denominated in bluebird stock and 2seventy bio stock granted to the Company's employees as a result of the separation of 2seventy bio. Expense related to awards denominated in bluebird stock granted to 2seventy bio employees will be incurred by 2seventy bio.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to modified awards is measured based on the fair value for the awards as of the modification date. Any incremental stock-based compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite remaining service period, as appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest income, net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest income earned on investments, net of amortization of premium and accretion of discount. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of gains and losses on equity securities held by the Company, gains and losses on disposal of assets, and gains and losses on foreign currency.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per share is calculated by dividing net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration. Diluted net loss per share is calculated by dividing the net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration as well as any dilutive effect from outstanding stock options, unvested restricted stock, restricted stock units, and employee stock purchase plan stock using the treasury stock method. Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the two-class method when computing net loss per share in periods when issued shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on debt securities, foreign currency translation adjustments and other items.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring expenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records costs and liabilities associated with exit and disposal activities in accordance with FASB ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 420"). Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available. Refer to Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reduction in workforce,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently adopted</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity's own equity. The Company early adopted the new standard, effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-08”) to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2017-08”). ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-10, Codification Improvements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2020-10"). The amendments in this ASU represent changes to clarify the ASC, correct unintended application of the guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This new standard was effective beginning January 1, 2021. The adoption of ASU 2020-10 did not have a material impact on the Company's financial position or results of operations upon adoption.</span> <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”).  Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as included in the ASC and the Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation. The Company has presented its oncology business together with its manufacturing facility in Durham, North Carolina as discontinued operations in its consolidated financial statements for all periods presented (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The historical financial statements and footnotes have been recast accordingly. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported are computed based on thousands, except percentages, per share amounts, or as otherwise noted. As a result, certain totals may not sum due to rounding.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. 2seventy bio, Inc. ("2seventy bio") was a wholly-owned subsidiary until it became an independent publicly-traded company on November 4, 2021. All intercompany balances and transactions have been eliminated in consolidation.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the separation of its oncology business in November 2021 and the sale of its manufacturing facility in Durham, North Carolina in July 2021 represented multiple components of a single disposal plan that met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 205-20”). Accordingly, the accompanying consolidated financial statements for all periods presented have been updated to present the assets and liabilities associated with the oncology business and the manufacturing facility separately as discontinued operations on the consolidated balance sheets and the results of all discontinued operations reported as a separate component of loss in the consolidated statements of operations and comprehensive loss (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, stock-based compensation expense, accrued expenses, income taxes, the assets and liabilities and losses related to discontinued operations</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span>and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of the Company’s subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in stockholders’ equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.  Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.  All material long-lived assets of the Company reside in the United States.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original final maturities of 90 days or less from the date of purchase to be cash equivalents. Cash equivalents comprise marketable securities with maturities of less than 90 days when purchased. Cash equivalents are reported at fair value.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s marketable securities are maintained by investment managers and consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Equity securities with readily determinable fair values are also carried at fair value with unrealized gains and losses included in other income (expense), net. Realized gains and losses on both debt and equity securities are determined using the specific identification method and are included in other income (expense), net.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity securities with readily determinable fair values, which would be available for use in its current operations, as current assets even though the Company may not dispose of such marketable securities within the next 12 months. Equity securities are included in the balance of marketable securities on the Company's consolidated balance sheets. The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Marketable securities with a remaining maturity date greater than one year are classified as non-current assets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2016-13” or “ASC 326”), using the effective date method. As the Company had never recorded any other-than-temporary-impairment adjustments to its available-for-sale debt securities prior to the effective date, no transition provisions are applicable to the Company.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date in order to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale debt securities.</span></div>Accrued interest receivable related to the Company's available-for-sale debt securities is presented within receivables and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities. <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and off-balance sheet risk</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, equity securities, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Fair values are determined utilizing quoted prices for identical or similar assets or liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Items measured at fair value on a recurring basis include marketable securities (see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business combinations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting. Using this method, the tangible and intangible assets acquired and the liabilities assumed are recorded as of the acquisition date at their respective fair values. The Company evaluates a business as an integrated set of activities and assets that is capable of being managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits and consists of inputs and processes that provide or have the ability to provide outputs. In an acquisition of a business, the excess of the fair value of the consideration transferred over the fair value of the net assets acquired is recorded as goodwill. In an acquisition of net assets that does not constitute a business, no goodwill is recognized.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net assets acquired when accounted for using the acquisition method of accounting for business combinations. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. The Company performs a one-step quantitative test and records the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has not recognized any impairment charges related to goodwill to date.</span></div>Upon disposal of a portion of a reporting unit that constitutes a business, goodwill is assigned based on the relative fair values of the portion of the reporting unit being disposed and the portion of the reporting unit remaining. This approach requires a determination of the fair value of both the business to be disposed of and the business (or businesses) within the reporting unit that will be retained. As a result of the separation of the Company's oncology business and the sale of the Company's manufacturing facility in Durham, North Carolina, the Company assigned goodwill based on the relative fair value of the business to be disposed of, and such goodwill has been reclassified to discontinued operations. 0 Intangible assets, net<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consist of in-licensed rights with finite lives, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. During the third quarter of 2021, the Company recognized impairment charges related to intangible assets. In accordance with FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Intangibles Other than Goodwill</span> (“ASC 350”), the Company reviewed its intangible assets for recoverability. During the third quarter of 2021, the Company determined that the intangible assets were impaired, resulting in the impairment of the remaining carrying value of the intangible assets. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:48.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated useful life</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or remaining lease term</span></td></tr></table></div> Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:48.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated useful life</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the useful life or remaining lease term</span></td></tr></table> P40Y P3Y P2Y P5Y P2Y P5Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC 842 using the required modified retrospective approach and utilizing the effective date as its date of initial application. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in ASC 842-10-55-2 to assist in evaluating leases for appropriate classification. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.</span></div> Common stock warrants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's common stock warrants are evaluated pursuant to ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 480"), and ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span>("ASC 815"). Management classifies its freestanding warrants as (i) liabilities, if the warrant terms allow settlement of the warrant exercise in cash, or (ii) equity, if the warrant terms only allow settlement in shares of common stock. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value under the first-expired, first-out ("FEFO") methodology. Given human gene therapy products are a new and novel category of therapeutics and future economic benefit is not probable until regulatory approval for the product has been obtained, the Company has only considered inventory for capitalization upon regulatory approval. Manufacturing costs incurred prior to regulatory approval for pre-launch inventory that did not qualify for capitalization and clinical manufacturing costs are charged to research and development expense in the Company’s consolidated statements of operations and comprehensive loss as costs are incurred. Additionally, inventory that initially qualifies for capitalization but that may ultimately be used for the production of clinical drug product is expensed as research and development expense when it has been designated for the manufacture of clinical drug product. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of cell banks, plasmids, LVV, other materials and compounds sourced from third party suppliers and utilized in the manufacturing process, and drug product, which has been produced for the treatment of specific patients, that are owned by the Company. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management periodically reviews inventories for excess or obsolescence, considering factors such as sales forecasts compared to quantities on hand and firm purchase commitments as well as remaining shelf life of on hand inventories. The Company writes-down its inventory that is obsolete or otherwise unmarketable to its estimated net realizable value in the period in which the impairment is first identified. Any such adjustments are included as a component of cost of goods sold within cost of product revenue on the Company’s consolidated statements of operations and comprehensive loss.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“Topic 606”), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations.  Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options.  The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract).  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (“SSP”) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.  The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.  The Company assessed each of its revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue within the following financial statement captions:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes product revenue in accordance with Topic 606. Product revenue represents sales of ZYNTEGLO. In 2021, the Company distributed ZYNTEGLO directly to hospitals in Germany. The Company determined that contracted sales with hospitals formed a single performance obligation and it recognizes revenue from product sales at the point in time it satisfies the performance obligation, which is upon transferring control of ZYNTEGLO to the hospital. Control of the product generally transfers upon infusion of the product. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenue </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2021, the Company entered into a grant agreement with the Bill and Melinda Gates Foundation. The Company recognizes grant revenue in accordance with ASC 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue Recognition Not-for-Profit Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, when qualifying costs are incurred and barriers to restriction have been overcome. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. In addition, the Company entered into strategic collaborations and recognized an immaterial amount of revenue associated with those collaboration agreements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as costs are incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, clinical study and related clinical manufacturing costs, license and milestone fees, contract services, manufacturing costs for pre-launch inventory that did not qualify for capitalization, and other related costs. Up-front fees and milestones paid to third parties in connection with technologies which have not reached technological feasibility and do not have an alternative future use are expensed as research and development expense as incurred. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, laboratories, consultants, or other clinical trial vendors that perform the activities. Where amounts owed to a collaboration partner exceed the Company’s collaborative arrangement revenues in each quarterly period, such amounts are classified as research and development expense.</span></div> Cost of product revenue Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product revenue which are associated with the sale of ZYNTEGLO in Germany. Reserves for excess inventories are also included in cost of product revenue. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s share-based compensation programs grant awards that have included stock options, restricted stock units, restricted stock awards, unrestricted stock awards and shares issued under its employee stock purchase plan.  Grants are awarded to employees and non-employees, including the Company's board of directors.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation—Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 718”). ASC 718 requires all stock-based payments, including grants of stock options and restricted stock units and modifications to existing stock options, to be recognized in the consolidated statements of operations and comprehensive loss based on their fair values. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s stock-based awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards with performance-based vesting conditions is recognized based on the grant date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its option awards using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including (i) the expected stock price volatility, (ii) the calculation of expected term of the award, (iii) the risk-free interest rate, and (iv) expected dividends. Effective January 1, 2020, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility given that there is now a sufficient amount of historical information regarding the volatility of its own stock price. For both employee and non-employee awards, the measurement date is the date of grant. The Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which performance or service conditions are expected to be satisfied.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion and modification of equity awards outstanding at date of separation of 2seventy bio </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the separation of 2seventy bio on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the separation. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. The Company will recognize future expense for awards denominated in bluebird stock and 2seventy bio stock granted to the Company's employees as a result of the separation of 2seventy bio. Expense related to awards denominated in bluebird stock granted to 2seventy bio employees will be incurred by 2seventy bio.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to modified awards is measured based on the fair value for the awards as of the modification date. Any incremental stock-based compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite remaining service period, as appropriate.</span></div> Interest income, netInterest income, net consists primarily of interest income earned on investments, net of amortization of premium and accretion of discount. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of gains and losses on equity securities held by the Company, gains and losses on disposal of assets, and gains and losses on foreign currency.</span></div> <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per share is calculated by dividing net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration. Diluted net loss per share is calculated by dividing the net loss from continuing operations attributable to common stockholders, net loss from discontinued operations attributable to common stockholders and net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including the shares of common stock issuable upon the exercise of warrants that are exercisable for little or no consideration as well as any dilutive effect from outstanding stock options, unvested restricted stock, restricted stock units, and employee stock purchase plan stock using the treasury stock method. Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be anti-dilutive and are, therefore, excluded from the diluted net loss per share calculation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the two-class method when computing net loss per share in periods when issued shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders when participating securities are outstanding, losses are not allocated to the participating securities.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with FASB ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on debt securities, foreign currency translation adjustments and other items.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring expenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records costs and liabilities associated with exit and disposal activities in accordance with FASB ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 420"). Such costs are based on estimates of fair value in the period liabilities are incurred. The Company evaluates and adjusts these costs as appropriate for changes in circumstances as additional information becomes available. Refer to Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reduction in workforce,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently adopted</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-06”). ASU 2020-06 simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity's own equity. The Company early adopted the new standard, effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-08”) to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2017-08”). ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption. </span></div><div style="margin-top:12pt;text-indent:12.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-10, Codification Improvements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2020-10"). The amendments in this ASU represent changes to clarify the ASC, correct unintended application of the guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This new standard was effective beginning January 1, 2021. The adoption of ASU 2020-10 did not have a material impact on the Company's financial position or results of operations upon adoption.</span> Discontinued operations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of bluebird Research Triangle manufacturing facility</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company acquired a manufacturing facility in Durham, North Carolina ("bRT") for the future manufacture of LVV for the Company’s therapies related to its oncology programs. In July 2021, the Company and Resilience US, Inc., an affiliate of National Resilience, Inc. ("Resilience"), signed an Asset Purchase Agreement (the “Agreement”). As part of the Agreement, and upon the closing of the transaction which occurred in September 2021, Resilience acquired the Company's LVV manufacturing facility located in Durham, North Carolina and retained staff currently employed at the site. As a result of the transaction, the Company disposed of $111.2 million of net assets, primarily consisting of the building and laboratory equipment, that were associated with the Company's oncology programs. The Company recognized a loss on disposal of assets of $2.0 million. As the sale of the bRT manufacturing facility and the separation of 2seventy bio (as described below) were deemed to represent multiple components of a single disposal plan, the assets, liabilities and results of operations related to bRT have been included as a component of discontinued operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2seventy bio Separation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, the Company completed the previously announced separation of its oncology programs and portfolio, and the certain related assets and liabilities, into a separate, independent publicly traded company (the “Separation”). The Separation was effected by means of a distribution of all of the outstanding shares of common stock of 2seventy bio in which each bluebird stockholder received one share of common stock, par value $0.0001 per share, of 2seventy bio for every three shares of common stock, par value $0.01 per share, of bluebird held as of the close of business on October 19, 2021 (the “Distribution”).</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, bluebird entered into a separation agreement (the “Separation Agreement”) with 2seventy bio, dated as of November 3, 2021, that, among other things, set forth bluebird’s agreements with 2seventy bio regarding the principal actions to be taken in connection with the Separation, including the Distribution. The effective time of the Distribution was 12:01 a.m. on November 4, 2021. The Separation Agreement identified assets transferred to, liabilities assumed by and contracts assigned to 2seventy bio as part of the Separation, and it provided for when and how these transfers, assumptions and assignments occurred. The purpose of the Separation Agreement was to provide 2seventy bio and bluebird with assets to operate their respective businesses and retain or assume liabilities related to those assets. Each of 2seventy bio and bluebird agreed to releases, with respect to pre-Separation claims, and cross indemnities, with respect to post-Separation claims, that were principally designed to place financial responsibility for the obligations and liabilities allocated to 2seventy bio under the Separation Agreement with 2seventy bio and financial responsibility for the obligations and liabilities allocated to bluebird under the Separation Agreement with bluebird. bluebird and 2seventy bio are also each subject to mutual 12-month employee non-solicit and non-hire restrictions, subject to certain customary exceptions. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer of assets and liabilities to 2seventy bio was effected through a contribution in accordance with the Separation Agreement, as summarized below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of November 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets transferred to 2seventy bio</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">bluebird and 2seventy bio also entered into a tax matters agreement, dated as of November 3, 2021, governing bluebird’s and 2seventy bio's respective rights, responsibilities and obligations with respect to taxes (including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the distribution and certain related transactions to qualify as tax-free for U.S. federal income tax purposes), tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and assistance and cooperation in respect of tax matters.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, bluebird also entered into an employee matters agreement with 2seventy bio, dated as of November 3, 2021. The employee matters agreement allocates assets, liabilities and responsibilities relating to the employment, compensation and employee benefits of bluebird and 2seventy bio employees, and other related matters, in connection with the Separation, including the treatment of outstanding bluebird incentive equity awards and certain retirement and welfare benefit obligations. The employee matters agreement generally provides that, unless otherwise specified, 2seventy bio is responsible for liabilities associated with employees who transfer to 2seventy bio and employees whose employment terminated prior to the distribution but who primarily supported the 2seventy bio business, and bluebird is responsible for liabilities associated with other employees, including employees retained by bluebird. Pursuant to the employee matters agreement, the outstanding bluebird equity awards held by 2seventy bio and bluebird employees were adjusted immediately prior to the distribution, with the intent to maintain, immediately following the distribution, the economic value of the awards immediately before the distribution date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">bluebird and 2seventy bio also entered into an intellectual property license agreement on November 3, 2021, pursuant to which each party granted a license to certain intellectual property and technology to the other. bluebird granted 2seventy bio a perpetual, worldwide, non-exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property to allow 2seventy bio to use such intellectual property in connection with 2seventy bio's ongoing and future research and development activities and product candidates. 2seventy bio granted bluebird a perpetual, worldwide, non-</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">exclusive, royalty-free, fully paid-up license (or, as the case may be, sublicense) to certain intellectual property for use in bluebird’s existing products and product candidates. Such licenses between the parties generally allow current or future uses of the intellectual property in connection with each party's respective fields.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, bluebird entered into two transition services agreements with 2seventy bio, whose President is a member of the Company’s Board of Directors. . Pursuant to the transition service agreements, bluebird is obligated to provide and is entitled to receive certain transition services related to corporate functions, such as finance, human resources, internal audit, research and development, financial reporting, and information technology. Services provided by bluebird to 2seventy bio will continue for an initial term of up to two years, unless earlier terminated or extended according to the terms of the transition services agreement. Services received and performed are paid at a mutually agreed upon rate. Amounts received for services provided to 2seventy bio are recorded as other income and amounts paid for services provided by 2seventy bio are recorded as selling, general and administrative expense and research and development expense, as applicable. During the year ended December 31, 2021, the Company incurred $0.7 million of net expense for services provided by 2seventy bio within Research and development and Selling, general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2021, the Company had an immaterial amount of accounts receivable and accounts payable due from and to 2seventy bio.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company determined its oncology business, together with the bRT manufacturing facility, qualified for discontinued operations accounting treatment in accordance with ASC 205-20. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangement revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,734 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of collaboration loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of royalty and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,537 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,621)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no assets and liabilities related to discontinued operations as of December 31, 2021, as all balances were transferred to 2seventy bio upon Separation. The following table summarizes the assets and liabilities of the discontinued operations as of December 31, 2020 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,762 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities of discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,018 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on fixed assets disposal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Durham, North Carolina manufacturing facility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Durham, North Carolina manufacturing facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 111200000 2000000 0.0001 0.01 The transfer of assets and liabilities to 2seventy bio was effected through a contribution in accordance with the Separation Agreement, as summarized below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of November 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets transferred to 2seventy bio</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,145 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>The following table summarizes the assets and liabilities of the discontinued operations as of December 31, 2020 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,564 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets of discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,762 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration research advancement, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities of discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,018 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 174284000 160447000 8732000 21637000 365100000 106826000 33972000 10664000 6410000 255556000 5650000 784178000 2982000 85659000 6938000 8957000 104536000 25762000 16264000 257575000 1896000 406033000 378145000 2 P2Y 700000 The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2021, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative arrangement revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,734 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of collaboration loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of royalty and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,537 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,621)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table>The following table summarizes the significant non-cash items and capital expenditures of the discontinued operations that are included in the consolidated statements of cash flows for the years ended December 31, 2021, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on fixed assets disposal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Durham, North Carolina manufacturing facility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Durham, North Carolina manufacturing facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 18130000 114064000 30729000 18602000 115594000 5740000 5762000 21076000 8205000 42494000 250734000 44674000 204287000 268647000 255294000 82078000 46945000 35518000 10071000 0 0 2292000 5396000 2978000 387000 -6468000 2747000 299115000 314520000 296537000 -256621000 -63786000 -251863000 791000 5770000 17380000 910000 377000 103000 -256740000 -57639000 -234586000 -256740000 -57639000 -234586000 57076000 413947000 11754000 12244000 495021000 61446000 145458000 5644000 7482000 116456000 7078000 343564000 838585000 7791000 48716000 15313000 9236000 820000 81876000 25762000 21581000 112290000 1509000 161142000 243018000 387000 -6468000 2747000 14195000 13730000 12995000 29175000 34036000 29545000 -569000 -146000 -108000 -1986000 0 0 11256000 23159000 57196000 110300000 0 0 8500000 0 0 778000 2039000 3064000 151520000 4989000 9745000 Marketable securities<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held at December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost / cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,638 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,421)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No available-for-sale debt securities held as of December 31, 2021 or 2020 had remaining maturities greater than five years.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held at December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost / cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,638 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,421)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation. 128902000 0 509000 128393000 49366000 0 59000 49307000 54065000 0 0 54065000 4305000 0 614000 3691000 236638000 0 1182000 235456000 337521000 151000 37000 337635000 98585000 216000 20000 98781000 38975000 0 0 38975000 20017000 0 14364000 5653000 495098000 367000 14421000 481044000 0 0 Fair value measurements<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,282 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,391 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2021, cash and cash equivalents comprise funds in cash and money market accounts. As of December 31, 2020, cash and cash equivalents comprise funds in cash and money market accounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities and treasuries, corporate bonds, and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts. At December 31, 2021 and 2020, the balance in the Company’s accumulated other comprehensive loss was composed primarily of activity related to the Company’s available-for-sale debt securities. There were no material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended December 31, 2021 or 2020.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable on the Company's available-for-sale debt securities totaled $0.3 million and $1.5 million as of December 31, 2021 and 2020, respectively. No accrued interest receivable was written off during the twelve months ended December 31, 2021 or 2020.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months, and for which an allowance for credit losses has not been recorded at December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities <br/>   and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities <br/>   and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that there was no material change in the credit risk of the above investments during the twelve months ended December 31, 2021. As such, an allowance for credit losses was not recognized. As of December 31, 2021, the Company does not intend to sell such securities and it is not more likely than not that the Company will be required to sell the securities before recovery of their amortized cost bases.</span></div>The Company holds equity securities with an aggregate fair value of $3.7 million and $5.7 million at December 31, 2021 and 2020, respectively, within current marketable securities on its consolidated balance sheets. In January 2021, the Company sold a portion of its equity securities for proceeds of $31.3 million. The Company recorded gains of $29.4 million and losses of $7.2 million and $9.3 million related to its equity securities during the years ended December 31, 2021, 2020 and 2019, respectively. Gains and losses related to equity securities are included in other income (expense), net in the consolidated statements of operations and comprehensive loss. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:51.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>prices in<br/>active<br/>markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other<br/>observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,617 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,780 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,282 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,391 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div> 161160000 161146000 14000 0 128393000 0 128393000 0 49308000 0 49308000 0 54065000 0 54065000 0 3691000 3691000 0 0 396617000 164837000 231780000 0 260629000 260629000 0 0 337635000 0 337635000 0 98781000 0 98781000 0 38975000 0 38975000 0 5653000 5653000 0 0 741673000 266282000 475391000 0 0 0 300000 1500000 0 0 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months, and for which an allowance for credit losses has not been recorded at December 31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities <br/>   and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,392 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities <br/>   and treasuries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,991 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,594 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div> 108695000 505000 2496000 4000 111191000 509000 45042000 56000 3896000 2000 48938000 58000 153737000 561000 6392000 6000 160129000 567000 105692000 37000 0 0 105692000 37000 38299000 20000 603000 0 38902000 20000 143991000 57000 603000 0 144594000 57000 3700000 5700000 31300000 29400000 -7200000 -9300000 Inventory<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the Company recorded a reserve for excess inventories of $29.9 million, which is included within cost of product revenue in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2020, the Company did not record a reserve for excess inventories.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,967 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 8967000 0 1731000 0 10698000 29900000 0 Property, plant and equipment, net<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,514 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div>Depreciation and amortization expense related to property, plant and equipment was $4.9 million, $5.1 million, and $4.1 million for the years ended December 31, 2021, 2020, and 2019, respectively. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,514 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div> 29061000 27146000 421000 447000 117000 1077000 12000 5949000 501000 895000 30112000 35514000 20406000 18141000 9706000 17373000 4900000 5100000 4100000 Restricted cash<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company maintained letters of credit of $43.2 million and $54.5 million, respectively, which are collateralized with bank accounts at financial institutions in accordance with the agreements. Total restricted cash as of December 31, 2021 and 2020 consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 Binney Street lease</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembly Row lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 Binney Street lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on the Company's letters of credit.</span></div> 43200000 54500000 Total restricted cash as of December 31, 2021 and 2020 consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 Binney Street lease</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembly Row lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 Binney Street lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 40072000 40072000 40072000 2753000 2753000 0 0 13763000 2675000 2675000 2188000 45500000 56023000 Accrued expenses and other current liabilities<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued goods and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and contract research organization costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,958 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,190 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee compensation includes severance costs associated with the Company's orderly wind down of its European operations. As of December 31, 2021, the Company had accrued expenses of $4.7 million related to these restructuring costs. Please refer to Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reduction in workforce,</span> for further discussion. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued goods and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and contract research organization costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,958 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,190 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div> 41095000 41192000 24273000 14855000 17769000 20912000 15722000 15763000 1665000 1541000 2282000 1500000 1152000 2427000 103958000 98190000 4700000 Leases<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office and laboratory space. Additionally, the Company has embedded leases through its agreements with contract manufacturing organizations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">60 Binney Street lease &amp; sublease </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a consent to assignment and amendment to its lease agreement for its 60 Binney Street lease (the "Assignment"). The Assignment transfers the Company's interest in the lease to 2seventy bio and releases the Company from its obligation to maintain the $13.8 million collateralized letter of credit required under the original 60 Binney Street lease. Although the lease was legally transferred to 2seventy bio, the lessor required that the Company remain secondarily liable as a guarantor for payment obligations accruing under the 60 Binney Street lease from the date of Assignment until (i) the Company has completely vacated the premises and (ii) 2seventy bio has reached a market capitalization of $900 million. Upon Separation, the lease assignment was accounted for as the termination of the original lease and the Company de-recognized the right-of-use asset and lease liability related to the 60 Binney Street lease and recognized the fair value of the guarantee pursuant to ASC 405, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of the guarantee was not material.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the Assignment of the 60 Binney Street Lease, the Company entered into a sublease agreement with 2seventy bio for office, laboratory and storage space located at 60 Binney Street (the "60 Binney Street Sublease") while it constructs and outfits its new office and laboratory space. Under the terms of the 60 Binney Street Sublease, the Company will lease 72,988 square feet for $0.5 million per month in base rent for the period beginning from the Assignment through March 2022 and 58,004 square feet for $0.4 million per month in base rent for the period from April 2022 through March 2024. The Company accounted for the 60 Binney Street Sublease as a new lease under ASC 842, and in November 2021, recognized a right-of-use asset and lease liability related to the 60 Binney Street Sublease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">50 Binney Street sublease &amp; sub-sublease</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company entered into a sublease agreement for office space located at 50 Binney Street in Cambridge, Massachusetts (the “50 Binney Street Sublease”) to supplement the Company’s corporate headquarters located at 60 Binney Street in Cambridge, Massachusetts. Under the terms of the 50 Binney Street Sublease, the Company will lease 267,278 square feet of office space for $99.95 per square foot, or $26.7 million per year in base rent subject to certain operating expenses, taxes and annual rent increases of approximately 3%. The lease will commence when the space is available for use by the Company, which is anticipated to be in the first half of 2022, which reflects the sublessor's exercise of its option to postpone the commencement date of the sublease. The lease term will end on December 31, 2030, unless other specific circumstances specified in the 50 Binney Street Sublease occur. The Company will assess the lease classification of the 50 Binney Street Sublease and commence recognition of the associated rent expense at the lease commencement date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon signing the 50 Binney Street Sublease, the Company executed a $40.1 million cash-collateralized letter of credit, which may be reduced in the future subject to the terms of the 50 Binney Street Sublease and certain reduction requirements specified therein. The $40.1 million of cash collateralizing the letter of credit is classified as restricted cash and other non-current assets on the Company’s consolidated balance sheets. Payments will commence at the earlier of (i) the date which is 90 days following the commencement date and (ii) the date the Company takes occupancy of all or any portion of the premises. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 50 Binney Street Sublease, the Company also entered into a purchase agreement for furniture and equipment (the “Furniture Purchase Agreement”) located on the premises upon lease commencement. Upon execution of the Furniture Purchase Agreement, the Company made an upfront payment of $7.5 million, all of which was recorded within restricted cash and other non-current assets on the Company’s consolidated balance sheets and assessed for recoverability on a recurring basis. The Company will be required to make another $7.5 million payment under the Furniture Purchase Agreement upon lease commencement. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a sub-sublease agreement (the "Sub-Sublease") with Meta Platforms, Inc. (“Meta”). Under the terms of the Sub-Sublease, the Company is subleasing the entirety of the 50 Binney Street premises which it has rights to under the 50 Binney Street Sublease. The Company is sub-subleasing the premises for $28.0 million in the first year with 3% annual increases in each subsequent year. Meta will receive access to 50 Binney Street at the lease commencement date, which is the same point that the Company would receive access under the 50 Binney Street Sublease. The Company remains liable under the 50 Binney Street Sublease, including for maintenance of the $40.1 million collateralized </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">letter of credit. As a result of the execution of the Sub-Sublease, the Company assessed the $7.5 million deposit related to the Furniture Purchase Agreement for recoverability and determined that the amount was not recoverable. As a result, the Company recorded $7.5 million in the Company's consolidated statements of operations and comprehensive loss as selling, general and administrative expense during the year ended December 31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assembly Row lease</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company entered into a lease agreement with Assembly Row 5B, LLC ("Landlord") for office space located at 455 Grand Union Boulevard in Somerville, Massachusetts to serve as the Company's future corporate headquarters. Under the terms of the arrangement, the Company will lease approximately 61,180 square feet starting at an annual rate of $45 per square foot, subject to annual increases of 2.5%, plus operating expenses and taxes. In addition, the Company will be eligible for a tenant work allowance of $160 per rentable square foot of the premises. The lease will commence on the date on which the Landlord tenders possession of the premises to the Company with any tenant work required to be performed by the Landlord substantially completed, which is anticipated to occur in the first half of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into a manufacturing agreement for the future commercial production of the Company’s beti-cel and eli-cel drug products with a contract manufacturing organization. Under this 12-year agreement, the contract manufacturing organization will complete the design, construction, validation and process validation of the leased suites prior to anticipated commercial launch of the product candidates. During construction, the Company paid $12.0 million upon the achievement of certain contractual milestones. Construction was completed in March 2018 and beginning in April 2018, the Company pays $5.1 million per year, subject to annual inflationary adjustments, in fixed suite fees, as well as certain fixed labor, raw materials, testing and shipping costs for manufacturing services. The Company may terminate this agreement at any time upon payment of a one-time termination fee and up to 24 months of fixed suite and labor fees. The Company concluded in prior periods that this agreement contained an embedded lease as the suites are designated for the Company’s exclusive use during the term of the agreement. The Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company entered into an agreement for clinical and commercial production of the Company’s beti-cel, lovo-cel, and eli-cel drug products with a contract manufacturing organization at an existing facility. The Company concluded that this agreement contains an embedded operating lease as the clean rooms are designated for the Company’s exclusive use during the term of the agreement. The term of the agreement is five years with subsequent three-year renewals at the mutual option of each party. As a result, the Company recorded a right-of-use asset and lease liability for this operating lease on the effective date of ASC 842, and is recognizing rent expense on a straight-line basis throughout the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining term of the embedded lease. In March 2020, the Company amended its agreement with the contract manufacturing organization, resulting in a lease modification. Under the terms of the amended agreement, the Company may be required to pay annual maintenance and production fees of up to €16.5 million, depending on its production needs, and may terminate this agreement with twelve months’ notice and a one-time termination fee. In September 2021, the Company reassessed the term of this lease in light of the planned orderly wind down of its operations in Europe. As a result, the Company reduced the right-of-use asset and related lease liability to reflect a shortened expected term of the agreement. In November 2021, the Company exercised its right to terminate the lease agreement, and such termination will be effective in November 2022. Per the terms of the amended agreement, the Company was obligated to pay a one-time termination fee of €1.0 million upon termination, which was paid in December 2021. In connection with this termination, the Company will pay for services properly rendered through the date of termination in accordance with the contract manufacturing agreement, based on work completed and expenses incurred prior to the date of termination. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $5.4 million per year in maintenance fees in addition to the cost of any services provided and may terminate this agreement with eighteen months' notice. The agreement commenced in March 2021, and it has a term of five years with the option to extend. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in March 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease. </span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into another agreement reserving manufacturing capacity with a contract manufacturing organization. The Company concluded that this agreement contains an embedded lease as a controlled </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">environment room at the facility is designated for the Company's exclusive use during the term of the agreement, with the option to sublease the space if the Company provides notice that it will not utilize it for a specified duration of time. Under the terms of the agreement, the Company will be required to pay up to $4.2 million per year in maintenance fees and an immaterial amount of other annual fees as well as per-batch fees for the cost of any services provided. Either party may terminate this agreement with eighteen months’ notice at any time or with eight months’ notice after stage 5 has commenced. The term of the agreement is five years, with the option to extend, and it commenced in November 2021. The Company classified the embedded lease as an operating lease and recognized a right-of-use asset and lease liability upon lease commencement in November 2021 and is recognizing rent expense on a straight-line basis throughout the remaining term of the embedded lease. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of all lease costs recognized under ASC 842</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows used for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term lease costs and variable lease costs incurred by the Company for the twelve months ended December 31, 2021, 2020 and 2019 were immaterial.</span></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under all leases, including additional charges for utilities, parking, maintenance, and real estate taxes, was $36.2 million, $24.2 million, and $23.3 million for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future minimum commitments under ASC 842 under the Company’s operating leases were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(12,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above table excludes legally binding minimum lease payments for leases executed but not yet commenced as of December 31, 2021.</span></div> 13800000 900000000 72988 500000 58004 400000 267278 99.95 26700000 0.03 40100000 40100000 P90D 7500000 7500000 28000000 0.03 40100000 7500000 7500000 61180 45 0.025 160 P12Y 12000000 5100000 P24M P5Y P3Y 16500000 P12M 1000000 5400000 P18M P5Y 4200000 P18M P8M P5Y <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating leases for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows used for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term lease costs and variable lease costs incurred by the Company for the twelve months ended December 31, 2021, 2020 and 2019 were immaterial.</span></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div> 25067000 18660000 20005000 25067000 18660000 20005000 22805000 17780000 17205000 P4Y8M12D P6Y3M18D P7Y3M18D 0.0502 0.0598 0.0666 36200000 24200000 23300000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future minimum commitments under ASC 842 under the Company’s operating leases were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Maturity of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(12,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 27037000 21460000 18009000 14639000 8598000 12356000 102099000 12515000 89584000 Commitments and contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease commitments</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office and laboratory space and has embedded leases at contract manufacturing organizations. Refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on the terms of these lease agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other funding commitments</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specified products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of December 31, 2021, the Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with the Company's collaboration and license agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. When the achievement of these milestones or sales have not occurred, such contingencies are not recorded in the Company’s financial statements. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various manufacturing development and license agreements to support clinical and commercial product needs. The following table presents non-cancelable contractual obligations arising from these arrangements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase<br/>commitment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,821 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is party to various claims and complaints arising in the ordinary course of business, including securities class action litigation. The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is generally unlimited. Management does not believe that any ultimate liability resulting from any of these claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, management cannot give any assurance regarding the ultimate outcome of any claims, and their resolution could be material to operating results for any particular period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and by-laws. The term of the indemnification period lasts as long as such officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations.</span></div> The following table presents non-cancelable contractual obligations arising from these arrangements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase<br/>commitment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,821 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 43903000 9918000 0 53821000 EquityThe Company is authorized to issue 125.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by the Company’s board of directors, and to share ratably in the Company’s assets legally available for distribution to the Company’s shareholders in the <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. As of December 31, 2021 and 2020, the Company had 71.1 million and 66.4 million shares of common stock issued and outstanding, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an equity purchase agreement with certain investors, pursuant to which the Company agreed to sell and issue, in a private placement offering of securities, an aggregate of (i) 2.3 million shares of the Company’s common stock at a purchase price per share of $16.50 and (ii) pre-funded warrants to purchase up to 2.3 million shares of common stock (the “Pre-Funded Warrants”) at an effective price of $16.49 per share ($16.49 paid to the Company upon the closing of the offering and $0.01 to be paid upon exercise of such Pre-Funded Warrants). This resulted in aggregate gross proceeds to the Company of approximately $75.0 million. The Pre-Funded Warrants can be exercised at any time or times on or after September 7, 2021, until exercised in full. The Pre-Funded Warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480 and ASC 815. Based on the terms of the Pre-Funded Warrants, management concluded that they should be classified within stockholders' equity on its consolidated balance sheets, with no subsequent remeasurement as long as the underlying warrant agreements are not modified or amended. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 5.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by the Company’s shareholders. As of December 31, 2021 and 2020, the Company had no shares of preferred stock issued or outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserved for future issuance</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved for future issuance the following number of shares of common stock (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock options and restricted stock units that are reserved for future issuance include awards outstanding to employees of 2seventy bio.</span></div> 125000000 1 71100000 71100000 66400000 66400000 2300000 16.50 2300000 16.49 16.49 0.01 75000000 5000000 0 0 0 0 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved for future issuance the following number of shares of common stock (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock options and restricted stock units that are reserved for future issuance include awards outstanding to employees of 2seventy bio.</span></div> 5534000 6262000 3427000 1495000 2250000 2545000 2273000 0 1347000 67000 14831000 10369000 Intangible assets<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, are summarized as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-licensed rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-licensed rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $0.4 million, $0.5 million, and $0.3 million for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div>In August 2021, the Company announced its decision to focus its efforts on the U.S. market and to execute an orderly wind down of its European operations. In connection with this, in September 2021, the Company recognized an impairment loss of $4.0 million for the remaining unamortized balance of the intangible asset associated with in-licensed rights for the ZYNTEGLO product, which is reflected within cost of product revenue in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, are summarized as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-licensed rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-licensed rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span> 5224000 1219000 4005000 0 5224000 1219000 4005000 0 5224000 827000 0 4397000 5224000 827000 0 4397000 400000 500000 300000 4000000 Stock-based compensation<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, the Company’s board of directors adopted its 2013 Stock Option and Incentive Plan (“2013 Plan”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 Plan replaces the 2010 Stock Option and Grant Plan (“2010 Plan”).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2013 Plan allows for the granting of incentive stock options, non-qualified stock options, restricted stock units and restricted stock awards to the Company’s employees, members of the board of directors, and consultants of the Company. The Company initially reserved 1.0 million shares of its common stock for the issuance of awards under the 2013 Plan. The 2013 Plan provides that the number of shares reserved and available for issuance under the 2013 Plan will automatically increase each January 1, beginning on January 1, 2014, by four percent of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s compensation committee. In January 2021 and January 2022, the number of common stock available for issuance under the 2013 Plan was increased by approximately 2.7 million and 2.8 million shares, respectively, as a result of this automatic increase provision.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any options or awards outstanding under the Company’s previous stock option plans, including both the 2010 Plan and the Second Amended and Restated 2002 Employee, Director and Consultant Stock Plan (“2002 Plan”), at the time of adoption of the 2013 Plan remain outstanding and effective. The shares of common stock underlying any awards that are forfeited, canceled, repurchased, expired or are otherwise terminated (other than by exercise) under the 2002 Plan and 2010 Plan are added to the shares of common stock available for issuance under the 2013 Plan. As of December 31, 2021, the total number of common stock that may be issued under all plans is 3.2 million.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not currently hold any treasury shares. Upon stock option exercise, the Company issues new shares and delivers them to the participant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion and modification of equity awards outstanding at the Separation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation on November 4, 2021, under the provisions of the existing plans, the Company adjusted its outstanding equity awards in accordance with the terms of the Employee Matters Agreement (an equitable adjustment) to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units (“RSUs”) and performance restricted stock units (“PRSUs”) denominated in pre-Distribution bluebird stock received a number of otherwise-similar awards either in post-Distribution bluebird stock or in a combination of post-Distribution bluebird stock and 2seventy bio stock based on conversion ratios outlined for each group of employees in the Employee Matters Agreement that the Company entered into in connection with the Distribution. The equity awards that were granted prior to 2021 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both bluebird and 2seventy bio. The conversion ratio for the shareholder method took into consideration a distribution ratio of one share of 2seventy bio common stock for every three shares of bluebird common stock. For equity awards granted in 2021, the number of awards that were outstanding at the Separation were proportionately adjusted to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the volume weighted-average trading price for bluebird common stock for the five trading days before and after the Separation. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Due to the modification of the equity awards as a result of the Distribution, the Company compared the fair value of the outstanding equity awards immediately before and after the Distribution. The modification resulted in an incremental fair value of $20.3 million, of which $4.5 million was immediately recognized as of the Distribution date. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, bluebird will not incur any future compensation cost related to equity awards held by 2seventy bio employees and directors. The Company will incur future compensation cost related to 2seventy bio equity awards held by bluebird employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense totaling $98.7 million, $122.6 million, and $131.1 million during the years ended December 31, 2021, 2020 and 2019, respectively. Stock-based compensation expense recognized by award type is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,660 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,837 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,912 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,767 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,123 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,313 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,636 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,740 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,596 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,083 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,989 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,766 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,378 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,751 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,830 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,705 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,740 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,596 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,083 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation of $1.0 million was capitalized into inventory during the year ended December 31, 2021. Stock-based compensation of $0.5 million was capitalized into inventory during the year ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrestricted stock awards</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company granted 0.4 million unrestricted stock awards to employees as part of its 2020 annual incentive program. In addition, the Company implemented a retention program designed to incentivize and retain employees through the separation of its severe genetic disease and oncology programs. Under the retention program, employees are entitled to a one-time bonus payment, consisting of both a cash payment and unrestricted stock awards, with the condition that the employee remains employed at the end of 2021. For the twelve months ended December 31, 2021, the Company recognized $21.2 million in expense related to this program, which includes $10.6 million in stock compensation expense related to the anticipated grants of stock. During the third quarter of 2021, the Company granted 0.1 million unrestricted stock awards, related to the retention program, to those employees impacted by the orderly wind down of the Company's operations in Europe. During the fourth quarter of 2021, the Company granted 1.0 million unrestricted stock awards to employees as part of its retention program.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had $34.2 million and $54.3 million of unrecognized compensation expense related to unvested stock options and restricted stock units (exclusive of those with service and performance conditions that have not yet been achieved), respectively, that is expected to be recognized over a weighted-average period of 2.19 years and 2.26 years, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option issued to employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value (a)<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.02 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.82 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion and modification of awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt">Pursuant to the terms of Employee Matters Agreement, the company granted 4,375 option conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December 31, 2021, 2020 and 2019 was $16.32, $43.24, and $83.44, respectively. The intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $5.1 million, $4.0 million and $29.0 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock unit activity under the Company’s equity award plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.34 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.21 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion and modification of awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.91pt">Pursuant to the terms of Employee Matters Agreement, the company granted 3,327 restricted stock unit conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $44.0 million, $30.9 million and $28.4 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, the Company’s board of directors adopted its 2013 Employee Stock Purchase Plan (“2013 ESPP”), which was subsequently approved by its stockholders and became effective upon the closing of the Company’s IPO. The 2013 ESPP authorizes the initial issuance of up to a total of 0.2 million shares of the Company’s common stock to participating employees. In June 2021, the Company amended the 2013 ESPP to authorize an additional 1.4 million shares of the Company’s common stock available to participating employees. During each of the years ended December 31, 2021 and 2020, approximately 0.1 million shares of common stock were issued under the 2013 ESPP.</span></div> 1000000 0.04 2700000 2800000 3200000 20300000 4500000 98700000 122600000 131100000 Stock-based compensation expense recognized by award type is as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,660 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,837 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,912 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,767 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,123 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,313 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,636 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,740 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,596 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,083 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 54660000 75837000 79912000 30767000 38123000 50158000 13313000 8636000 1013000 98740000 122596000 131083000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,989 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,766 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,378 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,751 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,830 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,705 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,740 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,596 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,083 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 42989000 49766000 59378000 55751000 72830000 71705000 98740000 122596000 131083000 1000000 500000 400000 21200000 10600000 100000 1000000 34200000 54300000 P2Y2M8D P2Y3M3D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option issued to employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.667 0.695 0.707 P6Y P6Y P6Y 0.008 0.014 0.023 0.000 0.000 0.000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value (a)<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.02 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.82 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,357)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion and modification of awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2021. </span></div>(b)Pursuant to the terms of Employee Matters Agreement, the company granted 4,375 option conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table. 6262000 105.02 1238000 27.19 218000 6.82 2357000 81.20 1339000 42.90 3586000 39.23 P6Y9M18D 631000 1835000 57.09 P5Y6M 380000 3586000 39.23 P6Y9M18D 631000 4375 16.32 43.24 83.44 5100000 4000000 29000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock unit activity under the Company’s equity award plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.34 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.21 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(987)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion and modification of awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(a)Pursuant to the terms of Employee Matters Agreement, the company granted 3,327 restricted stock unit conversion awards to bluebird employees which are reflected within the "Conversion and modification of awards" above. The weighted-average exercise price per share reflected above is related to these awards, rather than the number of awards reflected in the table. 1495000 102.34 3359000 26.43 526000 112.21 987000 53.58 148000 16.84 3193000 16.21 3327 44000000 30900000 28400000 200000 1400000 100000 100000 401(k) Savings planIn 1997, the Company established a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. In March 2022, the Company expects to make matching contributions of approximately $2.8 million related to employee contributions made during 2021. At the same time, the Company anticipates making matching contributions to 2seventy bio employees of $2.0 million for their contributions under the 401(k) Plan during 2021 through the Separation. In March 2021, the Company made $6.0 million of matching contributions related to employee contributions made during 2020. The match contribution is included in accrued expenses and other current liabilities as of December 31, 2021 and 2020.  Expense related to the 401(k) Plan from continuing operations totaled $2.8 million, $3.0 million, $2.9 million for the years ended December 31, 2021, 2020, and 2019, respectively. 2800000 2000000 6000000 2800000 3000000 2900000 Income taxes<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,976)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,981)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562,380)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560,370)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555,567)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company’s effective income tax rate as reflected in the financial statements is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, the Company recognized an income tax expense (benefit) of $0.3 million or 0.0%, $0.7 million or (0.1)%, and $(0.5) million or 0.1%, respectively.  The Company did not recognize any significant tax expense for the years ended December 31, 2021, 2020, or 2019 as the Company was subject to a full valuation allowance. Tax expense associated with the sale of bRT and the Separation, accounted for as discontinued operations and discussed in Note 3, is $0 for the years ended December 31, 2021, 2020, or 2019 due to the full valuation allowance. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets and liabilities are composed of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. net operating loss carryforwards (federal and state)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards (federal and state)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized license fees and research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-right:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets. The valuation allowance increased on a net basis by approximately $183.4 million during the year ended December 31, 2021 due primarily to net operating losses, tax credit carryforwards, and stock-based compensation, offset by the sale of bRT and the Separation. Effective January 1, 2021, the Company adopted ASU 2019-12, which simplifies accounting for income taxes. There was no material impact on the Company's financial position or results of operations upon adoption. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of approximately $2.63 billion, $2.03 billion, and $1.62 billion, respectively, which may be available to offset future income tax liabilities. Of the amount as of December 31, 2021, $1.92 billion will carryforward indefinitely while $711.0 million will expire at various dates through 2037. As of December 31, 2021, 2020 and 2019, the Company also had U.S. state net operating loss </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards of approximately $2.39 billion, $1.89 billion, and $1.56 billion, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2041. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019, the Company had federal research and development and orphan drug tax credit carryforwards of approximately $268.3 million, $235.3 million, and $203.1 million, respectively, available to reduce future tax liabilities which expire at various dates through 2041. As of December 31, 2021, 2020 and 2019, the Company had state credit carryforwards of approximately $16.9 million, $14.5 million, and $13.6 million, respectively, available to reduce future tax liabilities which expire at various dates through 2036. During the fourth quarter of 2018, the Company completed an analysis of prior year estimates of U.S. research and development and orphan drug tax credits for the years 2013 through 2017. The analysis resulted in an immaterial adjustment to the Company's income tax benefit, which was offset by an adjustment to the valuation allowance. An analysis of the U.S. research and development and orphan drug credits has not yet been completed for 2019, 2020, or 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was enacted. This law temporarily suspends and adjusts certain law changes enacted in the Tax Cuts and Jobs Act in 2017. In December 2020, the Consolidated Appropriations Act was enacted. This law modified the employee retention credit under the CARES Act and created credit extenders for certain credits. In March 2021, the American Rescue Plan Act ("ARPA") was enacted and contained extenders to the refundable employee retention credit and provided further limitations to executive compensation effective for tax years beginning after 2026. The Company has concluded that the provisions in the CARES Act, Consolidated Appropriations Act, and ARPA have an immaterial impact on the Company’s income tax expense due to its cumulative losses and full valuation allowance position.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which it believes has resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code. The Company completed a study through December 2020 confirming no additional ownership changes; any ownership shifts occurring after December 2020 could result in an ownership change under Section 382.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files Federal income tax returns in the United States, and various state and foreign jurisdictions. The federal, state and foreign income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized tax benefits</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,945 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to current period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to prior periods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,994 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to current period</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to prior periods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,960 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized tax benefits at December 31, 2021, if recognized, would not affect the Company’s effective tax rate due to its full valuation allowance position. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company has elected to include interest and penalties related to uncertain tax positions as a component of its provision for income taxes. For the years ended December 31, 2021, 2020 and 2019, the Company’s accrued interest and penalties related to uncertain tax positions were not material.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,976)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,981)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562,380)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560,370)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555,567)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -487404000 -431452000 -414586000 -74976000 -128918000 -140981000 -562380000 -560370000 -555567000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 0 2000 7000 258000 684000 612000 0 0 -966000 0 0 -198000 0 0 0 258000 686000 -545000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to the Company’s effective income tax rate as reflected in the financial statements is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.210 0.210 0.210 0.039 0.031 0.037 -0.006 -0.006 -0.008 -0.031 -0.024 -0.007 0.043 0.060 0.054 -0.019 -0.046 -0.037 0 -0.003 0.008 -0.236 -0.223 -0.256 0 -0.001 0.001 300000 0.000 700000 -0.001 -500000 0.001 0 0 0 The significant components of the Company’s deferred tax assets and liabilities are composed of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. net operating loss carryforwards (federal and state)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards (federal and state)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized license fees and research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,044)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.</span> 703125000 546098000 281687000 246742000 2237000 1558000 604000 398000 25181000 37164000 22916000 14787000 15598000 12894000 1051348000 859641000 23053000 15044000 1546000 1212000 1026749000 843385000 0 0 183400000 2630000000 2030000000.00 1620000000 1920000000 711000000 2390000000 1890000000 1560000000 268300000 235300000 203100000 16900000 14500000 13600000 P3Y 0.50 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized tax benefits</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,945 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to current period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to prior periods</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,994 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to current period</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) for tax positions related to prior periods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,960 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 15945000 3149000 100000 18994000 2949000 17000 21960000 0 0 0 Reduction in workforce<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced its decision to withdraw ZYNTEGLO from the German market because reimbursement negotiations in Germany did not result in a price for ZYNTEGLO that reflects the value of the one-time gene therapy with potential life-long benefit for people living with β-thalassemia requiring regular transfusions. A total of approximately 50 employees were impacted by this reduction. During the three months ended June 30, 2021, the Company substantially completed the implementation of this reduction and, in accordance with ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit and Disposal Activities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, recorded approximately $4.6 million of costs including severance, the portion of the employees' 2021 retention bonuses to be paid in cash, and the pro rata portion of the employees' 2021 performance bonus.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company made the decision to focus its efforts on the U.S. market for beti-cel, eli-cel, and lovo-cel and is executing an orderly wind down of its European operations. A total of approximately 90 employees were impacted by the reduction in workforce associated with this decision. The Company recorded $21.2 million of expense, in accordance with the related accounting standards mentioned above, for the affected employees. This amount includes expense for severance, the pro rata portion of the employees' 2021 performance bonus, the portion of the European employees' 2021 retention bonuses to be paid in cash, and the portion of retention bonuses to be paid in unrestricted stock awards, which were granted on September 30, 2021. As described in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded $2.5 million of costs associated with the grant of unrestricted stock awards to affected employees as a one-time payment. All costs associated with the April 2021 and July 2021 reductions are reflected within restructuring expense in the Company's consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all accrued restructuring charges will be paid in cash by March 31, 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts accrued<br/>at December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021 reduction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021 reduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded approximately $25.8 million in restructuring expenses. During the year ended December 31, 2021, the Company recorded $2.5 million in research and development expenses and selling, general and administrative expenses related to the grant of unrestricted stock awards to affected employees.</span></div> 50 4600000 90 21200000 2500000 <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts accrued<br/>at December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021 reduction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021 reduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,801 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4625000 4625000 0 21176000 16503000 4673000 25801000 21128000 4673000 25800000 2500000 Net loss per share<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.</span></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.</span></div> 5534000 6262000 5483000 3427000 1495000 1127000 0 326000 19000 8961000 8083000 6629000 Selected quarterly financial data (unaudited)<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains quarterly financial information for 2021 and 2020. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,844 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,973)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,834)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,327)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562,638)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,808)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,702)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,816)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from continuing operations<br/>—basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from discontinued operations—basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,665)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,678)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,321)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,611)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,465)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,745)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(618,695)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from continuing operations<br/>—basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share from discontinued operations—basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.86)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains quarterly financial information for 2021 and 2020. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,988 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,844 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,273 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,973)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,834)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,327)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562,638)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,808)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,702)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,816)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,052)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from continuing operations<br/>—basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from discontinued operations—basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,743 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,479)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,665)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,678)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,321)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,611)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,465)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,745)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,874)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(618,695)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share from continuing operations<br/>—basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.05)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share from discontinued operations—basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.86)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share—basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 894000 143000 1019000 1606000 3662000 146988000 154844000 155468000 137273000 594573000 -146094000 -154701000 -154449000 -135667000 -590911000 -121504000 -155973000 -152834000 -132327000 -562638000 -84304000 -85729000 -63982000 -22725000 -256740000 -205808000 -241702000 -216816000 -155052000 -819378000 -1.81 -1.81 -2.31 -2.31 -2.23 -2.23 -1.83 -1.83 -8.16 -8.16 -1.26 -1.26 -1.27 -1.27 -0.93 -0.93 -0.31 -0.31 -3.73 -3.73 -3.07 -3.07 -3.58 -3.58 -3.16 -3.16 -2.14 -2.14 -11.89 -11.89 0 0 0 0 0 144479000 143650000 131743000 139387000 559259000 -144479000 -143650000 -131743000 -139387000 -559259000 -146392000 -140665000 -137678000 -136321000 -561056000 -56219000 119200000 -57067000 -63553000 -57639000 -202611000 -21465000 -194745000 -199874000 -618695000 -2.63 -2.63 -2.33 -2.33 -2.08 -2.08 -2.05 -2.05 -9.02 -9.02 -1.01 -1.01 1.97 1.97 -0.86 -0.86 -0.96 -0.96 -0.93 -0.93 -3.64 -3.64 -0.36 -0.36 -2.94 -2.94 -3.01 -3.01 -9.95 -9.95 EXCEL 109 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 110 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 111 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 112 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 250 558 1 false 70 0 false 12 false false R1.htm 0001001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://www.bluebirdbio.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 1001003 - Statement - Consolidated Balance Sheets Sheet http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Uncategorized 3 false false R4.htm 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Cover 4 false false R5.htm 1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 5 false false R6.htm 1004006 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 1105101 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 9 false false R10.htm 2101102 - Disclosure - Description of the business Sheet http://www.bluebirdbio.com/role/Descriptionofthebusiness Description of the business Notes 10 false false R11.htm 2103103 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.bluebirdbio.com/role/Summaryofsignificantaccountingpoliciesandbasisofpresentation Summary of significant accounting policies and basis of presentation Notes 11 false false R12.htm 2108104 - Disclosure - Discontinued operations Sheet http://www.bluebirdbio.com/role/Discontinuedoperations Discontinued operations Notes 12 false false R13.htm 2114105 - Disclosure - Marketable securities Sheet http://www.bluebirdbio.com/role/Marketablesecurities Marketable securities Notes 13 false false R14.htm 2118106 - Disclosure - Fair value measurements Sheet http://www.bluebirdbio.com/role/Fairvaluemeasurements Fair value measurements Notes 14 false false R15.htm 2123107 - Disclosure - Inventory Sheet http://www.bluebirdbio.com/role/Inventory Inventory Notes 15 false false R16.htm 2126108 - Disclosure - Property, plant and equipment, net Sheet http://www.bluebirdbio.com/role/Propertyplantandequipmentnet Property, plant and equipment, net Notes 16 false false R17.htm 2130109 - Disclosure - Restricted cash Sheet http://www.bluebirdbio.com/role/Restrictedcash Restricted cash Notes 17 false false R18.htm 2134110 - Disclosure - Accrued expenses and other current liabilities Sheet http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities Accrued expenses and other current liabilities Notes 18 false false R19.htm 2138111 - Disclosure - Leases Sheet http://www.bluebirdbio.com/role/Leases Leases Notes 19 false false R20.htm 2143112 - Disclosure - Commitments and contingencies Sheet http://www.bluebirdbio.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 20 false false R21.htm 2146113 - Disclosure - Equity Sheet http://www.bluebirdbio.com/role/Equity Equity Notes 21 false false R22.htm 2150114 - Disclosure - Intangible assets Sheet http://www.bluebirdbio.com/role/Intangibleassets Intangible assets Notes 22 false false R23.htm 2154115 - Disclosure - Stock-based compensation Sheet http://www.bluebirdbio.com/role/Stockbasedcompensation Stock-based compensation Notes 23 false false R24.htm 2162116 - Disclosure - 401(k) Savings plan Sheet http://www.bluebirdbio.com/role/A401kSavingsplan 401(k) Savings plan Notes 24 false false R25.htm 2164117 - Disclosure - Income taxes Sheet http://www.bluebirdbio.com/role/Incometaxes Income taxes Notes 25 false false R26.htm 2172118 - Disclosure - Reduction in workforce Sheet http://www.bluebirdbio.com/role/Reductioninworkforce Reduction in workforce Notes 26 false false R27.htm 2176119 - Disclosure - Net loss per share Sheet http://www.bluebirdbio.com/role/Netlosspershare Net loss per share Notes 27 false false R28.htm 2179120 - Disclosure - Selected quarterly financial data (unaudited) Sheet http://www.bluebirdbio.com/role/Selectedquarterlyfinancialdataunaudited Selected quarterly financial data (unaudited) Notes 28 false false R29.htm 2204201 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies Summary of significant accounting policies and basis of presentation (Policies) Policies 29 false false R30.htm 2305301 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) Sheet http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationTables Summary of significant accounting policies and basis of presentation (Tables) Tables http://www.bluebirdbio.com/role/Summaryofsignificantaccountingpoliciesandbasisofpresentation 30 false false R31.htm 2309302 - Disclosure - Discontinued operations (Tables) Sheet http://www.bluebirdbio.com/role/DiscontinuedoperationsTables Discontinued operations (Tables) Tables http://www.bluebirdbio.com/role/Discontinuedoperations 31 false false R32.htm 2315303 - Disclosure - Marketable securities (Tables) Sheet http://www.bluebirdbio.com/role/MarketablesecuritiesTables Marketable securities (Tables) Tables http://www.bluebirdbio.com/role/Marketablesecurities 32 false false R33.htm 2319304 - Disclosure - Fair value measurements (Tables) Sheet http://www.bluebirdbio.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://www.bluebirdbio.com/role/Fairvaluemeasurements 33 false false R34.htm 2324305 - Disclosure - Inventory (Tables) Sheet http://www.bluebirdbio.com/role/InventoryTables Inventory (Tables) Tables http://www.bluebirdbio.com/role/Inventory 34 false false R35.htm 2327306 - Disclosure - Property, plant and equipment, net (Tables) Sheet http://www.bluebirdbio.com/role/PropertyplantandequipmentnetTables Property, plant and equipment, net (Tables) Tables http://www.bluebirdbio.com/role/Propertyplantandequipmentnet 35 false false R36.htm 2331307 - Disclosure - Restricted cash (Tables) Sheet http://www.bluebirdbio.com/role/RestrictedcashTables Restricted cash (Tables) Tables http://www.bluebirdbio.com/role/Restrictedcash 36 false false R37.htm 2335308 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesTables Accrued expenses and other current liabilities (Tables) Tables http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities 37 false false R38.htm 2339309 - Disclosure - Leases (Tables) Sheet http://www.bluebirdbio.com/role/LeasesTables Leases (Tables) Tables http://www.bluebirdbio.com/role/Leases 38 false false R39.htm 2344310 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.bluebirdbio.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://www.bluebirdbio.com/role/Commitmentsandcontingencies 39 false false R40.htm 2347311 - Disclosure - Equity (Tables) Sheet http://www.bluebirdbio.com/role/EquityTables Equity (Tables) Tables http://www.bluebirdbio.com/role/Equity 40 false false R41.htm 2351312 - Disclosure - Intangible assets (Tables) Sheet http://www.bluebirdbio.com/role/IntangibleassetsTables Intangible assets (Tables) Tables http://www.bluebirdbio.com/role/Intangibleassets 41 false false R42.htm 2355313 - Disclosure - Stock-based compensation (Tables) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://www.bluebirdbio.com/role/Stockbasedcompensation 42 false false R43.htm 2365314 - Disclosure - Income taxes (Tables) Sheet http://www.bluebirdbio.com/role/IncometaxesTables Income taxes (Tables) Tables http://www.bluebirdbio.com/role/Incometaxes 43 false false R44.htm 2373315 - Disclosure - Reduction in workforce (Tables) Sheet http://www.bluebirdbio.com/role/ReductioninworkforceTables Reduction in workforce (Tables) Tables http://www.bluebirdbio.com/role/Reductioninworkforce 44 false false R45.htm 2377316 - Disclosure - Net loss per share (Tables) Sheet http://www.bluebirdbio.com/role/NetlosspershareTables Net loss per share (Tables) Tables http://www.bluebirdbio.com/role/Netlosspershare 45 false false R46.htm 2380317 - Disclosure - Selected quarterly financial data (unaudited) (Tables) Sheet http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedTables Selected quarterly financial data (unaudited) (Tables) Tables http://www.bluebirdbio.com/role/Selectedquarterlyfinancialdataunaudited 46 false false R47.htm 2402401 - Disclosure - Description of the business - Additional Information (Detail) Sheet http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail Description of the business - Additional Information (Detail) Details 47 false false R48.htm 2406402 - Disclosure - Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail) Sheet http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail) Details 48 false false R49.htm 2407403 - Disclosure - Summary of significant accounting policies and basis of presentation - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationNarrativeDetail Summary of significant accounting policies and basis of presentation - Narrative (Detail) Details http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationTables 49 false false R50.htm 2410404 - Disclosure - Discontinued operations - Narrative (Details) Sheet http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails Discontinued operations - Narrative (Details) Details 50 false false R51.htm 2411405 - Disclosure - Discontinued operations - Revenue and Expenses (Details) Sheet http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails Discontinued operations - Revenue and Expenses (Details) Details 51 false false R52.htm 2412406 - Disclosure - Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details) Sheet http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details) Details 52 false false R53.htm 2413407 - Disclosure - Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details) Sheet http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details) Details 53 false false R54.htm 2416408 - Disclosure - Marketable securities - Summary of Marketable Securities Held (Detail) Sheet http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail Marketable securities - Summary of Marketable Securities Held (Detail) Details 54 false false R55.htm 2417409 - Disclosure - Marketable securities - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/MarketablesecuritiesNarrativeDetail Marketable securities - Narrative (Detail) Details 55 false false R56.htm 2420410 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 56 false false R57.htm 2421411 - Disclosure - Fair value measurements - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail Fair value measurements - Narrative (Detail) Details 57 false false R58.htm 2422412 - Disclosure - Fair value measurements - Schedule of Unrealized Loss on Investments (Details) Sheet http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails Fair value measurements - Schedule of Unrealized Loss on Investments (Details) Details 58 false false R59.htm 2425413 - Disclosure - Inventory (Details) Sheet http://www.bluebirdbio.com/role/InventoryDetails Inventory (Details) Details http://www.bluebirdbio.com/role/InventoryTables 59 false false R60.htm 2428414 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail) Sheet http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail) Details 60 false false R61.htm 2429415 - Disclosure - Property, plant and equipment, net - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/PropertyplantandequipmentnetNarrativeDetail Property, plant and equipment, net - Narrative (Detail) Details 61 false false R62.htm 2432416 - Disclosure - Restricted cash - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail Restricted cash - Narrative (Detail) Details 62 false false R63.htm 2433417 - Disclosure - Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail) Sheet http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail) Details 63 false false R64.htm 2436418 - Disclosure - Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) Details 64 false false R65.htm 2437419 - Disclosure - Accrued expenses and other current liabilities - Narrative (Details) Sheet http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails Accrued expenses and other current liabilities - Narrative (Details) Details 65 false false R66.htm 2440420 - Disclosure - Leases - Narrative (Details) Sheet http://www.bluebirdbio.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 66 false false R67.htm 2441421 - Disclosure - Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details) Sheet http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details) Details 67 false false R68.htm 2442422 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details) Sheet http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details) Details 68 false false R69.htm 2445423 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) Sheet http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail) Details 69 false false R70.htm 2448424 - Disclosure - Equity - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/EquityNarrativeDetail Equity - Narrative (Detail) Details 70 false false R71.htm 2449425 - Disclosure - Equity - Summary of Future Issuance of Common Stock Shares (Detail) Sheet http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail Equity - Summary of Future Issuance of Common Stock Shares (Detail) Details 71 false false R72.htm 2452426 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) Details 72 false false R73.htm 2453427 - Disclosure - Intangible assets - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail Intangible assets - Narrative (Detail) Details 73 false false R74.htm 2456428 - Disclosure - Stock-based compensation - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail Stock-based compensation - Narrative (Detail) Details 74 false false R75.htm 2457429 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail) Details 75 false false R76.htm 2458430 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail) Details 76 false false R77.htm 2459431 - Disclosure - Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail) Details 77 false false R78.htm 2460432 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail) Details 78 false false R79.htm 2461433 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Detail) Sheet http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail Stock-based compensation - Summary of Restricted Stock Units (Detail) Details 79 false false R80.htm 2463434 - Disclosure - 401(k) Savings plan - Additional Information (Detail) Sheet http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail 401(k) Savings plan - Additional Information (Detail) Details 80 false false R81.htm 2466435 - Disclosure - Income taxes - Schedule of Components of Loss Before Income Taxes (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail Income taxes - Schedule of Components of Loss Before Income Taxes (Detail) Details 81 false false R82.htm 2467436 - Disclosure - Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail) Details 82 false false R83.htm 2468437 - Disclosure - Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail) Details 83 false false R84.htm 2469438 - Disclosure - Income taxes - Narrative (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail Income taxes - Narrative (Detail) Details 84 false false R85.htm 2470439 - Disclosure - Income taxes - Components of Deferred Tax Assets and Liabilities (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail Income taxes - Components of Deferred Tax Assets and Liabilities (Detail) Details 85 false false R86.htm 2471440 - Disclosure - Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail) Sheet http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail) Details 86 false false R87.htm 2474441 - Disclosure - Reduction in workforce - Narrative (Details) Sheet http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails Reduction in workforce - Narrative (Details) Details 87 false false R88.htm 2475442 - Disclosure - Reduction in workforce - Accrued Liabilities Activity (Details) Sheet http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails Reduction in workforce - Accrued Liabilities Activity (Details) Details 88 false false R89.htm 2478443 - Disclosure - Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) Details 89 false false R90.htm 2481444 - Disclosure - Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail) Sheet http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail) Details http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedTables 90 false false All Reports Book All Reports blue-20211231.htm blue-20211231.xsd blue-20211231_cal.xml blue-20211231_def.xml blue-20211231_lab.xml blue-20211231_pre.xml blue-20211231xex1023.htm blue-20211231xex1024.htm blue-20211231xex1025.htm blue-20211231xex1026.htm blue-20211231xex1027.htm blue-20211231xex1036.htm blue-20211231xexx231.htm blue-20211231xexx311.htm blue-20211231xexx312.htm blue-20211231xexx321.htm blue-20211231_g1.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 115 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blue-20211231.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 250, "dts": { "calculationLink": { "local": [ "blue-20211231_cal.xml" ] }, "definitionLink": { "local": [ "blue-20211231_def.xml" ] }, "inline": { "local": [ "blue-20211231.htm" ] }, "labelLink": { "local": [ "blue-20211231_lab.xml" ] }, "presentationLink": { "local": [ "blue-20211231_pre.xml" ] }, "schema": { "local": [ "blue-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 677, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://www.bluebirdbio.com/20211231": 1, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 11 }, "keyCustom": 79, "keyStandard": 479, "memberCustom": 31, "memberStandard": 35, "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.bluebirdbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101102 - Disclosure - Description of the business", "role": "http://www.bluebirdbio.com/role/Descriptionofthebusiness", "shortName": "Description of the business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103103 - Disclosure - Summary of significant accounting policies and basis of presentation", "role": "http://www.bluebirdbio.com/role/Summaryofsignificantaccountingpoliciesandbasisofpresentation", "shortName": "Summary of significant accounting policies and basis of presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - Discontinued operations", "role": "http://www.bluebirdbio.com/role/Discontinuedoperations", "shortName": "Discontinued operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Marketable securities", "role": "http://www.bluebirdbio.com/role/Marketablesecurities", "shortName": "Marketable securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - Fair value measurements", "role": "http://www.bluebirdbio.com/role/Fairvaluemeasurements", "shortName": "Fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Inventory", "role": "http://www.bluebirdbio.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Property, plant and equipment, net", "role": "http://www.bluebirdbio.com/role/Propertyplantandequipmentnet", "shortName": "Property, plant and equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130109 - Disclosure - Restricted cash", "role": "http://www.bluebirdbio.com/role/Restrictedcash", "shortName": "Restricted cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134110 - Disclosure - Accrued expenses and other current liabilities", "role": "http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities", "shortName": "Accrued expenses and other current liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138111 - Disclosure - Leases", "role": "http://www.bluebirdbio.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://www.bluebirdbio.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143112 - Disclosure - Commitments and contingencies", "role": "http://www.bluebirdbio.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146113 - Disclosure - Equity", "role": "http://www.bluebirdbio.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150114 - Disclosure - Intangible assets", "role": "http://www.bluebirdbio.com/role/Intangibleassets", "shortName": "Intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154115 - Disclosure - Stock-based compensation", "role": "http://www.bluebirdbio.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162116 - Disclosure - 401(k) Savings plan", "role": "http://www.bluebirdbio.com/role/A401kSavingsplan", "shortName": "401(k) Savings plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164117 - Disclosure - Income taxes", "role": "http://www.bluebirdbio.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172118 - Disclosure - Reduction in workforce", "role": "http://www.bluebirdbio.com/role/Reductioninworkforce", "shortName": "Reduction in workforce", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176119 - Disclosure - Net loss per share", "role": "http://www.bluebirdbio.com/role/Netlosspershare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2179120 - Disclosure - Selected quarterly financial data (unaudited)", "role": "http://www.bluebirdbio.com/role/Selectedquarterlyfinancialdataunaudited", "shortName": "Selected quarterly financial data (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies)", "role": "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies", "shortName": "Summary of significant accounting policies and basis of presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001003 - Statement - Consolidated Balance Sheets", "role": "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "blue:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables)", "role": "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationTables", "shortName": "Summary of significant accounting policies and basis of presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "blue:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:DistributionOfAssetsLiabilitiesAndStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Discontinued operations (Tables)", "role": "http://www.bluebirdbio.com/role/DiscontinuedoperationsTables", "shortName": "Discontinued operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:DistributionOfAssetsLiabilitiesAndStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Marketable securities (Tables)", "role": "http://www.bluebirdbio.com/role/MarketablesecuritiesTables", "shortName": "Marketable securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Fair value measurements (Tables)", "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsTables", "shortName": "Fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Inventory (Tables)", "role": "http://www.bluebirdbio.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - Property, plant and equipment, net (Tables)", "role": "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetTables", "shortName": "Property, plant and equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Restricted cash (Tables)", "role": "http://www.bluebirdbio.com/role/RestrictedcashTables", "shortName": "Restricted cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335308 - Disclosure - Accrued expenses and other current liabilities (Tables)", "role": "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesTables", "shortName": "Accrued expenses and other current liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339309 - Disclosure - Leases (Tables)", "role": "http://www.bluebirdbio.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344310 - Disclosure - Commitments and contingencies (Tables)", "role": "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesTables", "shortName": "Commitments and contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "blue:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347311 - Disclosure - Equity (Tables)", "role": "http://www.bluebirdbio.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "blue:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351312 - Disclosure - Intangible assets (Tables)", "role": "http://www.bluebirdbio.com/role/IntangibleassetsTables", "shortName": "Intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355313 - Disclosure - Stock-based compensation (Tables)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2365314 - Disclosure - Income taxes (Tables)", "role": "http://www.bluebirdbio.com/role/IncometaxesTables", "shortName": "Income taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2373315 - Disclosure - Reduction in workforce (Tables)", "role": "http://www.bluebirdbio.com/role/ReductioninworkforceTables", "shortName": "Reduction in workforce (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2377316 - Disclosure - Net loss per share (Tables)", "role": "http://www.bluebirdbio.com/role/NetlosspershareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2380317 - Disclosure - Selected quarterly financial data (unaudited) (Tables)", "role": "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedTables", "shortName": "Selected quarterly financial data (unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i3da8e3f36e3946cb992a9e04e8aa36fe_I20211104", "decimals": "INF", "first": true, "lang": "en-US", "name": "blue:NumberOfCompanies", "reportCount": 1, "unique": true, "unitRef": "company", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Description of the business - Additional Information (Detail)", "role": "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail", "shortName": "Description of the business - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i3da8e3f36e3946cb992a9e04e8aa36fe_I20211104", "decimals": "INF", "first": true, "lang": "en-US", "name": "blue:NumberOfCompanies", "reportCount": 1, "unique": true, "unitRef": "company", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i9f29447c1682432a827094d02bcb36d7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail)", "role": "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail", "shortName": "Summary of significant accounting policies and basis of presentation - Estimated Useful Lives of Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i9f29447c1682432a827094d02bcb36d7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of significant accounting policies and basis of presentation - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationNarrativeDetail", "shortName": "Summary of significant accounting policies and basis of presentation - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Discontinued operations - Narrative (Details)", "role": "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "shortName": "Discontinued operations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia5fc9c95cdb642b093df4c0a688eff14_I20211103", "decimals": "INF", "lang": "en-US", "name": "blue:NumberOfTransitionServicesAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i5023ecb19b9240ae99275338980d38b2_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Discontinued operations - Revenue and Expenses (Details)", "role": "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "shortName": "Discontinued operations - Revenue and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i6514a1dc71564defa5e60616f40e1c64_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details)", "role": "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "shortName": "Discontinued operations - Assets, Liabilities and Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i010b16e09d434d7794b27614c78daa40_I20211104", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details)", "role": "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails", "shortName": "Discontinued operations - Significant Non-Cash Items and Capital Expenditures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i6514a1dc71564defa5e60616f40e1c64_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Marketable securities - Summary of Marketable Securities Held (Detail)", "role": "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail", "shortName": "Marketable securities - Summary of Marketable Securities Held (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Marketable securities - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/MarketablesecuritiesNarrativeDetail", "shortName": "Marketable securities - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "shortName": "Fair value measurements - Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i416f981194864af89001342ac0963566_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Fair value measurements - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail", "shortName": "Fair value measurements - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Fair value measurements - Schedule of Unrealized Loss on Investments (Details)", "role": "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails", "shortName": "Fair value measurements - Schedule of Unrealized Loss on Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Inventory (Details)", "role": "http://www.bluebirdbio.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004006 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428414 - Disclosure - Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail)", "role": "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "shortName": "Property, plant and equipment, net - Summary of Property, Plant and Equipment Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Property, plant and equipment, net - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetNarrativeDetail", "shortName": "Property, plant and equipment, net - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Restricted cash - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail", "shortName": "Restricted cash - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i55a96d9c69a342758d81fcc7c6d5f419_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail)", "role": "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail", "shortName": "Restricted cash - Schedule of Collateralized Bank Account of Financial Institution (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RestrictedCashAndCashEquivalents", "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i2b119423fd55450a9776403cd2662f9b_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail", "shortName": "Accrued expenses and other current liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Accrued expenses and other current liabilities - Narrative (Details)", "role": "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails", "shortName": "Accrued expenses and other current liabilities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "if552d29a925f427fbcaad5d1849ca8e3_I20190430", "decimals": "2", "first": true, "lang": "en-US", "name": "blue:LesseeOperatingLeaseAnnualRentIncreasePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Leases - Narrative (Details)", "role": "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "if552d29a925f427fbcaad5d1849ca8e3_I20190430", "decimals": "2", "first": true, "lang": "en-US", "name": "blue:LesseeOperatingLeaseAnnualRentIncreasePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details)", "role": "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails", "shortName": "Leases - Summary of Lease Costs and Other Information Pertaining to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details)", "role": "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails", "shortName": "Leases - Schedule of Future Minimum Commitments Under Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445423 - Disclosure - Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail)", "role": "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail", "shortName": "Commitments and contingencies - Schedule of Non-cancelable Contractual Obligations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "idffa06911647459ab72047656333b21d_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "idffa06911647459ab72047656333b21d_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448424 - Disclosure - Equity - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/EquityNarrativeDetail", "shortName": "Equity - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "INF", "lang": "en-US", "name": "blue:CommonStockNumberOfVotesPerCommonShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "blue:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449425 - Disclosure - Equity - Summary of Future Issuance of Common Stock Shares (Detail)", "role": "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "shortName": "Equity - Summary of Future Issuance of Common Stock Shares (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "blue:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452426 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)", "role": "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails", "shortName": "Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453427 - Disclosure - Intangible assets - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "shortName": "Intangible assets - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i92748d2fb3644a059437dca69277a8fa_D20210101-20210131", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456428 - Disclosure - Stock-based compensation - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "shortName": "Stock-based compensation - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i92748d2fb3644a059437dca69277a8fa_D20210101-20210131", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457429 - Disclosure - Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail", "shortName": "Stock-based compensation - Summary of Stock-Based Compensation Expense by Award Type (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458430 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail", "shortName": "Stock-based compensation - Schedule of Stock-Based Compensation Expense by Classification (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i129166dac589431191224ebe7716cac9_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459431 - Disclosure - Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail", "shortName": "Stock-based compensation - Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie6f969b1b3554adebf8c3fae3a886415_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460432 - Disclosure - Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail", "shortName": "Stock-based compensation - Summary of Stock Option Activity Under Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie6f969b1b3554adebf8c3fae3a886415_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie8b07caab7e0414eb37ae3fd685dc383_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461433 - Disclosure - Stock-based compensation - Summary of Restricted Stock Units (Detail)", "role": "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail", "shortName": "Stock-based compensation - Summary of Restricted Stock Units (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i22ef529e0c05445e82eba7dc7b7e5c09_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie992c3b5ba774206bb970cce319a14dd_D20210301-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463434 - Disclosure - 401(k) Savings plan - Additional Information (Detail)", "role": "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "shortName": "401(k) Savings plan - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie992c3b5ba774206bb970cce319a14dd_D20210301-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466435 - Disclosure - Income taxes - Schedule of Components of Loss Before Income Taxes (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail", "shortName": "Income taxes - Schedule of Components of Loss Before Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467436 - Disclosure - Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail", "shortName": "Income taxes - Summary of Provision for (Benefit from) Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468437 - Disclosure - Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail", "shortName": "Income taxes - Reconciliation of Income Tax Provision (Benefit) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469438 - Disclosure - Income taxes - Narrative (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail", "shortName": "Income taxes - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "0", "lang": "en-US", "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470439 - Disclosure - Income taxes - Components of Deferred Tax Assets and Liabilities (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail", "shortName": "Income taxes - Components of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia95682afeb2d42409a8ec32563916312_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ie6f969b1b3554adebf8c3fae3a886415_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471440 - Disclosure - Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail)", "role": "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail", "shortName": "Income taxes - Reconciliation of Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i3435e04b45e04afca1f2683602738361_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474441 - Disclosure - Reduction in workforce - Narrative (Details)", "role": "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "shortName": "Reduction in workforce - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i4bc768ec01a6414d9b7b026389dfc244_D20210401-20210430", "decimals": "INF", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475442 - Disclosure - Reduction in workforce - Accrued Liabilities Activity (Details)", "role": "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "shortName": "Reduction in workforce - Accrued Liabilities Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478443 - Disclosure - Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "role": "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail", "shortName": "Net loss per share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "iae1cb185b3e145e4a259a8549647742c_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia16cc7edf768406489e2bd454d77615c_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1105101 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "ia16cc7edf768406489e2bd454d77615c_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i5023ecb19b9240ae99275338980d38b2_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481444 - Disclosure - Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail)", "role": "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail", "shortName": "Selected quarterly financial data (unaudited) - Quarterly Financial Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blue-20211231.htm", "contextRef": "i5023ecb19b9240ae99275338980d38b2_D20211001-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "blue_A2020AnnualIncentiveProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Annual Incentive Program", "label": "2020 Annual Incentive Program [Member]", "terseLabel": "2020 Annual Incentive Program" } } }, "localname": "A2020AnnualIncentiveProgramMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "blue_A2seventyBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2seventy bio", "label": "2seventy bio [Member]", "terseLabel": "2seventy bio" } } }, "localname": "A2seventyBioMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "blue_AccruedClinicalAndContractResearchOrganizationCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued clinical and contract research organization costs current.", "label": "Accrued Clinical And Contract Research Organization Costs Current", "terseLabel": "Accrued clinical and contract research organization costs" } } }, "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_AccruedGoodsAndServicesCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Goods and Services, Current", "label": "Accrued Goods and Services, Current", "terseLabel": "Accrued goods and services" } } }, "localname": "AccruedGoodsAndServicesCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_AccruedManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued manufacturing costs current.", "label": "Accrued Manufacturing Costs Current", "terseLabel": "Accrued manufacturing costs" } } }, "localname": "AccruedManufacturingCostsCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_AccumulatedOtherComprehensiveIncomeNetGainLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income net gain loss.", "label": "Accumulated Other Comprehensive Income Net Gain Loss [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeNetGainLossMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "blue_AdjustmentsToAdditionalPaidInCapitalSeparationOfAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid In Capital, Separation Of Assets", "label": "Adjustments to Additional Paid In Capital, Separation Of Assets", "terseLabel": "Distribution of 2seventy bio" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSeparationOfAssets", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "blue_April2021ReductionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 2021 Reduction", "label": "April 2021 Reduction [Member]", "terseLabel": "April 2021 reduction" } } }, "localname": "April2021ReductionMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_AreaOfLeasedSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of leased space.", "label": "Area Of Leased Space", "terseLabel": "Lease building space (in sq ft)" } } }, "localname": "AreaOfLeasedSpace", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "blue_AssemblyRowLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembly Row Lease", "label": "Assembly Row Lease [Member]", "terseLabel": "Assembly Row lease" } } }, "localname": "AssemblyRowLeaseMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "domainItemType" }, "blue_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.bluebirdbio.com/20211231", "xbrltype": "stringItemType" }, "blue_ClassOfWarrantOrRightEffectivePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Effective Price Per Share", "label": "Class Of Warrant Or Right, Effective Price Per Share", "terseLabel": "Warrant price per share (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightEffectivePricePerShare", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "perShareItemType" }, "blue_CollaborationArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration arrangement.", "label": "Collaboration Arrangement [Member]", "terseLabel": "Collaborative arrangement revenue" } } }, "localname": "CollaborationArrangementMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "domainItemType" }, "blue_CommonStockConvertibleConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Convertible, Conversion Ratio", "label": "Common Stock, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "CommonStockConvertibleConversionRatio", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "pureItemType" }, "blue_CommonStockNumberOfVotesPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Number Of Votes, Per Common Share", "label": "Common Stock, Number Of Votes, Per Common Share", "terseLabel": "Common stock, number of votes (in votes per share)" } } }, "localname": "CommonStockNumberOfVotesPerCommonShare", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "integerItemType" }, "blue_CommonStockWarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Warrants", "label": "Common Stock Warrants [Policy Text Block]", "terseLabel": "Common stock warrants" } } }, "localname": "CommonStockWarrantsPolicyTextBlock", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "blue_ComponentsOfIncomeTaxExpenseBenefitLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of income tax expense benefit.", "label": "Components Of Income Tax Expense Benefit [Line Items]", "terseLabel": "Components Of Income Tax Expense Benefit [Line Items]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitLineItems", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "stringItemType" }, "blue_ComponentsOfIncomeTaxExpenseBenefitTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of income tax expense benefit.", "label": "Components Of Income Tax Expense Benefit [Table]", "terseLabel": "Components Of Income Tax Expense Benefit [Table]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitTable", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "stringItemType" }, "blue_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "blue_ContractualObligationMilestonePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation milestone paid.", "label": "Contractual Obligation Milestone Paid", "terseLabel": "Milestone paid" } } }, "localname": "ContractualObligationMilestonePaid", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_CostOfProductRevenuePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Product Revenue Policy", "label": "Cost of Product Revenue Policy [Policy Text Block]", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfProductRevenuePolicyPolicyTextBlock", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "blue_DebtSecuritiesAvailableForSaleFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Fair Value", "label": "Debt Securities, Available-for-sale, Fair Value [Abstract]", "terseLabel": "Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueAbstract", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "stringItemType" }, "blue_DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Capitalized License Fee And Research And Development Expenses", "terseLabel": "Capitalized license fees and research and development expenses" } } }, "localname": "DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_DeferredTaxAssetsStockBasedCompensation": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Stock Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsStockBasedCompensation", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationLiability": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration, Liability", "label": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationLiability", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationCollaborationResearchAdvancementCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Current", "label": "Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Current", "terseLabel": "Collaboration research advancement, current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCollaborationResearchAdvancementCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationCollaborationResearchAdvancementNoncurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Collaboration Research Advancement, Noncurrent", "terseLabel": "Collaboration research advancement, net of current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCollaborationResearchAdvancementNoncurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationMarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Marketable Securities, Current", "label": "Disposal Group, Including Discontinued Operation, Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationMarketableSecuritiesCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationMarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Marketable Securities, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Marketable Securities, Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationMarketableSecuritiesNoncurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationNetAssetsTransferred": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Net Assets Transferred", "label": "Disposal Group, Including Discontinued Operation, Net Assets Transferred", "terseLabel": "Net assets transferred to 2seventy bio", "totalLabel": "Net assets transferred to 2seventy bio" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNetAssetsTransferred", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current", "terseLabel": "Operating lease liability, current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 5.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Assets", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Right-of-Use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Prepaid Expenses", "label": "Disposal Group, Including Discontinued Operation, Prepaid Expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidExpenses", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationReceivablesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Receivables and Other Current Assets", "label": "Disposal Group, Including Discontinued Operation, Receivables and Other Current Assets", "terseLabel": "Receivables and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationReceivablesAndOtherCurrentAssets", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blue_DisposalGroupIncludingDiscontinuedOperationShareOfCollaborationLoss": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Share of Collaboration Loss", "label": "Disposal Group, Including Discontinued Operation, Share of Collaboration Loss", "terseLabel": "Share of collaboration loss" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationShareOfCollaborationLoss", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blue_EffectiveIncomeTaxRateReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent differences.", "label": "Effective Income Tax Rate Reconciliation Permanent Differences", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "blue_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation tax credits research and development.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research And Development", "terseLabel": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "blue_EmployeeAndNonEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee and non employee stock option.", "label": "Employee And Non Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeAndNonEmployeeStockOptionMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail" ], "xbrltype": "domainItemType" }, "blue_EmployeeStockPurchasePlanAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan And Other", "label": "Employee Stock Purchase Plan And Other [Member]", "terseLabel": "ESPP shares and other" } } }, "localname": "EmployeeStockPurchasePlanAndOtherMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "blue_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee stock purchase plan and other" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail" ], "xbrltype": "domainItemType" }, "blue_EquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 2.0, "parentTag": "blue_MarketableSecuritiesUnrealizedGains", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity securities unrealized gain.", "label": "Equity Securities Unrealized Gain", "terseLabel": "Equity securities, unrealized gains" } } }, "localname": "EquitySecuritiesUnrealizedGain", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "blue_EquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 2.0, "parentTag": "us-gaap_EquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity securities unrealized loss.", "label": "Equity Securities Unrealized Loss", "negatedLabel": "Equity securities, unrealized losses" } } }, "localname": "EquitySecuritiesUnrealizedLoss", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "blue_FiftyBinneyStreetLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifty Binney Street Lease", "label": "Fifty Binney Street Lease [Member]", "terseLabel": "50 Binney Street lease" } } }, "localname": "FiftyBinneyStreetLeaseMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "domainItemType" }, "blue_FiftyBinneyStreetSubleaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifty Binney Street Sublease", "label": "Fifty Binney Street Sublease [Member]", "terseLabel": "50 Binney Street sublease" } } }, "localname": "FiftyBinneyStreetSubleaseMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_FiniteLivedIntangibleAssetsAccumulatedImpairment": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets, Accumulated Impairment", "label": "Finite-Lived Intangible Assets, Accumulated Impairment", "negatedTerseLabel": "Impairment" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "blue_FourHundredAndOneKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four hundred and one k.", "label": "Four Hundred And One K [Member]", "terseLabel": "401 (k)" } } }, "localname": "FourHundredAndOneKMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "blue_InLicensedRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-licensed Rights", "label": "In-licensed Rights [Member]", "terseLabel": "In-licensed rights" } } }, "localname": "InLicensedRightsMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "blue_IncreaseDecreaseInCollaborationResearchAdvancement": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Increase Decrease In Collaboration Research Advancement", "negatedLabel": "Collaboration research advancement" } } }, "localname": "IncreaseDecreaseInCollaborationResearchAdvancement", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blue_InterestReceivableWriteOff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest Receivable, Write-Off", "label": "Interest Receivable, Write-Off", "terseLabel": "Interest receivable, write-off" } } }, "localname": "InterestReceivableWriteOff", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "blue_July2021ReductionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2021 Reduction", "label": "July 2021 Reduction [Member]", "terseLabel": "July 2021 reduction" } } }, "localname": "July2021ReductionMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "blue_LeaseArrangementsAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease arrangements annual increase percentage.", "label": "Lease Arrangements Annual Increase Percentage", "terseLabel": "Lease rent, annual increase percentage" } } }, "localname": "LeaseArrangementsAnnualIncreasePercentage", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "blue_LeaseArrangementsAnnualLeasePaymentPerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease arrangements annual lease payment per square foot.", "label": "Lease Arrangements, Annual Lease Payment Per Square Foot", "terseLabel": "Annual lease rent per square foot (in dollars per sq ft)" } } }, "localname": "LeaseArrangementsAnnualLeasePaymentPerSquareFoot", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "perUnitItemType" }, "blue_LeaseArrangementsTenantWorkAllowancePerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements, Tenant Work Allowance Per Square Foot", "label": "Lease Arrangements, Tenant Work Allowance Per Square Foot", "terseLabel": "Tenant work allowance (in dollars per sq ft)" } } }, "localname": "LeaseArrangementsTenantWorkAllowancePerSquareFoot", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "perUnitItemType" }, "blue_LentiviralVectorManufacturingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lentiviral Vector Manufacturing Facility", "label": "Lentiviral Vector Manufacturing Facility [Member]", "terseLabel": "Lentiviral Vector Manufacturing Facility" } } }, "localname": "LentiviralVectorManufacturingFacilityMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_LesseeIncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Increase (Decrease) In Operating Lease, Liabilities", "label": "Lessee, Increase (Decrease) In Operating Lease, Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "LesseeIncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blue_LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset", "label": "Lessee, Increase (Decrease) In Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseAnnualExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Expense", "label": "Lessee, Operating Lease, Annual Expense", "terseLabel": "Lessee, operating lease, annual expense" } } }, "localname": "LesseeOperatingLeaseAnnualExpense", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseAnnualRentIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Rent Increase Percentage", "label": "Lessee, Operating Lease, Annual Rent Increase Percentage", "terseLabel": "Lease arrangements annual rent increase percentage" } } }, "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "blue_LesseeOperatingLeaseMaximumPotentialAnnualMaintenanceAndProductionFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Maximum Potential Annual Maintenance And Production Fees", "label": "Lessee, Operating Lease, Maximum Potential Annual Maintenance And Production Fees", "terseLabel": "Lessee, operating lease, maximum potential annual maintenance and production fees" } } }, "localname": "LesseeOperatingLeaseMaximumPotentialAnnualMaintenanceAndProductionFees", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseMaximumPotentialAnnualMaintenanceFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Maximum Potential Annual Maintenance Fees", "label": "Lessee, Operating Lease, Maximum Potential Annual Maintenance Fees", "terseLabel": "Lessee, operating lease, maximum potential annual maintenance fees" } } }, "localname": "LesseeOperatingLeaseMaximumPotentialAnnualMaintenanceFees", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseMonthlyExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Monthly Expense", "label": "Lessee, Operating Lease, Monthly Expense", "terseLabel": "Lessee, operating lease, monthly expense" } } }, "localname": "LesseeOperatingLeaseMonthlyExpense", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseTerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Termination Fee", "label": "Lessee, Operating Lease, Termination Fee", "terseLabel": "Payment of termination fee" } } }, "localname": "LesseeOperatingLeaseTerminationFee", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LesseeOperatingLeaseTerminationFeesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Termination Fees, Term", "label": "Lessee, Operating Lease, Termination Fees, Term", "terseLabel": "Lessee, operating lease, termination fees, term" } } }, "localname": "LesseeOperatingLeaseTerminationFeesTerm", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "blue_LesseeOperatingLeaseTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Termination Notice Period", "label": "Lessee, Operating Lease, Termination Notice Period", "terseLabel": "Lessee, operating lease, termination notice period" } } }, "localname": "LesseeOperatingLeaseTerminationNoticePeriod", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "blue_LesseeOperatingLeaseTerminationNoticePeriodAfterStage5Commencement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Termination Notice Period, After Stage 5 Commencement", "label": "Lessee, Operating Lease, Termination Notice Period, After Stage 5 Commencement", "terseLabel": "Lessee, operating lease, termination notice period, after stage 5 commencement" } } }, "localname": "LesseeOperatingLeaseTerminationNoticePeriodAfterStage5Commencement", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "blue_LesseeOperatingSubleasePaymentCommencementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Sublease, Payment Commencement, Term", "label": "Lessee, Operating Sublease, Payment Commencement, Term", "terseLabel": "Lessee, operating sublease, payment commencement, term" } } }, "localname": "LesseeOperatingSubleasePaymentCommencementTerm", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "blue_LetterOfCreditRelatedToNewLeaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Letter of credit related to new lease agreement.", "label": "Letter Of Credit Related To New Lease Agreement", "terseLabel": "Collateralized letter of credit" } } }, "localname": "LetterOfCreditRelatedToNewLeaseAgreement", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_LossOnUnrecoverableUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on Unrecoverable Upfront Payment", "label": "Loss on Unrecoverable Upfront Payment", "terseLabel": "Loss on unrecoverable upfront payment" } } }, "localname": "LossOnUnrecoverableUpfrontPayment", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_MarketCapitalizationRequiredForReleaseOfLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Market Capitalization Required for Release of Liability", "label": "Market Capitalization Required for Release of Liability", "terseLabel": "Market capitalization required for release of liability" } } }, "localname": "MarketCapitalizationRequiredForReleaseOfLiability", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_MarketableSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Marketable securities amortized cost.", "label": "Marketable Securities Amortized Cost", "totalLabel": "Marketable securities, amortized cost / cost" } } }, "localname": "MarketableSecuritiesAmortizedCost", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "blue_MarketableSecuritiesUnrealizedGains": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail_1": { "order": 1.0, "parentTag": "blue_MarketableSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Marketable securities unrealized gains.", "label": "Marketable Securities Unrealized Gains", "totalLabel": "Marketable securities, unrealized gains" } } }, "localname": "MarketableSecuritiesUnrealizedGains", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "blue_MarketableSecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail_1": { "order": 2.0, "parentTag": "blue_MarketableSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Marketable securities unrealized loss.", "label": "Marketable Securities Unrealized Loss", "negatedTotalLabel": "Marketable securities, unrealized losses" } } }, "localname": "MarketableSecuritiesUnrealizedLoss", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "blue_NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnChangeInOwnershipMinimumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating losses and tax credit carryforwards limitations on change In ownership minimum percentage.", "label": "Net Operating Losses And Tax Credit Carryforwards Limitations On Change In Ownership Minimum Percentage", "terseLabel": "Limitations on use of net operating losses and tax credit carryforwards, percentage" } } }, "localname": "NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnChangeInOwnershipMinimumPercentage", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "percentItemType" }, "blue_NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnUseOwnershipChangePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating losses and tax credit carry forwards limitations on use ownership change period.", "label": "Net Operating Losses And Tax Credit Carryforwards Limitations On Use Ownership Change Period", "terseLabel": "Limitations on use of net operating losses and tax credit carryforwards, period" } } }, "localname": "NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnUseOwnershipChangePeriod", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "durationItemType" }, "blue_NumberOfCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Companies", "label": "Number Of Companies", "terseLabel": "Number of companies" } } }, "localname": "NumberOfCompanies", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "blue_NumberOfTransitionServicesAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Transition Services Agreements", "label": "Number of Transition Services Agreements", "terseLabel": "Number of transition services agreements" } } }, "localname": "NumberOfTransitionServicesAgreements", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "blue_OperatingLossCarryforwardsWithExpirationDates": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, With Expiration Dates", "label": "Operating Loss Carryforwards, With Expiration Dates", "terseLabel": "Operating loss carryforwards, with expiration dates" } } }, "localname": "OperatingLossCarryforwardsWithExpirationDates", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "blue_OperatingLossCarryforwardsWithoutExpirationDates": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Without Expiration Dates", "label": "Operating Loss Carryforwards, Without Expiration Dates", "terseLabel": "Operating loss carryforwards, without expiration dates" } } }, "localname": "OperatingLossCarryforwardsWithoutExpirationDates", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "blue_OptionConversionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option Conversion Awards", "label": "Option Conversion Awards [Member]", "terseLabel": "Option Conversion Awards" } } }, "localname": "OptionConversionAwardsMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "domainItemType" }, "blue_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "domainItemType" }, "blue_OtherNonoperatingExpenseIncomeNetPolicyPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other nonoperating (expense) income net policy.", "label": "Other Nonoperating Expense Income Net Policy Policy [Policy Text Block]", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingExpenseIncomeNetPolicyPolicyPolicyTextBlock", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "blue_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Revenue", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "blue_PaymentForPurchaseOfFurnitureAndEquipmentUponLeaseCommencement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment for Purchase of Furniture and Equipment, Upon Lease Commencement", "label": "Payment for Purchase of Furniture and Equipment, Upon Lease Commencement", "terseLabel": "Payment for purchase of furniture and equipment, upon lease commencement" } } }, "localname": "PaymentForPurchaseOfFurnitureAndEquipmentUponLeaseCommencement", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blue_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-funded Warrants", "label": "Pre-funded Warrants [Member]", "terseLabel": "Pre-funded warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail", "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "domainItemType" }, "blue_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "domainItemType" }, "blue_PurchaseObligationToBePaidAfterYearTwo": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "order": 2.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase Obligation, to be Paid, After Year Two", "label": "Purchase Obligation, to be Paid, After Year Two", "terseLabel": "2024 and thereafter" } } }, "localname": "PurchaseObligationToBePaidAfterYearTwo", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "xbrltype": "monetaryItemType" }, "blue_RateOfAreaForSubleasePerSquareFeet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rate of Area for Sublease Per Square Feet", "label": "Rate of Area for Sublease Per Square Feet", "terseLabel": "Rate of area for sublease per square feet (in dollars per sq ft)" } } }, "localname": "RateOfAreaForSubleasePerSquareFeet", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "perUnitItemType" }, "blue_ReceivablesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables and other current assets.", "label": "Receivables And Other Current Assets", "terseLabel": "Receivables and other current assets" } } }, "localname": "ReceivablesAndOtherCurrentAssets", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "blue_ReductionOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction Of Right-of-Use Asset And Associated Lease Liability Due To Reassessment", "label": "Reduction Of Right-of-Use Asset And Associated Lease Liability Due To Reassessment", "negatedTerseLabel": "Reduction of right of use asset and associated lease liability due to lease reassessment" } } }, "localname": "ReductionOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blue_ResearchAndDevelopmentAndSellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development And Selling, General And Administrative Expenses", "label": "Research And Development And Selling, General And Administrative Expenses [Member]", "terseLabel": "Research And Development And Selling, General And Administrative Expenses" } } }, "localname": "ResearchAndDevelopmentAndSellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_RestrictedStockUnitConversionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Unit Conversion Awards", "label": "Restricted Stock Unit Conversion Awards [Member]", "terseLabel": "Restricted stock unit conversion awards" } } }, "localname": "RestrictedStockUnitConversionAwardsMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "domainItemType" }, "blue_RetentionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retention Program", "label": "Retention Program [Member]", "terseLabel": "Retention Program" } } }, "localname": "RetentionProgramMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "blue_RoyaltyAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty And Other Revenue", "label": "Royalty And Other Revenue [Member]", "terseLabel": "Royalty and other revenue" } } }, "localname": "RoyaltyAndOtherRevenueMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "domainItemType" }, "blue_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Summary of Future Issuance of Common Stock Shares" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "blue_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of property plant and equipment, estimated useful lives.", "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives Table [Text Block]", "terseLabel": "Estimated Useful Lives of Assets" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationTables" ], "xbrltype": "textBlockItemType" }, "blue_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based compensation arrangement by share-based payment award equity instruments other than options activity.", "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Line Items]", "terseLabel": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Line Items]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityLineItems", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "blue_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share-based compensation arrangement by share-based payment award equity instruments other than options activity.", "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsActivityTable", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionsAndModificationsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Conversions and Modifications, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Conversions and Modifications, Weighted Average Grant Date Fair Value", "terseLabel": "Conversion and modification of awards (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionsAndModificationsWeightedAverageGrantDateFairValue", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedAndModifiedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Converted and Modified in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Converted and Modified in Period", "terseLabel": "Conversion and modification of awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedAndModifiedInPeriod", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Increase In Shares Authorized", "terseLabel": "Increase in shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAuthorized", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award number of shares authorized increase percentage.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Percentage", "terseLabel": "Percentage of automatic increase in shares reserved and available for issuance determined based on shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreasePercentage", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "percentItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionAndModificationOfAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modification of Awards", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modification of Awards", "verboseLabel": "Conversion and modification of awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionAndModificationOfAwards", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionAndModificationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modifications in Period, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion and Modifications in Period, Weighted Average Exercise Price", "terseLabel": "Conversion and modification of awards (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionAndModificationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "blue_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Abstract]", "terseLabel": "Weighted- average contractual life (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermAbstract", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "blue_SixtyBinneyStreetLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixty Binney street lease.", "label": "Sixty Binney Street Lease [Member]", "terseLabel": "60 Binney Street lease", "verboseLabel": "60 Binney Street lease" } } }, "localname": "SixtyBinneyStreetLeaseMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "domainItemType" }, "blue_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares vesting of restricted stock units.", "label": "Stock Issued During Period Shares Vesting Of Restricted Stock Units", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "blue_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value vesting of restricted stock units.", "label": "Stock Issued During Period Value Vesting Of Restricted Stock Units", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "blue_TransitionServicesAgreementInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Services Agreement, Initial Term", "label": "Transition Services Agreement, Initial Term", "terseLabel": "Initial term of transition services agreement" } } }, "localname": "TransitionServicesAgreementInitialTerm", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "blue_TwoThousandThirteenEmployeeStockPurchasePlanESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand thirteen employee stock purchase plan ESPP.", "label": "Two Thousand Thirteen Employee Stock Purchase Plan E S P P [Member]", "terseLabel": "2013 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandThirteenEmployeeStockPurchasePlanESPPMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "domainItemType" }, "blue_TwoThousandThirteenStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand thirteen stock option and incentive plan", "label": "Two Thousand Thirteen Stock Option And Incentive Plan [Member]", "terseLabel": "2013 Stock Option and Incentive Plan" } } }, "localname": "TwoThousandThirteenStockOptionAndIncentivePlanMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "blue_UnrestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrestricted Stock Awards", "label": "Unrestricted Stock Awards [Member]", "terseLabel": "Unrestricted Stock Awards" } } }, "localname": "UnrestrictedStockAwardsMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "blue_UnrestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrestricted Stock", "label": "Unrestricted Stock [Member]", "terseLabel": "Unrestricted Stock" } } }, "localname": "UnrestrictedStockMember", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "domainItemType" }, "blue_UpfrontPaymentForPurchaseOfFurnitureAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront Payment for Purchase of Furniture and Equipment", "label": "Upfront Payment for Purchase of Furniture and Equipment", "terseLabel": "Upfront payment for purchase of furniture and equipment" } } }, "localname": "UpfrontPaymentForPurchaseOfFurnitureAndEquipment", "nsuri": "http://www.bluebirdbio.com/20211231", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r752" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r764" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r145", "r152", "r158", "r238", "r495", "r496", "r497", "r534", "r535", "r565", "r568", "r570", "r571", "r767" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r145", "r152", "r158", "r238", "r495", "r496", "r497", "r534", "r535", "r565", "r568", "r570", "r571", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r145", "r152", "r158", "r238", "r495", "r496", "r497", "r534", "r535", "r565", "r568", "r570", "r571", "r767" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityTableTextBlock": { "auth_ref": [ "r753", "r754", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of distribution of assets, liabilities and stockholders' equity.", "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Table Text Block]", "terseLabel": "Distribution of Assets, Liabilities and Stockholders' Equity" } } }, "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsTables" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r328", "r335", "r445", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r659", "r706", "r708", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r328", "r335", "r445", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r659", "r706", "r708", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r209", "r364", "r366", "r665", "r705", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r209", "r364", "r366", "r665", "r705", "r707" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r328", "r335", "r392", "r445", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r659", "r706", "r708", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]", "verboseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r328", "r335", "r392", "r445", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r659", "r706", "r708", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]", "verboseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r153", "r446", "r763" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r153", "r158", "r446" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r153", "r158", "r312", "r446", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r146", "r147", "r148", "r149", "r213", "r214", "r235", "r236", "r237", "r238", "r239", "r240", "r315", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r534", "r535", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r623", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r765", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Accruedexpensesandothercurrentliabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r65", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail", "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r39", "r40", "r68" ], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r63", "r282" ], "calculation": { "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r80", "r82", "r83", "r690", "r716", "r720" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r50", "r498", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r142", "r143", "r144", "r495", "r496", "r497", "r570" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r453", "r455", "r501", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r348", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Costs from public offering" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r327", "r348", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of pre-funded warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating \u00a0\u00a0 activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r455", "r485", "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r121", "r267", "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded from the calculation of diluted net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r135", "r192", "r201", "r207", "r234", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r553", "r557", "r584", "r624", "r626", "r671", "r688" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r35", "r37", "r79", "r135", "r234", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r553", "r557", "r584", "r624", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r573" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "blue_DisposalGroupIncludingDiscontinuedOperationNetAssetsTransferred", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r279", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r220" ], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r221" ], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Debt securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r218", "r246" ], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 1.0, "parentTag": "blue_MarketableSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost / cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]", "terseLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r215", "r219", "r246", "r673" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities, fair value", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r217", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Debt securities, available-for-sale, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r457", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r120", "r550" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property, plant and equipment included in accounts \u00a0\u00a0 payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r59", "r123" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Restricted cash" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Restrictedcash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r43", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Marketablesecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r116", "r123", "r129" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r116", "r593" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r59" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r351", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of securities called by warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r71", "r311", "r674", "r694" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies Note 11" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r308", "r309", "r310", "r313", "r738" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r142", "r143", "r570" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r49", "r348" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r49", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value, 125,000 shares authorized; 71,115 and 66,432 shares issued and outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r86", "r88", "r89", "r101", "r681", "r700" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r180", "r687" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk and off-balance sheet risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r130", "r555" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r353", "r354", "r365" ], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r105", "r665" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r103" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Total operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r299", "r300", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring expenses" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r136", "r530", "r538" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r136", "r530" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r136", "r530", "r538" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r227", "r250", "r253" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r227", "r250" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedTerseLabel": "12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r227", "r250", "r253" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r227", "r250" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedTerseLabel": "Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)", "terseLabel": "Realized gain (loss) recognized on sale" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r225", "r247", "r253" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r226", "r248" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r224", "r249", "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r531", "r538" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r531", "r538" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r531", "r538" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r521" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "U.S. net operating loss carryforwards (federal and state)" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r526", "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards (federal and state)" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r522" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r509", "r523" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred taxes" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesComponentsofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Expenses related to 401(k) plan" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Contributions to the 401(k) plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r121", "r280" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r121", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails", "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r19", "r98", "r697" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "totalLabel": "Loss before income taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Net loss per share from discontinued operations - diluted (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Net loss per share from discontinued operations - basic (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r9", "r10", "r11", "r12", "r19", "r24", "r510", "r537", "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Income tax expense, discontinued operations" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of in a spinoff and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]", "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff" } } }, "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r13", "r28" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r278", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "terseLabel": "Non-current assets of discontinued operations", "totalLabel": "Non-current assets of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r20", "r27" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of royalty and other revenue" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": { "auth_ref": [ "r5", "r6", "r21", "r279", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current", "terseLabel": "Deferred revenue, current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent": { "auth_ref": [ "r5", "r6", "r21", "r278", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Interest Income", "terseLabel": "Interest income, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Expense", "terseLabel": "Other income (expense), net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome": { "auth_ref": [ "r20" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Income", "terseLabel": "Other income (expense), net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "auth_ref": [ "r5", "r6", "r21", "r278", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 6.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Restricted cash and other non-current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "auth_ref": [ "r5", "r6", "r21", "r278", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r5", "r6", "r21", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r20", "r27" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Total revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r29", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Discontinuedoperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r441", "r447" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S." } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r102", "r150", "r151", "r152", "r153", "r154", "r159", "r160", "r163", "r164", "r165", "r169", "r170", "r571", "r572", "r682", "r701" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Net loss per share applicable to common stockholders - basic (in dollars per share)", "verboseLabel": "Net loss per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r102", "r150", "r151", "r152", "r153", "r154", "r160", "r163", "r164", "r165", "r169", "r170", "r571", "r572", "r682", "r701" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Net loss per share applicable to common stockholders - diluted (in dollars per share)", "verboseLabel": "Net loss per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r166", "r167", "r168", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Netlosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r511" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "totalLabel": "Effective income tax rate (expense) benefit" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail", "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r138", "r511", "r540" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income tax expense at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r511", "r540" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r511", "r540" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r511", "r540" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r503", "r511" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r511", "r540" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income tax, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofIncomeTaxProvisionBenefitDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-based Compensation", "terseLabel": "Stock based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r68" ], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation capitalized into inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock- based compensation expense related to unvested stock options, restricted stock awards and employee stock purchase plan" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted-average period related to unvested stock options, restricted stock awards and employee stock purchase plan" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "verboseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r91", "r92", "r93", "r142", "r143", "r144", "r147", "r155", "r157", "r176", "r238", "r348", "r350", "r495", "r496", "r497", "r534", "r535", "r570", "r594", "r595", "r596", "r597", "r598", "r600", "r711", "r712", "r713", "r769" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r582" ], "calculation": { "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 3.0, "parentTag": "us-gaap_EquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities", "verboseLabel": "Investment at fair value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail", "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": 2.0, "parentTag": "blue_MarketableSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "totalLabel": "Equity securities, amortized cost / cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r233" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Unrealized loss (gain) on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r233", "r702" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r573", "r574", "r575", "r579" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r329", "r331", "r332", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r435", "r574", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r573", "r574", "r576", "r577", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Fairvaluemeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r329", "r393", "r395", "r400", "r435", "r574", "r632" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted prices in active markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r329", "r331", "r332", "r393", "r395", "r400", "r435", "r574", "r633" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant other observable inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r329", "r331", "r332", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r435", "r574", "r634" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r329", "r331", "r332", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r435", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r578", "r580" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value, measurements, recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r581", "r583" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r222", "r223", "r230", "r231", "r232", "r241", "r242", "r243", "r244", "r245", "r249", "r251", "r252", "r253", "r330", "r346", "r561", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r753", "r754", "r755", "r756", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r272" ], "calculation": { "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r268", "r269", "r272", "r274", "r666", "r667" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r272", "r667" ], "calculation": { "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r272", "r666" ], "calculation": { "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency transaction" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss on fixed assets disposal", "terseLabel": "Loss on fixed assets disposal" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r121", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Loss on sale of Durham, North Carolina manufacturing facility" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r261", "r262", "r626", "r670" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r263", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Goodwill, impaired, accumulated impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r121", "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Intangible asset impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r277", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r104", "r122", "r150", "r151", "r152", "r153", "r162", "r165", "r551" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Net loss from continuing operations", "terseLabel": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r137", "r539" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r97", "r192", "r200", "r203", "r206", "r208", "r668", "r677", "r683", "r703" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 }, "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r137", "r539" ], "calculation": { "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r95", "r102", "r146", "r150", "r151", "r152", "r153", "r160", "r163", "r164", "r572", "r676", "r678", "r682", "r696" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss per share from continuing operations - basic (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r95", "r102", "r146", "r150", "r151", "r152", "r153", "r160", "r163", "r164", "r165", "r572", "r682", "r696", "r699", "r701" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Net loss per share from continuing operations - diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r19", "r24", "r552" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net income (loss) from discontinued operations", "totalLabel": "Net loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r98", "r102", "r161", "r163", "r164", "r682", "r697", "r699", "r701" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Net income (loss) per share from discontinued operations - basic" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r161", "r163", "r164", "r559" ], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Net income (loss) per share from discontinued operations - diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r441", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r6", "r13", "r14", "r15", "r16", "r17", "r18", "r22", "r25", "r26", "r27", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r284", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r138", "r512", "r519", "r525", "r536", "r541", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Income tax examination, penalties and interest accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r156", "r157", "r191", "r510", "r537", "r543", "r704" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 }, "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit", "terseLabel": "Income tax expense (benefit)", "totalLabel": "Total income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail", "http://www.bluebirdbio.com/role/IncometaxesSummaryofProvisionforBenefitfromIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r90", "r507", "r508", "r519", "r520", "r524", "r532" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r118", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r120" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r120" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r120" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Intangibleassets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r131", "r271", "r662", "r663", "r664", "r666" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r266", "r270" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpensePolicyTextBlock": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.", "label": "Interest Expense, Policy [Policy Text Block]", "terseLabel": "Interest income, net" } } }, "localname": "InterestExpensePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r114", "r117", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r74" ], "calculation": { "http://www.bluebirdbio.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r76" ], "calculation": { "http://www.bluebirdbio.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory, Total" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r32", "r76", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r42", "r77", "r132", "r172", "r254", "r256", "r258", "r660" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r75" ], "calculation": { "http://www.bluebirdbio.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r76", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Reserve for excess inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r255" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Excess inventory reserve" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments and Cash", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r618", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of Future Minimum Commitments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2027 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r619" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension terms" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease period" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "Annual base rent of sub-sublease" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r66", "r135", "r202", "r234", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r554", "r557", "r558", "r584", "r624", "r625" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r55", "r135", "r234", "r584", "r626", "r672", "r692" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r69", "r135", "r234", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r554", "r557", "r558", "r584", "r624", "r625", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "blue_DisposalGroupIncludingDiscontinuedOperationNetAssetsTransferred", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r279", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r278", "r285" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Non-current liabilities of discontinued operations", "totalLabel": "Non-current liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DiscontinuedoperationsAssetsLiabilitiesandStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table Text Block]", "terseLabel": "Schedule of Non-cancelable Contractual Obligations" } } }, "localname": "LongTermPurchaseCommitmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ManufacturingFacilityMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Structure used in the manufacturing of goods.", "label": "Manufacturing Facility [Member]", "terseLabel": "Manufacturing Facility" } } }, "localname": "ManufacturingFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r675" ], "calculation": { "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail_1": { "order": 3.0, "parentTag": "blue_MarketableSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "totalLabel": "Marketable securities, fair value" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r33", "r67" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Summary of Marketable Securities Held" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r177", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Description of the business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Descriptionofthebusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r116", "r119", "r122" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedTerseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:", "verboseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r84", "r87", "r93", "r99", "r122", "r135", "r146", "r150", "r151", "r152", "r153", "r156", "r157", "r162", "r192", "r200", "r203", "r206", "r208", "r234", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r572", "r584", "r679", "r698" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental cash flow disclosures:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationNarrativeDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r192", "r200", "r203", "r206", "r208" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r611", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r606" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r605" ], "calculation": { "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r605" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r605" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r607", "r614" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows used for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r604" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r617", "r620" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r616", "r620" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r30", "r141", "r186", "r560" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies and basis of presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Summaryofsignificantaccountingpoliciesandbasisofpresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r39", "r40", "r41", "r68" ], "calculation": { "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesSummaryofAccruedExpensesandOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Restricted cash and other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets, Noncurrent [Abstract]" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r85", "r88", "r91", "r92", "r94", "r100", "r348", "r594", "r599", "r600", "r680", "r699" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r81", "r91", "r100", "r510", "r542", "r545", "r594", "r597", "r600", "r680", "r699" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r122" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r107" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r115", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Amount paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "auth_ref": [ "r113" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Payments of Distributions to Affiliates", "negatedTerseLabel": "Net cash transferred to 2seventy bio at separation" } } }, "localname": "PaymentsOfDistributionsToAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r111" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of intangible assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r216" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment", "negatedTerseLabel": "Purchase of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r392", "r394", "r400", "r417", "r419", "r420", "r421", "r422", "r423", "r435", "r437", "r438", "r439", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "401(k) Savings plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r457", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r48", "r333" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r48", "r333" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "verboseLabel": "Preferred Stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "verboseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r48", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and \u00a0\u00a0 outstanding at December\u00a031, 2021 and December\u00a031, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r34", "r36", "r259", "r260" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r110" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of Durham, North Carolina manufacturing facility" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r112" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r108", "r109", "r216" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of equity securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r108", "r109", "r216" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r112", "r490" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and ESPP contributions" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r63", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type", "verboseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r289", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Propertyplantandequipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r62", "r281" ], "calculation": { "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r44", "r45", "r283", "r626", "r686", "r693" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r61", "r283", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r44", "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property, Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r44", "r281" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type", "verboseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "totalLabel": "Total purchase commitments" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "order": 3.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail": { "order": 1.0, "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Purchase Obligation, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/CommitmentsandcontingenciesScheduleofNoncancelableContractualObligationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected quarterly financial data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Selectedquarterlyfinancialdataunaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Selling, general and administrative expense related to transition services agreement" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r505", "r661", "r744" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "verboseLabel": "Research Tax Credit Carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r43", "r123", "r129", "r669", "r689" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash balance", "verboseLabel": "Total restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r31", "r43", "r129" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash included in receivables and other current assets" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r38", "r46", "r129", "r737" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash included in restricted cash and other non-current assets" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r291", "r293", "r296", "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Reduction in workforce" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Reductioninworkforce" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Number of employees impacted" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r121", "r290", "r299", "r302" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring expense", "verboseLabel": "Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r47", "r293", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Accrued restructuring charges", "verboseLabel": "Amounts accrued at December 31, 2021" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesNarrativeDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r51", "r350", "r498", "r626", "r691", "r715", "r720" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/DescriptionofthebusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r142", "r143", "r144", "r147", "r155", "r157", "r238", "r495", "r496", "r497", "r534", "r535", "r570", "r711", "r713" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r421", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r440", "r441", "r442", "r443", "r444", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r421", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r440", "r441", "r442", "r443", "r444", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/A401kSavingsplanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r188", "r189", "r199", "r204", "r205", "r209", "r210", "r211", "r363", "r364", "r665" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r133", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r96", "r135", "r188", "r189", "r199", "r204", "r205", "r209", "r210", "r211", "r234", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r584", "r683" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues", "verboseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedQuarterlyFinancialInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r615", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from stock offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/AccruedexpensesandothercurrentliabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails", "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Capitalization [Line Items]", "terseLabel": "Schedule of Capitalization [Line Items]" } } }, "localname": "ScheduleOfCapitalizationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the capitalization of the entity which is comprised of its long-term debt and equity instruments. The table may be detailed by subsidiary (legal entity) and include information by type of debt or equity detailed by instrument.", "label": "Schedule of Capitalization [Table]", "terseLabel": "Schedule of Capitalization [Table]" } } }, "localname": "ScheduleOfCapitalizationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense by Award Type" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Summary of Provision for (Benefit from) Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Components of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r6", "r13", "r14", "r15", "r16", "r17", "r18", "r22", "r25", "r26", "r27", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Summary of Revenue and Expenses for Discontinued Operations", "verboseLabel": "Summary of Significant Non-Cash Items and Capital Expenditures for Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of Income Tax Provision (Benefit) Computed at the Statutory Federal Income Tax Rate to Effective Income Tax Rate (Provision) Benefit as Reflected in the Financial Statements" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r455", "r484", "r500" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense by Classification" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Recorded Amount of Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r268", "r271", "r666" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsNarrativeDetail", "http://www.bluebirdbio.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule Components of Loss Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r42", "r56", "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Restricted Common Stock Awards" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r63", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/PropertyplantandequipmentnetSummaryofPropertyPlantandEquipmentNetDetail", "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SelectedquarterlyfinancialdataunauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r43", "r129", "r669", "r689" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of collateralized bank account of financial institution" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r292", "r293", "r294", "r295", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceAccruedLiabilitiesActivityDetails", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r297", "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ReductioninworkforceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r457", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r461", "r473", "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity Under Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used for the Black-Scholes Option-Pricing Model to Determine the Per Share Weighted Average Fair Value for Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/RestrictedcashNarrativeDetail", "http://www.bluebirdbio.com/role/RestrictedcashScheduleofCollateralizedBankAccountofFinancialInstitutionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r518", "r533" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IntangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197", "r198", "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsRevenueandExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r120" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested balance at end of period (in shares)", "periodStartLabel": "Unvested balance at beginning of period (in shares)", "terseLabel": "Unvested restricted stock awards outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested balance at end of period (in dollars per share)", "periodStartLabel": "Unvested balance at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationScheduleofStockBasedCompensationExpensebyClassificationDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Common shares reserved for future issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Canceled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Unrestricted stock awards granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period", "terseLabel": "Increase in common stock available for issuance under 2013 plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r463", "r489" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental fair value from modification" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, shares issued in period (less than) (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r454", "r459" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquitySummaryofFutureIssuanceofCommonStockSharesDetail", "http://www.bluebirdbio.com/role/ReductioninworkforceNarrativeDetails", "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofRestrictedStockUnitsDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockBasedCompensationExpensebyAwardTypeDetail", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r457", "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Intrinsic value of restricted stock units vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r479", "r499" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationAssumptionsUsedfortheBlackScholesOptionPricingModeltoDeterminethePerShareWeightedAverageFairValueforOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r612", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease, cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r73", "r91", "r92", "r93", "r142", "r143", "r144", "r147", "r155", "r157", "r176", "r238", "r348", "r350", "r495", "r496", "r497", "r534", "r535", "r570", "r594", "r595", "r596", "r597", "r598", "r600", "r711", "r712", "r713", "r769" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r142", "r143", "r144", "r176", "r665" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r126", "r127", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of unrestricted stock awards to settle accrued employee compensation" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r48", "r49", "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r48", "r49", "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r48", "r49", "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of unrestricted stock awards to settle accrued employee compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r48", "r49", "r348", "r350", "r465" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.bluebirdbio.com/role/StockbasedcompensationSummaryofStockOptionActivityUnderPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r48", "r49", "r348", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Purchase of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r48", "r49", "r348", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r48", "r49", "r350", "r456", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of unrestricted stock awards to settle accrued employee compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r73", "r348", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "verboseLabel": "Outstanding stock options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/NetlosspershareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r49", "r53", "r54", "r135", "r212", "r234", "r584", "r626" ], "calculation": { "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets", "http://www.bluebirdbio.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r134", "r334", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r601", "r627" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r601", "r627" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r601", "r627" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/StockbasedcompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofCashFlows", "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/EquityNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/DiscontinuedoperationsSignificantNonCashItemsandCapitalExpendituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r222", "r223", "r230", "r231", "r232", "r330", "r346", "r561", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r753", "r754", "r755", "r756", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r140", "r393", "r684" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities and treasuries" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/FairvaluemeasurementsRecordedAmountofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail", "http://www.bluebirdbio.com/role/FairvaluemeasurementsScheduleofUnrealizedLossonInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r393", "r684", "r721" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government agency securities and treasuries" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/MarketablesecuritiesSummaryofMarketableSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r506", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance as of end of period", "periodStartLabel": "Balance as of beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Increases (decreases) for tax positions related to prior periods" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases (decreases) for tax positions related to current period" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases (decreases) for tax positions related to prior periods" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesReconciliationofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r178", "r179", "r181", "r182", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/SummaryofsignificantaccountingpoliciesandbasisofpresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Approximately valuation allowance increased" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/IncometaxesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r613", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/LeasesSummaryofLeaseCostsandOtherInformationPertainingtoOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average number of common shares used in computing net loss per share - basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bluebirdbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r29": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r602": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r621": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r745": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r746": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r747": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r748": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r749": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r751": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r752": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r753": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r754": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r755": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r756": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r757": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r758": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r759": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r761": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r762": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r763": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r764": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 116 0001293971-22-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-22-000016-xbrl.zip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`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�I"IGNC:F7\O G MYV@,"QE)$]:?MP46J19^QH( ]*V[/TJ@F4=@)UC P\_V"*2:P?_,!!>S8?7U MY8;\A!7#^ZSE$IAT'9+J<8P\OUV/MPD^=MN\K"Z#KV$VK!9?$;_/,SVZ41-= M_I+U'T\VYS-%>/\1J)&XL3V/'T=XD$NVQ?\-JPFM6#_^^'#J\\QQV_5"S=Q8 M[^6A46)$>?[@MJ!]3##7$0E/,$:BTN!EP]L8R)_UTW88G3YQY+!=+,.8!$^?^U7C7ZPUGE3CKF>5F&=Q*_(B M6US^_(E>E^^0^\A4'2C)UOT2[K)M&6(@./#1=' 8N2IYS##/E1%FJ35LW-@]E\:?)#NN<>7P$-Y"/$#07P5K3*?@*9G7$3\ M.O42&D3C^B^##R+C(;PP^0\OW&Y^@QE5_8H,#!HNNV0:*&G7\(S#??31(UVB M!RL.RW26KKPTH1MHJ$2=U_1D0GBMN &7RUJ[9X2LF[]N]B;E+L_<7F@[.<<5 M1$8FMW]B4LPDS,;]]OQD!XEI^GU.ZZXP4NZ;W/G'_['C4+W^6XY05((-"9G< M$AA\IS,;;3X3>+Z[I^.%0*ZIN$CN BCD6/R3B/H7D #>A2^N0/^:'0_M%N!. ML(*)D",'%06F*6',GN_-%&R1.^L2SVK%HMA?\/FBS'%8#1K*C@KDQ4!-@U-6 M(;/=O#B[X^[ZPS4/GX"B58/?L:FS1#9*/V.QO\\N:BAP\@26)M1$4$MF*,'[ MGM2GP= =3=#&'(D(O+$F]Z:)9 MZD)BI]D(]-;1*U">3W,$X<.M2#:X2$7)VYG5KZY2KKC23VB=ETI='Y E"TV2 MJESJOV[ 'M$S?0 B50PPP-LRWOE5 $V#Q=ZO*+9F/.>[(UOG!D388D5'<*,= M(Q:XI>OJ)N!;&X;9YO!0IA%7WSG71:]"^4?CEMBG+KNM =@05)TGU9NH,1H2B 215P)Y I% ^*'Z_0_:LG;*]EA+! M6Q*!6N<'DO5 .:_/!3F!!-X-*H7_062A/B&);E1HU*D=WK3.?XDP[V%'//SL"_3HV_^5P MDO9VP_0(5,_DJ1G:[#^5C3Z$P!WX@#\IR0/-$&C$O: 9=7_%>E&M6O@%44$1 M05(1&U(UPW]Y%ZH(//,T0>=K %^^+Y;T:NF.9OW9+D0C4;^\Z([U^LX1R&D- M>$+>-0%;,T9;&V\S/J/8!61/IO0?7DODW=5Z?0U-ED6.]%X!_(Y %\J!1F;> M_PH^-*MT7D(=HTD@2!NXG$$LQ^_*T[.:8%Z_0_AG6A%OQM\@>F-/=$5U).XV9D.DT>L$:WOUZ MQ]!S+M;0'\?%(\_@.D[NQ;J$BR?]C,7>]SNEQF$-[8]"+Q&L5?6_@86V_N_L@3+;D1\4\;SUJ^/]?-16F@%S_WLXH<% M+]#?(Q @BZ2]#$YAAG_Y:L3F'ZB7\RB$=%5*PQU"D2,E?JI1Z.[^KBKX"/V% MTB$(*18_/(R%Z$*\8[2Y)@&E''37>^>PUF+#<1&J\N3=JZ5(_C1>)AD3PULT_ZX:-*A.M%CEXS%U3/_FJ]=TI/=.$,;"83/P]Q M]38 M/X&5-SKURB8MG$"'9TQQQ2" .H!H0A"#$7AW\0T+>I5F?]FX%W?A9:/31KVF M6=>BZ/.VY;<@_Z.].P^'*OX#Q3]"1++ORRBDLJ5LV89D2T)ECTD(V5*6B3$C MN[(KBC(D(>[]/?>O^WONG3]> M_XUCYIS/>2_G?#[G), _!F=0M,F^$!,<;R\X0X81O%+_5CJ?RC&_9:$I^3#CB&"@R>+NM9Q02SKG6PDQ(PY O?_;3S_Y"V M C;I@!CAN9=H;Y4SMS%2+!DFU!SX7900A!?7T4RH7%)+J:9X$%P=TMYF;-PI M<+LD?KFIV_[A+""5W?Z6]1=M'UG6_RPNV[_&BQXAB[C2 29C']1("I^KK,DF ML,D(=I9\$'^/1/.#ZH@* 9! Y;[C1ZC"86V)0+C0!T@%E.)IH4#0'=A3.2!+A^NT\M0^8DX4KK[5P9K4D/U%@_ MXL%8:W_]0LNNL>E,2 @04$A['?.XF2*"I%G[="\2+\TP3EV>?]'>!&YL6$8_ M:GKY%EZKI,'5/Y^S04!G(/$FG[I5QJU,N8PPX5\(O%W&=%G?8J-YE[1@-^QX MCO6S6_6$XQ+OTA@%L_K^VO7]L;+%MWV=GL+?3:F]RRI0,:)?;Y M$;YI84 )$"8_%87*.WL[C<*59YHU%,)[I6XEG?BX] C3H]3R;'"(8K# MNR(#Y"N?]LA3_0L\8X:G("9.^'[4O;P#U6I_A3?S;7\A\Q8Z!AF7V!YRLH46 M\7X#3>=A1#<-2#W,1Q] RJ2D1)Z_49O_W4H&H)$\X\=9.Q9>4='O E1E92%V\Z8!$N!?)$"?JV+*7]+6:_@M]*YG7\*C^3V9@)^ M.K^R?[2;^7N0C8\;T>BXX8%%S>@ML<&42=$$:WUV0H%%(UC?;\KCC^_2_@U+ M@4LBOD[!Q_X<3Q5FMW$A@$6@CM1ZN$>@KG043NI K0^1I#7%WQ,&D^>5O[HA MQ'K&XH_9W?"D+'G;WA,/68@9C!Y>GY3G2;X,[]XGL> ,M,T(I1,?9]9UM6K5 M_ZV?G18?9I:^X\@4.YNMGGE,7*R($X4I+P2-PQ@E HR/D)LJ+^'>4NF7 M'\]]ON?M8+!>H,=TXH/HOJ@I] (<4PA3EJ.E[-,!8^K7J64@SW5X*O!C(*IK M^YA[SUNM-)[\E8^+N>JL <7\][QN/!C\),)EH1C.>W47F01BA_OQ^!,]2 7X M9ES"=F*P]R?\VHJ[\*?Z HYDK]2"1*=^1QD+GK1%):]'V2P3\"[ES:4DHBCI MX4JQB\^/^9&] O+5U4?[9X )D.;XDY8@3,."SCTC9WUMR;-H$R*W.F(@BS0U M :RSZ?H,)\*HKZ"2&*#@Y]?Y?W*(BPV:\>^=; JB] <;GU: Y"L+.2XA+^'W M-IJ75-1H7&=Q\+1QJU+$T37="TXF$G/J;;OLC>WFZAN=DF^#(D+[ '?@7>[P M7\.-0#*/$WPET%V:D;Y.I^^C,&]01R2 )+QS:/!A1";>:N,=WX;).TZ!F]&= M0$'8&*)^?C&V74$A/K*W-:UZK*GTHJG(P,_<_1=.RXBK*Q1CLO8J6 CD_48- M"TRS=W8T_CC^OJ7A9/[,&J>=@Z]SDGWHP,"O!V;'A%AVS1E5_3U&L;% !W2W M:GY+(U_WBS//_R*N'!^I' 6-DWA)(-<46'R BK MX;;%5QT^FIY.+\^\KRV2$:Q_GTVI6?9Q580P3:8]1/$)31 VLUAODS3>N< Q M >4F<'<1O8O&@C6'"7/3LW0 0*E%/?V+BVU+IPZK3!+Y-*T/=@8/[(L.7G+L M!PNZDGIP3=62IL"?78Q"YD)"8/R'WTTL8EP?R@N>!WTSXG@!&PFONPWO\H#I MMB>+8_!+@^*T=9]KMVG7S)?<&2F+W9P.R!$D%= !#T:HNB[VH'C4Q^74=D$R M#&I'&BH?*FV.AUJ6:"9DFS!2F;S*75CH&0!P9>RA&".;(&72R/Y0R2E&.@-. MY_6[L^![IM$U]Q?ODO7 7^[&/W:LO49^J<2_<^4G9O)T.J)V@ VB)C=MP#AB?.P1,!.-'>D#\@WR?F_!C MOA$[SI="C]_9>5W"=^&2CCS7?@91A?KJ<%'[M W:8>%$VR1%I9HBIMVLW:S& M#6S,)@B;B/GVE(CRU9]4+O$'H"_) J,YXA53['/1=JEB6\6 (3_=-Z/#,O 4 M)YAL)N1TC%X@5Y1D-:]-P37UI@*%]N#['K+%R>5GFZ6;EH3WIPD[F-N,J'_7 MD/MT2ERYZXI=Z7[>ZE\HN)K,4[8F$;YC)M[L=)KN0@VC>:U+-.&,]$.\\2 M'<#ES.K_;BU_-+2EOHEUS[_AXQV 5L)IQF'7,T*_APT"ZPR;\0XP_=9BM$)L]T'G4:M)_KL[?E*Q<^.B$V*"MC17X$_V("\@X^H#*J M#2N1_]R*G $?WHKL0\[T8))Z T^XJ>B#,+/)OW_D;F&S'XI@+*"-G";0DA:I MJ74E3_[K5P\1X41XC^/Y=/UN%UGR<2EC<0^$1K MC8HF&>'Q$CT+4+MKJ+,Q&G[>,'K7/8' VMFJW;O-M@X3)/"4?QX->V:I7(/] M=LQ<3,'FGK3QAI%!)88.2%JL']D,(RLH+,;2!-<+^0@C/2VJ\CG6AHJ+4JV^ MXTT7HAAI,CF MOTKV<,Q;Q$XD\",'-?4[?+6_OPJJ2HV#G8=$$'OQBOTH24C;54(@Z2ENO;=9 M2/59;KS%LA#+,A!OSWOLO@P[/&&Q03%)=KX:PNN< MJ#3V^G%NABRD![%US#@#^'?'/Y_ZOG%(;=:$V$?BQS>;Y9#-NR2BXPTU)IT> M265>?79!+@/BH,!!*US?6DP#'0\PU( J$GR>_%.I]*]9'7?>3[WX:V"(W&+T MSYQK:=X4RJC]V5:HR11[\OD%$JH7P8?4H%KUN;P3F7%[GJNM]D"V+L%\\'.6 MQ:!37K"1[#5;#I[#BG^)^)V:T8F!=UL'TP%EDA*5^'-7Z@[7'D%],IP'.EJ_ MBSF)0^9W_#;:'DWMG9O78W4?)[L>WG,GS9*O4%@(J*32L7$SO&&],.U#^'M'5BE'@LP0!#KHABAQ'O[F<^-<\IT %9P@G4+?=-? MUA8T,Y\:A>NX0GVUU%% XUS%L8VCEC9(_KV?_BDMNVVS+@9M1.&JH$8D7C*8 M-B%S[ =4@:#G@H^(;5=M^M@V#0E#;$I\_G'?9?KT72]N_N;RP)OR*_[+96Y4.ZI[&%T0(/H MA@VA&2>24N($=:.^IYP["(U8",IO[6L(-YK;D-L+."(2^(Y2A+@=XM;_OS:W MQOY_<7848!F%>:N%"J#6H#S7_2>MD-K@YO1PNX0<;>+)9*(^(]H9@^5IDXN, M4-^A11L% :#!V-70AM%VWJH^^(?JS1[SBV;-X>/ LY?YT %J77*O'1DA81_) M&'2AZ5O@Z6#<4R<1T>'JZ[7"WZ ]GB)SGATAKBB\J=ZSDV0]R-@HP.T&4/CJ MWKE%B-ED;K=^>I&WPOJNCZ@E;0L;5W44)&!HDAO*A ](Z3I%>D2^NNZC]U+_V)]"S*Y]X8[Y4 M 7%V]"K'/>_]$J^%6P+OG@(87XV]+(J??)[DX:-$7,(-/0K0F7_B%]9.![3% M7MQRZ,BFOC<4I^B1^O#J[4""HEL#_D\6K/9S34E(E'!EU\,8(!)6T+Z;O2*[7\BU"9Y5\'+0%+CX/ MORCJ9"0>Q++_Z4A'+[4:Y1VM1ZPDR>@+1T=3(T= ,WS)\O3?J+J53Z8XC-PF\ATJ/;=ML &:;=8[5Q=L\RYI*>: M=,!#+V)?%*.+/4GVOH]JV$+@4+R0D1X"R0<'C%<56;1O;'9T\AX:*'@AE9OV MHL0[5/G! ^-E[F49X!@=$#S"Y?N 9'R:%%*-9@/=2^IKC?]HT/TA1GCVQ<+/ M+7R=GF5 3LXZHDYM(^$16=VW0W&BW1J)? H[2>K8 /NWOI--CD@,/R9^1[S# MS^O>7=&0X-;S9UA7\Y7^(*;CL"/HC*.4ZZ24?9K_LU[WAPWQSIRBXX\/#]87?FZKO\\>>RQNRYE$F=7]ZSIV+-IFV7RPQ_L*P*V9D"_BO[0"O;.(OQ MH.V:EZ6-53;Z52SRIRKN/M#%\SR 'Z&!(&K$#'P [0S^=(E668EQ))%78_*C M:^TK?ND\_YB0IBO+91HL*PW_[PW^CSB^I)REEE".$4KZ:)KXD03-2\C&#(YY MZC.G1%=+#[ZA/U8RPF^,X/GB1QT-#/IDQ X_N\2;5BA'LBE=>V2]!.>=D9R_ M/%BM<"5=UD-(Q53I3R_\I5PIK#Q M257(9>4#]JXJ#<..'3ZS\@3(M_K4LATI&O<,S&?N>\O-J!P_YYK[37_@G7T8 M!P>'F(Z.HO#J+8"=>P2A9VGO"$ES3_R)RAIL/OPV]NP\MMRP-UM^^?0HXP\3T?Q%*/3774))DA?.A".41L^H( M\(0&L/#/V2&XOM;, H+G5\@@D3056?6A4^N8N!0FG[Q($]?#)%'Y44ET ,GJ M)QU ^$!IQ2,Z#Q>0A3/"[!/8=UWS)X:*]Q'<89(&EP_6HJVLI1])%^Y9IM_T4$6P['S\ 8P59H.2 7A+QXN\/D"(",ND^"8D80.X0EEBC;6 M&MCCHE25Y^@@(8/@>?=(.Y=5W6+B5IT]=\XW@#BN78^H1NK!F[N3N'%P$:@Z M_A>*IYV]]/Z4XLT,AZ=*=^K1@6S9<](Y%FW0]\E>M:"32\6&G[$V7/<7V$FB MWMC-"/=/!+/Z][[W)G==6GW\@KTM+/R>GM^;L;"[/) DL[ K_,*UT\+RCA=GC8WRF'S\)868940%R+-R9'K)!0ZD7"8I M/G0AN^1MNI^LW?5Y:N$U+_^!IP3K*9YM5/6L@=)EV57$8S.C2.-BP:.(H80K M,$&4+O(IY1[V$98.X)E5Z>MU3;2U<'YQ*RNN60%O/!O++EPS X.R1S7KL KN7\^^=P=\1#6N\!G)VZ$L'X\0,:F8[/_DZ&'+3 MCB!U\#ZK"G)_>]/!I29)V7;>4Z_]?43:3D%WDWJF.9O7+]92TC^R*420Z(]_ M2,I!YZ.)@:\_/M9JPO=[?VK+8]MXJOGK]0G+[M34K/Q]N"WC2[= .*[%JEQ? MQF;T5@;S6'P1=?DTYI$NP@$\?SKP';0'J'7=O$;I,[6Q70XO@W;' WN1:0OR M;;4RHJ\[,DI2KM2"OTA[>6N]U?9[Z&#PL[/3MI=K]W,$C2L" W[FL/RE)1&BNE'2AH UV 5\ MT#M-:RXZP*J=_XM=26A8VL12J,<+;]E8WA]>?#9#*+P9<%^3)YC6/SM"56BH M$:0=DPM31M0M]@U(F/EZ3@2+\_V],0.]A)YBW:G9IG'VT &GBZOI@)^SC^F M=TW/6?:J(4D]B)FE;J" (0@RA/G7\:K&=^$\OE6_F;O2^/@#-[.:9W^,!I7J MC\BG]?^^V=B%MC7H0.F@@BH=J*]0 =MQ\ ;-#R\U#*Z&?6\W/W5"*^&,VVB!-]$1IX8GA;E;TU\45W.C^+K.B]D[<$ M6)0OF+OLIBD1T:0([8W=,HK/E$\'WB=>DT5Q6FX*EZ:FRM7VH2KDRDZPS\[T MBUO9MX(PC\ &\*Y;[>!RR) IR0)D"K#.BT-)O8X2^F!OS\R+6>K[\/FAT'W_ MC> CI-V>1<%VQ3)(07?KYYJVHC7^_=RIR>#62TCK87F;%/[$MCZW8>]KT):!/@P(%Q-@3V?=R6;UVOO%.DV3@W== M-Q2&Z/7G)\6WZY622G .G^]N"O?"^,=-OZH/5#?F??5Q^ZD?9#24?31:E<+* M^ =9T ND50*7&DL3 L?+#NG /G7UZY"O=^KXWF6UX6 >B&P08$T8,_E<7?T-3S62]6<^JOPN83>=C:W- M#3(Y3Z4#@C# $D8F@ ?P'H&-@/G:@5@UT?=EP=HIV7[%/[!/Y;S]I)P6]DZ, M59Z+>;13^8#G\>(&'4 'L"N2@LD64"\@+U2IF/1*M?2I7_4_O2&+[.DQ!>6O ML]ZJ,4O<+8_E61M>.WY#X>UYV7L(DL0R:@%%Z6&A=TUSN,9J7LAMM,H&)R7= M_ NZ%):]TL'S75];.MO/Y32B3"4--:T"&PK(>NDA+RC!IW/#2/[$,?$BGGQ< MAQK4&P_OS&";AR#[#^8D3J>Q_)3/4UC.C'4XDPD=NP3 WA*,L3&RV/3?*:!Q M>1/.C:T3?Y#LL,$"*P=ES_1YL63.QF^!,?)I6##I M+#).<_O$W(I$1B=OGK@HJNO-EMR9D>Y:I]Z#=X7N+"^R3GM9#.JP=2PE=K^66*$#?$9( M9T6[MV=8T:,0"4F#J&X9U9>M7660IZ.G!%MC^S5"PWLVV38?E,4>A8S$,/:# M8(>4[RA%B8#*D.D_IKG_KZ=$8:G([U2L$L3[3#SU^W#(-]W-V]11!Q#FO8M* M[A.R/>U+QYGQZJ7Z*608'5!_&WRYV"M71TWY^%5TQZ+A;9]Z?B-@-/0:Z0T6 M$==Q[$>[*X[JPB-J/#X.W;N9\P-?_N%2A&>,L+'\:Q:PO.\BWF$[(?+%SL@C M+%#:#R:8C7%5?%H3^MR?+R)P[K>"LF@%YB*\OE I@7$ZE5N">D&IP/J\[K/+ MV4!>4DXOUTRL&1G:O0C=6- QM3U$D9^& G:I.A',2F9X'K\WB'ZNJ!'<*5H)P[6B6: M.UNU*S%P6O6Z5S.F'[4VHG^GU/<_" M7Z=P^V:+F;?G_92+1V*0:B=3H5]T,Y7TL,$483VL8R\P60(>^^^-9)\,RY3F ML;&%69J DGRZ:!9>SL$KZQ6W>J=R\6.@=EG"X9ID*=^%4]1:D!^OZ'V1\VYK M[C*3OYMJL[V.!\[\(6ZT%1E(BF CPEA>AIYNW2:I^"1I3)*.81""T=F:4U44 M.^%4T;6BJYE6_H_DBH(^J;%99]@7\7X'\D.>6>'3X^#5_I$)'2_>.5V>$G5L M?LB)2]04OW=/'\ .=0MA1)(')-?3%=#0C*.DO5Y#B3JXZE)O9%!FX@1\MN=+ ME:@82,>A'P9V=Z1Q_5ZB@J]3G[<+%[O>;O#LTRVMBHQOD;62>O J7%WJSM#O M9LJ1#BS)&S]B1++"[YGB?9*J3M:/AK9=:4P72N6]R)T8T;G_YIOSRYV^% -? MUH$.(=K\(C=-"^H1AUV.\_G16+#Z%[&9_,^W.-GI);%"/=MKU\%^/C9-K(M- MXN 4ZH+A48K:*(P?W@76#RPFA8])@TP++A?8-M?' #+%L ]$J>+Z+9A'RC&2S'Q_ MDJ?&E"#I_N"OK)EY[HOJSPZ??;]CB3QQ..,1/ECNBR!J3=,!JRKST4_PYC0+ M5 Q\ SQ.!_S-UP604,0#ZA,HKVBW&QCGV#U_=+&S4 N?:NX$)IGG;&3.&1_; ME>\-P=ZX8NOE:'3BIM2OP -!(C]I/X)L#OM*$R4X5)X;QHF9K.;7UQA&O;P^ M?I(UQLM$*AX N' GQ(T.V.0O=UD% 0P5%A8^5K^3D?CQ+B_"^NWDM8S^CL-O M%T5Z=I-D>GB7EU2]I.3LHO13-:SZIG5.4+A%KBU:'%V4>PJN"SA06[*A" 5C MX=UJTM:8 F[K*!SP69&G=/\K++=FF];8V1YSN3R[]CNQE9\J,#'^GD0(M<-0 M##8*.\W(Z8_6"H4)S^\@2.;MU@%-S3<#;WP[U?.QQ?:84N;/Y2 6=">X%K@9 MB 5/]V#3BS6GNC.D(/5]K?_^3KDDI3147_*Q>LX3G^9]CRWA9 IP\=ZZ/1T0 MD#$38G@)TH;=RS"4@9XF3"7 3C%*6->,S:AAQ2%MD:7C=6UF3DU3=C$]DN[& ME"M\O!/(5#I DB).!I%.PX5)R\[/S,;D0@1$;NS,7356$K)#?MTR4@0\8%$$ M"!C>9,25V%;HQ7M-J!_Z' 0."WSIUXYKAG(M8YY:[W[Q]%:5R5'GA\>?[B)G M9186E[8I0JX8CA[I0'E$%V%UJ,JJ;/B%\YNTWC&E"DRBE47F7I='%KBX0QDO M$[<$9UMSYY_4F(U"\MX7"?343$GEI&2WA9?WB[**H2^S2)\Y8G.4-'69E( U MN-B[(#6A\B^:XT;,;9=%UR;/[(N+A<:,4HB1DXQDG^Z[HA?QMVP2"B4(87N) ME+,ED#)<]+]TV$0(EINMI3&5]W.*51H&_MC8G7?X-GJ3'[\P1#SL),))=$ / MC'6J<:CTTXN3S6T3]](ML=J/>H36TJ1\^:'U9Z6\+@J^SB?P_EPD_L3[;,SB M@3TTL7$:%^F ;)>KUK@6V5]0*F=>/F?H.GP"K/SDZH=ETBU;CCE&- [>+,"/ M$]^YKL,YUT0=7#9CU,*PU/O"S:@4%D!'Y]>JXN0;=@5L,2%9^0@A4.!((NIH MASJH!R4Z#"]Q1[]M:CM=IQ'"8R KB2]H'U$O]12W-TW=4B[RRJ:D4P8<'C'B$\PMN0)X-#OS]ZJX?<&C \[<%]A4=T ($G9'[ M#O++2'+1[@LF*2&[1W@@L5]4S"T05Q+_1%GV>[YT14<_X$\*4^%CD^$C9I M8/R-[83%8U#K$"Q5%7V;E%(QW:OX@S=!)1NW,,BU)>-5U?4HUG#+:) M5OW& M?U;0@CPJ8;V&!KE_)B\IC+MTKWV[7'+>0NV.]=#*53WD:%H O$N'PEH"$26" M2-&G\SQY&K_5W=6T(B=/\89H5 VWC-RXO&FW(L1B)-V\,4)VA' 3D?C2/\V8 M@LK2[&[[1$93\^,MO]O,Q2,W(RLOO+@C>;S*>*;G$AMO7+LT8:H+58^B"!40 M,PD1:?^,R_Q"5E6.V[W=+ESS5$AQ\KA>\^NLS@I /I-%KIF:\G<=S&B1NBQ! M?M;2P=\1<;HB.-:1F+I "X-4,IAA?]L)OVS MMT@Q;^*I0(>QA; 3"/^^*KN6&^?#CTDGE9SC'RCB#<5G4(2ML&;UN&'0%8)6 M FX[2:G"4+E13=BO(MCO%+!U8UU.B"UK]T[Y@$+,GXY!RVR+7/LPWU<1'#*C::(\OZJLM]IE+ MY0^5?J\H$'W/^$38F_/]',L]);VXT'M14B./T@[:@$\ M8#$1T7AJT95D;MOZ<2J A7$.K]M6?Z98<+(3CWI['[^"4:R 8+O7^@C?K9Q&@]]Y_M/,FGH97Z\W M#9YTZ6CN)&T*XQ>M28SFEAU*BL!NWOMF8'(U\,+,SI\9CY>_7"%!/EP]K;DI MQM*<.OJ.J\.)<>_]' 5LO,M)8YX;. M6*^,2PC]2#VAXK)L:)OG]Q,LM3F?NO3:<1!4A]H0#<2[S/;)R)(J1)((K+CK M;17#(5HMIS1QU6UW8CJ@]QW,'\E=8GU=/L@-]G#,IWT'#-Q-X>VB998J1[,4'F M) &4U*[^:$GE8;\\62;!!S7<]N*WQ839Q#U,QU*"_MG5292F6OO):GB7(DS? M%W;N'IO9)>P(.AK<=:#61P>D1Q!;O8D5AX]Y6S4\4:]7,K8YU!$ &6#*P$Y]^4_*Z5GX(-'\&K4U!XZP-('.>KRO_UJ)A/3_RDH$]1D^._3 MB ;TX5K:U>YSU',?:OW"PYMOS/7XL3D*T %5^3H3;OLC\L?S&XW$#97I@"Q' M9SH >1;UU]7QCRA%\-LRSC2)(EB"2]CK]DF%;(WT-8N*G!\,RMG'!FKL*M]' M=CV2H794"44@)T[;?C$6YXCE,?8LFUFM$ZO:+&Y(;L)EFO$)CNNP(EEWBGCC M8,*'+TV#G2#E8-W>9Q'>1KWA[<_-?3M^>ZQ1AQ0\=;Z/)MQ%7?^8)X?5=\%ZOI/ MS+>]S;XL>BYA K(*+M%M9L03[O69[/L2B,2_:6:T"^*J-1MW<^UE^3C#;YBQ MR"$?N=;UUYF5/^47\K W \C$QH!4.M@H5^B )'?*7<)R#S+E(*B4HP?(?Y_# M#K_]-#!@QNGZ1+^8JN7IBQ*M-/7MW^V/9I6?7O..2M^TJ)M2GAFW^]C\ M0\5UVSA,8"!IK8KSPP%O8BB<:YJ:8SH6$!IELX_U",A4!&X4'8D!:< QQ0YU M4#UJ$^T$U(R4]=8-DH/9?!'OD .4&TF\-&8Y=$RPY+S?R>>Q'"\_W/+Q8YUM M9Q09[ JDP$J(!T43?RD,F +B"U.ZUS3:$ @T;TG4>RP>_BY'W-.HKE@VLV4U MK@':LU%M8MTP455:W]&82!SS:+**2N[-^O3WG!GGP80*:[<+,.%DMHJ@V?A? MR#N]-QID)XR#X3M9<0V6_19&<5+\<@55OXA&C%:BPDP(;QVLN9B MGM\84H@)W%8=.?SGX[7O["U99J>\<(V"\]:#FR$P9,;V)5(%[ MF9H+YX$J>&(_&\QM+89Z^+9_+7R'G'E]('YSYG,PC0N(1_<7LI-&&>U!'OYT M!BAY&1]97=A8.M/O8E-7\H46)/HFX?0;Z=KPV*0BG3W03U%BV"=J/AW@(RUJ M-(%U:K]987'0T1A[S/654>^5/?7^NN)?:5]ZPY E9UAQ5G1&EX[NM(!R'?2] M^-,8A6,]L=)^(73:\Y/?58*D51RG9#HW1U!\#(2-I/:8;$9Y0,VD*:\MZ(>- M4RQQT:H'P&.^W5_T]))/0>2Y/\54<=?'7R;=X;ND^$#SWPS% %\5.3 QU:.K MN]:9*(KK/FEH;O(GME.T2> 1T#U4W%2A*"EF!*.6W!2Q!YRI M=U^9$KCM?N17T;S0M:&Z\++Y]>"+W>CY*])@7\--VU;[[>5($!'5^/?!=96(*= M/TT'W$B-S\L/1>^GE61K7?@E]X9/Q9GHEWHN>+OZ U[J^5B0VP1=IR M+)=MDKI002/39^(RPUYRRM%0F^M_'3X,ET[/#1\?=S%6KGTDE"&1FT$=,PLK4\-X#3X =*,_?8VC,7C^#W+TS'M#T5O2;6D M6\@%EF17T6)N:J!(2LU=:2:=Y]=.\X22)BUZ/;MJ5\<^#\W+L%F>!Y^I@+$& MS<<:7J,T[@G?[<(@>5W6L_UM5W2]=+^BUC4Y-Y9FW"B_(>3>#OETKF0LAC4/'?5(=1C;6Z8"S3TC[ M=,#=(?A*I#TL<7:5V/3(6D/D>X\R.O2CN9A#YN[0?Z+%F/G[&9/'"G/AM:5S MFBC:B_LO#KL QD#/<<8W4]/# M40 HE]6FW O6"HU56MOJ\TJF8C>6"YV>C-RY] '7+J(S2%%!ZDTN? MFR]#9\,L[?)";F:EJI^-,7N\GV/$&*V?(**F>-H;GR4Z@(4T=)64Y1_\R]WO M;*EY;@M *7EH(/7#M\] =]="IP6G^QR2DA/ [849:6>'/2 V6C="!YH%$&0F$K*(UL=7G1Q ME.&A ^+?_O1K54V#E@:Q?SI?GO4\IE,Y_'O1/3N4:B=+*G73",@.[_)!_?JA M84.6#* #_N9NM=@D@?%.R#A#?E(T-HUKM\=0+WO;:FPSX#U$63DU@-!;WF?9 MQI9:T6^DLPDN$6V-KBGE?+HU(UG^9$[ MZ*W1E/$+QA5+T>W=*O5E6D/$<["67C^M]?1O/2S^P4 M%RS?BVZ[3 QNT^<@JZVX'Z6^@&,M7>;=^=]\RD.-^9KATP_B'\/;FB;LT,-[WUJPPXJ]Q'OC3F,;C?XFD]SKH?D7&4?SCJF> MZ7>-$9[I9P9RU@UCFRQS*AM%3IZ#:^'EK!HL^+S#%QXB4Z''"'%8^.993/6I MI=XQR!F5]\WO9]&MX#JYP9-YO\5G'/SC[['^FJM.#>H?>0K"U(#9I[ ;S32A M/,A X0@>KCMY. M2ABN M,XR;?=+UPFKWQ>.YF5;]M_*2'L5]2;'0CU4:H0.\1F898PAY0@EVGT(,0(R$>Y1*V%'SUA&YJ7Y<[L5S30?/>]E-] 9X!4&>@. CC*"B08CF$B1$'3 M[0#XWXZ95M1/1]HU.@"K2'U&I .^?.Y>FY1!.]OR4T/'W8;FW_G*F7^ F MKC'A9*)&HKR8TY+MAY+O+&,Q(#V4%WS_JO:F AW@?@.^:MH(Z8$&3,!],DAG MF_LSI-!8\B:\.SQN8^$T;<1H9]II0 4^=GGOV+E>FP"!8^+#L):>]S.N\U:/ MA*O4;P_UYLC?T:->O^ G:%6?CO./;WCB\S(PVS[-1.>O9RJB/P9T"7Y_A'1& M-($.\,U(V(,?,V2=7I?1)92EG:*-A"59YPHW--\]WM7>^:[.>BAKYXQR7^(H M(A1!5,E"81!R& &P";6VU%MKO_#+Q,D+S97"K"$'DXT 6"!L$-',*)91/H@D+2"GH:'SN@R M$!$O1V9[..]7;RW=]_%73^_5#<[;9_3"SW-UI5_7XTT"-?'V(F9FB26C&S > MXT?O* *C $/9*4WK"Q?4DO5>V;V^IQ7\@O_6%J"^MK.3'-4KP_L=ZBQA7KV2 M'_XQ*],NC-MBF N_27@GHI5UW#PX4 (MP6M4!#C#NCO2 M#][)MSD"_UFO2,M<<%RI=@C4&D4ZX&>Z@WX$BAY5_\,RSE)7N+Q;J<&2MF1] M8KEW@7=*XYG*U27S]A_*/HUQ=HT/%;(28K" MMUG^*,#F)05WS-:0/A)'B^-%;$]\C^27^6<:<+&^\$C-&O6&J=.$_:USY9WV M8H!(^T UB[KO&Y/CUS\VCV\Z;G7Y"_3'K7P 5(:R[$\PAG,#H\A@QX#)XDFT M[!'PVT87LG7#CR6G;16/-E.]V!&Q![PUG(S?OXM( P7RB';!&Y,2:>S6V"'R M&U?7Q+.>$R6OV/B3+,6.E/W1V1E9!IO9.VNTG0T6(&QL+FSJN":F7(M;^3GL M\O^#*=E,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q, M3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q, M3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$Q,3$S_<[STZ?\"4$L#!!0 ( &*$9%3/ M.U52&T8! !C<#0 5 8FQU92TR,#(Q,3(S,5]L86(N>&UL[+UKD]RVEBWX MO7\%QCTQUXXHV'R )'AN=]\HO3R*T7'I2K+/[5!,9. IL9V5+)/,LJI__0!\ M9#+? !-DT3WW1!RK5"*)M1?(A0U@8^]_^1_?[I?@411EEJ_^]3O_1^\[(%8L MY]GJR[]^]^NG-Q!_]S_^[9_^Z5_^#PC_UXL/[\"KG*WOQ:H"+PM!*L'!GUGU M%?R#B_)W((O\'OPC+W[/'@F$_U;?]#)_>"JR+U\K$'A!L/^OQ=]B$J*0I!2F M0L80(8XAI@F"*0^1Q!2G'/.;+W_S9>)%H?0A1C)1E]$84N9%D*3,3R13]P5I M_=!EMOK];_H_E)0"*.-69?W7?_WN:U4]_.VGG_[\\\\?O]%B^6->?/DI\+SP MI^[J[]K+OQU<_V=87^VG:?I3_:^;2\OLV(7JL?Y/_^OO[SZRK^*>P&Q55F3% M= -E]K>R_N6[G)&JYOPB+G#R"OTWV%T&]:^@'\#0__%;R;_[MW\"H*&CR)?B M@Y! __GKA[:N1IR\T*]7O&IWMU-4U=#'Q^QJ]Y%^4#:&Q1X[30T]OQ;'S9@"C>0"CC@6;E63?WM7W[:VNR._^5S ML;J#MN2TZ.TG!+G1>>\5/+%<^VD,% M=_I1^[17$5+E5[UX33<\YW]FRZ6_\-+4#QF7, G\%"(2I1"3*(8IQ8%( M&$DE3FR4:PB(NL M)>T:"IWJVR @DXK=-53M*]]5SQHF@Z^E%*S*'H5J+K\7G\BW#\JC_""T]=DR M:Q2W>B/4$\E2S3ZKM7ISGG8N7B0LD"+ /HQ%X$&$$8,XE!CB5/+82QGW!;%1 M10>8YB:2+5B0U2!!1;X!\>U!K$H!2 7*S@:@.E?8":F+#C33U8F[9629W5@# M&H1 000:(]BUZ$9W4-=]&ZOV;[H!:H[+E,OB3H,=TNU4DEW@FE2A'1*Y+]@N M'SU,O]^)2NG7G7Q9")Y5?Q?W5!0+R0(1,YQ"QE@ 49IXD"81@2&-_! E:2,[+.[?,"/C<0'4Z SS'@5'J.-C2I MEIPS=5\*)2_+S#QXHCQ&(:Q MGT DDA2F <4P#B-?)HSZW&YE[4)[<]. 7T0%EGE9 N4E@U(#MO2E+M!KZ">Y M(VUL'ZA%JIT74&-5?DR-%GQN_]2P08W;H6 8,N36;;G0YK0NB1D!!^Z&X6W# MQ.7ENBB4!ZO=%'&[XGK_=:F_)D_[5[9^DX*__6&>5FE2555$'WI1WU5=1?/I*5G:ML(NA&G_3% MK7*77W:##WR?K1I_JSS]^3YOIQON>Q4'?:-"S&M GT+^N MM1S4IM^ QGC0LQ[4YH-*V0]: FY ^ZZH5Z4AP>$.[,3=YG8+=RKPT^X!3]PE M!YO(4[=O-^C1Y5H,Q]@B>9FOVKA4-2;_/>>9S)J0R3M97U8NPA@%DL<^C*FO M(VVPA(3[:KP+_#"D$2=I0!?J&32_Y*Y/ ]A&%_NP1W1=-Y!KO_6^!UJOJ9$: MMOWX-U'_GQ_UYM>G\Q_K-J/9WHOQ][T7H[%]5B\#;P/3Z]_^A5Z*'=S_?W@Y MC/V?:?NJ\7ITF[4KXP>M(S,1BDGU.F< A$H'R;>,PQ1!Q$D(<(QTA1U*/!$F"26BWX7BRK;DM!6Z@@JR'U7;W M\32UIIN03@@;?2^RXZH/Q/N3%PT_W*:\?,LPQ7A#LN(W MHK3M[ZJ)==$\>?/+_SL3A7KDUZ=7^3W)5@O/CY5*1!%D@1=!1-6LA0@10B:Y M'_I)DC!B%45FU?K<5$7C!#50L$%:NQ*_W/YFIRUVG6"F-J-1.[+^G&,5?&[@ M.E2A030YU24[!),JU2!R]K5KV$.&J=DOHFH"M][E9;F(&$,^)S'DC%-]$L"' MJ60QC'A$ QP%,DK%HMJT\W4J-3APQ&R.NPDYY=@E#81!*3W@0>XD/ MD3( XB2.H> T%)Z'B)#"1MZ'$S9A(,HUA)E)\6 :1I9:S4 ;(_N]AO8#N*VJ M(J/KBM"E %6NYLZ%TWC9HTPX5=/=%B95RZ/&[:OA\8L&+$RK">A]OOI8Y>SW M?Q ] :W*_5"H1(@T\64"4U]PB,(PAFFJONZ$42QQ)&1 Y//V;"]N7W@#6)0 M:LC@SQ:SQ6J? <,&:[=N>1L["*2AK$8+.KA6<6:#:+18]71+YT3+ED=I=;2T M:$[(V;5!@\=,M[AG;M/.ZIS%;3)(*8) F,".4>BR(L?=_&>SK;VMS$=@,6+#5:4&?+@;F$:WU\ M2B.V=+3.#EC<&39W9)7 [T!'SKV%%A0HW7G@QF1XM0G.]_BI#Z:D?'[ M/IO930./N*LI55$(_HE\JQ]7;AM3#N)+)6-/,B^:S4$_"9*4^Q1BRO7TC'N0 ML ##! L6DUB0A"*KD^WF;<]-;G[]\>./8*7F+_E6=_2A M8'#;Z7[9E O7ZD M#W *R] WF]XQDZ21.!]9H#K4=31P@_L&]%1+4[^#W>$Q=WO"W)YNMVA_VD/M M]L05"&1+E9-(@A#5@"61(&!*6>P!&W.MS@#-K<1'(' M;'>6W=(-<]AQ9@+Y/-TQ^KQ:&06V5C7Y)K5=ZBL"FVPB6]/TKW>-F^;4EWOV MW9[9< =OVH,=SFD]./WAOH5A2O^^: >5>AY>1\.4=^M*YP[5B5(6%/D,8Z&C MLQ*NG%@J(>6)A"A6?\2QQ[S4*CW3A?;FILD;N,VZY$T;D@KR+>3A)S4N<2\H M\04-%?<>5=S'DL$T3A%,/<0\%G@A#@U#C4=@?YI8X6?EWVP$=,CIR,/:ELR/ M#9D-6-!#ZVYH,J3%Z7ASJ9]CSBPLF))PD/7 M^,9A,M/LF==GF_5^79=W_O9;5B["T-.Q/!PR3+'R* 6"V,,"AFG @B1A$IMM M8J<](%$\4\%R#AS5ZL(6_V6;IC!-!R'1 MPY]D)X1E42T^Z+-I[4&E,,"8>3R H8<(1 EA:AKF<>AA2L*4RR25@=D"T-Z3 MY[?0H\>3K*PRG<.H%WE^^0C!60(]PB,92_7NQH$>'I@.*><)1$31*@*Z+GV<3>RUH]X]KSC/U&\K](\ M('SZ_ILH:'S\S\XNT-PMT6>#T1TU-5W NEMN=H+:'3]Z8-Y'\46W^D$\Z"G) MZDL3,K ?X"-9F*(4,RBQ8+H*:@B)C!AD89@$+.1JSF%7,\ZDU;F-EBUHD&VK M85FF6S3BVFQAQ#F#8WO:+7D;P--$/5G1Y#:QH%'+TV8%M"'C(*6?UU#+V$H2",S+W\ M01#F)E/.SNML/"U1^^- MB5SK$7O%SJ>^BM"S+O2P)T_G,5]E^8Z#?-V3[(8@+C(UQ+%UD55/K[^QKWHI MZQ?UHBTH"?PHI1*&"57#2N*'$*>^A"+%)/*BD ?",QE@3C4PM^&CPP@ZD$"C M--.JDR2>'P]<4#.Z^VK%BK%67#+]B$M:"O;CE_SQ)W5K[8W^@?2/L/FQEHF3 M#YU$!"Z9U'WB%Z\;&+989Y!N'YR)\LWC+]E"ILHSC!&%RALD$$E$8!HS#CF3 M3$8IBZBT"DT_ULC$ P@7& $$1Q3"&-$J:<;R_! ML214IM@NS/Q:)J?9A1E54]@206D3F3VJ'-<.:#4;+I_+4TCRV/[KFWQ MW8 WO\%?WHX1S7F&";KZHZ#S_+"S7?KYWV M.HSK9;Y>5<73RYR+12@B&0J?PB"02@PH"R!)/ F#E&),/$Q]24T](X/V9J>O M-62P@_FF+;*4%Z!%#C1T<^_)A/?+SI1C-L<6#P=$6CE<%O0,]K],VIC,';,P MN.^=V=PVS%G[GVM2J&]U^?0F6Y$5R\CR[79Q75=>7^8Z)N.6ZKT/5BV4IX8C M[<*%@?(Z4. QB$4BH2>#P) M[] >,G-G1N1]9+%R2[FU]S.0.*>.D2V&27VF@03MNU-#'S-@WZ,[QOUSD:\? ME-@NU_KPGFXC5_J[6@O>KG?EJ^,[QNU^\$)*P=.()VJ2&^O3,EA +*F$.!$L M8(F/$#>J.^X4U=PD2MF_R0HJL4@Y ^0^AMY\$OWU4%GT1/^OUL-E^?+)2E*H%ZS)M_' M; KC6KTZ9I.I>8"=D8X=TYW05?0>ALS\L^4K'3^L*&$U-OCH.KI?,0H==ZRPZNA27&JX: MU)]TM8QM9"[A1*11&JL7UE<3[#1A,$V9@%+GJXP0CQ-AE._ RYC>'U6G[YSQY]N#^P5\KLUR&YOMEN&K3U(Z M@#+9 4QWM/7/;3I\ZH#USUO^'^LFMJ+\E-]RGFD89/F>9/SMZB5YR"JR_"@> M2$'Z^!:AI!2S@$/AZ\#OD 60!H3IM,$!#W B<(B-5SN'89B[ @>EFE*OU%=, ML]QBC6Q@AQBL9HY/\\A:VC- %]':F@"T#3K"N+7B!FSM '>=Z([?"1;+DN-W MQD2+D&-UBMV*XW5TGEU?'/CHZ583K[-]9^WPRD>YJ/ZS-POY('0JB.X?/XGB MWE_XW/=#X4DH$AY!Y$<)I!Q3F,11* (J4>I9Q2'8 IC;R+-9^B#MTD?186X/ M(2D0]]=4"3+H$[/%LC&9'GGP.3B\__NNRUMN#R@\L\ 27 MR@$/J*Z,EB8AQ)Z'H)0D9 D6B'E6=64'(YF;(K:& -9: JJM*9:Y]09WCIDB M3D+YR-+8L=T9 ?I6U*L;?3LF.7E^-:UN,_ -1C-M(KYK23O(QW?U P>L:-2K M)6_+R+M61L:I-W_[K*E/SM\3G,4=20(0E MARCR!<0"UTE*4T^F,O&14:7)*W',34U;L'I1H]C ;>O_KC5@^\H.U_:4P7+' M-/R/O9E:D]Q8 1HS0&-'5Q.BZQPUH][:TI;$K:V9ID,LECZFZ9B)EC\:HK.F M@WC300]-![454!XO?3T_.EH#N9[7L^L@5SQ^NK60ZSG860]Q\+B!:R)ZF[99 M7?E%F=T6HV!(A"(6*611BB$2F$&*L7+_9>CS*)*44:L2?4=;F=OHTU,U1LHF M=#&OHT%6^0JVH(>50CY*LN%*QK74C;U<43/4[39N(3I:U(.0/.<-#%CKT VNE1;JJ)!-_M)<5NKA77)X MP3TI2!K ( X2B*1(((YD!"F2$4Z(EW!I%#9GV-[<1+Q##$0'N2E:WX*VF!P; M<&VP*N&6P9&5!FV3)+G%.R21M0&+%DL);MF<:,G@PBOI:CG G)NSTWZ# MQTPWO3>W:6<:;W';Q(>=-K'5:KJPOF]"LO7Y*SW=?94]9ERL^ =2B85,TQ@C MYD'?5PX[\D@""4(4$AJF)$1Q*HC55M_HB.B,QUHVV=P1LBVF^9Q_,<8]5_C9(]M)S@[ MM&/=\,2#UB]K/62V$Y_R]I%D2SV1>9,7]9FA!>$15L.1@$BP "*F9ALD(ARB M !&4(L2X;U69>BR@K[5O0[O#>[KP%M<4S&*(,^V0>(],EL'^- B")*8"H"-?MA:0PQHRF,"8N"Q,.(K28]DJ1?XMS$*^A_JYON_Z%W9!) <5E5HT_1TJ=BU>_]:2N7R+V1"=*F# M "9U4"(.(DB%C"%A 6C"UV@TXL977:%\10F6?;[6-O8M2]K/\+>A;=]*,E7W9Q1?N_V[FA MC;L\4MRFGWIM4Z)"DP$:-AR.(,_2BVX'H6E-F'8<>Y;N.1@*GP?%@/WKMROE M,BLD'P03"H":7/RCR"IQ)^4BPH0E-/$A]ED(4%8$TJOQS MH9VYN?<=4C4"=5!OP)\:+,REM-AH/4.MP3:U&\)&5O8-5Q]Z7-4XX9TKKBPV MH]UP-M$F]$#N[+:@+S-R=NOYS.W3;3E?MF%GJ]G@\J'U0-YD2]$LR2QPX"64 M)!)&44(A2NJ5$1' %">ICV2"?&*TPG[LX7-3Q 8?T #;M5';@AX]XLY+W[5T MC*QW%DP,J,AQ:/*5Y3=Z#YRXUL:A*8>%-8Y<,Z/8C]]R?3!RJ7#640$\I#C@ MB$$A(@D1BE)(A(@A09&'> M_+?4+L9_;(W_*T2 '.^J>>RT6>#^:VRZV7?$)'$@)YH>- ??G^J_U/F[:;Z7 M(YX_ZN ##6XA D9I0")("$_5<.2IX2@. NC3$/DR2#R&T\5*?%'(N-'LW!:! MD3REC3SU<8P9U-M#K)>/VSH+6\Q6\U'K+C&:TX]"\U1S_7;5=;. KS/+[9"^ M*6YQ:T"Z[41V*'47)KC6CYURXCO4YKT)\>#'#//'C7+8:;VE^Y+\0>\"E6JV M_E$4CQD3S5*HFLGG7U;U4YJZ #%GR,-Q!'FJU2\-U;R;!13&H1_J8 0>8:M3 MV&,#GILG7A^2;QTUUK/&SAT?O9O-?/$Y==[($GS[_NW+F^-N]M:7N=GNC\FZ M?&BSQ-C9Y,ZSGHIXIV[UZ* G]:FGZH)]AWJR=B=>$+KK7'Q1L*P4Y=M5@^^3 MCHMXNZJ*;%5FK%&G)$DP9W$,.5%O&I))"K'D!"(LF)=(I,:G:>H:68">VT"T M0=>4DZ\#K^NT/'EC$Q"M45.=$K)Y 49>*AJI6^>_5G2W71QJ3=>A0HWQ>G#K M7IFYE!,:T%'S6"FR ?[76"H:T!7.UHJ&M/T\PUNOXM#MBK_^]I U,\$-Y$7" MDL3S<033*$D@H@S!-$&ZW$],_ C1P(LBL^6ER3#/<$%*3Z>72M^4%RYWRO-- M>W3(N->G&=#<].1?;S3KV5U'.O8LWXYO\QG.C+MI5F/99=1_J8',N!-I=7I9WJZ98;CWUZZI9^ O)DY"D.( B2A!$/N$0TXC .,%,. CE+)NG/\T*=V[(_6G_U*LFXVS[M[9D0=)#11\KZ'^H/GKH=V6 MVW,WKIG1XG10NM#DI".*F?G[PX'A7<.T?*?<>7F^WGFY/0NVK=/ &65"M$4INI7T)<1H9%, AY*&[6_%M#V=IS [86@<^CE-5PQ:]3@;P:U*02ZHK"?9%U]MPA1425DM_3 MY=.'_,^Z*E*;R"^*&>8)3B"OHU:I$##UD0>]. TBG"9IA(WV*,ZT,3>Q[% " M!;,IOF93=?(XC0:A/=>3,_;><9^7ICS:@.21)PBR*;MY-5%3E=4\(,Q5I 0;E!? -( MAQDP'0OR4_V'Q3=_F78#?71*YLA2V>-Q"Q9LT-8A-4[YLY!/ISQ.I*1'W\N] MU])5SEUC?L[J[.6G3">YQA;MJ*_Y70/W(->T%'^LU\BK7=3D7 MOE"^I92Z,$Z@-!@EL?XIAIB*P*.",C](K.)B3K4T-\]S"Q342(&&:KG'=Y)5 MP[TY%UR-O:=VC";PN<'ILJC#)2[<;ER=;&W:#:=+1A]L%%V\89@^O!/*_1/O MFKCSDA59O:_T+EN)MY6X+Q<1E8)&-(4>9FIF*I3/1G&2PI0G<2I)',?(:H?G M0GMSTXH&[DU7R;H'&7S6H$&-VC*9W"7.S33$(9,C*\FU)%I+BB$U3H7E4IN3 MRHLA ?LB8WK;P$I]Q1>RROZS=F)?YJLR7V:\2T+W7I\#:QW<._DF6Y$5R\CR MH_I-4QAFDUV1A RSF,8P)D1 )'7($T(2!I&:."8)]X+$KK*?"U1SDZV^43=@ MQZPZIJ5OF-[\VY@&MK8-SI7III_-1'#RWAM9*J?J./L:ABZ)=EOST FR:6LD MNB3SH*:BTXM MF''B]J#;^2:G/:9F9/[!(3.SNX8IR:^KHCES]I^"?R+?NJ33W=%)G:YQO=3% MI=\H:]X765ZTT?SDV_LV?J9<),B/TCC&4*2ZUH:?8HA)PB'FG,08H5CXV$9O M7(":FRIMP(/O>7L O?RA/IE:D6^@BT4J02&6.M(/5#EXT):U-=PMHUR<=*N9 MSDW=62.K8=\>>*-24!_XZ VJDO*JV_9V.5..5VR[%1?G0";5(5= M4KFOU4Z?/4S1?R-%IO<[ZF6&9ELM26B@H\BCD&*(8C6E)UP?:N+40[$,J4>L MX@H/6IB;UG8 F[B7&XN-WM,DFHGA5=2,K&P;5MIUPK/;M]8"==)RIVISV,JD MTG'2R'T=.'WAP G?JLIXMEQ7V6-O(_/U-QU;)[@6DZ:R:.LDOB;%2HF,3J%= M'V]1+N1Z52V"V(]"GRLAX'4F:XP@QI3!.(QT5L;B9.-17JWU>B DM]BD*Y;LT9Q^&G'=UTO.&, M=>KN''MBV[.G'\'R>JS;I3NRLTOY<SM]^(!8OS?9*JO$.]4\WY_YWS*VOE_7L\6W]P\D*^KT>YQ$01!X I(@ M32 B*8-4GV#WDC1) X(HC7R+HVR#0!AIP/0GV[8 +:+6K#O@O-:.Q^Q-(3*(#$ MQQRB*-&5;>($)BAD"2(BX(FPVO"W!# W_[]##$@#69]]KCQ";C>=8;@K M/R+%8V_ =]"[58@-W2U\T.&O\Y_7M&Y2U^%N=GU;Y):1VJ:Y(LX?D=:KQ^6=_#G/>?DQ7_*%FL,C MG+ 02AX)B#A",.4AAL@COI\DJ8Q]J^B>*[#,3=#J),_J.RSR)[*LGNJ0OKSZ M*@I0"-6;9])D.N\E,[V;B/N1)7 W0\3E!!'-WE.I>ZHV!VA[1LH-,8S4\=)" M6.)YOHP0PX@[FPQBX".'2>RFGL.*OU(?_S)_T+/KUTT\8'M>/PF$3Z,P@)SI M_&HIYY#0B$'J<5]@HMYVC!?*7:6YJ9@:M&KSX?;;'N_[W=0KT7K)M[#MU-*$ M<#-5=$SBR.JWPUX/+V@!7\XO8:UP%@0Y53*3=B=5+ LB]I7)YM;A9X,SGI'B MZ2/1'F5=;N3V6U8NHD023OP01I1*Y;A%'J2ZPC27$E&"9$*05<#DR9;FYJ!I M>'K8KP':GPD^SJ;AU-(%1V//)?OT@,\:G>.3P&<9<'X2^'AKDY\$/FOTL9/ MYV\8I@8OUME2^S[M2.B'D9=X6,"$Z'U:1E-(69C "*D9'!)A&B!J(P&[CY_; M=]^AL_OD]R@S^\Z'$S'RQ]T!&\$?.&ZST\]YKXE)O^'CYNU_N">N&O:UOB^R M1[TPO21-*;CV%422A2R@"?29\""*4 PQ]RA,?8]SCPG!DMCFJSW>S-R^WA8E MV,"T^XQ/<&GV.5_/T,B?]0$Y(WS?YTEP^IV?:&K2[_V\N?O?_86K)ZXM\OJ/ M=58]O5V555''@Y1W>OWQTU>R:E/*_ZP>46WRQ^]MBM7_^$I9LZFXNTBPU">H M L@8"R BL2[RB$-(940#YD5$BF"2^EJN+9N;RM4(V\HD7%<&+7H1O%,5*7'^ M^AA.CN:"=T;"[J#H2<,.Z-$#:GY I0C:ED1I..I7]SJ(BJ@O 9JJ7@WY&51) M&:O_YU%-Q;EU?XVJ*V-UJK/J+*,!'!"A_4K0JI=;\)%D2[U3_"8O]/K!IHE- MXA64L("%E$ 21SY$- XA]IBG<[/ZC+"$2[/3>$,:G]N06TO9XUDINY[P\R/@ MV#2.O?6JD/?.MMR #7@H\P*6"OY-;\2P3CHTB'&+D.P1F9\H(MNR!QR%8@_D M[6PDMNTSIPO$'FCM3ASVT&<,73_*F1"\U$>$_DZJMM7WA7AHAC%=3NPE62[+ M.[D/90MR(:6'B60$XLB/( IH" E' B+D"2%8*)E=(A\GJ.8VB'1&-1A"20$O+$CTBL)@@D93:B/PWLN8T* MNS&)X!=UZ:4-]>?L=+/Q87Y=.?;TQKX7K0>!:4EU.DI,!'W2863:[M@?9R9N M?[^ M7"GE_9H]O/RJ5]C:A:$4,E;_* 4URO@\"KJY M#2L]T+K(Z[JLX[5TQI=\<[)Q6=M=N[4ZMQ^K30>L;_M-F];/8A'&>;\;K(L] M9V^./+(HT\#&-M 8!Y1U=0*_QCZP8R#H=_W="B@;P<9(T%AYJ7K]!+UJL?;V MG+T[T>+<+Z8?)MAT\_+(%[[I9M9T<_/QNJK5-%8_G%WL<][H=*N!8_&ULUPX M6B,CQ:.4I_;*ZO_H>C8Z/[GZ.+0/W193BE*$.:(,RBA0TTV."<2^^D](&&,T M%.K_D=/0D@$@Y^8 M%OZ-6#',2%#NM!1>,?('3/R6%Z#'*U^UHC<31OE, 3H MO (6KJ#:.O;@FK8&:KP^:= $,+0ALBP.<"1B"@,<)!!YDD 2,@%1(E-)?#^E M<6QW/O&@#9O/>)K3B'?KJJR4CZ8]MB8+9_YP/INV(9N&6GD-0R,+73OXW+7% MO9S'&9^TW:U0';0RK:/=]/C>?J<8':H"@06CV*1\E[OQ7?"T= M(W_ %DP8?[SG3#[RW9:"_?@E?_Q)W59_LG\@_2-L?JR_TZ,/G.03/6=*]W6> MO6;8P-O,Z=X0EBV5O+:>-4Y9& 5^ #'QJ?Y Y@& 8-!$$7"@VD<"4ABA .,D.#$JDKW[N/G]GU?J.=E M0IC9!SVR\<39/&;T3YG%F["3*>2VE M#B79V1FNBPT-&S-T^K@_L^6R2:@N^-$J MH0$AXB'UCW%DY?H9MSPWC>^ WX"LA7X#2*^.0+9!7^^@VTF]>7^82?@H+(\L MS5N"WVX(/EZHH0Y$<2>UUF0YE5#SUB>51FM2]B7/_@$#POQ>2RF8+CO41"1^ M(M]THO0/0ANI9L.URF["$P6/(U]+ ,.J4@91$*FD/J278 M]-KM;L;-J;O+(M9NZFZ;*+YNVWU9TWTZKD[720'%;O=MX^UTB>OC'YVK>#J7 M7)^-H7/2T'1Q%.N*UUGSMQ&Z<::6BY$ M:P^HK9TC>Y>9NF6 M4/,SG_4R-_T\J\6U*TWZ2ZW$N>D^U\MVCE#-.SGC(B94$L_'$*?Z/+8,,*2A MB&#LQ$S]C_,PM4H,?*2-N8TC&XC-P8 ;\']Z/WH^>"!M%L$;$-UXGM>.,8"L MJZ]YD?VGX/\=;'Z9E>6Z]?#_KW_V8^^_-_\%>>_8@9I4OA*LCOEN_C7T;X#^ M+ML:/T?^R;/-*G78H69CSY7=-/(PL>VACTT/_=;TR]N:=9>9FTZRX#@/TV$[ M$V=5.FGH88ZDTY<.SF+W((KJ21]STODOM.C5JW7O\V7&GK;579-8.<,$2QAB M&D(4T4BIDI]"SY-I&E&.,#/*(6';\/P$JL%] QXT\F;)JL-NG7?.C'M3V7#/ MZ.A:TI'Y?D/F!K;Z90T5D6F%R9J,6Q/ 'IJ&B\1]R#W6*@+YE*(@]"#)/6#B*=$)I%1T:5SCJNG2728*/: 3TCZ\LA,Y>/5)I39+$Y[("JB?9[+5XFNSW;"Q2]T.ZL7T.]LEEZZ]GGV/WL+MUVH?.+[2*88"NJIZ25"$A)$E&JRF(:QGX1A M1!;-GMO'BA35-!N;!SAM/I)]M.-])W>[DTDJOF2KE?[+#(+G#[LZ\7S*I8A@ MG6L $9:H83' .M< Y4$4B"!!;5>_7O&_3$=W6"?KYIFV@>=V.N)D)\QC,?HDRK_&JO,EDEUOLYYN:)B;\$%4)%L)_IH4>C@J M6U\UB".?XI0KQ:=8C?!!HGXBZJ]4A@GQ$I_&5O6HCSS]'(DMD!!!W"40K9GR/!<>WZHTU-7*[^G+F'%>K/7CTXB7TAE-J\ M$LV?;U=U$OV,OVH7CW5 QZK4R:WJ':WF0.]"IB2($A%#G% $D:>K5J%(0,^C M8<*$STE,%ROQ17],9AHQ#(C1]Y$VWT3NYW.[*X>B4']_EQ&J$Y;HNC^UVUFZPUU@FM3J7V.D23*JX3\O:%U\U#!^IOJ^V? MR+?>0]\I_5<0^OE:%R*-I8PC"6,O2/6!?@S3.&%0RC#U>4HI0WYN MZ0<=?0US"74"^R&.J#GOAF+IE,NIJJNVP4SZ]&D/]0UH7#UTJH"U7;M7. MN/5IE^AK=Y#U\5LFI+3K!S,9&X_=D;5L MG]@=Z&"+'7P>)9)J&&]N@[R90Y[RH (JX_LJ^#KI;B3XT70 MW^HSY>J2=]E*O*W$O9I-][/A/F M)K<=">!.-GN?X,7Y/=(73SO7[>R1GC[A\ZEWP@=TI(#/FA90\V(3&O\4:-OCAYN7*91-6TT9IL/[+17:C.?K7M86B M :E?+M&\7%GOY9!-%Z'YK,SOQ'\^+Y*! MT:4;S+?*I>39%+4IGW2>ST40 M<:3^%T&:+-UT93P]>T#6P-!9R'0KSWH MV:AOVL1O*#/;\?9S;:EE*73';X'9?/OY^G8J9VG";K6/1AR%?;>AB&XA3AN' M. J]!T&(X[0RI'9Y'<-X)S^I(:ZL*ZE_%,5CQD1Y^Z40[78"(?&1+(4^QD:6.K>&SG3]/F] O"%942<>J(>* MWAX7PWZ<^A+&B8PAB@,$"4<$,@]SE/IA1,P.WHZ ;6[JKTWK^8 W8&,=E'D! M2Z)KAL->P-X/_@R[Y#;Q\$.Z"-#!1^; M^;&U^D1TJX[V:FS0#N[QJYR&NPYGT768ZP D4X>W#B?K2%CK%0\;&!Q&'K** M+.N3"CRKUNI]5M^^CG;G+];5+WGU[Z)Z3S*^2/T@821)(&4)A8BS$-(@T>D8 M8N(C$E >V=4?-FQX;LKX7CWH*]&G _31^G/YM70-BF:Y-%OI E;Y6F_K[23Y M>R!/32E#=1_9.WU@&5QFVH^&864C],[8 64-9-#'##K0@*XKH&"#)U$!#=QA M))DE56YCR$P;GS9ZS)*2@[@QV_L'K/V^R63U]");K<33QZH0HM*!MZ)+S(4I MYF$:0D&0A,B+,*0)5RYB&H02^W[B2Z-:?!=;FINZ11YHD((&*EAJK!;KD6=I M-5C1=476R&)3P]RCJD8Z)&7769&3M1%(XO]IG>4'?H M)N?+G?:6F=-39'VM2*$G/JX5$$4Z"B.L$5#%$'J60 MA!RI?D181!XC/#&/"K-N?F[JV> %?RK @'2(#TM?_@%D99A\=&"W&*PPC$KV MR#+9^)1]\#>@Y5[C!QL#FB#ZU"7 M!<9IQ 0*8:IT1(F+'T$:QIVZ<&-A MG=3O&YGP?6=Q[.9&3#%X2\NJ(*Q:Q"PA ?,Q3*E0LU[& T@"G&JO$[&8"$%2 MH[19@UJ?F]R;Y\'K++"<"=OUC9F(C\;XR-+LDNQQ4@[NDS9]QL$-@ODE'-PG M9U"^P8.'C)Z'_^0$?Q'Z4<)\SF#,< B1SQ-=ISJ!41JGH9]RC_*QTO&?!#4W M@3Q;P_H&K(1EE20G'647:_LO/'J;:79Z"34S61_&ER9$1I"3":41@C+!H5BM2)GR( H$"0AGS/2NG M]&1+<]/7;>J,;6!IV6*U4];3Y)K)I1/*1M; +5O;2,^/E]BR%K2+3#A5J=.M M32H]%XW>UY/+-PP3B9])MM*GU>]6^@3[G7RQ+K.5*,M%2&4@A1="1C!2$]=( M:P0-8)R@T/,%X^J/KJ+')W.I.-6>T6N_6\7CTP2"4:>(T"F@2!NOMRZ^DOL; M\$M>5%_!2Z+P9"L"[LEJ+96?O2[T-Z)^.A\&;=<39H)R%;'3Z(F&"+[7('_0 MG#9#9-;EU.L NU.62Y0X%9:3C4VJ*Y=,WI>5B]1"16$+L1RF,/4YQ* *>X&11Y159&FZ2'&O%RN78M#7B(*H/%FH5J:," MZU21Y.%AF;$ZJ+?*];['O588O17R-5\JDDL =6V'$85ZOLM2YH?[PLODA'V M)8;U?\(.OI#:@Q.MS2.4>!VPV9HRU-NYURSMB#S9"S%P^3Z=W3.FT%SP66.)&1 MB&'B2081CCQ(0X&A)_PZ5@818C4[/-K*W&:&VQE.?=#PIDM-8??U'R?4[.N_ MFJ:1O_Z]TWXW7<5?=Q__60:Q]N8VX>_00E:F!;' M!TZP>/Y[=\3-R%_[ 2U#DCV@+.G'$[<.MU1 MAO/8=\XK7+ATF'OSZ\=/NE;YNGBZ7?&?;6UNJO?KCQ]_!%\V( '16\=/H-S6/]#;5U5CD/4) MX//$F[E#SN@<62A__0@ZH#5G6ZB7%=/:0S(BQ:FG=+[%23TF(^/W/2>SFX;I MRSM1ED*<2'G01D.6K];BWP4I/JE>$0M?J,E3XH$/&CT"K$MD\$$\"O4/+W4JPU6U\*(X MEAYBT&-,32TIQ3 -XQ!B)!DCB'DTM,K% M/# UUFB%+'_)5X^BK 1O0D\6042]6/@!1&&D*T>FRG=-H@!R(K#T$Q(AN_/[ MDR&?F]#_VJ)30J],R)C^L=[];>KCEB!?5V6EYI):>/2>9+T/65IN1$[W8D0\ M37 D(NC[L9K4>$D$,563FL1/:1BS) T873S4!W(^5J2H_L*OQ[X5$[PDE"SK M_"JD4O[[EVRE-P'K=.PUE+_"^X$EBM,X)# )]1$H#X>0DE@Y@I+QT(^\D/O= M^_%ZQ?_R;T=GP[3OAECQO]9;8>9=SK*?1_9"^V=J^U;W#];J"NM'S]YJVV] M8SWHF0_NMB766P9T%&/+@?JQ9L%A8L&I.\YM*L+)T$^;O'#J3CE(=S@Y@ %[ MXQ8N_8D%& 6FG;LOTB")O%B]81Y*U.!'4P))@'P84\HD%FKXLZBNX!+9W+SB MO0"<3:;OI_K8FQ[;!BV'N.]1@]W]Y^JGV2V/G,P07H\][,)2R<@=:1&&\%P= M.E'PPM0=:Q<",0;Y9P,GG#8X7;C%&#SM!&F,TL" 7J;-/GDT#=.,X8-0C D$S+8)8N_DYL3YNT!\]N=A)5, MO1+'W ;&9BTM:^I&?]^>%/EAW/PL._WB?&M^*-OSFW'67>/\:,J55#[7UOL. MEKENN!\C[(IM]J./&S#+N U*O5&OJPOF;>1RE/C2"]64(4B)KB=%U.2!\ !* MDHHP];PX]8CQE.'P^7.3N0X@H%ENX34>(<[ <;^.CI%UJ,_$D(,P1RBQ\(JO MHV8B%]?H9;'S5D_;?=;U/'+;='[D:EG%FQ]M96ZRU8(<6%S^.)%F#M?5](PL8QTS M+< 1@A7/,N"X)L:QEB8N@W'&V,/*%^R+OYJ; MD;_X#;X;H!G:0+S1,RJ7N9;.$N'TPS_>TJ0?_EEC]S_\\Q_+0>)HHX)RD)8!3K/!X1#6'JJRD+]]3@SXD^;":-9RN& MCS+TKJ=*9GMO0-7XH741=-U MOO8BH^LZY8%J0U>JV%:O6"@G+:!*O*$?2KW0%$F8I@&#E,LHQMQ7\S9DM>YN MTNKLM+N=OX%"+.L=L2H'R/.___V'>NO,K?5S;,].O8A7R[?Y(6^:>''/.#(CZ%( M P%1S"-(<1K ) ID&@4(<9;.[/Q8#_[ZR M(I5MXGK3CC!>(G%-[_B+)$TF'TUQ@_FF_KF!#79P.UTRL2'*]:*)4=M3+YO8 M$')DX<3J=CO5*HMJ\7)]OUXJ)7P4KZ44K'I?IURXD[<\KYW-6_X?Z[+JY3LE M-"!1*C#$ E&(8HJ4=%$.HS (<2 BQ+S01+J&-#XW_=KB!XT!-Z QH3Y5U!JA M/(Z-&68B-JA?SBO9V&R/+&?61#O,5GL-=><$3CVW)V[J;_O"-JCA2=3M&DHZ MB;OJ&0/B#/Y.BM]%I7V\CYNTT+^N"M'44M>5H\J%E_HA\6,*I:=+.B4BA@0E M(11QP%**"46!9U+2R;1!*SV;H+K3%G(O=_8-6&]0@R\:ML76N GK!M$&CKD< M6:UZ-&[A@BU>\/,(+%H$%SAFILH05'9Z,*3)XS742!A54[ MT00V]PV;.>L"\*)@&5F^)P^;B)E(2BZQQZ :'0A$)/'T+AN#+,11Q'@B<&!U M8N]H*[/S*C<@P8-&:3?S/4ZDV3SW:GK&=@.WS-0 1ZA)<)8"I_/5XRU-.CL] M:^S^7/3\Q5>OEW59-92R+&*6)#+U$42Z4AL*$8<4)2G$*$KB*.)!(*--M5[S M"IO'6S-ZO_=J]4Y4:9-WJS@5^69[\N,$M=8+7K9,/\J*/@ DP#'/HQC!(J MZK/^$ C@(AT?&A\\W,3OI&%M.#XE,=QK$*!.]S,&*% MX$U3SU@B>-_<\S6"#ZX>J TZD$YG;50?P]LZW]$F-91/=#5P'Z:Q/F7,<0!I M% :0)"2.4XX80IL9IZ% G&IKP'QS;)6HPVI7^0K6*I%5XMY6"TX2:R@'5Y$U MD2+4++4@P=LV75:+\[3[:R\+E[APJPPG6YM6'"X9?: /%V\8DB2I$.1.UHK# M/^K78($DB[C/!/2QGCRF'H>4!0PF H<)]E#H":-C'L>.RX:>^S-5>W$G[SR=..KAKPKQ)IQ#OIDTZ>=4P]Z8)HL@>12.(G\BW#\I[ MT"?L5BQ;9O4;<'RZ]OH;$Z4.+GLA5D)F.A"#Z41!(>(LX"2&0>ICB&+)(<$2 M09^3*&21DK_$ZI2;:&/6OWC"S@&]LZUTWO M'&CSP*Y]39ALZTR [UM[?K@YOFRV7>:H(]*8T_13HW6'4P_2/*>1SCDG(9ZKYNI(99@*!3U M(J"2^21>/(J"YL_!<[_A\9BN]]/[!40UWXYY-AL!77(W\H#6>STUR/JH3/U# M#ZZ[LXX7$FPYKBO*$'TY0*F(02(<$D#B-LO%=EW.SX#(U]$,'W0-E;5H3VS% M2>1QBB1,8RF@FHY+B/61&$[3*/6)D $Q6GT]\?RYR78375,T$"U$Y AS!C)\ M'1\CZVU#18MN2#[R(YQ8*.AUW$PDE3L<.5+"TX:?E;PCMTVG;:L:@]/91\L_GT&(0^]V' #OU-6V2:](M,CWU,\")U$YP?/(UA!@<++Q)D M=N+P\F,&'D7UNI;QPD\C&6$40BY2 I$@#.(@"6'BI3%" M,F+(KAC=V=;FYJWU*X#OP@6?:\"&[HH9U6;ZY8S D=7J"N[LC]J9<.+VV-S9 M%J<] F=B_,%Q-J.;!N_4"G63W@)^I7RQ9=Z42V]"S=[GRXP]+8B/0R\F%(K M#R"B@0=)%#$84D19X/E!0(W2ZUFT.3=QZ2#7HS7?@AY8 M.$=>-=5Y=)/GU8+Y2*91%$!/Z*APR80NQ8>A#'B,XD ($AAE+Q[4 M^MS4JET*7VZV'?0:+2AKO$ JP/4!&IXOEZ0HVW^S/$QCW4'#-R* MKM7K^>)I)V]_>3YQ?]G,#957["5>**%@%*FQB/B0>#I?6"P9"[%$(;/*ZS 1 M[KF-8KME-,K+=33*81/]J5X+,X=^AIT]]E*I^WX>4%Q[4M8=E^N>!OO$!< G M[9##DN+3-F\WH'&1+5ZK)U9/O^7+M7*MBJQ")D7N23 ,61R=!SLH6Y#1(-2+!!"1J89B/ :1[/:[43=D9655MBC"7S MHO%'Q*T4[,-/ZMY:U_Y ^D?8_%B+V>FG3B([%XWJ!.+RA=?XIN_RLGRC M0+UL]$*)QU8PE"?\*ENN*]$$="XX]CQ&$()1BC!$OL20B$ ?UXM#GRE?$U.C M3WTP@KE)@ MX$B=,K("=>F(-/H?FJ[8&M#SYNI3ZJ UH@D\=^W8#2!P!!?-!L4S.%L#2#KN M-@UYT##5U-OKOZA7\/9;5BZB*.0,I0)R'WD0$9+ - X8C%-).?(P(LRJ@%W_ MX7/3.HT-:'!V,K7#EYD"#65A9''9$ ^:V0.IX+'#'8J!CL-3/J='S-M_Q,^ M>LVPK[,I#_>&9,5O9+D6V[G2+2VK@K!J$<AO)==I\U6T_EW>KE M5[W3\'9U]^=*?=M?LX>_9ZOL?GW?/["&I RD%T.*?5W=1W"E33B A'#FI20F M'C,*H1L9Y]QTK AR';F\2$..1$1B MB*(P@@BC%&*&(\@8DS@)""7$LUGE,&IU;C.$G5".[3Z,Y2E#([[-1,0YBR,+ MRHE8F&E"YJW(KAW55OM,!^GY[ZMZ7 M/O&H[T,_3)0B,28@2908)[SFVS:3($8AKH#6@9&Z'HL0$G3G7F M7'N3JHN!X?N:8G++T PPO^2KS92_/=[3[/*JJ5JC6OW_;@?A, X)B=(4TE0? M&O18#'&2AC",99P&":-2&I5)OQK)W%2H21.2M<$1[?G!'V[T8JEM/I6A?6.P MJ#D5XR-KUJ9 UG;9JBNCT(:GZ#6MUG,:X$@Y[AC;E#@3=-"DR7-6_8[:?!O= MQZ*W$QYJ2URM$+H@\7(BGJ$-3)RRYTH>#I/[7/O 8KA.9OZ^R!\S+OB+ MIU]+P=^NWJX>1:F1W&JGKT[2L=DN]U'D,9(@F'(?Z3 $-4$/0@F)%R3ZS46& M>31.D!<:Y5V>"O#W4L2]_B.NBAL_D&;*P& MK=E@:S>H6B8S?LP(-G--)WD M.%/.R* G3K,S31<>3S) []$,8TC'4Z M'S4W2V()$:*"BT0BBLSK!IQO:VY#3P_MXTY"DP&9J"^P;+ .Z(Z[D15Z!V@_ M$\^0;-47>+-8IG/'WT0+<;L\]EX_5VMN9HR<756[\(CIULW,;-E9&3.\Y9I3 MQ$JLCYP)(4(@[),0V.S1B M3;*9X^R(NI$5=3!K P_IGN5CA..XQ]M[AH.W9PT_?L3V_"U#LXE\O"?+Y8MU MJ3R^LERD012&L4QAE$:Z&F?"((Z]%.(TY#Q.!?*%4:3(B>?/323:A!DU1M"! MM,TCLLO@>35PP,O("F!'R8 ,(D<-OS)_R.XS)\X>! M=C4A2W:RK%5#EACFS[?HHRS M6Z#95XC9&M0E*VLYJ[*IOVECFSM]QR[13U\@1M$F] M*+=T[CM)<]ZGVI2KWD&5V*YE3#.S6(O*W$O9)P%F IB5)O M%H>Z?#J%*14(DB3B5,:)EY@E?[-I=&X"W6"&-6BP10T:V."S!@YJY):S/J,> M,!-:U[R.+*,N*+4/_[7@R&TI5/=+%AG5=[J_Y M4MU?ZJ)'U=,BB(.4<<%AF+! K^!+2"-)((D2(GSN8Q\G-@]M7)M M =@UX08TX>T]*VZZI"?NU.L:,ITJVB @DZK<-53M*]]5SQJFALWC&"O6@O>$ MMYU\+ECD$X:8!W&JIH#(9Q@2/_8A#CB1/)9QX%OIWOGF_@LHW 4^S;3,'4LC MJU:K10W2W=JT+5AWFF1&BE/UN=#DI#IC9OZ^HAC>-31$0 FZ:TD-^ S3V MWO0#;.%?$5)@W"FF$09C4#UZP($SE@>$(-@2YC@BP;CYB0,4;&DYC%>P?H*+ M"@K'TVSH]&)2+\OO)>./H@CK^BB0"20@"@*E=!Y*(4?*8>()C=5,A(#0,)8NL@E9- M&IV; K\24BA@O(O_O]F&E.2%[B [@37BW4Q)7;,YLF1V<,&?"B_H -]LIL!/ M(TR ;2AR*FI^J7C94[,N4U;T#]S%%60JQS3ZK@SLV3;35:,M7:_'O@A1O MLD>Q\&2(4D]-BE& ?)TJWM,)(P*8:H=1$![&!-EHDRV N>F4>A%CRQU,6\H- M=S1')'+L'\1N@30#:!H>;H /9<[LI:@MBVDW2 M@10=;)H.?8Z=PI5%M=B4,OW(Q(H465Z7@.*Z3&"28AC&6%<.#'WM7B$H0J5K M$GF4!4:5JD^V,#>-ZK"9Z=1IXLX+D1,Z1E::#I:S^ED7C3XG$.KFGCBHO^T+ MP^FG3_+E7S2N^[0O7SC,.ZEG7"^4/O"7^;U.I;5_?K!\\;2]IM6.6WU*^^ZA MGL2]_B8*EI6B?+MJHE/_(;(O7]5<[O91R<\7T?W[>YT==4$D]M0\"T'DI0E$ M5/DVU->91%).,8G#T/.8C6\S+?RYJ4X'SDVMT8E?!3.?:[X=/+:.:J,@U5:! MONG](^BE3B35O["U']0$:&^O78#;D*"S$SIP^= M^HT3FS"IU_D\W;/OLSX3BH&CIB@>U5/:M U)0"F): S32*@).U/C69HP @7' MD9JR1T+&5HN).T^?VYC3@K-+&G*<-\,18"@;8PMT2X3[%.5'+78K9SLM3*LV MQXP[$(.C%PU(!_21?15\O11W\J*^G)*79EOY[:JLBCI/2EF'T7SZ2E:M\+19 M_)X^$;H4BX0&F% N8,B%KH- 0XAC-?\-:*HZ(Q"Q%QJ=;G\>^+-3FY8 <"<; M1P>\..L1@1=/.]?M.$1=R$>/C#: 5M/1>4M=%LXG\+FFQ":_S_2OVWD-G?]+ M-/IJQ/]^?\Z^/Q8IIV;]'DV4Q6KS/N6RF6.W$R_6?Y_ZN=74!*U_W4/[/I'Z M?6I.9ZDYV?9]RNOWJ=+O4]Z^3VTV9F?)Z9^M'\_FWIH>U73IO)Z-\9T,8<^' M8F!I3,[K,^YDJ?>DWJY>DH>L(LN%QV1 4N5<^9)0[6%Y,/5#3R\IHEBF6&"/ MV$RW3K0S-U=H"U.I2,9AM@*L06I9)/,$K6:S,0=DC3SD]WC2$/6*U\L+/-E7 MQSS/@MO:F"?:FK8RYGF##^IB7KA\8$:BCS_GCZ)8U7+T1:Q8)NK8WVW(;[NP M0'Q,)0DYE$DB(2)Q!(E(4N@GL4^"!%/?MPJ[-6UX;I+QZX\??P1?-M !T=B5 M0[(->:^+;.M\(^H7PK)HIG%WF"G+&"2/+#6_?@1;S* #W1PQZ)\K<+Y"9,N5 MVU0^IHU/FZS'DI*#=#RV]U\3#59'9+P2)2NRVF]JYF*^G_B!%\8P8(%R9WPO M@#CR*12>[WE1%$0BM9*M,VW-3:FZ^*0V*JD'UVX6;4*SF1PY(F]D!;J"MX$! M7&<9&2%6ZWA[SQ"6==;PXQ%8YV\9LIR=?:N>7F2KE7CZJ(9M4=4MM,-L(#P1 M^!Z%GN 11'IR1"+"(4*"H%3&4.V(KK'7F37, M/:IJI$.J!)SES&;!UA%W4ZVM]CDL>Z^;LX5/ S[.KU&>>\"$RXD&=NRN_)G< M,/"T%2F_ZE7!1[+4ZX&WU4M2%$_9ZDM=-WKA(>D++Y00^UR)ITB5>"(RE-:D]9#> *++ M)S9@FSKQ#H]1&;'B]@#5^2:G/3IE9/[!H2FSN\9)^[A)6!'CE'J,8X@]IJ3% M#PDD<91 +TK"-$4)B6.K4H2F#<]-9/:3%W[<20!Y(97A=5U@.),>@=BQI]5' M$T*.DB#$EIU):4H))@BQ M6-&O'!\D!=:5P",82Q(R27"$A=5IAXLMSDV;.G@Z[D'CLT[9<8%@,P%R2MO( MRK,I(/!]A_8'O8.Y(?+]!2*'),TP(\=U:HP+K4Z= ,.,A"-I+@QO'*8Q77J5 MGXM\_: ::PIJ'DVGL9^'>R$I]I0/A&#LAUPY2#Z"*4EB*$,_DB1)0BF%C?I< M@65NNM3+-D]J@#=@)4YG9W#>-6:Z-1'A(RO:)D-0;49=(J6M8GP\7]#-82T M=VKG@%*G.G@-GDD5T@%Q^]KIXI$#LWZ30I)@,8XL-J"/=G2W!11I^C2:=BVITT\;+#B3J(I;WB40-"3"R:^2"8R![U M+%>OL]5' =J4:>TTAR4^EY%4,ICH=&8HC2$6H8 ,JQ<\B7SDA>=U]3D[9G9BN]^+S=' KO+G!2D>MQJ3/[ <3Y? [_4W?4BO5ZPA0H)+ M03CTL0[P9,R'J1>K/@Z\Q,<\D5' K2KQG&II;B/E-G^E:)'^S;(DSTE.S680 M3I@:>>C:DM2!'&7G^B(5;LOOG&QMVLH[EXP^*+IS\8:!:YA[U2[>//Z2_4RR ME4ZYOD@YC2)&=0KA)-$G25*8"II %D1Q$@0X#CVZ6(DONI:\X4+FF>:,7OVT M>?7[C8[W!>C:VF19UV>O%S6__Z*@_@#R57?D?GL$SG*9\QSKABN=US(YT6+G M?GF<&_#F-_C+VQN@P;;U(1PN>1JPXG;5\UR#TRY\&IA^L/9I?[U=#>9UU0KPB%>ER]\>)'_*4!) (@2'RA( XP0F4,O(CC%F,J5%2WTL- MSJ@HJ]:%>9\O,_:TW>'SX]07<80A M$X$.-"&>/GC&8!1*-1=1DY,HM)J-G&]N;O+0H6VK60V()+E KYE;X8ZTD?5A MPU>+] 8T6,'G]L]1ME3-Z'$X@5,)_[A_Q]W[]KDMJUMB_X55MU;]R95C;5) M$ 2!?3YU'#O7IY*TRW;.JE/YH,*SS;/4DI<>CGO_^@OPH4=+H@ (9#-[[UI. MNRT2""J5'/3K#9JI%9@SO- M,$]55N^9<*.D0?$=F*5J^Y+&^*2Q?B><73MPUQ1:[%3_=DY$U($-Q2^N5JRW M%>/JR8:"=*(Y&WPC_ZXIOU6+ZFG[U);TIBD33)4I,"LL#A"&*> I02"#U"RY M*"\4=-*//KGSU/BJ-7XKJ-U03GK MS&'WD_,?"(L]?MJNJX5:K]\LGWBUJ,]RWM2G.X]FL61^6E>R/>(Y%*!_\\7^ M^'YQ_V0S_!_TA4MVG9:R&1*PY(00P#A6 .4%!IQF N0%E05&D.:\](E81K)[ M:KS1.&#K8#2K5LDW2\DVYA$[1^R/>T_\PI^Q'@:WH&F"4SPP.78>)P3YBAK:C67[J 'AR!/R,HP<>_BP M%^!O;/4OM;&9"_LSA%UOY$(*G>H"$,Z%669C"2BV67L(EIKGS'R?,Y^75L]8 M4WO1[$T-/B'L0];M#1 )KZ%#VCU4AV>$T1L=.Z 1E1/[QAN5QQP_KN3)T<9[6Y7A';"G)M_??Q%+0Q?S^\7\EX^58O*IKC:')3VY'C& M$%)"<0P(S(CATL*L+@U_ I$S33#7!4^=N-1OV*GQ:FOU7?+8V%T7E+ CRWW[ M:3JA[WA<&QW3H<]H.SA_.8#SV.@NR21FN1VGCYPG/;Y]+IZ MH!;W5QH+OUNNM*HVVU5=Y6-LJIK-.+QRF.8J ME53"TBEK=A+>3(U0WS#SD,Y-Q+!<);IQS/SEAVJ1R.5\SE8'HV$.F+@6H0R9I MH=FE_R0U.!%?-U.8X[AOL5?U:-R7XQ0F[^2=.PFCPE[E'\R#J%:K=AE3F[F^ MWVZ^+%>VUFNF(!9$,@H4)!J@0BF;B,X HQQR+K% U*GWMMMP4WL9[JQM>H;&=Q?6;L?FMY^OP"O!N[ZMX< [\0MDC^:E!LK$UV1L;C^#=0(G*P%>& M')4BW=Q_R6&.5P6VF5RLE%@^+NRM/K/O/YG%B:XVZQE/I9(%8:"P H%(9Q10 M1E.0IIH+KKF$&,V^UA3X:<-6&S>.N3":S[?AY9@#INJPN8VX$[:V>39<=UH0HJR"TDVYCD/456\@*D;%]R.U,!4T!E8T\!]J^E=&QE1/+H7A+BZ MT.>'&E?RN=?=$S7G_D\'M]A8/BE[RR:XVSS_O'QBU6)68EC 4DB0(U@:)B * M4(THR+3-KY<_!^(5^T(;,*;?/E>GNH/4X(4D)P M"D1F99F9(H 5)GY(B2HX(PS*S.O8V7GDJ?'&QWURA>U%Z-]_T UO-PX9!,6! M2677RO%E>\)D;_= :O#><$5O5^@V^NB="[U .=?$T.\&@60U-\'Z@_XGLQOL MFX?51[LYWD4Q6L.,V/UJE E#3UD)*!:&K01DJE!8F.6.%SU='FMJA%2;:O2@<-W_BN8Y(7*KI&6]<&A+>2VF^&NM/&S/2 MP^K#:OFM,M#,,E@0D>,"$&'+;LMA9N/'.+UNW@:W%WY MO+^BW)N&=FS1A-9*;)I4S =]+QM)R/OOU7HFF4(BSPG J3N? "Z607/:;#1Q/%\7#_4S/.Z+K!)D>UZU)SX_VX<:=L?=4UUH&"9)!@" MJ:#-R&8<$)T: J(%L<$(RJ!71G;O:%.CFZ956)>,LK?7I1M/ -9NJ[IH" [, M+[> Y]_*R 64N.V,>D<2W&PC9OO>)M)X^9%1H'O)'\RSEU#\ZV/-K%> M;'$U8I3;Y?9@.\L.^F&YKJP]&?S-?.++^F'UZW+QJ%:SG')8<)T# 2&S/>@@ MX$1@D,M]#P'N:-3_(*.$B MG\O5L?)>)[CW>?F3:MH=*_F[^K[Y_)>:?U/-\#-5<*)DBH HLQP@AC$@*%,F MXBXD):HH-&>^:I\AADR-V>\7BZV)_*SB1%*O76V?GBT'YG]SZY._)&C0]+CQ M^1B@#\SY5M MCJLPO]9FQV7#IKKE<17*&S8^KM\[,/!MY:7W'&S<\O.KV20!X_8H L?ASNO3- N^C&<$0UZH.-)5YK!8;]JAF M-,LH+@NV*SZE@*7F)R6E)BG#"*G<63_>=_2IL4EM<,(.6AXEK%D=U]^7JG7 MRMRT'GBHIGM/33_]# [X",O@L[TRVOT(ZT#2>9!\& 5Q#^GZ(9$?2(<$RJ(TSO$:]2IO3NL5;4@6MWRLRY3JQ4NXW4YWP/N%IA&AW'@-X)# M-W-C=O.!B())7C"-UK1\/_)D&I6?@.'3G/STXC!&JC5"MF+3W-\\/VWY/,K+ M0C"H@812 53D)6",8_/7%"E"M";8JQ_DA7&FQCI'9B;6SD!I@DNXNE%-!+0& M)I<0H+RIY H,4R M3FU_CE;T\;,]N=YK 64B51CEA0&8%0"E:0H($0R0DA2E^:LND-?.V0VV3(U: M/FV?GMCJV<8S=>G/VI9*Z.4J^:$UOT[0_+'+_S/>^7:AO67B'$.@<:9CZ,"H M]:)I&][Y8?]VH"+7^K*;G1^3/VN'DD'DGB( &S>4NL&><0.LVX$[";LBW/)U MFA:U71>L2;V=9G),>5[P',BBE !E. =,B@(4#$.L"HD4PF.V)W*T>VJ,?F!V MPC;'FMV3Z$?D^CPXDO_T9GGH%T7$'D,'WO^-.@EYSMFD>@:YVOZWZ@[D.2&Q M^P#Y#A^<5=4*,C;OX,[.CZH6V7BS7&_6)V:N]\%L*01BJ4Q!D6;(GM]K0"&' M0$!!-"IIR7*OS8L;[9G:>ZO>5VKI2ARXXYT[==,DN;UT1H1^Q)?)[B5Q\!X9 M1D76DJ9%B8VNR-_9:*W)/8!VR#V+!-3"174(J M^;,QU7&G_#ID'ND#L: ;*57 ^V'S2P5P0:/WV+_W!N,=\;OX<72<[W1!6$SZ MCE6K^N3M_>+K=K/^57U3\[Q]4'&J4*I) 13#AC09Q("C'((D.DJDU/?JB-3W+/G8\^M-T"QT@8#LRE MULKN,+XQ]"YI$;M.I][!H ,F40.]OO%&#>(<''\9H+E<$MK?Z)MYPRQ7S^>: M:>2*:B$% 9JD$""")&!92D"6:DB%SK7,E5^/H\N#38U+=K;Z-C?JP=.-+&*A M-#!;[,PVEM-8SUM3(HC'2OYCZ$I1N1!$)H(%Y MHLM$;NQ,_FPL'>;DV@&1Z.7-E\8;O8+YBN/GBI2O71*:QE=O&WU@J\WSYQ5; MK)FP*Z%/:FXN>OQ%+=2*S>\7\EX^58O*UL74^I#-4?;ZG7'NX*KU/ZO-E\,[ MSC1B6IY1^.7@43AVN,L\:@7[#GU._C).)T>WCYEL.<;T1,[9'-3DD5,_ MQX#_-(-TE%$#.]8(L=S:1=AI&Q3<(P 8QB:]Q/. M,==$,^&UXW9YJ*F]3/:6)IVIP=+"/0"[47HI'=\E'9Q'KS>ZO.9BW=LOEGM7J" M,Y'13&%F F*948!X#@'-*0,ZI8I"FBI-O<1[7L&'J5'<@0LG>94!"90C/Q!N MS#GQ:1Z8DF,F5AX@<2:Q DCC[S%"%B-E+)X M!K-(V8I7,.A-5+QT[7@YBE>L/TI/O/;9X&W2E:'4#ZNE5FN;]AI\H@,PPTC0K M2PDPS0WW*54"KM,<:(6P)"SCG'DE1UT9;VH\U]KIR6Q7,'5DL7A(#%M@U^TAFMA,L?YYQ3%)1<@9$837# M88D!D8(#@E&J9"D4\B.0"^-,C3@^V\:W74/:Q6-2=\F=DQ);8_2C$;89]8:QQVV#W.WS2 /O*Q_UX0:IJ]G.[>_=YE^S[ M4=E61C,,K90B)8!Q*@'*60$H40HP\[M"9PPQXK2BZAMD:HS0V9GL#4T:2]VH MH!?0?AZ(!=/ )!" D#,)N$!PA@',XO8?C\MO_V$NK[_\_T;V1]#\6'_C>V\\ MRM?=Q;7NN^[TV=#*SZYUL\V<;1M]&C;9]3I:STI$8$:5!*7B$" AJ?G:9QH( M#+G(I20BU3Y][*\/Z44"(_2J_UUMDOFN7[W861S?XMLHX-,&_)/Q_WO-08ZMQHS.#?)E"5#! M%* R+P'$D)BY0)#Y)5)&?O+_FZ+N%AW'Q7+@=V0KXON#-??'!LN]Q?N.A'7& M2-U"TJSS[I+[S695\6VS<[A9VNJ:J.<<[A!&+JN^.NS(Q=6N,)R66#M?&;C/ M5^=IU4DJM?##3)4J+4H(0<$5MCT0,&"*"Z I106FT+R74Z^-O1<#3(U_WAPD MJMTE_W?ZCS1+OK)5\JW1)\E@<9>F:9N^EK#MYLMR9;N3_X^DS.ZRK*CWWS&^ M0SGL/E0U&5OV'Y;'6=T_*U$??O\__U>&T_^19W=-3JMA M]PNCS+=/7^?+9Z4^-5H(YY6L?[?2?VM;#%$K_]6L MWR]L=[I:M_QA\T6M/G]AB[9Z<>?AB]K%7\RM-S^;%\%.?7.&F,I+"!& R':4 MRU,%"!3:2MPQD?.T2"&:-2^13QNVVKB]C:?@F@_-OG1P.,;]H^-3SN9U!2/; M)%P]5HNZB'HB_8UB/F"*E9@ADH$R%R5 4@E 2]L,2R&BA,@$3&G[@+U=R/_. MCU?GWK@/UX3:9L5\K-P"NRF8.M%P+U 7H@$F.4 FJ:%)-@:;O6K$#IXSFA$U M1(G%*-GK7 MTKVXL(V&-0$*<@Z0ELI*, F0\;P4VB;2**^FPV[#3FV+I;:Z?I.:NW;UP'XO M3D>\W5YM\5$<^.6S W!O\EW22BE12]8/C)>UY7AV>*E!M MGMKBHR87X5$MK)3=C&8T,\]:"G AL::&@4= MF%KORHI#8^VFG$JRS/_D_A+2[H?X$? ;X3S_$+HC.^.>Z%\!(_KA_J7Q1C_G MO^+XN2/_:Y?+@[Y"GT>KKE_OM7# MU:N"%5^V3]OZP+1>F]D%WDI],6N\ZIO:YTG^KC8/^C/[/BL1113G=H&D4K- MH@1P3'+ RJPH-8,<^;5O\!Q_:@QS8'ZRK/>&Q*$#=0ZVMSR,UX2X$=* , _, M4(<(-[MO1[8G1RG:AWG8475E0L"++33C9=]]U[M-)S!PN#]-*>#_,ZS00 M/G'S8MO@TT\&K(\NZ*O7)_'_2ZWM/M2#_KC+HJ\__L>BVJQGI"0X(Y0!22$% MB)+2D(!(@2:HQ"8.0'F*G1=/P69,C2A:8^W6Q$GMP=8:[+%:")\;A^77*(@/ MS#R7.SPT^5=)-QL/.MF[TA3 )G^,-AL>"[M19F6D55\#%D5NOJCDISD3_P+&>6/)NDV6 M!Q\,\]M7^V]+:29RLTQ^5L;(IVJAZFO,^Z+)QS]-I-]GS]PR&CK9;QVR\UE-,T81]NZ*)G8O)X1/T9^WE,*FQPTQ W*J'N":. M6[\P"+PGE0C#C!+VXCD2K'@S9^MUI2O1#/F]6L]X82+/0BM ,U&8 #2#@*., M :T+6)C8%#/%?-XD5\:;VJOA6.8E.38X^=.:[-ED_AK@;DP<$<:!J?4F!+T) MTA&7J(QW;8E/):KZU6G7[AB2_FZ?FYZ7MSCLC7&0Y M0AP4FMH47P7-,C?/@$0JA3#'>:F<3EY=!YP:S1S:>]"GYRZQ)GOFWEW#VHU@ M8B(X,,/T@I?\V=@;D6-[&-V[!3XYS66L_HQ0UA MQR F.FY#QS*MP4EK<9>X.W#[(C^TRJ^#6L@A1ZD5O@Y^BX[N-]AR==>+P23K_@= *]G5=UMJ^!=8SE5(" M"[,.I32W-6*" ,(E!=*P=LZ*PO"W\A&6?CF %X6/)AB][SZG6CM]R]-?P%@4 M5.0RST&.2PI0S@F@!"F0BTQ*I#,#HU>H?1.,K]#$+Q*,;O'T+> ,SG/KMI+_ M[35$ HKXS[L=N7+_Q2 CE^N?=_&T1O_"Y\)8\5P;X48Y9%:4.46J+(& # +$ M2 8X3KE90Y;5GNCR4%/[BD=H9-Z#J]LW/0Y: W_GS[8>'T="Z#H^ M4*ZVR\)P^&*".>*_4+X[Q?F:ZO6FV8I/DL)$05!&F09S0 B5 !2 MY@BD&&G&$5=".77ZO-F2J1%/9UU2U>;=)0OEV CT]DD).)4<"NI1SRM=&GOL MYJ7Q9:##S! XASOF]++F]0Y 0T#K/1H-NF'@DI2MOUBA)?,?*T'YC<#QLD2T.OB>()MN^[O M?RRDY<:MS6EM:DOOG^S?9BK/=4Y* M)<,(!XF0*6:@X$*G*.L,P1Y%U783>R M"K+#Z4MWW&-X8/JR;OQG4CU]W=ILX:I]B=PN^79]2MRX;#B87U4@;M^2[?DN M.70C:4NB&T>&58YSQG%P0;GKEKRZSIPS6"[R<^XW"RSIV/)U)2NV>GY8-1KB MOZG-EZ5\WZB%JT^L3@&VR;X_/9]^N/M8G>T[8Z2$-*4**,SM/CKD)LQ3!9 9 M142AHDP+KS OIG%3BP;WYIKYZAH@-.XEG>%WB?6P3O>O<_IM$X5SEW6?;[/Z M/7-]HSX";ES]6A,[,(6_RISZEV<, '[%&4.,$:I,TZ8E MW3=MQ3?/=7% F6&4*40 @42:U7YA5ON::C\=&$#NZ>;- M5DP;G@4 LY)_!-TDP!E+ML\PB;M;=G\@<^K MQWJ4WZJY"9^6"_6!57(&E92J(!D0R&X64DH!T6;!6^:E1@4FF.G"68+K^GA3 M(["=<P@_1(?00_8J+I0CZ5L=0KK< M0_IT]%3&DK!R1ZA7J\KA-N.)4KG[=*0^Y7%96$SYKEJPA:C8?-_/L%X)L2(C MS(J=EE19P6.> Y:G.2A3S""")>?:*WJ\,,[4:'9GYD&#U*"J_DNXN@6$$= : MF&-#@/*.\*[ $#66NS36J%';%8=?QF?7/AZXS%3SN=555@L3[LWO%_)>/E6+ MRI95V#+=+I6XZRNA6<:*(@<9-O2 S*H3,%I(0$J5&_/K! IVY(#G:M-K+AQ7FT,A//1JLP/WEP-PCVW?%1-<;UCAO]P,@2WN MU>ON]3>N[7Z_M M4;&LVX1I2K7,,D 1R>T25 !2" &P8DH9JLNRU*M-6( -4R.\:[U-HF'O1FT# M(SHPP77-=NH]RL[^Y*_*]I-H/;A+=CXDG1-Q^X+= &%4L@NQ8U3*NP&HE\1W MRZUN/$Y\^YT9CJV7E1_4@LUMO8=AWBYQ^5Z(U5;)&:,IT3DK09$I8EO(4\ 8 M%B#%U) >E#GQ*]OT'']JM-<>L&W8]T3M';A+OG8NU+%)E[B7L,:+P"-*QRGR M/+N,#_QXAYIO#S'_<(3YKO;B_@KFX>>=?L@-VR!=M =,:A1@52!4 E3,T?$II5+R4 %[*$DJNRM"T5W24!;K#%BR#_-NH! MMTR.&QV.!/G U.A?HK;/?&Z]>94BM4N0OE:9VHD]4RU4NP3<#:5J%V\9(/L#UW^4['&_$<^4_;T\/EP.N#XLROY@GJDO;*WV9]@_;]7[Q2=EW)3_ M6['5C OS'M"$&-XO2H $S0%!&02TH)"+G&BLO-IL7AUQ:OQO'KK<+SJ^#JI; M#!P5JH%YO+/U(*_GSK9A&%&,>,Y +B4#2"$!B#:\4BJ>%4RD$BNOLHBS MHTR-01HC:[6#VDH_-CD/I!N#W S/P*S1(K,S<(#3X5X(HC+#^9%&98->9U\R M0/^' Z50MJN5N=<%K>8WS>+6=F;L5K?KG30L337EJ= @YU8DA4(,*.?8,$6) M""X(X3SWTD<)-F5J_-%Z\I^>&BGA4^%&+N, //3ZLW&B5Q^^+J!HG=GOU:VC MB@'' S6NYDJX.>,*L=P,VXDZR^UW#-B@^[!2[[8+J62[]NL2R%),J4RA562Q M(L>,VY884 /;\0NEI;:[<ELO!XZN6/DL1,6 :N1=KW.8!9I4^L*!KT;6)>N'6^SZHKU1QM3USX; M%C2^??HZ7SXK==!.L7T0%2D5XO;D5M,2()DCP,JR! 5E:5J6@A$N9]_4BB]= MH\*+8_D\L895=*)&99='&S7HNNKTRYCJ^@4!(=,?7XUEBTT[W^^6 MJ]W.EGZW72VJS7:EK-!ZM\Z=%:60J50"Y(65YK"EJV;MB0$O,%*""HF0DVQQ MT.A3"[):^Y.O[=?%MKO>L!OQP#<(]P;$OB1XL#8$^ 7*X8"V!M$>M]TO.@RU-^CL#/X)H%-<.7_ MV:XW]D;KS\M[*2O[0+*Y/<=ZOWC#OE8;-J]?8>_7ZZV2]D]FD*A;>LPP3!5D M) 40"?-V@:@ )-<24"I5YNFB"W M<'T?J4]FD6B2M+W>M%%_CSEW2.934'D5LR1L!U[CM>F\Q M:-Q6OA&@.VGS&^.>@:O^6HK/\\SA^*()?=%:QO*_5%+=;5-]6<.C:M M(%YV-<$4X@QB"(A.;;_34@&2VEX-G(D"BRPKB-<"PW7@J?'2D=W)?+GV;MWI M"+@;'PT!X\",=(S@^[97V2A-9#S!BMP@U''PD1N'^D%RVE#4\_K A/%F#V;] M;KGZJ*RVD=AL[0)^AC*1HBPG HN &)6:8BS N0DQZE.E4A%T?6,^>R1+GYA M/*>OT7%OF,\CD%+3C\)#"O(JKF[L_9>2 MOYHW]H?ENMYQL%U?/G]ABPS^9C[YQ2R]9&$X(]= ,U@"9(@%4(4HR V9H!P7 MN=+:J[5H5/.F%@I9^Y*-,3#)8/)4F^A9SQUW]MPXZ_7F9&"FLXX=-5+>^08, M]X&U\6Z74FK\2_8.)M;#I'/Q+CF:V-_Z)]:_'GP0_..6B,M-<)+6*8#.B\]P4(9?95HTFN.E^)E7%UV/O69\,V]*!E95(6ZDZ M2VGU?/BAMD^Z"3@QSB2VK>LI0-3$G[Q0"'"EH!"XX IBOXW#6\R9&GL<6E@G M!&Z^J 2EV0__^C'Y:C[INVMXTU2Y[A*.-0&#[PK6CB2'1B;6E;ND"IL6EG[5W]-=Z$%.QX M8^]&FD,@.O3Q&0 MM29B)UB0B;0H72. ,O@.XQZ4Q,409XP) 'I62MP,U4CWD*6"12AW[$>@M:+QP MZ7AEB_VV'Q4G7OGHK;'8RR/=_6'OKR94?+]13^L9@TJ4!2Z Q!H#A$0!.%0I M8"+-N"H+GJ596$#F,/K4B-$A^R+YTUJ?U.9[M@_UFQC?:"TRW(.O:",A?4/T MYH'80"&=,\3@9NA'.UPH+;T+OEU#V-K[0 '!;VH#'-F<'[(USD^Z'7_XDE"_U6! MB@XO..Q%UIPP@?9V;FL$?EDMUR]RY9J#X;K-J- *904!4N6%(:*\-&$6+4$A M-1."ETS)LBMQ<*.B*'8Y?27KO]POY ?SE>FV2A[TNVK!%J*RTA7&IKKMU$^7K2#]VOU=@Z )(] LD>@OJ: Q"2/0I)!T/R MYR US*\UB7'7#6,[,>Y*Y)6FZ&1M\UIV#%'+^;%]M?_"JD63A9F5G%/SFB28 M90!)K@ 5*@.RA!1R# N5>0E2^ T_M9=<9U_R: Q,?IC7B>@K)99FXNRO;6&0 M<2-F?>;)C+B]A8;#>0I+FMT\_%+/0^1!<_ MTI.JFOWYNB:/?R/[(VA^K!FC[[ZCT(*#8]UWW^6C@>8U71YS:E_]*#MYU;!6SGAYD:S=3EZ6V;%G%@9Z*:'FN>&3GGH77CE-L! M&YA(KK:T^=U\,]CZ2]>U,&*.32\T<9-IS@\U;M9,K[LGZ3']GPXCB2,]+D-" M'U5]I')ON[[72Z#]5M#!(06#*4., E$6'""%F:$0LUK)"_/;HI"8^LDLA!@Q M-8+YJ*3QP#**6?K_M5S]2R_-G?UH)6@RW$AG:(@'IJ0C\^O(IG4@V7MPN$4_ MS/;[+2!&):\@0T:EMEN@>DE\-]TKM!W+V;8$74=Y6+*L)! PH@.^GE8R5%@Z$XT]OHV5.F#V(W5H@$W,'V]Z($" M]CU0!E"G<@(E[VX4'N[/07MG!!W(YCH. Y,-#L(ZQ\.3+Y+V";IK&Y:0D34P_-!*:Y&GM/( MX^KF^8!QHJ7G=7%41NHV1JE !.LR!47=_YB9/[AF",AC M+WZ!@K>BK\!]$P]-;Q/Z)OQB$<^0N\]7AIP"U5S9=W:\ZA;QSEK,SL92,TFE M4A0S4%"M (** 6Z72@CC0JNRI*GR8I,7]Y\D?=AE42*;K0HK=O15K:JEK'L0 M5(U,V,;:'Z+%N0?6C3=N@&M@HCA4P:P71;$5,$^<'D#6M#[E)DW;#Y7\J?G]G/K]H/K&:<" M"Y@5H)2EK60B$M"L4$#GJ6)%H9G$?G'%;?9,C3D:R^L\]9WM9B%DC4_X<_)7 M:[YG[''CG#D&)^/-Q-#1B_7$SD%K8V+;QE@C[Y+]_.P]2M[LYJ=S:G=%Q*8) MD?"-&P;=:-.X<5(< $\"J4BW#= DJK?$*[%1LC[8_F-1;=XL%]\,3]D,;T,6 MLI./45(;AC432'@N ,JH B1GQ"SG$%$T);3(G70Z_(:=&KON#6]:)"1;8WHB M=K8GK#;>0ZW'?0;Z270X7,($I([MA[B2(-@/))> MDB/6D424O)'JU55RO]MX4DO>'AZI+_E?'<#PG_]:?OZRW*[90G[^4JTV2C4M M-AZ^MD4\)KHW#U[U3=G\L?;K 'F98BM)CABE-L;. $US#7@F(4%(:*K=R3[$ M@JGQ/DRSO/W*-&;7>U,[P^M,20]B"IH4!_X?&NJ!7P7&_*2S/^D<.(;]_@3V MD!=#$/X>[XBAYV&DUX6=CTTW'YMN/IK 9[G_&E2[^>C5X?9[>=P"8>][).C& MX[U2;O'[Z.URTXT"50XV7]3J]^5B>:RLWZ9WSJB"::D4 S:]SRJ=$D!ES@&E M$DHFLE04PDN3H'>XJ;U":FN[C=L?VG3A'^^2A?+46[Z"LMM>2SSL!GXG-+ = M6KKKD=$:&[--AA,J<:O8^X<+\YQKLU M/]G;G_P\--X>$>N0N(\4K4;&WR]<#<6O-U3UONEX86JHOT%60/ \V#SF"". MQ-X]3V G%OR/2%SMBDXO-U^]R7A<[.K/$?R*6!5\QMFXM<"' M XQ; 7S&M9.ZWW.?"=0C::JYUY^7]^+?VVJE+FH0S#*40XF468@KG &4(@YL M A=@4.4L):D6+/<3GG8?W.F)'E5=^H.YT18;-RMW$F"S7Y@]89IAA24GIU63ERGA3 MBS@[ZY*5^J86/?5X0>"ZL5)$R :FHAU:QM2DL?4NV?VR,3=JIV(77&*W(NX= M<^Q>PRX G&DF['29'Z&L5YO9;^Q[];1]ZG(Z,@H%(0P8^D Y1D!!&<46/49 MA97FVJWYYLF=IT82K7%NW'"*4S\+W.3]P-_WUJZ(^@@7O>W[%IN+#K[!YF\O MO[VG=QWE>WK1F>X;>?D#@2_SG<;*@S[4GVK%6.HMJ%JAJM8-ZV*,79FKHH(3 MJY9"\OH+6Z: 0*J 5*HH4ZW+(G>2M8UCSM2^Y0?*1689<^C/3N>H]N@N.:/- M%EZ:?..<.H88H\W4T)M;_;)X@Q0XQP$O;IARFTGC1C%1X#L)OH0-3?:"L1B8 [ZU0$ ;Y(YXVI4QCB\_ZA?_S..O?PNG_M( MI-V.W]5>;;K,&!&1R!@K['+84P=)KAPP&38'8[# 5]W>^.,ZU?W-LY=$WCJ MON]\W1PK']#29]M_9"_W2GB:EUE) %,L!8@7#-#"T D1J)2$9:F&TNM,WGGH MJ?'*06N_W6%\D[O<]/);UAGH7_+1&6[2[E)\#NY,_ M:\N3061W_0&+FQW@/ORXN0/>L)QD%OC?(5!.UV;/?#;7WG^OUC.60D5*HD"1 MEQ @:\_T^YLU 8TU8GK M7VJ%D_>+#[7DV3^5%3I1\OZ;6K%']?:[6HEJK3ZL*J%FQ'S5<\HX0.;[#E"> M2L#LCC"TC<^4R#227J>_(]H^-8ZI+3.KLM;;V_:VOOS0JR0?VQ MMCD-;>ODQ>.^%\5N7ZK ""*I,H!I9M]O1 .J.089I!CQ/#?K=*^%NK\)4WM- MU>*H>K[\:YW8QS'1G>EF_=[9[KDS&# O;B^=8=$>^-UA-PQKL#OS[7OB!^N! M>07\F.R<.&R>,\0&8SB(42D\P(Q1F3@$>L.=!EHP7"'PA^UFO6$+6:L/ M;%;58EV)IC\#IAJ6$&F )), E5D!6"%*D):LI%CD:QV[V,?BLC!N^!UL[K6#] M5M"]0_.;!PS0 NAJ?1[XO'JL#?J\_$E9;?-[;:C5=NW^_-=RIH7B)6:%K8T2 M)O(N(."I*H H&&>%(AE&VED1P&W,J;T$S+O MB(#CK<:3$O#S[4A0P//2$#DP2T)M08(HD$ <,D"XX 91P'G.@,2(IDRK9#* M4G>EK_V-IT; M6D^&E$'&#GP:J#G Y-GH_D7H.MZZ+V/^%48"F/I6O4^ IXR M5:>>]BM0'7Q^1'&I4RN/=:/._'M@%K1:KY7:ZU I0V!=\L+S;\S*HFR>7V3G M0$FQ8%0 6>@"()8C0)0@H$B%PJ(DBA'NLZ,08,/46.H@A>K==F/+3WZK%G79 ME8GZGZK-DW_WS9"9<=L.&!CO@;FQL=ZNUG=J=]:!NUT6U?-=TCDQ:#;5#3#& MS0H/L&/<[/%PH$ZRS&^XU0TZ3E^6;5<6WF_K%N%DF'UBO3F.8R-A91.)+C1T/,[[@V%DW MS\J.G?]D8)>!BZJQ,U5(+J#A4,)MSVF10T A4D"+#"J#)&.E5Z[$Y:&F%H'W MB7U[MA>X#*\;)\0!;>@MAAZQZ(C]!*Y"$;>7P.7AQNTC<-7MDQX"UZ\(V#"\ M]?#IH!O70OZVE)6N1'T+M[147$*N<"Z!,B0$D&(4,&2B/,AYID6J$IT=U!RSI[.O5TX$]=Q]6HK-Z2QSP!T%TVWV'!-*:Z]WSBE4T<[TAD&G-Q= HS$9/&C O? M+\3*[KF^7]3_OK[?;KXL5]5_*3F#@A4DAP)H1G. L$P!QRH%0A4Y8T66H@P. M'^Q=-G!J$5QGJ:6U.BY;)VQG;!VY-;\=)5SKF=4KQS!#S/5)PL;]&X01UU&+$QLXC!.V M:VP3$99-!]SFSDTGC)G."Y(5B $NK:!H203@$.: I)#@DM.\*)'/EO&%<:;V M^FW,;,XT[[H7<%6;ZO_RO8:QV[YQ!.0&?A6VH'UJ0&N,O(O>IN8*#E%WC"^- M->IV\16'7^X57_MX8$N;52O+=?KXEAG%4&00I+E!$-DR7*I+!:C*:)EK3LQS MXT,1EX>:&DOL+(U,%#U@%VF.(>04"*$50*DD@%M!4H5D7J3*_"SUS*P'^7)< MN ^'' /P3V,![D;.<4 P "BC&A"ID.TV1@UM,,R04\?OES>> M&A._J7-7C'&)M<[MRW\"5O]7_18(A@Z\W+QW_B)?E]_^PUQ2 M?V/_C>R/H/FQ_IJ>W&R4+^4E%[JOX,5_#]@O_;E:?UVNV?R7U7+[U:S0YEN; M:F;ERY>+3;4P7^?V_'ZYL%JFM:CI9[/46S=?_ID498%*L\8J\T(#5% ,B#9K M+%'JK(0%0J)P+Z2\T9BI?;&MQD8C9IQL]E;:S#2XMOV9FR<20Z]27;N-(K7C4?)@4LCSH_'[O*(\S323O+@\^6W8QP)X-[=X5O' M&&\G.!(:1[N^L>YY@X80O[[GS%_N.;?GT>WQLDT,/Y::R&9$F,!%IAB(%-L& MYI RE(&$,EDD9=E6N;*6T1H$%.G%MX<6!I#16B8Z77; IG&I$WAM-P4=9AJ)@V//A'UCU;Q^,^GE MJMYBMY5SR79AICZ!:9;7[=_#-]V'?BX\7EO3F.V_T;NKD2#9N9W\L'/\QWTB M[H3$\-PF:5J2>%=L_GL)X[E-0'1Y/,=A S9]&ZV![M[=K=\OSJL/V(:()(-% M@3,%"I@K@&R#7B[*'& LLT(+3)EPUV3R'GYJKYV#BLSZ[>/=."IP%ARV! ?% M=F"2[_1/=F_U'3/_:-,-+\JB# V[QT[?H/"/M+<%H]B[@>=_U_&V M[((]/MJD"[]+V.KHE^52_E7-Y_<+:99=YAFJ3,3=[/WM&R ?=#L01:89 UPS M\PZ1@@ F. ,8IJ+06$J-O<2UO$:?VBND,[XN!MN;WVV1'W1[#^W<[C3\+1HW.@\!Y&6N'W<0_/^GM8F/S+J0T#^?:IF \ MK#XO_UK,."[3$@D!2H*L;A8SX;%**="EA%RH0FCJ1&T]8TR-P!HSD];.NZ3. MXUFN$FNK>P[3)4"OIS-%@&E@T@E"R"O/Z0H&P2E/E^X[6O;3%<<.$Z&N?31@ M>?QFN=X\Z ^KI=R*S4>;_+%5'Y;S2CPW?^Y5*;.4,USUO0]5CI#H+R2"OI=O+K?;;Q%J[>'1XM5_ZO# M%JF7 \+]H+$NI1%[Z+$T=QIP:B1^LBIHT M2+_5I@O*;FO,R-@-3-S]B\E!U)D] (JZB'09=]2EHP<0+Q>,/I>&%ATNOZK5 MYOF#>5PV9EUJ]3&_VG?;'VNEM_-?*ZUFO.!%9GO;RQSGAG84 J0P+)3Q@A), MD39O ;_JPZMC3HUVWJXWU1.S>D?;VL9D7GU3ZUKH+8"%7$!W8Z'(4 [,0IVU M=TEM;[W-M;/X+FEL3JS1,2OEG!&*7#)W?=R1:^><@3@MHG._-);(^V[+EW+$ M#/G8@AV6 80-\3">98!E&58(9BG.J5?NT<6AID8ZQ^K1C=R[9U?A'ES=""8. M6@/SBH?,]B [Y]=!&EAY^W7VQ*^[?5V).U+WWH]J4ZWJ=!7+49_-3>Z_5^M9 MR:4LE-2 Y1D%2&+SDR@Y$)R@$I4:(>RU8#H_S-1X8V]E_9Y-K)U^M'$!3C?* MN!VD@>GB'#Z&%XR1$3FA'X6H?'!AJ%&YH-_=ESQPY=-A'/"[L92MO[Q?F,C< M9A&80&77+OS]1CWM.H7/(&)%JG((,"P%0$(BP%)> BPIIK2DN2Y XQ!NMJ#3D/OJHS.0-RDNR\K]!X!I(?%%R.UDFE<[9?Y#CQ+C4M+YY+FR"I\MQY77*',P],JL=:(7^,1ZDK2N#-HQ M\'9,XR[DPLT9=Z%W,VPG"\';[Q@JPFD\7FR:$O"/U?I?;U9*5AO[TXRGN8(8 M$J"*W IHFXB0EK@ &(DL*[.TE-13B//B6%.CR2-3ZWUM4=N:K(RQ=?RRU+8O M8-W9+5E_4:KY)U]USLO@NY%B)$@'9KTC*Q-KW%W2&-K^)2!?(D#$\RI4D84\ M+X\WLICG5<=/!3VO7W)KJ[BC3JDVIMRN[(;DC%"=IRQG0 ME]ZBHE>W/,')U^7*3E!H-[E+,^!&/5%Q'9B M^EHS[PT>HLO<%6P&:C9W:=17ZCEW!83+K>>N71C&0>]8M:IE!GXS]]\V^V[O M5NK?6[40SS\OGUBUF$$DF"A("G"188!09AL 9QPP5C*E!=89=:J<]!AS:CQD M36ZD0>Z2 ZN3G=E^O.."NAOS1,9R8.XY"UWR9V-GQ/C& Y6HK.,R[JB\XP'$ M2^;QN32,>WYNY7??+\3R29D%WMOOMLAN\-XTLE^&^G2[7?HN82BD)RBD0 MA<@ XMBLQQ M -.%+(72L!!>E7@WV#(UKNI<\=R>OV4VW+AJ)(P'YK#.BZ1Q MH]ZM:AU)?FA=^;%NEM=ZLY<0'&9G/P*L44GP%GM&)<<(P+TDS1BW#%;#.(X5 M/ZO54[6HQWBGU(P*23F!R&:%9U8XEP,NA0"H%%J;Z([1PE?^HF^\J9%BIZ1C M5HR;O:&)5CXU/@XP]S/A . -S':=DL+)JO' XN1=;!2]Y2IBH3FR/D4PJB%B M%"X8.:A/]-YF;+D)%Y_.Z$LX71; PQ_91CUH*VK_;KGZM.7UIM4'M?KT[RU; M*7/SS2R#Q":8<5! :1;3.;%UUM($KD)FL$28*X&=>?CZ>%/C86MQG1IOVR58 M8;MU:W73 KVVV[+RYK0]^K\3O?'IM^DP&0YL'1?B@=FZ0_>^0[A!UW'A'(FN;X?5CZ_=0>KE:X?;C,?7[CX=\;7'98&;$.?TO]?W M"WDD%^Z]U/6[ZX0HY+SX_;H^YSV6S!]H-1N&7-P5K*<-XZY:PP Z6:D&WB8X M!Y]5"R7?LM7"A%WK>V&(>SNW57-FR5R):C.C5)2RSD[#=H&** 248 XR4F1% MJG/&L%)-2&V9.!82$*)L%\,BY1Q# MKAF<+=2CO>;SZ!NR3\?_>F+N],N(^KT,'FJVQ26=M\L,ADJW!EZ/UD)() M1W1BET]<&W;L4@I'&,Z45;A>&4;QEU;6#]KN>C;RB9!C;$7%&&/<'MIH0/., M &9$B(C*2ZD#\5?'W)J%/]KM]3U;C#B *\;S\0%[36W'^V2K+,Y'M.XXQ.5 M:1R&'95IW&%XR30>5P9LL?W&5O]2=>'N)R6VJUH#UN8)L[G-$OYUN5[/3&0C M.>$"2$4+@)B)=B@N[%]%P4LE2GW:8 H>-M4B(CI2XLD=Q;VVR-S>Q]L:%T&-3+2Z4(VVJG7TP7SZ7 M_XBTH^:.4.^.FL-MQMM1<_?I:$?-X[+0M?YZLZK$INVK_ MU[5F)- &7V;N\*H-36I+DQ^,K>L?DS\;>Z,6YCO@$GF!V3?BR&M+!^=/EY4N M%X4*_Y@@R;Z)'G2/5@UG2E(""Z"EU0#2MGTW87;S4$K; 5/EI5=VLM.H4R.6 MG=%V3716\B94@]]M$MQH)SJT ]-/%%0#%(,\4(HL'N0R\L@Z0AY@G$H*^5Q\ M@SK9^_5ZJ^3/)II:/#:]K>J^6.NW3U_GRV>EZ@]],(_E%WMZ:9ZQM:4ME8J, M XU*!5 A#&,590:P$C3-"I&5PNNX(]".J1%99UQ=VG78#K'I>_CVTXN2LXS>V M'3F^Y\@M1\XZ=-INY/S'1FXQO:LQNS=,\]0T#;6%]>]6M@><^9\=(:TJS-W1,=GO;Z'WQ[3WPK9IZ^TW,-VS]Y7Y1_\?N$GQCB_/IG(D>5%J M(+0N;+L##7@N.3!+^31%+)LXV3.W-MX8#B2>YV['*ZGF>0-U62[/_U:!.GGFMB]N?3+T\2\./KD[,LA*5(J,8!.S MD!*@%&I %81 Z4+IC)-4:2^AY2A638U<3R5*K=SL7:/'K Z^U?:KOMJ?EMI_ M]]1_B#.K;EP[^EP-S+YOZDEY2;4FPM[/R(Z07_[NB)L'.$Z*BG5<5< HEHVK M'Q@3S!.EP:@W#VTU:(4K=@=GN^^U+"C.2I6#,K5]ODA9 ((T!#F$!.LB+TJ< M^[47/#O.U/BWU7C9'P2''J-?PM6-+R.@-3 #A@ 5T#:P%X;(K0+/CS5R>\!> MAT]; O9_//10YJ-ZK.RM%IO?S2,PXR5E92D%R 47 .44 Y8)LQQ..6,9Y92D M3BE\EP:8&@FT9Q![(Q-KI>^YS L070]FPJ$9YV3&%96 HYGSKM]X-O/BIB,? MSIQWZ?1TYL+G0M_IWPP;+%?/^Q:AWN^?BW>8T!.YL_*H@>T@[Z&K<$1^%UT> M;^3WT57'3]])UR\);D\KE)+K=\;,.A/AH=DJ?OM=K42U5G)6X@Q#6E# %"\! MHIP 4F -!,)I(3@MB2X\F]/VCSBU-U=G<&*G,E&MF78;H4FJ6G[=BSO4J556 M$J#NC&A_[=VX]LITN'%-5) '9IQC?)N,J-;<9&=OU'ZU;M#$[E9[9=2Q>]6Z M@7"F4ZWCA8%2VM6BVJA?JV]6_O&X-_=/S[^Q_[-E7!>(P]-8YJ3 >U[SW:+KF?Y_"5Z9XE0095[!*;1Z 64)2,DUP 56E/(,BL*KMU<, M>,?;VQX06)_-[9O@&F=S^ZS2>^S=[8LX#+"[?3K6*^QN7W3X_.[VY8_[[V[? M/ZF%K/M:S-GC+&-0"Y0J@%(D >(E L1< E)-E, I9KEVRC$^N?/4OO@[XQ)K MG?L^]C%P@T$8^.OLZ+_7CO597X.WJH_O-MH>]5DG#C>GSW\@0,6G*<&\ MJ'VB(,UTR1@0T'P!D-XR8WR&Q&E\BS F&- "RY6;!GML@22VJ6/Y2;0*?(2^:E MQ=@[VM0BH/;YWAL9J(EQ%EFW54\TO,9AU+U]T3<&G9 81N?B[(BOHV_1Y_Q% M78O>BR+UD;I?++9LWJZY9C(53.=:@D*6)AZ#AC$80=!F!!*;!EAD'NU+K@XW M-=[HY$B7QVV)[Q)66]WMH]S8#.D8<8?P+"J. _/)1477QN!N@R4JA#>VDPJ& M\K6[23E">GLSJ;,(>?>2.K[+Z[:2.NO1U4Y2YZ\*;DRR[\/P?B'F6VF&.=NV MX1>UL#5W]PMY+Y^J19TYMJF^J>[YIZ7"E"$"-*;()FRF@-.,@IQ2F!*H5":] M2FWBF38U@O^DYN;.CW?)8V-WG1G#CBSW[*H:;Q;=XLK7F9N!7QK'C6?NDIU? MR?EV-7?)+P?S=^Q=/#H<#O+8W6QBF3=VHYO(L)[I@1-[A- 4^\_L^WMI0H5* M5Z(>\/=MK>>J"JBH(A0H+DR4#9D O( 0<)YREDN*L'*B[JLC38V)V_1R>^9V M;&[2V.N;?G\)X.O'&-%@&WJE'HI80&K^%31NS-&_=/>1D_6O.'F:M7_M@H 5 M^4&;EH?-%[6R:_V5^F(XQY!/$>"WV,/8.AI&&E;X-I#WR96+;ROA%K^/=A=NNE%@_GHGN[2OU-GK.J29R%A:%B"#. 4H M)07@F&B@&2_+$F'*F)?*>M]@4WM['.BG'5@;7 K>B[/;(C\6>@._$,*!\\\N M=T D;CIYWX#CYH\[N'Z2,.YR31B-W)OX5U;SK5T=[T^VWWZWJVLE;?&-Y;)M M\_9[T%T_0MO3N5:#>SY_@_IH%>:8$929%T,F$4!4<[N1J4$I4*EAB;A(G4Z? M1K!U:B1V:.E!?HP?=0TYMV[,-Y$9&SJ2/C]9T8_>1T S*ND.:>^HG#T"\"\I M?XPAP_4)UAN[(OIL;E"3 PL3:Z)O <8)@FYT>ALN [/@"TBBL]]EYZ.K-[P89G31AO-NGM-JN/!) M_W.-G]M=CG M[=SBJG.'9Q;7/QRX *SKCM]L5RMS\YFDB@C!,T!(3@"2*044EPH45O\57?+2*5=$8E[#:5,\5UA%XCFNB4$B&7L74=MTEK641ERWG'(Z[ MT#@:8=REP3GG3H+YLQ\*^[Z>2V3[M6*\FE>;YU:7?_WS5LU*F&>8%R5(60X! M2K4"/,_-:SPSWVIN@O0<"Y^OLNO T_R6UYF_R=?63+]ON3/D;@0P!) #<\/% MG-6=W7?)9IEPE7Q@540))5^HHK**\^"C$HXO)"^YR/OZ@#2(SRNV6%=V9^*3 M6GVKA%K?/ZY470/Q?F%^S^:?U>II)KA96V34ZB@5%""K]480QP 6I::8*,FQ M4U&3QYA36V>TIB5FK"9&L6S<2UOGA<>CN. /]A#40K@-SU=[@I+,X MV9ELDU$;Q*W5\0'UR%N(#^Q(F0HQ /;+3_"#JC6E@ M72JSS4IJ!3XK;ON@ZU%9W;OFY^43JQ:SM)",8HB!IE0 1 0!%&48E'E*6*:1 M8,IK^_?ZD%.C<6OQKNNX9W7J=7S=PLJXJ U,TD> )7\V]L6L4G4&(VZIZO5A MQZU7=8;AI&C5_N,J\]?V*)5"'VW7&E5;:RX7K-- M-LM*L_+-F (J5Q@@"4O "1) E8Q*G*92^&3-XTFI@'V_SW: MF89/3+3&IC>8<&/GA]_59I:E.->9U,"J- D,O/.*C,.%-$%)RG4F?!2PS^\ M^=3"YYUM_GD4.[S<6#X4A8%I>&?6G:VW&*#UQ8&[P_2ZL .\3G.+ ]4+1QA#AP(D;TV#\9MT2!T2 >,9K;16D'@=R?C<4# M=1,.AVZ$6*K?C@G$1$Y N<4V;K<*3!>1_V?;))VM/R_OI:RW']G<'ON]7[QA M7ZL-F_^3V6=N\WZ]WBHY4Y2KDI8%R&&I#0L2 6@&&> 0"8D+D6;*2:@WV(*I M<:"UBIF9L?M?7\WW56\7TGQA_VIL]LU \9X/-R(<%.6!:?# =GLJO;>^/IVV MZ\_6@;ND=2%I?(B8\Q(*7]R\&&\KQLV="07I)+\F^$:!8D]*J]5*R7=*6IF1 M2X+ZN3;A'X,YH%I3@#)"S!*.8: 8S\T:3G.*O+KPN@T[-;IKK?448G)#V(W+ MXN,V,(%U!B>MQ5TM_L M#?QPBJMZY#;TN(I&7G"I2'P(U27VUJ!V;>5YG5\/+YF.@/4V\?Q<+7*="/ M">[%BOZH@]RH//^@WU4+LS*M3.B\;!*+=DH7>9:G7!(%**<,(,$RP%*SE#\;^'7D[!V@N*AJ[W+ML*4N]]I\^_^W8JMWU3"@X*9%L'I64.B,I3D)8D M31%&4&.ODQA? Z9&BO=?OZZ6WZLG\R*;/R??.F\2UKEC11=7=BHOGPS$F1DW MGAP2[X$I,L7%FX_"!-= E8$>R$0-]US&'37"\P#B M95#GB;FQR,TX#\X<_1-ZTT0M!5*(X/]*HU-#K[$LR MZ/]P:/#7+A+K>H$/;&4B2WO>(.LSTT[D=L;,-YY!QD%.D!481RG@,!> 9YQ2 M#6&>$J^$%;=AIT80.ZN3M37[+OG*5O5NEDH,2S?UN76EKES.YVRUWO_6LVC7 M<59<(Y386 ^^C.Q@_M3 ;&PV#W726-TV3C!V-[6R,0,6'Z BQRQ.0X\%T=T@+,8)DVG67WY1>KY>.*/;6]C;(2*5S0')2(U:'>\L3EJ3?=I*7<6YGX?BHS<1I+55*IW2HOSMY]:HS:&)@T%B:UB;[M5@^QZZ?- MFQ$9F"5]P CHI'K&Z1N[IQ[><>2.J6><.>V2>NY#X>T%UK8.8O5UN;(QUT_/ M'VTTIHRYMB*Y+D@VT5&!,4+F"YMA6S3%)2!"$2!D"WB7'4]PYF=P?3O&U=A.C3*W'0O=UIWBD ME?'K3+7?RGJXB>A=B@\P['AK]^$P.UKL#SC,P*_ZHUS$!_VF_L2CM6.Y6%>R M_=@NLWO&LBPG2DL A5FH($49H"0M 41:2B0HQO\_>>^VY#:.;8O^"A^K(A*] M>0$(8+_9+KN.SW(YO6U7KX=Z4.!J*UHI94M*MW-]_0%XD:@;!5 D[5/K-4N M.Y,DYAR3'+A-C)D[+33$-G1RG7]EOY5BT?;$;;U;M=*)V/EA_[IW)%+WX!ON MP$. B$&=DS,3"7RD 4+$%V"Z(X7 +T*\4Z7YU@H(_[>:?_N^5?+5#V/F-U7]\C>V M53NY@!G-85&R%($,%2F 7$/ 4Z$ 2F')$66$^IWA&MG^J8U#6H,35EN;65JG5=3>6-GI5_G<)T"ZC@IO@2?ZP&V'3".]\J8/F0%#J4O.!Q[MG#0S\H#DDING8X:+5PX5 MH5N)?]7BS+_5)TFJT40U\-B<'Z',LLQ6-1?83'X9!3#'&+"ZX#GC#'/%)&%^ MFG3>-DR-(KK:\D_+M3V:,Q?;]FA(PNRPK1)%WZCM=J$2)L3:KL^IA\?%ZEFI M@Z(<-Y1W&Q!-1QJ*&Z,Q)IB;1FW^KIY';N[.SR?WX^]6,:JI-_44\G3)#7@& M%L?SMV-DK;S!0)U*YPU_U) 3*4]ROGV_U*OU _.0E.R]=T+?5&5BTK'16X>S M'R6?0Q !T!IIW^8$M5#G':Y T'_,X=+-(YYNN&+_X:&&:Q?'U;W\J'YNO_Y' M+7ZH/U;+[??-3+-<0TH00$H* #'#@):8 X%XBO-<,UXZ92#>:LC41D7F3A,!M%#,&L)%IUU?TLI*[O%^^@-KE)1!?1/#RQ)A):EY>@FRH[.7%YXV\ MZ5H/L>JAUZX^= HI%8Q+("'- 4R;SRTVZ0/5:>)K\LS-M458W^]04*BY]]-2)O MF-X:\.EOAQY,>"=5^;L/^VEL89ZU\.^Q0=D';K#MQ]Y&!A9VZ^89;?H3C38? MS:?3[)HI!I&P0H1(EPA (36@5IV*HC2#"F5%IHE7I;=A=DRMLSA,#DRLH==W MXH(&QHW 1X [,E4/0MJ_0-QM.(6M&#?0EG%+R-T&V$E-N1L?-_)HVXJ!_;&2 MUMK7H/JG:A"Q)RA%1!2@YM+7GS!^LY 2DYH>2$J6X\F+0,8R> M&MUV3.TF+]K7,GGHN#32B-HG_)$'VI&".N+X^^RV4*5TV/6KT<]OWH'0>^#C M@3^- ;B/X7^/UB'U=:0:"M(O%^^JK>Y.S7V7BWEO:V%M%^[ MVO]NADUGD^9V_&ZZ'P!549BO,$4 991H7C)&2NG3&=UJT-0ZFE=MUD!=R[:N MD;FRUB>+O=5^W3NX4RIE.I451.<;LU2&Y_*I>YRO4.DO#N) M4/ &[0!N-FI4<@\%X3%Q!WON,%+^@ZW_I;:,+]076\6T>N1'@TBCP, TRY1$ M"J2<00 S@H!-X#(A11JG3'%<>DGY]C<5?-W8,1QJD;FO M ]C>TKMD;VLX2G/#)"AA76ER5#IR<_^8;!SONK%@\8==U7+*%"WR@@(H* =0 M2PX8)R40LL"IT#F3)1Y4GOC#5.O/[TOG#J\6-]2Y#=^=]YYY%C&2"T_?ST @%[J32KCD=)[=+N MH''E5?*EB=6;%XN51^;LN#$;*<=VI-CY)>B&0[HWE3= ,^,E_8;#Y" ]..!C M!RZ$/CRR^=H^Z%Z_-Z][75JMJJRV>3=?SK=J88NNS52:,2(%-\/E,@>0X S0 MG!7 3,D58I@@QC.O]4ZW=J?6+^Y-35A5?6Z^\\-S+=,1=\MP_,N3JJ![TQ?VE_ M]K;>8+"ZD.L?U?)DM6;)%IL94D@RSAG 0N9VC\:,]F&> Y)9E?@2,U%Z9>T. M,V-J%-;:M=^1\NVIPV1L#UN\>"DA=W]E*@@6F@-"HH4@"DJ 2UR MNQXJA&:I2KEV7_*XVMS4:*^RSW_OV1%;AS6'H(B]!(O5"+KL"0]Z.SWD4T,B M.98(ZFV(>BJ8N@+4KT-Z]2DCJHFZ>G2H">I\UPTEJ"OQC#=L\[VSE5J:(6:: MYQ(0B S!:FTFRI1G@.-,:BZ83*G7;/E20U,CV;V=B3"&)O,J_[@^UK,^^MT^ M(6BY6H*VC$?58J%7:WOCK" (:L@$ MH))@ $FJ 2,VK1Y233(E6:8]I='&=F%JW->:#79"P:JQ/'E<-_MD]8'5<16 M![P[\??(Z;\Y M3*'U@&^P9%@/^^H'FR]LKMF[U?H+ZZ:<_:;X]FPZ9%'D.>

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�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

,<#5!\P"1=.$3Q$D=*@1R>QYD32%.[',7Q? M!''4HEY, F2R*283P4.&+!6 59#G7 \5'E+"$DYJ$=Q":7F!^4CZ<<-?UA P M/">:H]86], .\Y&$$H^=.&SA [,Q3#6$;]A3VTM^TB_3%TX"L?\N*]&74)3 M5&@\5$P)LAA 2V(EE^E=W>5 \VP(6@-Q!S)%2%I*U&'F AO$N+B9+D8E;??( M*FGR6!ZJF.6Y,M:0>0:Q<*MJ[-*WJ7P;(TQ;6#4>Y&@',6JD0&D=9_?PXCF8 M>5?[WTP(T-#*##WOL$N"!-C3;HAX@F.03$%E+@9M"P@OTS5O:8_JE2P DMS/ M]QL'2A!B?11LBENTW3&Y/"X=W5IH4GL9FO\DNVM,'\:)G)U>>1/'T";O%%!@ MZF2'@LT_ C*.O%I>K(DA50T3=W(P4OTFB3CHCS%'>C 'LDST O#-]")@'0@Q MBV"B%@BL70<:\-$70DXJEME_=5EH=(D3\4F#[[='RG MK1O8!-.,E]*<)2U' ,Q9Y ;Q4!Z7\#"<8ARJ-D=)4-+\2I",')OC8X!-PU4I M1Q0K.EU@2*#0JE'Z."-WSQ3?A>>@"SD,]0S?=$I"[>VUGMY57$'$K-FL%#,4 MA:DFE)XF#-30Q-I= T66L+*HPSU>%!=AKI#QNXW'OR/,]/?AE-;Q5CM")+M@ MUY8$NTXWQIOP<2ATAV F2]I2 A9ID/,*>-$LUT9S8U_X1E># MU7F+$Y<=!\0%:EW?D2R7^!Y MM"J8@\Q[C!''8%JHI_J/9Z" 3I-@_C1.:27HIF?5\^:TR2LD4?EGT:;.CP]. M3\Y1H2I!?RDC/;#H6@>D:STIH^9OQT<'@[.3SI\/#P:=ORU\[/'!V>#R^S_V M\.!R<+[28Y\0)9@:0.]B&J3_?'3\J+8DM&2@%*-Q$$>>WE_R*V[7YH^RW$^/ MIE^]05O]6F.]LNG?WW" ].N75S?7!KM1D^R'I<:KU___]4OOZMV[WZ_>>!_= M_@I_DC(Y#[*UA'O[_MW-;V_^RWO][M/-U9LWV ?AD_?^E;>8H#_8#FR'![^[]UN7)5L_O'QA7]V<71P6J/: M;LNU;KFCW99SMMSEX9D_&)P>G!_N=MS*.^[D\,*_.#DZN+S8;;CE&^YXM^$, MZUSZY^='_N'EV<')=Y-#/\*&NQCXAX<7!XG"V.^&^8<-=PBEW>%DGVF[#M6ZXB]V&,QON M!#;SJS9 Z? M]U=GQ!^U*H__;@G0V%W=5:)2 M-C^B+C'-;:4!5[BR>H4*5D%$:BL#[-CX4::<.L!JYK=D,0>U%&:IWK/7=4W< MPA\JDUYU9QQZ2Y L^ %C +$E.1[(B]D%MN,(I^C/(!;(&N9I( MN]#&ZQ0VNYGJ09=+\L*=$W7:,*G3'23;DM*9__W=2EF9:>83J4]L)J_SZF<$ M1*08;?1**HWU)964^'["3FN8I-.]X3[NW;6B4%,E2+4BE$?7=L5)]$&D_I//PTQY+=4IW[P$L+KZ MZK[I_.W'1!^L@-$R PIAX1 )SJ+"O52C8):46-M>K8G3IYY3PSYZ4+&=@?A; M44EH*]>W8'&Z3I]VOL<][G:R^F^2U:R8E+"706PW\&*-VE*![@[F+$>+&:R$ MF)S(4?0EZR_[ HE0?1Q"1A!"GH $U3C6 !!J6 6"[]/U:P;Q"AZALYY847H'4F0Z M$6!*1B$\0]@?// 0Z"[8IVG>9J [I3@O>&H0"I"0%0&5WV]G<42*%0$,85DLS+K M!JIPB.6I5EKBB5;6<*0*XEA:H0L->!<3H&=M?I;.I-^"H -*$,C9,(E#V+A! M @<8"*S\5B$9+ *.+>VU(_N>FL+4)W'H X%3^8L BPD:!L&'XQ%HD+ \U1'R MN/CBTN/%^W^]?OEX<+E/*&YP/#D4PF]R=3N#M"GX] MP:J!+]#:]0DK&4C "XE]%(9JGHD%SH _5*Y+!EZ6-)CE6V".%I" M5\*#0)%3@( #[6JV[%Y&M8(WHS:/!==3)VB8D-7)O2TTYFP[RZ^ZD1H;P?A. M5G++-MM=$!J511JBQQ%HTC17=W$V0Y!7C>FT;S4 >H(TC,Y2=%EH,R#'@QR( M+MX>.MJ7$9#1 E(Y?WDB&=6BX]:.OZ*Q=R;&'GN_=!./.,7E#Y7K,F[18AEP M:I6I:+788CC1O1:R<*6'A(2GOR5Z!.S_'N&7'!IB=30&K1H"._R:/_T:<7\ MBRX/SLZ1#E>HRPOR"!]N((+3%DN1)#.>+NAL:L$WB/#O'J@B<+="?HHY6.5JL M=$-O40?17F\#-10ES#ZQL6K'@=L>K0PCKA&Q$D MG[Q"%;A%\1"Q(CS.D@C[ET6SD+ Q4>/+1FRC&&@:W+RTN;=%+O=(,)\=')\@ M(9;!=74HIGB'DZW P3,4PUT 0=\,\%63,3YIK;L$ 8>=3G8) IN9(# &H8;' M))B)(2'7(9GW6V2VL39=T0[[91)\,<%1?208.>\"KFN/-5:5-9JP2&.!]U." M:H:=?/T5S@8R4BF+X";XJDS'I#?U*7W0W9+>!M@AB43#*Z5AI;'+T4W58OXT MIK:.HY8!3;CPUR /;B7X"P,@PC!_>!%,IC,;\6_Q*X$XR0A/67L3[#7B#8-U M2U7.PLZQI>ETJN.G]3T L4Z$RD>_P$F.2-]U[U%#6=R:<[M'!S?V4T)*U-4[ M.E!9N4+?C.N2D^Q"W/_$ZW32U^\WL1=@/%S3C'UTC*5-+K*BE%A,"Q*UR!8% MZS8AG[&&FS12JB7D9_,)C)QJ""DM&>QN%JVTK=W);0:O.0J0+?5,] /K8\.\ MB#:+[4'+7C?V%>:UL\9.73CL(Q/SW M6SI@+E$;6:R7]))XX"?'J: MI8]A0J,8M0<,3D99.*.(H83>"JSUB(NQEDP2V&LY*.@ :\S7T!A)RVD\S72) M*39,FF0Y=S$WIV-]D$TY2E@$$6 MRSF$<2SLNW@;8+0*6YT4V!&SZC-K>NUPQ/K"[E'P=31+H\JC&QQ]W[$/.QNZ M('-Q0*^E332U=C$=1AQ/8_/0W%_(N0E-MD;W;C6N_PR\=IVIVP^&HA13;<.8 M O0MCMXN)FD*:Q&Y-9%'8 MHBYBDM3')RFEENI^0\L=PYX^1IW>ET%1VR5L9Z '.$R">((##:GA-.>QZK:[ MC71"'!S3DQ9E)G6F3*(-7,1D))+B)+4(*67"S$KNQ1N.86-PHE"+7ZO2_*FC MA9C;)@PC;@OZ'G?U8NTHS;3SI%0F[+>L0/^#&\ PGZB2NG#6#>QM$0%1GT3 M-^1 O&"&6K,P:-L405)D;3N#,JCN0>-7^1WZBMS$-& U-1W#Q@5].0@+V+KH MH,UAXY@#GLVSG6/]6D2A,KX_2OMX22STN:?<;9790KMXH[B"9S^ M+5+N&[2/BCNQT4G>Z".@0\8IR+00A=P5-0ELD$\[Y1JE#PL:W6V QKE.401V MDTF\!P%=SB1X.^0,&SA1MLA1OZ?Z)/27Z'U7,S0X/^+]/13VF#+JM$;%KRBG M@S002>9Y Z)8*9V.7O/D'PP.&\Y\S M"(55O8JF^JCR,J]\;&1(0G61PV]ZR MHC9M"?N.]G_^:7!V^*SY;S]%W!O4/5EAX2S?UWB8J_66-^J*.B>1J,4]).U_ M)>H5M;DW[S&UFN(0J\<@O(#L&'..LGF &V&4S?)=_HJ[4*=M*1R[_)7^YZ^8 MO)43SEKA4OT"I 1J%.25[82\:.R7VUPITF7O S1GC2M ;YWR/O/VCO8EJ$=E M!_-.W 7?YBQ26!%G5MF/L.TG0:2T,CO"(?=.]ZUE02KM@DR<6H]I;L.'EHZ, M0!:\=L=U/:1 OUP$K[5Y$;(T6F_I.G$)>9.JZ[J,+]J]_CJ7H.F,;S03U^RD M^9$G4G#&ZU#!E>KK&)0;%_T ;-19%9;D<0WQB?MQ-\\1J_V BE44.HZ&[^AL MCKUBOZ6LBB%111$"=H%&.RL9"!X17XA2O=W@.'[EW/,X7@5&BG M:O-LBH#*:2KCU%T+-1"0YNM+V8\[\;@PISI:FB'F-6L_6NT!M8[MVCQJOFS- MK(VD1+\>'JP,7'[]J U*W!BFSA)"# ?.#&X[@BOIJ@^_VN\+U$M,S52308US.XG6< M*_7QJ9UR/"',1#R0:E/1]_GM?I/FU)H#+5,?)/+V, BOA0>]!21I94M4YH 9 MJZM238&J44._L%F'*!,3GX;BU;;/),8B"<"6BQNKXH-1/0S^ (/6WL+RJ91K$C$!<31+O$E64,A"G=W&ING(38MD@ M!S&@9,()B0CD TII!L=SA3GRTP*&@6E#RA(3&ML>I4+02PL_)4 M(8 $G5K>2,];1W]%49GE)4T08\= J(2S'>"G$6'"F'AL3# OJ2CJ9+OAVN1L M? D5$#OGCUD^-^\&ER -O+TAPH8 "U>2.O8%:P.?@&DF.29.2^Z+",+Q" _C9)P%V$R74;["),FQIAJI[CR0/.\01 M>)RN)PH+GM0.N#Y\!!D]@N'113VH60_?\M(^K>:7Q5W@=9^96D [!Z_X>ZK6;7%;/J!/9Z!U-70*3[U!9*/0K M?X'G 96#LL@P(E:CB8EZ2!9^*_1F5Z2G<_F[7\'4_'RG%T!,"ARS6CA9SIZ+*"/LJO^IWGJIRM("IU+'6=>B">2&%5 M:K1MR.RPUDU]P8';[^(LJ;RI- +"DU_LP@W(ASU?=]4ZE3:[[3^0C^Y HP43 M-F_E*,-!]47H-Z4OUEU$WE:6PB'*+=&;+C;&K5Z75B]@#Z!<80W[HT+,-UT: MN-[BD^W@C'ZZW"LL$%980"?B89Y3(VQX>O&,SG4I)6"E,)$2&%8=*3^D>092 M-#1U,D?P@Z[S:%[.>8-TNNN8-:E^?!L#,SL),BBK-21,P2#AU;="6R\V]=KU M9'2*38MJZ0S0$9J6PSQ@1((*++-&,/F6^6"M4% 4LTE+F8Z%/C0$,10AL&4Y MHU3UE23'!Q%9XCR<31AJN7!@R!LI2_;VW^Q6[2Y3P >WA<2J;BL" SY7V=CHT"29*T,$,/?ZJD?6B MW%76!(NHQ%&M;9@@)D 4S;CR*S.,5@()K0G]3^&8@Q&F;UUT"8^9NA$-G**),#1HJ!J-EGWK'M;":E^Y17BHN8!J M%N6^)GQE"S*@.H/KIR"T*3>4ZIGK,'O&V#9,6 A_T)U!TF:XF#%K@V*?@,8C MXGEKY$.Z86L8XENUWRG*C3>A8 MH5S:KH YG9?J24Y4Q^0E67H+(QAP!*JIBXNR J%6O8?$[)+#9DOXJ4<,I6&7 MNQC*24%SDC<:O(7P5QQ-#,HZ.RQ<5M]57P7/YTN:W2+##:PH"2TM M?DY'8.;[2J2T8RII;2Y=DD?>8F-F M%)BJ5CRY<4XQ(BO6TG8L=X]6>^%2!P6VN,/ZX%LT;7#-L39VEF-JE*DKX[0[ M,-]GDZ&2!!#B 6Q@9X.0F+C!W@??BV:4/)+9ZK2B[IO:<1U1YSNTE=2"O?%FYFA776$*3=G-LRYHM<-IVU^.GBPF$G M0116QBQ*TSC-D@CG3>E9:6DS.C@\G<%*Y.9UJIG1+CT"<0%>82""DF"'$^_VUI;A!FQVFJYMZG$J8&H[T()L,\1EK F$40CF>%*LOBH$D:D#WX%AQ;,6T2 MQ6O)+LLV:K45%K>EDUN'8TO%;[M?MQ,)D=ED6V1*5.>+O4$N*L)0(&O4T5MZ>XT$#K4"Z M!._#!=-YPPE/&PI%I;Q;@+C'2I$S&#QT#+X!KV[8T[M8+$/G!8OE)YL-O]%N%Z;HV MJ<.()(?M@Q3!3%0;M*Y0!)"K>#($FZN.>$512(1X9@.<:LD6%MQTO)]!-E_< MIH!1TP2%8Y;2YM4X'P]#%JKG\5!+>)HD2(WN<^='##E=[$).6Q)RNNR-"K\< MU$,KA%UU&CJO@5/$$;MU!'M_W=K)EBBL_3=W,C=GH/+35;^84PC<.V-Z7UERNM[,1N:)'QC'Y M#MFDG[21J,AZ24.!">HV-,L11+4PFX+Z5(QA @ "QV^SK!B0'SB4&H+4L?&T*2!AF0;G.S48]2$0\3_+OW& AG5C M*QK:GJ^^]05JMK1)S:\_'%%6OIDV+4@M-@^_/L*U!3?%J./W&$S78?#S3!YZ MU]I'3CCGFP>O1H(X][P^T'.\%T%A'_#\1O=8.U#+2!]R!,UQL0YQ.-@;U=\? MPI$-'$7FF:^=DWC0MFI-Z&\9HP'\\SWXI@DGI"?00NIJL/P!PUU.^JAGH[2$@H'MR@#?NOSZN.:'CIEGB7X MI(Z@M)MOS0)I.4 W?]2^D<5OUI9I4(5<12U(E%[03#@EMZDW-47^Q3//VQOL M2UF?Q,":D^DVV@CH>O7+<69N;SR,P2$XQM\%\+R90=&@&D.6/7W$RV8<;Y6, M:UA8 TY]<#CPW4]'E4_']M-1YX#=H7+Y<>5F M^'3L[6%+1_<++40(;+S9X+FE:B%+D[DOX"2MCT+P6$)B,PIZ-9%^W\[II#+# MDPHA3BJ$@$\GWEZUJT3-V5@L@JU'L/@BS.,A"]+*8X-BDY#-L7,N*H6]0Q2H MKNM%Y=.E_71:6>536E>'*^F+[\.5E4=] U;X>D#9WA6G]/9]YO3 MV4/F-#BL'DZ'U=/)_-0[]F M;L#!#]9:'#9&Y-^NHH@\HWA@49>/#WQB^0U\>51@,5XK=_A@8%3"UM6?:7:? M,3__C<(6KX5#..=@/3[<"_>K>@%]\YT4@\JSEK%A6_JHPYK'@[VH-E7ZYCM- MM?*LUJDNF-K1#O&S$A+;!3L%_Y.*Q^ M#/?96!+O2B/S7CM8PH2 =$1Z-\'X%CMQR=[U<.N]?\IM@J-D<''[["%0*QD-M)I^C6 MT]FGE<./78/5.[G0BQ!=FDZ%]WE\2W:H1(GHVERMXNC8MY$FF;/N^T$^(^]F M' ,OF'FT.&\>#('.>6EI5L/FJ0"<"'\W4=$I1Y-R6S4"=8.HG+S9=-R81!G7 M4]/PS9CT*N?.JHO&FJH['\VW^&BV)8E@ Q!3>"_Q7K&Q:(K?MN$2+:RR"8IE MQP,/5'V(E':T(QYM9<_JOB5#/_KEI5*IS'9$@G!QE3CBO3<#*-J^>"-"V5^SB/U-S('=*"4E.1KW< MJ95TOEI2-Z8G$ZR=2UGSIA9D>:CP+"?@'*DLKIGB_7;*KKG=)"=P8R)O(R+6 MK:K[!K[-C0Z"^C1*XK#L"@RN'.83F&:L\ ?.B;3"U]C$^CK2>OC*KKC?+7;? M2W4.$X8 #[:D$&QPV)\J90AIS MTJDPLUVI" 2S_6RO0V/2P4JE#M\$>ME/4,J5&W_;\A@NMT?1"'.!5QBUP=BS M&2D:,C$MWHD]P$WC:3W#!^']M/%")T*KD+2C-^IAE, 9J.NQMKX/ UJM=JAS7R3W"+QU-))(L^Z(;#S1]NJ8$Y]NV:#>- MG3(HW0&UX3*KKE=-@^+JF6^937?OD99:+,Q@9&Q:H(=N0._L<#TR5?Q*$X,A)9NRAD#\P+'Q,=S%I>UY[NHVGU79T?2<[BU**CZ"5QJ7 M5L/1F[$^/K-JHJXSA(]+8SNE.GX@@;=(D%;2J-KG\+V(!70?Y)!Z ERQ*6Y Q92PB12 MYLN7+1D'/MYR(3:U[A-LC]RJ[DV%J".6Z7.^/(18 M5/HXT8OQI.6[YIP7%':S^FU H%LQGVM-$?*BDY*&I@QA:XRV[XWM&S>(N= @N54_FUF!.K45LFLM1%+*K M'ZO4TIB2!A]36(BYI3[!IW^#Q/?>D[V +W MK5=;OM,9- 7EBD1J9-_+Z8?A M>S?!5X9ST'900Q)]R-% *='@3N%LI%=ZI?!>C1!! ^2PM*TZXU=.H.P9I*RV,-51O&X'#Y*BC:9@0L;)PV975]VV1)H=;8PT^\@F <<2KY)2Y;LV==L*#;&(#ZZT M]?51M.%^1'ITI+/D<^<^Y0@""[$O2DVKB27:%6TL*1',R./:5]U4PY4+9,X8 M&7 M'59O&]X3:2$9G_O&_N#@-A)4JT+&CAHMS3NJ1DM:(/!7XX_6"-R"<,NRB),X M&AYFY^FRN> NBYGQ,5,F@X5L3X)IL8O%N].EJ&@"MQG.G4S3L8KHD8!TX!B>+BP93[C:4ZLP8R2"X/B MY"$;*25=Y774)J9F6YCNR\#P3#F2=6SAMT<"ZPW7MT0/Z%UVYV*%<()ZP)J/ M_P\ZFTQ9V ^[5VMP#,A7 4Q?FM96&HQW.+T61/_1"F5;IK5\K'$&[&)2%3_. M+B:UL3$I4\&P4)-I/[-!:%02PSL/*2>SH=:P0M0:2BEW%/BB>^,W<%@T,CDH M1?>(1E$T*: )U:K$*Y.1NZ 0N.FYJ(4F3W]7-1JN(YA5Y>HG>5&_E\F?Y8YFN;7G %@BYW!!4 MUM^U&9%Y(ZW:4I-2"59]RP[J\L]*4ZG91&/9.ZNU$+JYS@!U(X$#&BN]U)9H MA(/CC?$/7E$;,2T(B'E*Y*J=?_#'\@]JOT6_W(-+JM,TYG\S%8--= LZT8:I MY0L.:7VL>R6:BP96=+PAA.W6$*#U.RS& UR_!I5$9P>:;FA@[033DG+_W%-' M6U.J);[78L#3X43R@K$N"N?XE=9P.2P[8MLUVA($'6!.!,-2/\XEM:-FRE%\ ML*B^SK=H"=LB5C;*W? N Y$B7%+++UJSB/FH;H,\(L6VJ=-HKURE3[=QU;4X MENNN4NJ:6)CCE#:YV3H6HH$(4]TI*Y1;TM.24IR04P''L;G ]4?H3C!X-<'5 M!&DU91U%*FW@126=C3W=D1H M+U!53O$3:QU[8_2E+ U7F\[R:ZD:I"IA5)KBO&@J&#/=CIO3]F UP@Q.]PD6CC%+>[9XT1%0%K# M/(4#U-=Q,&,+P=2DZ$>P2J[?A/O0\"MNB9 TBFU MXLB10AP..V5PX8SZD1H'2$LZK]\,IRV(EJW<=74UO[,HU;&20]!KX*<@\T0=&I:&U,HU;8^5]4J>/KU$0R MMOI6M4GXXD*FS*1#M].UK767#CL)K+O7P!-=&.^5A%?,#Z\X(&T2T[9(O-.- MD7ARWJY9ZJ&.@M(MSS5F5*5&5F-*&_1J6.UR5J(&,D&@B!@V'(8X,'VNJQE* MX/4@J:,'U-:6FF9!R&8]YA$D23^:IG) M%C"+!O:]*"["))-:9)?-O-%DTUS=+'K=/EZ8QB;J4=NNLG_::I] XU/1X/E$5VO&N_U0)? M7FOSJIJ#SZ^'^>K7$^X4=7""O3U1U-B)VV>I?;,-)++0N??0BQY0LV[>2N\Y MR*D1(KLSSIM9J?5-6(UM=,[ P%DB]TDS0_.KYL-X']<$/9>IIA/7*E)/+%I, M@]Y(/\ )8EN \P+92TV\@3+)S"<.U'A%-D,XL^U^L/VNVBPSA>+]W_^:7!V^$R_WA0X M(PYA='[/2E0^). YB7<5*LQ5*>@19D@'_2#/9K=CF/\B7Y10JD80*QVPXR/N MZ@JQ(W6GDFQJA5KM=G&AK;P)F.]#GA CA[I<'X_8WXU8]+4J'73TTH:?"WO4 MR/==J('*E=GK/%?*L61/'EBXI8 4+Q07=2&Z##]AL13;)T\_UF6D5*A<]>63 M+[M4TX+0HE*!BZ%IZF(ZD)61YB&S2 [-[>1]3PM,"QP;N$A-D2(?.O)^0,+< MH1:&*XTV4R.!\>UWDHWP8+0LN]IW-Q*%(XH*4$P2W"//#N>T*?.('0H!O-@L M+VTF"L..3@B"PAMFT5QOY3]F>5Q$,:NBK%()>HKSLK:VOKZ@'/*(8$*4-A-S M>V,IHZZJ8H527U!YX#6)*>4S(NT!9<+S?13IXC#)IG%J),L,5,;$/K6J+0I% M@N@N+@(!N.>P+X:]^*BH19\E51CC6QB@@??$Q =B?-I&[J-A L;-6CUI<,XO MVA='R#9W)B)Z A$0-((J)VB->S2*DQC(6,@OKL;-L2Q$Y61!G>&? =BV>:KF M^"=#F[&FCCMCEI2F638O!-&([A.5J#IO*W#MM"G69%?0P%'B=!T4]&_$2O"Q MY"3).%47=S3*09;QC5FE(/7S+(CT(50EJ=4M[\<&1J3Q&$%#JI[Y=SKQS+D0 M?C,UMJZ&$E8T3EKZERLO?8V&\"QJXH1"67,6I8DQ,)X]A*[;1J@U&FFIYA&R MQ)A?CA8Q[OB2J(*_),#KB=E3+3EM7/BH:=-=O>E(NY:FA0KX+^>'!.5B>Z[- M;!N+TLQM3+2VPO*T8.11R>+9F??+/*6H":,N4#GHM%G&V45=^P&6^;-[1NLK M)+XN>36[)?A&#PO[2#JT[[A 5%U.VT+1H'/BJ"H CO R+DAYJFC(LP5J1AK( MD2SU,A,4X< "MBM\+LDM\Y:]:!Y#FA/:X>3]83,PY+B(X^P1)]PW.'U8JZ>6 M!XKD&0&"J82<=_:\KZ(J4RQ9XH3$KZ#.P3IW.X-_R/CD\2X^^2?CD[T)#UQL M3'C@_YO%8)Y?IW]DE$:P[DP^JV=64Q[B0MJ9FV373ET5E=I_TULI_5:-G*QJ M?BX8I;-\R.*,@$]&Y%DF_:HM39=D,WI7J'4(XTCYQG@W NU^[8E]'6Y,;S- MO4G7"Q75E4TH&9'-Y)XJW%LU/ZC:2:+V1(%Z\[E4U4*]^ RJ[YVX%"Q*JWU4I::XXJK)\FI)-&H]0-+4\5$L3M3'R!?CLJBO MP62:<.\H-&^M'69'R!PX81A-PB,XY='<%FXYJMB^7\>>;7LC@Z9G\T5Q.6]3 M":#DU880UCZ_M0;&PA%\I]] I=:!:KB&V,R'R28M=Q@(@U%]*7L1A\4( )DR MZ).2:3#&J\D<%@S^>.1-@CA1U+"GO:653?&AQ_'E^+(A:N,4\R%BWZ(O$LF- M5V!C S@$4L-P N2+ Q&[@SY9@NJ%6OXTB",'>1\#&\:GB2['Z:SD>O28"BYN MX5@@QR58V(AOR"C8/J+2%/9Q]O4U=B2MKK[+^ :*RJKK0)#MSX'\9FGF:OXV MK$"5S02;RUV;]U2Q7UU] @_.)I6QXJ*R#0(W 6JH8!\338+2]27* /APYZ5X M#*?4CY_8Y;2,N2-?-4FK_S;LY9K/G3<5UY')0C<.;X*OUGO;%0)VC21$HA>! MJ@8BZ^X1@25E\)OA65CKJL ^3$7II"HPDD1W01Z+@,H(5HS#<]$L_#;PY(IJ MM$8%\?6H!8.5PB.=;].7J0^3F1IB[LDP!CWJ=1IV+T!?IGQVZ#V/TU2!F5+" M>5CV?L*F+,?WWEYYAT>#DZ/>S_FJ+"59X<4X5B,'_1V5'Q:T[SG@\\WOLMAE MLBG[W*F'V,1W>:O*P/L 9@3&.0K9^K N ^^W(/P">LCG8(Z?WZHTR;P/0?[% M]UY<>9G^+UED)<2[>.:8>"+:] ;2[6)1!&%%@Q25 AW:^NNI_>"]:I- M),B6K.N'8); $E*%>.&]>?.!%O5PX+T(DAC6.HT#.1-][^3B+U'[S@\N5G): M-<(7939]^OCD %^48D1AD(BW;PB6&JNLY7BMJNJK),NZ3[,?,D!SL@O0?%. MIB^2 F?_*4B]5WF0AG$19B+@!X-!5J_P+#.R#O/_W1IIA M7+\;Q;=Q26X $/9[#!(]RTM5S)V A-ED M.X(M1YO3HOL3D ]$7S^"+8N:5U&LA"?[9Z'8&\6BG< ?N//LAAM92(^+@\.C M^J.[8-%T][O\@ MTWPNV!O>7FDAX]99?_-6SQYYL =%-X)\TNA'* !PP'08HUZ4&4-]EI,@;&M2 M;5-KA(EEF2I4\ *GZ59INBOY&AE O/%Z?XA#U[9 KR-P;4GP^FASVKBA(;IN M'--V>4HAFU+#5VH0H9O[S/L-YH\1M4\QB S0H_:.!F?[&#X@J" "$"ITROBO M08[,J\NM4.URCDA_Q:V&VFGE Z*9;@ '3FR1I[;^&U/Q)N9 MD+"$]Y$RN?L@Z+ F;E1%SJJ?01J-J9WJ[:#330XK@;OVCO8)E*\HL(0CHN@Y M%3GM#6I,)L=\=B_)W+*(Q32C$3#36!'+L,P+4" MO)T;A,=8%<'N32A$%2BQ;0;WT# MUAXA6L17%#'TIJF)66HDZ-V_+%MNH9@T?,%&5ZI7O@)K1^N'.7C/+H*?* M=_=,[C206]PBA94I7W,8(XKXG-%/+\GU1@HKM$/%'? X-Q=Q+P5=HJ5*2O<3 M8Y=;I:?9PMERUX5"#/HPSL/9I* N"86+/<.0G?4]PC*!@9RZIU\IS@I&([B9 MT+)!;<8Z*]*F,:G=J-5ZX-J\*Y[!=CEE'. \%WJBG8J6@ AXCC$6@7.99@57 MSE?\7B!=JM$?@7W!%@D6<=G.CD P_IA%MW E-G7K6$>=>RU$4;<@7<@9JEN) MCP(@,E*%>NA)Y4&$8F0B_C87VZ.B1!MZ[-(\W#2/TUV:QV;B!%M;I]!=KRVL M!SJ"IU."FR/DF\Q3)%H(!P=!X!"L KN4%':#.QM00[Q(YP1T+>(N![DG^%); MVAMZG;C!WZIB7Z<&QP$>B961>[*^/Q>CSGB2^Y M^J[-E=3\UJ+[%VT\JY@N9O16-;_@AXFB6ZF6I@J_&1[[*M(8HGCB)P4KQ.@& M2O!L@RT!EJTYI:1]:YX'*;=E+Q!,&P[,G(X?WDJ^2Q5\%"VH#G0X/89:*,;* M0(HQ(%(/4(/1)_JL8.. "KJG%H,.V\6W](LC!U9JJ@\IMHC 3'?DE&*,)I,) MTGF0VA4)L*+*FV0151SZ6).GI,X3F)JGIMO$F=),IS+3>(VL8>V72XX]:&X)>YITY6F9[71S!%:SQM3B ^V4C3# V\&RGH. MLR*>C$!?S+:%XU2?.&[)X?5:RZFU0P<#UWW LF3;ZKK);X:% N^/+,;% 3_IJ1BLN48,A-$7/%87MH5=;OO# M+LN/5BR=0ED'R[!NEFG&:L5NY+-62<,X.U\'N183:-F$E#[,P"MCJ\L'D7V( MN5Y+/QCZ.5Y=>;117:TT++-;Q4 *!F2CTLD+U?7$Z.ZZI7%( MP!H.@K WC48:?<6YRIDM=@S%["X,4\[Q#D/MWP\^'7@C,#_0C+K^]/K7=]Y5 M2,?-$3#)?JV#,Y@MY&.; /$R=NLQFIXE0I$YK[ 0OH25)'@$^0@)6%K?1X'Z MBO.03;<[0?!++&P?JG(M[UPTQ@95# 1/D+C7U+/'.[JUP7,F 9M7!LJ';4H! M,2%/8!OI"XTN;#B5@4% W!9I18=.FF9;:;_G^CEP'55%$U!1[X.E$89S,8)<%8AHS NL[ MQ26F8Z9-8=GW9KXELN%H<]HP=R&H2>+U^L4$LC^J M%5QJ-6ZF%]=;T!N7_1U"_3O0;)W0C]THSV"Z?'1R8-0V M3K4'LP.OC[T>R*\(9VX<^!JJJSEK-)/9Q$4$M*'$>:GLJIXGOP<:9.,-J[G9 M^[X(NF3)349^/"QSG!,4?9U5S<*] >3'(.W]XZ5% 12I(-+HD'%-# M>E4WU^8_P6 O4##?*OCW$P@VM@=?S(HQO);W\T_'%\^\S\$7-8H5RK:6-A)- M)5?KM Z:JA.+T"G>D9JDP+*.OJE=LFQP%Z5;]S-W',&F]M@\Q&GL).>VVP6) M9J1N,^YT8SME2**/D&_>";@[5(VN%QIAG[T%V''(@M_:P;!2.A*R%Y4B1$[/ M;ZT@K\8'"_:F.R'80CN?;$*0H/C.\KM8JM_4UVFLG? @.K,LE2PG,,0[7?/; MHGEO3I/=FF9DN+>FU?1,(V\#9G9W#3G N'N@3FBK]X=H];%7M3$090B[BRVX MN^IN(S* Y.+?&U\:"]QRPPEP6""N/"U25>@K5O4O8;\[4M);PE+2VRY MIP&+^9'M(UN@1CP&L=)>^EMGJ=9S1QD("SEQXGPA@VV+?-N<#M*O9GD:H\=W MS1+K?:K-.RL\;N T!,DRF6 F'OFA7E)V;#L+&]!]-[O)\.%(OZ?;'C;[NXJ% MVP3%"D%7[_EZ*X7+$HX(\1G =NV+@.WR!/6"E[6HU4@P0J^K3][K3[X&)F O M1^QFGF&,V\4A^N9MT"2#58Z++(F:1?DHD]^GO 5!Q1RWXY(A1]BP@C0G&"/7+5Z26&&:+):"2(ZL-#R=LX]9 M%>(A@+T]FPQS"@ MGQH"=3F+V-S:>.[AED6FY09B927SAD^!)ZW#?8NG38MJYEWM0%J9@^T\RX7QX7R1 MVWFS].#-:97V_M756@^++;%\-JIJ^V/%T\AR[#.[&N.U=Q:[%N?H4$EL^(;QZX::-X8_<70&?_BK+%0(<7A4%]H1_ 83*LT2?X90G]A+=K:6; ME7"#,;X9IFKT0+=:MQPQYH?.SFXA&JW"ON\NS#M=T$-.NEF>314 )\!B$69[E<3'QN>&RIR9#8,Q,%/:&$/2!\^^1YPTBZTK!.-]N'JQH MFR#@(.S/A-$P*N$W:2UH2\KBD=LJNAHY@_GI)SD$\(+]#-0=&5$=2K&PO0LX)Z&DM^\^+D;0L?RTG/ MG!+.*=.^A_7S<9!0CC>%C/!OFUO=E5+MVC8X&\+'RK-17%*^?(:='T6I+F/, MG2?81:K/@ L0](5\4 AJI5UVV70*1S6-S!GSYA=R(>:S*3YQ7]RH\%8JI<)^ M4%VHX']&_$9M<4T+Z,!)OUE-@Z J' ?Q=X,@=]>O(@#M>D^B=9HQJ$4-03ME M5*V5ZT!8LRF^10?>L?".A?]2%F872IJECYD]3>(CZ>HZP:\%I,2;3>$M='MO M*LJ1E*QJ[^S:8[?$BW)TN3&A@G>PMB^QFTNL5#^XBLA&/P6W&%(3L\[0OJ M#E&(3X1.)'Z"]B>9JD1LT',;Y%$BW>TY;PTFJ3!?(T%D4UYW)!^5SF)8]RN" M'2F\%_87J7BP :D_&S85G5'H]^N,;]'G$VA\BK(M."FI9(U6OA/]E"Z#)2@9 M*O%.@0R!U=,/C>)"\J]]6RC-'@-[$T,8"F:EH=LJ294<>(81(J5]^77/VLG M>_'JHW=V2)',P;/!P0D<5K[]XOCP\.!4-ZDPWYZ?#.A;KFLGF)O;62)',TR= M,SBBRD8SRC\N,ML-J+'?Q1%\+O"U36>K.!<2$>A;G7RDSKJW$DL96AKXJ67S MD$3YKAE4>,8R!C'+*MP DZQQ&B;W9KG*J/%8V:";K(TDY\HNF^:(B6LWF@;] M&KI?E<$7 N2L;WZ$LJ*-P<96=,J$1).#MQ!E;?PY(K1L-LOS2*'J MCMB2\_!X9&20>A^0KV*L9KX*UYT-_[H]-=E!LM-M$%PL[.4E MJ#YN]*$""3F2(T4E(U>&-G)1<'\EZ-TON%D;<7CL)*!D]X*]RV$SD4)R9G4] M%8-MM0I[6X1?.=6L;72G)1R7W_N+H\CD:Y:^/R7,^C:XY?0_3A77805[K>YI M.,JQ.H#*@6!*$ET!H3HAWX2/>>?T7P;I]@U>F0X-\^^>A?'.1CYFY\0A!4#H MR&._$O[(@1PN_N$Z6*#:79#,8.VDPIV<,_CNPUFI@Y6)P"X@E ;H'10""?@O M%*?P !1RCF-'XLRW.;>%I(BKK[]%!TQ$L]/9GO"X41"BO&)F@Y>BPW.?)!D! ME] "#)DQ;N-128 *A*M KEO4V2:$ISC.BBDJ%208L34;O*$&((:K91SQUYC\ M(Y^A4U 1$B&;9-&M)B"O!SUJ-*-D-BO;]S5;)7-]9/(G7ZJL:6WY<)][O^*) M0S/EH#XZQO:"0HJ..286J1$6(E.TB_(.TA$L4!HJ#<#.1;FA0: /6A\+;(4; ME,-MS._X=1A,@01(' Y'I]$,G]SZ"&ENYSS&SD7ZJ-_:V^CM-7 .+8#&I20B MPG P'JE?]TA,RO/C=XHG"$V+.;5X>I:P=]CKBW<-F7"2"'XJ6+,GV,TVU R_#VFM+4O<@TP,*PIQ13/Q50D'XAX5^:P] ML1,JH12-Q^H^9)/(7UATF85PN\.=PCDD3/)Y'9EDT8#.0R*3)D*V3!K.?:>& MD@9&10\_Z+2/59_]V&2$.-\YR2&*$1)CW69WV9.GP'EQZ"G8WH9"11AS:4?H ML[N[4$%.0I_W3F7:TPSE)%*1O3-9WCU>_6+[E!"!%[#(C?(Z=Q%6-\)ZL8NP M;B;4NNPMUB%7V(YZ,U(XRC'6;H,T_N_ W7:1>]@%C(-=T:&E<%OO"])H\ UI M0X-=62@*#@K85"5ZA3TI$DQ!C"26L"6&X.9T-;XNRFPZ58GW C16%,,@%WOE M&I5V*XN+(YJ.=U)Q&[:? $#Z;BT$L;BNT@C((Z'T\:QSMIR(N!3'LH.NS1?7 M&3VOO!?JNOL__S0X.WP6$N7G;#Z1,=;HW@1J7*JARS7* 39!\2ACES8W P/N M40NGD8-SCN^C+3.!==1]9?BBT%K3RV>"W9PS\W1N&^/.Q&(NVFS6B/*'3;<9 M=D>B.DY7L/.3BY8+RLN:!C';J>RWLH#S9!W8E9-,P/;"C ;28"*;599V[FF M P!G(\Q25/F1 2BUH]#-VPF3LB7!T> ,D72CA ,F&%'4/$62_*C''^8YX$I( MRB"\0Z%*AMR@0";=.9KE7)HB$X]3\FNT=K8B3$CVD[9B3]: 0ISN&ZU\S!91 MVE7!].?VGN;VOVCG.:TSE^T[*P70\EV!U>OMQW$Q^[(-&W.K[DN(BV!HB6Q.$[8$[-_RK]ZU?7=('[N(MT: VI^?Q;P@'-?8^ MH(-SW;F #^M*KSG1,J)MA&+Q!DEO!R-"Y>)E0-Y]4SDJ/)46,QW)TJEJ&+5U M'-K:=^W$L?Q:7,OW$K &"O[N=F<+;.+V+2XUZ0G*JD'TND(!<@92+ M&Y3D*C5)-JBOL($-7I.SQ_9"]&P0V W:+SUPD/U+WK\'7K%] WANJS;:E:\Q M;XE*T)FB-10$8%G6+&?024''1[VH"NO-OC;D)XQ6R\A5,+BK#KPF/E4J+Z,7 MIN"\WVJ+UWW>O00P)'TEVX?$DP@5C+EW!Q=0@A1W9WWQ_E^O7SX>7$I6,?;: M8G\U)?;")A8#0 MUQ31]".$Y0^E>QS[,5 %I.IP>47G%>*TP,2)1@4D>G-#!62-=*H"EA.!?I)Q M?]W .WI,?^,R(VTY*X:+,3^,8,%)-WF;1>APD1%5L<]N3WFR[B# 3Y)K[*/^ M,QNG.'U&$)1/9MO])U"B !:1V_9U0,0LB'X>*%:HZ*&FS'B[W ;+]AT:D;M( M)#T%7'1-*,>-!DWZ\E\PAVX8QT-#A6#,$X-L258 W' RI; MW+>S90AYXUZLH-4AK.7.[Y)X&G'!13C H>H<3G#=Q M/4@VT0[6#V991N=H[ )>57D,2\HFF%=#!J^0TA8>NOQ2!1$QG3"[W2,%[)YB MI-.%&A-\V-3VG-[A7?"!U!@WQK(+8__*H!:.L2JN>)_GJ'MCFT-.*A<-PVE> MQ=@H[BUB:IF6+?0NQB&N(<7$[D91YX[;- M!,W4CBVN[5B&9)SI5.)X%[&J1JPN=Q&KS8Q8A;6J=D?]%\G1!5!:Z52G:Z)R M[<)9K2R]J_7( ]TG?]$>,)2D)SZE)*)PI4/OGIT=J<'YY.!PFC/R_F3BX/MD'*]=*-2=1\_<[[_/KFW?6G M3][GWZX_7K]_M4K^/EFNU.7,:5C71*"@@A";WB8BK5"85D/ T[WLRYUK%O> M=9X3*Z^CO8U#,6;KYC#/QVBK!--"/=5_/ .C:)H$\Z=Q2H2DFYY5A0]RZQU& M1\(@D5%H0/Y9&/GD[.+@\)#6O(29EI$>6?C\@'][4D;-'R\'^M;6GQ?>N_C' MHP')N.__Y*/S@Z._Y,''9W_1@P<7WT"+)[2&>>W$&/#M)=F\Q31(__GH^)$5 M@^2^?WKH#2J#/.32R\:E1].OWJ!Z!F*7+U[ M^>;]QY<$&&:V;#=5+_\FHJ[ETO97/OJ[WOG!C%1F4SZ6U\-*S]_\?OW\]<>7 MWO/7[WWO];L7!_Z:W#FLG\#A$W@O03^\IQ"M=.QS"CI%2>B![.@1FZ_QG3=! M7CZ?-T6D^U9G&_E65!MS1B>5W@?T-N?AF.5KW <]'NCB!X)XO$I7$L% M1I&'1'VV26OT+IBHQ;RW;6^\?9RX4=1'A/0?B^'^A3F)'W)5D,O?]]Y/52ZE MUQ@22A(,E6P-$WX7R=EOC6+[M:B-MCIOKM]=O;M9U>:\^/'8:&=S+F&DM]O?,FR,OMMSK?Q>$X2T#;_Q@,YQNO8FV'.OSC M69S;Q86;1/F'6)LZSZ#*;]O!B2\%[)054T\ONM(]P5O28BK_#K-H#O\9EY/DE_\+ M4$L#!!0 ( &*$9%2;Q.3,!00 ! / 8 8FQU92TR,#(Q,3(S,7AE M>'@R,S$N:'1MW5=M;]LV$/Z^7W%UL'0%+.O5MF2[!E([[8HEJ9%X"/IIH"3* MYB*) DG%]7[]CI2<-K"-!0/6--,'@92>.][++^?PZ_+R H*>X\)2D%(RQ7A)@66UJ!FOMH*MU@H\Q_/@EHL[=D^:_XJIG$YW>B9V,Y_89I%)S-/M M=)*R>V#IVPZ+^TX61V[4#X,D2--AZ/EIF&5>EB0D) /_#Q>-M!'>R$BUS>G; M3L%*:TWU^J.@7ZGQAJ5J/7(=Y^>.P4TG&2\5+B90N!DV.O8T*?I%621GJW)D M_.DTHKO?"<^Y&)TXYAGK/U9&"I9O1Z^7K* 2KN@&KGE!RM==B3FP)!4L:X"2 M_471)C3/3#>-O4/4D[.2[NQW/6WT^9XX]Q>F" MB!5R).9*\6(TJ/[[O 8'G;ZED+1^*PYJ38&5"1<5%T17*\1;$#1#[\M$_S*( MC.],/QTUT?5R1-49V5TTR-?/W%<(*9!(PL-WRV M\+B]G1O??_7'87&=7E^'X7#(X9?W7!1P8_EPQ7O@^[[E^8,@C-YH.L=Y36,F M4H@9[R*YDU[W?Y$=[Z5E)WS(CAM&_8'S!BHJ%&&E+J:V_FXH%F0*9X7>?U(@ M.+ZF4IE6YSF.!^=%E?,MI5V8,T$3Q84!Z>VKSA7!Y18Y*;L(=AVT@2=W\*DR M!FG8!_$(X>\CD!]H,[NG+4I_,\C=PJW(HA;)FL@&=H1F6O@HU8X0JVD%?]92 ML6S[(W#-[2/7_.?B&J[^K[DF6[)%@1\XW69;P.-0Z._&T=#MMV-WX ZC=NSY MKN_MQM%P$'8?MI1HIZ?O^U%HR-%,AZ[?/\3GIY#L,'NPC43[;>0E=5=TB]<" M.RCV4R4A-45\2;!N(.B:DVD7-DRM$2$K+.5=S'1+YCEK\!DK29DPDH-\Z+"' M V8BJ^5IEJ$VC&Y)I<$R?:["L[?6K 3/@=]3\8WFQD*=M2-UC*>"O-;[D3D# M, EG95FCX+41;$GG.M9O1QH.'AJ$,6U+B8!F:YO3A!8QVN&[)AA?F^V3DOT\ M*3T]"89C:=YP+DJIX/3$#\?P&8^$*[BX6+P ']YQJ3CN[)=$2I*L:TF5DC^( M;8^JXVB!?WNWJGASLQP)FA--^KW;UDZJW0^'@S,3$N:'1M[5IM;]LX$OY^OX+KXKH)X'<[;TX:($VRN.!VVR*;0W&? M#I1(V40H44M2=GR__IXAY=B)DZV#?7."*U!'$H?#X-$Y/Z E^)1>G?SOYKM5B M%R:M>-;O]OOLJ[&W:LICNU=> MR].%GI-.O#_IA$%.$B/FIR="39D2'QJJ)T2V?S#8&_3VQ3 =#I+]P>$AW\]2 M.3P2HMO_3P]&=B >^S@_U_)#(U=%:R)I_-&PWS[8*_WQ3 D_&?6ZW;\W@NCI M268*C_$L^L?+J&9-F9=WOL6U&A>C,*5&[+IH3HTV=O2N&_X=4TLKX[G2\]'W M-RJ7CGV2,W9M>%V%DT^@!ZM"KF80J]/1E_> M352B/!OTVKV'%C]M:PKG2OL7&7M^>7US]=//S]K;L[M&*'RID2_ M\H_W[/!)8Z^:[*P0%LH^)[)P$ZZ*)DNE]2J;,S_A_OV[ONV%Q7_^Z,X_<<,4F?"J9E5,E9V ./U$.GB\J MKMFU+(WUS!3L!V-SUNNV_LE,QA)=R419P1)EFNRJ2-N(Q=&KBT5_ZV+QD3M$ M .[.Y^RV,#,MQ5@V8TALC(4P,*$P8'J,@#7!>#%G5>%M)3$#<']( P@29SGN MK$(8,Y[BD64F!U-Y$^76! J92N>XG9-(SF\EQEW1Z?!,P!@,J4,.P1@DD"J+ MG &Q MUAB9"6S28JG3!7T<^R_TQ:62NA">3*:207RE,SY2>8H"ME&@PDO25, M,P+3G*(;H#9?=<.KQ-O@]>!-LDP5B"B!8QG!)L &<33;E7959" '3G4,KE-= M">@$2E;"U03"E-5S5B+(A$_"K=9+ -:Q=X^&!L9%*)":)%%I" !U!M (P[E@ M3\K=A&7:S-P"DE:.E?.HKCSC]##:#2N;*\AR"V/6K'V5X!IN';AN'D3B_;O# M?N_@V-7PJ1,Y+7Z390JW(497C%L9T(#HJD1+BAJ3@&"BE9N0.(GE(#XB/[H7 MRJ7:N K]B!*MT1$6I36I%'CLV Y0("1@%4-]>9=.>#&6[ QL*NH9"LB'$D_(TI:06E$#=FR\4#9@X$R#$3S?(Q=2%!N?EFA M\R 6@_WM0>@.W]T6B.ZWCWKDAPOI4)0C6"%5?1M)3FX,3HW 'G5"T2@+D5"S !WHHG2BL_IT3^U+"TM +N J3BJG@@ MNE)MAL1Q5T^HK&P)2+M0>*2IL2(8$.K.L2Q03V@@&RVRI"5#(JBI(WJQM%0) M[GXK^$VW"+^1AB^G7%>!JRBX,LM0"JHIPN*>*.GN"XD-N#?>/EWE!;BB(WC3 MQ5HR,95_WH)-L@._EY94*&??WLBP9%&"AQ4HHR=@3T ;#? &$">V"'$U8\9@ MKH."=M-UT19:GD3>"WB2DKE)T\I2Z%R1=&XY]D0P' 71&$(YSHEV[T:H)=_=E!G%?P+P4(2D$?]2$/<=V M_U;J^E3@D7SS-[OHY3C?$E3OO9$-5SC]$XOUT%P2$O'C*B:7W$2H>D&5L5:N MWIO&4;)Z8]U]8@\/H#+/E?=2_@K[)P:E [4+!?N"DAT@%V3KB,SQEPKGQ7*3 MOU0*YH>E515I.#S8_?^^ZH]*Z&<:I1A*0P6@T4Z6]L2IDD!&G93O]S(YPA, M(<^[*@<\X*0PF3IU/'DB]I;2^/9M?,Z0K3,+TF@BZC+P'' 3#I=K@#5CLE/% MU.BII(Q7\'%]1FYK:I1YJ_ MN];A7OL@3O.;:CO!$=$9<+?&A,6@L.M18&_7+.]9;+,#H78+?8X]'9__Y MJS*\-;\ T$,B8S]Q"]X;-L/+_7NZJ5WQRF?YI$Y@Z94T_^P7+2LEP*./8DH3OPH: MQ0/?J5S[3&89HI %NLLN/$&<*K_>Y1M?UM2_\3N?\,71Z?\ 4$L#!!0 ( M &*$9%2![,P%SP< -4D 8 8FQU92TR,#(Q,3(S,7AE>'@S,3(N:'1M M[5IK;^.V$OU^?P7KQ=TF@-]V7DXV0#;)MD';W46:B\7]=$%)E$6$$E62LN/^ M^IXAY4?BI.N@+R>X"ZPCB'7. M&JU.Y\O@O-.YN+E@W]_\]",;MKL]=F-X8:63NN"JT[G\V&"-S+ERU.E,I]/V M=-#69MRYN>Z0JF%':6U%.W%)X_2$GN!7\.3T7R??M%KL0L=5+@K'8B.X$PFK MK"S&[$LB["UKM6JISTY-$3IA,WC7DH#\ M^E@W4^)=(Y=%*Q,T_FC8;Q_LE>YX*A.7C7K=[K\;7O3T)-6%PW@&_<-E4+.F MS(D[U^)*CHN1GU(C=)TWQUII,WK3]?^.J:65\ERJV>C;&YD+RSZ**;O6.2^^ M;5J$H66%D6D0M/)7 9M@GK^=!I,/H$?)0LRGT.N3T9=WF8RD8X->NW_?XL=M MC>%<8?XA8\\OKV^N/ER=G]U))M[U';KAB&9\(9L1$BBEXPV72LK.BJ+ABUZ+4QC%=L _:Y*S7 M;?W =,HB58E(FH1%4C?951&W$8NC%Q>+_M;%XCVWB # M!B\';X*E8-XB)G L(]@$V"".9K/2+HL4Y,"IBL%UK*H$.H&2E7 U@3!IU(R5 M"#+ADW"KU!* =>SM@Z&!\<271TV2J!0$@#H-:/CAK+D$6-I M'6HKQS@]#';#RN8*LNSI MQ*V/T17C1G@T(+HR4H*BQ@0@&"EI,Q(GL1S$1^1']XFTL=*V0C^B1*-5@$5I M="P2/+9L!RA(!& 50GUY%V>\& MV!K:YKA0D>@/>ZNWMB%W?M;>7A+MP*ZE@ M*P(<23\C2EI!:4 -V;+Q0.F]@5(,1/-\B%U(4&Y^7J%S+Q:#_>U!Z [?W1:( M[K>/>N2'"V%1DB-8/E5]'4E-RJ(QK^SF72B=10*HJ$<*"5)7!@I 1!-I/;U! M2A1>#Y6V2V)<)5#+'3A$'8 OI.)0>^XTIQXG!,RQNQS-'H$3+^:J&" MJTB0(&@6_47R/%K=7AA'6P3CP7 =QAO3U1J:-R>ZC4&-A3"1"6&56UUP8G1N M@7.J%@G W"1S, '>DD=223>C1/[8L+2T/.X\I,*JN">Z4FWZQ'%73ZBL3 E( M6U]XQ+$VB3? UYUC4:">4$ V6D1)2X9$4%,']&)IR1+<_5KP&V\1?@,-7TZX MJCQ747!%FJ(4E!.$Q3Y2TBT*B0VX-]P^7N5YN*(C>-.&6C+2E7O:@DVR U]( M"RJ4TZ]O9%@T+\']"A3!$[#'HXT&> 6(2[8(<35CAF"N@X)VTW71YEL>1=XS M>)*2N8[CRE#H5S+G(UIS;1V>T_D@=-D8BGZID'BA>N>)+BDP# 9[(%T;CGV1 M\ 8;M_*U1]*O! OOF'7?1\ MG&\)JO=>R8;+G_XE\_707!(2\>,J)I?<1*AZ1I6Q5JXN3.,H69TV=I'8_0.H MS'/IG!"_P_Z11NE [8F$?5[)#I +LK5$YOA+A?-\N8E?*@GS_=*JBM@?'NS^ M?U_U5R7T,X52#*6A!-!H)TM[XE@*(*-.RHO]S53P6\JRH33S>=87E?ZX,'J#/XG\Y'KYK9O MZKADO6VXWS[H'CS9W&WWGFS[/;6#]D%_^*=KA;']_:.-U':\(X(SX&];\N)= M8]"8=ZC!-NJ7=ZPW7X'!O82_ARX/WO[[EZ6/Z060[C,9^XD;$-^PZ=_M+_BF M=L4+G^7[V?UL_3IF]?;-$ 3B?Q^\ZKXWT0W1VF4^^6[BG U$:UKR>:F$9^@\ MD%V LOU%A=+AK'*9I@(@ M83_3$9C970]8QQ/V2L9_\M.6E6K@P=]$K'TOLPR73PC=91<> M(6:56^_RE4]LZM_PP8__].CT-U!+ P04 " !BA&148VT'92T% "?&0 M& &)L=64M,C R,3$R,S%X97AX,S(Q+FAT;>U9;6_;-A#^OE]Q=; T 6R] MV4YBV0W@VLX:K(V#V$773P,M4A%1B=0H*H[WZW>DK,1-ZJX%VBS-&@2&Y3L> MGWOAY M(J+@FDM!4M>=G#6@D6B=AZZ[7"Z=9=N1ZM*=7[C&5,=-I2R80S5M' _,+_C) M"#W^9?"LU8*QC,J,"0V18D0S"F7!Q26\HZSX *W66FLD\Y7BEXF&P L">"?5 M!WY%*KGF.F7'M9V!6UT/7+O)8"'IZGA ^15P^J+!>[VCB+:[0==GO0XE,>E2 M_7 MAE4]'L12:-Q/X?KJ:V7FGC'-KG6+I/Q2A-:E1K6T%DQ?WTA:,-*L>!_,\2$\.SELH)\B'92+ECM@A\8 MT)/KA"^XAG;@^!\C_C36"(/+U'\$=C2YF)^>G(Z&\]/I&1;GQ>SM\&P.\RGX M1_#6F3DC!V:3D97Z[:[7?/0>#6@$P9#(4J2P@7+I=* DA.I,O"]UN\@8UBD)5MP16'! M91-.1>3 GEFUNW,4!%Y_)+..81WA5R]9>6).+%:!(\QAQ-"$O M55$2S)66FV>QBF'ED3V0:(98I82C564LP04M-O=S4D&)_E5PQTRIM=N]D M:H_LF^SXW3VZ7R=_H^QN2FX8:2/V>^T.)J_7-P7YPR4P>)0)Y (Y(B.6@Y". M-.'F1/+J8-?9)5QA>G/%"I/(IA&3- 5?;6_6'OZ0VNR/L:)M>X W1&&SZMCN>#M: M; _,C^3ER]7'+?!I>+6[TSGL%_83ARBJT.ITP421(*5]Y.H7UJMG//[\:?@* MU36%V:Z48VQDRBG40?G*,&>6W1++$3#DN= M2(7 *,S,"*OV[]R%;Y19'8,:5M=6RD.6WE>H_J3W)^#ETZ?WWW#"Q(E1%*L4 M[?XD]V\;Z2W1?6S47O'YRC=9R#_3_N[4\#3]<>_=YK_ ^\9!^ MXV'%G>?\N:Q>=(2*I<3,'O>>_-]2CKV[]6Z7D 7R3JGO+_F7EP7KS^K5A7V) M40+D 0 *C$J !$ ( ! M &)L=64M,C R,3$R,S$N:'1M4$L! A0#% @ 8H1D5/)A\2'/&@ M!R\! !$ ( !.I $ &)L=64M,C R,3$R,S$N>'-D4$L! A0# M% @ 8H1D5)D'18#I,@ [!X" !4 ( !.*L$ &)L=64M M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0 ( &*$9%09YU"/PWT -.\!0 5 M " 53>! !B;'5E+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4 M " !BA&14P7:;6:.* P TBP8 % @ %*7 4 8FQU92TR M,#(Q,3(S,5]G,2YJ<&=02P$"% ,4 " !BA&14SSM54AM& 0 8W T %0 M @ $?YP@ 8FQU92TR,#(Q,3(S,5]L86(N>&UL4$L! A0#% M @ 8H1D5,<8+@WPP0 3R8) !4 ( !;2T* &)L=64M,C R M,3$R,S%?<')E+GAM;%!+ 0(4 Q0 ( &*$9%0BJQ4*+RT /PS 0 8 M " 9#O"@!B;'5E+3(P,C$Q,C,Q>&5X,3 R,RYH=&U02P$"% ,4 M " !BA&14:^-2#$P,C0N:'1M4$L! A0#% @ 8H1D5+EL<0>K6P 1$L" M !@ ( !)WD+ &)L=64M,C R,3$R,S%X97@Q,#(U+FAT;5!+ M 0(4 Q0 ( &*$9%1J$3V%D"P *DO 0 8 " 0C5"P!B M;'5E+3(P,C$Q,C,Q>&5X,3 R-BYH=&U02P$"% ,4 " !BA&14[X>3C)U! M #.80$ & @ '. 0P 8FQU92TR,#(Q,3(S,7AE>#$P,C&5X M>#(S,2YH=&U02P$"% ,4 " !BA&14G2NVEM0' #,) & M @ &%G@P 8FQU92TR,#(Q,3(S,7AE>'@S,3$N:'1M4$L! A0#% @ M8H1D5('LS 7/!P U20 !@ ( !CZ8, &)L=64M,C R,3$R M,S%X97AX,S$R+FAT;5!+ 0(4 Q0 ( &*$9%1C;0=E+04 )\9 8 M " 92N# !B;'5E+3(P,C$Q,C,Q>&5X>#,R,2YH=&U02P4& / !$ $0"(! ][,, end

D37H.\9/;U8?K-]14!7KTG5,EP9$+_ $GK/ON92VO7!!=SKVT*4G M1N<.O?@U>9G5A#,H7HW*J4]([W6X@-]\2<^0Q51A4\.&>XV1:'52T!M _K7N MU2]2&UF5:\"Z0O F#?#CXX<'@X;81!;R-= Y$,H/4S"W">_)%OAHH?Y/S,E7 M P/\;Y3RW,Y)?WU@#:N4H@%4+@W\VK(I2>4YGM37E!Y7Q'I,W;XBUV2XG_E. MDOS3/LREGGL)BTV*S'WTGOYF091@$?'WMR$N(@_@[H%2>9@R'U:RUY[EE]_* MZ7Y(M^TCTZ+[#8_B ER*D+4B7=X6"3F'X:XHL];G@17:)L>3]5-C43QX$^3/ M5*MVE,9V%5G G?B,L!RY2V^&=C&JXNIP/MC0/\5Z\_'G@K/#?EQ?QZ]^>_'[ MXN: L.;^:\,1*VOJ# 1OS=4^L]6?L=Q]FJW#(;(">_*T#/7+1 MJX+CO; .+>/-$9C 3&X531=L07OB=2,2[7LU@O_T6^>.6>.DL M>PZE+MGS)L3,1K*,&-;V][%7/M2_O6D/+S!",&QY!9OKM3.V^U'02 .< -DC M'4M_/MNI=&Q+V4F6K7,"2G^4J)P_T$Y^/2['VIC-BSP.(HMY6J98/95QSC8O MM82+?Y_B/<]6E5[W^=ORI;)%)"[)P;+^#F"%AM"_C MQAKD/K)FF20Z)75?D[*IO8MIH@&@(@W8&,0F'@5S.ETD]00-O%1% MJ%S-OKIR$GBF[X^XM>HW$\?)+)!YUO)VU-J;%L&16!MEED#\7+O5 X=O MQ_)%["!%X,;@/,;IL9>S;%+E:;C&!R\!=>T'AK.F][V?W$W2R MTA6A\N<(T _\:ON#%RT$X9=E'NV'R.QSN/)=)<_3D;E:_IJ-+*W=)QR9?\4< M6M+DH)C^Q^2X$%)#+W8O5,$>$5^"^MZGB^/)IY4Y2AT]/Z8]BQ;@$.S2@.AU MP(MO28Z>8?MED/,1Z@Z)MX*'@*;Y8#/IU);^A+N%@M68WQU886V3I6Y/-W!U M*=)VL[R5]]+.K.+_>E\ P/#OZ3W[%;W/"\KIKY6TKL@[19JD?N%/$Q/1"[# M]+H0M]LNI0_1 *>1@Q9WH>UELK !MCA&3QQ^&H\,;[D8$E!DC%E_65,R/]ML M+#LW5VX?#ENI'"^]K?VB$_4*(?.=!MP63Q0@WWR)_I:$@3; (M?1$\[G:M_R M'V[92V9QJ^-V/'1.0OI5=B/<]5D__:NW+N[OMZ-#EQB64FBMG MW,QR5']D8&C&=8!MPSGS@[VW9L#\ZIZ_B\/ N92YJY]D0T1-6^/;#?S$:4"G)@WP:8:R>F0K9CJ/WF_]:#8'^][+6^KI+Q)S>N^C_0V=PQ?D MA%C\>R!3B;.#?30 7XF\[Q>S<-Q>MQ0'A\+JM][=#9(YVX/<:K@*[$!!,W7H M ? [^H\L?S!B0MD>^FQ]/TQ4RFY\8/72&O[_ 1A>F;!L!2B&9@+Q)[ MT:5/S+G5^U&!^7LN1R5/5_\1Y7.L@P&A,K($0::]B!\3FK;;%@'*_OK'?FY? M[;0Q+E4HNC'Z]S3$3OQ7+M]_;V%9:@RN83LQRD$N"4?0Q6#PKG)_23CRYB M+<):S%'MHL,?9KU>M7R$:3:^_M$F2W9-N.%OI$O M$.K2>ZJBJ&($WW?L'Z<>SX5S[(<7H$Q#2\0!2]/@&8&4HR,# \%\+TQ]W MW#SI>#?)&:[8,'9:-6\,;E-P;:KI(JXKA?]AIC/'V0'3,Y]OSO^H11Y4M(VC]WNVS=YRA1W3DA!XJ@A(IZ> MF2VA'A;QBS4AB2_JMJ*T7VO[100RG4[+>_QXVM=A80,^>J_(%M 6[NA3X]_M MW$_I@C1,=;>Z$IO3L2(OI3_7CRN C]6?410=1!U\#(*#T@A5IP:F[XI&.Q7_ MEEZR9)NG 1\7<9\+$=/9_!,S.R.@,=DI/\CU^KBM.4&[#9=RN?^WXM6/TG&E M'7)+ JO(VATH_V8;&RR#[T5N8K2:,O]J]2\%H7:I#V?O"Q:59NF 6Z>YH]%<;,K[9FU<9&!T M8;V)"'IN+X45=R/%R 9HEUE#'[+:'=\J#]Z<(FT:<'_!"+R7*@"/B]/BZ7[" M[MPOS;R,C(I;K(G"E=VIH$XV\3:7PB)^AULW_"AJ,WMS-_W)=)4R0V%8R*!< MPH>'HWULNIL[PXC[].T-VO16G MOHRZ_S$9[^*.-Z*_U&1EEE>7^JC M,9+JE4:]?JLX7>;AIU-N]4;'D@'64#TQT)4&L!10\C3XHA[L+6C6XR6'U+X$ MWD._U3A9> A^^(]D[FF)!YTBOYV6F1Z-,W]'HM[FU"WW*$'BI]J9]!36M&:' M>BMQ&R=^R*LY32\XLGE6+-C*9W'VJYR[-A;*RR=50Z(W8*=]FS@L!;4_H:?D M;04^ZG= 9JCLD"[J/4G8.30L[GB8]X+3!YOI.\^_"8:[G*1OKDO6*$>,(O&6 MIQ]A?HH]3D- /D[46? [US!_.JE"W@U;]$>UK3:X-O7L,,636+Y0\N@MI$NR M&W55+A35^+6X&\(^Y_%354-:7"+4>E%V!Y(*W\<\ MRR-QT3_)HIB@&JV\*8,?F-RL.[]P;%O\6KOIC9;;(>@C69%L2&?7MW1W0+<=$:=H MP$\E&F":T:KWGUX.,S P_+]W3M<>+2G2GRW9]AUN6.3@[7!ZY[Y2IOC*B^JK M;1$6;>P7]8$$;Y2W*BC?'H:C =[[@<+XP\UD 2>!H=CAW:";2"\_":%S^T6: M2ZBLG*_M5Q1SN4>X07<3_/UPU[P5;9_*Q(+IGN-UU9]B[D8*2@K9& $T0&S; M(L&E&MFY.*MD;7Z]C\K3T#J9Q.)J6Y-A9O;>*I2YY9^VV\!MO_GGXT*X"4NV MEW >2CSU".+;TT]K4H?Q@6U995^S'=<:KIL]#:S=Y9(K[SOS[,4L[P76UH3M M;SR7QYXYELA^KLL2.WGG+7-A=#=W>7$8N]P1+R]%YE]0062G*KT&@0AYCZV- M@3RUJ_=?#9YN>UMZ:\[Q\X4!?N5,5PG*=-?SY_VW*$SX?K3Q"SUNT)J/!Z;0 M341(C-ZYBYDSK;.%DT]^Z9?Q[V?5WC$V7ZZ'^.]W E*7]3DY8>\UR-&L[:HO- MF+7MPQ>I4F2@QL]1IRL'R\J\'$Q,?IL]>* MO25_%0TAG]QTLUSIGBYE;=>D ?<7XR'L"'GX%3")8("%O'QLQN..>9P,<]?' M+Q2<]U3>.4XJ,KV\I+\,_ZQ:"U%N/ ^?JD-T+,A.( 3!E_WM-1:QOMDACAWI MYD%HTMN1X9#\;W/8.VM6A;>(4AY6>SQ 2*:AH"73?T.L=K&ZUPM A>Z]V+ >5+,0W>YVIZAYU;87?6W+Z M$]3()[M!-:*\&=G2#E@=#BHF"__IS9C,0KE$ZDG5I9G42EH?$-?VK3Y^,CMT M^;CM+F!^LO^?T.#G+E"R B593PCN >+NX&E UT%HRUB=:D32&M[;ZF=MO/ G M>ZU_UL2!\HBDO!5 *;1;G8D$12.%/!8T\92$9C3%>MQAM*K@Z)S+S:%/W:<. MRDYV+LM.ARD-MYVC3BZR(]W75\KAS[!94(,)-TM,I[5C66YQ@?H9V:;2C:NA MWN&42!K@1@..4@?:^>H6>;RRM:)ZB0U39L_?GN%(X*L'/J Z1QU"). ]].?&Z6 ]I1U<;)AAJ?.$[4)<*USN:M#'-_^'1X M1'0NCN"+1%Y [I+++32-V'#]56I+YZKV)U=&;.X*$[K#!GT+Y\9G^! M=^\RKXG=[(QT!N48_6Q4PMTF$$>I7]/3@C7&9]80IR9DOI-7'!_$^'Z12WD5 M(BJS/5);R[2B=X*^[0O$B-01@GH3:S$!^H_3U9,.HH'%-?\.]_'GHB[ M31BT^PR[WINAFM"BU$ZH>=(D-"^%4F8 M!G1JZ+(1UHFF-.#%2$^R%P=FBS^D@22S*9XB87OHI!1[3)S_?O*)^_,_3)@E MS2U F<5>G)TIF(J%1#1,'94\0>RL>^;H*1ZMDI9>_JOMQ4_45&3UJ07J"[+PFC_>M M*W'BX^ZNN+7RO:(9^V5\P];V]163KK?_G-/$\ VKPIFNT5LICCJH+;)A1^!" M]\>V"=]:$Y.O+U@VYVP=-)?/^E76TW4EZ7,WAR5J^;5O/\!,W(S%Z+&1+]. MB#J\7Z>>FF*U:>4*L>E%=;')4K*\N_[.W6Y\Y<+_N -"]W^[B8EQ6Q/#?UK9NVI*?NKYUDEQW[-45)9 M2';#-. C#<#MB^#BJV#-5_4X/N-KFY0#Y@VTYRF5HL>?G!):O/L@15;Z=I@6 M\FD.$T@#Z&F['(PGZ2/&I4X0$%4$I6N)7=I9(UD^ ?XIMUQF+R-P'_0CXN3@ M)7JW!SK[3 'FZ8UV5/GBX<#VEPXB8;4W=W&V6X&/\AD]W]UM>K)%SAK]Z6RO=>EU>0GAIW+#'29:;"IO\2@91IGB MJS-.JYE&AU;[)IO0 %CO]2>C<>_U]P=R6>%,]'QVNK-X\:87#1#1M1?.K=8> M5(B"ZY7+I+!()M]JY+ZQL:CGGCA._/R$"<(N8DTX>5$:BR1?RV#Q\UVJ6?CRPG2P.68H<)6F1!@2[G M,_C-TMQU"*"GZ>*IG56>]O3)&$Q?#.D(*P4(0+F=#CL1;98%7ID M"TU,PYY:$O3>$*_?6OW3DI!TYD&XW#W3V^6=5TJ8.H2(O?\"!>___X)4<1=( M&C!'8@GH^@BU)1#C4RW=]'&B(O1/N>^-(Y]48++<-J_Q'4F=G9 XYU.4-.HY MQ""]*JDL14,CM2F;=9AYR!7M[34IL2=UC7@GX=SW@?7HDI^7@F3>6K\^$Y\Z.W/24[5KT2A M+X[JG<8KD 4?T@ #2FX!V%D%\UAKDXOJE.TV8J_4[ V$E1?YNLG=LZK?O"=Z M08XY_!737B)90(&X0.##7]9M]A+Y60^A'/8UIX-1! M/;#/>.%WFS2]:YM1AZBGOM="),EF!(V*J4B7WGKDS,'EZ#B!?=Y_$A^_)',Z M#FZ#RW=DXP0P>H6T3[Y,U;6[?;:D^ MEQ5Q\Q"[^*-F;@,51>;TQ&[JWP^QHDZ(7=R*>7R:#2.55>+(@0MT%:CH*,EK$%8(=)R57>4#E7\W^&$2GT,X BO.V3:.:?"8;J+>G.1=S8?FY\? M*/!2O<;F!OBZCJSTXT9)B@MD6TK\1@L7FLNO8=V9STRG0N;')://)/43K/%! MI&&N-A'=CU9;ER39R )6^[A]:7G#'M[)=_*PT[$$=HD>;-(?3"6AJS:2R_R!I>6?P3$6WJ:X?!/9EN9?K.TY?;>P9^CUHPOZV CTP40"%"6\BUFL@X23[4GLU(4 N/NG[VX3NO(E MZP_7->VX4L/\:LLHG[XWLAB?D'^G*+N9>IN=A=>/F$?)U36D 84. M^?8SI^+Q!&#W!MDU1&B@'"71 +)H)U5H=<>2+0$N/K%5EQCK(N"G(:EB+KQM ML3%RKL_>UBCQR'G1>Z@E "E&U/[#1Q^(OOB 933 OXIRPFOG %#,CV5@^*^K M*I8&>+:#IZ*Z7>AYIB>CX<5.A28-Z)=2&7?S?I;Y3-/QF4Y0>F2LZ9S"PVSV M*P\DPO19[(9=F*&H?$AM/TZ6= GF-=[5)C0^U^4RR]];NIJ!R!CQ$2K0VI)K M;'[HH'GC"[R6S)ZK=OI05\@RJ/ M<:?&RAW^^3P.QR8JVN?]9P[K3A9N&QNS?] F"%/ ]3HRVQ&N"\944^8\WIUE M>R<@D_W6N7L#,KM,/(%_BHOP02=AG*[;C%;NB-[3W'-P?.]P\DE0]:>F3W]^ MY?'$A>DDG%KLA$P[HJHZ(#4_87Z=3]*#A\[+.DPBQ_VT^#"V"%GH[K!UJ"CJ M;6#5G !1ZSG2%6[%ETD873IX8Z]^" M9%!YD)W']"3!:[]4$N>2W3 169T=[TYR,2-DG"TX\696@>BUPE&8JQ38HC4;OBR.9_\V_W.WJM C M]U UW J5PPMBOCP@&^>N(J1KKZ&/^5BF M,U5Y5X)]P]VNF;>E>TK6!NW.AG).TSOYK\"J"#T.@DJU5$49J'/I1Z#)-^N# M/;,PSXF#J'O*4.TUV?B[\5:",HI='^* BX>U8X'B,H]91/L=^81B5Y^2&=/N M.:>N3WV+-K?UR]LYR'KXAE!TFBHWZ&V,W[#^(^.IR>]0]B?[BI>:T^'_:P6D MWU+T\CUYCF!'1;L<_/-C=??_^<+.?_8B30P,_]_=PO7W^'',PIKFNE+ L.H M7I%3SCQ'S2\+M:9>DDL-K2<"AQZRZ;LH(SNOM/OR\5,'@BTBR\FGT=$:%QU= M!#YY9>3KV#NR$\.:+4N#>/$!C0#KM4>7(&Y3L@1O3.1+O NZ/5K7#R-P?K36 M\7J@?WWU?G+C &?)9]'[=W/=GH_(\7H32G6Y2/>I"\G*337>I>AG!:\."FB MZPJ:]\P@.]_=<51BE]+((>H(50(,POK8Z 8^\GPO";5N:K/0 MU*GSF8F.^@+[<=-(ZZ$-J[$70.X$B^A%*!RL(5R_(04!#=&*+6>FS'\YMOA+ MVMUX39S.A'^T@*JF+7^?^D&ONB1]4;VP M_Y-GY'L()I@35\*\;'$$V:F'8('58.J+"5P.^"O:V9]+S8F9;U14Y#4?7KOF M<#_TC-%]W7K4C6134;FIUA4]J;$6I<*YU6"5M^X%JVGK]>(Z7(_#CO7GYP/ M >?W?X'+2/\B_FM=N]V?P_;CVM&JH4@!Y9;#3]$0<5A_3X/#W34:< ^?D"*Y MFO!S@!#6661$&@@^Q&IDH;%C#O<.H@$GW3_2@$\WD3NM*X>FR+J9!C0@7X30 M30,XV&G ODPB&*0910.NJ&*CJ$?Y:<"V8C^=3*Q4'_$;-?I)L]_T>C&W'A MX1O>&!H GK+KL>!<0/0CSG_'D(WY"@1T>MJMU+6 U^KGND^J"9U@W"[&-6@*>B>O,>S-.*Y7Y\ ML)%NJDKBT/>Z>2V'1%_<0ZU9OY-*#,N,"SRV M6WM[QOM($Q8/_F6]?]FO$K-*YKQ*CNZ,#.WH'R.HT"$7^E%P&BD M,4MP@M>/?X%2YU_/?YE9AB,?Z(QTMCCF4\N<'K_:>^G;PF9-2#6$>2RA4&S A?8_3%?X>ZN)-T]$@=I M;.'VL0[J 7OHI@?S;@%F"L>#GT/91#<1EN-JJWA9Q9,7,#Y3YQ)O/&]^N7VF'QMP7 \]J- MNX_&)5;ALC0@3 =N"D:5('W)S@2XGCC)+*A!N'Z;!GAZ/4R9,#VIYY!#;# = M+PJVZ^:;'D'[=4% Q?=)^(.YRRX"L& (H%GK2CC7#W?>P_E WMW(_2?"ZO]@ M[[W"HMJV?=^!B.0H.14* A(E*R %(B B8"*'0@')$B135"%(SC !!044$25* M1D **+(!R5!(* H4D5 E6 RL=)GK?/?A[/.=[Y[OW+V7NDFV3XP/')$]^E"?)(]$C%\9Y=4J M3T/4:W>R]LUL:C>RQ630R$[7I\;9H2?@7J8 6/[UJDBM:_H+.16RCC&CX!:L MF3\TP(M8[V#?(];<>9G_["W]I!1M@!&X.4D'WB)=0/8HP:U(6F3F&;V38.( M1N^I=#YQ"./\R$^>67?^06(R[*[*%_K]D+],[X2K)-4*RQL/%YRYIH@4,Y?),&Y(H2]BFA$\B]KL6N$GP).:5= MBQ+QI[28CH%JTP#L$.)073PK6.$DT\61?5BM#SM3U&O*7,LB*KQX6P?V"9S2OK_(8 M.-4/T6&122&ZA%%=&G ,Z:\\-V7FN2^NWCGQ=$URK/E6M7X@9=[O!S+U=3< \K!.T[P::VB5FT;/WQ'#B2B/@:YF\%!. M,"! 90+=TR:"HWT%^H,1J/C2B%AU?O!UH81MM+.&^$\B++63&5N7).PUT7D- MNZ7<%QDQ^DNIQEULTO'G@=.ENFRJ"K+G%((1?GEWNXE5AP8D8JK(O>8\T<3R MM_:+3B.,))4_ONE#',-U!A$B8&+98%6X VP";O3"=-]?O:-M^^3HBU4I^JWI M5A^"ZY\'QILC,3I$I^F2OD.-1C8(7+$M%1(HYGL3I6CBLDGL[PI MJ5+1Z6L MZQT&!LYZLF3YZ:MJ/U;6L)AOBWW;E^OB$<(V'I(IX*6[MC*$?2=X,]5N\=O.@1^(@)N3Z M)<;GY"!*]SPM+'D"\)VXT_Y)$W(FK)I$''5@( MF0]E!'X@70CWZ1;60M=<9V=U;"?Q:M?T8YHQE[KS0EN-Y+ATOFB'PTX(% 3^3=S*C&=]'F6:.1RQD&;5E-#\]/VRI MMI]L%>U3MMULQ2V$R5FTY#^\?W??94TT!1O&' M<\G>*/-ZJ+!FNJO_"R]-KIJW-4^J;YU,T!"TLA(%@!J6WY^[_2O#>0;/2/W2$90"U+L.E+_3B&/]!A? LWS<6%"2(BF3I1KF^3O;[^AFH3D\"JZ@RJ0E+-3/7H9B3IQ M-6+ DN_@/H&5^(GR'.K/R><(ZF 1V2_7(WE1\IY4X=M2/Y*[?=Y-M'H7&WPY M.WJ!/8P&-'*2>6#]T./^N0,H<0TSRDG68;W)7\*C7[P+TI94?!X5A>4]_H%2 M3Y318:J;'$U L9 E\6&]^/"P'F?Q>OR7=,Z3F)'S'?."BYM!X^<&%?KJ#X7; M;AW1_U 9J'TK1,XUEZ0+?R4V#W+2 *;%1'D3@ ;<\2D6H_3=.F/"T8LR1D#( M:OB*WA+._J>@#KH]+&'OX0%_NU][7_72HB];H_CFG,R;VL(40+Y73Q?1AV1" M>2GS8<)S!Q'B)=>G_7RG>W6*HB]$P7MKMRNMM0#L^\JX^"AR_U& M ^9:J?'LAPJ&,0Q)#LH$@VG YCP-N)#PE ;$=:"HYV NU_0A$LIDGCBBG_51 M4(\2;"IL9!TG7704FE[B?K&XF'VL8CNL^=[ZBX_BX&>1'DJ@Y)+*636 M8*HT>&+EW,_F9F2341GL?0OF#S8.@UAL:-GKK1*%M #;&2@>2F7)(_@3(V82 M8ZF:Z]J9R5L*MH;G)F]KMJ^5BI=W'P\1G'DG>&4:8)WJ!(:1+X<'? M]'3P:UTOK[',>W-GRA$_%1.NZ+E_?=+Y:O ]TTJ,-"A",H;K40_R&W[J/E8E.=6Z_I(,%-X"F89LD$F:7^'L^7#O M!H$_LR+_D7)P[.VI:M>-7MM5%[ MI9>A:(%419D& MQ!<8_-A>JX_]L?)IR7NB04WI.AMOVN/HW@;NC+>'44?[S+O#*(O,2]^#JJ=, MESQ;^B:P*$.X6^;I7[-7I67KFB&VF;)[90XCE-V-J448#XEZK(W.QBU#MF U MC6LF"IM?>2SW;;>]6T)[)3FUDC:?5@4W)'R M$,%/#I]N\G,8[&)[39 N>WZDY=[GIA0KTV$3IA&I*ZN;T2/,4FRY^I _[ ?) MO,K$EY27Y"OJ)?$8JX%TEDO5"KJG7A0]XO584_M\J:;)XQ4%([Z"NM$\&G>= MC*04;L)9"3F\!=93ZE77:C5S)=+ZX??%GL?'R FY.V:P/'9EL. L!SUZVY5C M]\+52SB_\0OS%P!]UMI^#0Z])=O/ ,8U^R:Z76@/$I2!=F?&*C)\+%D&R:95 M_4-3NA:]OWPSTKA>)@M&/O?V^>9FE6YE=:$RC>%:#&.Y]E\@:(\&L-M=TIL(G&2\-YK';Z*$KL<( MIME\7&HU(?,)7 9U9ZB,X(WSM6]Q[@OL7YK[IB-O!,N5/9_@M&Q+W+DK47J M(IH?^O<@$$=\06 "RPB-5Z<4X#JO+BE?7KR\A"F<#C!T?Y/"H[(K?AGG B0 MHA=G2IJ@9+X;*R:Y/)3,7LWCL:[7\9[M%XKC,Z6]6DJ(CU>7Y?8H>I1<&N"R MDPAM*"YBGR[R[#I!*#-I^=KWZX'AZ.JM?(95_2?AUVWC=M5LVD')[D4(Z(>- MAJ(1 N.*P>J%RF(&/9[)+MZ.'SYW*,)7*,3U7@_D_[RD<"H.C,I?A=XG9 MI+NH9U((1L)FT7/M\C\D-V<:0FB Z0,7%1FJO1+D\1.P/SKY<(81!AEQ-EMT M-.!H-QC3Q4-P+M XC"CN9#_V;,UI_+:?W/&E<&"9?JW^HP6CM?AM#T&*%Z4( MZ;V4B&K6BK>H67YK$[+6_@HUYJ\BMI4J/FZ2FR=3]DHN ECETK%,@3*3)0EE MO5K.@H3:>*\5=GYW25_4X6QYV>);4,QMV\ >N)_DB2F3JYR82GFLY6PBE>4>=@=# M5PT7PQ%\L+ D!7[YB#C?^JFBTA_#T(X_2@[N6#"3GG_U)-7^_L6QO_G/1YYQ MH%@7OX1^PN'DVF]/+,(NR"F_C:AT.M49L<>VZO:+;KB.Z\];F1CHP=.$N)55 M& =9?L7NIY@W5DJS5=%=RKK5(J9Q4*3MZ&NK.VL7LBJ.$O0AQC-%<'/*^V,(-"9W(.=1/88;]$ [Y+CX;OZ M>%3/O/DM7>Z7MK=]ZCBNO+ZR[S#_WB$U=N13J7D1PMWZG5L]%FZVO$3F1O;K MG6S/M 9;<;;!#QZ1YYH6N"BU/RY8V)H&X&YK.>MGW9N.@1H@?2S3$9*@&DGG M>Y<.7CQ>(/6GK63\5K:A^1$C2>"NK?$]*>^*L!%C T8)MYDU;5"'^([2]8+S M54M;,?\;W^W)(A+$^.99-%,,["S;/PH+9 HIM?C,^+TE>O"&$7XQDZYE7#U* M-IATUN[=P^44C0R-SZ8R+*5N/P+M)^EV.3>/DR!+U,.X@R,D&F)-@)*EM%\T MAA84J-A7*>95R?GVG7@CE=FYJK3U4C.]D\)8#D+0A>)O7OIH^R?NO87:3HJ$ M?'GJXRYJ(Z#X72KEZ6.\'N&\_-W?[^'^%?F+>N5ZLM,*1:!;3V@2;KBB:#%O M/*:^;A]5];V56?223N[W6;IA*;H<3WK#JY.*P44BJ?/?'_INUI1Y5;2U99F( M7BI3V!R,OTHG50SP'8B1_)$]EW^.I@E/HEBZCC;O$\U74;?>3.^!GQV8$Q!V%@R%2O^IO ME.BM?^7N;?O,G3$%J#V.$=A!SB*IS/O8S#E+TT3'J:[1%K)V/6?RI[AW*8TX,I'KD-#'#_SF7/SQI_WLTUW M"6]\(JN >_LO/D[#Z@U6%"]HD>X^W@@]T*HT_GK56"O[+3(U8 WI4+6*G(^B M,N]B_3&-9D6.XXA1;%VR)N'VDLW-/IL>8WZ1TF.V 4#6D7>#B_1^0/2MB@W^ M]N;TMUOI[[7R;52J/SDZ#$EEW+R5%W(+??HHE\E1X7I8,JS1OPK00> M9#R*+SC] JZ'N+M58MJF4S$1!P'!QJ#03O-WOHRN03=?297,60)P??Q.OS+3 MMRY9_(L:OYIU[0<(O[=K5>ZVP1(9E=VK?!)/R-(_?98B"_S-OSJ[2VFP M)@$T*D9;U[X@DVQ7 08)Q0F>: O:%Q!![.>QT$L]'/HX=79H])J^>/S_'#EK M'!00;E!97;$4+9N,">Q2C+\&Z>(?S/X_.[+O2%V-X.Z[/U_\OH][07[C,!:( MPBHG07U&YV D1G1[S>#]9J=0S.AU_E]9X0/C59+V3D<9_H#/NM"A)9;34H A M<.[0#3@/MX6PRY[DE?C)MOP3E_*-!KC!,-_1 MR.;]V&;S*(/QG3W3IH[1^H79I:W;SVM7W4.P]R$7F'2#9=8X8Z%X(Q0C".^) M)ACVVR#DVQW5O.S/:(9&;->5]1OQ7Y)9 M!1S,I+H]SC(L9-C-+KL_S DX5\HYDGYHIF$D8W(XV%SM#3L.#ZQ@A38/M\(Z M.Z,&"D\.'L-,(:=J59)F!WA=./*(%9NMAU)]&821E+_G=\DT^M 7O#CHN:E MG^E6?RB^"9'[PG25X[:OX"6NU?G+]@)5ZMY4I)/Y0-+H!7 M>K5" P0VLKV$^9^('WCDYKN259[]#'/M?;F:JW\(%@GR38K"_;L M AI+)4B:5 _"!/81&W& _##R],U"E3!?.:?&F'@]7$_)M M"LMUNSI0P1Z-^)Z=Q4F?U1%;>N>VT.@U@L1L9 MG_V60/E FA4Y(,K)P!MDE'=/:C"<)'\I9$SQL-OB!DTV_5GT=L37I M11IS;5%MG^A!(/T8W28K3T1=Z?_?$=4BUE"RX7PDNW"I;^(GXS:U%RKKQSL- M_ 2U-"VBD*U"T$C5@,A8P6.0W$4F,)Y01F6V([0C.7VF_5^&V_^":>+,E08M MITJ/#G M_S+@>^M./.''Z[UU=,)1'MDC2]TT(,.9B_*T"V(;CNZ)S-D0=A^:5S"/+QYW MH?.\U0+5PE(QR21#>*A29%6*6%@K<08P[; MK[^./*';]QS&!6F-DMA)VM2Q8DY*A9XH)KRU5Z#+S2]I)_@@24#S.$Z1K5(; M8CB6P#14RGGM]WN+O_F_H@V2 1'5/472)>MV$4K2E8O?F32[)RFH/)(NMOXX M5&:Y^@D_4 #?/$&R13?&8;B#IFW\7SHU1;;XW;=X-A:SV=5 MO3W/C6B?3]#E$JH$N+2R$]L:5B*F>"?U9N%/5*/#]28SASE%%K:#,;G:L8X MIQ'!C$X_F<=X#S)/*A&.3TRMTY@+5C3K,U7_H-&55P-[Y%NC:LJ4_>QI"+#, M;&\!?+14IUN%U5N2>;5P ELFI(LO$L.6_92@P/#1#V'W7O2G2N+D+DC MM_90(2K@S2(3O==H-6(&BC=_RTEL !O+0 P-&/A5DAC?G&/K;&O@77#$,_M1 M5M\F>MBWPT-N&1]P;G1Z$8)?S,4J2K/+&XYO-OFI?O9+>&?9>NE$6J2[,H5W.2BX7=/.WM'_2%?-_]3W@5H'#3'U4J&!PB(+FQ46"G,VGIFOZ M#+Q_\Y^!^*UER($BB@^YS4<#GG]P+G'^CP_^BV9E7/Z7P@)!4%B!U7Y^7*@6_A-_IA1[=6%0D.%=P9#_U MRGI4JW0'&F,E9C>+M3*1RF*T)]N!%02SE1(RGR'N9V:\KHRKYA.LB)"]F9B> M]!4DOPAF[-;4TJ9PM3S** M7@Q=-A'U#NTJBS36/^%0H4-_U.E]'VIC?_,520&\0;P&^C FP,\+=DQ6S&O6 MU)@*VOUD[B8-UDXZ9B5Q\!Z?S+]-YTJ$40K()TARY'-Q:''!N-&. M_VXGI5 MNL"7%L>T4,_2LEYR\(JOUNOU_">5??;!W4 UK'*F,]VDKAC.7%'#7!CO43OG MDN7A.P:]F7VO1WQYE8<3)Y/6R4VX1V4V)^G;?V_7>.==S(?*&O2+'#'*;_3F M,&_NS7RCFA%]DSQRJ6Y!#D=5A)_"HP9H -T&@I.0\$B\ZIDWF8U MC'[*!X\:%&<&ZPX%=3GE:4W(AV/??L*8-SC>^81)G)RP;694] LH>_#(0'P9 M6Q!KA$!1/\*:;!X@O4836IR5\4]FW0(DNR:>WR*FZ^& )M7,:W/M9WI$A8&? MPG\!T?HW_R>\,%0/XTY,GKXHE3YD("HJCF@"?LG_$,"AR'PS*] ,W6L16&B< MN)"PJ'D L:5U%R.R8/WU:,PP'8.D3.V?2[1EV<[W28SP(Y17VP@=K\-0C"H+ MICJ--?$GW(JH ..N>MT-X0T?NM3UKBW)RK$*CF4YU1?_2O)#]IBH*\_) M.[?B\S(3I0FPM%J%:7SO+J5X?%KKU-4ADFV]CNWFM4]!Z)-=/!-(+^5Y+>(D MX?P;O%3A0.X+HR A)%;@P3>,7R/]N,^+GJ+\WYA"<>)X: 7P:?/ MWOHM#GK4L^O45%/SG,^]5_;5Y3=T6L[H:L?E\/4 N?>':XD# _-FC0GC'Q?E MS2Y=->'EDKB8;F)D)0J<9P BEM+UF-9I@$@7QVRXS,K;)W4I0ELU1=?SYT/: MWVYZ:HTR.]6(PP(%!T?ZQ)GY!'I0Y_%RK\8; ^ MP\.?E=%Y=_"\_.3OK[?Z=^0O4T-V6BCVE=0RAZDZG8WU5'63F-+NCTPZ\ADK-G) MNW7GD?&4M..7;>3VQ;)[LG?Y#.[TG'6NH+*<)OELE#0EIM\&3^#S*J;@YXB3 MS>U%YN^Z.B+:&%)TH]>YZS,^HL,6K&2V=F8A1(EQE-O2$0KJ9@:[X8I>/=^D M>-@V\V6HS+R/$_Z';V1,T=4BN%*934C&1J^\U(8K09NKO@Z?+Y7[-K\[$W3K M(=N#1VH_+X2Q5<&7VD/09 ]0!6N96<+9K'P,?&?N9'+IK6/LF8;Y$;HY=I:3@ ? GN#,F"'T? MNW^4ATGC6PAH(X7D12[GTH"F3^Z[&IDL&V+,(_8^TW3M8=RCXM$C*E0I9 DQ M;'ETP)(5'@6&E8=/]/R*75K?__9IV7/@=J,'MP*4G:4DJ3\C.2??\SL0*=U"\@(3 'KJ"QF)%^R M*:4H9)0-A&*_)N+,EKCLFGO!E(VQ6I-'7WA_*.)(Z7)8NU9&P3P]YWOZD,#O MSA+C9"WO5ONNQ#FN;XE7P\G0 M8&+UG'!BVIU[ 4D1\@Q9!UEAF(MFZSY$G6XJ?2,>ADYG[*G1Q4PEY)7WE LU MZYJ=F@R\6+]=(,EFJV0IN/J)$<>P/Z \3T]EH8O0R$R4F'J*[]QVS9E'KP=_ MD-88E5=\=V97A3*8G2FJY+-WJ%"_DV3#JXCFH%V59Y<"04J[GUH5V5IF61\6 M90YE;GK@ 32V,B1=U;.B/SO\*V=Z6D0^O&8+F\%T\FIV/T_\S6N?@+-'RDLY M[AF _E@(JT]A?O,ST,%H7..).<9ARQAMF<":VBISJCS[IEI.Q*GDVHS?G6?X M]X;^O2X]#3C5NE)'Z47M/:J:^/X?'ZS_4YI2]QX*RLELK4GG*'KJX.TSU3GVW M/C#E2J .M_C&!2SMC;V^Z!W-*@ZP8R%XL\Q99[\+&Z.XNKXB4YEB&Y)-PAX) M;[<:=(_R5/:NJ7^.;OG#9YY/[2 MN&ST=1OPH%!R0VUHO3M/5YB, &$$D148F0=%S.["CZ8HOIB$GP[?"&$5-"7I M57B:LQ+3Q[?4LY15[J1E;QU=_D_Y1/AB<86:0%45 M1VFL[!'*7R )\S?_+S8JN)WD16[0[GEM!0YRW$M/\'7H;(%P\VKHQM;@2,?0 MYPA1%N#;ADA'FX*B^YLWA3H^X3<[J[/J1)G!G,QD*30VULBKD) MFIDKJ69VZ4V[Z_MC3E+78YB-/6=C @QZ-GU^9!(S*.50'\M,F+"N#7ZP6UR$ MP!D?O*#]R^Q$Q;IF'0/Z8K65=-O;L[.U>BY6XZJUC!\F*SHZCR==.;2QU0>!#GMT;CZA$[ M0[YSUTT,8U6A1Y#:(7\!S?/?@[_"!FR;!]39DF;G.)(T6::=($8#\J)66#], M8Z0S/B1TM@W>R+AHFO5Q(8%QT9UQO$L>?AW_M0>9^<K=,&T1Z:6*Y_I]#P MW;GU^E*JS)T35E$Y\@17XPD]"62/-=)'J'9'V$^FMR5<396,7R]TN==RZKRP MUSD:$/%.E 'V!_U+2CS2O80+,4\#A#7\4VD GW.T36_^_IG]ZN=V;A] MRTKCCRUT!_ JN+Z:)UUC4YE'BUXSKC<2CK_T":@L=0$8#6RAG)WTI61%O',F M%LKVC? MDC_W;LMT2_V>E9CI>;OD4ZGBIE+%YL'J_Z4#NXV#[JNQDT$G]=>58)@E%#7P>_]X0& M]A.43>.^)ISA]='<@$ZV4C2O46LR86WAF*OTV[*KIF5VDN[!+D)V%@:,3X\] M@>7!\%>@\^-^2MN#RV%]I&'%12T2)#'$[(?52D!H*G-JT+D5U4A(+BD&4?GI M]V\E_>^.Y!DCA3ZY^SF6!HX5#Q"*X3*#OSY6/0<]^C$R22'GI5ZBFL9W5MIR MYJ7NO[V6L6@@NG\TI)2CH>V#*\XD!@[%.7 R;CBK?:J&6R%Z%)OL?C+E;UM# M@YG>W1W>5!GUG?FJO/6!,$%\24 ./O' 0M$P#C#5 $\VX,'@T,2[,I.N;D<_ MSL0@MG5S]*SUV] \WB6;'33@:"+!J#5-W5\$[D(0U52U6S1Y20-$B;0>0;+?S_DGO0;W>G]]K7\ M8O\7C2X"(\F2F&[UHL<)[M -_+E5N"G^*Y6YB*1/G2C\ =:M["0I=2HS3 N; MC?)8[&/*GIZC4]Q';'(8S[C-#PCPD,= 0TKB2.!G@@$_>+50@M MSX(IT@L/+M6?R/%Y]) GJR]N1\=/+P8PE3AB\J67!O1X>, R>;S3L5NF7;PB MD,;:Q)99&&M:'#%33?R1N#/YWN,9.QK T#OQ\U&G"/X%D2&O$\KPDVSC6QFJ MB!YDC@O\EO,J,+/,Y@_$AU#D,:CG*,;?#%]37.3ANKQE@KWNJ<5__&*6.;JT*&RF/3G+0Q=TFS*J1^A#9!XJ!L-8 8S+X'(EQL_3*M]\U[,W.59E?HF M(G?VYD5ZG?LNC&?%SLA_J9NSH3([07J54W^5I.E)>Q<*]%7=:RU&UT\Y$A"?$&\3.L47*!N:>CUG/3K M^N:WD^\#ZJ7JZ]&YW1R\//I'W \K+Q'4R+L,P-XSJ0>0+V_7"*B^NT(X25]F:$"F30-BA ;@KR$9$--0[FVR"':)W0=S_F=7D=*+ M&>'2N!'9G(OQQL."V^_+6LYJ'-20^$ :0+3'RZ"C':@""? MJ4AQ<,YW6K:EWL4JX.,XGADJ8V&,O$8#W$K8J1\B]]3"=Y:M\TK[@UQ\1*K2 MM<^=;+\OE)=VPTA:3-7UNFJ93A"SZ">&'4PN<0WT(DFSREOR?G;V[CKQUE*3 MG='X8OZZT1#/\-LIU[37$CQ!EW0,_<[N0N?VJ2SU^ )<05HU_'285R4H:8]" MRGWX62*+L3Q]]M*#H:\^+>%LED1IP)LV; "XS'06^MU9R@/=:/O$4R(H6#@2M4W M-DQ"Q5-[\[ 35)W[7'8.A!!7<*;BTS\L\6$X(]7,OQ]&BD=^4[.IF/D/?W_Z M+YT*KCDY&;KZ*?;WU<_/]R:82N?%/I,54C!=!LX-O_+YL4-E>4/R-?5MA1[I M9 P=ASG&6QZ'V6O:6;VV[F?:^)#E-GC[^.,V0%R = LQ)BY_V$]QU$_VT-[1 M!!7S**R\ \Z_O/M!)>R*JA2JB%1?N2U?TAY3S,H-JUQJ:-TA?#>M)'OJN.4KR!-$3C(3?6$G5@/#H M&ATI*@_,GU"T$/(SV%S%/A\D )T/CE*>_E/"5\C#)?Q-_UD94N32-7 *_]7R M=/5\W+T5<^FQ,W>O&9MO>D/7GMU_!)"Z_4D]K9&,?QZ5OPT1T]7B1,-$O0&R MP;A$?]X:&H[IK^1X XT,[S[H:$@G9ZU&XT>$+DE*X WJ!I9 V5EZPRKT),;09B1ZKZ[BTDW MQ:MOWZ&><*K;ZB== %.)KB#CR_"97JHHC-L[-8S]H5I5TQ?_6NVCC4QL>I=N8M75,J%."EG26%A]QWM-N4J'"]B7KA<9S->> M09.6>$%M'TL1AYK'^YKT)IT9GLW,DM9]U]Z7%RA\;]1=IL@3?$Q '9+-H4LT M:C:+=NT3L(\%[9;>)UZ=L9WUXGJU/DW<0'7BTL?*/"!J8753=;-?B;!F2@Z" MPV3YI<8PV3!$8Z_]R=9>_<$ECVQNEGYQBSY6G@!3J>V[6BX PBX\L0_5(D#F MI7=^._9L(N2)#AIQSS#PQ7P?QB+;)R[!] G>77[!Z4D;-LKF,PUX;4,^_A3I M]C9H?T#O!$'U.U6EZ[4?=&@BNZRA*?F)6+?B[I6^@8>W7P*,:SLPW]^=+OOW M1]R+@('$(Z3Q3C3@ 55N0T\\T6#R&66K]@V2K];88H[[R1]51YXG7F>2[UE! MG>A20?;H7$/YI/MCM7IK;EON(=DRC]LI=9RYD]T:X]?W,DYH"-,7>2CJ^*)1 MAXK4@)*FL82YT2L,2>GDOMO:I8(??W?J#J$P'VX%5V9XNYVH!C-TJ^U0$A9E:XAG_=(FI\_0 M*II#1S0A\S 2_R"49(KTHUC)MUXN^#"7VIM$O7"$U4>E>O85WVS9'/SBSI#U MTC7O(/$* Q$V3R*2QVF >PDG*J%3G?BKKF_+F'V:^"$QU2P]4>!XQA9E:-2Y M8HWTV6:3DW0:;"0:@$8$SA63U*8W/_V3(EN>G)IT%JN7WE@V8O.7D^^B3Q8XQX?I:U&3J.*1Q)H$&>(TF-(#R_6&_:I^4-4^&92IE MZ@:,V)^9-U#*Z B:ZW$NM5E;H4XMX:\R7&6,A3L#RW3X+1IP(-SUA5*#NO,V MC(BBY 0KGK1C2.QC-?,Y[[W@+_F#?HDUZ%2LP?VUG5VQR%NV2L8,@ T8>"@! M^BG%_"6Q2B(ND%&3."?)8Y9Y6^7Z64 MT(#EY^V)Z'29JVWM8U)3(9ELBZ<*E*<]1 M/LIS MT-<.E,K!-EN3G'<^]5B"++QA>SZYOO>QF3#NZ](-Z!=:I:G@H7/VS] MT5%*$MP?"TW:IP$B5(4Y1Z\NB2=*' 45WJ+.CVJUF+>_.M?76V=?T'H/'Y1B M4]+7\Z?$3>U!0#FZB9WC(W]NJF,'K\G?BRG-*#=4RM)1E/=12JD>V_J,/5E .V:JO'E\RWYC M902?N90L8? &6_#U5$'%0VP+^?E!+6H9B3&DLG@0XM"JX>B>QG U=*3CG86= M>;.V^HG-ITILVPE!'Q2VXD7X,A>NQ%^UCX%>H0$N-9I^\L1SH#D;-F_>,"6P M[; M!__CWA1)@B$UA2&1RNQ* X3W?LG2#^JQSVWD0WB[I'MJO+DW"@N1=R): R^< ML%.CS^OE>'B=$5OX3[XWI0V: 1'JU"%!R,O:2CH;4F]7'BZ2^+[$-YSNB:!='9]/TAY M_P94%AJ!/Z/O"X\Z_"+J*.G;5(GPA^1H,)FM=7IL85@OCH_JM%.GE7MJ+[X+ M;[+05'SET5U--O!K-RH!H7[X]A+$5&1%*MQ#ZA-X_>/-$IM"_I,Z9OJ#0Q-; MHW=P-<*#IN/5V(F]=X(\F.GQA2,F;)>>7N/EB $ M\4FZR']6&50CW 2[H-;_Z]C39S[69S8BC9_2SSO-?99>_Y+M,P]H'Y7(%%^^!U 10!J&USUT$Z MHSR4,:QH:--@[UOE@47!(J[/G'(_!HR/^8CDT;^/O1(F=!2RG B5."8C D!1G(3$2H$V@ F:>1 M6(GZI&L@BBEXL&/'3Q4TL&UVTJW_42=Q=/ERB>:Q\%M2;C_, <3Z-=LN=D)^ M*H&UM]TF&:[STK!R/;*\W63\HQQ@M\2MN-FY((I;NJ/7?APS]\X 50%ID MR'SW^O5$P/@5Y802ICW>YLFFCH/@9+(!DKFM+>KAYX'O?O[I91PL"=$D5/O9 M4LXQRS04GWIF+(P5;HY[$D+\UGXJ=T'[+F;B[,K9/VA Q.=*SE"^ _E7B$DD M-PUP@S+WUQIBAUZ '82GG*G-$"[O_"VIT- &LY-V&(?!QVJ5VUE5;A+%&G(+ MG?O+C)LT@&!(+*:\;GK"NK**6>CO[[SFXRQE'FD3]6!B*N=B:X[J/8'"*][U M6>56Z/AN/E)9X%.OUES;#WI/?'1;9$*>Y^A73W\%[JB:O.L64QF/@99DBL'I MP$'<^1NF8#VA9QG]M86'XB[GVH'!IA CX*':U>+7P:]=9^*EQ MA#99A@"]K]$,<9FNQBQ]F&_K45Y,<81JA4%R:23S5XTH!9W^)(2L$F*<[CSN?M(=%MLOR$YU^Q3/68N:I#WX^1 M[Z*7RA]]7I85S;&\!4N&M80-[O#\>="Q%SLGUA^M_RLQWM>_J M.?*TF*05>U-)AW!C@%-\M.2A5'>C-''&-@DA6,,U27=15?HB?5JA.[OV]F=' MYH]HZY;E[Z7=C_OB%BE /LY(5*(!"4CPT ,S+Z5LZJ*2]$ZU7C_Q*."7>^JM M?+;0;'PM98 O7"Z(;J]DY/ =6;_3[V>R/-A_2S,/Z]5\K#G;/P/Z>B?5 M]?VHY4G#]#YXV4G]P(ZPS5_:0Y4C/7D)AJ>')*>[_I0TA0@T/6[_P=**0.RF M 9CXS(%*G>8[:(XR$OJ!UWX?=XK36L@"8=[E\^>=JI0W\\XM#: DCK2BX7.6 M7,?N;6,>IWL9BAL>IJK3[R,J-0.L# '$X['?O_+^[XWC8%]F,D(0-%S>,NQW M/C/MMR=VI-_0,B+(XI@%GY6^PGM30"[6=%W^!XF8\K30=8=V2@@8?2IQ(LZBOTCX-K5?G\^C ^^TW8 MZOG,3*L%,U5"3T[X(^RYD):V/6:]318_4O M]96:A8;/BINW?4[JVQM]:!%YNJZ=!KA*@Z]P=7,MLEU0K_H/==ZJCOK3A?'/ M3#0&'F_P66]S'4GT'6'9@DA_0$O-N.+#B#= ,_RQ[2\[W8AC$\$BI-CYG:ZH MU"Q.*[L7'B&&E"F7/X_6A9*/FV!16T+8^3I>L RGV5J3?MS^OOV[BP0QG*-S M=%FX-,XUQV]2:6TV-#<[C^[FS*QU"5,GIRNNJDYX'C2\F-B_;];B%Z)P4B!# M)<-]OJ,4V!VB/R]?^RQ&SX (1]_AKY^^%J(F"=4""$=KGR38/7=>8,;C+)U ML+IMFY__1\4 FP2>ERS>0V*7"KQ31_4%.LMQS&L!".I("',;85+N38 M*#S@,+ZNM,37MA+#*4E[=7.DE1<=! ;$B?#1@:X3T]70QIU3!(T?CA$CPJJU M6Z]UVI/R;N9C3<7 7Q:_/T/Y-[_Q&"#Y;I0?%%-A1LFELB^&I\#DOO>USE?O M*6H:T@"(P"D$B:/+T67;=<\QMO=M5=^B]#A9!+M@Z3R]"24EV)B.2P9VA8KI?F-F M7%@0T+G)1;>.Q)M#YVRL*,\1\C!R,)@O/17L(&:TO84!/4BP&PN=0W.DL;Y! MF?KHJB$;/A+$D0;$P)F?P57PSNE82_;9P1?KD48-]O8.)F39LE?G9Q_7NPY+ MY0[7QOZ>?6;D[,-_NPS1'P;C(%]<$M<3<7CGZC9C>J]VWNO 9&)[/[9@;&O- MJD2D/KTN@2K9^K.]TAMC5=Q1ONC5GEZMA8E>5?8/] FXCRO4NEZ=5A'[G(?I M?#H /QS\HWN4IAJD=UT"#9C#?"88$$3TDX];M0K"6DQZ:U9]U@?INDEUL\?L M?TVC.%!>=;'B*H<-\:&.%RKW01(;K^B>"@F>6-]7O1L^9:GF-0-=%#&EEU%X MZ!(FST<)H131 $\H.V("QA)<)Q+N?;7^, 8F]CQ6;Q&XS/CH:/%RED'WYW+; M $_ZR=]M(/^65)?PAC<:X?7BPFK 1.N&3WM11DN!T2\M7AMR_?2X#=2EUM* MY5H82VV7JJJMK3J(?2Q('0DY2OKG,W>:)8R$O@MT.] M^TSSUXH7\E@GY%@-B_GKC47I#*=671S7_,7UY>-I:FUZ+^6_0>8+B,S^\Y*V M^(2GD P9?/T8CT.$WVJ35H"I:%JUT_'WY@WP-ADPX5-@2X?R'(K(!9J15/O] MP[ 4)N]%&2,TF&G7MQ]5/YR9_CH#M=%]=CF_E%TY&<:P5S)O2 S\U.2?5&A1 MCO5Y9T^/IO*;@P*RX^\1IJF#<$>W8S;BG9P$01V49)CDZ@J-] M5\GT>(4?SD;L[UW[V-T+?#K>HH?KKZ*B7/WNB*X1E1F8H&[4;DC#^=;-5_B[ M@AJ"KD@QGZ?*&O-Y:,%Y2$?S#@M<=YIL&!);PI:D[\ZX#SR2+.3X\P0^:9(59/ZFJL M/"@F]=KJ:)W^UCD07;..I8+,Y-(S2IT]^,5 -G>X_"82U\O!C^8W%0G'!YF/M.D M X:80ZZWFE69O0M=$!T[._):;WFZ''$>V:-. WS9+8E(\'X@7G(ESKS?_Z-7^EL7C[QXJ\V26N887=MHOIP/ = MUVX@3 .'9#\0L5=/LW&:;.8O,G0B]MQ1+;ICL.&'+S.!"OW?-N::_TC5-244N%R'X*'DAGG"G5QOC8./@DDQ[;.R9M]#":[KN6(O0S';5 ML>S8TAC$QVO.C"1!ZA1&:\L#GS'?QT\U+TCV#<5\;[^LI3DCB)T4A[\"%!(W MWIPRCUK["RQM_2OCB.S/3'7F T\L.YGT4]6FRL;VY+ETAY^8J36**GBFL.K4 M+\N*4^C4Z69MM B2@X7(7AJ02)4B)%3G#K_PM(?_2A]QD#X0/IO5P2#^G ,4 M?\Y"+J*40@\-B9NJZ>/:4W)D[[PANJ6U(;J8M^-:]$+XB!N[^>]*6CV269$XE M<51:& #TN\HKL*T2TD7$(E6V#0]%*_+0 *-/2GHV8YW:6U_4I7 A6]CY![IQ M[P,?+\=&4M8.X_SOE*20DCD!-$+B+4$3)5ZVHLS-BFSRPD2I-#;:MN;1)1TS M53OQSH4NC>TG]$:X5K>X(!CVHNL)UI+]F[C@Q&K6"+%=(\TZ6ZVX^KH&D/L] M9>DO(!O^YO^+?_:J61?L'^4ET_DTH '5XY.\-Y]$ [#G9N+F/*V_'OTS.!IC M!&^S<9YWR@J6@5P,1_=C+&/@\E7AF'%%"\C(-O/>G[SK#-1XF;)%YG%P?-[3[7.8?GJLR@&X;BC>% MS"GA^NPG:8 XV>MH@5RN&20Q?U=I1N!H]OGOQV>\/J=86JN*5[Y V ]9/_@(3DQ' %X>KHU]'\G1"JD"' MOD*X?6U\Y7QS\\)S]%JP'L6 \>B952ZF'KX_K_KA]VX1_W-7^0WJS#4GAXA? MK0^V?]Q2".VO^>:+#O8U8=7U$.NRL3HKBP[;\D?#DC",_:-'/+O.X-_^V-#F MK[O;RC]1Q\@86PV-G[IO?6/(7;(Y8G3K'DEY'=H?$IT:-LN M6AM7;K-Z)L"_[ME[<1*ZR-9Q)^[**GOX?Y5#Q>?O1\4T8RY3WQGD9 M J6.0_!V?LKHPJ=C5#9/S469G-.:[^I\QB[G![G\>-V=EG,6NG3GBFN\RSV8 MR\821S!RWI#HB?]9T ]A75@W<6QLF?PZ/AZ:@K-HG\\:FAV2#,0F&J,YGK7Y MSWE0F0?Q'40/DG0M$85_!&(4M(C$&IYL^E_SAB/]U/WWY)(B1KZ??D"$0#=D MS@Q;L#GZO+GB?J<6>][JJX:O-NV4GY2ACP&[W$_> )N.RL]F:L=^OTW_S?\9 M$8DQR-46LA4-:+.AYFI$1O\O#_X3?PZFA_@,:3Y5L/D*;W*5<-2?M^OTI);M MNF:0RT'!%=1WH:A!P8/Y^MY:@UOZ$$X:T.. \GY7PA^>,KH,B?V2LW6[^+3& MX?RWAOFRGN72<%6/.&XUR[;VWC7V@V5H@'O'4O*B+@HDX?[(IV)&?EB/+>XK MS&"2;]_IN(W I]4#NX^8SQW3I@3_=GWQ/SO_/PLQBA%],#Q*EW^)JQ/BVK'" MF+B5^<3OB/M/'XUW@J^U1QXWA-WZXZM\9H=G*><'?_"4\E8GW*MLGBQ &'A: MPN7U&H=NG6'?=78XN>O=]S/GC"IJ4=\$#U\JUS@X#*09SE$R?T)B]703<4OH MBT57QBM0&=]O.$%E?UD_[51UDM;;#-)3H\QQEL7H?:4\0/JR0XE-H$5!@3E[ M18:Z2SYFNT0<6#09#A2D <5!+H^1K,>4W>\S M5UYYT8KWP4H7!#[WU@RCMVR;/ADS^G+ARHB:6+6+6-R7;E^U5H;0?8 B7[ B M$^]">.#,D]N'T47(Y2OKG6>O6Q$8%5?K-.B(<#QR+RT0QG#X\9OI*I/,X3<( M7Y*7+1,BK5]IH9]<[K=>,1=W3]!)C=V4,ALV.Y(=/Q=_F[O!\KVQ0"PE$;E< MB.)2I,IZ0@419[P+A*THZ1L;+;_4"]C_'_;>,ZJIKNOWW@A()Q3I)0@(*E7I M4D*1IB*@ B("(B*]2*\)@O2FH"B@!*2+$.FH0$":2I4N/03I@00Q!%(X\?[P M?CC/..>\S[F+USO>BS%^#$9&2/9>:\\Y_W/NN=;6*0KRT[F7N6'?>VJ%:DRP044-PI=@R<\?$T:[AL\/\6;X-KL'UQYCG'LL MN!C#,,_\2L]H<7+-Y8\'^K_Y;_(?6W-*;V9G53=<_W'@LN7[Y#[SNKAM>?G[ M=VJZ!<^X!DL7 %SF#5#1R$LXM:0C8+$BBY"HD"#SL13J%29CW"B]V#EC0*?7.%O.*3 M)R6*3'2#A44>&HL;.*Q2T_I176BY>0+;6Q O&3 M8QSLJ^"%N^S!S,!A0KL._3 M3%/I+'OZ/S]U_S/'79,BU4H(?9W3V7%54YT5:X?//D[/?9^57UM)&JN4 >DS M(;K,D]OH<,J\$&$'.W,1AXR3IXP7;3P^2*YZ*,G%+BH 2'L6N9C\$N9BE&Z@'L1W M!O1^,FPQ'U)_OPG;N72MSQTE]/&;=Z5!7Z_[F?84BX1TRRR?I>.WSK,S&?(0 M/=U#CA=ZLHV__38[=5_/5N6I-,[KC\LZ?LYQV/9?TDVI3BU7Y M_ 2;L K"=93W4P<%G-G;#&\=1"#S>G;FF;,=?@:W%<4RGKX)/)E7$NY+XM[' M3^'4,''>: V5G>-V!"@;EYMA8V%92YJO8E;8KAV,5*];F,1 IWY@DS8#9H,L MYD*.0?E)!FVXN+($>97*=1^V@9+L]^H?ZD9?O%SB3X[V"Q>X$N>G: B$@DG< MCC?)93IG(LW'VR0BC295GA,"*FZ^OQSE%N9GWV]R3N59&Y!TXEX.I_X[](H6 M8DV? .Y,6>K!Z6(IV5I7AEGN3\0]A7F=8W^2T[@S\^4@('EZO7WQVK_,J?W- M?Y;_3+1RL")>)<&^(>_#8B_LIS=$99EZ@K/*INKNS#NHBY\VCN3NX_QFE>'Q MZPHZJQW1A9CQ1!NU$L.AX[?X/BTD9."/ /;UIH&2=0<[L-3&(GPO;U6"8ONF MHC,@$2VKZIE0)Q=6TRY".M)8\%$$2]01<"PT&++'=A;(\/M*.W<%ZGX? MAG_UQ=$(2$H$R,ZOVRY3U6P8Y3M^H<&F4^&=Y_5>OBY'4-<3CV$_I%?&=LF2 M0E&@G[K-%JT\M/[/)XE_20>6 M?@0T-J4DI%/D-R^4)=1[9O?GEB5RYE*6% -JI\?0?5=#)<4!_\*:9(!LA'7L M40!!)Q=H2&;ED6=Q-PX#FR8FP[4N%-EIA0BZK"Y8YHS-AW-2 MAB!8HT)W1-M[7%.7GZ=;5EUI0L&0?%\UE-S=^:8-).T!A#&$+MLL' $ !2!H MXKT((=Z+"_0WOWB6&DO<-E/IRG?IGMT"W$LB6=\S%T4#S R'PKI^7KH+ , M0T4)P4-ZV,$,ET*W"?=:%B%&Z]./(TZ+F%\SE]SU]/CS=^+_YI]H*?B/=#&L MM$F2]+_IB*KN\^CR+47V;9-WJ>'@:'P5)')+Q?G'S/>3,]YWTJ::+5KN/#X%?8^8]?1T\\(L-34E MB<5(\."QU&VW8 !HIJ-/_06F['_)FP^ESUVKW9^'!Q=YLF'B?K>!>_L] M1&>KTML*F--QF(@=CK\Y38M=Q3\F:*)!!*D$C'818:>=:X ZUL]^=,ZZWVI?\PJ&/[V$O6W;Z&A[-EOIM'P-8!#MT)JT_XU KN%>5_KAI26;LT8G3< M3B:N-X?N!>64-,+/*H'UK&.&(RU)A7@Q4GXB$K24!U,R1U[I]HL.:\RJCGR/ MEBZJ(#&>NJHG1M$DT1,JT.8$*3#&K#)4J0L4D*/2.M=NV7)*.4:&7 MYC.ZET$2X<**0KH0__(W%T2;G);,!'NM1Q GQY3[UKA6)K;G.GN5KQ8^&4LO MB&'4^17^%W@\S%\(F4$=#>APVS'R2Y+T$<#$D*%""(RP59.K0IZ_/7\A^I(! MQ\'+W?/A\GIW&50.(G!"%.8L7!-ZIVM J1-.0X(\*+03>J;::&EK#"O? (0I M1X!_K;&HHLEM;X'^1Q8,:QF8!.*M-4@M7Z>;ENF;]2;!E9+RVT+:2I>;'H#A MI_6[6AZ))!;X^YF+ 1'0:PN>1T#])(F'I7O U?U$#<&(">N-6G O6)]:%G"$ MJ^JRARU(0T[3/B2>7$(\^L#7LQ-_:)2$L^D4O-JJ\,PW*.S>UUO\OCPT 2RK M_M'=3SG\;SSV9V)XAUV-KXP7L M8+POP1C2#GM(X<#R3#2H)?H$7C:@^Y!Z<-S(U?6DG@9C"5Y,F_-&,.+27T!; M_LT_SW]DW9/,K@R%>9QH[A!IC%O)P?)U^,K]:HT;,WMK[)KM.6"8R#%]&AS1 M-\LDO&),"_0Z1D!GX/48^!8"JV"%$]>Z%II+O "-DU\@=$Z%$F\0?J%O9%/F/VU;%IN&_6S8?KV<4_T"WOIC6UU[ MV=^?-9!F'[%E0%3\3OE*3:7VD.P7C*63$#7EGI/NL2OVM:D]0A^,%%.F%AMI MG!UU_P)W]OY/\.Q.8HA$P>_0"3!+BOL3 U\6=/%C16;\&P[$CBVL%_;278+/40F'!2MO5$ 07)QF^E2'JP6=N\P7<3H>W* MMN#5[<\F:T> PF8)]#ZLPQIYEQ=W*FZR9^?8=\ZJFT;@KFS5OH$N1D4%#A Z M%0"/ SZJ(O-YU#GH(S=SXV.QET)!W?OM),-AN7;;%=\\Z_K;-(K2;RO:L]ZC M#OJ\ 6+N'\]B_@K(#.S!IR&H^%;[ /BZ M(X>G(]8F(QZ&?5\/I@^UZSQ$I@1&$-?VB!D<,^!3UTR%Q5^(N2QO][@K9*^CV_QLM6GPX)3L[?B+ ML*?EGSL0P>2L(V#Q)9P-=E^J;N)'"H4;+-)%"_/UL 0:A]*A ^PF*>0EVT-2 MN[ %?<8,-YXJE3!Q2XZLGN%-R4&.[+-KPPU%O:Z"EX6Q2CMB,GX9+TDD7&I% M.\*6P$E4(6F1\R)5E6''0L/99$W>R#W+/"(='=9OS/5VI54["F9-^4_^^9AIJDV(+)QB71P!,0T0<<7 ML)4404,LHK.IS3&)9$OC;;CDFS]I]L6:8;A?SWR?U]S"C1:-R)B_\#OUJ<./ MC) D4 +%HCR-K^KGQ(VN.3?5&7Q8(?>"8>Y0/Q-.Z=NN^#P4HG. &Z467:_ M0/ 9LW7+57ESR\YP#&/9=VZ[W_2^=A_W?)L:]=LM*5_0B\A/2C@6Q[K=%FNH-KFC^97:CT_ G=/!PZ%F'\XK' M=Z9S5W7$2=K#4)E0"5ML1M(>X9ENV;%\GDXRD7L_+OE\S$:)VA6 M(+4@C%DA-=@QR9(LR\*"P^<:9[Q]3:S[;.V=7Q[S=X;:"C5_AIQ_)XIVC$MO MTZ&.]37*1'L%W ;[:M4YK 4C;*93XYL:)J03]KNY#W%L;5X!VWKH M$WWQ],0-[=B#7#TRUGVMP=')%+*DK[L M!K_Y$-U^CDL4H!43Y2/>@TXZBK9=( 7AU-J1\;?D:PJGIA;,2EO3LUBDBLK? MJ/;DNM<1FX5V6'GL4UEJ&#+\R(^0B\]]L0K=MR!=&8D?ZD/F%6NL,WLOCMJI M3LBOV036'@%]ML=J^"TX1/U)G(]:W5!-=J0A:JJ?,(X%^?^#GG+BK<\K%I+)M']B2?#.BY$LTW ]WK M#Q8%3H0@\H^ ^XAI-&HU%>(A)^%(>,X&C]-24>LLQAINJ9F,?!\2WTK-> (U M*4X%MP"W'U\%)&GWAO#:Y+>!X.E-5!A.->?^H4Z5L]K4+V]Q4ZU.3]7A]LI% MW[2'7QL9]!D_J^P:8YBH!_1@K!Z6]-R!@7!FL<]1P'YZMA6.+]D8\'M>)V\@ MU]I";S^F"-'9R6.@Y7?&[W\"Q<%8(F46(W)T3JR'BZ84$F)FU?"(N"[']4L\ MSR2YJT.>S\"GBEAWW."I)9"!4XX\Z%XVTBFU!5G.'JU)Z(^.RLN3A;_VQT M8BQ$Z2./E<#R.T2O.>%L4UJ@>3JXH30.E7',@/=]M7NCWYJ:TE1TS\K!JG\C M*H'5XG/E5G\?2:HME^KCD1Z3;4SDISJBHE2TU.2 MQYC?242;,_S>#I0050SK/$ZP_K3]Z0RFQ23WZ8>75V/YQ.UR"D_V^CE=="Q MQ%+E\^/P'[V/8%XBOITIFMK51:_GITUR/M5UROI+H,?H_" +RC3XYYA6ZOR> M?D?.T;("/=22*#1)Y?#O._[*NIQ/\N[,YWVL>@2UB% M[YDNA#[J_SAEV4SP86K@W)X7,M_&^EG2A;!Y::QQ%*M3\WV;6EC' ZUS]S(C M3^%.^+WV.,]F;)Y[!ZG\1.&)I(?YZ[JOQN1 99K#2N$468^UCF_Q5D^7.3?. MC*,A-?#D:BU/XAG2V?'J9??J8NRO8J5+JW(273%2=Z-,]J6RNW M.=NLUYY(A7]\?\-R]AVB9^@[! 7]2!T-#G*-"B)1]$+T+.%^SWJ0MXN0')-% M\/3ZACGV\<,'1X#6$G39M8UZJ55!1T*. $$=67?PL4CV>V-O]_+6T&WQ0RN> M9-O!KFCG'<8F3._^W$-B].0:8BN(J+I^!-0NM,_Q?>)(+)TH!GM/((K N)_A MB[YB^S< (^16@;9I )_&3 2]"+M"/.<1:MW0B=LNJBNY9KO5#!D^G('0X\H M5ZTE3D:O2>?&@W(&ZX;;-8V^M@Q22AN7\OEY .(U)O2'>(W")R[QANR91AW/ MGJ;&,&XP5LCLSE"8[(D/OJS8DI@)":$X!_TKH@)C"DQLO> [C_-3%2-;#OF) M8I *Y3\=O_[C7',5SJ?S5GJ:MHC> M2[V3%>.;@=1AP&4[90*S M[52G&:;%8-4=E,O,'LZN,3%!SOC<7J# M$GA70R!I][/%36&PDHA593\UR,()DJ"';0(;IE6D*V/.A*0W^L2JO>Y'G:6] ML1U/F.3.H8LX7CZV^C"Y1I^6UICC2E_RJL4Z^[%8^FDQW21!FN@W1=' UFG: M3AT0I=.1'DI/^/"SB\*-M:\7G!VI?S?G\'G?S"7K5>.2_D6#S/-(57:E=)GY M\C]O;G_S3[@J37PRN8HZX4.[,P384O [[WL3XB][M^0, MZMX7+@U&#&7FHXFG*=U-\)J%=B2_'FJSSY #WQ]MZSAN..\E/VD@IXST#Y M\R=M^3/[:;R['JM;'JR#25QE^+P$1\IL!O&LG"<&["F8&HZU>ZB*F7=[S-:Q M'_!18TB9YM<"B3N/PC2BPYP"24)R55V#@!4%A<"V;G2*Q8*81@=F,-CJDICU;S2N,NC_0P="VC@F<1ANV -0Z101<2 M*+RC1P#.ZM 1QX"/J"/\("IU8'M[E?KEY9533.05EK(&LEFFGC"^NDG>E;S] MDKQHHNU&.PA;S&D3KVLAQU' MU7Z/7(C;;"S=1QT.O9;JRM[!ZI-P[&.^8Y8 M4SEYSJ#9O/:YZ9K[AUGKB5$)^4\[PH],!0)I;HIIT-*].]:&(D?#[JHC[X'I M/:YO[&,]*.J3I***V].QRW9&.6=\.=5E:>[++K-UI2N^CH9H09S5'5%' (G' M="_*LKNE K%Y&% ?ZZ;PPYZN!];2\6"S.7SR/560_?)\4$8Z.=(9&SRR$7** MYH<%BPL=V92JUP(G XC^L YUDA4.O%0/X]=AW?BV#E4**VQN?9>]/%W3G$@C M,E#?^2AK^4I%NZ3/7*;>+NPXU>^J(]U TVI+C<^6(-.0+C;>C+N5PE_DBWCF MEK%%/KS8MW2]7#5RV9\E'JA+#C,L.+[;25C%(K=2L+D]2THG>G4;W]^[HR?J M?]#.N9E$'Y%FX.IZ'.Y.7U5O2E_/6&-XPIDYN8A&=PO@40%X5L#8TB"%P],4 MV2.@O>$(6/(<72L "1/47O>A=I(=N0,/&F1:'4Q@=4IAD:C2+$7-R"[V[^WX M8ZWI_TI=>#"#WR*7BY&SH;0;X9CZFM_/0JA8O3KL/75\H.],?W?$V\O/M9.8 MRW9LAIOX.&]U2/[\_+A3\'F8Y)TW;XZ;2NX!(8C.C/1YE=\[/Y3 &WMR4([, M PHD\>S1QKP2$[US,S>+?-ZW.8TJU#44R(\Y@'P=_Y^![!6YL>Z/9J! ?L/Q8DNU6'H':BZWWCYAF&2:=0 MFX:UWP(C3+8P3B+ZIWMN[M_U[_HEF1D^:?@7J O]]P$_ V-O[$Q!HT3QF^C> MSCQ;N6D-^J$D62\]XWA=?Q7&QEV-WIQTO2[X@L0:@B -QB!!&(U%",$HTC)( M,/+R\!W'ANU/1X#[3.K9.3$*WL066#S'JBA,@S<GK!>'&E#L)/%BW(TM_W_ZO_C6R 7/^ZQ0!O2*YHT2;>C#Q3C]-YZEPWX=TXLWE+A]2: M-J@A6JK:<<\'G='REJ'I_R=MQ#R[:J03$/S8..P>^'AH5*1F0>\;0D97Q@.1 MDA]89]?[-6=]0YCU0OI3&LXSL)JBZ6C7?44B3;!EG6PB08Y\A*Q+V)[<$<;L M3>N6]&G5@&\&&@(ZG2,M*?BQB389Z:W-\GD2:PKQ MFIIF*W+59V02V.I:MMEJ^KWEQ ??3XX).D+8^^D_^TK=K#FF[+X$$G\$I>EO M.V\\R >$LB;2'6"+PKQ",HV&GD&Q2;.!M(='2YI?=5F%XOM:M"?@=;\_/C@U"D;$_PEX, MSD8_L!?Y7YY$K(2@KDD(**B1A1PMY(O3#<6)$UU2$O=(I1YWXNZS. MY&?/I^N1BT_!M7#2&<0C;QRHB]?!/(7DS/R%^6MSA)E:?))VZN_[44_9F7.I M7M29$(* =1@AO3".O3K*#TNPK:]&-J:[+F;'B5U/L=I:6?$#[-',0-!?( ;]7Q$ XX2*AL*6>F.",IA"RZYF6 T'W61K M'7];5*X5?WW$6J,B[NUDH7CHS!=)EKIA=W_Z3'/VR)[Y\G@ M9Y4!-;\Y;G1A Q0!7':KEMI MB/V'M[F /FDZ7UV 89N-Y[+AA%>D8;&MQP?[Y0OQ>1',M^WL9YI#5]+:78*< M.N@X]/8KZ_]XI>+?1R@<(T"\&ZE ?KY7)YW:L'RALW?%SDT0*HULWA/72DN& M(4]:+?[,/TT[([,"GJ'%$['26T].A-OO*1&R>B:MCP"WAF'9%U)CDG&982;B MDI+"=Y2$_9I7VKS(KV"+94ANF-O.]/.+V-($+-'DVIU>WL^C$W8Z"-A%$B.TF,7*!STKU-&8=(D!P+JE3//'[.X3*KC67A M*=Y[U]1HLD;I8F-, #4?P30DNZ2JY&^"BG3P56+&,=KV)Z4TODBIKWL"&V^ M*T L$0W?R^[X8GQ>Z9BN11DMWO$6=O#94@J_7-"WUF8-,Z/9[6M%065L5R"L_OID">(EVF MT8?M)7^!9K6_^??S;VL(_$<3X!SQBCW)"$?)PH([AD[M"4:-7?/X-LTU$%+> M1L=; &K]$4^7[K]]G"8=J8OT6IB^UH>W(W!7A3;DGE%93Y@*O*RA\7/'_NHG MXT!=UK2M1ZZ2-JM-)"Y7O%0>$%U>%?('0]!S%BHCC>Z?/;AQ^([ MC)-C9[Q%8O M,["L?-YUNQV3'RXALA#T(F,J[LY71@V&QX:1?%2Y(4^.>8Z>3%@EI"W: 3KB M[G[WMP?I5VT;#8G-(JZZ.@;CT=^'OF3\[G]Q@,[O5%;#L=>7S(A2E3[T30DJ MGCT=.38/G<] =K\]2/Q";/?:X/-C6,?\Z>#_+\<:DA+I7!C*T+D?OIJDDB+" M8MQ@/[K@P?U6L4?[>Z* =L+UZ6A5F61"':ZH T*KI2"=J!6TI*G OI[R."WP M"&AY%3WXN4@@3(C\E&[<-^X($"+QX18^[1\B.^'5373HJT_O6-DZA.%>Q:ZLV M#LP$+L4DTZ!,Z2P89N&U1P#IA$$[I,&F"Q/0 17Z]JOJ_$;/-T253]#IX5/+ MC!OI4T92YUD*@5\,Y1(\RQ NR&+F(:S[")B^WK7 $6F%8[%XC^VI"_6=N13# MZA#O>^"T6G.VYC3-C3C)TRP]:C9C\+J,K3PL&G]KV.4=UBC=N>V#H1WF_B_2 MYDQ_X#P!D(<]/(:(=,W%7P"6H%PD'JQQ.Y)5.H'$@OH(9E\O.F[88#Y_M?V. M5JUP2UK&DK]9\-B?GMB_^4\BZK0(/I!#\L"V>8Z X@$'N,/__,)__V,E% UE MN\X^S#37N^S(?@1T6$$\A@B61\#Q(P#%..S+JG,>]]3<1U2J*SL<-I?OH,%Z ML#M&?,]P1A?, 9U <@K#/^> M-C#531I"O[JBD)UY&2DZ)^MV289+Y1?#;UU"JC3F/>[H+3PAQ'/-[GK;+?"X[/-F?%J4VWF)9,55A;,TA1.%IB0.>I.;0] MI,WSETZ>I*>L5WKAMWB!F_HH_4 M'>2,A=B*X1%0^I5AL+5=7GV6;_L-*8 ZNH\HG;F(K9DE D4U4LPN3:WSP;S< MC_'&O&=1QS>AUC=Q(\>]G&NYF[:?T6(RIKCQRZ,03Q ][+[G>;OU!:[ 1&/\ MLQ@GWMUST?(%CMM9:5]UT)S?GSX&5?WI8?Q7<58S);'**:STR5=)X",';?4EH0#P*9C6V;9:=5W:1EYFL[P/7V[K7R)BG&00[GS<\=)J#Q/43P2)*R_4T*R]:;U@ M4V'!\(CR&5DK'8>\!Z:96[O%]F.BIL+CNEQ/1>4\D!8@7CW.PK^D;&''D@EU MSE;9'OOS?O!O_O/\&V(//S7K3W^"W?]TH3>I@=@UNFP456[0@JD;6?)^=TN&/9UT M1D) 3B8]OO4GA86)>,TTZ$$9B0G;W=DGHVPS+T[4D*P35FDH9;B^[^*TP]>, MJ(8LPF&UT]"^!1HOKR"A(',!SYD@N>"K:I)QL!!?N,E3S+9:#B.JG';=3E-= M>5-=3NY.^O0$X\3IPCC]8KWWRI@"EMK M/B05Y$^C:'MEO1CON6AQZ(G%3JH0&HCWH5_R924WG/Q\-\OW3B['_*=K(@(71YID2@K MZUR7.E.QCL^N$E_'%W.O]@5/D9?0&1^JH18YXM$ZU;\K;^8 Y7/-C/MT/9_# M25P4YOW[^N% O)6OPBEKTQ(?<7VK:/7[FE=/1)M!@Z8HXXX-0Y@.G/B(0GQ& M>:COE=J/QC=;U 5GS&N7.7SE\\BNPD_]#>Y@,E[:K/?V[$PA4-(8$#I-J#M? M SNSD=N6Q]C$)C+[KJ1++T4VX*SB[)O^KD#(.;HGW>$[<9&G7H>"]1N^16H6 MWUP+-WRS%=-KWG3S9&J$>#0]<"\T"U6=@)/IR YGR-BSE^X>/MM]JE\-[RX+ M\DOI3TYEGP]Q;J9+7E..XC/';C_W+'6WYIV^G^<1(Q.AJ6[-[Z3WS?($4!!. M8^/V%U@N]S=_BG_USN@ME?A\PD$Q90!"'VF KKK>EWU9O:6214V=:(]>-F#L M59?K@(UHIV^0DS!"4K[6I4N3QU>*,8UA M4^FJ1C2ZO2>M)+U0 X #U9COD6C'8>Z(:6X[PG=TZV%IWFL/-NCHK+SU$6#S M^"!96[6[V41W[8H$OQ3R?N4@S!41$75^EFF[$55=+;22 M>W_?51+]KGV-/ESECR^7^U<3, _!LC_$7>[X@(B+O%YJ\-;M0K$42Z5&[]>- M,#K.K^_$%)UB&.DX#*$RI/L$;9P:A2F J.M.4<5:+4^V@3[F%(TVG'D>J.8' MS]E2L/)36XSP8191_*H/79Z4PRFAX/%MB@2)&]B,E/KFH#26:RE]^?-.HQ\^ MJ%D%J9_M?*PK'JT.^QZ!AV,S,%;8^85N40'XEX\I7K=*,Y1B'Y3=YLS,V"BC MJWP83UO#RO!N$O6\RSSX.X*=R5%-<% PI=TW0NQ M7VR$%9?]&0'1IC]=G/UO$UE&-()UF+:Q4X;@'J/Q54< 4UFRTRE(3:3.ID(V MNGYTM2^#(>;\(.2CO?D6$;?2BU\BY_VJ M\?Y4.GW\>K;+V1,<&;NI]PZD.\ $\=4$+4BU:3G)$N>5+]>8?.W.2&#B_(C M4U'6D.$821L[U EFGUG3X1H./ +8U[!1?=H7YIPRM*>B M=>YK3RWGKT3K&."D25PA*%BZCG9HQI)TDDI5@/7HK\H#%8U(C17&U\2+U0X6 MHPH[K"XYB5;3-^[XB-E,SC-@0?$4 8+_C"ZV-,$)A1&GYS<;\0KT/%<9'2D:S'I+,$*U84;ZF'S4*@W=)+AJ1VI^A!5 MBGG([X#R5U]^\@S494?I00I'PGQ4P(G(^B,@19GLX-1*_>,8:*M/TSGVD;5^ MJ2%=^J4S8@%#RC3X(!X<7V(DF&A!^6J]&YK1F:_F.PWJL(:WC6DI+;$X\;Y[ M0OO$ OE&Y@M$"D4:K1>-JI 8WKR!7W^B$L/ MX93%UG1 MV:Y+T"$6G%.Q81T>&''9Y^,K<7Z1JS?3 M99(G(&Y'P*-Y\'W!LF[0\?7^,G>[*NB(TDM7?G<&=8RN:(IAZ/$:8A1TZ!:_ M%'II**&XG8',?O_]QH,C0/999<8X9+'"L@P-PQ@'HP;= ML7-VRH"E(Q!YBQHJ.@FT*$27 F>H=5_'+7S+H=SL!-?\P3>[7DF_L5U7S&I)0\TL8'WS),$7T17>EZUX!:.R-S*X_-=5Z\D:K M:YH$KH\7]JL+C2OV[;=3V'U[.8,@MY.64[RK(^C&62%])_,P1&;])0U\%%L MFMR0P?7T45B<<)<\/TOX)E!.-%L_N=$)FGZ4D;5_XZ",;D\87(B8W %M^&_> M8L\K-W=1S5.9JP]H?=7>]5A)S%GH"*@O7B0F \.O7W_(-/$NR3S=X7N M"2'W]Q,ID#Q(5!/$Q_&0AA![!# Z'0&??WV/%"2_0WK#.2-O8*MSR@G7;XS5 MS[0:\?M@=DCBWF*[MNU/\EV2KNC=R%YXR7IOV4\78K_V^KUC\O1D8J0:MK<[ M'/&HOF12R]*E9';6/=?SF.' UYX>=2RCM"S0+I8?G3K,8&4(E34C^D)G,V3> M82FM'+(F:9%LGXBL[>:B*SE' -LFT=,-MBX8'_>&WV[YV'['?>79L,7$YR]I M%R:B(1[E__4TP=@]T'2=WL$O,/M4K>DGEAW6 ?[/>]-]6;K@AALV/U:WJ"=' MSTT@XN#HG?B6DTL0>O>F#\>+)'JC=. EM^V^N/+K1_Z4,/G*8R+ JC'((&FS M(0*15"D)=JD["4_F2O J<-D&\2H]L7"Y,&OP*@C9:.3QN1V-M?1NCY(/3H7)\0 M+0?IS9;U"R1_ASV",#8XE1([/E,8Y$*%0U/GS^^,ID4PI*( M:[WY2#^!06PQ-M7OP6-0_>G7+1GXY^0RD@#Q#(%WIEM'F3*<.[&!\:KRVBNW MMLOY<78@SCK0XEB%9!W-<) 8!^CVZS90'=6(^]G^;W1JJ'@F/<)VA.J8JGET5.(G'&>_Q MX85DOOK'^MNN_7D&;3)[!T[.A];C&:03HWBWL9 7;:?M2OM=AT9\49OK;33P M3]$Z\-#Q_,B/1J-1@.W7LP2#]/5NJ MW(&5ZTLUX";CJ^\.:GT.B@BY?7A/&PB^8>U=EA28IG]SJ6'UK:D&N./ MYB% -+3J['^CLMIVA8 B7@^=Z0+S5$-92, WKX8C0&3:"&R/$WUCCK=)>))P M3%^'U(K_&?NP8?"'!>CM&B+-B9Q D0M-NFZ!\\78X&A^39#1(+8GI=\E?ERE M.TVT-6)<*UA5%XY-6%+@A'Y#UL@Z.^"DFG4@)+$&L0T;J6_>#60IT%)>;-*S M\.S[7HNK7P7NT.RK\#Q>'2K.J[2KFJ@9%8ZP6 JO? A M_:5\/3IA3KO_VU:U_\_RK^W>NS'>X*G-<*EE[)=0^=MZHKK#RLI&,(OP.?'L MD+OA (WD(3-PX$EAUB/> 'TO6]3N%S1@E\*X0Y1YI7"IC;"PI&F^-_,KL[.SXKS_X^6W^P;:L[&"^1^MKQ9N MK@R$$W\G0X70V>%IVX8!Q*-K!B?DC@!=,B]#WR6]1=.37E2]U6?Z+)R9W(8= MBM\;8@@-N3)<[ZF^1Y8P:TP?')G@?!0O:5%>- 70 ^[?_ORD_%LF^@OI.L$6 ME9$F2C^N=7*)+"_GJ#_F_%V6R^\K+/ZB3_E&F+5PC S.<\FQTS$%C+UT!&1, MY)_"MNY-)SS:N2?C4OX!7KL1?-!G._<:*TF[/GR!,[9IW^A]1I(CFY8*+J(C M'/Z(9%_<4>5V(15Z&U^7T6U[T[^ZC$Y1+(;F>+0ZZ'L O@+KB['#4B"/:)S'E343CJ^:O\CXT!ZUK'[JGK B0R%KT?=*["0ZH=TW&8Z]8IYF+:J) ME:\("$.=63TWY7D$9#]..M;.UI,D2$9.#S^%Z@R_.]@WC^,:WSF M_" B(H#MU:L6;^5)/G8N]2=&MCD9 , DB3UG6DH5FQ-P;UC9G%Z4UZ9X:_\?& M 87]Q"+_;7U2FOCJ2Y"*1=17@!A?U-R9G@B2+;71O[Q7;5L>[6)N?4L]%B..$N>[]DGRAM6 13 M[\!\2]-O7R!#"B&7M#BA[,# IO5J^[&A+VTC/BJT[JQJ4$_N!Q<>YCPM3)6G MY=F=859SB=;,2 -CK4 /X8PJ3B73&TWYFF.\9EF(.+3I8G2(5$A0&N5)7< D MSR1TTH$&!\-8$66[7;$975^*S:M+2LN$LS1GY$ONX)X3-=6%BN9%5=<'!ZJB M>UH,\"'4,=,A72 $3WQHZDK3-T^\-78/,L5CUI8C%-2A&S(02UYACBB)(OOZ M\KQJL=#CTJ.[Q*6.MGB3?!P _ "1C1 CHK/*NC'2:A*!.M_([ MH\@"\RRG=#+-=_ND273&OYP<7[=Q8J$)BV#VFVNB0B->>]IP)UQE\KY)'YZPU2+1I?; MTD$![3NCN>C:N7 N")F<+Y#L-B@Z/TCVE;J^YIP004NPB2$,45C8L*!.Z-UU MN25S7G5)&?07 _:N/I8.J8":KR M&)"*4CKQH!JRL_K#X?8"]KKC=.=2YWF"TL6FZ/?3L9\H_)E[L9_;?T9NP:G) MQ/3&/S8C3ST"%E_I2).+299EH8T[Z.[2PN.Y&-JUG:J;ALYA*R(K+ARO)1AQ M/\B_^+44<#1X;P :">URY*6 "8Z?H%H$,DZM.]9X'HG262V_ZW$,.K8<.\"4$X2Q\"X7*#DSH";FUUS>A+6/Z'OH=M7S1 M@' .D085IGS*%R!\0R-.D#AQYLF_0 P$)*JQ,O#0PY#./\U&__UCLQ/EJ48" MMGV\ L#5Z'29M05F6(< A=&M$&PSWF*[=*9YMF[!D,YXK>8B/U0^W.(X)!&R MV+# ))LBG[&XP^^1VN+3G#S]72B_=S!@5/N&S6.]>Z@,)I$PH,+M5LN>QV,XOR!0W\5G&,-Z_ULS%7G'VSB$0.?H&UG&O38.0NS@=&O$I MG[LF9+"[:72[NIK!6WY_$JJ,ZQ)-"" 2V:=03061$ZH$OVCCU0MMKS//=W?>2W)05^ MU+TXP2O:%;MIWY9&?8O&^'WF(-^4B> $ 9>Z80=HP#!O\]4Y',%F4^X$S4%E MT1'0P4'B9(EWDY1>G]O[4B85F]C)_",IR^Y8G\5E_T,_4([W1J>#/S\#'.%Q/&^ M*[8@*6*]+,6F:\H2,#PWP@&)I48GPO7%O&"CE(YI.J]'//=&Q>A-UHS[NH-N M6!P/:DH(S-,8\8R2'V3*>I:I&6@-UJ=W^_:_=Q[2#B#QVE/8X(?*OL*YHGF2 M/LRU*L7W%+7U^-?M3E@PG#D"F.'M1\">% %&3='\8#B>'.DM,O:#K< "JNF1 M_=2/G'J9:Z:_(!^K#Y.!72+BN^MBZZ].\P!L0GL(MZJ:J4*\5T[Z\>.F*=.MZ V*G]1^>*G$SG^/2^;C MZV@=PP__V$EKP(:[_@E!?'><_=R)6S_6+7N]1[(.)WAZ25S<^/!7IYB.-X!]M<.TZT$B- M+W*1FILR+-\C@E-)OL?0*]RSME_-1WG[,B:0^FL%H#S8/?B4>0>DEOX(2 P" ML6U,#S:4>UH:TM5MC!A=M#PIR\.K;/E%0W*UH$=C:.2&I2Y8"CH'?Y= 4K7 M5LTUI19C&XL*F- 7_[W(][,2[ (Y['4T1 !64Q"\E[C4VU3P]X;R?A0=SE$,#_B":US MAK/M G85-@WJ/ )VV7"0V)G!(\ 6+^*PK?-*S:?Q]B_US7FD1WD!J-N<$ S' M^!;1TF=WLI(0%Q)ORSC&*J!OJN^2",8 V'?@V-_@:8S#+NI M&6S\7I:?CM=\:/"2!J.V.M?I7I1C@[(%0QKT,XPOTA8WN@A.T')!.[(AXGZ1 M#09^RHFGFQ0]XS6ZD<.E;\\S=HR6>X.)SJ:6:DY0'\KX M8*P4FB(>PL00!W M"$@6X1UHG2S5,N[CDGXYWFU"?^.-(C?[L5^?!8;41?WAV-O>;N>W"<9W;+3B M)F]SZ;090DLW\QFPJTG5O%'.G8<.51?*LB7;:M/OLY!G:[/2S7GZ38F:I+/9 MJL8$E\55(WX7[V/#,=J@[37:GVT*!'D/Y41)PMDOHD8KCCP^8B%B4:GW*.(- MSE0+6'*3,@1AGUO>&.JWL4M]K)V0J>3H/T"4)+$WQZ%]8_-IF!?L/C/13CW()=,0G''8#T;_5N5%; $87LS5,Z^BJD%STRK3Z%0.J=GU!EVFZ:?4+%U1:H(!JB10?^LW=8%(?#>IAN+B MH4#B-5^4.2W5U\-LLA;8[ _9U0X'D2Z@\7>/@->N1\ S\G5JDNUYYO>"M#K/ M23503XCR(C&5NADE!'>1-EZ%ZL^F%W_)FFN.OHC MP>GJ^STH4-;2D08"41@P;;)271?#XUK"5IBNQIUO>O#3_<^Y6NS?1). M.9TY E:J>]=_\HE%CN]EOZ>:838Y'Z%LK[]@AETI+-LX/_-%I&$5WSJ6?['$ MQ%3U^QU >11>1$R#>SV2R[UVH^FTX,5G MJ=?XLW6U&BWKTEF,R.6TO[@&=]GT!UDJW:TCW-&V=[.5G@4Y/6X_Y#"\L#0O MTQ=V)U\RG^E&\9//A<_&4CGT%F,T+>DXISN%%7MJ# 0?F5"E]!NJE X$K**< M;]9@M[,BWGB$^$VY-UJT#@R,=SY*YW]R6;-.%/C]]#0@,HI(KP_E)=T@%[0Q MSGSN[:1P3"Z.[9G8IPA%V!&F'4\&#(Y-PZ]M14Q^;\ UD;@/Y*%2H1_1(;U) MWB6-(VUBGM]FUCPO\+@K$WE"G?,82C$S)EMW5?!F?_Q.Y7^:?^'&I#P'U(N+ M/IK\!HEBP]HC.I @!Z\)+3W!.4__B[.==X66'ST9_KJ91?G$$1I.;$+;=+>" M%AT_[7"&KG:=WQI5CK!^V< MNR6* SD(DGL4ZRDU)N5?PRY!1Y_J3'YWU9-1CT$?8X@MP+8*DM--. M:#&LMCW04<'%&$<%UU9+UC?T>&/(>M,S4WXA.J/[]%$Y?[X>\V^M]:2@%>C7 M8)Q:"N6$@*X/]HT-A1OG^'W>^HP&^I^A7!3F,!:+UJ.S02M@S(@B)'UR-%3B M%LF:8/G&@RM49WXUJK$,-/2@A%=]5SY>$:<:G"#AZ>H)F,P1W:V"S.2';H_Z MU&.,1EB(+,VY+"EV+[J>F D=$Q QZ3Q#%P.B$P0.?/$2Y+86.>)--TMWM9Z% MS@4NN9-S$:_YND)T0;D1UWIE7WV]5QORN1-<68DCXF>IX>&!YP)-4(6.7"1; MQ-[PE@LQ\-#^409^CN?I]L^J*9$AQB.@[;%_B/PEXN06U='2ZXQ %8W+0KF7 M2L;;$M!%C2S:3C4\I=6S]&S39X;V0VT@(72/"D##X7^!C7C^*P@X11,ZMT!5 M>:X5);4XA93"UDD)3;N+WXQG%$ZLTEVHF.$4>2"AT.A&N\:,@LI&^F/YV@=8 M-RB:..L\U,?_P=YW1C7U;GT>1$6:H7>(=!4!11"E!42:B$$0$!&C M*$*$J3 MD"!50$! 14"(B(I2I5<)'1213BA*(%'ID%#"D;2)]\Z:->O],/.^:]Y[_W?6 MNA]V/N3TY^SR^YUG[_V;]?3L]@2$QAX[]/G6&"]"=O5YT8] O83L9.\K7+\ MX--W1RF$)%7O5;$->]?SU*&N$T9^/U:3EVI]/GT(C2Y/BNOM,C;:8+^@N_2S M?^94#K%IEU/GRNEM3)+_VT3XL';\X]5A;9,4-=_P(==4TQ4#[5#2E[D?A*DE MZB7&RRU$/$( ?1A<'*:YM%[VZW&QN3&VSGU&SQ=>(Y(P?C+US(T+=5KOOG], ME'D&*X15PI=3R&M4NP'D$0/A@F_2O0PLG?5V=-%GOY4NX,$(35;+E^@0KQ]*%YV;8 M@3P,"D&='D*J@ ^(O$66:_=8@" BXH-Y6A?/)R3PV_YP.U_GN/ML3'@Z0A+= M,JTX@A8!$[MQE? $_]QPEY8,F]!96F9_7_BKKU.DZXL77E^ARGE=V.8/S_[G MY6F*FE[$5_4)EF1<&/$[(K5HPL<;J-?E<7?0_HYTRH=?90,<9NY@X\7F ?JA M$I_+5S-5JM\[3]C<\7W;T7IU]6)2IOQN,N\'7NQ]NN\H[!9ARHD:,:I1;*#X M:NGR&2-?"^6R&/K)G@\R)-]OELF4U&'EL0B8M[_&] ME"1GR*ANWH/2WG"Z"KZ9'9]+-/*H3AIOSMFW?*-V_PS-3>(!YN" M*_=D=:YU#WD[LS4-W0G<=TK!S50B]M+UE!/;+ZO&HUQNXP+,:I._3N!F G2? MP]:^7V \90$SA7K8%67::6\Y#F1L8O["_>*[OX.#&J)<;7SZFC4&517J1X6/? MSNRC*BYET4ZS:3!V#_HS;"]3]K??+)MW&(E]R(4U!C(R1&HYF9,-EE=B7*>.TJ/-ABJP<8'OI[5@=7/ZZ*L)SA2^FU&T2YS6(%KH"':@VQ_JW4-X10MQ60_H1- F9:&B%,+&,4KYV-(F.6R",3^THR;;]Q> M396V8"L<-/D%YL/@S&0SK)H([:'C0FD M^$\+[L;;B&=>+VX#=JGUD.^V7,#YWBY:3RMT6E@\R$FZA/&"3,ZUW3F14\KL MRW)*U-GC^KX(#.NT=;E\ED!8?SV]:/C\_8[CU?=D86H$HZST935(>N]-X$-+ M*A5I,_>0W^"QH>_]3@E^=SVD5GN2]LBD^[LC#VF%?6K==K3,L %TEJ%O.GCK M^K!VDM[NZJK*6M?R=B&@L- 0$'WSUX..?SK(^6^;N41MT.ZAA\=80 6^Q<\) M4?OL.+'$6B\HRG]L O% M=W-D>3-Q?K:QMNH'87%=-GY?-^+@"<+V]U;:2_P"UW(<36^!4,$"6K[SM@:] M.A5X%'=K3%,12MD(/R#GZ]E0*BK.>'+U=UD_ 53276Z_0UP3]<'(&;CR97C[ M:M=,"G]/Z_M;[RQW[,>J8\;??N;T7]R+N^SUUR>>_Q.DK*]_JHC)[7:= OC( M&8"G/)%O0EZLYM+:N6O47(VW-)&#-YZP@.!H)/6\-3IUT!B:P@+*4^@BA [8 MGD!+IB0JT,:<9%&>L7S!5SSUU,B]6/NJSH!H9)K.%@NX]+S[RU'Q+5P[4V&( M[IPWX:NGD>=7Y*T[>(2*KPDH_M G.?_Y\VV+H68DHQQW#<&)'I.ZDI5X.,2W M>Z"S!M_A6+[+H^6W6[U)BHX>@%ZGGOR,[8/%8229^IA6#::*U2Q49,$. =H1 M[=7F:[4J+R%40NLJL%QN;$G[2Z4ERD8R;IB*F(@+K0V$!$W-,'@YR 34+3"H*T6P=6N(N=':I M'M%:=#R]#_G*D6-:2*:VMSY Z>)) \ZH"$C>ELWE7M/A5'71R MKU6\=,;)WZ_V[[V_U?V5!=3,+=O3+)C#+*#*X4O0_95LE(9[3%57XPB]R-!@ M]RZS,(_>JL[MG%EI^2?^@!_"CI&-FTF'\:'Y%B\C'QHXA=ZE<'50[90[$#XF M>[&["P.*:V;2?D!_SW\I %9$.$;8B-*B61P5!):3U]H;8*V^"VX/5G^ZAL$K M1]P^U#7$/SUCT1=L?..*]4==U-1P;#=4E\YV2I'J4^W4<'L2).'RK_,R\W(R M-]XOU;AD2!I%*Z1XZNRP8^JU$$@+&@I>GV%HMDV+#;T<1,'>M/^X?&DJJD+G MDVJ:U0VK(Y?2+J59*:4C#% (1N0]0@)&.E SX01,!!4^@Q1".'?>6)G-L?$[ M??IAT<_\W=.""6JBWR,G#)<6?=BAB06 P;_8!-W"D-+. GC>P]I2_N,?S2VO M(HPN@O8T#F\"?[.N%TZD&I) $$ AB8:')UTLLSL:LKYSR]^[MYZ3J?N\-?7Y MP6NZUQCHHG]D:69AP[/W'J_&^\+>N;9>]]SW7;GS2Y&,EZ'S\PBNL>;;8 Z; M"LHQL&BQWX.N(3O#'>*4.3&TM/F(Y,-%@QX6< ]"^WJ0V*N::'!G MMI]CH<"6<@+W!@QJ\=2]7+T<5'X'/Y<:P?#]I1F/(%]>(R!VJI\1L MAO:5Q2[GWD:G&_7 9WXUW:6R77ZD*]A/?<+(UTF1Z:9(M;6W3Z89ET\13+2W MQ0ZG'I8@&9\6^9P!U5J?4S3(68O%D^>AM%2@W$C*%VWLD(FNIDB2SH/KX^4?*NJ"+L%?^6L$>\9->$_;H'MLD<4_UG02#.:!7#1"\B8]A7.,_4I MTDBW"F>-NH5,PKTXRI\V)W1_,H(NQ$5RZG#UD440G1YM]@GW!>IJ68=JO'^W M\A5^7]:P_ZX N_$.X:3$RX6MS0TL*B*:-O&G,;R+JM5JZ*_ M,KGXW_)?D?^6E<8Y5;+T0]R?.5UZE61MD&SL8*MEI?JRK!T[*=Q]>9LNDDT= M&Z++STJ.@XYCLU4?%?Q>=_-GR>)UEV%3DU<\=[^+U\-/PLB.R,DRIBBT+80I M[26>ZY1 O\ZK/GQF/,Q&5]D=Z79H[S%F3T;>K@PF]W$:&Y&WO0+AJATYZ(%. M(DZBK<0GK51NV*;'"S_^V?@Q&\LIS)N\A%0;R=!A@VA14/@T.2[.S^S/@K(6 MGKX"74'ONGX93B0[9[^_J;15FOPO@'?^65*J29QKQ7&A[I']\#%T9)Z+;X,! M"SB:?#U>'B6@%-_=)_WHA=;C4,4\A<:S!SDI]M1H1B1: ]W1K $38D)\]=Z6 MS?;N]3D$I/;928E.>!J2'J+IM^, MII15@Y5B\A'OC'6YNT=\C@L+CY+D7N<+9P&;\'@HV;9L#\H(S"\+V=_?0A!H MNELT'X]47NF.UKY45C)@(]0+[9LKNE:4'#2S$7GG$I:\[@=A/D1T0^A*BBS@ M1P*]!3Q%&28&TX4QI.X$;3\+BPI>>&+G\A"OR M;\AW<2V5+0_20NB'& 5YD<.GQV#E*+O>3 /=8M'8M9-SGT]-'5W:YCXIZ7$9 M(&)F?TQ"&0*X9"AH:<$"/HDP])D\KC/U3?#9/NE+H!O%O@TS-?E"RJ8TCPC9 MW^GKHYK9]M*39F+T.H;O-G=K9W@80HH-+,ZR[U*4S,O\G,N&LB_[C*$>_WQ: M98L/9!QOV['Y^KYXT3'+//-6X]S'YISKLJU.= )8#XQ@R[:_B<3 M2,#TC;?]XK2N@FV&;H-H!>/9GJ\2\X3 9:FCY^@\4\/3^>P@AT+\$^^-/U+XGFC!(>H;N0QX@D MZT9DU4)Y:;E_WK+FV('/R@Y'BO._Q#/M3!QEU[G:6 '9B;Q6%[M"%,3K/H\ ML7\2$ON5JU2I/O#3IKQ &.P^0P%T(>>W8?:@Q#UGX7N\GNWLC_)RSJ^.NBMV M\Y1G\ WG;]LWE@P@5^L4_>;3,?AP?:OX5Q3WWV(AB_XYJS$K? ,SJ>;%2N)+.'+82 M0Q=U.<]XA?-25YO]6=#>N*)X?C3-HVI4BN&9Z9Y\(EVKHSSBG<.^GJ#6;ML0 M@#965Y:(E3(0)2NV^1$18XS?-@J MPK$>W D!U2W:,9#?'T*@;5*$Q%4G>7_-'.TENS !R]!]U(/5&^;5;-ATA/$> MYF5C[JHZ6Q/#>"*S+,84'%1JKN?!X)0BST&I3U3/41!Y4%X6,)/) BKGVM94 M+I+/H _A4I@(@PO'F@E;T43HYV,(:Z])N9S9[T9J_*KPZN$C-R22Q[Z*QBK) M/;@(L!UEF U[[ +1HVS=?+JIA^T(O^%Z0@5YS)/RK&;;[E5NH_RC'EOJY!2, M V&)TF3O>BB$Z\RZOT$HR<^S4Y]6N::=9_J@L!_C*#8"] !"T^=>W M$_BW_-?EOZ/#QEVL8/,!+QP/G;L4Q'4XG>X],UBBU-3PA*1_T=,G>;F;IVBD M$M##6R#2"&0G[&00J9-Y>-B($SSKK$&JSI+.N:.NU7IHP-Z MKU&%4L ?+K_4TO!W]#9J@"""$N#EL=E FZNRG:]B^Z3]JB-SC9@#<1+*CHY+ MB+J!MF<4I0L*W4('']0$^R.B!\QQT(J^6- MA!#^?/ZV2>-KZVC9>+YQZ:1P_K_\/?P5 MV'T@21L\A$:*WFBO!*I+WA5EG8.TRH;R"\72K<@'W=*^V$^'0!Z M.M1Q&[C+I%2ZRG!&/3KR7!&ZQ%WV!G>3\-O2<\6)!5RY!V$HBE(= /01E!+; MZ:33 QE/4<;-/" N#P&^^MPO^!'[T&&EVDOXI7O=-=3HHLECH]6C,TXUS"$6 M4&/1KCF9WX[9!8G<"A5WK@&S\^&A+Q>/A>K6?(J_6'[E:>">)TASCST12L() M#$ZPC QOP/D'9FB+YK>\>=DLFK'%]05C<.6APC8@S M,0+82,K*B =UGZ:3%A+%%&"?,H;939%WN1ELF)^M@SMEK.\3. ?M9O+A*.+JH_ M@VW%55U:T'N-%=@:7]]3$'?V8T4M+?C,[Y"E;=W4!6/H#:<,E!>CP$B MGSN'.Z'5@H=ZQZP_&,W/N.%_ )IYEM)])0&<,F=KQ;&0Q$Z$4/5'-R*LTV%$ MNRA[0F//= YO[WL?GKZ<#8/V6UHR:7=^/1K@&H16_FF6R ):8%46W8G(V!U( M[-:4Z(A"9M7*9=!\][J9].=%RB$5G4/2 IW)MSEXLV9@R+)Q&'%[Q8F"-1NY M!Y7P_@#*Z6M'7_+)T.K*NE<(?[XDI,C-&[E_%4)^ ?"'6Y YJ<:@ ^UXBTL+ M4S(![Y"FJ1+N0^GKW/QLJ23ILOK^@(?MX1?[U2;F.6?9_HG&Y%8GI\_*4.^7 M)4S/$6$/U2<\'$&S.C A]>/]B0W0HE\W0%<*W6&C;IWU^<8SU5Q&&Q 1Z M$YC/UNNZH96;OI@XS/Y5Y("<)MWJW@?.%$N%;Y9&;TTVRP;6(G&"RF M.:/M MZG&L)?9T]I7AO.9PO;FU%E>3KMM:^E$/'INT] %!CUI%*@4*]UH9[D&QD0B3 M5YF6:4'A;.JZ7>ME)>'K!?2_GVD.#:SVO)6]M+A3W%Q7E/8WD^ M]"@.-5\E]].%=:E!Y.[XTNI.,I]>3L>P]N#D8K#=M\LF=>GE!]1_/I6<.7J+ MPQB:RU1@JTPF>AA;=>*]1A*Y_S2SBW^=D=%VWY0P[7>*MM[P*67[J7W!6#H; M^I-MX)-1U(11A3&TBF]2?E$.P8<25+J-OP[?5C"51VQ?>GMLLVP"NQ_TM" G M9XAEYGF?T-/(%M]I--2;.!!C]#""8R"H1 ^@;X,.+&#W==!I-C"!U"VG,-9T M)ZA.'7Z^NDH@B7D2=UJ46P0 M"[AYHOMDV5<(J Q?GGM']P<[B^E!E)8,N\HAS==90V'E=7]F!->.]5\0"">L M-0AN6Y8>IXZ"U:7H:4+U=#RYMT4K<0VR4%N2O\!7?.[X6?B.PX8;")C&2C*^ MN<1-*^"N&_'2E0>8>^B:Y+4'3?KB&6_FJ46[>HPA!CGN;*(R%7QD[GL=,4+? MYR_/:?IKQ.@V^">A=1N4I[1W[V0D&3C/)F;C!!9/PZJON"P&'SWR1O'2R+(% MS_Z."RV27?=_U:V!]UC \A0+.!V;QP*B&G',4XAK;!@&90'M!>SW2=@1T8'0 M9;^S ,KG47(!75B<&D9&)&BG"'CG"C796)]M3-@9?3.FD>/H]4U/Z.VYHWPO M9\AW^L*=S("[:",VDD,DW-_=H)I(-WP+II]-3_=][W+D,V0[0_$GTEQ"L;RL M?RV%0#:'<8=DK.AEM"$%>F>EJ;T:B<7'OU\ZMERDJ=5A.-6WX[2@+L(!!B*) M:Y,L@,D]=5L=21SY08ZIGTQ=W!?HRI]AL#L5OGH<[U/EMZBVB(S$D"]K5@]FSB&M0YJ?&:W #"7#)4:?"VG[<^N7W/:XVI"%5Z2V*L>G%^-Y+Z M,^G79VBJG-M0$]WHIKA?^N8?B^3+U>,/QY1:IY2)*$=&3+@0G6;1^=&,* M:49?58,+5[_7Y!S_EJ/J$,?XUMS^H,O1&.ZQ]X$5(>@>X7&G8W^S:%JW)I(5&1L!\Y\L>- M@6MV8@B&CUVLH-9E%**,1 M:8Z?:<Q MOCUNUMHCK_M!<8]92,HRVU;W:((%-&OFT&1PS/ L-1L:Z3]D$J"]E66UV<'S MI;+W]ODVK5TSKS@?&KRPX+' MW]_"_.;N8-.KOVG7,*VG-J&32T3/./KU=V"O/7EIW%DC)]@3>2N]I./PZM+/ M9]=_-+NCTF3DC"Y$PL/(NE0(J$:#:8M?E26'?V36[M\WMO7EZO1>:$'/UO8RPWD%.MK M144]8J.&/6Q<+F,D"AG1M?0!Q:]8T]<^-4-M\?ON? H)<5N1F[IJ]JF M6 +018Z+TH;&,:%5 TW'\R_-2^F\4]L3F^/_P53NO!7/2[[T-+B=E4J-US_( MLZBE@3&4NZTP[DU*. DF.L^4J+GF+'WQ8S*GBKY">2_68S>^&RL&FRF'[D4) MS[F 9_LO@0_0<3S4#]EJ6A:V'L^YEKZ[70L/-S8BOVH^PHC"(5>"J6V4@H1- M/XN6.V!0[]E*E_% 7OV,W /G'NP6JCPHW>/7^\C=G.XT>8]C!E;-M5)/QE// ML4$^)7HGYE?UN]-XL2RC='_E'!)_;9B8QQG7":!RU^W;^_E1'!1])J\9J5_D MVXE,1AZ1(;PH5&U.8AJ=UFR!M*T,L,(9!!DZ4?8;RM#H?84YAL M'0E[K6:V>PP?,*7]N/S;C=3\:\ZZ :=V"]TV/W^?$ L#F#)TR5H!4+'ULF;L MU^])=]QN)AI$,>H?:K 1G8HVQ^]]N-TLP \W=2PZ5S6[(RB+?[P7TV9QEY%2 ML&((&1\Y=,TB,*9"[3M3&-,J=*\(H;)$=.K@S3%IW;-)X&N13TDF>#TY=BT\ MWWYM82?&# CQ;$..Q\W$M2)4$/PHPZ'S>7+[1JI/]FT-(->.I(L=Q'R;-"SZ M-O_7!YQ_RW]=C,ZQV4(B<_QRW'(FN=(:R=^Z>UJ+HK0^N5#AJ@*6N"5=[#MU MA?ZED<13\*A.]8 ?+ ,Q!:T6@4EIH (9C>_*.NKH4@9P]98T2!7FQD\7.4>" MIK1E^J>I%_NSFR\SN-DGKT)_:58!E\AE[6AEDC(5] ^J7\*< AC;["L',L00MO/U M-M[=?<3SE[FDC-S+2.[=4F"C+?LN$"'Z;16H*V ^*<>FR:W$M;MX20K]K%RB MN#C+1+N\\L>S3/R!C6J3_L_C>R..8F;2L%6>'67)1CI@HA^I7\+'2*6V_$/U MLTG],;MR?:L#-UYR/(J ':;-D9#)N-E+*!E*=^+3L5/:AF(;M@\_<&E9\&KQ MR>V_=+#[(YH=/""X'VB0#9&N]6HRI)7#P]D1[3PE';2@JE.>7!!SWHI?WJSR MX(K8R&\.?W2G@H71AU38_S[-*CF-$:W]_8^$$OT4VN[CUH03GU< M[(B/2O9=8@'CJD2+%4_B6I)43$:WFLU]"%=IHL&'$^]GIWSW-8^K1!P0LMAU MS"\6D7'2X,4=A!BZ!R.*\V8!T82]6Q:@(9EJ8]^FY2/L$WR_?E"IP3=^M[>T M0LV,K*W9MIN=R/.'PRWZZ![/E(N]>0J[NF9B60\U*E>ND; MH1=&'0'.2K8FA^HK=(^V[ 8@&HQZ')(%Q$L%=TLT[T/Q/+(@GER5KVPLZK4#+8TN345Y[=2K\=4VE^S&%L>4IGG[0)R )D)K?CUO*= M?U4VN#BKT/2-QG*G?W%LZ E@@I8M)-I6^4YBQYMGF^ZP[^HB]E+S+F=W?)/) MNZ.8-8E22DK>]91S3G^60-T$I_BVVV&;Q[QAH*PX"Q UE@G^CX5 \';#T_B+ M8#?E[*^OOZ0;O6$5-3:<<>:=C5&1)PTB83Q;/O_G#O=$''A8=\69!?! 9HI" MG$XWKC=YDR1^5#W(OV68DWO,@![ S=5[_D7E49B*VA).,J31B@R)WL((^=;& M%\Q/VA1G9 1KW4M6LOL2_I4+"#@/E'5@@'F]/U^?:%1BX^C6PU5UNK),Y")% M5^:2MT"-0HVC#%>Z? LP0HJ(P7LX)G&5_L(R.%BJE2,%EQ;Z), M[X;+PN\];R3GAX]*P+Z9'9CM*1O\7%:P0&TXC_5S\T#*OGE:;+U;C/SN8H(. MA\/%_7\Z/F\6_>7)KO\RXHA\:*#[&JRTPEKCM1O5/<^]N.%B>/J[:JS)?,], M%)@PQ/;X)T&V@NU^ PI23/OKAZK"<,!BFD=,=YSG%(?_1.UC[>OACU7'FD]2 MUNB"O41"^]3:"C*V67<89:%>3^!:4QI"MJY\6'7OKW_J2]5+ .CF*=2'C!J< M.RR]\QE3H7'0[ZL,6-A.L^LAU4XYJ+.OY086D-B,K,89SWX7@L^#CF 3T"=920PN>B7O3THJNTV/+[U 5>I M79QNM[M'WT3D']M)-Y:!MV/!0YAE"@7:FPR3,YWM[>[R:[+@'%_I+RXVP'Y: MFE_;#Q:84= OLF)CBL9]'2';_E5+3^H>,B2Y1&* M+I5>[0PJ7SSQ:=/^YZ??/;YSFFQ>HXSS@D?OI/M@]C@26SV0\\2;!=8-B5H[(5)778\_6JC%>7S;CFHQ:,H14B3G.:4>SA MJ<'P5\LF$I$<8+9I:IQZ@=6>39_P7FT+J%E_=5A<-&RF@%"9DIA@P0*XMZDZ M[9A>6;?S];7=8_ CW2P@Q99K]*(3YRQFDG,V+NG9\5D6\#!7=,R:,5(QYO<3 M_4T4\CA41C#7MRG9[)G.O6OS[8<_!^S;$@$6_\N0H2P=XP<'#\)C86X,4SAY MPTL7?8@2F^=!!6\I/G&9:N<.2I)SMG3;T#(2O8A]/.=O<@#J["1/<2-VQS#W M@6Q\F_(H4'OHGKJAR;.;=E^^=.PY+LX<<_KZF-H(%0+ A/U*[;Z9>9 %!.">=E,ARE!<#6T7@H-](('3H MQ8QE^V2-C"FUE: >OOD5\V37:TONW8#AA[,#7'.XKC50W6&+U/>6KD2VF]JK M+WR)MW2-4W4X@FT4*V FI9N(;6-X.H*C;WO]-*><:%([ M&W 7WNQW9]-H>0XFY><'4JK\>P/&^^[KML+&\3/;R[2?-C/L8\=-"KO[J9WK MV8W+VPK>6I]R3]KD)S]=N7+<5*\]5M@S(QPAV2\C.[J%BS+@GNV/TY/1TXVIDM5O;S@'"^@_5VT=\F!K M\N4N>$"H3N,_HJK"(5#=KM_L0R[-MC&RZ_,>@GK?ET29.V5%QP6 G8$]A6H_ M<8E0LMW:! N8A>7P-1^'BRX>FV-PM0V&U]7H1V@D8\:NOI=_MJ)CM32\6]SG)FG5HRAA5M))$T)+P*$KE8( MIG?H4A;NJV3X;SMEI'O>NO#NTTD@?1E0>@%PEU@[]XT6'Y?(%590>_Y#PKWG MZ[XMT0P2=)\7"Q P8!^+[! 3]+FO\OX6->,9^]CR#ZTR 9 \F:C(4R(Z[,VFE^KP< 95PO$MS'EABW^:S"T&K>20;MZQJ+L2"*#(G__L0]^DW1G>MD')-[CM_]O%=.[(F R:#DVN99#'T59 MCNPOH^AWZ6%BY69BL[]D;H6;I(1W'$V9,O(-)N&7$=$$LE5_!(&?GIV$L!XQ M"'WW%I)3]AVJI(LR$3BC.+&-GZBRW0N+:8*^!*6M4LZ2?\47>$FY8P)ZK:N2 M)T5),@H E\EDS;\ K?BW_#_2,GM&%0QIK3E.<":OQ.;/L#V(4&F]GQ)UVW'[ M/5+ Z]N1U#2'9..0?CA)='TMH0H6#:O.6)D-?P?&+&LRH8L$/F$GY@#--N)R MCZS%BR$U_K3.M(([,^\=9,C5:;#U^>N/+I[FS5\#4MJ]B+H='+!\(_ MUL5ZXD3() MP[Y-VNFU #:X.RIJ#'@^2H-C2!A^%M#F,?,18TRS&&45 MR*G41NG*1X]([UY"/B-!^6UZ"D&$!2Q+>K" ?/>R0?ADCW+V_7UO2TJVR5[O;,]J8T>:^:['25_O/PH6_8'[P#Z234GX/(D041\, M.8=]V>N,>E_^VJ>,%"I4L3?(;V+CQ_><[T>/)>RH$N?:D'STVV!8<8AFYQBG M[:#.R:9Z$=D*\Y:?RDFXF-&(:^$6=U*-9?#+:[33["=] )IZDK"\/0W^2;0? M=94-7J0,N-=$E-+G8H?] ]#2$Q6YL3@5C!M3>9D\=3O(AZI2X:_1*J-5%)WV6WRUQ\[7 M%,/S,Z\KP@BBRS#R%8C4I2N+&!ZZVIX.NT7'5,*BKFV1!]&*CYM;\8.;S$=, M(P+.G""0ST.YT6-235--!3D5SF^H?P M)+& &-T9Y([()I:^!TXN_9P K,-C]'12XI@:*-L/PW[RY15Q-,W>V@>[7OWZ M/CX#L;.B^XXM?3'@9 '*M<0R1AMN,[-H>/[_D,&WSN:PU.@AS$U89-9VLLYQ M&;RMZL1FKZ0T]-;'VZAW<2AWL5L!@C+4EY ';+SW 5&MG>$D!MN%TKP]U+/" MO_8PJ?[3326=ZMR_KX@CII_PAR91:$=4ES^253X/V]5#;R&0SR$G-AP8;YH-EV#2]/!?/@TW$]_IS.?.N_M(-6*/ MAODEWG[\8.!YW+D$1L:_0+'2O[#4$\11I\C8E!5ZBDB(FSE%26+JY^(.RLDZ MY9QE0<(\V\5D&5S_6R'U"[KWQU*TU*6%2EVK>V&9RS6TZ 0S>)]-".81;"81 MMJ\Z?#TDK-/H,'FS+^?]D0'7EF;LH20VS(26#=P_R+ENVD$@FQ($IRJQ$-3% MH:T]_3T-N>G*[W>$TJQ_D\BE@KB9IVPW)][NZ$G&/JRJ?ZC_! SKL)\\MLT@ MFO63)O_>U\F,#*>+J,VB154IC,GN'MZBSN)'^V]S96N@L;'Z]KC9,HP_"XAK M\LW23%")-#I>!,H[[).!3BLW^,LD!\M]PZ_8B'" ];YLHI( _IZUZBQ[:* \ M:QV_UU1]-3/8[X2%; $0<.IW^'TGES=L#'/;P'D_K*I9;!Z/@H!;HRI1N2P@ M%%JVL(8H%7>\C6@9N-(JVZ&>-/CYP9.9'^Y2/W7@45[WOQ]OK!E#<[*%;-/R' M$Q'X7E^D!4>@G/T[F^_X^WEPW!T1/OR#5 N]O#-UD9'4O'N)Y\R?BAD1[*$K M4UY!9+G[&U*:1@RS #S;Z1 F>FU3KR)B+I]]*B%W!B\(^:0$#' E7F(_B"=S MSU7DQCVXC+-?EP'CQ,CJSJT&)%[6-P@*JLTM;RE9KH03#V8^$99>X']*/7E# MRS"^-(O&Y$;0CE\U%].,&W8^L9QY !^X"W[5*'3<(= )&MD=. M8&T]+S6KML28P[&O?012VL/K^F>OGB&0S1 /ECO8"LXP,=R;[\'V1VF!CC3F MOGQR@.6(,]C>?=0([68X^N)ERC7U#!&.50QY'3I1RTQXAF4!$4X8^LT4,!3R M9ZK6S!K. EK4<,SC"!@+:$]CBF$&MD@0VB*>!3P:9 '[K4%G%F"*?P1;*T(P MCQO+S0;^Z1#"R+PUYX4@WKNU--+YRL=.\QRYU]^$SF_&IGGFC.>X^;>8GYQL MHO?#9]T% 2IDM 8^,.M.1(4>(710KDXHY(8=JCI)7T2 06MD!TI] ',3!>; M!#^>YQS%S,X3*L49(OWTESY8>M*Y;";/4]JQ;N$&NI6W\\54*2^]7)?QF^-\ MV "U7LSL9^QNV+PWR'[\*&DHT[3 E&W73B!4YMT*$0D]6]CRG'"AHCU,YC)G MU+(9$(PC4R'L08AE_-DM T/WSVOZV_?MKR<&,E(Z)DNF/!E7]-1[W%A ^$%H MR5T,^11BYA6)$+HP#ASU70/988#A57@CHV/[]0O1 M*"N@K)Z@P'Q*0E1CZ,)ELW^2:^8<*-WMFOM\K^J,CEY+&W4;?5,7;:+(]VTY MY=?3TX]O%X!1G@"^DP7LA9>2LV?F)5:_7$C3WW-#'R995M#,S38SV68QT*7-R*DCC3PJ%!Y$YUA;/_;F?L#E:9:[B1P1@LCP MFJQOA;K_;36%)^C/,(EJ=:@#Q;.U3#"DT7XH7JS"5\KC\;ZXM )QFU\:H>,S MI5:&OHM0,+![F3TD9_I9@-I. 0M0&DV$@BJZRWT%G]T39Z./= 81P]ULGZ#A MM\U#V"^&\_4?YX&&>.GY-6/?HDY2S'.N^S?*5U=%?CV8CS!S> (81A1AR#1X M#'93 6QG_F;;/FETDXNN'TSU8P&O7-B7F/$CL "Y?*9L(^T$"QA49SLZ\HFU MOWW#8=_%?SAV!-.^8L2VJ42V3?UBVU2*TP"4O$)@JV&\/]L6']1BZ/=3P*"U M/[9XIO:/+4[AF(;&94">R M*3,&^1 *:I2SK>PS57H-5$$N#[X[7(SC77E\J&==QP6$$^WN8+O>LZVZ%'93 M0 *\..T(3)Z/M!-?!KDH28RZ $[M+.59[MRY M6YX%-1BI^4T"> BQ/%ITK95BWJ?%1.R[OOK/+?;4BA"^K/RB0Q'Y 04E/\=2S ,FL(F8U/ MO$YAE#(F:F2DJ>^\:4K4\G1?@_(&&C7 M.TQ[(^86,JXNO=U(/LM*^!=B&2IN6.E9MM<\\<4#D+0(P'P.EG4BEV'@0<_V M"RG'N[=S$5 *;7]E+H&0;1C."+N9BO-?F_*A D0?T5D ?43M.TJ:=A:E"L9\"+E+M(BI#KVR2WUE*X2OW?"X MW J)(L*Q(&*GMM?6I,<@\I#7?ZZJ)O6YPK,;HL:?5%^6\8!%M 4/WA"):4# M)G@O7C._1R_HJ3RNGI\Q9FDJ EM;8<>Y$:=?JIUP4+TFRF/.!74*Q(05PLZ, M&%C/ M5B?)A<-LSB1+WYB7%7-^\4BHN&1=;>;H5[6E!')9/(+-15OAB02A_A24ZTQB MN%L'4N9.W_%O?3).TGM'O&]8<"ONX0AH^;&'ZZ0$0!^G9-!%TTEK7>&V\QC> M)E6_V8F"_J?(_'&CLO$\Z6MIL,ZC-NL*0OR/[#2S1J>"OS_3_M_SSY/^E MH@:MC/Z&E=0A3)51RP:-Q%"&F!5^+NN/?JIG]W5_JJ]79:A0>OI71PZUWWU( M/&)$$=V&T$6%J6PCBN$@7V]2>_G]]]43E.B R\:#-7)?^Z4]ZTB/.Z#J$)GR M:^AS3IEL6Y.'N;, \#1*'-8%%YQ8P1N8"M8.$#/1OF%\2TO)V'?;$TZ M8B.,B* PV=>4@66*A(2UY,K!-_E5OID/5T1L'X=F.6,9!0%]*R_V Z4[_P(E MQ?__"ZE9#84@![>P@'UP(D9FB=HL-R@?^.C;%?\;JW>CS]BZCD><']T](_R( MTU@V2?1W$26*R>LTRR_>7PGZS?29=M1R_G2U=GGL[,+)^)D4;$F::*IDH/,8 M"3 ON#!Z% M(=S8KD[?I"GJO:X/%!/O<2S^X*A2FWO574HK9\SG@DG]\_3*@ MCTW$5E*S_MV>%6,7S<[A"3Y>:J[X;1>@+A, B4E@@WA["$Q MA"K=KCJT3 @2CB\ITU3(W&18V%:?B5UYE?0ZU=CI)OQ[_E&-O4&/;]^&?#$2 M_U-NN)A5^ZA:UI1-8T28$V^M[ZW_SG*M_!1^O[@CXYESLN+C.=7X4ZKI8\VS M#"SF1EDTME*;X$=&Q%*72K@C;>[:998B9<]K<>KV2IR4%"R,2C8#4*-L!"@" M'J==0-T$D_*]"'REJY#VL$319-]P?O:HELO-#Y4I0&.2UV-%SZ([I@T%B2*3>@S0)X MO*1NQK^>4G_V].UDIZ?WK>A4D6,OSQA;*444W"!O1+7"[T'OOUPD] ?H0)HT1]RA]E#A&9^91XE4-=BI$3KT7"JW:<" M4EH(3?^M'K7LY?Q+2!3*@TW+?$#YLK5TLY$F^]G0#T'*'S>#!:)6*[J^W&&" M93SL^"A V=\3 R52_L:[DO]FGG$2ALI\[#"?*9(D2^6ZYTB&^D=877NHPLD"S/&C&'[,S%MH97]'V6$ERLA5R8_H MFF;E!\M!C)NWVEE JEHCF$03IT/ X@JH(/WX@$I=^IKK^%1XP@PM\]K!.8K. M>EE'V9\);AM,7W;K54U\D^+M"07>$1OSB7" J_,ZZ0-J;6B ', M^PTNY@CRCHCFNJ#B6]+Z8Z,;YTU.E65LK8'*M2N'R&JV&2Z@-]$Z_*K7;ZNF MXT6?WA)$9=9+W:!D0<6;3;@9V$HW)8-J.DIW\=EQ>%LF]J;LBDUI*Y'7F2_I M_2ZQF=">SV?J.0\\DZ7T >@L%M#V@%&*F5]D:QI=GOW#5$@!;6'5_0Q9)_C1V=N66+)RB(LP"F$_ M:"S ';NS4H99T':@.OS/Z53GY@,4E=19PQ,V%BZCMZK\C&"XX'=7E 0U1[]% MP/2 H5?-3N"?O.,3C-QFJ=_E4&G-!"2;L64@^*:J5]=>MPM@:;\1*O0_R7G3 MYZ=O02%H:0LH?:.9HC-[B^$WV\U,>@D9+51;)U!U&.]AOMA)3A(^#JGC=\(3 MO*Z=/)FGQQ>4=>_V+8/.@$^_CL<>=G T5]J2#O#=4H@P"*.^8[Q%P6@'46H8 M*3"V:\,^V;IGDZ8O+<#9?WMQM? 2.;%&5SEE.V3W8\@O3#)NIAPJT:RPR&G% M=J4EFNUI5V0_%)JJE+P3GKIY.F\GU(*.N6(02F:S1(R(P;'@68+8_+.K!P96 M:S*+D40A\T[+P[?O"Q@?2#99L 7%9U.BF!(++. :.2ZF"L/G/,.Y/]U-] ,R M:#S_SO8IE0B8= ;U'J.&!?B683LKP81AL_I3@10'%D#UR)K#C6?PLP!4.T/M M&U,4TRJX.1680"):=.@G=L\T8V>S[_! D%7G)-C1OL9Z:Y-A]BK"" ,ZT/;0 M]X&&/WI?H?2'UG3VDS^+7^137\+3\.,JAHIC03 M;'"-XY,2QUC-TGH8DV>#9M]/5 _HGM&,OIGV\\8S::Q >,:1X6]"4M-?./#^ MCN8R/Q^Y1;ZVY7J(TB'//<3,%!!J5G[5EG;?X8I^]=B5\*J\,_:I\ UIL^LM MH2>O)!>O&YW4H:7^7_+CRG)@US 3-Z$3GC.NR1EANS'DYTLN@;+W UL5;N"4 MZ_R7A'(^WJGK:5]S&KKWEV>P_7\K_ZO E =\3PM \8&Z:E-@"E$C#3FRXLNO MGL62_YO@,W:88RZV8A?K-==$P8NBO.]B.M1@J@?RB:$%<+S;)FT>O>KF\ MZ('8%Z[OOQ0/G?/__/A4V:\:F#1E1+TMG/OE MF-J$T]X_FSE5:\ #,$JK1THT;]8E3"]*_JS%:'@1'Q\_,_YU#"#?&<>W(6K$ MZ:+6YQ@Y:'E?!*1)=V:BR8H8?L0\PZDAIG]B.2^5Y PXV%Z]HE:*GE.:>7$7 M1A>NI7)0,I;?$TON=DX?HWB\&:66%(0_G+]_)LW*G_NINU"O8@Q!8>7PT=>0 M8TRW7/0[BN[R++FV*UG+!,C,6N+M1"CU65Y!M\$CD>N\>WS6W#5*2M%-/N0C;/-Y"/!CI.W@A^V:G]4OC9XXW?7F8T>B8IK 26* M,IP/LAB&C *=5KKSSL&!$P#T..QLN?H07']6IL)P-//]%EY@ M)*]I3CM%0KY,?"78_B;[_ZE#9Z[P8=:+E*[-D)=O"AT=%]@.<']BX M][^% ://H=3 A6+P[E601$YOD1.KH& [^J51MF-]);E%/+W7"R85#Z:M_KPD M\'G_;8BDH^I)'A90O 4R:##F4.X>1AK&&S)IT7E5BXQ)U,EF@P\QPD+-Y-N8 MMYT&8JG*RVO:<*5T<]&<1TK)(4DV0!@V%C.3A 9&JK*S^Z$AMD2"^B"V42N*/]L)]")Y L3R [:N%8U MHNN-[[$PD2F\? ))C7_D- C[^ BH9MJ*&,VE@U,80$J3D]0?RK5IVO7KI/% MVX]"Z)7-%%DFYJ0\E.888:2307T.3I@8_Z9 3'@I6#1;_?-+4)9GHO.J MU/GMCV=V=B1)B.8O(;DM4X;_HP.!/^B$5?C+34?L3.+ M8HBU$Z-"!0.*#-^-QDX6((K60H\@JL022=+\D&6<@$Y=5O7R\_9;?<$PD99P&Q+$"<+DR)LI3"1C8YO 9S^X%&[UHK-;/X_\'>>P8U&7;MH@\" BI&BG0(" I* MDZZTB$H3$6QTC H(B! !Z2&A@U1! 06E2!6$2 W20D=!1$! 0DD"T@DDE!!, MX>#[S9E]YLR9.?.5O=]W[_E^K,F?I^6YU[/6=:U[E8E&Z/3 M4_. G9+KQ[Z3WL$E];G^A:E8?+#J)QF>=3G6K55"+IT'1D#&PC_0W6?D+OVD@3#[P.OF'Q4[[QEM(J3RUK&^P6B][+N MY.]]H+=\_%]@H_^_Y5]"_D/UX&>K35[T#)OTQ>75J(D!'+?,@K"-X=2]M7=[]1:HRJU>%4S=:WGJ[QQP%?B"6\L7_GIR;V0?8"MG9.V DW(% MZJ I$CI;?CJ*9YBF'Q\UBV9;CK[="(G,>:\X6;,/Z(ES0J1.MOWM5LO;;'! MU\085;6P0X$2C[([QJP5B]TV?7Y\E%Q8O>G-&#[Q:?VF-#APBZ9(RB8@HDE0 M0F\LG8_0A*QQPVJ435X^KF5BK"R=.CJ=H",QGP3XU?X+-%+_WT?, VQ&W[P^ M5_KUT04@^ =K*4J"[$J,)EFTB^S4)WVD6Y!&ZTN\5=L4YS"F65JRP#6GJ5,2 M&[56R .=,#6ER=-Y6LC3Z-ABLOJJ'_5,^V1H_W-A4#F'P?8R-#^7 M9)'"0O?FN=V4!>R^91S1HBG1[1O$V MAG,9:3- MT6Y>"!GXY8867<$1N-H3J1LZH>_O=X?O Y770AF0FVYYQZ&$E$Z+XW1QDD02 M'L>UO%HXJ?;F_G[ ,:8E >:N$9 2,']J'ZD'"V8$'7N$FFR M=/KW8^W$F]=QZSWV(6 7MO'?@G0I,#J3>.7[^QG-VA$OR)A2OD\C>_[MJ?;7 M 2B]U(9EQ_'.?8!Z"I:T\UQ@L1?*HQ[*%X23T3:L;8PJT7UQST*.=5T+HI)%]\G!#1-"5%W+6$LU8:TFP0.(NY"J[6"=(&02+;N]!V96B+FXGR^?A2*+O@?<\W M+K;-N,[G_..3Z5_IBE1K BR"R3'2+(TGGA(7O/S)LM0U) M5=07P5VG8@C2*JEN".&T,2.ZJ?$?V<<,$!5"NP*_0-TI8C2U(91'X)?+ MPN?K(QPSS[..? LGGT*VO;+F(>,HHE0MVM6C"2G\@48SXP[9+U%NU)K6:<:" MG]"K?6#\KC<1FI,KB,&_R.5K%5B)[,H]W&R_#W!)U2*UL=,ES('1BB_+\WU" M1K^1@>JN0VZL%)%X.I0*.UAM]0,ZI+JZ3( DZHL?0'F!!EO%YBNL-BM5)9>L M0C'-XC>63_;[/Y7?EL6#Z/P0/)K(3O'0T^E*(&!XS*.9G62!2=N)05+/[]?S M,MNCE9IM;Z RK_UA:[.S2%G#T[%DE2)J3$Z?K.VM+?R1K7JVE_$%WPW>P] MXEK>E&ZPWJEK/8=:RR:5=(%)-R'8#7MJ[-P2=K&#(FCV8?6(SX/[QQ6?;0^2 M'@"0[>^:7Z?:7H"JD7_;W5:[TL_N ]$59/DNJWO0!#KT4%W9M880/?470ZB: M:Y%L+M<.#")L&=2@\1TS$"TB? M"5-?^JAC(4:%68:9>\QR*RT(X$VYUZZ7B =QVS]N?W7"!R09#]C)0YB\W K3 MH:\>6R'=>DV\7=1_6_M,CY/\O@.4QZTI,)5D0N+L'4/$(F24K M+7O#GA[^Q J)DA_/2!D1=FE.E?H'.1E:.;]4BH M#J)BNN[VJ&Y=/?7SC ;@>*0BTP)5G$["@B'3&Q9D.UDP&-3P*IB)RCN!1)7 M]L>U'<.Z[@>92+E.M25?N0,3G.I_KY3^$=5W^3;H"4Z6N=L7N2%$OK09..Y]+BA!.-Y5[K4/U.?%83RJ;7(PC3F-J\(0 MS]*,X0'-^T!42)? +OC88@3[IYK&T:2*HF3IF^?Z#T5\7[BTT2R?)FZ$< - M@3BH')T0D/K@VL;1P(!KI)G<=IK22Q?QC\[)465R;&,[ ,+A[UN/.&TS,6UW M#VY*C;%5+]?W8EL["AL,XZ<7K'I6\OA4+,)R^-. _=-L[HX=JNB[XO M\#(O34TD[-"+B2_ \=;T?$/ P-4%5HSM]G!GLZH?4OI%B#YT2FZ-_RF[Q7_6 M?%S/FBI8^?C\6,B%B<"DR UG5Y?-ROP[IHEQ5_:>F^DK^P#QR'X.*O5>?.YC>=I M?1>V%.!:#_DD&G(>'F!U1"EKZS_TL83Z@$!6T. :V6[*TQK/)Q5]+8,>?'Z.6M((GB.T M5<(@G4^:$DCUG?^B>Z+U3/-U9%%@\OR&5NA#F2O[P(O5965NJL45DE=6%C)V MVQ-RY1.TR:,86]1\92D.8,BQ;GE0I$@HXIM94 K6.%'_]./6TR/T8U7]C \N MLR&H<_)1*I^NQO=*%F;WG0^- VZG(581[X8,@0?4D3:F!#6),/F.HUO[=&S< M,_NT8@_N:].NT7TO^JY]DI8,,UCA'## XV*8?%1?%PKD2*"3,6FT4O/ULVS. MBCLI3^/5J./&__]1 I]<7GW^0)U99@16.0FN44S--K\H?[S JSK(.5$@*>5; M$G/X1>CJUN3<+ITGX-(88N@#_!19/0?<>-'E1QW%G*IUHW4;;3XL37Z,DR$YF1WTZ,_CP 2GM+R/;O,9O*QG5^?T&)M<[1+_%V]NZGAQ_3B4#$0-QA5!M*Q#SS'N8_J MLGHK=X8&;>)O=THTN&EBY^%U5U0'JH"K)A^E(:E:EDB 4L]L\D 5)+4-3/E ]^^>W%;\K] M/IV&/-"/^',QL2CW'+EA3S]'T9NUH[7]A5N*&T]<;?/?()N3"\M!3Q\S_@7" M1?\M_PSY=X^KAIY!MAM#/ P9KYE'^CT*'#GI ;,N:;TF=V YHRK/*\G,MON" M#/2]/!& &L(\XDHS?(RK[>TU!^-AG3BUN\.U289/L*)&7W[Z^>O;"B_7BW\+ MRV$5-IT[C+F^#[B )L9-&9FM1Y9RN$82 P2K4-@Z1P/!OZ68NA.0:2'.O$T> M?@D?#\(&50:\ED'1]*7[DN_F>_2/IHUW>CN WCC)?-R%[_J^_KD/!'S3C3F, ML2S]7P"K2/N !&(20(I=T?5JS=..J2:L,Y]6%' MYM@).=:IQRK>?#=^/#_QK4RX8$J+_2*0NO04>8[N. IYB)G,GO7/]P7'^X6Z M=4J_;:V8,_F-EES4<8H/P#;GOI+$;Z/R( \&J6=2NC 36W,YV631'@GUX5OR M-EX"CFI7JOCTX4;3J^2ZO;E9 M$%5)HTSW>3[\5);+UPG]?!3G=[4>)S/_WRF4!OVZ/Q9XY1BF"-4)[ZC5WBHR M_&!$5Z.DS9.XO=/_OH#7AK=Z'@O*V)HV)"O2!1D^(TTN?D=* M:.?H2HO^] ,/ V'[-E=XUVTNRTO1/KL?J52M^MO87)[.P2C1V*#*61/321V3 M/1(B"18D=&3&AFWD]>'=?J#)9-=0KQ]]?U7H'L= ./U1TR!5OKZ"''#OI^YI M/(:+"K8<@XO/&W],\C =.=WT.>%6LBG_N:]"9WA3B=+Y,(W/%^96E7_%4OQ3 M*)Y4UOPEK:=&NK=+E2DYF*< [O3O E^I!S^-5(2(FWQ3XZT_. B8R'W '369 M.>=9\6U&X"?=MM(.ZR#*M3C\[*A-08Q+I]#T,#M+F_S;MV%&P>.KH(@GK4JK MN=5P@1RIEOIA?37'0!^WI(6?$[!2=2^I ,XCA]EZH&[G1/U9A$X>4,E--R@: M1?]#UZ!.4PU=9CD'EQ<%]X%P=6;J^.0V"[7*FW:2.:U_.@=*= SHLEB$9$KC M I=,A'V3NH[&['E/"O=ZC6[GKO'0Q)@_D&RM:J:SR+@<)3 I23%J;'CYBFT& M=4;'Z9$EO8P_:;*F21IXD(2(OWD)S+8/M%_&W ?'0>M*NBR.4V,[6E6&GSR; MY-:U^5KH46,A9HEYO3[2/=\KJ4!X=>(2I GZ.I%E2PQ)NHJ)/V,(FAOD+'-= MD*>\OT21L!Q ?+UY24*- )E8".6@W$S CX[';U2Z'O $'T]V^M5X*YSJ,N,AJEYP'^^QZGIKL"E] C6/E6/&07RE, MKC<5B'ZDD$6*!DK"?H7(G3CV=!GK6-.5MI=WR.61UQTGJ4NT]AM&4^*PR5XF MUW@E2AMSF1ZX_E M6,E]BTS.E^2S7IJ3]$NDC_5TQ.;5ST:[>U>=$75_S F0,.V2Z'W F8HX(9NH M+&J5TIFVE$I]<^)CE0FY6B&NJ?JD%E#@?[E4F".+$GQPM>(Y)F:%Q,^*7C M,M;?NQ29'!WI6 JI0(P,79)0(3C*SJ['TF1[2W X[ I&1)(T]57\9V6,UL_F MXLV *E&AF%]'P>EQ,B1?Z&O50!3S")A@=3J/_'L?N C+-$.WSB-2,1+3H!;$ M\,$#OL-]4NY!87&]8*%*]=Q$A,0X1^2-7(7AQP>L,D;0Y/PUS;V'LC8/>05D MV9_VLN6HV(-)EBF3([.9:P5DD.$07 I?<6K7H''$:M,1YEC[.>OL(U55H0(5 M,Y$/E\INF,I^N\/)WBL>VS6=^T"M_[M0FN(DW&/TF0=1^;H^6'NG)Z-\X4:\M-)-+JR0&/RC M?P2G4UC@MOGMME;1<;'6 @)1WM*GN]_1UO#L5'#N&PO]G9* 8NQCD6?8T-&/ M6II\5W^8>:@_>)^FJOG*19K=1.9$8#> @+E#2/:#;-=Q9'6J^^Q1C:\+PW^. M1B;C F7W=E#O]X%'$*HE .,7+\EH77$7Q+/ +W>]=NMI3BG<+YY%BQ=:U'F3V0 MPQA7#)]#8&R;/E?LE;$2M&9%X.ZXM=;4OVW$1DW6X' M*$Q"YM,/W= Y#T=6FY98XHF);(^$6)ZT.SI[*I@,+@YV\ENQ9QHOWQ\0^9KU M%O0:3J!936#-B8A&NJQX#V8)@E.NS4,>6U!ED9TP;%,W9>8<^7@^RBU',F9 MH76D8.IJU8!(C>K>IUCI672+\E#]8!B/2)&8-2.P,_#]T S9KW_?P_&IZE"KG8VCPU8#MAJ"]< MT)"H>Z-:2L;K,B<>O[6# O^$N$;5,-(7J6J$01ZH^[4<">V3Q6BI:6W$QOW4 M^KG(:6OP64FG>'KSYX,[0Y@_$*"&D!108$''+O>[/JQ_A9^GRN2N;R,[L.F] M)>8[ "!&;D)S<22+W D,Y155F7S%YC.U8-;C33,?(VN,[([6)OR\Y9&T/-]L M8MN<5P96W'SYXGS(;08&(8T81W!16Q[M QSJTX\M6,^\$XZW +D]74DZW2YC MMBAM*'\8+,?*XAUQ<:(=?Y\OW/7#A=5B,;E M',I5?*C[(MCW[?C*F1;RXBV2\EH90C$PNR/ ZD\+*O;!F'*SUE'^C+-8C4=1 M&6QY5EYFA^X<,I%Y&*:7%D]'_<#@&TA5=\80)TR%F&<_PB^)8IP]O"<9J+[6 M$D8:!)\_--F?3+#N'%'BGYN!V:]8L4$%)J3D.M_[FV,WZ86,= M!.6\=X3:[4X_ \)D[]8E$:?W/]E&"PYM@MH<-LX)M?)),Y-4;'V_^..(F9943M QX7];DK M!CKA:M2DAUDI,5XP,71Z6;M(4=?I%-'"HPV,^S>_:NRV /S6B?1;C&K]HW#! MT/>!V,_,P>' \AM# M%2BX@1_[[V66T9?7SGH/\^F#0:0^]#X".,CZUZIK.4_E, MA+P:7=Y.)I4T;FP=>JD^HS$U;B;!,Z%I M8/,/-ZT^9J^1,@E5H8XP.0="YG )]V3))_>![HQ8XU$-+M3[+?6>QM93Q@JW MC-WO^J@ET1>%L=J6'*,YHG_CD,Q!YGEJ=%&@LA%YV_K/V(>G&?Y%3Y329DRG M"-)\Z@]4N\(NMLL<6XSO86 @3Z8M*#HD6,Q&;0I7"L^*R,ZW,?+4])=E5_?Y M,O3&D<2:^HUTU<^X> M8DOM:0;\;H7I]X4./Q)FC80Z/<:>>7?P@CUO=(S?JC\NXS_.UR5\K21/=PLA,[O M2PFFNB_T^I&/]SHTIQ2A8E-W#BW^,#VADM+=#80J&B(>P$T.5GK:S>J]#9R= MA+/\:?\B,T>JV5/.#C8^R*3N4/NPA-H?S-'59F"S*%F?_BJ+M';I+=O8JG.(=+Q(+)V_G%)&900IY9(6+XL$.M7TD9+# M3V^O@'9S#)2.0^+8>^_);\<2,'0^' 5!O?6?D+O+#!7M;LA7D*):M+A%\"0$4 0J&;QL7\A:NM M+8>DU'FLRI^UT!*.82YO4Q%I4HX_9]T7( M\/2\D94]DN>\U?UXZ#^N,:H'3D4V_H[M*;]S7^:DPO$1.O'4?DK2@0KED$)]$HL:E&A^%BJL B[)*#LPZ&^U MN\=J")--$\VGTH)>KHB75WU]>K<-19B?R .4T J<66]C0S@^=67 Z[6>-17CZFYHFF\TE Z%U"+O_2C/H/ MHE\N:*7>;B;U61.^=62=-] %>M=/!OR]3IY$Z\+4Y!(M#JY('JN$&^('+C/W M@GTOE9_A@;/@J$=6&-$Y^9F3L9C"KLO#M#U.T/ M6>4:<_NW>W?4_G^7A_RW_!\K_\Z*(5;1GGOGA_7!5 MKLA(F1.+=^V7-ZGN. MTZ;#%X;,5'9UGW+(X(^;(V0"8>9D+?I)> M_F$F)>.=FV/]Q/-VR@&KCZA#C&;>TR0;EK0IL_4K_K9TZ,"2:OKKI@F2[8_R M0HE1Y><7E2R?6HY/@C_!UDH\:.?@/#7#Z[-)=)>/GICQ]9<&UX.:NCBOM)#GATZ!;O6&R1WJ/IE*R!5%8(#K=KY M-[F*Q0@VC"C--20Y -AR=I9P8R4VRF\V=>!(MH.\@7.S)3&UYFH$ MPT([HZ+23I?3U2NJCE#M+P0U'INA -]W13>\$Y/K=GJ)>P5TGW']XQ/V=*Z& MSY'WF,-72I/T%W1">FI_[0,KA2_",/H=_B^ZGLT]S0,5HF 5M9.V2I7KI^KJ MX[R"BI_&1?Y\V5:ZW6+7ZU"5O&O>C/ZI\/M[?X*MEQPL@O&E2,QU\C MR"C35W,XC4OQH]E?-(.YZUK/7M3@B@E.G0^:8MB$>FS'4L08KY20SI!HK1F! M%K).8-:NY4_HS2R3617[MNMNV:^P'.MWQ%EDNYT^.UQSK$[Q M%#8TH!M-4=.KS?V5(?][+\[_$^]UKM$$K6?!!<\?J[PXZM\E)&'M\"1P]+>6Q<IT=^B5O-ZMP->-C[V&CE\F]2TR=M)S'K:K@FXS6"#PYN MC:&UXT"ZD/S'EA],=D1#^#UJ;YV_]"[\)9O?WN<\$/]?! J_P7:X5B%]#ER2.TD3HTN3=#NC$Z@U29M<& MCU8<_&KUC>L?_'A#TZI^K[PZOM@J7'O"B(>DHV_*55EOT^\/R> M5,.(W64G-+HFXFRZZE,1JQFA.;$UX7:\:\KPP3<]CPG+)9GC(L$U@XD*NM;Y MOQXW#L9]9 U-VP<<6OB$A"J'5^+BLC]9G [\VG,!]1YNCL\]3L6*!C8;YKD' M;UL-+K1+E+B*]W51>^:/E[COGD0; G>&MQ/$>4<]GZW*AQQU6>;^:"9R'*"5 M 4L _=ST_R/[Z!X/[1;SJ[86\:9@%*8.?G=6^:A#X*--LU71%-"4C/FBYD"U M>-_3)2=VX:?6BJOW-NZ)TAP0PQP4/VJ(JWYJ,>@$=:/+^GD!U?6R\)E-RN5# M&4#$31^N=N'3UM)/)5E[FPUIO)"H9PL_-7#8\;GC"?<+SS;^A+M2 L/U#B^V M589T0&HLHELE[S%2.O:!^L6N%%['3?W!0OCE^)4;YRWZ1?EZC!<=C3LQ5-GB M=W,>K^$>-*-5+8R OJ0#ZC4EP-K'N,@]:/$+.D8UKW3)=U/,67(E!/(7,5V MN.*$W14]P&&>S5K^>:&YMTGT8=NIR<9$^0^WZUX[0;0_R:9Q+83I[@-=^P#I MNHZ%^!4GV&QN2JX WT.A]K."PMK4)H]YGO* M&^J'D@9^TK*H-010ET4 H/?7.$ @ZTT([1>L$%CY)]%D*;PPA6S/YF0/0H\S#*\')!7@+=G>$".;G M"4-?7[>H+^2(XVW?3._V1=Q]R@6D9FWWR;$N@+$'_&J2E$EY1\ZFUG3U5RS? MDTJ;5BQN&5*^):V:UR%@*YUJQK[G ^"/+1YJ#1W%X./V@>/%;\659\'Q"@1< M6N;320?-Z6G5TK=STA=6O^M8+[/SL\PA^3"N@71;F@(.+DQ::/(C3,+6Y-3E M%TO$= MT^Y-XM+-7.2;)O:8Z2;O[Q[;$?$ _=XG1AW2*Y=SQK[W(]6I2SLJ<44 9TV2 MBNHS)7CS\^0\O=2KF[/SQY><,%>,(050K'_JR^*HU\PPO.Y_-"IV<+$/7\P> M?:Y;E"X<)NML+BT F4Y*:0DQU!AUMK*R[.MDMW'F6;X$3LU2I@NR=OO3D'5, M@:7Q3OFF-;O"^HG%A9[?+X6)RQM0Z-\T$))EDBRE9UQCF@LN'D10]+A6:[^0 MA&(G-K_(Y/262U85$H"^0DGF!*+R-%#A&&ZZ*88&)>Q&USG2T*%HP_IL_Z"+ M4[&HX!H\.$K_,-6:LD&]HBN>'WB;^*W"CY%03WZ1F[Q/"7X3^#9[2"3O3?:; I)FM^*%KWNWEZ(HS_?XT0.H"L9V?98=2-[?!386U^P8VW1E7>**KPETVTUJA MNU(_*P"4;WSG].Q/]/O">O'D0K %$47BLYN@(!-F0"D(;TJ+G;Q73NL#!X2> M1\B 9:(8ZT#1=O%3[DCA!OJT'51[I6\9G?#APB_;'BB5639Q,+CJ<9_ MHZ+BU.#[N F,@)_.%30KT4[!E]!R8^*E].1.'F@(=9A^E83JLC\+TST[ZPGN MHJ2>J'9P&R<[]D1MLKC]"G\K,I6V(K1^*GPA2?85G]B3-K6Y2@ZX]5=H%8C. MMSY.T1RGFWW,%9L*;-VUJ4O^)CG2VGE,I7Q#IN3=&8JLT$4A8:&%9@CE ")$ M/( ;,0KTM5<1$-)X4JV:>VFW5ZK[C&3:K/0CZ>=.*@7&_&'%=QKP/HNZ]"[6 M[;)X^KT1)/X%LM8B>D?>J2BPLZ,>VFS+/9/]<<9P_CPDA*DW6JU-AA;GUBIW M(N.8"HS,'1A'(*C;QY9^R5,;B]7S,L-%Z$NB';M9EBS)%[+*WDQW3_ M43^==P(V#T1[37384?%(INP]AM8TP=CG/E@>I+4=_V@"! M9U0]9YN)K?[P?5YX4<1>-&OP<:XVR&LHJ1J#SX],J:)?V@[- PFOI8&^=ND7I=WPML0N)^ETW3#0D_>8D]D4VP,M"5_! M+:&S>I/9FW.11,B)V4!&T,U@"TL=Z[]MM%%A^T"M8/ODAJ #W(E\>I22'LI_ M]D$1SD/QPY>7\N(CAZ(D/>\JIOE<:MM!?<^=A#*Y["RA M8U?R?**S_R+Y@"M/S*($W%K923N4EEEQJY&K0T]N?_N,:7WS,.;D%Z!&I>VK M).C6I8U[K!4'UL($\HAQ2&\=1S4AN= M3'>$JP;6:-9/W;\/'S+%J;/L]+:!L9V$3.)%B:I]X BMB[MLH/ UV$ MPEKTEBWK*ZMS:T^%#OGO?%>]J$^FJ3-[]@%NC(N0'XQJL 8SIY17>>V(WU@< M?#?$)2\D>:XLHHM>IM9CVG9P6!+&!1>5R]OL*!NO>Y>TU6B#(T828)%\"V@? >B$O\UE9ZC%6S:U(K".)"51@3=7,VH>5P_J/L^Y M*^YT28@<8;GU:_PR=K<;EY2Q#P@@'P_&!.MUKS>)55&A;?Y()_NF;,]S9U4" M_-B."3NG/Y<6>B+8('3A)!&*%D@AX-BIQIU@=@3?P<^,.'FQBX9;"Q0U'L;7 M>^A=N#_]?<8N0M"U#SFARM,W/IY[E"E^X"+4D/8L-OT;J>]MC5T 2:_[ M!>R3HZ_G7^\JF .(<]01?"_Q,^W*%8^*P/(K9/_WC6<]C49HUTS4%^M2C0(Z MN=Q^F6XFLCEVA.QEGZ):RV=!,6!R' 8-BM,7-V,FD!9G<6]0U "(@F96 M-6@[VV5-*]E[F>+'SV(VBZ'S0@BX[L$$YBER3\$.L,2GSG+K\BO!LL=DL^V@4D&>DDE!T)CD@V/E:QPZU\8%AJ[,'J3G_WN MS; #E/Y?T='P9#O\$G67A"-M=]B'@^]SP M7O)1YA$RZ6A[ZY-@C9G/<_;1>*2S^P"_?W,88R (36&"(,X9"A9,ND+0EW;.D!O]F TDFBPN?2"VC-X MO6$?L/JC%[^4\5HO8REN4[]:!O<=H0NYC?NG,Q1X@C.0#M>-#G**6B5Y M?-45S+KV^!;4<45T[MP'GM@#Y.]AAO8R1JHYOWZYA#UO+[,QQ;(5BGJ1,6E#>/DIHUT:@ M7(L'_TY$@QBH7/J\S'Q%F(!L+*&P_>4FRA78HZ^=&J*K&B]:JKX52XQ%Y%M->VQ]'[P>]ZU MOWNL-?8?17$65&3!GF_@9*_=XO/B>]=%''B6?_ M33:/2T^IYI9<8X#?A^F* M$GK79$F"!&CZF>>D?L.,%=V33:/O/8WNXV:XGT+=]X$ B='UC/I/$_:][,TJ M[6P>=:>>7RX+_P%<.%3T/V%*R)XTY?7!JKK23S/R6\?+)@X@1@?7'%-.S%']"(?D K2-;23G0]LE@1BJ2I'1AG:/-1,M]:EG*WC@;I>"O5@FAB M9E9T8Z9PD^3*:.D[;^H-S=LTJN[YLB(N]." VDC$M"HPBO8!?#KF"%,KM-R: M5&M&FNOV<6$.%5WBCMK8!\P]??A=:4.O='_'Y(&J:]_9]=X;\:SC5MW$W?ST MV4!&T"KM8]6UV +Y#U+A.X-1O?IBV#X!F M>+VW/K1'3Q:;Q%])/BZ_#IDH8!X9)8W,+DX\0TJ\IVN1U;,MS0.4&*H!NBZN M;9LUX[QA'*PA(@"M.CX>NR#:'UBI.&^*3V=+[1<];'U+58BGG2W@@]L_.Z+X MW_*O%[G]M[W>XA'*;:IT2(7]5_X!M =HAY-[Q2[KJ:P-%)GWY ;K M5@_L0BXAB7#T"^"BRY,V>H+'XY'X#^#Z MHM8WA2W=F=%23MSY+GO/!D[),N8[E2U4+_M&COZ^^AUHXZA"MI_!N(1@XG+4 M6ZA[8X[@CDT9L* M3WCH[*L1#;,&Q)!GL?UDOZ^O0M Y4>?'_A_.M:FELWT ?EMR5 ]!LW,.#$[$ M9.!1LUZ>]<*KU&%.2FC\[& ^M?L+4HQJ7 MJ-]3&JME__E,1]&47_O:BJ@7^+U$LCC(T#7T;-[:;855#*BY,@-%EC7M$[C-DO M+JXOSOH[9EO_%CK.K&699 [C2+>@T> :Y42E9NERXX^!"=V:5053[G\T&D_6 M*^4/N:09&[(5R#\(.,'YY>0F- Z#1V/KOE?!P#$(?KNBE*S\F(*RYIKOGW_+ M)6MP]N8=V+*4:[38V.N(+KO'.@PMW67EKS(5!]Z][RQ]WS>55>3 MWY8F=^_N'E'+VH"ST'3HRE0KLBE!.98I]D/I(0WM'_S$S)O:CPZBFP/>X+I$ MJ #\ 4T#BFG'0$S)H[_]1PH/7XT@2CT4<2L(D+IE>5S51/<\FZ;\EF8ODRN% M=@<.:XRGS1YOXDYXV= _B^,Q+;W!4)TX?*G216A185XK@/5]:C\Q^32O);6^A%/;$A37,7] M>]7?"/P(V7@@)WX+PH,8R>74/9WZ$7Z3A,B5W 0^;"DZ.; ER M/5B'8G -+&:7"W':?J9/V[C$?3= IQ')>]4:XZ,M,?Z%K2?;#7>-,1NN5_Y88Q%'R?YOYO8!CJ6<,T.N6MKZ-2['\UU5 M;A41TEGS);=U;)X&6QX>X+>>0W>E_$V7#2@-I-T;J@6S#Q#F7(,4CA;_HCXT M^TRXXQ1&/-6Z,!EA X L 746&I\AXBRJ"W1P2I<7.[I+U)+1$RWP0D>9XVN" M.!+U9 1#2-L'8,IQ;U?M,/&$^I?U%7/.FVVZX&G%_I-BQY(*=/WR0-B,^_&V M<7=997(BJOAZ]45?WHJ]87'"'59J'G[R_4R/"WP;FUT=+!%9A[BX#W3F0]Q0 M N8@VT%;R5XNNXVXFDGAI/4H<)NC46MY#E3:KK MJUKCY[\GL&UXUPG;[WH1-/6-.=XU2P1;O3FNT0\ZMH3^TUH>=#RWZ)?! MZ='1Z4[V9*%4,YTJ/0!("RW;<:)V=@1#4W1E/U(][.MICU(^V@X\"((UH-X< M*[TY+IV:[O3EP%;TV970#XBP]\A$E(3A&O](FICAUP_C4P0LH(08Q).L$/*/^#T]DG3;/L!:I\=A3%[LR.6D:F+' MUG$,/ML?M2%NLEBC,:/4$]J?YFUM?HM%?O?XY<8ZAZ*>ZWYOQ^Q3HV:)=5<$ M.CF.^#DJ+9MPL[>]9RH_8!5Q3'M49TS+;>+<6 WC]U53A/SV/'_&TR.;BE MZPU8=>Q==V6.4G:27[H4;0A8^5/"R4U?GM_VUW9ES2D.@P@A"3M(T7U@R8J* M/'B;JQO,ZP5,L#49PXR&Q1X0%J76O^,K&!\.\*WPD[\#@R""O">4FD_B/Q8& MC3E_]4.3N%KX ." .L2HQ3QNP#A#HL:8RK#CYK,AY0-&>JK8 5>:KH=TK_1& MFGE%]"&U-F&9\%Z9$*)K8&1GED6"^N=G S"SZK%G$R:JMBL"R[K*D:FOGAJT M ]O$2^!,$1A=\)SAYK@E51.U!=^<#'Q1*3@A\O/W/M!67CJ"Q*.9H%<@-%UY MC)A,!]<\MAS8) ^>>[LSMX-"^RE/6./KJQ9$<5$(CH8T0^PP.M93]UO(^11I MDD;_"O03;&VO+$,-?IJ$]3*/71OK.7YQ>3Z]?1%E!^SU_U78<;A8NCVQ%43N MKG$]^AL[T:>RXNO30$_RTX20;& 3S UD%E.N>C(QZ(^)3N/VA/2SW5Z[#0W0 MWYDI@Q\TE_6%K_"Q8[E;4:6&*7#%-C:&H<\NCF0*GA@FONC.\Q"P#X[3>/-] MHW(35P2$6+2!L9.$ *(ZMA *HE_U,VM1N;F^MJYXNCY+_>'EU@E^+X<(U<_M MJXF)M).!RFL#-'ZZ)N/E>EW3(%O[!_/2QTNI#O<>CU\.8C,QY2D>O7OWZ]#\8C5Y3": YVU&M/'5ZP*0D*!5)/)*Q:T74 M^[BJU&%ZI*T@4F@O["*'T&RK^"@2'Y\K6+MWM5$KB0[V'ZK_[;[05(^XR.89 M3O+=H/[@6.L^247M \?G&9^:!3>7]$\%'-%,64,*? 7:+T)""^:DF-(XP&TX(V_SSK!2-!O$#)3["W-RF&Y[NM;U MXF@S?XS:%]G=\B>%R9=H4ZYBUDNH-1"Y?]:U%Q,YGH7KV@>.(3L@Y78KRNZ> M3Q5^UPJ2HFXO[%E\Z50[Z[)G>CN,4YUENX7?N@]:BZ'S1Q)*UM#DD<>9@5QZ' MZY)4<<483Q'6#WY,&[L897Y%BGERI].W-Y=:7GN#&_],\.^;7@ FA:EC%S>L%/G):0YY:6_J=!_DY] M/40WD@OC#N-U_W, NYX=3;*X6U4K<'[*H-0"%G>E)EI>-.SI]\4+@P/;*-5] M(-:".8#9EGL,INHT[0-SZ11V?A;R/D#71OZ=Y9-_Q?* ET[C]@&QBMS#?RGJ M@:W;8*$V&9*54@DZO^H\)3;E:1=EQI2F;[F]U7URYVMDC.73P N+IUI+_H.4 M_VRU2971]S4>?I/@2Z#B@#]>/DM+4K[P7?\ M*; &C^X>Y*7KDV#AM=1U]8NM_4HELVKR;]Z6>I([$E]?%CKY\]Q.=;M MO@^/_XSE$FB"+:/*Q&>3%YB,[O\[I?!O]5Y,'.,SQEWS**$?>1*[7/,TB3 M MY#[6G_LG1*X0H3I*!#.Y[&EF\(<_3_ULE:1&])J]VMP*?&G_\E83L-.;N1 1 MFI!2 2!2_[:+C(A #.9RTW_^;)5UV]WE(?]V<]DYH\B8FBPOA=Q2F6D-)LO2 M!4H(1KD5]MBE&1ZR$>K!0ID#]-L+>_;KF^1BBFO;VJ2:P\8_^B=I1:[I?M;U M((O:C667&[RW,WSXAKF^K#MKW,K/D%_&Q"!)-U 3-(+C? 4EF\0)&[VD@E G21\V(>Z/TV;G5-'I@Z\CTRS M[#[ =I5\>J%()D>16E",M=M0W =XW^G;OW&16#!*E(*0SOTQ(RS2>?GPLI&) MMU:ML(M)E8(+,*+GU<[C&\YHGKGWJK:!SJD\! 0 M-?B.D*"F]C/3 ^@6[-CTBV%:R?Q?QY4/B?;KA!H->]@W2#?6O3GFTZG*87SK M_-U7) /Q)+@4S1S9+H,0AUO95[@2?GX@K78-9M(43*#7&F!&4;[' Q<@KWPW M^:#!0Y? ,=K@KESL_\7>>X8UU77MHD%0I$:DUZB@J(!([P1%FJA@16I40)J M2 L8$A#I34!!:0$!$04B76KH1:0WJ4E I).$$A:0A W//OO/.>?;W_N=<_9^ MWG-=SX_[S[K6NC*SYEQCWF/,,<:-HK-\F#%4='4>F($=+VLQR%O2P"A:-@ZE M.KVE+W;,L]X/O>*E);5I2WG\EU[.!=K'^LZ<:1M4$]OLA>?87[M#/\ZD][J\ MC#UYRR/$-=:S*>UI?399,E01)>CHZZ]DRU^Y/AN M))5 .U3>BO6'A.M-UY!L[\# SLSR*J'E1N8KO[4\V-MEN3;-)JNT3$V9%V-X M@3!2%V68]A'ZZ, GU,7'15@H9Q4Z^ORZWTF2KNJ@C1OLW MZ''S#_XM>@CQ;A!7Z_;N_D+^@!YUK]4I9*=?&/)]N* L_VBG\BQJ1'X[]I1O MI>UZT14/'8@ JM$*Z])YZ5PFBG_(CX<>>E#'3 ELJU&M4)"Z.MJ%( MQK)C,%.@EWQF;Q;7PI-ZYULQ-B% CEC2_7G)ODNKLW?ZX?L$L-_Q?5"&G=GR M_X.*?C/)V=XH&Q8 YD1!"\!KKI%:-'PO#&-F*F7I"SY'X[YUJQ#0K1AFA!UI M;SGC.%DT+,+K\Q\7AZIOR?XY7QC.-W])DT_CZ@N>#E1?DEI'S\Y3^2Q;ZL7( MH5@"E@$!_59"_UF7TN L)I%D;A^?_2*DOA>2/)<6O)[\S'?S,]8>-LY,Z0>F MR!--ZAG9MOF0,$P A((9WSQ?X-5H=^O:5$^>HK6G8Z]GG-9%!B<%#&\ :X!09<#%LA']S8 M'0OFM08JUK0KZ*+?_$HWDV[&0QJ732@+M+#VU0]Y<'U5JKW*ZR($5'%%Q9Q6 MQ#+[7A\BMQ,1!I-V?;;]R/^WWV%:E+AL(X[#[PZ09TGFCRXR$YYQ&FD;QN*Y MXBZC<..@70P!O'HTBXH"I+5/ ZP#&[3?U1L'YN1:>Y ?7CW\!OC MZ?!FQA1J 9EY56OO!0(Q*EM&Y'2TD231*M,Z1FP@I#V+L\6=.T)+UZ9SO'9R M> ]X#VF>4!F*Y (T3$B8X,V7 &6D=*@ M*?,?W KOWD7Z(/((,,4/1ESH4:V+/4 MJ#5AY=D_JKM02O*!V49196E?:EURX5];!Y:3A.I"/IH[1)XVT6+\XSSX##LH5SK,@'[E@+E\.I^L*BF(K1A]+D4C@G16[3*O%.N".) NA6U&=^7>&H]B7(RR?_,G4&LI$C X MX/?FLD$I(*_^%<3=&;_B=:5/&6^NW7I9-B .;N3P[UUQV/. ^U(Z*LG7%[7% MAC354)E&X'1WOS,_$_0N[8-DAH?85=92+QJ(/*I4!>T^B)0B0('SZ";<>-0, M-)*J &F4,;L3W"1NXEC.=E/8,NKZ>VM!8<\?J])/#7\^O8T(VT<3J83B/PN.2,TC@,WMZRRQM=V-59X,*-LXJ.]2A1N0,7 MW&F?M2DF0(#3,2LZ3"?A*0(_HJ('?O&$-K3 MIIT ^\5,@9,\=!^3T#K?)P;W'J@,::G3LG)Z;]'I90S]R!^HLOOH52.2@S%Y M*R/"DT LOZE4-A[0DN$8:SCA\BS9>2=B8<) 38#)##,L"KXZB%#(&5_TUT:[ MY"PFY<]-C#UL^-;,N@_RYM*Y+]9P?PE$Q=**D2#Z&(Y'6PL>#BB8#_P3J=SP3_ ',>W,KIGM.\C..7P;<_]%IER>V%S?J- M0IJ0BVNJRS9Y!W[2&723L6AA(;RY3:@L&'"=JZB(WEK23':_%:V.Y-T5U ,A M$@GNP%G4"H'PX6,*[*C5LJ=^X[ORFQ:+HZ>VKWGKB_W,,1NN=DMU^KA8D8)$ MNW#$A.08':TK+'NBFA5S[^+'\X1[(!!CX%'S_\!?B(6+5X<:/HVQ#]4[3^[( M>O/Y!^-_0S4^H*O;%21 MI,A?/HY_%9.V 7MZ6T?L)93 MT\D>_I-!4E!24+M\Y9XII"HW4DTO#K0I%9/3#7=T>05_\ZH)MCH=2G-:DS[1;GL3CP*E!O%A,HX5HQ[Y MV^<>3D#TJ%*K*&$$&^!!OOC'&,T'9VZVD:B)OUK>DY_3Z*$,:J#-9CT.-!30 M-(N%H^DL7_=4@,^EO:2!@3;;CD3C^NJRB5[[6%-L2M\Q:,@!?\['E:(BE OJ M5=#7/E3K?7%2,5H>'E"^,ECCR[M7BA0 7 MBI1!177I@+0KT:U^ZB4[B\BVY1&_@:,,:,?%Q,0X?U"5WIV1VY%98)=>>!3H\C\T_R3LXR3H[]SXZA\N+9=9/&+E/:F*3Y+NP]O+1I16K7D M0)S'U+O&QWWIP1G-N2!D[6U8"OU0U6T:SKWPN5JN@?7 MLM.?OYQCX6$H_-_">9\?[+.92 $JU.Q@_2?.0$(V56R*85!,6 #)9@N-F^MM M)7H>* \TQ=#K#O*S(R/%(A)(I;/TDD=_$J.&L@% 8FUV=44T 8F&E9FT!P7R*>ZVB!QT4E[,3HCU9AA1G'::ET7H3*KVD!P)N0SF^,Y];; MH@T@9=,?1+T51V?9!^T]0:#LD]O]RZ?*:Z./NPO"/Q3Q@&_SN"I@A\)A)VS9I/8NCIW6Y1]X\]IB'S90> MB#=9)<3+,N:QMY_72Q8E>Y#,QL3I-(8^%KF:N$+GOU^']! BR2VXU].<0#?A M0ZW6K#OG+WBB83)T8;O83:Y"KEY%P!%'RSD=5HA\1!^ D0SJ7C8EWP'0^*?E MRCE)1,IK$B7[^9FZH* .Y5%-J3<>@7L"MD0YS,B!U2=GXU6HO-PS[2N+,V#@ MJK;R0DIR1(&TU16UH2?*NW/AV[)QT%B/GDGL%?CUKWMN[ DJ/#!RDE%"1X\ #D)$4,(C6Q!N9V2 MF+IX1Z*[.8N?IK>\R=N=:V=J3V_6B-<#(0=NP]X=VB6D\+]P;+YF$&38_#9YGT0%T+-"0/ S(M'-RW+IS@H M:/4N[MWH?'SL:[$K^$!'QA?_!N(2_^!_#?Y%T0[V?= )(/@6*2/X\[)%ZV]U MG\0\RTY?7U\-U_]^-KP)XH:%B\F,U!YL'4=OT//M.P8V MWT_Z)7/6:8ZQ,(M.S=Y8-36H1C6:8UW&J+I?)!MD&4W.#OKU0[B,'9*=_D@( M/#,3?3YAWC#OT[I4 !XY<(Q,T&-BX#$8?LCHRQ5A.+&%05:IJHWE-7['YPNJ MYH1MFK>/YZ :)>_P>9H/U(0D-4GY85))][JVXRZ5U9684+0$^C4^I66T)Y@ M))EHN?FOY&RV(XR 5KQ[=V,@A(;RHGO@[K43S]=;^SB&5>( MAR4][:5LT?+-!]R!FP5>8^^_%N0B-!SO]F'6$*T0?4G1;A!RW*P36Q9'Y:DA MJ*Q,S70167"7"F?<><8NTCXVZP6Q^ZPU/S>RCQ^^TL@4,JFOK^\2=\!C/.DM MV!-8^_2[K?[$V-J[#G[*=>XBJ%_5KBVE;1)F4_,_U[ZP!]KK]\%]=KX.TR4. M:!Q4FQEA!63YS>)XX7I;,B\V3U?K83/87H;=9RW1]*B>J_@2'!P<>T5-D8%\ M+NM@\K^1'U3.=&L/-N%8"BS:7%Y'K?BJK$].6\T%3@C&\$AE!+HB#9=A[O0) M'"?] M6*AG[:3S_IH@#W;96W;O30E/*E&!45^GQ+^'7C^/J$ISCW]R/B4FE* M_K[-N" 4)YV[+0)/9'+4%K871JQJF$1>2*WL/F6]$O KT?KMZ AE0Y>]M)5G M\.29F,EC".]QL)5#.0BI!0?3CS>2=5M'H>[D[=@R=\ZR><3'7\9?K!-Q2$19 M[WDJDTC#BZ=7(>W-1_OQ;L<[,^,%!) *W/TJ;]<,?AG M'V1V+BJS*-U-8?&%[=V=3AU(^8:):(&L](#T[5.3 QI'[XOE9+R;$U.@%=:S M(:#32L1(;;[2#\T]X/M*-SG:8[<^K[*) M_C'AAR<9+_+CN 1[3(9>SM2Y-T))NH-[50@8V11,''=,,5E/,8)2TD$!Q:1$ MR@H@2>Z:.0E(-2+EZ,.COV.-'H4:LZ5Z?S]>DZ8_T)85^5E2U/".OD[WRU5$ MZ9[*855@_4GZSWKY(/-P'.8N2YA?+T&Y2 ME+9($/5)'PH?"Q/1M/>C$/GAV.84JP3(M)''2X\ [^7$<$H&=F.@+KL12[H& M8;/8<9W!1NRVY??5^BNG\R9IZ3@)/:/YT'EW70Y@DEU6+'#S=E?"@*?0^=K7WBT8SQ7X[Y_S@3_!/.@&L%>&C&KA-[(\9"( MI>*EE&N^:LN-=DF:/O-."_#Y<*S#X0O%M(!?[8/$:B&S)H"YD-& E]9UJ;%8 M- ]YRJHE)BG82?AJAWQ,,E1*A3D7^?' 9ONA5M5F>_FI<@#'+(0'#KYRX,0D MMZ:X?NRR_;1CR >%&=D*.:C[^OH1C M19SVD I8G.W/C+Q[X =RZ2++&#:80U'X4AS3EFO^EP6D;%\N_5S"#Y89R-5$ M/NAVMS\Z#(7/@Y6ZAU/.4/7B;GW SF5D?[*Y$O?U?05J=MBX!4LRAH[5M.AE M0!EO9M^8LAOT=BG;7(@1/[4X]C)E'<>%:N2E$29Z"7_&9TX# M KQ8\A)H3XJ ;8\+@PF(P:G4()>A M/NH+XZ=WHD@W<&#Z#RQO+GD8&U,N>]*Z,*W"9Z1D_&R91\3QR9[[$W[CEYD9 M);7?[UT-9)7Z(PN?6EG"6UD:6=^)N?H^=7C>VCHF[9&#? M *Y\?D<@VJ<#FF%,=J>S_7?CUI:!1<;)^WW 53^69G M9.IQJYBP#'[L8LT*M]7X?)%'U5R[>UX="-G2#TL6XJ?R"]]*?+(,/5Y4&-[@ M).T]EZKYXFH92^Q+-ZC%'B-%GU91*[CWV-REO=G?[>O')0M(@OLS;\/!M:X: MV[:%GX(OHM4:!18[,L%9"Q]KEV=&5\$D'-[8*6H6=]B3-/'.4[[X:3792Y-N MC[ZPC,O+MSRR\]01B]*#5\3O.2..CC2EHJ*F.>.>2P24FH5.9+5KNUR"%OJD MF+01PRPHQS[,$MF6)%;;QY12G9#;4WM%_I2M3,Z1R%<]NQ.WPWK*OD_6KIF,*9RI6RM+M8\5%61\OXI XK M@[0AZ*0.)F%E'_0,' L1NU:)9:AG;9=\7?_8=:97S)H6RS;)&!HY96[])B.Z MJ&%3X^8#8"P'/-Y,P?713SA'.P"NI&WCN!;ZJ<&2J\[\ZR=D,A.'KQH)SV;= M/;\FM?K2Q?'9ZDQE9<2I5Q)<[3S.O+=U&DR900SC@=J*6%HVU!D6_#S=;,:] MD8._M5[P-;H"1E7#^GZOT+EEQS=04QOLKKJCTW@VJ3X>$"L3!Q3UE-Z3HP=GM(/[^:5I9P^3[D MC@L>+;HLQDM[>_"M[8.8@>:FE#^)3OC>B$'ML)DIL8%UN:,568V5=78)[.!-]6XS6!B[/ M8GI-K_5XQ/J!]EA!-/!'[$4E(G!)X]V%C]13]]T&8S[3M445(WU-KX867E*7*;:+MFW,_[O9'U;-^!&%)O*Y*W;#BO MK\B[\-*\2=3=BMX/S@-M'1("I]*XTXZ OR_#DFP@?_4FK/ACY8+F\;)6UT2G MF@R>JU%=>4[DW\@$5R.,#B@@#RVM5JIF%1L"=?CR&M#[J3I6 <&G>S-_= M!SUM='?(P.+,Z[#BR^T%@ .=179/;4&ZT(\P9=ERUF\?%)%1K!X\^OEUFT9< MQ\O?C//[('Y4X_,R@-I!E25]^C.O-N;Q=9F-4XLE5C45NOV+ZN)+@1[\A0S$ M#5H.U#%&N%&%SM!_MSGEU<^GWP=.SJ[RL<;71-C%_[:[\(Y5?[CS<7#:A3W^ M)E0QNJ&7Z;6Z65,9Q!06MLT9?Z->@W%A]$EJL]/7P"RSZR!U@-:A%X;RW5WD8 M-C#!*'P&JK0RB"(,":G66HF*KB^Q'_+EFBQLKMY8.*;U=:)6#H_B ,Y-K-!% M2?3D3,M9L0?)]J(EMH/',Q_,_1LH,?_/P; ANWJPR3/M &9[)@:>GW&+.%(T MO+51:N:FD))1CAO.,6ZM1]VN L+(,()5U#0C&?Q59^4$?)QMH?,/77*C2MB) MN6%R\K\/7C(5.SI7ZM"E.NL9R_980C*%UOGI)KOOB4Z>XH)BPUP;%=#7"P*G M@H=,F1O1):-4WKP&*!^],PMA& L.R[B .%6;<-7KZZR]WV28 MWQ5-7]-V17GI;QU9 X:_Y$OBWUP1O<)+0J_>/!AS*A! #EY-(3:WAQ%PD;]_ MADX+= X4I6V$AOB]1A/U&N9_V\*X 8-9AU6I0X).OB![EC0[#E''5ULEA2!M>!JE%=WD8^8W]GL7OK__M"MG_PMT.SN0&Z;HF\N ^:/%@X M1BEUVK7_ERN!K#N)%(!6Y JUAP276C\TYJE7&VD>=WP0R^B*0&Q?JALX=67^ M*X_-ZW@B]$1M0!95AJ1?/H,[B3N7GN7$U^WM_9SV[B4#]48[ZQ/L4MF?7KD2]O)(7&IB+EZ2MLD3]J?F]V-.B;+>D_A M#LW^L&"$QB='];-OU=WB/TVT.SDY'%DU?*+'^H4Y$_0@_3_(78&=I#H=-M5" M" ,F,QQF.H.NWEC!974OHHL*Y1D+;^8[%C.8^@.FP(:8']&.A#7V[#W MV.-8/,;F/-!(WFB,18/43AV/** M2&BIU^A3>HC0);PK3=F25:S@9DDXU=ID^_5(=,TM3GU.J?4N I'*I=%F41;E M/4L,3[D578#H/-5?^!O[KK3SF)%F[H/M9G!A0"NIL@4"PCZ!A%B@ MM;5CE[ MQEM_)\%6;SYAD77XT+,HTA+F:_/C.R,C1H*1 U'D\SW0>'T"T.Y@W01.+]1 M_YD47=&RE,#$VW4>Z+*_.91OLWE&J#NV;M@3B1; %D'JL&-+\ M,LJH?ERI^Z*,]BD?N< )@[ELO@WE5PTG[OK,W!JT3CJ,#IVC)6IS3-ITX[ME M5[<3:Q17"1#VW*P/G5T*FA]!8UJW;OEOV.C.Q@&7V&U_1C7N@]@$JW8N;77? M _<(9$-WY0.U0VDE*'SJKN^J-UE#G_QV6K.6U)+D[^]4R>>2%U66I!@_=V] M&>^W_JC8/R4<7RS;(M\G>KI*?VVJNAG]0Y7](4@N$K169BW4W%RME_0NU_Q* MGE.2:6Y=>7K!$]6L"-#]:[>;/H- S#?,NM'\*'S. >?F@ ??Z5,RX37YZC+^ MK-?=-V^A0GY24?Y"\^E$-C[\%2;WCE/!D;NOZF7)LM23,+Q#E/:999M+0Y8M M/;OEORL'%^66C$13.L7Y MY'_0052XH];GNN.A.HZ=F&(UD260>&+L&7@%A="'ERR:5?L@\9\5]3U@?FA2STH MG,]=P "6@SQ."T(Y](;1;P]J\RZ8R1MT)#Z,V3K7B]DU-NI=7XW?'QDBX9@7 M9I>/8(-ZGXW>)V'I+/SD&@MR1MP,5!@^>)VT;#G5ZB'3HK)AL^2Q\GSL*L^Y M-55M!^846L1A]L/,M-1GB5?P 4>[.W$BD8+FAHU,8IFQPV=Y&+K@Q@2S5[5' M6@^H#(VY.=I89%'=CB]/,I\V'ENEMCMZ]^^G*?]EF$$Q"&U29:0ORA7N8C"\ M[> [L7(&K;:<_L,?C[S?=UM'3 .#;(9J0@UB3+G M'#1BU("4B(EU]XX((M_LKW(5G#5^'D\YI4MC2.=I#= M*$H/Q'O HOSVF !92L.0HK69U8B2*Z/E@.OT@'"=8K;$FU*W"0FW/-4GAH=9 M7FJSD)NW=2#)XY74$_/Z[[$4A]:)Y2OQE:O^K"9!L5=03VZTG MYO=49C[%^\BC9I>-DC@U L8@F$4BK,C+E'EF:YO*93 K\>)\*3DLR"%.I&S; M-_Y$P&49R[BVS$0ZB\J>\6+LS;P(*O1TI5I$8?G>VQY<3:F75&RP8#L!5LYC MRMR#_A;7B(Z 'J$S[X.:M,BZ+5A2O$N)L_R49=[X],K#B1)]/@:IZ,J>$FWF M'^SOQFC=8725 )]@L@('* ]]_JQ@O\2UJ)1[PO1,Z5)")W.NYL_1S MKMK;ND9G_CDF%3K[&+UE"EWG0 X?_.5([#B$9-HM19-U:&%>WYF@P!UZW:O* M*[TW%;%_]:U!;\R3&?=!+!THH!4YU'_PQ#)9DLXJ])/' KX/DIA%H-J[W"F>Z6U, 1:9 N+!X;;#'@AY!'/@V._=LZ3WF1#85N_:#-1?A(<9"WU((+9&7E+2>%@J]&?1 MX?$%O9C JW/O;#5!4L-F=!;L'LRE!-72W-+(\8.^0ZPUETXW.$U)DAR,IM_? M-=JS0O[<1HLJHL% 6.-N PG3"F6>3-T'<2RGO>;TJ)]^QO@^9YP!/RO*FO1@ MO9N1SBK'WWPT3H>6KI/)]\-;3/N/K,3^,?P;)1'X^]5:SQX5I&! M_ Y#Y0,/Y5;%@:XDWT) M#LU?<2*+_NAP30]XOT!9C9&$>D"!CE+K(+.]])>:R+AD9-N"4!:P]>FRP[8$8 M=(2N3'6J+J\'"C&6;!JNRIV5%G!DLQK?MW5](O&R)%#_]-)* ^0J58/T#,*) MA N34F59OPCXV(?7#\9>'M-Y'YX'&'+.;_7,*OVCHIXY)!\39E\XD<7<&>RYF^$B/O_GYS]O\6#R QFF#" M 2N9%JXE[8,B%5UD7NK56)<^Q#65M-'#F+-$KX@$=YRI/$SFPXP'TX]O>]IZ M0".UF9QOE>A/PTD5N9X5UQZ]T.YZT?Y9M>F'_F63#WUF:,31 W*8CC"CI=0> M^)#')=LYN.^3SZ&?S C>R@D5=6L-\-76),<:O/<5^6T4S4I+PD@#6WMR5#5: MKJ86[=TL%JS[N=;YP>B=L&VSBM?;D8\W&#)\TO+7/@7*(KAI69H,>[IP>^]> M!B!VU*+25+O_69Y]=S:$D,*]<7IYZ-'LJ?AN?QFD#-7U8!!>""?:&^J-:6U MJ7 I0WR@P"A!HYNGS*(\+>!Z%^L^J.@6Z*S*,5"2'N\*K*27RG=N8*<0H49N M:W :->>2C=S\#DYH_^3F.OI6N_"$N.3:><%,\-!%*=EF[0O]5*I>W/V:?VHD]V_7&/L'_U587:2ZDVZ@!2 $Y^5'P*KB/FCU MP0"R6X7ZTHZ#[M8KFP^YM#H]Q##U'X5+_H@Q[(,2)LAF= )L]\;PXM;_Z<*& M 95GFS*T#PI%D<#44\B3V/7Z4T#"9&@&7_.BS\UW3B5JYA#V_,G'J:>^_&:< MST?V8WD5B4%HCNCJBIC'GW,+&[YI8,NWKD[P*;5/QY[3,'BR%W?: M='0A;\5R3\8)51+7& 7F:#E313Z[-M'M>R?:895?ST]/"_&]O2,[EN'9D6[8 M^7U0HR3T"1;0]5+55H+WM M1\EG$1$N_FZ0,#+<)+03WSS&S+0I*HA7B!E+^ MC[!W9FU]Y:"K?55-AI2E8^CBN0]-9\!W3$"F3)MFP0"1L@(PDJ9M..?)A99_EJD:%\8616Z;^0M%:"MFA7#TOB\Q+!$F5GU MUT78.#.=Q9@ &V>0.??:U>OC7 O\7M@L/JC(%_]PFT^^OV?%Y\(]V-OL M1_/, HR=4.>X7]@F5'%O4QU_*^PX7<"(S-;*\L6 HZUP1NY2T8C-:]&MD[.^'=HS6[]'PQ#7@+$] M9DO$U1&$N1,)URJF-NPM'%;K O^9E/+H0^R?Q\(_7Q^32,\5U+\%PIL5 ++T MXT&$KS 9JC49>G]HYRBAWVNA@*01N*Y8M;L*N;Z-.Y0#NXAR,&'V<_<@:."X M)_5?2(YL&:$W#%-4>V<^!1[J]"(0_@",/-]D_ZK<''TI(2%BV2LF7* M^$K#7JR7.49+< HB'[$AOHN#S-[ (?3CJ*\WYSIG(9'*#^#B 15AG[3:B*9G MWPU"MALQ(Q;G&0DX)E2C6/T1N(.MB]0,E+^ST7NH''I&8>5H=4L#JB%B&Y-) MY=H[1>4!O,O+P"%T@?)TY.K/<2]?!>V?O&UP(L? M0;PZ"R#1H]I_?Q^A_ZWXO"8S4Q-"R)!(D11P_&WZH[DO>"3G8Z#4V"^+Q6\[ M#Y+ZQEO3IZW.@+-_#S;'3/[",\PVM 0>['U+ >9J3]@F+3Z9+)]X==#N7VKAQ2\7&(JRF MC[C3%#&KNFXG'NL#-8TV4-J>7\'L@XX: B[D!0O'C(MPNA@P<.-4^= YR.,: M)/K[=U50(O6DJV8@VQ:FI%Q4??#AM^_%V/)0RH\_RI$O7<);XG]$7_[Q0U^ MJ_$85A/JC 8D("$(/TKO"<2IJK#&E.6G!GUN4:+R^%U]'1DWHQ4521U>9D6& M73D]Y.D#:U.,=80"D@<\-9,DV9)^,F-D^O] &.CJ+ M#V3HQ SAQK"4#L!V[[:3E.QKI?(HB]C+VS:0(0\.&C9_?2."!X64[^KH9(X$ M47;_[MGZ!_\RM#D.X\[T06U)0)A4V:PM2 K-4H[Y"J]_^19]M_Q):;/+D?8_ M$L_4]'TRY+Z?T'G 6&0P'Q"VHCL;8#D302J,"^?;;EO%WR-/2H%\_')=BZ1' M;H[)\SYC4>=O6-PP6TJF\IA1=+"T@GKNQ7[X"\?3Y.0PR03BC=A%BH%7;.!- M-\N/_&."[/ ?H.1]@8\IR#A%-K M\)G6BRH7E1^+\)L> YT"@:!F6'R&RCY(1!PP?IF%<.]7DI(Q-DKGOCZLY)1@ MG#KQE%GJG.C[LF??)P$)]:U&I5ETI225E[EY'P16G/)L@+"ZP:S(RXHI 2.% M(C=DRI*9>JUT;(*PRUK MSC^WQ2<47MWN;Q"S$5,+0 0L,01]#R)!=VBT>1.XF1V^Y*CRL M3[88SN'N8C3AZ5D^@I?0G9=Z9]T*EW9DG(T#SC#R T'DV^^3;#^9GS2YNSBSD$N+2..[?03W]/TI(U-!]]P9;O>V)%8^5:P@TQS@:PQ>%^ M'K /$M]NA>X=,TA;V-V^IB[ M( ?NF6UO++J\O6G*8381H#N5WT]:LE9FV\L?7Z/-]'Z84Z=^>]48#YJ]J,\# M 96/0#]>UFJ/!2PK)_6\C3Y-T'N5Y[:^=*.<43U*S6YP1GFD6* M3YXP^2&%@^)3E/O'Z0>OEVU T]7%I9,3!%& 6Y/R"E/B_'\ MV&EKZ+U*NUNO+NN" DJB=DV9,^GC:(BV!'T86OX#V8OEW.KTLCXV>)?>+C?1 M0Y(9'KB@HF"ECFA3+3[U2UZ.2U5B-!6^?07HW0EQ="YC;5GEC^VGY@: M=58X0Q>^9SM>MQL(58/B\P ?UHH.)_>24(0:B_I<6T*,]N)\763K MO0[)ZJKON-+S*B>X)3S#=\UJ#I5"J> \JB&M &NW#^)T[LOM27[YU8;V9?K* M^LV31D^)@I1'(28CAY!'<&?K"6ZH%RH>]*()C8"Z MA/0K^/!I(B?'?OR.C80*:4O3RHBU1GL*BSC&0CH$;GF#E)NFO%)9+$%$47[] M4IAF84_5[9A^2OA&+2D)CC9E7DU>@7G(C*XDDR*-&4G".9(?(31/VYIC&K8"K4J8&%11!JA0IS@18WC-!V .!"@# M7'FT-:QIER/EH44SODY]2<%#*//V?-?Q.]K!,=*INNH<>ECOL@\HP+<*8 M\DX2?7>P]W1N[:@[O@*1L5)B](=['\1P+A#J^Q1()SRD"DU?#+/Y5M>GW7PI M5W3K75-/XD1;R+3A#^[:HW>05IN8;F($C&3Y5?5<504)W.SDUJ=PO!QR G8\ M"$2Z67O=1 LUPFX&(?'3CV\?N(9 $ '#!6#:A,!ASS8G%MQMM,XX%6%0/HT4 M]K;X?%6V])_'C!K;P OSK[%VL%?U1X=L]D'7 $N"B\:(ZPQ^,?XZ&4UA>W67 MSA@) A0..\N\2D4\)8=B9V"\ +&Q8AO-5A8@MFQ:7]WGE?_8TB &]:+XY_KE MIPDWBU>?0N&5#$+U*K1*Z+,870J63$__VIZW)"9"HJ?;58SLBNRBQ[,V=&N4 M&DS#OZR(WB.U']=^]@B\H+QG5#RL6+79U27ULDYYAJ\RI0?^CI!P1OFMG?A1 M0_PKNIN)[([R^1VI)@,RA$3MW&%&;J"/>>,='A>$XT*> M\7-HHC.2)H*;T)WA#]U;$X^55'VZI1@M =^UO%8D$HFPAXC?Z!(-V$@9)>VL!":LUJ7<[Z:$"Y R7Y1]_/V?_!__;P!@'Y)+"&K'"FE+0,$UWPK(L ME]/)C=]3>=W<*.1_+^8ZM3P3[% %*^D721I0MX8IR0WI]"CAST MTT3+2%SGT*J "&]58,A)VRIAJT>_U3!#F% T+T*<'-5$H9\AP<*E$0;9W0W? M2Q)]VMI\U&D+DP[O'@GX\OZ!E6%6S$A82L[@)/!5GP]YZMZ$^XR6M+1*_Z/' MNMK'WS%O2[ SJS;^P"V?\/[6HM+J49:X'\PA M]64:@;#MX#9Y[4?P3/#D1:F-9LJ# RM2 T!G9']1H61G-A0C$%(LM&R:2'OW M8DJ^)6'D]X&I-%>5J"9);9[Y0<'=*0U=&X 7%3IR,(4CU'G6LYI@/4\I)88LQN%>:X5M9-_W%5AX&7>TGWO6#EN;/.'G/E'/@ ]'/:6G>5 ME@)]"N0)(>E!F)?DJ3I ^LR$I4NXIG2%QV*\DIGC0%[S[JL@_J+S'K1Y$>FH2J9*C2DF7*5[6G\M!-U2TJV\+\GC(%X:0. MCP71F2NM%B9?=RV!?NR5(.Q>9>Q-ED]NO5CWC=&E'X:.QG-ZR M/ A_\:7+H^\ 8RUXO'6@4-^N]&[LZWPDB&J$"QOE3YIEV"0<%NJTCSZG/E*.^^69!/LM387((Q/E64! MI/2"K_6[^G%=E5_OT.&0+D(ZB>#MWR@*]*$RP0"Z9"O+Y4 MCFM'N+CX\/P.R-2O]]&J;=I:."Q.2861[KL+.Z/8Z>K(;OKE 6GTG5K25EO> M5Z6< /O08V5)]MI1=/[CFW)\='5P^BL9GMBU&NTS[FD \>^>3E=62.&5>;J])KP M#$3*T1.@S;!#R8MTP4@1]'% QKO-.F&U6 M]B](%KK[S32W-C51ZIAKMG2!\+=3CTR9A[9QQ;A&7#2L+*]E'W0"WM6H//XG MGV4@TDAIJDE?P9'GC\0;?7B,.L;=$\9!QV7P#T!MT>$9>(X6Q'#\!S)CGL M\;JT>*2LAFZ&8/PYQ^2CV;$/:_OD KNE;&D/I":EW;!N 9YM&5JE_2L(ADQX MZ+42Z^N[4\T\VD8GRFQL.ZHN)+S(<1BH=;$^#,;1!^B7^ZDFD(A-,!.0UU)_ MZGOD#$K 1;V[9;=,S/*(>$C7CN/K(SE^#G.J/;P^@] M?MI"W@=9)=45U2X?3!DJGWH! .,AS"[REEU?'?V5RD,&+>07U M40LETE*WZ^5]T+W?GB$7FV,6_,W6 FR!FL9=_KA:J&\6/-&P9-3+I7Q,*S;K M2#=/\-1#KO@ALI5< M M.'2;D*G?.,E%>1&^ @:%E>,W9VHO\-*S0'-"X,_K2#UMENKMEZ$2-)/ M%LI/OA(0X?9^EAT\*G."LKZ;0KN-^8!RE@4D<4V]XZ\TTO7W028'YM&V[9:V MR4E'\I<;J[':_9"I-*^Y;X 9QD#DZ#.6T4 M]$,_3^9]7KCR6XS#=920%ZE]@CYPJ/S:RVLR ^&$35H!>G/';MZ]\:!JP&U4 ME,.O=4#3O*=(5T:_XWO$H.HLD'AP% M<1G5%C8&-_?R:%N-G>'.F<36ZCP]D331A!7:!SFA@7/H MB$*JRDR ^I_E)OVKIP>\G[JDR\\9W'5XD;/C(+)ZMU$-OM&*3*)W'0H%HT-0 M9;]]JKV3L@\X7V6T'4@E3"F"]VP\3>8WP4'T.3\X*.%5_2MRV*M-2+@8I*:O MUCC[U_*XTL!J1KMIT-.(]NIOXN+%2^ S6$64$Q$03U/0Z@U',CNCGGR_8W]@ M=LT>?-=0&.4;E7Z1UV_?2_,2/<^X=2:2:@DH')A'/F!J[S3P <%,3M8=HAKE MCKU),%\.^CA<:-O#J*N!*KK%(KQ]K(%U26I+$L^\>ILT2GG?1\?AW;ET7WH+ M,5 M"O:.X>BLY!E<6'4"W'BV(LC[JX'C/NAIJGEY!=]N^E?.X]\K-1Y#V2L0C0%)[B[]3@T]YXO8;.4$6:0>PL"U@Q6AEL,J[)X*0 MH>6546""\(!C)<4KP2U"'B><3W@$18 TAGR,&&7+D3#JP[]:62-HT8B;DK%( MKN64Y/"RU!O?AVK5A;2N'B]-J.3+1,NISKMMG;)_9\##L&>IA[1"_D23S-E< MDBKZM%6?S=X=9_L%_BG^Q%=X_^ ?_,X#?HYRP M@"2Z*6[\L5NY<+<*G0LF8)PD=J;_MFV2P58&M.IRC_PM""-#*](9/DCQH7V" MXM.0$M_)9L%;QEV];%_=4BWZ=$ULI6TSZ\H?^7A,#7V6G$-LP*H4H[.&OH)^ MZ!_7X@ AO9'=AS)>QP"\A2.6SXN 3W1LR!"?.9AGO3,AB^>?#ONNM,Z_>F$?Q%0&F) ' M5RTP885AS6C>_\;>F\=#_?T/WV^1?5\B8F1)D52V0C,D6Q)I4<14$A(JV9FQ M1?;PD2*F17:&;%G'3DFR,\*8D7V9">/-;/?T^]V_Z[I^O^MZW(_[?CSNZ^KS M_7[]\7SP>!OG=<-C7V.KY,?F-G.K MQ<0MH;$>AM6(99N?\QG?E[4L32VOQVE?* MARLH@33H*@]%*D+8T,M=[K-HGC]O47:80-X;GBM_@^W97?[7^$>%(&>J?E\O M],P3Y?^'R[" H!,4#0;0 M;$N7#+*E'$LBS, CZ8I!2IF^QVC'?!924:Q?>I6$0][GD#6W-.,WJ_*=]_[, M;+/Q27F3? 3WD-25??=D*2Y,-P:$DY\S[9]IT$FP:$0'$\*,WI^ZXY6Z7ZK> M67_R.6.2-UP\Q_&@B7UDHVR&.:T(B4NO?6_..IG(<;3^,[^WZIZY6;HB;'%_ MXF.YY^13_VY1U\G>S!*;@W3!*+*]"MX^EGIF!,)%>Y-1HO'9+L_=#XE;Y-'GN;"[66)WFZ]P^[.%VFFBZ:WE[E QS>_?F37KO\ MEY-O_Q]N,]]EE_\W_'[9K+[Z!1?>#)=ZWNQ S'[[W_E3..4KS8R H$L4(Z:= M.TP7#G*B7,R=OI[8"A)[G0[]QXSO- Z4"/O!1T\FJR_JQ&S[DN.8!=T)D@'7R<7G6RVA M .G<&'+%8H_F=2>O23V9U-&VS?O4;9+- MR\@]ZAN4!-9!9R8R;/7*88'1/O3GI_ M,.RKR56]A,;P#[Y3X[!J&QJ X& 4SV6#"#A.\>HJ$TG _BOS_NI K1WC:?, M*%=AS5-Q.FJA*_?26M;P4H$HSECT7UQMY_?G)(5^4^CBAD7,Y;T10,__P43" MN_P[ZP( _CL#A8R@(=HVJ'[&SO_\Y,_7LE=_G'97B>'TL+I_(B^;B]OO!JO M28Y?Y"U+JH*DC*JG+]*_:Z\3;+//;EQLNYOD1N>"DPK)B*$/)'@+1+@;'^AF MY"ILKSQ=L6++MFC?QN<]60EX(+#,Y[4OK0Y3&]/Y()=>HSX2CFP^0V>CPL %"KN? MX0727,3&E/"XZF1V6<./4UD')KI31+NCY:'S+?6=A!&JT+UAW(_[2$X]V^'' MCPEG20?5("6CJY=\U=[PQZ_B0V#6;@2[WFWS,U&TY%8&\&$-SC9*?4(KA=VR MZWK" ,3L%JL=)*/;'HV#+]3S79/Y0^_475,\-1^M3- K#A!OAH.'?0?1<8P!?V? ;0-;11D;6OSRDI["JC+[=ITH3,"]! LDKZGDR[*LB[S.XNF-NV%IMO^Y36$G*&_LX[$ M;/4GXFHVJ2O[5N&1RF8V'TTB^2U1'J>V4D-QG@1]IV5^'T/8"I\A!MZW=G#1 MN?NBM#W_P[?A0Y-^ S-C"OY7.+,); =&EM:H<@$0&DL% Z#N3:0J]R3$YBXD MJX^-VMGJ\JH;<+^5_XZSXL!/Q<%N0;"^Y+,CATA*+1-W*&W[+E$[*,TC M(# MLGI'A^^NIL!^P#6#W2I ;695GY/F0M&13TE1+5QXH0=TBW8Z2J)T\)TLM<.4 M4ZA.8#54?!@#=_L*54=\G>)%NO"P5Y.FPBLF/-PSY =Y$5=GY*NZ(]IBSE3? M(CQW87T)2E$\J%*TM_LX@U0)4J:5KQ["2C?O'%T+1WH[>D4+U#MU-@16(JY0 M/9ESUI':RHZWQ+2.C-K:^48E"?E&X5E%*N!"+YZL-QXAV*Q$4]A^M#OC7;RC M@[1Y(LR1PN>\+90-GN\Q>5)T7H LGQKP2UT?\NDOFSGG)@8 'AUIG=I'RVK% MVT2MU?,A1J\-/B@/OF7I]*T+@IX07$H8$$ M=>BK)REL2N!-UK\\R==95_2E+?X&EZ7]*R)S&P?95L6((5?%&$!VCP/*X;\^ M^.-5W.6?""-O-[[-BJJMXYV//)7_2CYRY:1.%J] M*5W)[D&%C>W>\87T=X=G9N5PVA["QDJ42HH1<_HY03W--'I%0=Z@0%$B7Y = ML9.J,#OX-)WOWE!%L>V)9"AHD?N60DI^M%6;3D'A,%0Q5IQ)AX <=J[-$^=^ MYX) *?AV[T?GQF,LQPEGM'52LE(W3-H\(QIYP(;WF2H=6>+]]1:.X1_/G!]2 M/)$R^%ZH1FK"%+I)'.E(!.4AK2BQX'=;T[W/O"&L4UHWCJJIYUW?>2KU+/7, M27O2@C[DK8_V,#;UM;:/KY ]]NM;?!8'?T+NVVL'A%:5 ZCZ];1TY /+4<0O M=\-F7\GVR6B>_3*$%FV.2V4I$HK9'YV4$I:)N-_OC7T@>M%Y+/#2_'<'H$?] M9%2OWO$\9F_9.K<\8I[ 3_'G[WRPHWJ^-FY#YMX^-P)'<6%)LI>2WQ)^A M3<)\]+//U4/ZJJ5U1E;YE!P$Y$)@QQOY?M_OIQ&X)M>+3PS-[?^@!RVBVZ_SR89%*1$%RXBHJ 5&JW(!.%.IG..BSA2>:]E;[%9EN8%-X[S[J;TP'-9G.? [Q&F;F M1M!YXHNWT^8Y+54?LK7'B\^,O==U,EA^9Z@/R7YBDT55H;V%2@5Y5-Z@\A'L M(6WNY8%VMC]"O21WZOFB1>AL[QJX_WSX]D\#^CA(HAB#(F1?8N8J&K\FZ#JL M'>VLV?,B21-KXIMW\HC<*47OZ]R.Z^0W M_Z=&0@@*NHQ64, M@%#9#T((2B&(0Q,WL;^#82F24T\!EU*4X=#*FHR"$LOK<\M71#HL !_1:[ 8 MJN,;/P&CM.ND8]6Y?H%F$:&*]$)?Z0I.2WW[+BO+X1ID%+)"H-4RUB9Y#-3N M;)0AJ6X8O%K>6#$^XLR=NY=:.EZUOE66& !L_$??[*X![?*W0#Z+<_5M\O[W M-VXGG==[?-C)29Y-,"!,9=8S#D6T8 A4_NIE%@T1^=TL.W-E'P_^Z=Q&8G7 M3H3<=LQZW)>R]AF=RPP8NF Q**(Q1!J\N+R(X=%[Y(SV5YUM='BM MZBKDJC2??U2' *@$:;*,RWJRE<4=WFJ;7:-D3:SCX6(Y8Q9O$!V]]"+N-5V3 M!&GW!.5Z8ZFZZO?A/%1_UV)FV]H=B]Y?GSC((:OPN69_0U<>#JHL.7(^]2>H^_U=XZ%8K$9."<#<(-'0 Y$','U0EQV M,I<_C>=T:X^AN<[41Y_M\B<<--U"V__Q Z7_T&#VO.V?IA5C7-42;.?:W'WP M_0S ]'OEBMO%4M>S9D>K7%HF>TYR,BB?;:8 M (E#\FO:Z?+<]O0J7DH76]((O"&4G67G?%5VC>5EQ^AV[.W2LR$":K_W[U_3 M]4B]80@!JB-HAE]19XZV%SW(P$/ECXZ[J,G5IHJ]N3[MWM45L_]F(GY1BG6# M@\Y]FN :)$ 1H9ZK27JALG+VF_01:RW%&R6'$HZ("I^6L3/U7]R+<$3TP*O3 M.CS'((9$]X2Z[)YBZI'&^)\#%;2SWPUG[;:+%-UTG[])1MR9LI5QYS]?=\?KT*JFT.I)U,N ;&\\KH'-=(8UY(TJ#EZUJWI):[J18- IRXHW M*5J%WJ42^N@4T4H5AJ-*UI.S) :\_9[P7+_R(H$=D.K.S)34#_K.19<8?-3C MB)B EU%AI9;/Z#)^(].),=[MYOG9YVKK7T&'G/TYC?G1DK+*BSV_5@AN>TP? ML-._]7,A<24CECYF]TB=SZ*53D_%_GC"5%6QS=_7N])-.UM;I^C"7+"-5_.L M*[UC4_CGX A1NXE^ZG!9;_&"U8\?G1+;U@2/L=3@B!A<(/?&^6U/.E>D$ZRT MMQ6BN[8=$ F;H/?5CN_<:W[C].A@!D#GQ3$ ;N"_GL'JA/(M M^F([V]6BJ],3T@[%^BN1G5\Y'BV4-WEV@/UK,7D+,Z?9S@T5.=&;C,:8B0QM9J??6R@!(:JA'BVTF M$3Y;WO=WCL4 U'2PA@&P60P=_3J"XM4+YON5-R&3@7>Y<)(T>O,L=QF4E->+ MM&3:I8A8,I;V#*QG_I99?]JUF7(GWO.\4(*^,()X-K>$U3A@8Q;S,.^-P)>I M""31S@EJA&Y;B_H9:%;@=RV( -_<,P7^>B:^[M_6XSCKQ]"QZ+*U)IA\9-/)I5 Y(=,XYLOAC0&M;2= M$DD:SU./(:=^G"G$HV)AQ',97-0E5"1*\%X%XKQKX^&0\RC+BK,L5K"E%$@ M0#/^CUM\1Z:W06W* T3[S.?I3M+16CXTT_/GW&P:UEAY7RAU%N+2Z1OMASX' MVC$=A@^DSL@Y>UT\/%2#YG=V\LI( -/T^43(F+=1^EX>B!,XBK02&/FB\E,@ M D.\O#;& /#H%+:LHY[LB]:"T$[\2T07Q_!#6T'H1X$/P2;92_LDZ2@^^JM@ M][S1K]I&WJ[*W:+A0S?,V((/[_GYIQ>G_\$0ZMV?OE^>OT_<^ITIJ>:Q3MP6 MN@TFB!A&26*<4<_@^QKW4UV'-GO%L?>Q[.^G-Q-6/9.5TI7LW.99 -%;_ATG M2Y#19T=6]_I;KHA3SH!PK;M+#NNQL,Q9N.FLB9 M5=0"E.LK2]5OWPBT"T@$W4EA?IZ5J(*#A-4?01;ZO==/G\ZIN1ZN-V"A$&'$ M:6WY0FA+5XO=RN1Q!6Z\-*=L?K]N;:N"+D7DRT\+=\5 MZQ_%IHITC!HEJ[_F3YX)$9NL\/$P]]B9Q_R!(^@%'8N$\)QQ5ZQ3:F-F+K9#+JR_7S'F M\/.'8I?TN3G>B+* Y12X2T#GLC-3L83+P1R-FI)ZW7PW(3"Y_YS4M07X'C( M8A5^],?Y"!MWKEV%CR^16P>0'IE>TW/AC>*@ET/F@]G4]H:56IZ,[IHP99,# MC^J(,<7)EHJ]^B>1SGIN. %>JEF?G0G).:H"(^)ZH<70J?!&I]>^Z=?';=C8 M]Y^23[I9W9HXAIEV;I$VVX2P@ZRM=.G!5S?X:*D1;@_%&G]%FTZ*,H G!QZ> M>K.7]IJ^#Q*&W%,O@//U3IXSZI^NKDE63W4+T[[0O7S767XT9B/@_WZW:_<5 MP5W^QM2OX=.6UXB]!/NZ3@*2=;Y1+BG-&5M2?,5>MN-X2HF")@>TA:9;B,'+8/'T8EXU]N "=NF QV35G"TS0]0:6U%4>* MVGV1112_IGGQQ;&+6Y^(UTI(IK@GPG:GC9\S@(]B[8BQ/GU(;);0[_U'Q/'^J3=BPK0I+3M^Y]@X@2"5=-1EZY[@&MPTZ\OOV)*H$"9WBB>^V M<&X2[VD],\A._BXR:LZI-E(3;[)!L6R?Y"#.M?$I;F!$YB6=GU6,4(8#BE_[ MGH" /&$J,[TQ4T0S5,B4T(4126A&OI^ 58K2U^\>GT.J\R-O+7)0CI1_ ((- MB5OXK3#HT>L9O>Q^U<8D/>ZZUPN^9=_Z$LE#%ZTHQ]EK%ZF>X%.F'_0$K";^ M8@ 4^#0J;F--^+-'.T[&<4$G+&NN>ZB3O!//CQ MNEEHV HI(6N$G.Q8VG"YI@%ZH^X[Q\J$V'82,9?.XSH]H=_J3A)O$L?JO599 ME(%\LLN+II,B+>+"YU<1E63M%O2X)RZJPU,9QA=DU->S\9(G=]$Z0^K=U,3U M.99:Y[H/[2@P.!]V8%.2'DKI%%=Z8_%H'@0HRCRD:G MIO/U+*!1;E\$^";X'%I9P<8NWQ6)U3Y^E4^_K\K>^QI,FN9ISJ&:$;5>X2$' MZVL^?%3+<F(+&E2>:U*+EKDB^:(R&.=N0(3VXE7.)KU8BWZG)B&S M:K, OP;:=-AR)%2\W+3D6TKW?*8Q!OTYF^8K_55UXXD"HI(DT&X)ROLV3TEH MC,@(#FYB6!RT? QY,9[E\*+'J.-TX9AMDW8X\?P45AWGDW^HFMC=]MSMH^%7 M&ZCTD$+_)M_[UZD^^@)!1^-<6,DO8J@7?M]*#:G,76[.,\BA&O>O5JI<]515 MI;J^U[.4E0ZJBQ"JB**]^P:MW.ADUEW5LG4%^:6:M!6^F,;_03Y&5)BVP>#=N4!W/'ETT81'_ N(JZ'" 0S4USE! MMGH"BO_X,L$_$KNODN_R#\K5(8TZ58\6-VGC;Y/T+T[CJI6#Y@H>9_9?%S09 M;G0&\YENY@ -U:BB,="#>TE5RS-C &J-XG^-BO4^$IX]0'G9$_S[%)]YT)7? MJ_9+6@COD=;$9S[I87$5 'DTMT4G@SAC+FNU26U9ZBB)<9P-@6/B12B>3E!Z5?0+[S>_<#Z[[SE>]XFD(7@;.X!&RVQDF-%8L=:]H0YZHR (^C$W]OJ3>+(R3 MC)Y/1.WH3?1>>ZWSX_8L>5@!?5:QOX(OQ&]L A0&8#A2T2OB6KJH WWO6NBZ MSM=G/_JMW$AVT\;:@,H'1[>KNM&Y*BG6]&_I?]5B6NW=*Z\:8E:@@L-97W[^ MA40VE,.W1Y:*F7YY%*V2XD7OQ*AVD9[L2*/A%7)+V,<= M.GP,H$%(K?2N_.A( 96I06'C]\G%?-5MR*@7U9_[+0Q;;?A8XWQ_'3HJP0#& MC<1V>ATNDO*:^N2A&:=UHYONOXOOCFZ"A0\?;3Y1F#\ MO K)JP5)O)J(E<>]*$I7:EOCLP/#3"\J5HUL=/97"G)(\,840(M%)'=:IVVH M^[1Q(W'U>7KVMXO]V#=+)'KS[@!RK<8 E0ZZ!X1TMZM5NFG MUB&I%HWGJ1FYT)#@*@]9>:/[G'*QY[EW]*VDC.84&ZA)7? MR\/YX*00G5+VP4*UD1#[W;]M1MW;I[SFYRO^$;F2[A MQNYW(3!IJ#RR61)Q&)396,3P!;GG@$G%XU_#3GIPBP'M,#$#?$JF9(_GGJ"YY<3\N^.SN]=3$;NS=BQ6?FI.73WVC6K+ZU[ MK]\56M"'I$UQ(W%5.U>;(L?Q)JW=A>(XLSSPWL][9X,1O2>LW].Q963T1Z@H M?0*UAW[BY>WO4#E7J_O".#Y=&Z_;C^HH!>5[)Y$_5$W:/4S,E;X'SP3%MI'^Z<%TO9;J0@&0V]5R\,L["BSB%EQZ*_>4X4&_QH/P@ M%.42<>02 WCPDO*=8Y%;IZO@2W-JI.&1+OGA3/@S=XHNG5EFV=)^/7GM9R5/ MW![?0$Z+-NA\2'',U[K 1;6%+-FGM:+ H]7M JR3\2IX>-B3*6$IGU]S?JR_ M>R?-6E(O5/OC[,^?%5^FRU4=V;?F M2E"3@/LZ[=@,RTB2'*()9PZI7F[=Z4"5+"0S@,+Z 8]DO/A:ZUO9SKA"TCRC>PBO48!\C76XA;8W(H7 E,HW.E M4"[0>W6*:J=:I9$43V>YI9;TPH6M.I,M@L^%39AR^28:6W"8E639BB1:KV&] MR-Y#*MN2.TMW.8GC_<[]6_2Y#KM!A09P WG?#O% M-K7QOQX:+ ;ZHO]J9%9>N9&%>G%]]:B&%(;UOK47&<7W8_O27/6J@H"@3%?A MIBC+!KP5'I_% K8[DC%L8*LQ2;]'.\@DIQRY+D8<,!GH!<+V33/?D/ &+0[WT;%AY&U2P P^WJ+6 F M_2M.#?5USX5+6R73?&7W7!05">':0*GRL5IHKW4-_=1U'BX#%A-YUY_ M&W0+Y"%,[?5#-XU@V3$E+N)8]\K5U(?5U^+U2G4.>@9'G^.N,5Y)AZP9P!1 M[Q%?X1N78;]""Y"_-"'$#<^Q6'J,,]U*TY)NC/X FQ;YS@#F^7(9 .XH&AJ8[HU):;-VE9,/A(R6N-L>/+02)=+Q-'3T1\FC MA$=)#FBX!.+KB])1!M!L@+G_3'4Z85(L7'_\P'DQDQU9/1:X\_<_OFGT?YC= MW=1=_G6X9&_;&NBIVM!VHI>MP-KT@]67Q8 P ;8K%58<[?"JD64#XF5K$$(2 M[QB>9!O84!.9WY%>S74/?L=ZE[?O[*\C?N_EM/>&?/NIL#/2#I5@ &%F8#G> MIMER+]6 J!1?,;;FW7-H_'**R?#!0$>>^MLQG3J>?)\)C]$U:_!\9)42-3VJ M T(1K;2D*287(-IAOUP8 "=R^489 ^@SUX>D0W@'R"1:>I#O.Q Q94ARCG[2 M49NP=V MBMR1JN 4@O6X\JDJ;O.'S)GW"H1T6CHS(@)'?E](_U-:V83R6M[)Y5VUT@&.JRQC#[,2& #H.UO# $S. MD%H9 '<^K"7QOSYH;&)JG0#9G?9\ SW6VRYSG"3GQ_QQFL01(SRF5JDF.JGZ M=4;_@%)OA?J!X_OO^!FQ2J"#_@:+2O^GV5V=W667?R%V%7Z77?Z%V%7X77;Y MIZ6,>IO )]XDLW\PR A_YN*4<9_&_(4MWQ'/CZ>>^RHMZ@./S8"[Z<#H.XPF MU9T!['U%3$"14EI?9$GVKU:J1<9\+*E#0E_:6#EC)R_;LCZ,+??IF;S#&C^Z MOSUX@&A.J Y#NGBRM>/1>Y9.+.[8G8Z\BG5,QUJQG#"7>AS'(NTG&\;%)@FL MS:/%:>]@;FN1D(^;Q:](WVIO#7I>:2A)<13Z5)_*L9=:MG59-O[;%6%.MJ2; MODT0\'!:T[Z*D_[*F1*'3SB!;6H^&!:O8G^8*.YE?[*\_,# MT%?O_OV&D=U+:W;9Y9\3="@&5SYB^Q7R<3)*.C3UR>=Z"X_TM-37HH(W-6Z3 MJ#)W\N?BFW7QC=LECGAX*X:/>IVHA9ZV%%\H79R4'GS[:[4X5]$ B.25$+R: M&G*K*8P[3,>*@P!97L,EAB/%&E417QV$!RJZ5:U5S4V&5NH=G4^BSJS%-S1/ M'-0C[M&XD,N])RF2'6.*<42.6IK1$M#U!M[9?KTV) 'RCQ/MWFZ^O(_L5N.C MS?:47)RN-SH!*I<2ON!2>-'YY&OT/BTI"5N6W!=OB.&J(NWN>M?]'$]?$?FJD= MA4H9@?%:5$3)J:]K(<2+D!(5J<@ELP@+ H*?-DHS;D^/$J M:N2Q_$-(&;[ 1*KX23Q,"=<&.9+A4TK[6!A[< =%8P^!&=,Y_4CT(T%21.TX MQ:MFFQ/"O9=>"=Y22&Y)6(3&F5)5JM!"M&=%/\MH25 AD^.MU9'+/R&K];=' M-FX[3.CO%;5YB6R?8P#Y(@Q R07XK^^YB_11I4AN1B3+9YKSBD2[23>D,^6L MZ<@]C5]6[QX >TX*G%9"G9]@ +&]#,!:B7[Q.T=NG\-M!B".HF=;4C/?T]5@ M-%/4MN[O%(3^450'Y$X2[)=/XN_,(IMRR)D5("!8;!9"\F< B^>8'C 6AE]G M (/1#""E@F5AXS_5;5?(KI!=(?\K(9MS<(Y-\XF+ZYUN_OZ/?*HF%6K#6/2* MZ%=N'1)ZC+BZ_Q1K3.%_$U6DQN.GC1^)%[ KY5Q.R#^-,L]ZR!6T^3"R*IXF/6*IVN:XZN4J' M9#9UGU# 3#N#5L2C.VW4H<$:7N^<_T%'G.[+FEB4^-6]=B^^W4JX.V(K4;^ M_1NZ*V17R#^I$!\HM":]MRE+_E-U*BY+56O6]&=\S,?CT<]NFFXRL;E C\#>_A"VE\N"=AY$ES M5TEU/PF5?&MC@_W-&WE4W;?46\1OX;FN^]"X:-4B]WZLULM)<>48T7VR+*_Y MFZPX2B_]_?ID5\BND']B(9MS4Q!-W1[(-.29F@:E9MD#;WK!=U^_QN-#]^(. M')=-X(+$7_KOHHN)\'W"7Y,OF>%N>?^#^UA'9A''__O)??]M_:\ M$;!\5]_Z'XTR^8_VA)R!QJP+_+=&_0_M 39V5+[^#XW:%;(K9%?(_T)()2GC M2D,_ YAFIXC];,_%ZEUV]-1.4E'*$/&497']8[ MI6?A-1WHKG9^Z/;0C8K4&M>Q=Q.50,K/YF\"\OM[3S5O+OX-MK'^]Z)"0(-' M1I;+T/3^J;T5"U1YH0:2S=/5+/*X!:_H9,OB/I<4!3X&H'RJU_ZIR5&59=O# MK-L@$;5RFZ0TW=NN%N'K($F-. 80=H_^%2.8V(X2IW^'BU8LQ8M<(^WY41D?/R-S;L#,6SOC M3/5[)P <^83Z81#ZEE(=]8N#ZINHMC'?XQC;QB6+Z\7 M=97B>E51(S@/52$ID!5H9A) ;IL$QK*?B7]!3,&[):W'T MA-X\ [A?^8GKZZWME+T>&::R/TT/V,178F(AQ*N]"5G[=7PCI%HGI0>F]Z%< M8H.J KQKTM1[%99%S90LDQ[:W0FI^8S^47"85:VE4:J,Z!FI$<]J'MLUH%%X MZH'[G:6/AY_+J>$*5*S_!EL&N^RRR_\?4%=I#3! TX?9!?D])W]=< 2B_^.V#7)\?E/2S[,@;(9X@FR7U_/&>TGY2 M^)N-BJ1]Q?C][IM2FI$6UW;L7L1?L!86K3O &CK07X'$Y<.KUF(PSK/?H9 @ M:)VD971EAF&>P^*76(6JX0]8#=/P/:QU"BCHR;>G9F8 1/@E>"P""DI3W(($ MP5O,B7+3,T9R*\5-U#<@\F76D;I/#>5QSUFR.&0N*[_8;]5;K13'FM@(PV7" M*W,^4*Y1I>KJ20I6N;%4V).CFD>*OROX&J0]N1QQX.#M3V('/,X:LP! \ TC MQ'UDL[7>;;1?*V&N"1..D!Q&5P06._QTJG/7^3G]^%B)]>2A.]D/WYWNA6:3 MT:4,P,426SZ-6LZ=_@O5CAU\.!7\6C,J:GG4'.GS7KE._MO9GZ;K!YYVP;3\ MW@BXO,/P-_(A1J8$F?^F-DYIUOFY]4S37MYH6,_(4Q+TZ+5^>;W5 [CRK$-" MA?IFGR+BWM&'ZC&T;/ IH5AE.C'4FP'L6TJNT#&.=M2D#IEB8$>'X'[5KL1JO/"$6Z91+ZYYP MRQK9ESEV.7NS]G->;=4Z/AUYW "@V?RY05F01,=29]Z<:9-%/&XR%7 M[E56-M0/?(GMKNM^$\]7;RUSA^5NXM'L$\>,]1V"[ @3>X M6*4T_&+ZZJG5?0*"$_],!A76][R6[KH=-S?J^T9@@%MEMA?; M35X#O2DJ\R/DZO0XR:V$%VH;<)ZQ\Y+!RW5))9R]23+<57:SLC\-;>:JJ2+A MY!#P*2F0/!NVU$97'=;D<;_&=Y'L?F)M5LMT1>K4E9"RJU>5N $<2PQ >_VN M\7[[?_I1QT][D4K(Y?-+.0KI6L)-W]IHQ MSX*4-G%D6?'/)>B[9A*K!W\+"K2.U&X]VPQ4Y3'Z:+$EOA.QQ'MBC[[4JV>L M"B$(#QZ!]C_ \IS^4?QK,84D] MZZZ\!/!>E-J;P19:<9>5'!!#Q(QZWAC4,Z0H4-4&O>V6,BVM/O4+S=;5O_KP MXMKDC_(R!=1C-QP$FT)N!(H,7IZ&'W#]KEF< MTY#;'E3UZ_B]IZ\0+I^ESU?][ VRXG V0K@$\9&,*TE3=.Y.DH"UQ;WM>A7< MIQ)"0OLQU/)3W+E2UGL^R7?][Q[PODD66V( 52BJ:&(SO'PXNM#/J\4V'AV# M4$P-=%E1E3#WS#'_DE;SJ&/F-.U[]]W;5>'I .5L##6'V:>GJ!=)B8GTPT'& MB6UTE6&JT0';"\*=,H5Y/8_S9KU>6"WK*V$;,YD?3$4,VVXM5Q*1YIZ9NON[-SX,FC8=\TK/J_"(7R_G@78LQ.?4U@8UWZHD+RZ<6A5E(+@@1@,HY@ M77'P\P5G.PLUNG!@7P#Y8% _7E8O\P/PW*0N:?S493*S ^7)M22!%1-B)[R< ME-+IB^_EN6G ]^V]J!MD_."KF^WR4"QV*@+ZFR6.S6R9CJC(AC#<^ _V'6HG<83HQ[ M+W@X*IH."S(-IPM*.]\D^H9M."7SB'UL>-$?.'M'N_=X?)1]@1B_3TA@F1C% MF3B\C9KV?.KI>8SG1%_QO72\\V>EKK-?OR*%S=[P%\10;P]A7-6P\G1N$1+% MFIC6 A.!^ZFU"G(Y5X5]HUOHJ 1J.%E"5_U,TG]V*W5I W#N>I$K)8UZB'X, M\2(ROM;X*4F^W2;K%)'6]NAFMY-WOGD>=G)L]7 ']D93LKA]$="""ZTYG_1< M %NK')E1Z=D+A]^V/G=_33Z&P147(O6G(J?JE#J MA,?4YA3GW5S@>_C]NNW-FUW#))["M S.B!7XL5/R#J]8:#T XD4?/(-IQP3 M([F10;JX"3OFA-QRQN>,;[OD7Q:N_GC58W?<*T9?WJ:^^HO^ZPX7R_/IDQ=7 MFK@'F$-/RV^I+4L'="4)(X7]HJZ2>(GWR0N\Z<7+U:J2+\T.FIM4QETX;S=IS$ZL MF7-3D2_QYY'E>.XV_@?=U/H1 FI%G,@ R(^(S<-4?[Q4L)SV-:TJ_;6Z!J>. M:Q(F7^<4#6#>OGQM_&ZDPDY4M78BS"412VC!3F84NSF($,N7;(.?)CQUS#<7 M13J)JWS]$B. ]L2&L1K+,T M9-6++I4OWV0 (HZL/V*H_D2U>,S]-? (1Z*>.2PBR L67L&GS:?8T%@(?94S MEAW7<9BK^K+"ZEGMKU\Z?WY6YA1EH3"]3;T@#EIQXVGZ9TRE8FX++%YR)7*1)TWW*U+GQ+53XY_F'7PTAA8'.!L![T.:GY;(:*=8&Y*"(4!U $CYVG%E1>&^! MB5,.]KY-LNFA)"T%OZ,7A]3MM5;J5Y[M%@ M'6?.KMLGN]7%'U,IMKZD^?/IAD%"!TJA1^HO)[87I^\J^\S6P9AZL5)'0 (@ MY3RH3BSX9:_=)IYD>.A#_@W HRWEN*!MTU13V^U8_H?S+! M?9C9/+I=X%EZ M[DHP V!C $-!*GBF"^RWL]ZFXU%\>L(YL-BR\(;>6]\S#2WF\2574.GJ5(7" MGVZ;XSAD>[PV@6DWN,'U\X9\635WTAP,;G5PG;YQ1\'[B%RMR&(%RX\^(U'@ MTA_!#[ER@G*'JDU[\62_,^E:N>@.I';T'N2?H$FF/G='@,8W1I*/+F571JTY)CM%F2Q7J MD0^\*NU$699$;?#5+1 ^^BBF.CBKDE LCH\G1WVX,?'RW4FW-)VK12EO^'Z. M&]Y_^C@T;>[6:9A?YM BLA2R\IYTN155<9FZ%^S,LU\J-_?VRFGUS?]RJ+ZT M,4)7U/_7A3[,BR]<1Q];A5=KL.P4&P4Q $I@T(6T:=AR(DG>KK+&S>*LNRY% MJ__ZCZ)8U>XBEN<)AH>37@H-> 3:=*+XF0&2:B#Y--,N.H&!'8F/H)4$C-1B M&H>%^[5[J.65@]YF+T\K)AVLLN'Y7A&;Q?5&8%!'A>0[G=N,&; MH&("VBL;6BVT,IVUHTN*#M5CSY=510H>C#=GMY+HX#]SW&U> %0<6>DD6,;2 M#P\AQ(+,ZE*N#Q<]2-^RJ-I]]&+^41&"U*@GKT3\E,JJ$M.OE7O7"*>5 M8#Q[HS ?)^/SKO-0/(6##*Z3W*8+3_M66(OMM5U(HYV_%=F\/2I4X95$1%*% MMPAIB705Q%A:/YC;OC->E@?,]D;RAXEUC^\R_ML;?[A>[Z M*J+V2Y6:HOL#MIEVGZK'^RS4UM-(^+N$@8.8: , !ID!E&:FT6.2&PKIW 84=\QR-* [%CES( M#6O[Z<@1UAS=95'$THQLOH)YT,/*G-9;W=UPY*=Z :@XJN$#U4W%^(_I]N]Q MU:\2M]WDB/F#*OM.;1LR W:BV>_\UE=!-8IN3_$243,'35#Y:VA?_SD5A7TQ M&>ZM<^!+\911T_Q,6I2F*]8YR[VM M!CTC>,*X+KEE[*4W]TCI"\@S-H3F]G8^\LN=%'KG2\R&&+J?Z6]J MM]9-Q4#*YMHRI2Q"2[PYBQP'W\:<2/,LMY!N54Y8ME8"^,U.B;)LNU&X@QR8 M@R,'Y&F#"# YU[V\?L!,^G1PYKNCPF?H1=411\9]3.1Y0O M&U6,<9P"#\_%5_;&(XDY"-WY*JQVS&R-FY3]^5.(+TL^'-V>>C?SU?JDCW,I M'_=EEW%CSE!.X! .Q;[ 3U#N+YW"Y^]^ZF9 12M >5KN_]<3XA(699_V@4 M7W7)@:3G_'J=A&LUN4&^S#XL=1&'"'C@A]XP@(@4(X/\A6P+J0+Q^>N_'M].^DM7\J9\//1F5P/T*)JD:*"G<@+GS&J\JLF[JU)WX]SO-, M1NWX(>.5NO6X.$)>24X,0"VF5<'N>$9B/D8M6Q96/RVZ-QADZ%UXW<0;+VU5 ME)9\;/WE]Y!]IWZI5^I_8\>/LC?TTCF9+NDA!(I\'(X\7#!"%9NC7QB_Q-3/ MH2AZY)#-?_IS'NLB92HI4J,%V'%FX^51-[(\.T.K!K5J(M]H3% M=&3?.FO67H0SLODZ WC@+MYYK8S*2S2,]YB5-C[MW;T$GY3KV2^G>ZHL<_5 MV$QP?T%]9G,PA,X=3_&'4^43+"-0 FNVO>UI5=V'*@M;3%,N5B<]?MX6>&'1 M5YR^]W;BJU!+8>:WYC,/*4]LKG,3B(:+0!7]?);P;.^_#6R\FG&VD)!)F#K" M]]#D]/PKPNP,@ A%-*/VH#'.\+&HEDF)X=3;(SG"]]-?WW+\G.6%^0);D7MP M-L")_Q3Z.=,ZI7=!3R'&&( ,7=WLU7+_#?=EZ6ULFLW1/O'\;JA # MF.XB(IN9MB5>CC@MH@=I[KM]B-9KZ91?E(/-TNO5J6LLWT)MEFXP\R M_^\YO%/RZ*/L6GS!X28KMI= @,U*)4*1 33K,("?"NEI-)\1&/D#@,#:S&*H M^P3(<9B^#8@ 5938\#6^T"_%?;),K.1"SKB?72 "-E<4&BUM&F]B,K?Q#B-! MY4G$9M"Y5WSS'#H\-.(A#I\^7"NE%.UJ!E'F4 M]]1"$!!BC*'@B$(-?DE*.1* M.4\], R5F5H<<'EAFSW\T<+?73#9Z+J'_,N",/UN_\#'7G%S'!+H'@AX!+/< M2J20;X.LQ'%#HE82V5&K4M?AON\%Q8:&VQSL-QZJQ[U6#GFOQ'W2C;P'HXG$ M5:-^F4,ED:/W" S@'#>P4TAF_;=ITY(Y;=YE3IN3#;H6H &1THI0]!2[[J?4 M:@M_)G17R;:JWWVZ[NJ#-1I1OTFZ)\O_A@2VV]C$D3HB_17\FR<KJW7]EB)3"KWBU,16D$2F]4BTE4(T M[S163L?;\EE:DEX/8XTSD1YF"4[^/-W59PQBN%Z$Z'73.1MPW;$H5JH%F)J_ M+^,2B;_B!30H?-93D;?_.-FY9FX2=G]CX?<6 B\=L@@1@QZ^C_>4 ,NO2#:B MW6D?)&,M3L^N.\&5A5[7>C0E=3]FL8ILT*9S48@S02=HB71)UWCQ-&__G'@' M@CROPT)\$]]JH9P:ER89P'S4&X$O&% .0DVUC$:2]U8S M@+[9QF*FL.#1R_E?^[!B)X)1O1,SX:7;MU9^ M< 3_&)EBNC.F4WNH>L3>)G=+&R(R!C9]B+2O[!&/WS.-0^REKP2W?2;MO"K/ M)0LI'>P^(='!X=HX4\H4<,5!W'=<,[BI^14Q;:S!K)5XZJ%;1:-GXTIM#L6S:LJP_*[LO\IY>>1X+U9U. M; 0F#\5M]E$T8?#[!9U[I>E%4V-=6=Y-UYT2NVV" M(GHS,L?M5@D'9@*?BK* H4SEN0Z>P*V%T-5!IVDXF\MSE_1S,I"D5XY2V5F6 M%:=.?IF;3?K&?B/Q%CNP!W,7*C[>[D],;+&R%+9DJY5^9W8@9K^]1>T>3CU! MD_O4#\P>^H'\[ +Z,X [5-2.]>9. _$U81H>;H9#WF%.&_,1;WB78'NHZJ"* M9['?Q^Y6!W'BN4?8M,'*V#,ZDVW;G-H0K2M7%8V_/[QX2@R<8EHDDR$8[@.J MBB.*JDTDMSA]7_GN:NO]E?3CA+FOF)"S MP.<(*=#R>I0IZ.R(J,+<3_=4EC[O'9RSZ+N?UI)UR1_G*?MZ[\X668^$6GY% MD0,/C+JB]NGI%OH5T$07Z;)_E29/1T%O.GI^YGX]K;YJIL&R 5F)QB_!0Y%E MZ,35(KOE:,?I]?>C[J?N^J>ZWU99S3&"$25_)8(*:ZU"TY#1X2_T<[\\J#>0 M_OEU)ZG-VL'IL-8'4B',H?Q_L??>04U%[__G1<" E(CT&@4$E28HO00+342P M0"A"5%1*I$D50D*1W@0%%)1B0T6,2%-:Z(A(+Z%("P)*32CA0MK&[Q^[O_*= M_6MW/C.[,/.:X6:26\YYSOMY/[DWYTS6+C%XI,FFDK@(+-1 [64/I0>\J&D[ M>-A= ]/GQ6O\COVKV[>(M#?A!%)PPTF:$F@]O08Q%KT;\WKL[USVJW*_$V7A M#I'P% #-34YC<"^1>B@(>@KF.$I+O8>8+XZ]?4(::V]?D6JU_ XCDF\+^\*\( MSC@0^-(3"X%[XP^@;>H&YFMZ<3"K(95/M%3@O#;)8BF27ZR%3XAL$=(,_^QFX]@7'FJ?GQ1\%.--.5(D8FB^4[? MD]PR5=10QN 4!T9JP@&M ;9/2Z/:M*HK/H8FFT[VRWE)B$L8+JD_DT\U&6$" MBVW+ CU=R%,, A/@8P)W8!'8,I=O[]&J<>>&T'>(WV=+^U6]MK('YV+W9\IX M'#R=*G=9HMJGX5Y'E4&ZL70V[2 3N)KE$\<$A,J)UND^'QRN'^Z1?)UHXFV4 MKH)Y1EA@ C2![)FZM1BLFS.V9;O7 $9ZC%*FY$;*W"D7B&].T_#8H.T4F5SZNU:OY0+QB6"]]T:WEPMF MS"X^Y. M!5:,I%_X,PYHLC2,IY(<4Y]V-"[FGMI*($_%(V\G*ZU>7+94RL#/ MIV]_\=+ZU<5MY<-9,<[I#B8;0*DR2Q*W[^\@,(J#7@'QE/Q<[PV#_$AS<6LJ M8Q/SDV4RL;>G1ML;*#+<).V6<,XW>>>I5LM?3CE[(A1YYLW''\B3A&Y>DP*4 MFO'3'Q!0,I;R".0F71H=%R58^(?(+5<%'_?^&*XE?TJ[K^RO,?EWP_GAZH^23GPB=6:^ ?&&CHV@5 M>@(#.KFD\3<'$7-:S#DE+ZYPM-73Y]/3VV:\EV.NK*0ZB0&'VO?5J"7!!&NU M28(SWA6SL(/PD4V^_0,_W6O37PL9G7:5R!_V]^\C>I1_:D0G?VC+BK^CR-GF6XD9R>3S3$_MO^N4"V5-)*&FM M83./3V^]/_Y$J,G)6 KVS"%SL96V[^GY\.FB2A?UP=F0<@O-";E6[B-7T)V^ M?0]^A\LG!L[V1QAUL0[TT]'$CZKP]_[WFKRI5BT?R5!!SA_Y?2D!,))YUQ6O MA;4G0)B,14D]B /;@ MU&+.H.,S9U6*_HNLTC,G)\?%5GC7VZ-"5^X%Z.RR[%+ZM!(>P+09<28R1*(V M;$4E:DPG,AX\*X0GGU5@ I$VD,'-_]"=6^$-6)O:"&2&";2OI5'R!0T"_<.+ MF]UN^MR!QKG**CGP6LMY/VOOGGYF].>$SH*O#J[H6 &T!18;ZIR7P!H)(1*8 M%QZ<,3&X%)_"JHK*9#.ARQ\N"@L;-[T# ,@^O"?:NZMY MU\V]-)6N?8W__&=<2B#]<;<2.;J!":P_+R-P?TLE+C-#!)N4+,408+5C(IXH' 75J M3;OREUBE0.]I)?,2JZT!WAW?EDB$OZOR2 .0X:NT8<;@'II&"C(&X95M%>1V MQ&>G<%'+0=6ML(Y]^?*3U^63.,O=OEF?A'].\=^.15O;@^_55N:H%B;%:"1Y M):UY#7)6_''WHZ?EU)/-(L/OHZO=9E6;,WADA*_@KV/=IM*09@0C EHV[&['EOL(>F!D!E0VET(" MO8R4WC6D"L=_=A"*L%:_:3B3G[HL:C]I:WXM^"U]F')Y2 MKMW2\.6"2%-M,0,,#GI<_<%SPIFI^:AB"_9QT*@,)6(^*(=MH(\5]]DRCRX2G]R[9CUV3N' M[Q?!3M$4ZTG;*P^HQHL8'?HK(\51,,PT)0,5_S;S51;Y/KI&WQ;8L7D'47P' M22X3@7W!J71;3XQU=BVGIAZ>9)6<;"_:]%2UMM^5))A_3U/%HE9_JQ0"TKJ?%7*.$%HW^*9 7? MCQF$":O2 HG68F!&$P7E[B57]EF+<5Z@[>N!FEG73A'7QT,IX=$F "80VYS! M$,'V;LU"J8LL.Y9,^$C39TFR?TCPC&(CC"4L_+5*L\Z>0N2Y6CM":%XA[]6Z M]G#R=)_Y=YWK($(PA,;2 :F$UY6GTM5I4D.&+"_7=1 R0X_6'4;?!-Q M=ON0Y1&O5C:=IN5+10^%EP(N&\,4KV,;]0R$_:@VT%1(2S6)# P1'!C=^Z%? M'B0"HPQW&0=)MS0!T%!R#8-KF]1.]$GZ%,@R*:CJN.;MVLRWWP9* M5/KG._WD'PO=N]::X5^N?KG/UB24"2R_H@(T;?ICG&I@BMAD2%QKL,!3I^M# MB<^.Q,\&^+Z,*(U.M58.]6X7WNSZ3]V3^R_8YF#E/F%%/,KHE%)?+2"TA87%'D0*:JW]='%O]3W_EH;[XX&I3\RJEC#"W/?L7'HWG4\;PT91( M19&;HX[$GC,#A9^=8HU3]&4C^C,A42O?XK=Q MB:%F"8$KY^R?K4F-3CXUZC;JJ\%.)&M+INKB/KH7[*NWI[_ 3N<;\=.?8S0\ MF8# 9OXA5'5WV7NGZ^,=_*]OKF=W9\H'2\I=??Y6;],5>;7/F%/H\G^.$.T5 M#^IAT(=23UJ-?@4^=A@*<#\=5E03:W6L]=OH8P^^.LGD4$1MG[$4LC&?-=@; MX3'UDB2MS&#_\*(_02_[)9.ZZN\ELKP=_S3-%7:]-;7V:_VM;GO#'5HAM9X@U-"U!AW]KC2;#UXJ1C%,NA>1H M!G?K:YH-*V%,(;8-V'(VE3/D'.4,6:3N8XA/B]YDF5&I9U9&^X>G M02^+USB#9)\O#-?%S2(:X5R87A>V.E)P2GGI^S\$Y2\IGURSN!&KG8*IE]NL MY=[)'SQS>#O !C+_<8IT'LY>^>5.$A$1+]HT,DT^?#CB&/>OS\]'>R1?T/LELJ,0'!@P6^ .N/7?CO M?U;=(9U,H")_&<(JA<8V6AT5ZHC6 J@!ND]XYFK>B7UFX(+ M'#2"-3\@?5EH/+@H:F>W_J?KE4(A_U3Y^5BH_(5ODL&1&_SJZ?W5UGW4T#[R.;>G9E:F\R@7!')D#.H0NS"LQK8 F5XR]6Q$@! M+4L^R@225HE]]=*.HTY.[EZWOZBLCFOB"7HV?PHY#F M:DK:3)V;[?"-8=6,50_-JR*_[U@5J+:XJ"^Y;)@ (7$KUM0CH"BEDE22ETW\ MOGIOB\\PSTK?86#4;G[HZ0X-+=%C9OJF7 :$'PR60$2=0.OVHJVDMQ-J M425@T86$YD^94MRWY1NI7[Y__'DME;\KKC>1+OHRXA0-/D/7;LJ1CDUY9=_X MUL/NX-&*DA6<^:TO$"TY6[$5 M*)4GQ:YW;U!UM5HOL%=K_%H17_B+M&.I J0][:$(4H8A&!+=H)?Z/ISES@?] MF@WG[>*^2ZH28+5%O=6Y;Z>]T=5/!,["3FX2:SKO$)/7*[H&5?MF644 M$6N21I>/V-^KU1N^<"3:ZWVD=2Y>D7=-<8+:M8*TO&PL8TB]PNC2,UMQ($U" M.9>J)]\7_BU=%/"$*F2X'KK@:F9K.OE1:VX[H-L6]1O_WX>?!'B&"7!D@8$D M'V)P;*W/VY#F5M'JV)C0[%ZGB5R?$Z97&[Q*V=,*A=?@Y=O+"?^>J/I,ZJK, MG>6Q*-F2E+6*K2K2:'_@D<%SHNPX;TKJY4CI-BZ.L#LLV=L@X1EP4;JDMB!\*-=#>=;@T8'H9('DZ%UV+R^^%[5V%++\ MP?-1.L24LQ^.B1T I@']:^7_66GH&+.F";YJ=(2OG%%LYZJUQ,'C88A\!SU_ M,:..^0M20DP 4>,^Z;?AEKBY-I9+<>N'>T[%:4WR$@*[KIX=D!V4&Y2QDF^3 M?Y8N;2L9^GG\F7; 8K%+^W]KZ#Q(;@QN?=+:='ZK&A^X<(&,35BKX./_X]SL M$^)%>R^V[^3X+8@41;9^AM5Q'J V57@4K41_6QM&?KO1&BPC.UQKHWI9>?Z+ M_956A6?R8REU25[V_2=]=2##Y5A4VDA[\U2E,"[6"VU!M$*=+^_-(]H7]E\\ M<_?!^1ME._&C)^0:VHRHH83>ZG&0"]258L"L4O]SU;[EP MDO9R'?D"5.J/S#$R?\F[O+S >O>^RQQQY[[+'''GOLL<<>>^RQQQY[[+'''GOLL<<>>^RQQQY[[+'''GOL ML<<>>^RQQQY[[+'''GOLL<<>>^RQQQY[[+'''GOL\?]#OEJGN:@-8F!H7C") M^.+(;)I=+TWWW6*0UPG(F=-:7RS$[QB:SHE++\TC'S(!7JS'5"+L $UR5@WT MQ"_W@.;E*$/D,I+TJ?P;IH<2?PBIAIF;J,)H>XFW^>K90,;*$3_PI&XF4+Y& ME^YAN#JK,8%41#9F( A6/K7<23)K01Z:HCRU%E9X.)P\9I '#'B)_+8,Y)6\ M^.'G-:BV >]S5SE= !;^/TXHC> AA\VF1=;O S$#U\G;\4=(\YF! *K_356JQO4@094X6JY/-';9*XX)F*^^8U_!Q^!%:H^2<4U^ M8&ZCWJ C)4:^9]_D.:GX-[TSV?P?0GK>!&[M]#$!CCEZ 4.*QDY/"$!-P< : M:](@0F*X\+>)[\^-GCCG-AV;TZD0\1-%XC(OZ[^ IZBWT-+T DWX4)VQ^D@)%L2/ ,/#H0)@R674TS)3&> M"WS"O3$+C-?_B'H44=JIEPH)73#BQ_3!_JVQP^-U979F.V&%9LF?16X/Z3VG MC+FJ9F_\:2KUCOJ/0E,8*NMG0E8KA3/0\$C/;1$O @36-JV M8@)]P4)LNUB3D*I4[+V>:#@?YO O$-92KU?>7XOPD5>W?-OAY=M=:4D-\9*Z^A+_-COP7MW3Y'I3:&,&8$"<%HA[P+\6E@ M:)<3MLK8?]%3)5'QXYT7O>_5>NI\7YNL4VJ3.=5;#POQWD:257%NA>Z5%O/7 MD?%RJ>._-;0RQ"# MV;BS?Z^]2;V+%B=!6RQJN7'@XH 5^?:I9B^%9T=V$"I=$F3* ?I4=W!B.I�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